assay_id,assay_tissue,doc_id,cell_id,assay_type,assay_strain,description,assay_test_type,assay_category,assay_organism,assay_tax_id,assay_cell_type,assay_subcellular_fraction,tid
1,,11087,,B,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,,,,,,12052
2,,684,,F,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,,,,,,22226
3,,15453,,B,,,,,,,,,22226
4,,17841,,B,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,,Bos taurus,9913.0,,,104729
5,,17430,163.0,F,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,,Homo sapiens,9606.0,143B,,80001
6,,17430,163.0,F,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,,Homo sapiens,9606.0,143B,,80001
7,,13799,163.0,F,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,,Mus musculus,10090.0,143B,,80001
8,,17774,163.0,F,,In vitro cell cytotoxicity was determined against 143B cell line,,,Homo sapiens,9606.0,143B,,80001
9,,3801,163.0,F,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,,Homo sapiens,9606.0,143B,,80001
10,,17430,163.0,F,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,,Homo sapiens,9606.0,143B,,80001
11,,17430,163.0,F,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,,Homo sapiens,9606.0,143B,,80001
12,,17774,163.0,F,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,,Homo sapiens,9606.0,143B,,80001
13,,11324,,F,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,Staphylococcus aureus,1280.0,,,50185
14,,11324,,F,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,Staphylococcus aureus,1280.0,,,50185
15,,11324,,F,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,Staphylococcus aureus,1280.0,,,50185
16,,11324,,F,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,Staphylococcus aureus,1280.0,,,50185
17,,11347,,A,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,,Rattus norvegicus,10116.0,,,100122
18,,16474,,B,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,,,,,,12054
19,,10091,,B,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,,,,,,12054
20,,16474,,B,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,,,,,12054
21,,16474,,B,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,,,,,,12054
22,,16474,,B,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,,,,,12054
23,,16474,,B,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,,,,,12054
24,,16474,,B,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,,,,,12054
25,,14352,,B,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,,,,,,22226
26,,5646,,B,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,,Oryctolagus cuniculus,9986.0,,,12054
27,,5646,,B,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,,Oryctolagus cuniculus,9986.0,,,12054
28,,10997,,B,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,,,,,,12426
29,,6309,,B,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,,soya bean,3847.0,,,12054
30,,167,,B,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,,Glycine max,3847.0,,,12054
31,,167,,B,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,,Glycine max,3847.0,,,12054
32,,11087,,B,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,,Glycine max,3847.0,,,12054
33,,11087,,B,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,,Glycine max,3847.0,,,12054
34,,13622,,B,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,,Glycine max,3847.0,,,12054
35,,13622,,B,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,,Glycine max,3847.0,,,12054
36,,11347,,A,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,,Rattus norvegicus,10116.0,,,22226
37,,5926,,B,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,,Escherichia coli,562.0,,,22226
38,,4567,,B,,Dissociation constant with dimeric 16S rRNA RNA construct B,,,,,,,22226
39,,3782,,B,,Dissociation constant towards 16S rRNA construct A,,,,,,,22222
40,,3782,,B,,Dissociation constant towards 16S rRNA construct B,,,,,,,22222
41,,4466,,B,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,,Escherichia coli,562.0,,,100263
42,,6592,,B,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,,Escherichia coli,562.0,,,100263
43,,898,,B,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,,,,,13053
44,,898,,B,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,,,,,13053
45,,13163,,B,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,,Homo sapiens,9606.0,,,20001
46,,13163,,B,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,,Homo sapiens,9606.0,,,20001
47,,10691,,B,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,,Rattus norvegicus,10116.0,,,12971
48,,10691,,B,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,,Rattus norvegicus,10116.0,,,12971
49,,10691,,B,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,,Rattus norvegicus,10116.0,,,12971
50,,10691,,B,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,,Rattus norvegicus,10116.0,,,12971
51,,898,,B,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,,,,,13053
52,,912,,B,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,,,,,,11512
53,,912,,B,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,,,,,,11512
54,,912,,B,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,,,,,,11512
55,,15103,,B,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,,Rattus norvegicus,10116.0,,Membranes,104740
56,,5116,506.0,F,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,,Homo sapiens,9606.0,1A9,,80002
57,,14578,,F,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,,Rattus norvegicus,10116.0,Oocytes,,104835
58,,14578,,F,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,,Rattus norvegicus,10116.0,Oocytes,,104821
59,,14578,,F,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,,Rattus norvegicus,10116.0,Oocytes,,104848
60,,4787,506.0,F,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,,Homo sapiens,9606.0,1A9,,80002
61,,4787,506.0,F,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,,Homo sapiens,9606.0,1A9,,80002
62,,3547,506.0,F,,Cytotoxic activity against human ovarian cancer (1A9) cell line,,,Homo sapiens,9606.0,1A9,,80002
63,,3547,506.0,F,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,,Homo sapiens,9606.0,1A9,,80002
64,,6726,506.0,F,,Effective dose of compound against replication of 1A9 cell line was evaluated,,,Homo sapiens,9606.0,1A9,,80002
65,,3455,506.0,F,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,,Homo sapiens,9606.0,1A9,,80002
66,,5726,506.0,F,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,,Homo sapiens,9606.0,1A9,,80002
67,,5726,506.0,F,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,,Homo sapiens,9606.0,1A9,,80002
68,,5726,506.0,F,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,,Homo sapiens,9606.0,1A9,,80002
69,,3395,506.0,F,,Inhibitory activity against Taxol resistant 1A9 cell lines,,,Homo sapiens,9606.0,1A9,,80002
70,,3415,506.0,F,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,,Homo sapiens,9606.0,1A9,,80002
71,,3415,506.0,F,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,,Homo sapiens,9606.0,1A9,,80002
72,,17099,506.0,F,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,,Homo sapiens,9606.0,1A9,,80002
73,,17099,506.0,F,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,,Homo sapiens,9606.0,1A9,,80002
74,,17099,506.0,F,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,,Homo sapiens,9606.0,1A9,,80002
75,,17099,506.0,F,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,,Homo sapiens,9606.0,1A9,,80002
76,,17721,503.0,F,,Inhibitory concentration against Jurkat cells,,,Homo sapiens,9606.0,Jurkat,,81072
77,,1229,,F,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,,,,,,22226
78,,11347,,A,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,,Rattus norvegicus,10116.0,,,100121
79,,17117,,B,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,,,,,11231
80,,17117,,B,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,,,,,11231
81,,17117,,B,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,,,,,,11231
82,,11375,,B,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,,Candida albicans,5476.0,,Microsomes,11231
83,,11375,,B,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,,Candida albicans,5476.0,,Microsomes,11231
84,,11375,,B,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,,Saccharomyces cerevisiae,4932.0,,Microsomes,11231
85,,11375,,B,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,,Saccharomyces cerevisiae,4932.0,,Microsomes,11231
86,Liver,11375,,B,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,,Sus scrofa,9823.0,,Microsomes,12083
87,,791,,B,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,,Rattus norvegicus,10116.0,,,11231
88,,791,,B,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,,Rattus norvegicus,10116.0,,,11231
89,,791,,B,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,,Rattus norvegicus,10116.0,,,11231
90,Liver,11375,,B,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,,Rattus norvegicus,10116.0,,Microsomes,12083
91,Liver,11375,,B,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,,Rattus norvegicus,10116.0,,Microsomes,12083
92,Liver,153,,B,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,,Rattus norvegicus,10116.0,,Microsomes,12083
93,,8269,,B,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,,,,,,11377
94,,8269,,B,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,,,,,,11377
95,,17653,726.0,F,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,,Homo sapiens,9606.0,HepG2,,81020
96,,14277,726.0,F,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,,Homo sapiens,9606.0,HepG2,,81020
97,,1717,726.0,F,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,,Homo sapiens,9606.0,HepG2,,81020
98,,14091,726.0,F,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,,Homo sapiens,9606.0,HepG2,,81020
99,,14091,726.0,F,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,,Homo sapiens,9606.0,HepG2,,81020
100,,17653,,F,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,,Hepatitis B virus,10407.0,,,50606
101,,13105,726.0,F,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,,Homo sapiens,9606.0,HepG2,,81020
102,,1717,726.0,F,,Concentration required to inhibit 50% of 2.2.15 cell line,,,Homo sapiens,9606.0,HepG2,,81020
103,,13105,726.0,A,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,,Homo sapiens,9606.0,HepG2,,81020
104,,13600,,F,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,,Homo sapiens,9606.0,2.2.15,,50587
105,,13467,,F,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,,Homo sapiens,9606.0,2.2.15,,50587
106,,17477,,F,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,,Hepatitis B virus,10407.0,2.2.15,,50606
107,,1593,,F,,In vitro anti-HBV activity in 2.2.15 cells,,,Homo sapiens,9606.0,2.2.15,,50587
108,,1593,,F,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,,Homo sapiens,9606.0,2.2.15,,50587
109,,15089,,F,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,,Homo sapiens,9606.0,2.2.15,,50587
110,,15089,,F,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,,Homo sapiens,9606.0,2.2.15,,50587
111,,1593,,F,,Cytotoxicity in 2.2.15 cells,,,Homo sapiens,9606.0,2.2.15,,50587
112,,1593,,F,,Cytotoxicity in 2.2.15 cells; Not determined,,,Homo sapiens,9606.0,2.2.15,,50587
113,,13600,,F,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,,Homo sapiens,9606.0,2.2.15,,50587
114,,13467,,F,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,,Homo sapiens,9606.0,2.2.15,,50587
115,,13467,,F,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,,Homo sapiens,9606.0,2.2.15,,50587
116,,14764,726.0,F,,Antiviral activity against HBV was determined in 2.215 cell line,,,Homo sapiens,9606.0,HepG2,,81020
117,,6531,,B,,Inhibition of 20-HETE synthesis in human renal microsomes,,,Homo sapiens,9606.0,,Microsomes,22226
118,,17322,,B,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,,,,,,22226
119,,17072,388.0,F,,Inhibitory concentration against 2008 (ovarian) cells,,,Homo sapiens,9606.0,2008,,80612
120,,16936,388.0,F,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,,Homo sapiens,9606.0,2008,,80612
121,,16936,388.0,F,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,,Homo sapiens,9606.0,2008,,80612
122,,17146,388.0,F,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,,Homo sapiens,9606.0,2008,,80612
123,,17146,388.0,F,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,,Homo sapiens,9606.0,2008,,80612
124,,10797,561.0,F,,In vitro inhibition of 2008/R ovarian cancer cell line,,,Homo sapiens,9606.0,2008/R,,80613
125,,10797,561.0,F,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,,Homo sapiens,9606.0,2008/R,,80613
126,,10797,389.0,F,,In vitro inhibition of 2008/S ovarian cancer cell line,,,Homo sapiens,9606.0,2008/S,,80614
127,,10797,389.0,F,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,,Homo sapiens,9606.0,2008/S,,80614
128,,4823,,B,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,,Homo sapiens,9606.0,,,100256
129,,12912,,B,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,,Homo sapiens,9606.0,,,100256
130,,2957,,B,,Inhibition of chymotrypsin-like activity of 20S proteasome,,,,,,,100256
131,,2957,,B,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,,,,,,100256
132,,3260,,B,,Inhibitory activity against 20S proteosome,,,,,,,100256
133,,3451,,B,,Compound was tested for inhibitory activity against tryptase,,,Homo sapiens,9606.0,,,22226
134,,13885,726.0,F,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,,Homo sapiens,9606.0,HepG2,,81020
135,,13885,726.0,F,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,,Homo sapiens,9606.0,HepG2,,81020
136,,3676,,B,,Compound was tested for the inhibition of Alpha-glucosidase,,,,,,,22226
137,,6043,,B,,Inhibitory concentration against human neutrophil elastase (HNE),,,,,,,235
138,Heart,11140,,F,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,,Rattus norvegicus,10116.0,,,22226
139,,10543,,F,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,,,,,19640
140,,10543,,F,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,,,,,19640
141,,10543,,B,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,,,,,19640
142,,10543,,F,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,,,,,19640
143,,11365,524.0,F,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,,Mus musculus,10090.0,P338,,80360
144,,11365,524.0,F,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,,Mus musculus,10090.0,P338,,80360
145,,11803,554.0,F,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,,Homo sapiens,9606.0,PBL,,80384
146,,11803,,F,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,,Ovis aries,9940.0,,,22226
147,,11803,,F,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,,Ovis aries,9940.0,,,22226
148,,12278,,B,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,,,,,,191
149,,8249,,F,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,,Homo sapiens,9606.0,,,22226
150,,8249,,F,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,,Homo sapiens,9606.0,,,22226
151,,8249,635.0,F,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,,Homo sapiens,9606.0,CCRF-CEM,,22226
152,,8249,635.0,F,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,,Homo sapiens,9606.0,CCRF-CEM,,22226
153,,8249,635.0,F,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,,Homo sapiens,9606.0,CCRF-CEM,,22226
154,,8249,635.0,F,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,,Homo sapiens,9606.0,CCRF-CEM,,22226
155,,8249,,F,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,,Homo sapiens,9606.0,,,22226
156,,8249,,F,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,,Homo sapiens,9606.0,,,22226
157,,16992,,B,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,,,,,,104290
158,,10543,,F,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,,Streptococcus pyogenes,1314.0,,,50264
159,,17833,,F,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,,Human herpesvirus 3,10335.0,,,50527
160,,17290,468.0,F,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,,vericilla zoster virus,10335.0,HEL,,50527
161,,17290,,F,,Antiviral activity against 07/1 strain of VZV; ND: No data,,,vericilla zoster virus,10335.0,,,50527
162,,17290,,F,,Antiviral activity against 07/1 strain of VZV; ND=No data,,,vericilla zoster virus,10335.0,,,50527
163,,10932,,F,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,,escherichia cloac,561.0,,,50145
164,,9707,,B,,Ratio of Ki at A2 to Ki at A1 receptors,,,,,,,22226
165,,2346,,B,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,,Candida albicans,5476.0,,,11143
166,,2205,,B,,"Inhibition of 1,3-beta-glucan synthase",,,Candida glabrata CBS 138,284593.0,,,18077
167,,11900,832.0,F,,Inhibition of growth of 1-87 human tumor cell line,,,Homo sapiens,9606.0,1-87 tumor cell line,,80609
168,,14864,,B,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,,Rattus norvegicus,10116.0,,,12166
169,,16474,,B,,Inhibitory activity against soybean 1-lipoxygenase (SLO),,,Glycine max,3847.0,,,100171
170,,16474,,B,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,,Glycine max,3847.0,,,100171
171,,16474,,B,,% inhibition against soybean 1-lipoxygenase (SLO),,,Glycine max,3847.0,,,100171
172,,16474,,B,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,,Glycine max,3847.0,,,100171
173,,3094,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,,Glycine max,3847.0,,,100171
174,,3094,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,,Glycine max,3847.0,,,100171
175,,3094,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,,Glycine max,3847.0,,,100171
176,,3094,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,,Glycine max,3847.0,,,100171
177,,3094,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,,Glycine max,3847.0,,,100171
178,,3094,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,,Glycine max,3847.0,,,100171
179,,3094,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,,Glycine max,3847.0,,,100171
180,,3094,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,,Glycine max,3847.0,,,100171
181,,3094,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,,Glycine max,3847.0,,,100171
182,,3094,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,,Glycine max,3847.0,,,100171
183,,3094,,B,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,,Glycine max,3847.0,,,100171
184,,10413,,B,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,,Mus musculus,10090.0,,,22226
185,,16929,294.0,F,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,,Mus musculus,10090.0,C3H 10T1/2,,80049
186,,1229,,F,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,,,,,,22226
187,,16587,,B,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,,,,,11489
188,,16587,,B,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,,,,,11862
189,,16587,,B,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,,,,,,11862
190,,16587,,B,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,,,,,,11489
191,,16587,,B,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,,,,,,11862
192,,8058,,F,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,,Bos taurus,9913.0,,,12347
193,,9065,,B,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,,Rattus norvegicus,10116.0,,,100120
194,Adrenal gland,8865,,B,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,,Rattus norvegicus,10116.0,,,100120
195,,9066,,B,,Inhibition of rat adrenal 11-beta-hydroxylase,,,Rattus norvegicus,10116.0,,,100120
196,,8394,,B,,Inhibition of rat adrenal 11-beta-hydroxylase,,,Rattus norvegicus,10116.0,,,100120
197,,8394,,B,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,,Rattus norvegicus,10116.0,,,100120
198,,6431,,B,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,,,,,,10328
199,,6431,,B,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,,,,,11490
200,,6431,,B,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,,,,,11490
201,,9295,,F,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,,,,,,11134
202,,10193,,B,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,,,,,12052
203,,13622,,B,,Compound was tested in vitro for inhibition of 12-LO human platelet,,,,,,,11134
204,,12079,,F,,Inhibitory concentration against human platelet 12-lipoxygenase,,,,,,,11134
205,,13622,,B,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,,,,,,11134
206,,12079,,F,,Inhibitory concentration against human platelet 12-lipoxygenase,,,Homo sapiens,9606.0,,,11134
207,,13500,,B,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,,,,,,11835
208,,13723,,B,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,,,,,,11601
209,,16474,,B,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,,,,,,11134
210,,1630,,B,,Inhibitory activity against human platelet 12-lipoxygenase,,,,,,,11134
211,,167,,B,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,,,,,,11134
212,,16474,,B,,% inhibition against human platelet 12-lipoxygenase (12-HLO),,,,,,,11134
213,,167,,B,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,,,,,,11134
214,,16474,,B,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,,,,,,11134
215,,10091,,B,,Inhibitory activity towards porcine 12-lipoxygenase,,,,,,,11601
216,,11966,,B,,Tested for inhibition against porcine 12-LO,,,,,,,11601
217,,951,,B,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,,,,,,12052
218,,10997,,B,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,,,,,,12052
219,,10193,,B,,In vitro inhibition of rat platelet 12-lipoxygenase,,,,,,,12052
220,,10193,,B,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,,,,,12052
221,,10193,,B,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,,,,,,12052
222,,10193,,B,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,,,,,,12052
223,,10193,,B,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,,,,,12052
224,,10193,,B,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,,,,,,12052
225,,11087,,B,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,,,,,,12052
226,,15569,621.0,F,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,,Homo sapiens,9606.0,41M,,80007
227,,12989,621.0,F,,In vitro antitumor activity against 41M cell line.,,,Homo sapiens,9606.0,41M,,80007
228,,16745,621.0,F,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,,Homo sapiens,9606.0,41M,,80007
229,,15569,621.0,F,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,,Homo sapiens,9606.0,41M,,80007
230,,12989,621.0,F,,In vitro antitumor activity against 41McisR cell line.,,,Homo sapiens,9606.0,41M,,80007
231,,12989,621.0,F,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,,Homo sapiens,9606.0,41M,,80007
232,,16745,621.0,F,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,,Homo sapiens,9606.0,41M,,80007
233,,6210,,B,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,,Homo sapiens,9606.0,,,84
234,,6210,,B,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,Homo sapiens,9606.0,,,68
235,,6226,,B,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,,,,,68
236,,17855,,B,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,,,,,10201
237,,17855,,B,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,,,,,,10201
238,,17855,,B,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,,,,,10201
239,,10413,,B,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,,,,,12220
240,,10413,,B,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,,Escherichia coli,562.0,,,11303
241,,10413,,B,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,,Escherichia coli,562.0,,,11303
242,,10413,,B,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,,Escherichia coli,562.0,,,11303
243,,10413,,B,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,,,,,12220
244,,10413,,B,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,,,,,,12220
245,,7587,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,Sus scrofa,9823.0,,,11303
246,,7587,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,,Sus scrofa,9823.0,,,11303
247,,7587,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,,Sus scrofa,9823.0,,,11303
248,,7587,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,,Sus scrofa,9823.0,,,11303
249,,7587,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,Sus scrofa,9823.0,,,11303
250,,7587,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,,Sus scrofa,9823.0,,,11303
251,,7587,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,,Sus scrofa,9823.0,,,11303
252,,7587,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,,Sus scrofa,9823.0,,,11303
253,,7587,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,,Sus scrofa,9823.0,,,11303
254,,7587,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,,Sus scrofa,9823.0,,,11303
255,,7587,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,Sus scrofa,9823.0,,,11303
256,,7587,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,,Sus scrofa,9823.0,,,11303
257,,7323,,B,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,,,,,,11303
258,,7587,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,,Sus scrofa,9823.0,,,22226
259,,7587,,B,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,,Sus scrofa,9823.0,,,22226
260,,13750,,B,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,,Saccharomyces cerevisiae,4932.0,,,100249
261,,7662,,B,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,,Rattus norvegicus,10116.0,,,22226
262,,7662,,B,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,,Rattus norvegicus,10116.0,,,22226
263,,7662,,B,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,,Rattus norvegicus,10116.0,,,22226
264,,12211,,F,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,,,,,104698
265,,12211,,F,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,,,,,104698
266,Ileum,12211,,F,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,,Cavia porcellus,10141.0,,,20033
267,,12211,,F,,Stimulatory activity of intragastric pressure was tested in the rat,,,,,,,10623
268,,15453,,B,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,,,,,,121
269,,11884,,F,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,,Rattus norvegicus,10116.0,,,22226
270,,7185,,F,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,,,,,12688
271,,6876,,B,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,,Homo sapiens,9606.0,,,121
272,,6876,,B,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,,Homo sapiens,9606.0,,,121
273,,11863,,F,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,,,,,,12198
274,,11863,,B,,Inhibition constant of high-affinity 5-HT uptake,,,,,,,12198
275,,11863,,F,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,,,,,,12198
276,,11863,,F,,Maximum rate was determined for high affinity transport of 5-HT,,,,,,,12198
277,,4639,,F,,Compound was tested for agonistic activity against 5-HT uptake,,,,,,,104714
278,,15796,,B,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,,,,,,10577
279,,15796,,B,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,,Bos taurus,9913.0,,,105
280,,12801,,B,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,Rattus norvegicus,10116.0,,,104744
281,,12801,,B,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,,,,,,104744
282,,12120,,B,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,,,,,Membranes,104744
283,,12120,,B,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,,,,,Membranes,104744
284,,11963,,B,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,,,,104744
285,,11701,,F,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,,,,,,51
286,Hippocampus,9995,,B,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,,,,51
287,Hippocampus,9995,,B,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,,,,51
288,Hippocampus,9995,,B,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,,,,51
289,,16394,,F,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),In vivo,,,,,,10576
290,,11574,,F,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,,Cavia porcellus,10141.0,,,105570
291,,15779,449.0,B,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,,CHO,,279
292,,15363,,B,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,,,,,,107
293,,15363,,F,,Efficacy against 5-hydroxytryptamine 2A receptor,,,Rattus norvegicus,10116.0,,,12687
294,,15329,,F,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,,,,,,12687
295,,15329,,F,,Relative potency towards 5-HT2A receptor of rat tail artery,,,,,,,12687
296,,15329,,F,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,,,,,12687
297,,15329,,F,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,,,,,,12687
298,,15329,,F,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,,,,,,12687
299,,15329,,F,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,,,,,12687
300,Ileum,273,,F,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,,Cavia porcellus,10141.0,,,20033
301,Ileum,273,,F,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,,Cavia porcellus,10141.0,,,20033
302,Ileum,273,,F,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,,Cavia porcellus,10141.0,,,20033
303,,12092,,B,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,,,,,,10623
304,,1317,,F,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,Rattus norvegicus,10116.0,,,10623
305,,12409,,B,,Binding affinity against 5-hydroxytryptamine 4 receptor,,,,,,,168
306,,11126,,B,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,,Gallus gallus,9031.0,,,22226
307,,11126,,F,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,,Homo sapiens,9606.0,,,22226
308,,11126,,F,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,,Homo sapiens,9606.0,,,22226
309,,11126,649.0,B,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,,Homo sapiens,9606.0,HL-60,,80156
310,,11126,,B,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,,Homo sapiens,9606.0,,,22226
311,,11126,,B,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,,Homo sapiens,9606.0,,,22226
312,,17807,,B,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,,Homo sapiens,9606.0,Oocytes,,104703
313,,16575,,F,,Chymotryptic inhibitory activity against 26S proteasome,,,,,,,100256
314,,15407,,B,,Inhibitory activity against 26S proteasome degradation of IkB,,,,,,,100256
315,,10797,478.0,F,,In vitro inhibition of 2780/DOX ovarian cancer cell line,,,Homo sapiens,9606.0,A2780,,81034
316,,10797,478.0,F,,In vitro inhibition of 2780/S ovarian cancer cell line,,,Homo sapiens,9606.0,A2780,,81034
317,,3469,,F,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,,Homo sapiens,9606.0,,,22226
318,,16037,,B,,Association constant for binding to AATT 28-mer AATT hairpin,,,,,,,22222
319,,16037,,B,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,,,,,,22222
320,,16037,,B,,Reaction Rate Parameter for 28-mer AATT hairpin,,,,,,,22222
321,,16037,,B,,Reaction Rate Parameter for 28-mer AATT hairpin,,,,,,,22222
322,,16524,,F,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,,Homo sapiens,9606.0,,,22226
323,,16524,,F,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,,Homo sapiens,9606.0,,,22226
324,,16524,,F,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,,Homo sapiens,9606.0,,,22226
325,,16758,,F,,Cytotoxicity against cell line 2SC/20 determined by MTT test,,,Cricetulus griseus,10029.0,,,22226
326,,16758,,F,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,,Cricetulus griseus,10029.0,,,22226
327,,16758,,F,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,,Cricetulus griseus,10029.0,,,22226
328,,14360,,B,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,,,,,,241
329,,14360,,B,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,,Homo sapiens,9606.0,,,241
330,,9964,,B,,Selectivity ratio of ID50 in liver and heart,,,Rattus norvegicus,10116.0,,,22226
331,,9964,,B,,"Selectivity, ratio of relative ID50 in liver and heart",,,,,,,12132
332,,9964,,B,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,,,,,,12132
333,,9964,,B,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,,,,12132
334,,9964,,B,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,,,,12132
335,,9964,,B,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",In vivo,,,,,,12132
336,,9964,,F,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",In vivo,,,,,,12132
337,,9964,,B,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,,,,,,22226
338,,9964,,B,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,,,,,,12132
339,,9964,,B,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,,Homo sapiens,9606.0,,,22226
340,,9964,,B,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,,,,,12132
341,,9964,,F,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,,,,,12132
342,,9964,,B,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,,,,,,12132
343,,9964,,B,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,,Rattus norvegicus,10116.0,,,22226
344,,9964,,B,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,In vivo,,,,,,12132
345,,9964,,B,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,,,,12132
346,,9964,,B,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,,Rattus norvegicus,10116.0,,,22226
347,,9964,,B,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,,,,,12132
348,,9964,,F,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,,,,,12132
349,,3796,,B,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,,Rattus norvegicus,10116.0,,,22226
350,,4251,,B,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,,Escherichia coli,562.0,,,19690
351,,4251,,B,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,,Escherichia coli,562.0,,,19690
352,,4251,,B,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,,Escherichia coli,562.0,,,19690
353,,4251,,B,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,,Escherichia coli,562.0,,,19690
354,,166,,B,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,,,,,,19690
355,,17861,,B,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,,,,,,19690
356,,166,,B,,Inhibition constant against 3-dehydroquinate synthase,,,,,,,19690
357,,166,,B,,Association rate constant against 3-dehydroquinate synthase,,,,,,,19690
358,,166,,B,,Rate constant against 3-dehydroquinate synthase,,,,,,,19690
359,,3548,,B,,Inhibitory activity against fuc-TVII,,,,,,,22226
360,Liver,9877,,B,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,Rattus norvegicus,10116.0,,Microsomes,12236
361,Liver,9877,,B,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,Rattus norvegicus,10116.0,,Microsomes,12236
362,Liver,9877,,B,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,Rattus norvegicus,10116.0,,Microsomes,12236
363,Liver,9877,,B,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,Rattus norvegicus,10116.0,,Microsomes,12236
364,Liver,9877,,B,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,Rattus norvegicus,10116.0,,Microsomes,12236
365,Liver,9877,,B,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,,Rattus norvegicus,10116.0,,Microsomes,12236
366,Liver,9877,,B,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,,Rattus norvegicus,10116.0,,Microsomes,12236
367,Liver,9877,,B,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,,Rattus norvegicus,10116.0,,Microsomes,12236
368,Liver,9877,,B,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,,Rattus norvegicus,10116.0,,Microsomes,12236
369,Liver,9877,,B,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,,Rattus norvegicus,10116.0,,Microsomes,12236
370,Liver,9877,,B,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,,Rattus norvegicus,10116.0,,Microsomes,12236
371,,3003,,B,,Inhibitory activity against 3-phosphoglycerate kinase.,,,,,,,104832
372,,3003,,B,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,,,,,,104832
373,,3003,,B,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,,,,,,104832
374,,17185,,B,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,,Homo sapiens,9606.0,,,10612
375,,6072,844.0,F,,Cytotoxicity on 3677 melanoma cells,,,Homo sapiens,9606.0,3677 melanoma cell line,,80616
376,,6072,844.0,F,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,,Homo sapiens,9606.0,3677 melanoma cell line,,80616
377,,5018,700.0,F,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,,Mus musculus,10090.0,MC-38,,80617
378,,2852,,F,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,,Homo sapiens,9606.0,,,22226
379,,8663,798.0,F,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,,,,B16,,22226
380,,8663,798.0,F,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,,,,B16,,22226
381,,3245,,F,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,,Human rhinovirus 14,12131.0,,,12464
382,,3245,,F,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,,Human rhinovirus sp.,169066.0,,,50085
383,,3877,,F,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,,human rhinovirus type 14,169066.0,,,50679
384,,3877,,F,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,,human rhinovirus type 14,169066.0,,,50679
385,,5861,,F,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,Human rhinovirus 14,12131.0,,,12464
386,,5861,,F,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,Human rhinovirus 14,12131.0,,,12464
387,,5861,,F,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,Human rhinovirus 14,12131.0,,,12464
388,,5861,,F,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,,Human rhinovirus 14,12131.0,,,12464
389,,13748,,F,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,,Enterovirus,12059.0,,,50665
390,,13748,,F,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,,Enterovirus,12059.0,,,50665
391,,13748,,F,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,,Enterovirus,12059.0,,,50665
392,,13748,,F,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,,Enterovirus,12059.0,,,50665
393,,13748,,B,,Inhibition of human rhinovirus 3C protease,,,Human rhinovirus B,147712.0,,,12464
394,,17699,,B,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,,Homo sapiens,9606.0,,,22226
395,,7145,833.0,F,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,,Mus musculus,10090.0,3EM 37,,80619
396,,7145,833.0,F,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,,Mus musculus,10090.0,3EM 37,,80619
397,,7145,833.0,F,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,,Mus musculus,10090.0,3EM 37,,80619
398,,7145,833.0,F,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,,Mus musculus,10090.0,3EM 37,,80619
399,,7145,833.0,F,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,,Mus musculus,10090.0,3EM 37,,80619
400,,7145,833.0,F,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,,Mus musculus,10090.0,3EM 37,,80619
401,,5325,847.0,F,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,,Mus musculus,10090.0,3LL cell line,,80620
402,,5325,847.0,F,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,,Mus musculus,10090.0,3LL cell line,,80620
403,,5325,847.0,F,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,,Mus musculus,10090.0,3LL cell line,,80620
404,,16169,847.0,F,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,,Mus musculus,10090.0,3LL cell line,,80620
405,,16169,847.0,F,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,,Mus musculus,10090.0,3LL cell line,,80620
406,,16169,847.0,F,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,,Mus musculus,10090.0,3LL cell line,,80620
407,,16169,847.0,F,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,,Mus musculus,10090.0,3LL cell line,,80620
408,,16169,847.0,F,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,,Mus musculus,10090.0,3LL cell line,,80620
409,,16169,847.0,F,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,,Mus musculus,10090.0,3LL cell line,,80620
410,,16169,847.0,F,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,,Mus musculus,10090.0,3LL cell line,,80620
411,,16169,847.0,F,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,,Mus musculus,10090.0,3LL cell line,,80620
412,,16169,847.0,F,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,,Mus musculus,10090.0,3LL cell line,,80620
413,,16169,847.0,F,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,,Mus musculus,10090.0,3LL cell line,,80620
414,,16169,847.0,F,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,,Mus musculus,10090.0,3LL cell line,,80620
415,,16169,847.0,F,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,,Mus musculus,10090.0,3LL cell line,,80620
416,,16169,847.0,F,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,,Mus musculus,10090.0,3LL cell line,,80620
417,,16169,847.0,F,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,,Mus musculus,10090.0,3LL cell line,,80620
418,,16169,847.0,F,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,,Mus musculus,10090.0,3LL cell line,,80620
419,,16169,847.0,F,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,,Mus musculus,10090.0,3LL cell line,,80620
420,,16169,847.0,F,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,,Mus musculus,10090.0,3LL cell line,,80620
421,,16169,847.0,F,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,,Mus musculus,10090.0,3LL cell line,,80620
422,,16169,847.0,F,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,,Mus musculus,10090.0,3LL cell line,,80620
423,,16169,847.0,F,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,,Mus musculus,10090.0,3LL cell line,,80620
424,,16169,847.0,F,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,,Mus musculus,10090.0,3LL cell line,,80620
425,,16169,847.0,F,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,,Mus musculus,10090.0,3LL cell line,,80620
426,,16169,847.0,F,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,,Mus musculus,10090.0,3LL cell line,,80620
427,,16169,847.0,F,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,,Mus musculus,10090.0,3LL cell line,,80620
428,,16169,847.0,F,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,,Mus musculus,10090.0,3LL cell line,,80620
429,,16169,847.0,F,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,,Mus musculus,10090.0,3LL cell line,,80620
430,,15547,971.0,F,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,,Homo sapiens,9606.0,3LLD122,,80621
431,,8663,,F,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,,,,,,22226
432,,8663,,F,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,,,,,,22226
433,,8663,,F,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,,,,,,22226
434,,8663,,F,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,,,,,,22226
435,,4504,723.0,F,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,,Mus musculus,10090.0,NIH3T3,,80951
436,,4504,723.0,F,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,,Mus musculus,10090.0,NIH3T3,,80951
437,,12695,723.0,F,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,,,,NIH3T3,,11169
438,,12695,723.0,F,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,,Mus musculus,10090.0,NIH3T3,,80951
439,,12695,723.0,F,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,,Mus musculus,10090.0,NIH3T3,,80951
440,,17642,723.0,F,,Effective dose against murine 3T3 fibroblasts cells,,,Mus musculus,10090.0,NIH3T3,,80951
441,,17642,723.0,F,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,,Mus musculus,10090.0,NIH3T3,,80951
442,,12340,723.0,F,,Cytotoxic effect on 3T3 cells,,,Mus musculus,10090.0,NIH3T3,,80951
443,,12340,723.0,F,,Cytotoxic effect on 3T3 cells,,,Mus musculus,10090.0,NIH3T3,,80951
444,,12716,723.0,F,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,,Mus musculus,10090.0,NIH3T3,,80951
445,,6277,723.0,F,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,,Mus musculus,10090.0,NIH3T3,,80951
446,,6277,723.0,F,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,,Mus musculus,10090.0,NIH3T3,,80951
447,,6277,723.0,F,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,,Mus musculus,10090.0,NIH3T3,,80951
448,,6277,723.0,F,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,,Mus musculus,10090.0,NIH3T3,,80951
449,,6277,723.0,F,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,,Mus musculus,10090.0,NIH3T3,,80951
450,,6277,723.0,F,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,,Mus musculus,10090.0,NIH3T3,,80951
451,,6277,723.0,F,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,,Mus musculus,10090.0,NIH3T3,,80951
452,,6277,723.0,F,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,,Mus musculus,10090.0,NIH3T3,,80951
453,,17780,723.0,F,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,,Mus musculus,10090.0,NIH3T3,,80951
454,,12751,,F,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,,Mus musculus,10090.0,,,104860
455,,12380,723.0,F,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,,Mus musculus,10090.0,NIH3T3,,80951
456,,14892,723.0,F,,Inhibitory activity against 3T3 cell line,,,Mus musculus,10090.0,NIH3T3,,80951
457,,12695,723.0,F,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,,Mus musculus,10090.0,NIH3T3,,80951
458,,12695,,F,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,,,,,,11169
459,,12695,723.0,F,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,,Mus musculus,10090.0,NIH3T3,,80951
460,,12695,723.0,F,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,,Mus musculus,10090.0,NIH3T3,,80951
461,,12695,,F,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,,,,,,11169
462,,12695,,F,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,,,,,,11169
463,,6277,723.0,F,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,,Mus musculus,10090.0,NIH3T3,,80951
464,,6277,723.0,F,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,,Mus musculus,10090.0,NIH3T3,,80951
465,,4959,723.0,F,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,,Homo sapiens,9606.0,NIH3T3,,9
466,,4959,723.0,F,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,,Homo sapiens,9606.0,NIH3T3,,9
467,,4959,723.0,F,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,,Homo sapiens,9606.0,NIH3T3,,188
468,,4959,723.0,F,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,,Homo sapiens,9606.0,NIH3T3,,188
469,,12082,723.0,F,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,,Mus musculus,10090.0,NIH3T3,,80951
470,,12082,723.0,F,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,,Mus musculus,10090.0,NIH3T3,,80951
471,,12082,723.0,F,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,,Mus musculus,10090.0,NIH3T3,,80951
472,,12082,723.0,F,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,,Mus musculus,10090.0,NIH3T3,,80951
473,,2643,723.0,F,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,,Mus musculus,10090.0,NIH3T3,,80951
474,,11926,723.0,F,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,,Mus musculus,10090.0,NIH3T3,,80951
475,,15204,723.0,A,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,,Mus musculus,10090.0,NIH3T3,,80951
476,,15992,723.0,F,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,,Mus musculus,10090.0,NIH3T3,,80951
477,,16279,723.0,F,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,,Mus musculus,10090.0,NIH3T3,,80951
478,,16279,723.0,F,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,Mus musculus,10090.0,NIH3T3,,80951
479,,16279,723.0,F,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,Mus musculus,10090.0,NIH3T3,,80951
480,,16279,723.0,F,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,Mus musculus,10090.0,NIH3T3,,80951
481,,16279,723.0,F,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,Mus musculus,10090.0,NIH3T3,,80951
482,,16279,723.0,F,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,Mus musculus,10090.0,NIH3T3,,80951
483,,12831,723.0,F,,Inhibition of swiss 3T3 mouse fibroblast proliferation,,,Mus musculus,10090.0,NIH3T3,,80951
484,,13497,723.0,F,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,,Mus musculus,10090.0,NIH3T3,,80951
485,,13715,620.0,F,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,,,3T3-L1,,80006
486,,13618,620.0,F,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,,Mus musculus,10090.0,3T3-L1,,80006
487,,11902,620.0,F,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,,Mus musculus,10090.0,3T3-L1,,80006
488,,11902,620.0,F,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,,Mus musculus,10090.0,3T3-L1,,80006
489,,11902,620.0,F,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,,Mus musculus,10090.0,3T3-L1,,80006
490,,14840,620.0,F,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,,Mus musculus,10090.0,3T3-L1,,80006
491,,14840,620.0,F,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,,Mus musculus,10090.0,3T3-L1,,80006
492,,13715,620.0,F,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,,,,3T3-L1,,80006
493,,13715,620.0,F,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,,,,3T3-L1,,80006
494,,13715,620.0,F,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,,,3T3-L1,,80006
495,,13715,620.0,F,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,,,,3T3-L1,,80006
496,,13715,620.0,F,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,,,3T3-L1,,80006
497,,13715,620.0,F,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,,,,3T3-L1,,80006
498,,13715,620.0,F,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,,,,3T3-L1,,80006
499,,13715,620.0,F,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,,,,3T3-L1,,80006
500,,13715,620.0,F,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,,,3T3-L1,,80006
501,,13715,620.0,F,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,,,,3T3-L1,,80006
502,,13715,620.0,F,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,,,3T3-L1,,80006
503,,13715,620.0,F,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,,,,3T3-L1,,80006
504,,13715,620.0,F,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,,,3T3-L1,,80006
505,,13715,620.0,F,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,,,,3T3-L1,,80006
506,,13715,620.0,F,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,,,3T3-L1,,80006
507,,13715,620.0,F,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,,,3T3-L1,,80006
508,,13715,620.0,F,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,,,,3T3-L1,,80006
509,,13715,620.0,F,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,,,,3T3-L1,,80006
510,,13715,620.0,F,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,,,3T3-L1,,80006
511,,13715,620.0,F,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,,,,3T3-L1,,80006
512,,13715,620.0,F,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,,,,3T3-L1,,80006
513,,13715,620.0,F,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,,,3T3-L1,,80006
514,,13715,620.0,F,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,,,3T3-L1,,80006
515,,13715,620.0,F,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,,,3T3-L1,,80006
516,,13715,620.0,F,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,,,,3T3-L1,,80006
517,,6411,620.0,F,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,,,,3T3-L1,,11214
518,,6411,620.0,F,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,,Mus musculus,10090.0,3T3-L1,,80006
519,,6411,620.0,F,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,,,,3T3-L1,,11214
520,,3966,620.0,F,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,,Mus musculus,10090.0,3T3-L1,,80006
521,,3966,620.0,F,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,,Mus musculus,10090.0,3T3-L1,,80006
522,,15556,620.0,F,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,,Mus musculus,10090.0,3T3-L1,,80006
523,,5845,620.0,F,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,,Mus musculus,10090.0,3T3-L1,,80006
524,,14422,620.0,F,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,,Mus musculus,10090.0,3T3-L1,,80006
525,,5845,620.0,F,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,,Mus musculus,10090.0,3T3-L1,,80006
526,,14508,620.0,F,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,,Mus musculus,10090.0,3T3-L1,,80006
527,,14508,620.0,F,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,,Mus musculus,10090.0,3T3-L1,,80006
528,,14508,620.0,F,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,,Mus musculus,10090.0,3T3-L1,,80006
529,,6349,1118.0,F,,Inhibitory activity against rat fibroblast (3Y1) cell line,,,Rattus norvegicus,10116.0,3Y1 cell line,,80622
530,,15899,1118.0,F,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,,Rattus norvegicus,10116.0,3Y1 cell line,,80622
531,,15899,1118.0,F,,Cytotoxicity in 3Y1 cells.,,,Rattus norvegicus,10116.0,3Y1 cell line,,80622
532,,15899,1118.0,F,,Cytostatic effect in 3Y1 cells.,,,Rattus norvegicus,10116.0,3Y1 cell line,,80622
533,,15899,1118.0,F,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,,Rattus norvegicus,10116.0,3Y1 cell line,,80622
534,,17038,1118.0,F,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,,Rattus norvegicus,10116.0,3Y1 cell line,,80622
535,,12421,,B,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,,,,,,22226
536,,12947,,B,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,,,,,22226
537,,12947,,B,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,,,,,22226
538,,4896,,B,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,,Sus scrofa,9823.0,,,11607
539,,6148,,B,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,,,,,,11607
540,,16432,,B,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,,,,,,11607
541,,4978,,B,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,,,,,,11607
542,,4978,,B,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,,,,,,11607
543,,3723,,B,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,,,,,,11607
544,,3518,,B,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,,,,,,11607
545,,4164,,B,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,,,,,,11607
546,,3518,,B,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,,,,,,11607
547,,4164,,B,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,,Sus scrofa,9823.0,,,11607
548,,3518,,B,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,,,,,,11607
549,,3518,,B,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,,,,,,11607
550,,4978,,B,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,,,,,,11607
551,,4978,,B,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,,,,,,11607
552,,6455,,B,,Binding affinity against melatonin (MT1) receptor (pC1),,,,,,,104733
553,,2222,,B,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,,,,,,22226
554,,13020,,B,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,,,,,,22226
555,,13021,,B,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,,,,,,22226
556,,14532,,B,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,,,,,,10619
557,,14118,,B,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,,,,,10619
558,Hippocampus,11884,,B,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,,,,,,51
559,,13969,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,,,,,,51
560,,13392,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor,,,,,,,51
561,,14430,,B,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,,,,,,51
562,Hippocampus,12248,,B,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,,,,51
563,Hippocampus,12249,,B,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,,,,51
564,Hippocampus,9995,,B,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,,,,51
565,Hippocampus,9995,,B,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,,,,51
566,Hippocampus,9995,,B,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,,,,51
567,Hippocampus,9995,,B,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,,,,51
568,Hippocampus,9995,,B,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,,,,51
569,Hippocampus,12249,,B,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,,,,51
570,Hippocampus,11799,,B,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,,,,,51
571,,14331,,B,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,,Rattus norvegicus,10116.0,,Membranes,10576
572,Hippocampus,11884,,B,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,,Bos taurus,9913.0,,,51
573,Hippocampus,14331,,B,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,,,,,,51
574,Hippocampus,11701,,B,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,,,,,,51
575,Hippocampus,11701,,B,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,,,,,,51
576,Hippocampus,12248,,B,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,,,,,,51
577,,12248,449.0,B,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,,,,CHO,,51
578,Hippocampus,12248,,B,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,,,,51
579,Hippocampus,12249,,B,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,,,,51
580,,12248,449.0,B,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,,CHO,,51
581,Hippocampus,11799,,B,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,,,,,51
582,,634,,B,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,,,,,51
583,Hippocampus,9995,,B,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,,,,51
584,Hippocampus,9995,,B,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,,,,51
585,Hippocampus,9995,,B,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,,,,51
586,Hippocampus,9995,,B,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,,,,51
587,Hippocampus,9995,,B,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,,,,51
588,Hippocampus,12210,,B,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,,,,,,51
589,Hippocampus,13311,,B,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,,,,51
590,,2331,449.0,B,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,,Homo sapiens,9606.0,CHO,,51
591,,1375,,F,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,,Cavia porcellus,10141.0,,,51
592,,1375,,F,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,,Cavia porcellus,10141.0,,,51
593,Hippocampus,11574,,F,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,,Cavia porcellus,10141.0,,,51
594,Ileum,12867,,B,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,,Cavia porcellus,10141.0,,,51
595,Ileum,12867,,B,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,Cavia porcellus,10141.0,,,51
596,Ileum,12867,,B,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,,Cavia porcellus,10141.0,,,51
597,Ileum,12867,,B,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,Cavia porcellus,10141.0,,,51
598,Ileum,12867,,B,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,Cavia porcellus,10141.0,,,51
599,Ileum,12867,,B,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,,Cavia porcellus,10141.0,,,51
600,,11574,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,Cavia porcellus,10141.0,,,51
601,,13114,,B,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,,Cavia porcellus,10141.0,,,51
602,,13181,,B,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,,Cavia porcellus,10141.0,,,51
603,Hippocampus,10639,,B,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,,Cavia porcellus,10141.0,,,106
604,Hippocampus,10639,,F,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,,Cavia porcellus,10141.0,,,106
605,,11883,449.0,B,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,,Cricetulus griseus,10029.0,CHO,,11863
606,,17785,,B,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,,,,,,51
607,,1558,308.0,F,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,,,,HeLa,,51
608,,1558,308.0,F,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,,,,HeLa,,51
609,,15740,,F,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,,,,,51
610,,17624,449.0,F,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,,,,CHO,,51
611,,17624,449.0,F,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,,,,CHO,,51
612,,17624,449.0,F,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,,,,CHO,,51
613,,17624,449.0,F,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,,,,CHO,,51
614,,17624,449.0,B,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,,CHO,,51
615,,17624,449.0,B,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,,CHO,,51
616,,17624,449.0,B,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,,,,CHO,,51
617,,14256,,F,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,,,,,,51
618,,3445,308.0,B,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,,Homo sapiens,9606.0,HeLa,,51
619,,3445,308.0,B,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,,Homo sapiens,9606.0,HeLa,,51
620,,17200,449.0,B,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,,Homo sapiens,9606.0,CHO,,51
621,,17200,449.0,B,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,,Homo sapiens,9606.0,CHO,,51
622,,15180,,F,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,,,,,51
623,,15180,,F,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,,,,,51
624,,16026,,F,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,,,,,51
625,,2759,449.0,F,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,,,CHO,,51
626,,2759,449.0,F,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,,Homo sapiens,9606.0,CHO,,51
627,,2759,449.0,F,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,,,,CHO,,51
628,,2759,449.0,F,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,,Homo sapiens,9606.0,CHO,,51
629,,2759,449.0,F,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,,,CHO,,51
630,,2759,449.0,F,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,,,,CHO,,51
631,,2759,449.0,F,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,,Homo sapiens,9606.0,CHO,,51
632,,2759,449.0,F,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,,,,CHO,,51
633,,2759,449.0,F,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,,Homo sapiens,9606.0,CHO,,51
634,,3445,,F,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,,Homo sapiens,9606.0,,,51
635,,5272,,F,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,Homo sapiens,9606.0,,,51
636,,5272,,F,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,,Homo sapiens,9606.0,,,51
637,,5272,,F,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,,Homo sapiens,9606.0,,,51
638,,17624,449.0,F,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,,,CHO,,51
639,,17624,449.0,F,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,,,CHO,,51
640,,17624,449.0,F,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,,,,CHO,,51
641,,17624,449.0,F,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,,,CHO,,51
642,,17624,449.0,F,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,,,,CHO,,51
643,,17624,449.0,F,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,,,,CHO,,51
644,,17624,449.0,F,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,,,CHO,,51
645,,17624,449.0,F,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,,,,CHO,,51
646,,17624,449.0,F,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,,,CHO,,51
647,,17624,449.0,F,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,,,,CHO,,51
648,,17624,449.0,F,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,,,CHO,,51
649,,17624,449.0,F,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,,,,CHO,,51
650,,6563,,F,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,,,51
651,,6563,,F,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,,,51
652,,6563,,F,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,,,,,51
653,,17296,722.0,F,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,,HEK293,,51
654,,6876,,F,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,,Homo sapiens,9606.0,,,51
655,,6876,,F,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,,,,,,51
656,,5272,,F,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,,Homo sapiens,9606.0,,,51
657,,5272,,F,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,,Homo sapiens,9606.0,,,51
658,,5548,,F,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,,,,,51
659,,5548,,F,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,,,,,,51
660,,5548,,F,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,,,,,51
661,,5548,,F,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,,,,,51
662,,5929,,F,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,,,,,,51
663,,5929,,F,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,,Homo sapiens,9606.0,,,51
664,,5929,,F,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,,Homo sapiens,9606.0,,,51
665,,16245,,F,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,,,,,,51
666,,5640,,F,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,,,,,51
667,,5640,,F,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,,,,,,51
668,,14509,449.0,F,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,,,,CHO,,51
669,,14509,449.0,F,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,,,,CHO,,51
670,,15331,,B,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,,,,,51
671,,15331,,B,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,,,,,51
672,,6563,,F,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,,,51
673,,6563,,F,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,,,,,,51
674,,6563,,F,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,,,,,51
675,,6563,,F,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,,Homo sapiens,9606.0,,,51
676,,6563,,F,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,,,51
677,,5272,,F,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,,Homo sapiens,9606.0,,,51
678,,5272,,F,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,Homo sapiens,9606.0,,,51
679,,5272,,F,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,,Homo sapiens,9606.0,,,51
680,,5272,,F,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,,Homo sapiens,9606.0,,,51
681,,5272,,F,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,,Homo sapiens,9606.0,,,51
682,,5272,,F,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,Homo sapiens,9606.0,,,51
683,,5272,,F,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,,Homo sapiens,9606.0,,,51
684,,5272,,F,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,,Homo sapiens,9606.0,,,51
685,,16146,,B,,Inhibition of human 5-hydroxytryptamine 1A receptor,,,Homo sapiens,9606.0,,,51
686,,17624,449.0,B,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,,CHO,,51
687,,13706,722.0,B,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,,,,HEK293,,105
688,,15250,449.0,B,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,,,,CHO,,51
689,,17624,449.0,F,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,,,CHO,,51
690,,6861,,B,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,,,,,,51
691,,17200,,B,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,Homo sapiens,9606.0,,,51
692,,17624,449.0,B,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,,,,CHO,,51
693,,17624,449.0,B,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,,CHO,,51
694,,12058,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,In vivo,,Rattus norvegicus,10116.0,,,22226
695,,12058,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,In vivo,,Rattus norvegicus,10116.0,,,22226
696,,12058,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,In vivo,,Rattus norvegicus,10116.0,,,22226
697,,12058,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,In vivo,,Rattus norvegicus,10116.0,,,22226
698,,12058,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,In vivo,,Rattus norvegicus,10116.0,,,22226
699,,12058,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,In vivo,,Rattus norvegicus,10116.0,,,22226
700,,12058,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,In vivo,,Rattus norvegicus,10116.0,,,22226
701,,12058,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,In vivo,,Rattus norvegicus,10116.0,,,22226
702,,12058,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,In vivo,,Rattus norvegicus,10116.0,,,22226
703,,12058,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,In vivo,,Rattus norvegicus,10116.0,,,22226
704,,12058,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,In vivo,,Rattus norvegicus,10116.0,,,22226
705,,12058,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,In vivo,,Rattus norvegicus,10116.0,,,22226
706,,12058,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,In vivo,,Rattus norvegicus,10116.0,,,22226
707,,12058,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,In vivo,,Rattus norvegicus,10116.0,,,22226
708,,12058,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,In vivo,,Rattus norvegicus,10116.0,,,22226
709,,12058,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,In vivo,,Rattus norvegicus,10116.0,,,22226
710,,12058,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,In vivo,,Rattus norvegicus,10116.0,,,22226
711,,12058,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,In vivo,,Rattus norvegicus,10116.0,,,22226
712,,12058,,F,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,In vivo,,Rattus norvegicus,10116.0,,,22226
713,,11440,,B,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,,,,,,105093
714,Hypothalamus,6238,,B,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,,,,,,11923
715,,10046,,B,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,,,,,,10577
716,,10046,,B,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,,,,,,10577
717,,10046,,B,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,,,,,10577
718,,167,,B,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,,,,,,55
719,,167,,B,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,,,,,,55
720,,11520,,F,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,,,,,,12166
721,,11520,,F,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,,,,,12166
722,,11520,,F,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,,,,,12166
723,,11520,,F,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,,,,,12166
724,,135,,F,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,,Cavia porcellus,10141.0,,,55
725,,135,,F,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,,Cavia porcellus,10141.0,,,55
726,,11311,,B,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,,Cavia porcellus,10141.0,,,55
727,,10193,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,,Cavia porcellus,10141.0,,,55
728,,12281,,B,,Inhibitory concentration against 5-lipoxygenase from human whole blood,,,Homo sapiens,9606.0,,,55
729,,11311,,B,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,,,,,55
730,,12576,,F,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,,,,,17087
731,,12281,,B,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,,,,,,17087
732,,12576,,F,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,,,,,17087
733,,11089,,B,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,,Sus scrofa,9823.0,,,55
734,,11006,,B,,In vitro inhibition of rat 5-Lipoxygenase,,,,,,,12166
735,,11481,,B,,Inhibitory activity against 5-Lipoxygenase,,,Rattus norvegicus,10116.0,,,12166
736,,10864,702.0,B,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,,,,RBL-1,,12166
737,,3595,702.0,B,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,,,RBL-1,,12166
738,,11311,702.0,B,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,,,,RBL-1,,12166
739,,11311,,B,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,,,,,,12166
740,,11311,,B,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,,,,,,12166
741,,11006,,B,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,,,,,12166
742,,3595,702.0,B,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,,,,RBL-1,,12166
743,,11311,,B,,The compound was tested for inhibition of isolated 5-Lipoxygenase,,,,,,,12166
744,,11481,,B,,Ratio of IC50 against 5-LO and COX,,,Rattus norvegicus,10116.0,,,22226
745,,11006,,B,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,,,,,12166
746,,11006,,B,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,,,,,,12166
747,,11311,,B,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,,,,,,12166
748,,11006,,F,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,,,,,,12166
749,Prostate gland,4288,,B,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,,,,,,120
750,,7587,,B,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,,Columba livia,8932.0,,,22226
751,,7587,,B,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,,Columba livia,8932.0,,,22226
752,,7587,,B,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,,Columba livia,8932.0,,,22226
753,,11249,,B,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,,,,,,10732
754,,8003,,F,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,,Rattus norvegicus,10116.0,,,12198
755,,8003,,F,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,,Rattus norvegicus,10116.0,,,12198
756,,8003,,F,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,,Rattus norvegicus,10116.0,,,12198
757,Hippocampus,12416,,B,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,,,,,10576
758,,16293,,B,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,,,,,,51
759,,13047,,B,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,Oryctolagus cuniculus,9986.0,,,22226
760,,13047,,B,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,Oryctolagus cuniculus,9986.0,,,22226
761,,13047,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,,Oryctolagus cuniculus,9986.0,,,22226
762,,13047,,B,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,,Oryctolagus cuniculus,9986.0,,,22226
763,Hippocampus,10085,,B,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,,,,,104744
764,Hippocampus,10085,,B,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,,,,,104744
765,Hippocampus,10085,,B,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,,,,,104744
766,,9841,,B,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,,,,,Membranes,104744
767,,8822,,B,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,,Rattus norvegicus,10116.0,,,104744
768,,9806,,B,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,,Rattus norvegicus,10116.0,,,104744
769,,9806,,B,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,,Rattus norvegicus,10116.0,,,104744
770,,8868,,B,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,,,,,,104744
771,Hippocampus,9036,,B,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,,,,,,104744
772,Hippocampus,11374,,B,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,,,,,,104744
773,,10881,,B,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,,,,,,104744
774,,8822,,B,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,,,,,,104744
775,,9806,,B,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,,Rattus norvegicus,10116.0,,,104744
776,,15463,,B,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,,,,104744
777,,15463,,B,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,,,,104744
778,Brain,14542,,B,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,,,,,104744
779,Brain,14542,,B,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,,,,,104744
780,,8569,,B,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,,,,,,104744
781,,10062,,B,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,,Rattus norvegicus,10116.0,,,104744
782,,4771,,B,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,,,,,,104744
783,,10062,,B,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,,,,,104744
784,,10062,,B,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,,,,,104744
785,,10062,,B,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,,,,,104744
786,,15463,,B,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,,,,,104744
787,,15463,,B,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,,,,,104744
788,,9098,,B,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,,,,,,104744
789,,3070,,B,,Affinity for 5-hydroxytryptamine 1 receptor,,,Rattus norvegicus,10116.0,,,22226
790,Brain,14542,,B,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,,,,,,104744
791,Brain,14542,,B,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,,,,,104744
792,,6398,,B,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,,,,,,104744
793,Brain,1344,,B,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,,,,,,104744
794,,11963,,B,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,,,,104744
795,,8908,,B,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,,Rattus norvegicus,10116.0,,,22226
796,,9098,,B,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,,,,,,104744
797,,8841,,B,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,,Rattus norvegicus,10116.0,,,104744
798,,8814,,B,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,,Rattus norvegicus,10116.0,,,22226
799,,11752,,B,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,,,,,,104744
800,Brain,11642,,B,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,,,,,,104744
801,,11642,,B,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,,,,,,104744
802,Brain,9231,,B,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,,,,,,104744
803,Brain,11351,,B,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,,,,,,104744
804,,4639,,B,,Compound was tested for binding affinity against 5-HT1 receptor,,,,,,,22226
805,,1205,,B,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,,,,,,22226
806,,10025,,B,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,,,,,10576
807,,13241,,F,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,,,,,10576
808,,16245,,F,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,In vivo,,,,,,10576
809,,16245,,F,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,In vivo,,,,,,10576
810,,12438,,F,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,,,,,,10576
811,,16245,,F,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,In vivo,,,,,,10576
812,,16245,,F,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,In vivo,,,,,,10576
813,,15740,,F,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,,,,,,10576
814,,15535,,F,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,,,,,,10576
815,,15535,,F,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,,,,,,51
816,,15535,,F,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,,,,,,10576
817,,9888,,B,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,,,,,,10576
818,Hippocampus,10085,,B,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,,,,,,10576
819,Hippocampus,10085,,B,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,,,,,,10576
820,,17331,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,,,,,Membranes,10576
821,Hippocampus,10845,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,,Rattus norvegicus,10116.0,,,10576
822,Hippocampus,10845,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,,Rattus norvegicus,10116.0,,,10576
823,Hippocampus,10845,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,,,,,,10576
824,Hippocampus,10845,,B,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,,Rattus norvegicus,10116.0,,,10576
825,Hippocampus,10845,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,,Rattus norvegicus,10116.0,,,10576
826,,13730,,B,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,,,,,,10576
827,,13508,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,,,,,,10576
828,Hippocampus,13508,,B,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,,,,,,10576
829,Hippocampus,12073,,B,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,,,10576
830,Hippocampus,4671,,B,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,,,,,,10576
831,Hippocampus,13631,,B,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,,,,,,10576
832,,12438,,B,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,,,,,,10576
833,,10483,,B,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,,,,,,10576
834,Hippocampus,10483,,B,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,,,,,,10576
835,,12352,,B,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,,,,,,10576
836,Hippocampus,14732,,B,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,,,,,,10576
837,,11049,,B,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,,Rattus norvegicus,10116.0,,,10576
838,,11049,,B,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,,Rattus norvegicus,10116.0,,,10576
839,,13657,,B,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,,,,,,10576
840,,11473,,B,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,,,,,,10576
841,,2014,,B,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,,,,,10576
842,Hippocampus,3086,,B,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,,,10576
843,,15854,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,,,,,10576
844,Hippocampus,10922,,B,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,,,,,10576
845,Hippocampus,13346,,B,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,,,,,,10576
846,,15311,,B,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,,,,,,10576
847,Hippocampus,10922,,B,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,,,,,10576
848,,10025,,B,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,,,,,,10576
849,,10025,,B,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,,,,,10576
850,,9742,,B,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,,,,,10576
851,,9742,,F,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,,,,,10576
852,,12304,,B,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,,,,,10576
853,Hippocampus,15789,,B,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,,,,,,10576
854,,9912,,B,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,,,,,,10576
855,,9912,,B,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,,,,,,10576
856,,9912,,B,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,,,,,,10576
857,,16693,,B,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,,,,,10576
858,,13276,,B,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,,,,,10576
859,Hippocampus,12678,,B,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,,,,,10576
860,,11825,,B,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,,,,,,10576
861,,12443,,B,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,,,,,,10576
862,,13830,,B,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,,,,,10576
863,Hippocampus,14286,,B,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,,,,,,10576
864,Hippocampus,14356,,B,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,Rattus norvegicus,10116.0,,,10576
865,,15306,,B,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,,,,,,10576
866,,15306,,B,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,,,,,,10576
867,,16616,,F,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,,Rattus norvegicus,10116.0,,,10576
868,Hippocampus,3651,,B,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,,,,,,10576
869,Hippocampus,14331,,F,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,,,10576
870,Hippocampus,14331,,F,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,,,10576
871,,14178,,B,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,,Rattus norvegicus,10116.0,,,10576
872,,10639,,B,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,,Rattus norvegicus,10116.0,,,10576
873,Hippocampus,12306,,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,,,,10576
874,,1348,,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,,Rattus norvegicus,10116.0,,,10576
875,Hippocampus,13605,,B,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,,,,,,10576
876,,17624,449.0,B,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,,CHO,,51
877,,17624,449.0,F,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,,,CHO,,51
878,,17624,449.0,F,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,,,CHO,,51
879,,15267,,B,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,,,,,51
880,,16532,,B,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,,,,,,51
881,,6563,,F,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,,,51
882,,4751,449.0,B,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,,,,CHO,,51
883,,15463,,B,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,,,,,,51
884,,3805,,B,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,,,,,,51
885,,5640,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,51
886,,6563,,B,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,,,,,,51
887,,5548,,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,,,,,,51
888,,6347,,B,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,51
889,,17296,722.0,F,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,,HEK293,,51
890,,13047,,B,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,,,,,,51
891,,15740,,B,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,,,,,,51
892,,5640,,F,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,,,,,51
893,,5640,,F,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,,,,,,51
894,,17211,308.0,B,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,,,,HeLa,,51
895,,4751,449.0,B,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,,,,CHO,,51
896,,6491,,B,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,,Homo sapiens,9606.0,,,51
897,,4707,,B,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,,,,,,51
898,,13910,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,Homo sapiens,9606.0,,,51
899,,16190,308.0,B,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,,,,HeLa,,51
900,,16633,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,51
901,,11898,449.0,B,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,,,,CHO,,51
902,,11898,449.0,B,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,,CHO,,51
903,,14331,,B,,Binding affinity against human 5-hydroxytryptamine 1A receptor,,,,,,,51
904,,17624,449.0,B,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,,,,CHO,,51
905,,17624,449.0,B,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,,,,CHO,,51
906,,3307,,B,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,,,,,,51
907,,6563,449.0,B,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,Homo sapiens,9606.0,CHO,,51
908,,14165,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,,,,,,51
909,,5732,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,,,,,51
910,,13366,,B,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,,,,,51
911,,17626,,B,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,,,,,,51
912,,6588,308.0,B,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,,,,HeLa,,51
913,,16209,,B,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,,,,,,51
914,,15463,,B,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,,,51
915,,15463,,B,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,,,51
916,,14770,,B,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,,,,,,51
917,,16245,1167.0,B,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,,,,Cell line,,51
918,,16245,,B,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,,,,,,51
919,,5548,,B,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,51
920,,5548,,B,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,51
921,,5548,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,51
922,,6876,,B,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,,,,,,51
923,,2598,,B,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,51
924,,17785,,B,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,,,,,,51
925,,6013,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,51
926,,5929,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,,,,,51
927,,16633,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,51
928,,1558,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,,,,,51
929,,16026,,B,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,51
930,,12469,,B,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,,,,,,51
931,,15874,,B,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,Homo sapiens,9606.0,,,51
932,,15874,,B,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,,,,,51
933,,3935,,B,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,,,,,,51
934,,15818,,B,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,,,,,,51
935,,13706,485.0,B,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,,,,CHO-K1,,51
936,,13729,485.0,F,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,,,,CHO-K1,,51
937,,15413,,B,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,,,,,,51
938,,15413,,B,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,,,,,,51
939,,15413,,B,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,,,,,,51
940,,15413,,B,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,,,,,,51
941,,3445,308.0,B,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,,Homo sapiens,9606.0,HeLa,,51
942,,15740,,B,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,,,,,51
943,,15740,,B,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,,,,,,51
944,,17626,,B,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,,,,,,51
945,,4234,,B,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,,Homo sapiens,9606.0,,,51
946,,5640,,B,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,,,,,51
947,,5272,,B,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,,Rattus norvegicus,10116.0,,,51
948,,4622,449.0,B,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,,,,CHO,,51
949,,17085,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,,,,,,51
950,,3025,,B,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,,,,,51
951,,15315,,B,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,,,,,51
952,,15267,,B,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,,,,,,51
953,,17158,308.0,B,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,,,,HeLa,,51
954,,14214,308.0,B,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,,Homo sapiens,9606.0,HeLa,,51
955,,17133,,B,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,51
956,,16532,,B,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,,,,,,51
957,,2391,,B,,Affinity for 5-hydroxytryptamine 1A receptor subtype,,,Homo sapiens,9606.0,,,51
958,,14447,,B,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,,,,,,51
959,,14447,,B,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,,,,,,51
960,,15086,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,,,,,,51
961,,13051,,B,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,Homo sapiens,9606.0,,,51
962,,16026,,F,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,,,,,,51
963,,17085,,B,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,,,,,,51
964,,17133,,B,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,51
965,,17133,,B,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,,,,,,51
966,,17211,308.0,B,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,,,HeLa,,51
967,,17211,308.0,B,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,,,,HeLa,,51
968,,17211,308.0,B,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,,,HeLa,,51
969,,17211,308.0,B,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,,,HeLa,,51
970,,16394,,F,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,,,,,51
971,,16394,,F,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,,,,,51
972,,16394,,F,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,,,,,51
973,,16394,,F,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,In vivo,,,,,,51
974,,16394,,B,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,,,,,,51
975,,15740,,F,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,,,,,,51
976,,15740,,F,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,,,,,,51
977,,15740,,B,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,,,,,51
978,,17296,722.0,F,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,,HEK293,,51
979,,5640,,F,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,,,,,,51
980,,5640,,F,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,,,,,,51
981,,5640,,F,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,,,,,,51
982,,5640,,F,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,,,,,,51
983,,2759,449.0,F,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,,,CHO,,51
984,,16394,,F,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,,,,,,51
985,,16394,,F,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,,Homo sapiens,9606.0,,,51
986,,3445,,F,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,,Homo sapiens,9606.0,,,51
987,,4316,449.0,B,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,,,,CHO,,51
988,,4316,,B,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,,,,,,51
989,,15180,,F,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,,Homo sapiens,9606.0,,,51
990,,15180,,F,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,,Homo sapiens,9606.0,,,51
991,,15042,,F,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,,,51
992,,15042,,F,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,,,51
993,,15042,,F,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,,,,,51
994,,15042,,F,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,,,51
995,,15042,,F,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,,,51
996,,15042,,F,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,,,51
997,,15042,,F,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,,,,,51
998,,15180,308.0,F,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,,Homo sapiens,9606.0,HeLa,,51
999,,15180,308.0,F,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,,Homo sapiens,9606.0,HeLa,,51
1000,,15180,308.0,F,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,,Homo sapiens,9606.0,HeLa,,51
1001,,16245,,F,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,,,,,,51
1002,,16026,,F,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,,,,,51
1003,,17296,722.0,F,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,,HEK293,,51
1004,,2759,449.0,F,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,,,,CHO,,51
1005,,2759,449.0,F,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,,,CHO,,51
1006,,2759,449.0,F,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,,Homo sapiens,9606.0,CHO,,51
1007,,2759,449.0,F,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,,,,CHO,,51
1008,,15419,,F,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,,,,,,51
1009,,15419,,F,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,,,,,,51
1010,,16026,,F,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,,,,,51
1011,,1414,,B,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,In vitro,,,,,,51
1012,,1414,,B,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,In vitro,,,,,,51
1013,,12861,,B,,Binding activity radioligand.,,,,,,,51
1014,,12861,,B,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,,,,51
1015,,5104,,B,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,,,,,51
1016,,5105,,B,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,,,,,51
1017,,16312,,B,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,,,,,,51
1018,,15180,,B,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,,Homo sapiens,9606.0,,,51
1019,,5033,,B,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,,,,,,51
1020,,16909,449.0,B,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,,Homo sapiens,9606.0,CHO,,51
1021,,2590,,F,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,,,,,,51
1022,,2590,,F,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,,,,,,51
1023,,16394,,B,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,,,,,,51
1024,,4540,722.0,B,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,,Homo sapiens,9606.0,HEK293,,51
1025,,17296,722.0,B,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,,,,HEK293,,51
1026,,17296,722.0,B,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,,,,HEK293,,51
1027,,15779,722.0,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,,,,HEK293,,51
1028,,15779,722.0,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,,,,HEK293,,51
1029,,15779,722.0,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,,,,HEK293,,51
1030,,6166,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,,,,,51
1031,,15779,722.0,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,,,,HEK293,,51
1032,,4199,722.0,B,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,,,,HEK293,,51
1033,,15316,,B,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,,,,,,51
1034,,14875,,B,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,,,,,,51
1035,,14727,308.0,B,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,,,HeLa,,51
1036,,14727,,B,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,,,,,51
1037,,15146,722.0,B,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,,,,HEK293,,51
1038,,5213,722.0,B,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,,,,HEK293,,51
1039,,16429,,B,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,,,,,,51
1040,,15042,308.0,B,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,,Homo sapiens,9606.0,HeLa,,51
1041,,14818,722.0,B,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,,,,HEK293,,51
1042,,4829,722.0,B,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,,,,HEK293,,51
1043,,17200,,B,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,,,,,51
1044,,13051,,B,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,,Homo sapiens,9606.0,,,51
1045,,5486,,B,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,,,,,106
1046,,5254,,B,,Binding affinity against 5-HT1D receptor,,,,,,,105
1047,,5254,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,105
1048,,15331,,B,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,,,,,107
1049,,13506,,B,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,Homo sapiens,9606.0,,,10576
1050,,15267,,B,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,,,,,51
1051,,16616,,F,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,In vivo,,,,,,11863
1052,,16616,,F,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,In vivo,,,,,,11863
1053,,16616,,F,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,In vivo,,,,,,11863
1054,,16616,,F,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,,Mus musculus,10090.0,,,11863
1055,,16616,,F,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,,Mus musculus,10090.0,,,11863
1056,,16616,,F,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,,Mus musculus,10090.0,,,11863
1057,,16616,,F,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,,Mus musculus,10090.0,,,11863
1058,,16616,,F,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,,Mus musculus,10090.0,,,11863
1059,,16616,,F,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,,Mus musculus,10090.0,,,11863
1060,Hippocampus,10297,,B,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,,,,,,11863
1061,,13704,,B,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,,,,,,11863
1062,Hippocampus,10297,,B,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,,Mus musculus,10090.0,,,11863
1063,Hippocampus,10297,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,,,,,11863
1064,Hippocampus,10297,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,,Mus musculus,10090.0,,,11863
1065,Hippocampus,10297,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,,,,,11863
1066,,217,,B,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,,,,,,11863
1067,Hippocampus,10297,,B,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,,Mus musculus,10090.0,,,11863
1068,,4921,,B,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,,Sus scrofa,9823.0,,,51
1069,,4921,,B,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,,Sus scrofa,9823.0,,,51
1070,,4996,,B,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,,Sus scrofa,9823.0,,,51
1071,,12918,,B,,Compound was evaluated for the binding affinity at 5- HT1A receptor,,,Sus scrofa,9823.0,,,51
1072,,5333,,B,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,,Sus scrofa,9823.0,,,51
1073,,4437,,B,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,,Sus scrofa,9823.0,,,51
1074,,1742,,B,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,,Sus scrofa,9823.0,,,51
1075,,16688,,B,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,,Sus scrofa,9823.0,,,51
1076,,12861,,B,,Binding activity radioligand.,,,Sus scrofa,9823.0,,,51
1077,,12861,,B,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,,Sus scrofa,9823.0,,,51
1078,,12861,,B,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,,Sus scrofa,9823.0,,,51
1079,,12490,,B,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,,,,,,10624
1080,,11828,,B,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,,Sus scrofa,9823.0,,,51
1081,Hippocampus,11866,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,,Sus scrofa,9823.0,,,51
1082,,12827,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,,Sus scrofa,9823.0,,,51
1083,,12918,,B,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,,Sus scrofa,9823.0,,,51
1084,,12919,,F,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,,Sus scrofa,9823.0,,,51
1085,,13047,,B,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,,Oryctolagus cuniculus,9986.0,,,51
1086,,15796,,B,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,,Rattus norvegicus,10116.0,,,10576
1087,Hippocampus,3651,,B,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,,Rattus norvegicus,10116.0,,,10576
1088,,188,,B,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,,,,,,10576
1089,,16616,,F,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,,Rattus norvegicus,10116.0,,Membranes,10576
1090,Hippocampus,16616,,F,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,,Rattus norvegicus,10116.0,,Membranes,10576
1091,Hippocampus,12306,,B,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,,,,10576
1092,Hippocampus,17167,,B,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,,Rattus norvegicus,10116.0,,,10576
1093,,14776,,B,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,,,,,,10576
1094,,12158,,B,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,,,,,,10576
1095,,13481,,B,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,,,,,10576
1096,,13427,,B,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,In vitro,,,,,,10576
1097,,10210,,B,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,,,,,,10576
1098,,10205,,B,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,,,,Membranes,10576
1099,,10205,,B,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,,,,Membranes,10576
1100,,10205,,B,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,,,,,Membranes,10576
1101,,12280,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,,Rattus norvegicus,10116.0,,,10576
1102,,17386,,B,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,,,,,,10576
1103,,13654,,B,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,,,,,,10576
1104,Hippocampus,14423,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,,,,,,10576
1105,Hippocampus,15412,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,,,,,,10576
1106,Hippocampus,12073,,B,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,,,10576
1107,,4101,,B,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,,Rattus norvegicus,10116.0,,,10576
1108,,10062,,B,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,,,,,,10576
1109,,6238,,B,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,,,,,,10576
1110,,16273,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,10576
1111,,11139,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,,,,,,10576
1112,,16796,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,,,,,10576
1113,Brain,9548,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,Rattus norvegicus,10116.0,,,10576
1114,Brain,10381,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,,,,,10576
1115,,13408,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,,,,,,10576
1116,Hippocampus,13825,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,,Rattus norvegicus,10116.0,,,10576
1117,Hippocampus,11147,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,,,,,,10576
1118,,10552,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,,,,,,10576
1119,Striatum,10552,,B,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,,,,,10576
1120,,17136,,B,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,,Rattus norvegicus,10116.0,,Membranes,10576
1121,,5778,,B,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,,Rattus norvegicus,10116.0,,Membranes,10576
1122,Hippocampus,13481,,B,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,10576
1123,Hippocampus,13481,,B,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,,,,,,10576
1124,Hippocampus,13630,,B,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,,,,,,10576
1125,,16245,,B,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,,,,,10576
1126,Hippocampus,14509,,B,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,,,,,,10576
1127,Hippocampus,14509,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,,,,,10576
1128,Hippocampus,14509,,B,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,,,,,,10576
1129,Hippocampus,14509,,B,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,,,,,,10576
1130,,14256,,B,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,,,,,,10576
1131,,11139,,B,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,,,,,,10576
1132,,11047,,B,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,,Rattus norvegicus,10116.0,,,10576
1133,,11047,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,,Rattus norvegicus,10116.0,,,10576
1134,,11047,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,,Rattus norvegicus,10116.0,,,10576
1135,,2395,485.0,B,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,,Rattus norvegicus,10116.0,CHO-K1,,10576
1136,,9699,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,10576
1137,Hippocampus,12028,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,,Rattus norvegicus,10116.0,,,10576
1138,Hippocampus,12028,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,,,,,,10576
1139,,5815,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,,,,,10576
1140,,16616,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,,,,,,10576
1141,,5815,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,,,,,,10576
1142,Hippocampus,2761,,B,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,,,,,,10576
1143,,13133,,B,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,,,,,,10576
1144,,10444,,B,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,,,,,,10576
1145,,13278,,B,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,,Rattus norvegicus,10116.0,,,10576
1146,,15874,,B,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,,,,,10576
1147,Striatum,10552,,B,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,,,,Membranes,10576
1148,,11130,,B,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,,,,,,10576
1149,,11130,,B,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),In vivo,,,,,,10576
1150,Brain,14542,,B,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,,,,,,10576
1151,,13670,,B,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,Rattus norvegicus,10116.0,,,10576
1152,,9888,,B,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,,,,,,10576
1153,,3678,,B,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,,Rattus norvegicus,10116.0,,Membranes,10576
1154,Hippocampus,11332,,B,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,,,,,10576
1155,Hippocampus,11332,,B,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,,,,,10576
1156,,1185,,B,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,,,,,10576
1157,,2014,,B,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,,,,,,10576
1158,,1185,,B,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,,,,,10576
1159,,14429,,B,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,,,,,,10576
1160,,16288,,B,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,,,,,,10576
1161,,5432,,B,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,,Rattus norvegicus,10116.0,,,10576
1162,,14429,,B,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,,,,,,10576
1163,,13672,,B,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,,,,,,10576
1164,Hippocampus,11296,,B,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,,,,,10576
1165,,11296,,B,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,,,,,,10576
1166,,14749,449.0,B,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,,,,CHO,,10576
1167,,15086,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,,,,,,10576
1168,Hippocampus,13462,,B,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,,,,,,10576
1169,,15363,,B,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,,,,,10576
1170,,15363,,B,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,,,,,10576
1171,,10796,,B,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,,,,,,10576
1172,Brain,12816,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,,,,,,10576
1173,Hippocampus,13542,,B,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,,,,,10576
1174,,13308,,B,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,,,,,,10576
1175,Hippocampus,13541,,B,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,,,,,,10576
1176,Hippocampus,10058,,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,,,,,,10576
1177,Hippocampus,10058,,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,,,,,,10576
1178,Hippocampus,10058,,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,,,,,,10576
1179,Hippocampus,10058,,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,,,,,,10576
1180,Hippocampus,10058,,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,,,,,,10576
1181,Hippocampus,10058,,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,,,,,,10576
1182,Hippocampus,10058,,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,,,,,,10576
1183,Hippocampus,10058,,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,,,,,,10576
1184,Hippocampus,10058,,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,,,,,,10576
1185,Hippocampus,10058,,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,,,,,,10576
1186,Hippocampus,10058,,B,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,,,,,,10576
1187,Hippocampus,10058,,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,,,,,,10576
1188,Hippocampus,10058,,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,,,,,,10576
1189,Hippocampus,10058,,B,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,,Rattus norvegicus,10116.0,,,10576
1190,Hippocampus,10058,,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,,,,,,10576
1191,Hippocampus,10058,,B,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,,,,,,10576
1192,,12879,,B,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,,,,,,10576
1193,,11964,,B,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,,,,,,10576
1194,,11964,,B,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,,,,,,10576
1195,,11964,,B,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,,,,,,10576
1196,Brain,9548,,B,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,,,,,10576
1197,,9098,,B,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,,,,,,10576
1198,,9098,,B,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,,,,,,10576
1199,,9098,,B,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,,,,,,10576
1200,,13248,449.0,B,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,,,,CHO,,10576
1201,,3147,,B,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,,,,,,10576
1202,,13949,,B,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,,,,,10576
1203,,11883,449.0,B,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,,,,CHO,,10576
1204,,11883,,B,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,,,,,,10576
1205,,11883,,B,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,,Rattus norvegicus,10116.0,,,10576
1206,,15535,,B,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,,,,Membranes,10576
1207,,15535,,B,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,,,,,,10576
1208,,15535,,B,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,,,,,,10576
1209,,16372,449.0,B,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,Homo sapiens,9606.0,CHO,,51
1210,,14608,,B,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,,,,,,10576
1211,Hippocampus,4795,,B,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,,Rattus norvegicus,10116.0,,,10576
1212,,13863,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,,,10576
1213,,13863,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,,,,,,10576
1214,,13863,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,,,,,,10576
1215,,13863,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,,,,,,10576
1216,,13863,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,,,,,,10576
1217,,13863,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,,,,,,10576
1218,,13863,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,,,,,,10576
1219,,13863,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,,,,,,10576
1220,,13863,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,,,,,,10576
1221,,13863,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,,,,,,10576
1222,,13863,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,,,,,,10576
1223,,13863,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,,,,,,10576
1224,,13863,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,,,,,,10576
1225,,13863,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,,,,,,10576
1226,,13863,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,,,,,,10576
1227,,9742,,B,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,,,,,,10576
1228,,12073,,B,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,,,,,,10576
1229,,4101,,B,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,,,,,,10576
1230,,15360,,B,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,,,,,,10576
1231,Hippocampus,11576,,B,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,,,,,10576
1232,,5834,,B,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,,,,,,10576
1233,,2395,485.0,B,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,,Rattus norvegicus,10116.0,CHO-K1,,10576
1234,,1375,,B,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,,,,,,10576
1235,,1375,,B,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,,,,,,10576
1236,,3967,,B,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,,,,,,10576
1237,,12884,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,,,,,,10576
1238,,2343,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,,,,,,10576
1239,,11511,,B,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,,,,,10576
1240,,11511,,B,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,Rattus norvegicus,10116.0,,,10576
1241,,16394,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,In vivo,,,,,,10576
1242,,16394,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),In vivo,,,,,,10576
1243,,16394,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),In vivo,,,,,,10576
1244,,16394,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),In vivo,,,,,,10576
1245,,16394,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),In vivo,,,,,,10576
1246,,16394,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),In vivo,,,,,,10576
1247,,16394,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),In vivo,,,,,,10576
1248,,16394,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),In vivo,,,,,,10576
1249,,16394,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),In vivo,,,,,,10576
1250,,16394,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),In vivo,,,,,,10576
1251,,16394,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),In vivo,,,,,,10576
1252,,16394,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),In vivo,,,,,,10576
1253,,16394,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),In vivo,,,,,,10576
1254,,16394,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),In vivo,,,,,,10576
1255,,16394,,F,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,In vivo,,,,,,10576
1256,,16616,,F,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,,Rattus norvegicus,10116.0,,Membranes,10576
1257,,16796,,B,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,,,,,,10576
1258,,16796,,B,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,,,,,10576
1259,,15629,,B,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,,,,,,10576
1260,,13241,,F,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,,,,,10576
1261,Hippocampus,12073,,B,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,,,10576
1262,Hippocampus,14286,,B,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,,,,,,10576
1263,Brain,14542,,B,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,,,,,,10576
1264,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,,,,,10576
1265,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,,,,,,10576
1266,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,,,,,,10576
1267,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,,,,,10576
1268,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,,,,,10576
1269,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,,,,,,10576
1270,,13630,,F,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,,Rattus norvegicus,10116.0,,,10576
1271,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,,,,,10576
1272,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,,,,,,10576
1273,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,,,,,,10576
1274,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,,,,,,10576
1275,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,,,,,,10576
1276,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,,,,,10576
1277,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,,,,,,10576
1278,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,,,,,10576
1279,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,,,,,,10576
1280,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,,,,,,10576
1281,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,,,,,10576
1282,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,,,,,,10576
1283,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,,,,,,10576
1284,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,,,,,,10576
1285,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,,,,,,10576
1286,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,,,,,10576
1287,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,,,,,10576
1288,Hippocampus,9783,,B,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,,,,,,10576
1289,Hippocampus,9783,,B,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,,,,,,10576
1290,,14331,,B,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,,Rattus norvegicus,10116.0,,Membranes,10576
1291,Hippocampus,15260,,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,,,,,,10576
1292,Hippocampus,15260,,B,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,,,,,,10576
1293,Hippocampus,15260,,B,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,,,,,,10576
1294,,16616,,F,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,,Rattus norvegicus,10116.0,,,10576
1295,,15629,,B,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,,,,,,10576
1296,,15086,,B,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,,,,,10576
1297,,5717,,F,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,,,,,10576
1298,,12652,,B,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,,,,,10576
1299,Hippocampus,14608,,B,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,,,,,,10576
1300,Hippocampus,12306,,B,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,,,,10576
1301,Hippocampus,12306,,B,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,,,,10576
1302,,15247,,B,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,Rattus norvegicus,10116.0,,,10576
1303,Hippocampus,17529,,B,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,,,,,,10576
1304,Hippocampus,14826,,B,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,,,10576
1305,Hippocampus,14826,,B,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,,,10576
1306,Hippocampus,13241,,B,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,,,,,10576
1307,Hippocampus,14093,,B,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,,,,,,10576
1308,Hippocampus,14093,,B,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,,,,,,10576
1309,Brain,14442,,B,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,,,,,,10576
1310,,9919,,B,,Affinity for 5-hydroxytryptamine 1A receptor site,,,,,,,10576
1311,,9919,,B,,Affinity for 5-hydroxytryptamine 1A receptor site,,,,,,,10576
1312,Hippocampus,11440,,B,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,,,,,,10576
1313,,11257,,B,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,,,,,,10576
1314,,10330,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,,,,,,10576
1315,Hippocampus,17331,,B,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,,Rattus norvegicus,10116.0,,,10576
1316,,16567,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,,,,,,10576
1317,,12058,,B,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,Rattus norvegicus,10116.0,,,10576
1318,Hippocampus,9699,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,,,,,,10576
1319,,9547,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,,,,,,10576
1320,,10330,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,,,,,,10576
1321,,14331,,B,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,,,,,10576
1322,,14060,,B,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,,Rattus norvegicus,10116.0,,,10576
1323,Hippocampus,14744,,B,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,,,,,,10576
1324,,13506,,B,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,,,,,10576
1325,Brain,10862,,B,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,,,,,10576
1326,Brain,10862,,B,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,,,,,10576
1327,,10062,,B,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,,,,,,10576
1328,,12073,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,,,,,,10576
1329,,14875,,B,,GTPgammaS radioligand binding assay,,,,,,,106
1330,,2391,,B,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,,,,,106
1331,,2391,,F,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,,,,,,106
1332,,2391,,F,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,,,,,,106
1333,,2391,,B,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,,,,,106
1334,,2391,,B,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,,,,,106
1335,,2391,,F,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,,,,,,106
1336,,17211,308.0,B,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,,,,HeLa,,106
1337,,17211,308.0,B,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,,,,HeLa,,106
1338,,6491,,B,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,,Homo sapiens,9606.0,,,106
1339,,16190,449.0,B,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,,,,CHO,,106
1340,,14165,,B,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,,,,,,106
1341,,14165,,B,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,,,,,,106
1342,,4234,,B,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,,Homo sapiens,9606.0,,,106
1343,,6328,,B,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,,,,,106
1344,,14770,,B,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,,,,,106
1345,,2598,,B,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,,,,,,106
1346,,6897,,B,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,,,,,106
1347,,6897,,B,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,,,,,106
1348,,6013,,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,,,,,106
1349,,5843,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,,,,,106
1350,,14454,,B,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,,,,,,106
1351,,16209,,B,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,,,,,,106
1352,,3935,,B,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,,,,,,106
1353,,13729,485.0,F,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,,,,CHO-K1,,106
1354,,14251,,F,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,,,,,,106
1355,,17085,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,,,,,,106
1356,,3025,,B,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,,,,,106
1357,,15315,,B,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,,,,,,106
1358,,14214,,B,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,,Homo sapiens,9606.0,,,106
1359,,3804,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,Homo sapiens,9606.0,,,106
1360,,2391,,B,,Affinity for 5-hydroxytryptamine 1B receptor subtype,,,Homo sapiens,9606.0,,,106
1361,,4175,,B,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,,Homo sapiens,9606.0,,,106
1362,,17296,449.0,B,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,,,,CHO,,106
1363,,17085,,B,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,,,,,,106
1364,,17211,308.0,B,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,,,,HeLa,,106
1365,,17211,308.0,B,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,,,,HeLa,,106
1366,,17211,308.0,B,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,,,,HeLa,,106
1367,,15926,,B,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,,Homo sapiens,9606.0,,,106
1368,,16312,485.0,B,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,,,,CHO-K1,,106
1369,,5843,,B,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,,,,,,106
1370,,5843,,B,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,,,,,,106
1371,,16312,485.0,B,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,,,,CHO-K1,,106
1372,,15926,,B,,Binding activity against human 5-hydroxytryptamine 1B receptor,,,Homo sapiens,9606.0,,,106
1373,,15926,,B,,Binding activity against human 5-hydroxytryptamine 1B receptor,,,Homo sapiens,9606.0,,,106
1374,,4540,449.0,B,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,,Homo sapiens,9606.0,CHO,,106
1375,,6166,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,,,,,,106
1376,,17296,449.0,B,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,,,,CHO,,106
1377,,17296,449.0,B,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,,,,CHO,,106
1378,,17296,449.0,B,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,,,,CHO,,106
1379,,15779,449.0,B,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,,,CHO,,106
1380,,15779,449.0,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,,,CHO,,106
1381,,15779,449.0,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,,,,CHO,,106
1382,,4199,449.0,B,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,,,,CHO,,106
1383,,14875,,B,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,,Homo sapiens,9606.0,,,106
1384,,15146,449.0,B,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,,,,CHO,,106
1385,,5213,,B,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,,,,,,106
1386,,14818,449.0,B,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,,,,CHO,,106
1387,,4829,449.0,B,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,,,,CHO,,106
1388,,14454,,F,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,,,,,,106
1389,,14454,,F,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,,,,,,106
1390,,14875,449.0,F,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,,,,CHO,,106
1391,,14875,449.0,F,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,,,,CHO,,106
1392,,15250,,F,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,,,,,,105
1393,,15250,449.0,B,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,,,,CHO,,105
1394,,15086,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,,,,,17105
1395,,3025,,F,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,,Oryctolagus cuniculus,9986.0,,,106
1396,,14998,,B,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,,Oryctolagus cuniculus,9986.0,,,106
1397,,14998,,B,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,,Oryctolagus cuniculus,9986.0,,,106
1398,,14998,,B,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,,Oryctolagus cuniculus,9986.0,,,106
1399,,13969,,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,,,,,,10577
1400,,13392,,B,,Binding affinity for 5-hydroxytryptamine 1B receptor,,,,,,,10577
1401,Striatum,3651,,B,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,,Rattus norvegicus,10116.0,,,10577
1402,,10025,,B,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,,,,,10577
1403,,13863,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,,,,,,10576
1404,,13863,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,,,,,,10576
1405,,13863,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,,,,,,10576
1406,,13863,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,,,,,,10576
1407,,13863,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,,,,,,10576
1408,,13863,,B,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,,,,,,10576
1409,Hippocampus,4622,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,,,,,,10576
1410,,14911,,B,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,,,,,10576
1411,Hippocampus,12678,,B,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,,,,,10576
1412,Hippocampus,12678,,B,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,,,,,,10576
1413,Hippocampus,14235,,B,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,,,10576
1414,Hippocampus,14949,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,,,,,10576
1415,Hippocampus,14949,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,,,,,10576
1416,Hippocampus,14949,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,,,,,,10576
1417,Hippocampus,14949,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,,,,,,10576
1418,Hippocampus,14949,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,,,,,,10576
1419,,16118,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,,,,,10576
1420,,3268,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,,,,,,10576
1421,,3268,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,,,,,,10576
1422,,16117,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,,,,,,10576
1423,Hippocampus,9783,,B,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,,,,,,10576
1424,Hippocampus,9783,,B,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,,,,,,10576
1425,Hippocampus,14356,,B,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,,Rattus norvegicus,10116.0,,,10576
1426,,15740,,F,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,,,,,10576
1427,Hippocampus,12306,,B,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,,,,10576
1428,Hippocampus,13348,,B,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,,Rattus norvegicus,10116.0,,,10576
1429,,10394,,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,,,,,,10576
1430,Hippocampus,15260,,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,,,,,,10576
1431,Hippocampus,10046,,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,,,,,10576
1432,Hippocampus,15260,,F,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,,,,,,10576
1433,,12851,,B,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,,,,,,10576
1434,Hippocampus,2148,,B,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,,Rattus norvegicus,10116.0,,,10576
1435,,13134,,B,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,,,,,,10576
1436,,12462,,B,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,,,,,,10576
1437,,12462,,B,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,,,,,,10576
1438,,12462,449.0,B,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,,,,CHO,,10576
1439,,11933,,B,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,,,,,,10576
1440,,11933,,B,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,,,,,,10576
1441,Hippocampus,403,,B,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,,Rattus norvegicus,10116.0,,,10576
1442,Hippocampus,15538,,B,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,,,10576
1443,Hippocampus,15538,,B,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,,,,,,10576
1444,Hippocampus,15538,,B,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,,,,,,10576
1445,,12464,,B,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,,,,,,10576
1446,,1455,,B,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,,,,,,10576
1447,,12652,,B,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,,,,,10576
1448,Hippocampus,12639,,B,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,,,,,,10576
1449,,13949,,B,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,,,,,,10576
1450,,12463,,B,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,,Rattus norvegicus,10116.0,,,10576
1451,Hippocampus,14829,,B,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,,,,,,10576
1452,Hippocampus,14829,,B,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,,,,,,10576
1453,,12092,,B,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,,,,,,10576
1454,,403,,B,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,,,,,,10576
1455,,403,,B,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,,,,,,10576
1456,,3967,,B,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,,,,,,10576
1457,,12771,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,,Rattus norvegicus,10116.0,,,10576
1458,,15086,,B,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,,,,,10576
1459,Hippocampus,14909,,B,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,,,10576
1460,Hippocampus,14949,,B,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,,,10576
1461,Hippocampus,2309,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,,Rattus norvegicus,10116.0,,,10576
1462,,4170,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,10576
1463,Hippocampus,11642,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,,Rattus norvegicus,10116.0,,,10576
1464,Hippocampus,11642,,B,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,,,,,,10576
1465,Hippocampus,12953,,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,,,,,,10576
1466,Hippocampus,12953,,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,,,,,10576
1467,Hippocampus,12953,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,,,,,,10576
1468,,12903,449.0,B,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,,,,CHO,,10576
1469,,12536,,B,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,,,,,10576
1470,,10058,,B,,The inhibition activity of 5-HT1A at 1 uM,,,,,,,10576
1471,,12902,485.0,B,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,,,,CHO-K1,,10576
1472,,14057,,B,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,,,,,,10576
1473,,11296,,B,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,,,,,,10576
1474,Hippocampus,11296,,B,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,,,,,10576
1475,Hippocampus,11296,,B,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,,,,,10576
1476,,16616,,F,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,,Rattus norvegicus,10116.0,,Membranes,10576
1477,Hippocampus,16616,,F,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,,Rattus norvegicus,10116.0,,Membranes,10576
1478,,16567,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,,,,,,10576
1479,,16567,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,,,,,,10576
1480,,16567,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,,,,,,10576
1481,,16567,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,,,,,,10576
1482,,17136,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,,,,,,10576
1483,,17136,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,,,,,,10576
1484,,16616,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,,Rattus norvegicus,10116.0,,,10576
1485,Hippocampus,17331,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,,,,,,10576
1486,Hippocampus,17331,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,,,,,,10576
1487,Hippocampus,17167,,B,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,,Rattus norvegicus,10116.0,,,10576
1488,,15740,,F,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,,,,,10576
1489,,15740,,F,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,,,,,,10576
1490,,4671,,B,,Ratio of binding affinity to 5-HT 1A and D2 receptor,,,,,,,10576
1491,Hippocampus,10058,,B,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,,,,,10576
1492,Hippocampus,10058,,B,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,,,,,10576
1493,Hippocampus,10058,,B,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,,,,,,10576
1494,,12073,,B,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,,,,,,10576
1495,,2759,,B,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,,,,,10576
1496,,2759,,F,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,,,,,10576
1497,,2759,,B,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,,,,,10576
1498,,2759,,F,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,,,,,10576
1499,,2759,,F,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,,,,,10576
1500,Brain,9737,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,,,,,10576
1501,,9737,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,,,,,,10576
1502,,5717,,F,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,,,,,,10576
1503,Hippocampus,12253,,B,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,,,,,10576
1504,,14025,,B,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,,,,,,10576
1505,,10425,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,,,,,,10576
1506,,14998,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,,,,,,10576
1507,Hippocampus,13694,,B,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,,,,,,10576
1508,Hippocampus,13694,,B,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,,,,,,10576
1509,,4342,,B,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,,,,,,10576
1510,,12936,,B,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,Rattus norvegicus,10116.0,,,10576
1511,,13144,,B,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,,Rattus norvegicus,10116.0,,,10576
1512,,13343,,B,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,,,,,,10576
1513,,12132,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,,,,,10576
1514,,15419,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,,,,,,10576
1515,Hippocampus,1479,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,,,,,10576
1516,,14287,,B,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,,,,,,10576
1517,,13116,,B,,Binding affinity at 5-hydroxytryptamine 1A receptor,,,,,,,10576
1518,,2759,,B,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,,Rattus norvegicus,10116.0,,Membranes,10576
1519,,2759,,B,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,,,,,10576
1520,,14748,,B,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,,,,,,10576
1521,,12304,,B,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,,,,,10576
1522,Hippocampus,12409,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,,Rattus norvegicus,10116.0,,,10576
1523,Hippocampus,12409,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,,Rattus norvegicus,10116.0,,,10576
1524,Hippocampus,13267,,B,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,,,,,,10576
1525,,15194,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,,,,,10576
1526,,14256,,B,,pKi value against rat 5-hydroxytryptamine 1A receptor.,,,,,,,10576
1527,,16567,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,,,,,,10576
1528,,15740,,F,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,,,,,10576
1529,,13278,,B,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,,Rattus norvegicus,10116.0,,,12687
1530,,1970,,B,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,,,,Membranes,10626
1531,Brain,10034,,B,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,,,,,,10576
1532,,13348,,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,,Rattus norvegicus,10116.0,,,51
1533,,13630,,F,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,,,,,10576
1534,Brain,10862,,B,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,,,,,10576
1535,,12058,,B,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,,,,,10576
1536,,4639,,B,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,51
1537,,15453,,B,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,,,,,,51
1538,,4820,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,51
1539,,1089,,B,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,,,,,,51
1540,,386,,B,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,,,,,Brain membranes,51
1541,,6011,,B,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,,,,,,51
1542,,5014,,B,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,,,,,,51
1543,,4402,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,,,,,,51
1544,,17066,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,51
1545,,17515,,B,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,,,,,,51
1546,,2474,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,51
1547,,4775,,B,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,,,,,,51
1548,,14294,,B,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,,Homo sapiens,9606.0,,,51
1549,,14294,,B,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,,Homo sapiens,9606.0,,,51
1550,,12249,449.0,B,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,,CHO,,51
1551,,11376,,B,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,,,,,,51
1552,,2474,,B,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,In vivo,,,,,,51
1553,Hippocampus,13311,,B,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,,,,51
1554,,4373,,B,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,,,,,,51
1555,,1633,,B,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,,,,,,51
1556,,11866,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,,,,,51
1557,,4373,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,,,,,51
1558,,4687,,B,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,,,,,,51
1559,,16946,,B,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,,,,,11863
1560,,13291,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,,,,,,11863
1561,,14159,,B,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,,,,,,11863
1562,,10812,,B,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,,,,,,11863
1563,,3032,449.0,B,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,,Mus musculus,10090.0,CHO,,11863
1564,,16655,,B,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,,,,,11863
1565,,14532,,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,,,,,,11863
1566,,13944,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,11863
1567,,13033,,B,,Binding affinity against serotonergic 5-HT1a receptor,,,,,,,11863
1568,,10321,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,,,,,,11863
1569,,2968,,B,,Binding affinity for 5-hydroxytryptamine 1A receptor,,,Mus musculus,10090.0,,,11863
1570,,13964,,B,,Binding affinity at 5-hydroxytryptamine 1A receptor,,,,,,,11863
1571,,15527,,B,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,,,,,,11863
1572,,12248,449.0,B,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,,CHO,,11863
1573,,12249,449.0,B,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,,CHO,,11863
1574,,15120,,B,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,,,,,,11863
1575,,13313,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,,,,,,11863
1576,,2613,,B,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,,,,,,11863
1577,,16700,,B,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,,,,,,11863
1578,,2201,,B,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,,,,,,11863
1579,,1274,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,Mus musculus,10090.0,,,11863
1580,,1317,,B,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,,,,,11863
1581,,12146,,B,,Tested against 5-hydroxytryptamine 1A receptor,,,,,,,11863
1582,,14059,,B,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,11863
1583,,14025,,B,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,,Oryctolagus cuniculus,9986.0,,,106
1584,,14025,,B,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,,Oryctolagus cuniculus,9986.0,,,106
1585,,14447,722.0,B,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,,Gorilla gorilla,9593.0,HEK293,,105571
1586,,3025,,F,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,In vivo,,Cavia porcellus,10141.0,,,106
1587,,3025,,F,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,In vivo,,Cavia porcellus,10141.0,,,106
1588,,15329,,F,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,,Cavia porcellus,10141.0,,,106
1589,,15329,,F,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,,Cavia porcellus,10141.0,,,106
1590,,15847,,F,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,,Cavia porcellus,10141.0,,,106
1591,,15847,,F,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,,Cavia porcellus,10141.0,,,106
1592,,14165,,F,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,,,,,,106
1593,,14214,,F,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,,,,,,106
1594,,14214,,F,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,,,,,,106
1595,,14214,,F,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,,Homo sapiens,9606.0,,,106
1596,,13729,485.0,F,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,,Homo sapiens,9606.0,CHO-K1,,106
1597,,3025,449.0,F,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,,,,CHO,,106
1598,,2391,,B,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,,,,,106
1599,,2391,,F,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,,,,,,106
1600,,14956,449.0,F,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,,,,CHO,,106
1601,,2598,449.0,F,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,,,,CHO,,106
1602,,2598,449.0,F,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,,,,CHO,,106
1603,,2598,449.0,F,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,,,,CHO,,106
1604,,2598,449.0,F,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,,,,CHO,,106
1605,,14956,,F,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,,,,,,106
1606,,14956,,F,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,,,,,,106
1607,,14214,,B,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,,Homo sapiens,9606.0,,,106
1608,,3463,449.0,B,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,,,,CHO,,106
1609,,15331,,B,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,,,,,,106
1610,,16146,,B,,Binding affinity against 5-hydroxytryptamine 1B receptor,,,Homo sapiens,9606.0,,,106
1611,,14159,449.0,B,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,,Homo sapiens,9606.0,CHO,,106
1612,,14158,449.0,B,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,,,,CHO,,106
1613,,14159,,B,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,,,,,,106
1614,,15250,449.0,B,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,,,,CHO,,106
1615,,15250,449.0,B,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,,,,CHO,,106
1616,,15331,449.0,B,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,,,,CHO,,106
1617,,15332,449.0,B,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,,,,CHO,,106
1618,,14956,449.0,B,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,,,,CHO,,106
1619,,3805,,B,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,,,,,,106
1620,,14875,,B,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,,,,,,106
1621,,14454,,F,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,Oryctolagus cuniculus,9986.0,,,105
1622,,14454,,F,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,Oryctolagus cuniculus,9986.0,,,105
1623,,16288,,B,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,,,,,,105
1624,,16288,,B,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,,,,,,105
1625,,16312,,B,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,,,,,,105
1626,,1348,,B,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,,Bos taurus,9913.0,,,105
1627,,5834,,B,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,,Bos taurus,9913.0,,,105
1628,Striatum,13366,,B,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,,Bos taurus,9913.0,,,105
1629,,1414,,B,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,,Bos taurus,9913.0,,,105
1630,,14998,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,,Bos taurus,9913.0,,,105
1631,,11473,,B,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,,Bos taurus,9913.0,,,105
1632,,11473,,B,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,,Bos taurus,9913.0,,,105
1633,,10639,,B,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,,Bos taurus,9913.0,,,105
1634,,10639,,B,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,,Bos taurus,9913.0,,,105
1635,,1375,,B,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,,Bos taurus,9913.0,,,105
1636,,1375,,B,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,,Bos taurus,9913.0,,,105
1637,,16532,,B,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,,Bos taurus,9913.0,,,105
1638,,11147,,B,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,,Bos taurus,9913.0,,,105
1639,Striatum,13366,,B,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,,Bos taurus,9913.0,,,105
1640,,10444,,B,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,,Bos taurus,9913.0,,,105
1641,,16532,,B,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,,Bos taurus,9913.0,,,105
1642,,16532,,B,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,,Bos taurus,9913.0,,,105
1643,,12827,,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,,Bos taurus,9913.0,,,105
1644,,12827,,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,,Bos taurus,9913.0,,,105
1645,,12919,,F,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,Bos taurus,9913.0,,,105
1646,,14025,,B,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,,Bos taurus,9913.0,,,105
1647,,12919,,F,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,Bos taurus,9913.0,,,105
1648,,12919,,F,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,Bos taurus,9913.0,,,105
1649,,12919,,F,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,Bos taurus,9913.0,,,105
1650,,14447,722.0,B,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,,Gorilla gorilla,9593.0,HEK293,,105
1651,,1375,,B,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,,Cavia porcellus,10141.0,,,105570
1652,,1375,,B,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,,Cavia porcellus,10141.0,,,105570
1653,,12409,,F,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,,Cavia porcellus,10141.0,,,105570
1654,,12409,,F,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,Cavia porcellus,10141.0,,,105570
1655,,12409,,F,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,,Cavia porcellus,10141.0,,,105570
1656,,12409,,F,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,,Cavia porcellus,10141.0,,,105570
1657,,12409,,F,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,,Cavia porcellus,10141.0,,,105570
1658,,11574,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor,,,Cavia porcellus,10141.0,,,105570
1659,,1558,,B,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,,Cavia porcellus,10141.0,,,105570
1660,,12409,,F,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,Cavia porcellus,10141.0,,,105570
1661,,12409,,F,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,Cavia porcellus,10141.0,,,105570
1662,,12409,,F,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,Cavia porcellus,10141.0,,,105570
1663,,12409,,F,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,,Cavia porcellus,10141.0,,,105570
1664,,12253,,B,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,,Cavia porcellus,10141.0,,,105570
1665,,12936,,B,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,,Cavia porcellus,10141.0,,,105570
1666,,13181,,B,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,,Cavia porcellus,10141.0,,,105
1667,Striatum,12409,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,,Cavia porcellus,10141.0,,,105570
1668,,10639,,B,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,,Cavia porcellus,10141.0,,,105570
1669,,5254,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor,,,,,,,51
1670,,13051,,B,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,,,,,,106
1671,,3463,,F,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,,,,,,105
1672,,15315,,F,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,,,,,,105
1673,,6011,,F,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,,,,,,105
1674,,14159,449.0,F,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,,Homo sapiens,9606.0,CHO,,105
1675,,14159,449.0,F,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,,,,CHO,,105
1676,,15250,449.0,B,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,,,,CHO,,105
1677,,15250,449.0,B,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,,,,CHO,,105
1678,,15331,449.0,F,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,,,,CHO,,105
1679,,15332,449.0,F,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,,Homo sapiens,9606.0,CHO,,105
1680,,15332,449.0,F,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,,,,CHO,,105
1681,,3294,449.0,F,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,,,,CHO,,105
1682,,14158,449.0,F,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,,,,CHO,,105
1683,,14956,449.0,F,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,,,,CHO,,105
1684,,12469,,F,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,,,,,,105
1685,,3463,449.0,F,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,,,,CHO,,105
1686,,15250,449.0,F,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,,Homo sapiens,9606.0,CHO,,105
1687,,15250,449.0,F,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,,Homo sapiens,9606.0,CHO,,105
1688,,14956,,F,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,,,,,,105
1689,,14159,,F,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,,,,,,105
1690,,14159,,F,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,,Homo sapiens,9606.0,,,105
1691,,14499,449.0,F,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,,Homo sapiens,9606.0,CHO,,105
1692,,15315,,F,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,,,,,,105
1693,,3294,,B,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),In vitro,,,,,,105
1694,,3463,449.0,B,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,,,,CHO,,105
1695,,15331,,B,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,,,,,,105
1696,,14159,449.0,B,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,Homo sapiens,9606.0,CHO,,105
1697,,14158,449.0,B,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,,,,CHO,,105
1698,,14159,,B,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,,,,,,105
1699,,15250,449.0,B,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,,,,CHO,,105
1700,,15250,449.0,B,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,,,CHO,,105
1701,,15331,449.0,B,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,,,CHO,,105
1702,,15332,449.0,B,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,Homo sapiens,9606.0,CHO,,105
1703,,14499,449.0,B,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,Homo sapiens,9606.0,CHO,,105
1704,,15332,449.0,B,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,,,CHO,,105
1705,,14956,449.0,B,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,,,CHO,,105
1706,,3805,,B,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,,,,,,105
1707,,6011,449.0,B,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,,Homo sapiens,9606.0,CHO,,105
1708,,16190,449.0,B,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,,,,CHO,,105
1709,,14165,,B,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,,,,,,105
1710,,4234,,B,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,,Homo sapiens,9606.0,,,105
1711,,15527,,B,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,,,,,,105
1712,,6328,,B,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,,,,,105
1713,,16209,,B,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,,,,,,105
1714,,14770,,B,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,,,,,,105
1715,,2598,,B,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,,,,,,105
1716,,6897,,B,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,,,,,,105
1717,,6013,,B,,Binding affinity towards 5-hydroxytryptamine 1D receptor,,,,,,,105
1718,,5843,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,,,,,105
1719,,14454,,B,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,,,,,,105
1720,,14454,,B,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,,,,,,105
1721,,14454,,B,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,,,,,,105
1722,,15818,,B,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,,,,,,105
1723,,13729,485.0,F,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,,,,CHO-K1,,105
1724,,6011,,B,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),In vitro,,Homo sapiens,9606.0,,,105
1725,,4234,,B,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,,Homo sapiens,9606.0,,,105
1726,,17085,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,,,,,105
1727,,3025,,B,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,,,,,105
1728,,15315,,B,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,,,,,,105
1729,,14214,,B,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,,Homo sapiens,9606.0,,,105
1730,,3804,,B,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,Homo sapiens,9606.0,,,105
1731,,16700,,B,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,,,,,,105
1732,,2391,,B,,Affinity for 5-hydroxytryptamine 1D receptor subtype,,,Homo sapiens,9606.0,,,105
1733,,4175,,B,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,Homo sapiens,9606.0,,,105
1734,,17085,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,,,,,105
1735,,17085,,B,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,,,,,,105
1736,,15926,,B,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,,Homo sapiens,9606.0,,,105
1737,,16312,485.0,B,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,,,,CHO-K1,,105
1738,,16312,485.0,B,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,,,,CHO-K1,,105
1739,,14956,449.0,B,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,,,,CHO,,104802
1740,,3294,,F,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,,,,,,105
1741,,12861,,B,,Binding activity radioligand.,,,,,,,105
1742,,12861,,B,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,,,,105
1743,,16312,485.0,B,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,,,,CHO-K1,,105
1744,,5104,,B,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,,,,,105
1745,,5105,,B,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,,,,,105
1746,,14499,,B,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,,,,,,105
1747,,15926,,B,,Binding activity against human 5-hydroxytryptamine 1D receptor,,,Homo sapiens,9606.0,,,105
1748,,4540,449.0,B,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,,Homo sapiens,9606.0,CHO,,105
1749,,15779,449.0,B,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,,,,CHO,,105
1750,,15779,449.0,B,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,,CHO,,105
1751,,6166,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,,,,,105
1752,,15779,449.0,B,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,,,,CHO,,105
1753,,15779,449.0,B,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,,,,CHO,,105
1754,,17451,722.0,B,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,,,,HEK293,,105
1755,,17451,722.0,B,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,,,,HEK293,,105
1756,,17451,722.0,B,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,,,,HEK293,,105
1757,,4199,449.0,B,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,,,,CHO,,105
1758,,14875,,B,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,Homo sapiens,9606.0,,,105
1759,,15146,449.0,B,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,,,,CHO,,105
1760,,5213,,B,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,,,,,,105
1761,,14818,449.0,B,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,,,,CHO,,105
1762,,4829,449.0,B,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,,,,CHO,,105
1763,,14454,,F,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,,,,,,105
1764,,14454,,F,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,,,,,,105
1765,,5254,,B,,Binding affinity against 5-HT2C receptor,,,,,,,108
1766,,5254,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor,,,,,,,108
1767,,10639,,B,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,,,,,10577
1768,,10639,,F,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,,,,,10577
1769,,12352,,B,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,,,,,,10577
1770,,9098,,B,,Binding affinity towards 5-HT1B was determined,,,,,,,10577
1771,,14430,,B,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,,,,,,10577
1772,,13657,,B,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,,,,,,10577
1773,,13657,,B,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,,,,,,10577
1774,,15854,,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,,,,,10577
1775,,10639,,B,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,,Rattus norvegicus,10116.0,,,10577
1776,,10025,,B,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,,,,,10577
1777,,10025,,B,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,,,,,,10577
1778,,14286,,B,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,,,,,10577
1779,Striatum,3651,,B,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,,,,,,10577
1780,,14178,,B,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,,Rattus norvegicus,10116.0,,,10577
1781,,10639,,B,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,,,,,,10577
1782,Striatum,13605,,B,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,,,,,,10577
1783,Striatum,5834,,B,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,,,,,,10577
1784,Striatum,10922,,B,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,,,,,,10577
1785,,14286,,B,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,,,,,10577
1786,,11825,,B,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,,,,,,10577
1787,Striatum,14826,,B,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,,,,,,10577
1788,Striatum,9699,,B,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,,,,,,10577
1789,,14423,,B,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,,,,,,10577
1790,,10062,,B,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,,,,,,10577
1791,,10062,,B,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,,,,,10577
1792,,12280,,B,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,,Rattus norvegicus,10116.0,,,10577
1793,Striatum,15412,,B,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,,,,,,10577
1794,Striatum,15412,,B,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,,,,,,10577
1795,,10062,,B,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,,,,,10577
1796,,11147,,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,,,,,10577
1797,,9547,,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,,,,,,10577
1798,,10444,,B,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,,,,,,10577
1799,Striatum,12469,,B,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,,,,,,10577
1800,,9098,,B,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,,,,,,10577
1801,,9098,,B,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,,,,,,10577
1802,,9699,,B,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,,,,,,10577
1803,,10394,,B,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,,,,,10577
1804,,12092,,B,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,,,,,,10577
1805,,16700,,B,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,,,,,,10577
1806,,403,,B,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,,Rattus norvegicus,10116.0,,,10577
1807,,12771,,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,Rattus norvegicus,10116.0,,,10577
1808,,11642,,B,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,,,,,,10577
1809,,12953,,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,,,,,,10577
1810,,12953,,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,,,,,,10577
1811,Striatum,12953,,B,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,,,,,,10577
1812,,12953,,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,,,,,,10577
1813,Brain,9737,,B,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,,,,,10577
1814,,9737,,B,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,,,,,,10577
1815,Brain,9737,,B,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,,,,,10577
1816,,12827,,B,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,,,,,,10577
1817,,5033,,B,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,,,,,,10577
1818,,9786,,B,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,,Rattus norvegicus,10116.0,,,10577
1819,,13116,,B,,Binding affinity at 5-hydroxytryptamine 1B receptor,,,,,,,10577
1820,,16429,,B,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,,,,,,10577
1821,,12409,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,,Rattus norvegicus,10116.0,,,10577
1822,,15194,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,,,,,10577
1823,,15194,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,,,,,10577
1824,,5486,,B,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,,,,,,104686
1825,,4639,,B,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,,,,,106
1826,,386,,B,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,,,,,Brain membranes,106
1827,,2474,,B,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,,,,,,106
1828,,6011,,B,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,,,,,,106
1829,,5014,,B,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,,,,,,106
1830,,17515,,B,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,,,,,,106
1831,,4373,,B,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,,,,,,106
1832,,1633,,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,,,,,,106
1833,,1633,,B,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,,,,,,106
1834,,4373,,B,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,,,,,,106
1835,,4687,,B,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,,,,,,106
1836,,11574,,B,,Binding affinity against 5-hydroxytryptamine 1B receptor,,,,,,,106
1837,,10321,,B,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,,,,,,106
1838,,15527,,B,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,,,,,106
1839,,17200,,B,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,,,,,,106
1840,,14423,,B,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,,,,,,104802
1841,,5834,,B,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,,Bos taurus,9913.0,,,108
1842,,11473,,B,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,,Sus scrofa,9823.0,,,108
1843,,11473,,B,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,,Sus scrofa,9823.0,,,108
1844,,10639,,B,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,,Sus scrofa,9823.0,,,108
1845,,10639,,B,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,,Sus scrofa,9823.0,,,108
1846,,14331,,B,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,,Sus scrofa,9823.0,,,108
1847,,10796,,B,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,,Sus scrofa,9823.0,,,108
1848,,9098,,B,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,,Sus scrofa,9823.0,,,108
1849,,14331,,B,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,,Sus scrofa,9823.0,,,108
1850,,11828,,B,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,,Sus scrofa,9823.0,,,108
1851,,11866,,B,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,,Sus scrofa,9823.0,,,108
1852,,13047,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,,Oryctolagus cuniculus,9986.0,,,108
1853,,188,,B,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,,Rattus norvegicus,10116.0,,,12689
1854,,11825,,B,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,,Rattus norvegicus,10116.0,,,12689
1855,,11825,,B,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,,Rattus norvegicus,10116.0,,,12689
1856,,11624,,B,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,,Rattus norvegicus,10116.0,,,12689
1857,,11139,,B,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,,Rattus norvegicus,10116.0,,,12689
1858,,11147,,B,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,,Rattus norvegicus,10116.0,,,12689
1859,,10444,,B,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,,Rattus norvegicus,10116.0,,,12689
1860,,11624,,B,,Binding affinity against 5-hydroxytryptamine 1C receptor,,,Rattus norvegicus,10116.0,,,12689
1861,,11662,,B,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,Rattus norvegicus,10116.0,,,12689
1862,,11662,,B,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,Rattus norvegicus,10116.0,,,12689
1863,,11662,,B,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,Rattus norvegicus,10116.0,,,12689
1864,,11662,,B,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,Rattus norvegicus,10116.0,,,12689
1865,,9098,,B,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,,Rattus norvegicus,10116.0,,,12689
1866,,10394,,B,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,,Rattus norvegicus,10116.0,,,12689
1867,,11933,,B,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,,,,,,12689
1868,,12092,,B,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,,Rattus norvegicus,10116.0,,,12689
1869,,12253,,B,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,,Rattus norvegicus,10116.0,,,12689
1870,,12253,722.0,B,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,,Rattus norvegicus,10116.0,HEK293,,12689
1871,,1558,,B,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,,,,,108
1872,,2474,,B,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,,,,,108
1873,,2474,,B,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,,,,,108
1874,,11574,,B,,Binding affinity against 5-hydroxytryptamine 1C receptor,,,,,,,12689
1875,,1558,,B,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,,,,,12689
1876,,13944,,B,,Binding affinity against 5-hydroxytryptamine 1C receptor,,,,,,,12689
1877,,13033,,B,,Binding affinity against serotonergic 5-HT1c receptor,,,,,,,12689
1878,,10321,,B,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,,,,,,12689
1879,,11866,,B,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,,,,,,12689
1880,,14454,,B,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,Oryctolagus cuniculus,9986.0,,,105
1881,,11574,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,,,,,,104686
1882,,11574,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,,,,,,104686
1883,,13631,,B,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,,,,,,104686
1884,,9630,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,,Rattus norvegicus,10116.0,,,104686
1885,,8822,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,,Rattus norvegicus,10116.0,,,104686
1886,Brain,9064,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,,Rattus norvegicus,10116.0,,,104686
1887,,8868,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,,,,,,104686
1888,,9064,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,,,,,,104686
1889,,9806,,B,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,,,,,,104686
1890,,9098,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,,,,,104686
1891,,8868,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,,,,,,104686
1892,,12765,,B,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,,,,,104686
1893,,11049,,B,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,,,104686
1894,,11049,,B,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,,,104686
1895,,11049,,B,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,,,,,,104686
1896,,11049,,B,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,,,,,,104686
1897,,11049,,B,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,,,104686
1898,,11473,,B,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,,,,,,104686
1899,,11473,,B,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,,,,,,104686
1900,,3086,,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,,,,,,104686
1901,,11049,,B,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,,,104686
1902,,11049,,B,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,,,104686
1903,,10639,,B,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,,,,,,104686
1904,,10922,,B,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,,,,,,104686
1905,Brain,9064,,B,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,,Rattus norvegicus,10116.0,,,104686
1906,Brain,10748,,B,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,,,,,,104686
1907,,11614,,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,,,,Membranes,104686
1908,,11615,,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,,,,Membranes,104686
1909,,11615,,B,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,,,,,,104686
1910,,11614,,B,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,,,,Membranes,104686
1911,,11702,,B,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,,,,,,104686
1912,,11702,,B,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,,,,,,104686
1913,,11702,,B,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,,Rattus norvegicus,10116.0,,,104686
1914,,11702,,B,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,,,,,,104686
1915,,13346,,B,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,,,,,,104686
1916,,10025,,B,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,,,,,,104686
1917,,10025,,B,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,,,,,104686
1918,,10025,,B,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,,,,,104686
1919,,9036,,B,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,,,,,,104686
1920,,9036,,B,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,,,,,,104686
1921,,9161,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,,,,,,104686
1922,,12304,,B,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,,,,,,104686
1923,,13276,,B,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,,,,,,104686
1924,,11825,,B,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,,,,,104686
1925,,12443,,B,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,,,,,,104686
1926,,13830,,B,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,,,,,,104686
1927,,9592,,B,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,,,,,Membranes,104686
1928,,9592,,B,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,,,,,Membranes,104686
1929,,10881,,B,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,,,,,,104686
1930,,13605,,B,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,,,,,,104686
1931,,11624,,B,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,,Rattus norvegicus,10116.0,,,104686
1932,,4101,,B,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,,,,,104686
1933,,4101,,B,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,,,,,104686
1934,,15360,,B,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,,,,,,104686
1935,,11576,,B,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,,,,,,104686
1936,,5834,,B,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,,,,,,104686
1937,,2395,485.0,B,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,,Rattus norvegicus,10116.0,CHO-K1,,104686
1938,,11965,,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,,,,Membranes,104686
1939,,3967,,B,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,,,,,,104686
1940,,11130,,B,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,,,,,Brain membranes,104686
1941,,13427,,B,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,In vitro,,,,,,104686
1942,,9443,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,104686
1943,,9443,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,,,,,104686
1944,,11825,,B,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,,,,,104686
1945,,12120,,B,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,,,,,Membranes,104686
1946,,12120,,B,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,,,,,Membranes,104686
1947,Thoracic aorta,11963,,F,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,,,,,,104686
1948,,9069,,B,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,,,,,,104686
1949,,8868,,B,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,,,,,104686
1950,,17200,,B,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,,,,,10624
1951,,17200,,B,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,,,,,10624
1952,,13969,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,,,,,,17106
1953,,13392,,B,,Binding affinity for 5-hydroxytryptamine 1D receptor,,,,,,,17106
1954,,1742,,B,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,,,,,17106
1955,,1742,,B,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,,,,,17106
1956,Striatum,14331,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,,,,,,17106
1957,,12861,,F,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,,,,,,17106
1958,,12861,,B,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,,,,,,17106
1959,,12861,,B,,Binding activity radioligand.,,,,,,,17106
1960,,12861,,B,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,,,,,17106
1961,,12861,,B,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,,,,17106
1962,,12861,,B,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,,,,,17106
1963,,675,,B,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,,,,,17106
1964,,12490,,B,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,,,,,,17106
1965,,11828,,B,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,,,,,,17106
1966,,11866,,B,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,,,,,,17106
1967,,773,,B,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,,Sus scrofa,9823.0,,,105
1968,,13047,,B,,The compound was tested for intrinsic activity against 5-HT1D receptor,,,Oryctolagus cuniculus,9986.0,,,105
1969,,13047,,B,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,Oryctolagus cuniculus,9986.0,,,105
1970,,13047,,B,,The compound was tested for binding affinity against 5-HT1D receptor,,,Oryctolagus cuniculus,9986.0,,,105
1971,,188,,B,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,,,,,,10578
1972,,10639,,F,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,,,,,,10578
1973,,12438,,F,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,,,,,,10578
1974,,12438,,B,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,,,,,,10578
1975,,15854,,B,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,,,,,10578
1976,,10394,,B,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,,,,,10578
1977,,12092,,B,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,,,,,,10578
1978,,3389,,B,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,,,,,,10578
1979,,6011,,B,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,,,,,,105
1980,,4639,,B,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,,,,,,105
1981,,2474,,B,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,,,,,,105
1982,,5014,,B,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,,,,,,105
1983,,17515,,B,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,,,,,,105
1984,,11866,,B,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,,,,,,105
1985,,4687,,B,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,,,,,,105
1986,,12146,,B,,Tested against 5-hydroxytryptamine 1D receptor,,,,,,,105
1987,,10321,,B,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,,,,,,105
1988,,13267,722.0,B,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,,,,HEK293,,105
1989,,1274,,B,,Binding affinity against 5-Hydroxytryptamine 1D receptor,,,Homo sapiens,9606.0,,,105
1990,,15250,,B,,,,,,,,,105
1991,,13706,485.0,B,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,,,CHO-K1,,106
1992,,13706,485.0,B,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,,,CHO-K1,,105
1993,,13706,722.0,B,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,,,,HEK293,,105
1994,,13706,722.0,B,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,,,,HEK293,,105
1995,,13047,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,,,,,105
1996,,13366,,B,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,,,,,,105
1997,,13366,,B,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,,,,,,105
1998,,1558,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,,,,,,105
1999,,12902,485.0,B,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,,,,CHO-K1,,105
2000,,13706,485.0,B,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,,,CHO-K1,,105
2001,,13706,,F,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,,,,,,105
2002,,13706,,F,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,,,,,105
2003,,14251,,F,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,,,,,105
2004,,14251,,F,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,,,,,105
2005,,14251,,F,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,,,,,105
2006,,13313,,B,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,,,,,,105
2007,,13313,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,,,,,,105
2008,,13366,,B,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,,,,,,105
2009,,13051,,B,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,,,,,,105
2010,,12903,449.0,B,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,,,,CHO,,105
2011,,12469,,B,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,,Homo sapiens,9606.0,,,105
2012,,5619,,B,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,,,,,,17106
2013,,13047,,B,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,,Oryctolagus cuniculus,9986.0,,,105
2014,,16633,,B,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,,,,,,105
2015,,16633,,B,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,,,,,105
2016,,16633,,B,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,,,,,105
2017,,16633,,B,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,,,,,,105
2018,,3269,,B,,Affinity against 5-hydroxytryptamine 1D receptor alpha,,,,,,,105
2019,,12409,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,,,,,,105
2020,,13706,,F,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,,,,,106
2021,,13706,722.0,B,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,,,,HEK293,,106
2022,,13706,722.0,B,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,,,,HEK293,,106
2023,,12903,449.0,B,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,,,,CHO,,106
2024,,13047,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,,,,,106
2025,,13366,,B,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,,,,,106
2026,,13366,,B,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,,,,,106
2027,,13366,,B,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,,,,,106
2028,,13366,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,,,,,,106
2029,,13366,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,,,106
2030,,12469,449.0,B,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,,,,CHO,,106
2031,,13706,485.0,B,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,,,,CHO-K1,,106
2032,,13706,485.0,B,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,,,,CHO-K1,,106
2033,,13706,,F,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,,,,,106
2034,,12902,485.0,B,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,,,,CHO-K1,,106
2035,,13051,,B,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,,,,,,105
2036,,12903,449.0,B,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,,,,CHO,,106
2037,,1558,485.0,F,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,,,,CHO-K1,,105
2038,,1558,485.0,F,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,,,,CHO-K1,,105
2039,,1558,485.0,F,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,,,,CHO-K1,,105
2040,,1558,485.0,F,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,,,,CHO-K1,,105
2041,,1558,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,,,,,,105
2042,,13047,,B,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,,Oryctolagus cuniculus,9986.0,,,106
2043,,13313,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,,,,,,105
2044,,13313,,B,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,,,,,,105
2045,,12409,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,,,,,,105
2046,,15250,449.0,B,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,,,,CHO,,10618
2047,,1348,,B,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,,Homo sapiens,9606.0,,,10618
2048,,1348,,B,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,,,,,,10618
2049,,4234,,B,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,,Homo sapiens,9606.0,,,10618
2050,,16209,,B,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,,,,,,10618
2051,,10444,,B,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,,,,,,10618
2052,,3935,,B,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,,,,,,10618
2053,,15818,,B,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,,,,,,10618
2054,,17085,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,,,,,,10618
2055,,12936,449.0,B,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,,Homo sapiens,9606.0,CHO,,10618
2056,,6166,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,,,,,,10618
2057,,15779,449.0,B,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,,CHO,,10618
2058,,15779,449.0,B,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,,,,CHO,,10618
2059,,15779,449.0,B,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,,,,CHO,,10618
2060,,13181,,B,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,,,,,,10618
2061,,4199,449.0,B,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,,,,CHO,,10618
2062,,14875,,B,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,,,,,,10618
2063,,15146,449.0,B,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,,,,CHO,,10618
2064,,5213,,B,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,,,,,,10618
2065,,12146,,B,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,,,,,,10618
2066,,13267,449.0,B,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,,,,CHO,,10618
2067,,14818,449.0,B,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,,,,CHO,,10618
2068,,4829,449.0,B,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,,,,CHO,,10618
2069,,4373,,B,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,,,,,,10618
2070,,4373,,B,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,,,,,,10618
2071,,14159,,B,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,,,,,,10618
2072,,16633,,B,,Binding affinity towards 5-hydroxytryptamine 1E receptor,,,,,,,10618
2073,,17085,,F,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,,,,,,279
2074,,17085,,F,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,,,,,,279
2075,,16209,,F,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,,,,,,279
2076,,16209,,F,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,,,,,,279
2077,,17085,,F,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,,,,,,279
2078,,14159,,B,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,,,,,,279
2079,,15250,449.0,B,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,,,,CHO,,279
2080,,3805,,B,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,,,,,,279
2081,,16190,449.0,B,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,,,,CHO,,279
2082,,16190,,B,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,,,,,,279
2083,,16209,,B,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,,,,,,279
2084,,16209,,B,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,,,,,,279
2085,,16209,,B,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,,,,,,279
2086,,6866,,B,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,,,,,,279
2087,,17085,,B,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,,,,,,279
2088,,16312,,B,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,,,,,,279
2089,,6166,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,,,,,,279
2090,,15779,449.0,B,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,,CHO,,279
2091,,4199,449.0,B,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,,,,CHO,,279
2092,,14875,,B,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,,,,,,279
2093,,15146,449.0,B,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,,,,CHO,,279
2094,,5213,,B,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,,,,,,279
2095,,14818,449.0,B,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,,,,CHO,,279
2096,,4829,449.0,B,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,,,,CHO,,279
2097,,4829,449.0,B,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,,,,CHO,,279
2098,,4373,,B,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,,,,,,279
2099,,4373,,B,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,,,,,,279
2100,,5014,,B,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,,,,,,279
2101,,11662,,B,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,,,,,,104686
2102,,11662,,B,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,,,,,104686
2103,,11662,,B,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,,,,,104686
2104,,14093,,B,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,,,,,12687
2105,,11200,,F,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",In vivo,,,,,,104686
2106,,11200,,F,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,,,104686
2107,,12352,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,,,,,,17005
2108,,13657,,B,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,,Bos taurus,9913.0,,,22226
2109,,14331,,B,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,,Bos taurus,9913.0,,,22226
2110,,14331,,B,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,,Bos taurus,9913.0,,,22226
2111,,14331,,B,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,,,,,,22226
2112,,12685,,B,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,,Cavia porcellus,10141.0,,,104784
2113,,14389,,B,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,,Cavia porcellus,10141.0,,,104784
2114,,14386,,B,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,,Cavia porcellus,10141.0,,,104784
2115,,5732,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,,,,,,104784
2116,,16293,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,,,,,104784
2117,,2078,,B,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,,,,,,104784
2118,,5486,,B,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,,,,,10209
2119,,11820,,B,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,In vivo,,,,,,104826
2120,,10297,,B,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,,,,,104826
2121,,13704,,B,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,,,,,,104826
2122,,10297,,B,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,,Mus musculus,10090.0,,,104826
2123,,11820,,B,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,In vivo,,,,,,104826
2124,,10297,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,,Mus musculus,10090.0,,,104826
2125,,11555,,B,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,104826
2126,,11555,,B,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,,,,,,104826
2127,,11555,,B,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,,,,,,104826
2128,,10297,,B,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,Mus musculus,10090.0,,,104826
2129,,16688,,B,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,,Sus scrofa,9823.0,,,104784
2130,,16688,,B,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,,Sus scrofa,9823.0,,,104784
2131,,5333,,B,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,,,,,22226
2132,,4437,,B,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,,,,,22226
2133,,5033,,B,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,,Sus scrofa,9823.0,,,17005
2134,,15267,,B,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,,,,,104686
2135,,15267,,B,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,,,,,104686
2136,,11820,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,,,,,,104826
2137,,9069,,B,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,,,,,104686
2138,,9162,,B,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,,Rattus norvegicus,10116.0,,,104686
2139,,9162,,B,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,,,,,,104686
2140,,9162,,B,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,,,,,,104686
2141,,10428,,F,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,,,,,,104686
2142,,9628,,B,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,,,,,,104686
2143,,12704,,B,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,,,,,,104686
2144,,15453,,B,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,Rattus norvegicus,10116.0,,,104686
2145,,188,,B,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,,,,,,104686
2146,,10349,,B,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,,,,,,104686
2147,,10349,,B,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,,,,,,104686
2148,,8868,,B,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,,,,,104686
2149,,10025,,B,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,,,,,104686
2150,,10025,,B,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,,,,,104686
2151,,11702,,B,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,,,,,,104686
2152,,11702,,B,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,,,,,,104686
2153,,11702,,B,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,,,,,,104686
2154,,11702,,F,,Compound was tested for the inhibition of quipazine induced head twitches in rats,,,,,,,104686
2155,,11702,,F,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,,,,,,104686
2156,Hippocampus,10085,,B,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,,,,,,104686
2157,Hippocampus,10085,,B,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,,,,,,104686
2158,Brain,9630,,B,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,,Rattus norvegicus,10116.0,,,104686
2159,,11070,,B,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,,,,,,104686
2160,,9841,,B,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,,,,Membranes,104686
2161,,9841,,B,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,,,,Membranes,104686
2162,,13291,,B,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,,,,,,104686
2163,,10590,,F,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,,,,,,104686
2164,Brain,9064,,B,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,,Rattus norvegicus,10116.0,,,104686
2165,,12268,,B,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,,Rattus norvegicus,10116.0,,Membranes,104686
2166,Brain,13508,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,,,,,,104686
2167,,11279,,F,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,,,,,104686
2168,,11200,,F,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,,,,,,104686
2169,,11200,,F,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,,,104686
2170,,11200,,F,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,,,,,104686
2171,,11200,,F,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,,,,,104686
2172,,11200,,F,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,,,104686
2173,Brain,9231,,B,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,,,,,,104686
2174,,9737,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,,,,,104686
2175,Brain,9737,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,,,,,104686
2176,,9737,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,,,,,,104686
2177,,9737,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,,,,,104686
2178,,11828,,B,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,,Rattus norvegicus,10116.0,,,104686
2179,,12253,,B,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,,,,,,104686
2180,,12253,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,,,,,,104686
2181,,11279,,F,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,,,,,,104686
2182,,11866,,B,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,,,,,,104686
2183,,14424,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,,Rattus norvegicus,10116.0,,,104686
2184,,15180,,B,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,,Rattus norvegicus,10116.0,,,104686
2185,,15180,,B,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,,Rattus norvegicus,10116.0,,,104686
2186,,9786,,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,,Rattus norvegicus,10116.0,,,104686
2187,,12132,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,,,,,,104686
2188,,5486,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,,,,,,104686
2189,,15316,,B,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,,,,,,104686
2190,,16429,,B,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,,,,,,104686
2191,,14617,,B,,pKi value for 5-hydroxytryptamine 2 receptor binding site,,,,,,,104686
2192,Brain,11351,,B,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,,,,,,104686
2193,,11279,,F,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,,,,,104686
2194,,9523,,B,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,105075
2195,,9523,,B,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,105075
2196,,9523,,B,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,105075
2197,,9523,,B,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,105075
2198,,9523,,B,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,105075
2199,,9523,,B,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,105075
2200,,9523,,B,,Hill coefficient of compound was determined,,,,,,,105075
2201,,4771,,B,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,,,,,,22226
2202,,5033,,B,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,,Rattus norvegicus,10116.0,,,104686
2203,,10845,,B,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,,,,,,12687
2204,,10845,,B,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,,,,,,12687
2205,,16288,,B,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,,,,,,12687
2206,,16288,,B,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,,,,,,12687
2207,,16190,,B,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,,,,,,12687
2208,,12463,,B,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,,Rattus norvegicus,10116.0,,,104686
2209,,9699,,B,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,,,,,,104686
2210,,9699,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,,,,,,104686
2211,,11662,,B,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,,,,,104686
2212,,1205,,B,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,,,,,,104784
2213,,11376,,B,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,,,,,,22226
2214,,11376,,B,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,,,,,,104784
2215,,4639,,B,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,,,,,,104784
2216,,2222,,B,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,,,,,,104784
2217,,1558,,B,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,104784
2218,,1089,,B,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,,,,,,104784
2219,,386,,B,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,,,,,Brain membranes,104784
2220,,2474,,B,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,,,,,,104784
2221,,17066,,B,,Binding affinity towards 5-HT2 receptor,,,,,,,104784
2222,,959,,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,,,,,104784
2223,,6398,,B,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,,,,,,104784
2224,,11889,,B,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,,,,,,104686
2225,,4221,,B,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,,,,,104784
2226,,11026,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,,,,,,104784
2227,,11866,,B,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,,,,,,104784
2228,,4221,,B,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,,,,,104784
2229,,13950,,B,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,,,,,22226
2230,,1263,,B,,5-hydroxytryptamine 2 receptor binding affinity,,,,,,,104784
2231,,13291,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,,,,,,17005
2232,,10812,,B,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,,,,,,17005
2233,,13020,,B,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,,,,,104784
2234,,13021,,B,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,,,,,,104784
2235,,13020,,B,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,,,,,104784
2236,,14532,,B,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,,,,,,17005
2237,,13944,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor,,,,,,,17005
2238,,14331,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor,,,,,,,17005
2239,,14118,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,,,,,17005
2240,,13033,,B,,Binding affinity against serotonergic 5-HT2 receptor,,,,,,,17005
2241,,10321,,B,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,,,,,,17005
2242,,12918,,B,,Compound was evaluated for the binding affinity at 5- HT2 receptor,,,,,,,17005
2243,,15120,,B,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,,,,,,17005
2244,,2613,,B,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,,,,,,17005
2245,,13378,,B,,Inhibitory activity against cloned human 5-HT2 receptor,,,Homo sapiens,9606.0,,,104784
2246,,2331,449.0,B,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,,Homo sapiens,9606.0,CHO,,104784
2247,,2331,449.0,B,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,,Homo sapiens,9606.0,CHO,,104784
2248,,2331,449.0,B,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,,Homo sapiens,9606.0,CHO,,104784
2249,,2331,449.0,B,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,,Homo sapiens,9606.0,CHO,,104784
2250,,4170,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,104784
2251,,15453,,B,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,,,,,104784
2252,,1479,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,17005
2253,,11139,,B,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,,,,,,104686
2254,,13969,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,,,,,,17005
2255,,13392,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,17005
2256,,14430,,B,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,,,,,,17005
2257,,13181,,B,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,,Cavia porcellus,10141.0,,,107
2258,,17200,,B,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,,,,51
2259,,17200,,B,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,,,,107
2260,,17200,,B,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,,,,51
2261,,13463,,B,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,,,,,,107
2262,,6347,449.0,B,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,,,,CHO,,107
2263,,6857,449.0,F,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,,Homo sapiens,9606.0,CHO,,107
2264,,4176,,F,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,,,,,107
2265,,4176,,F,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,,,,,,107
2266,,4176,,F,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,,,,,107
2267,,6347,449.0,B,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,,,,CHO,,107
2268,,6347,449.0,B,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,,,,CHO,,107
2269,,15331,,B,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,,,,,,107
2270,,16146,,B,,Inhibition of human 5-hydroxytryptamine 2A receptor,,,Homo sapiens,9606.0,,,107
2271,,15250,449.0,B,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,,CHO,,107
2272,,13631,,B,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,,,,,,107
2273,,3805,,B,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,,,,,,107
2274,,4011,449.0,B,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,,,,CHO,,107
2275,,4012,449.0,B,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,,,,CHO,,107
2276,,6366,307.0,B,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,,,,L929,,107
2277,,15949,449.0,B,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,,CHO,,107
2278,,14093,,F,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,,,,,,107
2279,,13481,,F,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,,,,107
2280,,6347,449.0,B,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,,,,CHO,,107
2281,,6347,449.0,B,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,,,,CHO,,107
2282,,14093,,F,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,,,,,,107
2283,,14093,,F,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,,,,,,107
2284,,13481,,F,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,107
2285,,14442,,B,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,,,,,,107
2286,,14442,,B,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,107
2287,,14755,,B,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,,,,,,107
2288,,16441,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,,,,,,107
2289,,14744,,B,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,,,,,,107
2290,,16659,449.0,B,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,,CHO,,107
2291,,3307,,B,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,,,,,,107
2292,,6857,,B,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,,Homo sapiens,9606.0,,,107
2293,,5635,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,,,,,,107
2294,,4234,,B,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,,Homo sapiens,9606.0,,,107
2295,,15527,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,,,,,107
2296,,6588,449.0,B,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,,,,CHO,,107
2297,,13631,,B,,Binding affinity towards human 5-HT2A receptor in BEK cells,,,,,,,107
2298,,17723,,B,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,,,,,,107
2299,,14770,,B,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,,,,,107
2300,,16293,,B,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,,Homo sapiens,9606.0,,,107
2301,,16209,,B,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,,,,107
2302,,12469,,B,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,,,,,,107
2303,,15363,,B,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,,,,,,107
2304,,15363,,B,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,,,,,,107
2305,,16441,,B,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,,,,,,107
2306,,8,,B,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,,,,,,107
2307,,4176,722.0,B,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,,,,HEK293,,107
2308,,17085,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,,,,,,107
2309,,17200,,B,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,,,,107
2310,,17200,,B,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,Homo sapiens,9606.0,,,107
2311,,4013,449.0,B,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,,Homo sapiens,9606.0,CHO,,107
2312,,5088,,B,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,107
2313,,5088,,B,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,,Homo sapiens,9606.0,,,107
2314,,5088,,B,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,,,,,,107
2315,,5088,,B,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,,Homo sapiens,9606.0,,,107
2316,,5088,,B,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,,,,,,107
2317,,5088,,B,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,,,,107
2318,,9786,,B,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,,,,,,104686
2319,,9205,,B,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,,Rattus norvegicus,10116.0,,,104686
2320,,11257,,B,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,,,,,,104686
2321,,9362,,B,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,,,,,104686
2322,,9362,,B,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,,,,,104686
2323,,10590,,B,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,,,,,,104686
2324,,10468,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,,,,,104686
2325,,13050,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,,,,,,104686
2326,,11624,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,,,,,,104686
2327,,10468,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,,,,,104686
2328,,10330,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,,,,,104686
2329,,10062,,B,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,,,,,104686
2330,,11642,,B,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,,,,,104686
2331,,10062,,B,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,,,,,104686
2332,,13427,,B,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,In vitro,,,,,,104686
2333,,12280,,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,Rattus norvegicus,10116.0,,,104686
2334,,4101,,B,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,,Rattus norvegicus,10116.0,,,104686
2335,,10062,,B,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,,,,,,104686
2336,,11147,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,,,,,,104686
2337,,2395,485.0,B,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,,Rattus norvegicus,10116.0,CHO-K1,,104686
2338,,2395,485.0,B,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,,Rattus norvegicus,10116.0,CHO-K1,,104686
2339,,9098,,B,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,,Rattus norvegicus,10116.0,,,104686
2340,,9098,,B,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,,,,,,104686
2341,,9098,,B,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,,Rattus norvegicus,10116.0,,,104686
2342,,9443,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,104686
2343,,9443,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,,,,,104686
2344,,9699,,B,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,,,,,,104686
2345,,9699,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,,,,,,104686
2346,,9098,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,,,,,104686
2347,,3070,,B,,Affinity for 5-hydroxytryptamine 2 receptor,,,Rattus norvegicus,10116.0,,,104686
2348,,9547,,B,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,,,,,,104686
2349,,10444,,B,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,,,,,,104686
2350,,14617,,B,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,,,,,,104686
2351,,14617,,B,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,,,,,,104686
2352,,11130,,B,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,,,,,,104686
2353,,11130,,B,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),In vivo,,,,,,104686
2354,Brain,14542,,B,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,,,,,,104686
2355,,2797,,B,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,,,,,,104686
2356,,11332,,B,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,,,,,104686
2357,,11332,,B,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,,,,,104686
2358,Frontal cortex,10752,,B,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,,,,,,104686
2359,,1185,,B,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,,,,,104686
2360,,1185,,B,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,,,,,104686
2361,,11624,,B,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,,Rattus norvegicus,10116.0,,,104686
2362,,1344,,B,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,,,,,,104686
2363,Striatum,15453,,B,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,,Rattus norvegicus,10116.0,,,104686
2364,,11662,,B,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,,,,,104686
2365,,11662,,B,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,,,,,104686
2366,,10796,,B,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,,,,,,104686
2367,,9069,,B,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,,,,,104686
2368,,8814,,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,,Rattus norvegicus,10116.0,,,104686
2369,,8908,,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,,Rattus norvegicus,10116.0,,,104686
2370,,9098,,B,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,,,,,104686
2371,,9098,,B,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,,,,,,104686
2372,,9098,,B,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,,,,,104686
2373,,9098,,B,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,,,,,,104686
2374,,9098,,B,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,,,,,,104686
2375,,9098,,B,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,,,,,,104686
2376,,9098,,B,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,,,,,,104686
2377,,9161,,B,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,,,,,,104686
2378,,9161,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,,,,,,104686
2379,,9161,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,,,,,,104686
2380,,9161,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,,,,,,104686
2381,,9161,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,,,,,,104686
2382,,9161,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,,,,,,104686
2383,,9161,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,,,,,,104686
2384,,9161,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,,,,,,104686
2385,,9161,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,,,,,,104686
2386,,9161,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,,,,,,104686
2387,,9161,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,,,,,,104686
2388,,9161,,B,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,,,,,,104686
2389,,12094,,B,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,,,,,,104686
2390,,12018,,B,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,,,,,,104686
2391,,10394,,B,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,,,,,,104686
2392,,15260,,B,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,,,,,,104686
2393,,11624,,B,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,,Rattus norvegicus,10116.0,,,104686
2394,,13654,,B,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,,,,,,104686
2395,,9541,,B,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,,,,,,104686
2396,,11933,,B,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,,,,,,104686
2397,,15538,,B,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,,,,,,104686
2398,,15538,,B,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,,,,,,104686
2399,,15538,,B,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,,,,,,104686
2400,,8841,,B,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,,,,,,104686
2401,,1455,,B,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,,,,,,104686
2402,,1455,,B,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,,,,,,104686
2403,,11752,,B,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,,,,,,104686
2404,Brain,11642,,B,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,,,,,,104686
2405,,12092,,B,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,,,,,,104686
2406,,3967,,B,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,,,,,,104686
2407,,12771,,B,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,Rattus norvegicus,10116.0,,,104686
2408,,11642,,B,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,,,,,,104686
2409,,11628,,B,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,,,,,,104686
2410,,13654,,B,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,,,,,104686
2411,,11200,,F,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,,,104686
2412,,11200,,F,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,,,104686
2413,,11200,,F,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",In vivo,,,,,,104686
2414,,11200,,F,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",In vivo,,,,,,104686
2415,,11200,,F,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",In vivo,,,,,,104686
2416,,11200,,F,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",In vivo,,,,,,104686
2417,Brain,15436,,B,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,,,,,,12687
2418,,15436,,B,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,Rattus norvegicus,10116.0,,,12687
2419,,14025,,B,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,,,,,,12687
2420,,4342,,B,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,,,,,,12687
2421,,13735,,B,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,,Rattus norvegicus,10116.0,,,12687
2422,,5816,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,Rattus norvegicus,10116.0,,,12687
2423,,14287,,B,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,,,,,,12687
2424,,15738,,B,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,,,,,,12687
2425,,15738,,B,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,,Rattus norvegicus,10116.0,,,12687
2426,,15026,,B,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,,,,,,12687
2427,,16647,,B,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,,,,,12687
2428,,16647,,B,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,,,,,,12687
2429,,13345,,B,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,,Rattus norvegicus,10116.0,,,12687
2430,,1543,,B,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,,,,,Membranes,12687
2431,,12444,,B,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,,,,,,12687
2432,,16404,,B,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,,,,,,12687
2433,,16404,449.0,B,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,,,,CHO,,12687
2434,,15577,,B,,Kinetic inhibition constant evaluated by measuring serotonergic activity,,,,,,,12687
2435,,15577,,B,,Serotonergic activity of the compound.,,,,,,,12687
2436,,2495,,B,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,,,,,,12687
2437,,15042,,B,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,,Rattus norvegicus,10116.0,,,12687
2438,,15026,,B,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,,,,,,12687
2439,,12919,,F,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,Rattus norvegicus,10116.0,,,12687
2440,,12919,,F,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,Rattus norvegicus,10116.0,,,12687
2441,,12919,,F,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,Rattus norvegicus,10116.0,,,12687
2442,,15194,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,12687
2443,,15194,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,,,,,,12687
2444,,4820,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,107
2445,,6736,,B,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,,,,,,107
2446,,5163,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,,,,,,107
2447,,5163,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,,,,,,107
2448,,6011,,B,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,,,,,,107
2449,,14294,,B,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,,Homo sapiens,9606.0,,,107
2450,,5014,,B,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,,,,,,107
2451,,17066,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,107
2452,,17515,,B,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,,,,,,107
2453,,6736,,B,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,,,,,,107
2454,,5163,,B,,Affinity for 5-hydroxytryptamine 2A receptor,,,,,,,107
2455,,16911,723.0,B,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,,,,NIH3T3,,107
2456,,6841,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,,,,,107
2457,,6119,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,,,,,,107
2458,,3962,,B,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,,,,,,107
2459,,4373,,B,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,,,,,,107
2460,,4373,,B,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,,,,,,107
2461,,3962,,F,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,,,,,,107
2462,,1633,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,,,,,107
2463,,4373,,B,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,,,,,,107
2464,,6576,,B,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,,,,,,107
2465,,4687,,B,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,107
2466,,16946,,B,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,,,,,,107
2467,,14159,,B,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,,,,,,107
2468,,3032,449.0,B,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,,Mus musculus,10090.0,CHO,,107
2469,,16655,,B,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,,,,,,107
2470,,13964,,B,,Binding affinity at 5-hydroxytryptamine 2A receptor,,,,,,,107
2471,,16989,,B,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,,,,,,107
2472,,16117,,B,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,,,,,,107
2473,,16700,,B,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,,,,,,107
2474,,3269,,B,,Affinity against 5-hydroxytryptamine 2A receptor,,,,,,,107
2475,,1274,,B,,Binding affinity against 5-Hydroxytryptamine 2A receptor,,,Homo sapiens,9606.0,,,107
2476,,1317,,B,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,,,,,107
2477,,12146,,B,,Tested against 5-hydroxytryptamine 2A receptor,,,,,,,107
2478,,12652,,B,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,,,,,105075
2479,,12652,,B,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,,,,,,105075
2480,,12652,,B,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,,,,,,105075
2481,,12652,,B,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,,,,,105075
2482,,16647,,B,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,,,,,,107
2483,,15851,722.0,B,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,,Homo sapiens,9606.0,HEK293,,227
2484,,6857,449.0,F,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,,Homo sapiens,9606.0,CHO,,227
2485,,3805,,B,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,,,,,,227
2486,,6491,,B,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,,Homo sapiens,9606.0,,,227
2487,,14093,,F,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,,,,,,227
2488,,13481,,F,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,,,,,,227
2489,,14093,,F,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,,,,,,227
2490,,14093,,F,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,,,,,,227
2491,,14093,,F,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,,,,,,227
2492,,13481,,F,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,,,,,227
2493,,14442,,B,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,,,,,,227
2494,,14442,,B,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,,,,,,227
2495,,14442,,B,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,,,,,227
2496,,12369,,B,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,,,,,,107
2497,,12369,,B,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,,,,,,107
2498,,12369,,B,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,,,,,,107
2499,,14447,,B,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,,,,,,107
2500,,14447,,B,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,,,,,,107
2501,,17451,723.0,B,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,,NIH3T3,,107
2502,,6857,449.0,F,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,,,CHO,,107
2503,,6857,449.0,F,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,Homo sapiens,9606.0,CHO,,107
2504,,5635,,B,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,,,,,,104817
2505,,12861,,B,,Binding activity radioligand.,,,,,,,107
2506,,12861,,B,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,,,,,107
2507,,5105,307.0,B,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,,,,L929,,107
2508,,5104,307.0,B,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,,,,L929,,107
2509,,5105,307.0,B,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,,,,L929,,107
2510,,5105,307.0,B,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,,,,L929,,107
2511,,5254,,B,,Binding affinity against 5-HT2A receptor,,,,,,,107
2512,,5254,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor,,,,,,,107
2513,,13267,722.0,B,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,,,,HEK293,,107
2514,,13267,722.0,B,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,,,,HEK293,,107
2515,,14157,722.0,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,,Homo sapiens,9606.0,HEK293,,107
2516,,12936,722.0,B,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,Homo sapiens,9606.0,HEK293,,107
2517,,14068,,B,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,,,,,,107
2518,,12936,722.0,B,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,Homo sapiens,9606.0,HEK293,,107
2519,,12936,722.0,B,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,Homo sapiens,9606.0,HEK293,,107
2520,,4540,722.0,B,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,,Homo sapiens,9606.0,HEK293,,107
2521,,6166,,B,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,,,,,,107
2522,,17296,722.0,B,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,,,,HEK293,,107
2523,,17296,722.0,B,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,,,,HEK293,,107
2524,,17296,722.0,B,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,,,,HEK293,,107
2525,,15779,722.0,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,,Homo sapiens,9606.0,HEK293,,107
2526,,14391,722.0,B,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,,,,HEK293,,107
2527,,15851,722.0,B,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,,,,HEK293,,107
2528,,15851,722.0,B,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,,Homo sapiens,9606.0,HEK293,,107
2529,,3832,722.0,B,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,,,,HEK293,,107
2530,,3833,722.0,B,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,,,,HEK293,,107
2531,,12936,722.0,B,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,Homo sapiens,9606.0,HEK293,,107
2532,,17451,723.0,B,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,,,,NIH3T3,,107
2533,,17451,723.0,B,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,,NIH3T3,,107
2534,,17451,723.0,B,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,,NIH3T3,,107
2535,,4199,722.0,B,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,,,,HEK293,,107
2536,,1883,485.0,B,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,,,,CHO-K1,,107
2537,,1883,485.0,B,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,,,,CHO-K1,,107
2538,,14875,,B,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,,Homo sapiens,9606.0,,,107
2539,,15146,722.0,B,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,,,,HEK293,,107
2540,,5213,722.0,B,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,,,,HEK293,,107
2541,,16404,449.0,B,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,,Homo sapiens,9606.0,CHO,,107
2542,,14818,722.0,B,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,,,,HEK293,,107
2543,,4829,722.0,B,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,,,,HEK293,,107
2544,,12652,723.0,F,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,,,,NIH3T3,,10620
2545,,4682,723.0,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,,,,NIH3T3,,107
2546,,12652,,F,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,,,,,,10620
2547,,4921,,B,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,,,,,,10621
2548,,4921,,B,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,,,,,,10621
2549,,16312,,B,,Binding affinity against rabbit aorta 5-HT2A receptor,,,Oryctolagus cuniculus,9986.0,,,107
2550,,14998,,B,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,,Oryctolagus cuniculus,9986.0,,,107
2551,,14025,,B,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,,Oryctolagus cuniculus,9986.0,,,107
2552,,13047,,B,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,,Oryctolagus cuniculus,9986.0,,,107
2553,,13047,,B,,The compound was tested for binding affinity against 5-HT2A receptor,,,Oryctolagus cuniculus,9986.0,,,107
2554,,1883,485.0,B,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,,,,CHO-K1,,10576
2555,,13463,,B,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,,,,,,12687
2556,,13463,,B,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,,,,,12687
2557,Stomach,13463,,B,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,,,,,,12687
2558,Stomach,13463,,B,,Binding affinity for 5-HT 2A in rat stomach fundus,,,Rattus norvegicus,10116.0,,,12687
2559,,13463,,B,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,,,,,12687
2560,,16326,723.0,B,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,,,,NIH3T3,,12687
2561,,14093,,F,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,,,,,,12687
2562,,14093,,F,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,,,,,,12687
2563,,15740,,B,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,,,,,12687
2564,,16633,,B,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,,,,,,12687
2565,,17200,,F,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,,Rattus norvegicus,10116.0,,,12687
2566,,17133,,B,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,,,,,12687
2567,,17133,,B,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,,,,,12687
2568,,17133,,B,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,,,,,12687
2569,,17200,,F,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,,,,,12687
2570,,15363,,F,,Efficacy at 5-hydroxytryptamine 2A receptor,,,,,,,12687
2571,,17200,,B,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,,,,,12687
2572,,17200,,B,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,Rattus norvegicus,10116.0,,,12687
2573,,17200,,B,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,,Rattus norvegicus,10116.0,,,12687
2574,,17200,,F,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,Rattus norvegicus,10116.0,,,12687
2575,,17200,,F,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,,,,,12687
2576,,17211,,B,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,,,,,,12687
2577,,17331,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,,,,,,12687
2578,,13565,,B,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,,,,,,12687
2579,,13730,,B,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,,,,,,12687
2580,,12416,,B,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,,,,,,12687
2581,,15295,,B,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,12687
2582,,1742,,B,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,,,,,,12687
2583,,15295,,B,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,,,,,,12687
2584,,14970,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,,,,,,12687
2585,,16693,,B,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,,,,,,12687
2586,,14776,,B,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,,Rattus norvegicus,10116.0,,,12687
2587,,14286,,B,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,12687
2588,,17200,,B,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,,Rattus norvegicus,10116.0,,,12687
2589,,15306,,B,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,,,,,,12687
2590,,14178,,B,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,,Rattus norvegicus,10116.0,,,12687
2591,,14229,,B,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,,Rattus norvegicus,10116.0,,,12687
2592,,12884,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,,,,,,12687
2593,,13149,,B,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,,,,,,12687
2594,,15295,,B,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,,Rattus norvegicus,10116.0,,,12687
2595,,15740,,B,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,,,,,,12687
2596,,15185,,B,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,,,,,,12687
2597,,15185,,B,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,,,,,,12687
2598,,17529,,B,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,,,,,,12687
2599,,14826,,B,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,,,,,12687
2600,,17211,,B,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,,,,,,12687
2601,,14826,,B,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,,,,,12687
2602,,14093,,B,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,,,,,12687
2603,,14093,,B,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,,,,,,12687
2604,,13246,723.0,B,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,,,,NIH3T3,,12687
2605,,13246,,B,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,,,,,,12687
2606,,15436,,B,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,Rattus norvegicus,10116.0,,,12687
2607,,15436,,B,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,Rattus norvegicus,10116.0,,,12687
2608,Brain,14442,,B,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,,,,,,12687
2609,,12457,,B,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,,,,,,12687
2610,,12457,723.0,B,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,,,,NIH3T3,,12687
2611,,14755,,F,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,,,,,,12687
2612,,4707,,B,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,,,,,,12687
2613,,13297,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor,,,,,,,12687
2614,,17331,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,,,,,,12687
2615,,4664,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,,,,,,12687
2616,,16633,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,,,,12687
2617,,4664,723.0,B,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,,Rattus norvegicus,10116.0,NIH3T3,,12687
2618,,16133,,B,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,,,,12687
2619,,16133,,B,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,12687
2620,,14060,,B,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,,Rattus norvegicus,10116.0,,,12687
2621,,16326,,B,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,,,,12687
2622,,16659,449.0,B,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,,CHO,,12687
2623,,14776,,B,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,,,,,,12687
2624,,13481,,B,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,,,,,12687
2625,,17386,,B,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,,,,,,12687
2626,,6611,,B,,Binding affinity for 5-hydroxytryptamine 2A receptor,,,Rattus norvegicus,10116.0,,,12687
2627,,14423,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,,,,,,12687
2628,,15412,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,,,,,,12687
2629,,15412,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,,,,,,12687
2630,,6238,,B,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,,,,,,12687
2631,,6648,,B,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,,,,,,12687
2632,,5667,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,,,,,,12687
2633,,6611,,B,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,,Rattus norvegicus,10116.0,,,12687
2634,,13481,,B,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,12687
2635,,13481,,B,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,,,,,,12687
2636,,15558,723.0,B,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,,,,NIH3T3,,12687
2637,,6013,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,12687
2638,,16633,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,,,,12687
2639,,6013,,B,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,,,,,,12687
2640,,6013,,B,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,,Rattus norvegicus,10116.0,,,12687
2641,,6013,,B,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,,,,,,12687
2642,,6013,,B,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,,,,,,12687
2643,,6013,,B,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,,,,,,12687
2644,,6013,,B,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,,,,,,12687
2645,,16293,,B,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,,,,,12687
2646,,17175,723.0,B,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,,,,NIH3T3,,12687
2647,,13278,,B,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,,Rattus norvegicus,10116.0,,,12687
2648,Caudate-putamen,3682,,B,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,,,,,,12687
2649,,2014,,B,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,,,,,,12687
2650,,2014,,B,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,,,,,,12687
2651,,4932,,B,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,,,,,,12687
2652,,4932,,B,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,,,,,,12687
2653,,3935,,B,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,,,,,,12687
2654,Hippocampus,5432,,B,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,,Rattus norvegicus,10116.0,,,12687
2655,,15818,,B,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,,,,,12687
2656,,13672,,B,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,,,,,,12687
2657,,13672,,B,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,,,,,,12687
2658,,14749,723.0,B,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,,,,NIH3T3,,12687
2659,,13462,,B,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,,,,,,12687
2660,,15740,,B,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,,,,,12687
2661,,16647,,B,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,,,,,12687
2662,Brain,13345,,B,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,,,,,,12687
2663,,16740,,B,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,12687
2664,,16740,,B,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,12687
2665,,15535,,B,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,,Rattus norvegicus,10116.0,,,12687
2666,,16740,,B,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,12687
2667,,16740,,B,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,12687
2668,,16740,,B,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,12687
2669,,4795,,B,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,,Rattus norvegicus,10116.0,,,12687
2670,,8,,B,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,,,,,,12687
2671,,8,,B,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,,,,,,12687
2672,,17200,,B,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,,Rattus norvegicus,10116.0,,,12687
2673,,2148,,B,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,,Rattus norvegicus,10116.0,,,12687
2674,,13345,,B,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,,Rattus norvegicus,10116.0,,,105102
2675,,5088,,B,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,,,,12687
2676,,5088,,B,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,12687
2677,,17133,,B,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,,,,,,12687
2678,,17133,,B,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,,Rattus norvegicus,10116.0,,,12687
2679,,16532,,B,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,,,,,,12687
2680,,15086,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,,,,,,12687
2681,,2309,,B,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,Rattus norvegicus,10116.0,,,12687
2682,,12953,,B,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,,,,,,12687
2683,,12953,,B,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,,,,,,12687
2684,,12953,,B,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,,,,,,12687
2685,,16659,449.0,B,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,,,,CHO,,12687
2686,,16740,,B,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,,,,,12687
2687,,16740,,B,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,,,,,12687
2688,,17133,,B,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,,,,,,12687
2689,,17211,,B,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,,,,,,12687
2690,,17331,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,,,,,,12687
2691,,16633,,B,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,,,,,,12687
2692,,16633,,B,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,,,,,,12687
2693,,16633,,B,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,,,,,,12687
2694,,15026,,B,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,,,,,,12687
2695,,15026,,B,,Ratio of pKi of 5-HT2A to that of D2 receptor,,,,,,,12687
2696,,16404,,B,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,,,,,105093
2697,,16404,,B,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,,,,,105093
2698,,16404,,B,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,,,,,,105075
2699,,16404,,B,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,,,,,,12687
2700,,16326,,B,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,,,,,,12687
2701,,15847,,F,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,,,,,,12687
2702,,15847,,F,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,,,,,,12687
2703,,15329,,F,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,,,,,,12687
2704,Thoracic aorta,16404,,F,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,,,,,,12687
2705,Thoracic aorta,16404,,F,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,,,,,,12687
2706,Thoracic aorta,16404,,F,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,,,,,,12687
2707,,12861,,B,,Binding activity radioligand.,,,,,,,12687
2708,,12861,,B,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,,,,,12687
2709,,12861,,B,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,,,,,12687
2710,,12490,,B,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,,,,,,12687
2711,,12827,339.0,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,,,,N1E-115,,12687
2712,,12827,339.0,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,,,,N1E-115,,12687
2713,,12918,,B,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,,,,,,12687
2714,,12919,,F,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,,Rattus norvegicus,10116.0,,,12687
2715,,17723,,B,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,,,,,,108
2716,,6013,,B,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,,,,,108
2717,,16293,,B,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,,,,,,108
2718,,3857,,B,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,,,,,108
2719,,3857,,B,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,,,,,,108
2720,,3857,,B,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,,,,,108
2721,,15363,,B,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,,,,,108
2722,,15363,,B,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,,,,,108
2723,,16441,,B,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,,,,,,108
2724,,16441,,B,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,,,,,,108
2725,,4176,722.0,B,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,,,,HEK293,,108
2726,,17085,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,,,,,,108
2727,,17200,,B,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,,Homo sapiens,9606.0,,,108
2728,,5088,,B,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,,,,,,108
2729,,5088,,B,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,,,,,,108
2730,,5088,,B,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,,,108
2731,,5088,,B,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,,,,,108
2732,,16659,449.0,B,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,,,CHO,,108
2733,,16659,449.0,B,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,,,,CHO,,108
2734,,17451,723.0,B,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,,NIH3T3,,108
2735,,6857,449.0,F,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,Homo sapiens,9606.0,CHO,,108
2736,,3857,,B,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,,,,,108
2737,,12861,,B,,Binding activity radioligand.,,,,,,,108
2738,,12861,,B,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,,,,,108
2739,,5104,449.0,B,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,,,,CHO,,108
2740,,5105,449.0,B,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,,,,CHO,,108
2741,,5105,449.0,B,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,,,,CHO,,108
2742,,5254,,B,,Binding affinity against 5-HT2C receptor,,,,,,,108
2743,,13267,722.0,B,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,,,,HEK293,,108
2744,,14157,722.0,B,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,,Homo sapiens,9606.0,HEK293,,108
2745,,12936,722.0,B,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,,Homo sapiens,9606.0,HEK293,,108
2746,,14068,,B,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,,,,,,108
2747,,12936,722.0,B,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,,Homo sapiens,9606.0,HEK293,,108
2748,,4540,722.0,B,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,,Homo sapiens,9606.0,HEK293,,108
2749,,4540,722.0,B,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,,Homo sapiens,9606.0,HEK293,,108
2750,,6166,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,,,,,,108
2751,,17296,722.0,B,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,,,,HEK293,,108
2752,,17296,722.0,B,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,,,,HEK293,,108
2753,,15779,722.0,B,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,,HEK293,,108
2754,,15779,722.0,B,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,,HEK293,,108
2755,,14391,722.0,B,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,,,,HEK293,,108
2756,,15779,722.0,B,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,,,,HEK293,,108
2757,,15851,722.0,B,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,,,,HEK293,,108
2758,,15851,722.0,B,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,,Homo sapiens,9606.0,HEK293,,108
2759,,15779,722.0,B,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,,,,HEK293,,108
2760,,3832,722.0,B,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,,,,HEK293,,108
2761,,3833,722.0,B,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,,,,HEK293,,108
2762,,17451,723.0,B,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,,,,NIH3T3,,108
2763,,4199,722.0,B,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,,,,HEK293,,108
2764,,1883,485.0,B,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,,,,CHO-K1,,108
2765,,4321,,B,,Binding affinity against 5-hydroxytryptamine 2C receptor,,,Homo sapiens,9606.0,,,108
2766,,14875,,B,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,,,,,,108
2767,,15146,722.0,B,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,,,,HEK293,,108
2768,,5213,722.0,B,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,,,,HEK293,,108
2769,,16404,308.0,B,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,,,,HeLa,,108
2770,,13267,,F,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,,,,,,108
2771,Hippocampus,13267,,F,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,,,,,,108
2772,,14818,722.0,B,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,,,,HEK293,,108
2773,,4829,722.0,B,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,,,,HEK293,,108
2774,,13463,,B,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,,,,,,11864
2775,Stomach,13463,,B,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,,,,,,11864
2776,Stomach,13463,,B,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,,,,,,11864
2777,,12652,625.0,F,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,,,,A9,,11864
2778,,4682,723.0,B,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,,,,NIH3T3,,11864
2779,,4682,723.0,B,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,,,,NIH3T3,,11864
2780,,4682,723.0,B,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,,,,NIH3T3,,11864
2781,,12652,,F,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,,,,,,11864
2782,Stomach,13463,,B,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,,Mus musculus,10090.0,,,12689
2783,Stomach,13463,,B,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,,Rattus norvegicus,10116.0,,,12689
2784,,13969,,B,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,,,,,,108
2785,,13392,,B,,Binding affinity for 5-hydroxytryptamine 2C receptor,,,Sus scrofa,9823.0,,,108
2786,,13392,,B,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,,,,,108
2787,,14430,,B,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,,,,,,108
2788,,1742,,B,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,,,,,,108
2789,,14286,,B,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,,,,,,108
2790,,5619,,B,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,,,,,,108
2791,,15086,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,,,,,108
2792,,12861,,B,,Binding activity radioligand.,,,,,,,108
2793,,12861,,B,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,,,,,108
2794,,12861,,B,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,,,,,108
2795,,12827,,B,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,,,,,,108
2796,,12827,,B,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,,,,,,108
2797,,12919,,F,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,,Sus scrofa,9823.0,,,108
2798,,12919,,F,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,,Sus scrofa,9823.0,,,108
2799,,16429,,B,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,,Sus scrofa,9823.0,,,108
2800,,773,,B,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,,Sus scrofa,9823.0,,,108
2801,,5033,,B,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,,Sus scrofa,9823.0,,,108
2802,,12861,,B,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,,,,,12687
2803,,14093,,F,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,,,,,,12689
2804,,14970,,B,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,,,,,,12689
2805,,14970,,B,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,,,,,,12689
2806,,14970,,B,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,,,,,,12689
2807,,14178,,B,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,,Rattus norvegicus,10116.0,,,12689
2808,,14178,,B,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,,Rattus norvegicus,10116.0,,,12689
2809,,14229,,B,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,,Rattus norvegicus,10116.0,,Brain membranes,12689
2810,,16532,,B,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,,,,,,12689
2811,,14826,,B,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,,,,,,12689
2812,,17211,,B,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,,,,,,12689
2813,,17211,,B,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,In vitro,,,,,,12689
2814,,13246,723.0,B,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,,,,NIH3T3,,12689
2815,,13246,,B,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,,,,,,12689
2816,,12457,,B,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,,,,,,12689
2817,,12457,723.0,B,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,,,,NIH3T3,,12689
2818,,4707,,B,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,,,,,,12689
2819,,13297,,B,,Binding affinity against 5-hydroxytryptamine 2C receptor,,,,,,,12689
2820,,16633,,B,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,,,,,12689
2821,,16133,,B,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,,,12689
2822,,16326,,B,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,,,,,,12689
2823,,14423,,B,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,,,,,,12689
2824,,15412,,B,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,,,,,,12689
2825,,15412,,B,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,,,,,,12689
2826,,15558,625.0,B,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,,,,A9,,12689
2827,,16633,,B,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,,,,,12689
2828,,6013,,B,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,,,,,,12689
2829,,17175,,B,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,In vitro,,,,,,12689
2830,,12469,,B,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,,,,,,12689
2831,Caudate-putamen,3682,,B,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,,,,,,12689
2832,,4932,,B,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,,,,,,12689
2833,,4932,,B,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,,,,,,12689
2834,,3935,,B,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,,,,,,12689
2835,,15818,,B,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,,,,,,12689
2836,,15818,,B,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,,,,,,12689
2837,,14749,,B,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,,,,,,12689
2838,,15740,,B,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,,,,,,12689
2839,,17133,,B,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,,Rattus norvegicus,10116.0,,,12689
2840,,16532,,B,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,,,,,,12689
2841,,12369,,B,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,,,,,,12689
2842,,12369,,B,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,,,,,,12689
2843,,2309,,B,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,,Rattus norvegicus,10116.0,,,12689
2844,,12953,,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,,,,,,12689
2845,,12953,,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,,,,,,12689
2846,,12953,,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,,,,,,12689
2847,,12953,,B,,Binding affinity for 5-hydroxytryptamine 2C receptor,,,,,,,12689
2848,,17133,,B,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,,,,,,12689
2849,,17211,,B,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,,,,,,12689
2850,,17211,,B,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,,,,,,12689
2851,,14025,,B,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,,,,,,12689
2852,,14998,,B,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,,,,,,12689
2853,,4342,,B,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,,,,,,12689
2854,,13735,,B,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,,Rattus norvegicus,10116.0,,,12689
2855,,13181,,B,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,,,,,12689
2856,,1883,485.0,B,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,,,,CHO-K1,,12689
2857,,15194,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,,,12689
2858,,15194,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,,,,,,12689
2859,,14579,,F,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,,,,,,12689
2860,,4639,,B,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,,,,,108
2861,,4820,,B,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,,,,,108
2862,,14442,,B,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,,,,,,227
2863,,14755,,B,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,,,,,,227
2864,,14744,,B,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,,,,,,227
2865,,6857,,B,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,,Homo sapiens,9606.0,,,227
2866,,16209,,B,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,,,,,,227
2867,,15363,,B,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,,,,,227
2868,,15363,,B,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,,,,,227
2869,,15363,,B,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,,,,,,227
2870,,17085,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,,,,,,227
2871,,17200,,B,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,,Homo sapiens,9606.0,,,227
2872,,15851,722.0,B,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,,Homo sapiens,9606.0,HEK293,,227
2873,,15851,722.0,B,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,,Homo sapiens,9606.0,HEK293,,227
2874,,6857,449.0,F,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,Homo sapiens,9606.0,CHO,,227
2875,,6857,449.0,F,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,Homo sapiens,9606.0,CHO,,227
2876,,15779,722.0,B,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,,,HEK293,,227
2877,,15851,722.0,B,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,,,,HEK293,,227
2878,,15779,722.0,B,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,,,,HEK293,,227
2879,,14157,722.0,B,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,,Homo sapiens,9606.0,HEK293,,227
2880,,4540,722.0,B,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,,Homo sapiens,9606.0,HEK293,,227
2881,,6166,,B,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,,,,,,227
2882,,15779,722.0,B,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,,,,HEK293,,227
2883,,14391,722.0,B,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,,,,HEK293,,227
2884,,3832,722.0,B,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,,,,HEK293,,227
2885,,3833,722.0,B,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,,,,HEK293,,227
2886,,15851,722.0,B,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,,Homo sapiens,9606.0,HEK293,,227
2887,,15851,722.0,B,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,,Homo sapiens,9606.0,HEK293,,227
2888,,4199,722.0,B,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,,,,HEK293,,227
2889,,1883,485.0,B,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,,,,CHO-K1,,227
2890,,4321,,B,,Binding affinity against 5-hydroxytryptamine 2B receptor,,,,,,,227
2891,,15146,722.0,B,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,,,,HEK293,,227
2892,,5213,722.0,B,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,,,,HEK293,,227
2893,,14818,722.0,B,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,,,,HEK293,,227
2894,,4829,722.0,B,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,,,HEK293,,227
2895,,4829,722.0,B,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,,,HEK293,,227
2896,,14025,,B,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,,Oryctolagus cuniculus,9986.0,,,227
2897,Stomach,13463,,B,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,,,,,,12688
2898,Stomach,7259,,B,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,,,,,,12688
2899,Stomach,7259,,B,,Affinity against serotonergic receptor in the isolated rat stomach fundus,,,,,,,12688
2900,Stomach,7185,,F,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,,Rattus norvegicus,10116.0,,,12688
2901,,7185,,F,,Antagonistic against 5-hydroxytryptamine 2B receptor,,,Rattus norvegicus,10116.0,,,12688
2902,Stomach,13267,,F,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,,,,,,12688
2903,Stomach,13735,,B,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,,Rattus norvegicus,10116.0,,,12688
2904,,15738,,F,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,,,,,,12688
2905,,15738,,F,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,,,,,,12688
2906,,15738,,F,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,,,,,,12688
2907,Stomach,12936,,B,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,Rattus norvegicus,10116.0,,,12688
2908,Stomach,12936,,B,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,Rattus norvegicus,10116.0,,,12688
2909,Stomach,12936,,B,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,Rattus norvegicus,10116.0,,,12688
2910,Stomach,12936,,B,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,Rattus norvegicus,10116.0,,,12688
2911,Stomach,16404,,F,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,,,,,12688
2912,Stomach,16404,,F,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,,,,,12688
2913,Stomach,16404,,F,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,,,,,,12688
2914,Stomach,16404,,F,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,,,,,,12688
2915,Stomach,16404,,F,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,,Rattus norvegicus,10116.0,,,12688
2916,Thoracic aorta,16404,,F,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,,,,,,12688
2917,,7483,,B,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,,,,,12688
2918,,7483,,B,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,,,,,,12688
2919,,7483,,B,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,,,,,12688
2920,,7483,,B,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,,,,,,12688
2922,Stomach,16404,,F,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,Rattus norvegicus,10116.0,,,12688
2923,,6347,,B,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,227
2924,,4373,,B,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,,,,,,227
2925,,4373,,B,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,,,,,,227
2926,,4687,,B,,Evaluated for the binding affinity to 5-HT 2B receptor,,,,,,,227
2927,,16946,,B,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,,,,,,227
2928,,16633,,B,,Binding affinities against 5-hydroxytryptamine 2B receptor,,,,,,,227
2929,,16633,,B,,Binding affinities towards 5-hydroxytryptamine 2B receptor,,,,,,,227
2930,,16633,,B,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,,,,,,227
2931,,15026,,B,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,,,,,108
2932,,15738,,B,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,,Bos taurus,9913.0,,,108
2933,,15738,,B,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,,Bos taurus,9913.0,,,108
2934,,15738,,B,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,,Bos taurus,9913.0,,,108
2935,,15738,,B,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,,Bos taurus,9913.0,,,108
2936,,16404,,B,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,,Bos taurus,9913.0,,,108
2937,,15026,,B,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,Bos taurus,9913.0,,,108
2938,,15738,,B,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,,Bos taurus,9913.0,,,108
2939,,16312,,B,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,,Cavia porcellus,10141.0,,,108
2940,Striatum,5486,,B,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,,Cavia porcellus,10141.0,,,20033
2941,,5254,,B,,Binding affinity against 5-HT1A receptor,,,,,,,51
2942,,3857,449.0,F,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,,,,CHO,,108
2943,,6857,449.0,F,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,,Homo sapiens,9606.0,CHO,,108
2944,,4176,,F,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,,,,,,108
2945,,6347,449.0,B,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,,,,CHO,,108
2946,,6347,449.0,B,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,,,,CHO,,108
2947,,16146,,B,,Inhibition of human 5-hydroxytryptamine 2C receptor,,,Homo sapiens,9606.0,,,108
2948,,3805,,B,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,,,,,,108
2949,,3857,,B,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,,,,,108
2950,,5635,,B,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,,,,,,108
2951,,5635,,B,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,,,,,108
2952,,5635,,B,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,,,,,108
2953,,4012,449.0,B,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,,,,CHO,,108
2954,,6366,449.0,B,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,,,,CHO,,108
2955,,15949,449.0,B,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,,,CHO,,108
2956,,17211,449.0,B,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,,,,CHO,,108
2957,,6491,,B,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,,Homo sapiens,9606.0,,,108
2958,,14093,,F,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,,,,,,108
2959,,13481,,F,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,,,,,108
2960,,6347,449.0,B,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,,Rattus norvegicus,10116.0,CHO,,108
2961,,14093,,F,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,,,,,,108
2962,,14093,,F,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,,,,,,108
2963,,13481,,F,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,,,108
2964,,14442,,B,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,,,,,,108
2965,,14442,,B,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,,,,,,108
2966,,14442,,B,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,,,,,,108
2967,,14755,,B,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,,,,,,108
2968,,14744,,B,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,,,,,,108
2969,,16659,449.0,B,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,,,CHO,,108
2970,,6857,,B,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,,Homo sapiens,9606.0,,,108
2971,,5635,,B,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,,,,,,108
2972,,4234,,B,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,,Homo sapiens,9606.0,,,108
2973,,16209,,B,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,,,,,,108
2974,,5778,,B,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,,Rattus norvegicus,10116.0,,Membranes,104698
2975,,5094,,B,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,,,,,,104698
2976,,809,,B,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,,Rattus norvegicus,10116.0,,,104698
2977,,1578,,B,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,,,,,,104698
2978,,809,,B,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,,,,,,104698
2979,,12469,,B,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,,,,,,104698
2980,,14290,,B,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,,,,,,104698
2981,,14290,,B,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,,,,,,104698
2982,,10609,,B,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,,,,,,104698
2983,,10609,,B,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,,,,,,104698
2984,,10609,,B,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,,,,,,104698
2985,,15253,,B,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,,,,,104698
2986,,15253,,B,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,,,,,104698
2987,,11683,,B,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,,,,,Membranes,104698
2988,,12092,,B,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,,,,,,104698
2989,,1946,,B,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,,,,,104698
2990,,11623,,B,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,,,,,,104698
2991,,11623,,B,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,,,,,,104698
2992,,14788,,B,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,,,,,,104698
2993,,5432,,B,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,,Rattus norvegicus,10116.0,,,104698
2994,,14826,,B,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,,,,,104698
2995,,2222,,B,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,,,,,104698
2996,,11963,,B,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,,,,,,104698
2997,,14145,,B,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,,,,,,104698
2998,,17819,,B,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,,,,,,104698
2999,,10394,,B,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,,,,,104698
3000,,10394,,B,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,,,,,104698
3001,,15034,,B,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,,,,,104698
3002,,691,,B,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,,,,,104698
3003,,12092,,B,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,,,,,Membranes,104698
3004,,11752,,B,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,10116.0,,,104698
3005,Brain,11752,,B,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,,,,,,104698
3006,,301,,B,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,,,,,,104698
3007,,16532,,B,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,,,,,,104698
3008,,16532,,B,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,,,,,104698
3009,,12092,,B,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,,,,,,104698
3010,,11684,,B,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,,,,,,104698
3011,,11684,,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,,,,,,104698
3012,,12953,,B,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,,,,,,104698
3013,,12953,,B,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,,,,,,104698
3014,,12953,,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,,,,,,104698
3015,,12861,,B,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,,,,,104698
3016,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,,,,,,104698
3017,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,,,,,,104698
3018,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,,,,,,104698
3019,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,In vivo,,,,,,104698
3020,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,,,,,,104698
3021,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,,,,,,104698
3022,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,In vivo,,,,,,104698
3023,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,,,,,,104698
3024,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,In vivo,,,,,,104698
3025,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,,,,,,104698
3026,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,,,,,,104698
3027,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,,,,,,104698
3028,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,In vivo,,,,,,104698
3029,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,,,,,,104698
3030,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,,,,,,104698
3031,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,,,,,,104698
3032,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,,,,,,104698
3033,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,,,,,,104698
3034,,10609,,F,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,,,,,,104698
3035,,12861,,B,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,,,,,,104698
3036,,12861,,B,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,10116.0,,,104698
3037,,12861,,B,,Binding activity radioligand.,,,,,,,104698
3038,,10728,,B,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,,,,,Brain membranes,104698
3039,,10728,,B,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,,,,,Brain membranes,104698
3040,,5163,,B,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,,,,,,108
3041,,5163,,B,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,,,,,,108
3042,,6011,,B,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,,,,,,108
3043,,5014,,B,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,,,,,,108
3044,,5635,,B,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,,,,,,108
3045,,5163,,B,,Affinity for 5-hydroxytryptamine 2C receptor,,,,,,,108
3046,,6841,,B,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,,,108
3047,,6119,,B,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,,,,,,108
3048,,4373,,B,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,,,,,,108
3049,,1633,,B,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,,,,,,108
3050,,1633,,B,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,,,,,,108
3051,,4373,,B,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,,,,,,108
3052,,6576,,B,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,,,,,,108
3053,,4687,,B,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,,,,,,108
3054,,12146,,B,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,,,,,,108
3055,,12146,,B,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,,,,,,108
3056,,16946,,B,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,,,,,,108
3057,,14159,,B,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,,,,,,108
3058,,16700,,B,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,,,,,,108
3059,,3269,,B,,Affinity against 5-hydroxytryptamine 2C receptor,,,,,,,108
3060,,1274,,B,,Binding affinity against 5-hydroxytryptamine 2C receptor,,,Homo sapiens,9606.0,,,108
3061,,1317,,B,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,,,,,,108
3062,,5834,,B,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,,Bos taurus,9913.0,,,144
3063,,11147,,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,,Bos taurus,9913.0,,,144
3064,,14145,,F,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,,Cavia porcellus,10141.0,,,104714
3065,Ileum,10561,,B,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,,Cavia porcellus,10141.0,,,104714
3066,,15847,,F,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,,Cavia porcellus,10141.0,,,104714
3067,,15847,,F,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,,Cavia porcellus,10141.0,,,104714
3068,Ileum,10561,,B,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,,Cavia porcellus,10141.0,,,104714
3069,Ileum,11454,,B,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,,Cavia porcellus,10141.0,,,104714
3070,,4639,,F,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,,Cavia porcellus,10141.0,,,104714
3071,,4639,,F,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,,Cavia porcellus,10141.0,,,104714
3072,,4639,,F,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,,Cavia porcellus,10141.0,,,104714
3073,,4639,,F,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,,Cavia porcellus,10141.0,,,104714
3074,,4639,,F,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,,Cavia porcellus,10141.0,,,104714
3075,,4639,,F,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,,Cavia porcellus,10141.0,,,104714
3076,Ileum,15253,,F,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,,Cavia porcellus,10141.0,,,104714
3077,Ileum,15253,,F,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,,Cavia porcellus,10141.0,,,104714
3078,Ileum,11963,,F,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,,Cavia porcellus,10141.0,,,104714
3079,Ileum,1946,,B,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,,Cavia porcellus,10141.0,,,104714
3080,Ileum,1946,,B,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,,Cavia porcellus,10141.0,,,104714
3081,,12045,,B,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,,Cavia porcellus,10141.0,,,104714
3082,Ileum,1559,,B,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,Cavia porcellus,10141.0,,,104714
3083,Ileum,273,,F,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,Cavia porcellus,10141.0,,,104714
3084,Ileum,273,,F,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,,Cavia porcellus,10141.0,,,104714
3085,Ileum,188,,F,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,,Cavia porcellus,10141.0,,,104714
3086,Ileum,12919,,F,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,,Cavia porcellus,10141.0,,,104714
3087,Ileum,12918,,F,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,,Cavia porcellus,10141.0,,,104714
3088,Ileum,1559,,B,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,Cavia porcellus,10141.0,,,104714
3089,Ileum,273,,F,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,Cavia porcellus,10141.0,,,104714
3090,Ileum,1559,,B,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,Cavia porcellus,10141.0,,,104714
3091,Ileum,1559,,B,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,,Cavia porcellus,10141.0,,,104714
3092,Ileum,1559,,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,,Cavia porcellus,10141.0,,,104714
3093,Ileum,14424,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,,Cavia porcellus,10141.0,,,104714
3094,,13181,,B,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,,Cavia porcellus,10141.0,,,22226
3095,,5486,,B,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,,,,,,51
3096,,6491,,B,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,,Homo sapiens,9606.0,,,104714
3097,,6013,,B,,Binding affinity towards 5-HT3 receptor,,,,,,,104714
3098,,12861,,B,,Binding activity radioligand.,,,,,,,104714
3099,,12861,,B,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,,,,,,104714
3100,,5104,,B,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,,,,,104714
3101,,5105,,B,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,,,,,104714
3102,,5104,,B,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,,,,,,104714
3103,,3935,,B,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,,,,,,22226
3104,,13657,433.0,B,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,,,,NG108-15,,105030
3105,,10369,,B,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",In vivo,,,,,,105030
3106,,10369,,B,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,,,,,105030
3107,,12918,,B,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,,,,,,105030
3108,,12918,,B,,Compound was evaluated for the binding affinity at 5- HT3 receptor,,,,,,,105030
3109,,10369,,B,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,,,,,105030
3110,,773,,B,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,,,,,105030
3111,,12918,,F,,5-hydroxytryptamine 3 receptor agonism in mouse,,,,,,,105030
3112,,10561,,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,,,,,,105030
3113,,12827,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,,,,,105030
3114,,12827,,B,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,,,,,105030
3115,,12918,,B,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,,,,,,105030
3116,,273,,B,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,,,,,105030
3117,,273,,B,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,,,,,105030
3118,,10561,,B,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,,,,,105030
3119,,5033,,B,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,In vitro,,,,,,105030
3120,,16429,339.0,B,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,,,,N1E-115,,105030
3121,,10322,,B,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,,,,,11765
3122,,14331,,B,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,,,,,,11765
3123,,13462,,B,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,,Mus musculus,10090.0,,,10630
3124,,12861,,B,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,,,,17106
3125,,15086,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,,Sus scrofa,9823.0,,,144
3126,,12861,,B,,Binding activity radioligand.,,,Sus scrofa,9823.0,,,144
3127,,10561,,B,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,,Oryctolagus cuniculus,9986.0,,,104714
3128,,10561,,B,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,Oryctolagus cuniculus,9986.0,,,104714
3129,,10561,,B,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,,Oryctolagus cuniculus,9986.0,,,104714
3130,,10561,,B,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,Oryctolagus cuniculus,9986.0,,,104714
3131,,273,,F,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,Oryctolagus cuniculus,9986.0,,,104714
3132,,273,,F,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,Oryctolagus cuniculus,9986.0,,,104714
3133,Ileum,273,,F,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,Oryctolagus cuniculus,9986.0,,,104714
3134,,273,,F,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,Oryctolagus cuniculus,9986.0,,,104714
3135,,273,,F,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,Oryctolagus cuniculus,9986.0,,,104714
3136,,273,,F,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,Oryctolagus cuniculus,9986.0,,,104714
3137,,273,,F,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,Oryctolagus cuniculus,9986.0,,,104714
3138,,13047,449.0,B,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,,Oryctolagus cuniculus,9986.0,CHO,,104714
3139,,1650,,B,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,10116.0,,,104698
3140,,16288,,B,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,,,,,,12020
3141,,16288,,B,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,,,,,,12020
3142,,10254,,B,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,,Rattus norvegicus,10116.0,,,104698
3143,,14532,,B,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,,,,,,104698
3144,Heart,13392,,F,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",In vivo,,,,,,104698
3145,Heart,13392,,F,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,,,,,104698
3146,Heart,13392,,F,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,,,,,,104698
3147,Heart,13392,,F,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,,,,,,104698
3148,Heart,13392,,F,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,,,,,104698
3149,,13392,,F,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,,,,,,104698
3150,,13392,,F,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,,,,,104698
3151,,13392,,F,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,,,,,104698
3152,,13392,,F,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,,,,,,104698
3153,,1089,,F,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),In vivo,,Rattus norvegicus,10116.0,,,104698
3154,,1089,,F,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),In vivo,,,,,,104698
3155,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,Rattus norvegicus,10116.0,,,104698
3156,,11454,,F,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,,Rattus norvegicus,10116.0,,,104698
3157,,12205,,F,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,In vivo,,Rattus norvegicus,10116.0,,,104698
3158,,1089,,F,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,,Rattus norvegicus,10116.0,,,104698
3159,,5094,,B,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,,,,,104698
3160,,2622,,B,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,10116.0,,,104698
3161,,245,,B,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,,,,,,104698
3162,,14788,,B,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,,,,,,104698
3163,,14788,,B,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,,,,,,104698
3164,,3020,,B,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,,,,,,104698
3165,,1742,,B,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,,,,,,104698
3166,Brain,17394,,B,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,,,,,,104698
3167,Brain,17394,,B,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,,,,,,104698
3168,,17394,,B,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,,,,,104698
3169,,14286,,B,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,,,,,104698
3170,,14178,,B,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,,,,,,104698
3171,,14178,,B,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,,Rattus norvegicus,10116.0,,,104698
3172,,14178,,B,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,,Rattus norvegicus,10116.0,,,104698
3173,,14178,,B,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,10116.0,,,104698
3174,,15034,,B,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,,,,,104698
3175,,1089,,B,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,,,,,Membranes,104698
3176,,1089,,B,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,,Rattus norvegicus,10116.0,,,104698
3177,,16532,,B,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,,,,,104698
3178,,12801,,B,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,10116.0,,,104698
3179,,15194,433.0,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,,,,NG108-15,,104698
3180,,15194,433.0,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,,,,NG108-15,,104698
3181,,15194,,B,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,,,,,,104698
3182,,15194,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,,,,,,104698
3183,,15194,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,,,,,,104698
3184,,15194,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,,,,,,104698
3185,,10610,,F,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,,,,,,104698
3186,,10355,,F,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,,Rattus norvegicus,10116.0,,,104698
3187,,691,,F,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,,,,,,104698
3188,,10611,,F,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,,,,,,104698
3189,,12801,,F,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,In vivo,,,,,,104698
3190,,10609,,F,,Inhibition of 5-HT evoked reflex bradycardia in rat.,,,,,,,104698
3191,,11454,,F,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,104698
3192,,11454,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,104698
3193,,11454,,F,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),In vivo,,,,,,104698
3194,,11454,,F,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,In vivo,,Rattus norvegicus,10116.0,,,104698
3195,,11454,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,104698
3196,,11454,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,In vivo,,,,,,104698
3197,,11454,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,104698
3198,,11454,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,104698
3199,,11454,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,104698
3200,,11454,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,104698
3201,,11454,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,104698
3202,,11454,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,104698
3203,,11454,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,104698
3204,,11454,,F,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,104698
3205,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,104698
3206,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,104698
3207,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,104698
3208,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,In vivo,,,,,,104698
3209,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,In vivo,,,,,,104698
3210,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,In vivo,,,,,,104698
3211,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,In vivo,,,,,,104698
3212,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,In vivo,,,,,,104698
3213,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,104698
3214,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,104698
3215,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,104698
3216,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,104698
3217,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,104698
3218,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,104698
3219,,11454,,F,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,104698
3220,,670,,F,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,,,,,,104698
3221,,670,,F,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,,,,,,104698
3222,,10321,,F,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,In vivo,,,,,,104698
3223,,10321,,F,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,In vivo,,,,,,104698
3224,,10321,,F,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,In vivo,,,,,,104698
3225,,10321,,F,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,In vivo,,,,,,104698
3226,,10321,,F,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,In vivo,,,,,,104698
3227,,10322,,F,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),In vivo,,,,,,104698
3228,,15412,,F,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,,,,,104698
3229,,15412,,F,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,,,,,104698
3230,,15412,,B,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,10116.0,,,104698
3231,,15412,,F,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,,,,,,104698
3232,Hippocampus,15412,,B,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,,,,,,104698
3233,,15412,,B,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,,Rattus norvegicus,10116.0,,,104698
3234,,17394,,B,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,10116.0,,,104698
3235,,12457,,B,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,,,,,,104698
3236,,12457,,B,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,,,,,,104698
3237,,12205,,B,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,,,,,,104698
3238,,14532,,B,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,,,,,,104698
3239,,1122,,B,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,,,,,,104698
3240,,5094,,B,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,,,,,104698
3241,Ileum,809,,F,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,,Cavia porcellus,10141.0,,,20033
3242,Ileum,809,,F,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,,Cavia porcellus,10141.0,,,20033
3243,Ileum,14290,,F,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,,Cavia porcellus,10141.0,,,20033
3244,Ileum,14290,,F,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,,Cavia porcellus,10141.0,,,20033
3245,Ileum,14290,,F,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,,Cavia porcellus,10141.0,,,20033
3246,Ileum,14290,,F,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,,Cavia porcellus,10141.0,,,20033
3247,Ileum,14290,,F,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,,Cavia porcellus,10141.0,,,20033
3248,Ileum,13961,,F,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,,Cavia porcellus,10141.0,,,20033
3249,Ileum,13961,,F,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,,Cavia porcellus,10141.0,,,20033
3250,Ileum,809,,F,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,,Cavia porcellus,10141.0,,,20033
3251,Ileum,809,,F,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,,Cavia porcellus,10141.0,,,20033
3252,Ileum,809,,F,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,,Cavia porcellus,10141.0,,,20033
3253,Ileum,14290,,F,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,,Cavia porcellus,10141.0,,,20033
3254,Ileum,14290,,F,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,,Cavia porcellus,10141.0,,,20033
3255,Ileum,14290,,F,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,,Cavia porcellus,10141.0,,,20033
3256,Ileum,14290,,F,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,,Cavia porcellus,10141.0,,,20033
3257,Ileum,14290,,F,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,,Cavia porcellus,10141.0,,,20033
3258,Ileum,14290,,F,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,,Cavia porcellus,10141.0,,,20033
3259,,15034,,B,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,,Cavia porcellus,10141.0,,,20033
3260,Striatum,5094,,B,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,,Cavia porcellus,10141.0,,,20033
3261,Striatum,5094,,B,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,,Cavia porcellus,10141.0,,,20033
3262,Striatum,5399,,B,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,,Cavia porcellus,10141.0,,,20033
3263,Striatum,17394,,B,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,,Cavia porcellus,10141.0,,,20033
3264,Striatum,17394,,B,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,,Cavia porcellus,10141.0,,,20033
3265,Striatum,17394,,B,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,,Cavia porcellus,10141.0,,,20033
3266,Ileum,13961,,F,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,,Cavia porcellus,10141.0,,,20033
3267,Ileum,13961,,F,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,,Cavia porcellus,10141.0,,,20033
3268,Ileum,13961,,F,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,,Cavia porcellus,10141.0,,,20033
3269,,16946,,B,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,,Cavia porcellus,10141.0,,,20033
3270,,16946,,B,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,,Cavia porcellus,10141.0,,,20033
3271,,15034,,F,,Agonistic activity against 5-hydroxytryptamine 4 receptor,,,Cavia porcellus,10141.0,,,20033
3272,,15034,,F,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,,Cavia porcellus,10141.0,,,20033
3273,,12918,,F,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,,Cavia porcellus,10141.0,,,20033
3274,,16946,,B,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,,Cavia porcellus,10141.0,,,20033
3275,Striatum,17394,,B,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,,Cavia porcellus,10141.0,,,20033
3276,Striatum,15034,,B,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,,Cavia porcellus,10141.0,,,20033
3277,Striatum,5094,,B,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,,Cavia porcellus,10141.0,,,20033
3278,Striatum,5094,,B,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,,Cavia porcellus,10141.0,,,20033
3279,Ileum,17358,,B,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,,Cavia porcellus,10141.0,,,20033
3280,,12953,,B,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,,Cavia porcellus,10141.0,,,20033
3281,,12953,,B,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,,Cavia porcellus,10141.0,,,20033
3282,,12953,,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,,Cavia porcellus,10141.0,,,20033
3283,,12953,,B,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,,Cavia porcellus,10141.0,,,20033
3284,Ileum,273,,F,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,,Cavia porcellus,10141.0,,,20033
3285,Ileum,12918,,F,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,,Cavia porcellus,10141.0,,,20033
3286,Ileum,12919,,F,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,,Cavia porcellus,10141.0,,,20033
3287,Ileum,273,,F,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,,Cavia porcellus,10141.0,,,20033
3288,Ileum,273,,F,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,,Cavia porcellus,10141.0,,,20033
3289,,13181,,B,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,,Cavia porcellus,10141.0,,,20033
3290,,13181,,B,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,,Cavia porcellus,10141.0,,,168
3291,,15034,,F,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,,Cavia porcellus,10141.0,,,20033
3292,,5033,,B,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,,Cavia porcellus,10141.0,,,20033
3293,,1980,,B,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,,Cavia porcellus,10141.0,,,20033
3294,,13181,722.0,B,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,,Cavia porcellus,10141.0,HEK293,,168
3295,,14287,,B,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,,Cavia porcellus,10141.0,,,20033
3296,,1317,,B,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,,Cavia porcellus,10141.0,,,20033
3297,,15316,,B,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,,Cavia porcellus,10141.0,,,20033
3298,Striatum,16429,,B,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,,Cavia porcellus,10141.0,,,20033
3299,Hippocampus,14818,,B,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,,Cavia porcellus,10141.0,,,20033
3300,,15194,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,,Cavia porcellus,10141.0,,,20033
3301,,15194,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,,Cavia porcellus,10141.0,,,20033
3302,Ileum,13961,,F,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,,Cavia porcellus,10141.0,,,20033
3303,,5486,,B,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,,,,,,108
3304,,16209,,B,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,,,,,,168
3305,,17085,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,,,,,,168
3306,,4199,308.0,B,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,,,,HeLa,,168
3307,,15146,,B,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,,,,,,168
3308,,5213,,B,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,,,,,,168
3309,,4829,308.0,B,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,,,,HeLa,,168
3310,,17358,,B,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,,,,,,10622
3311,,17358,,B,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,,,,,,10622
3312,,16946,,B,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,,,,,,10622
3313,,17358,,B,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,,,,,,10622
3314,Cardiac atrium,268,,F,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,,,,,,11249
3315,Cardiac atrium,268,,F,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,,,,,,11249
3316,,15086,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,,,,,,11249
3317,Hippocampus,14875,,B,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,,,,,,11249
3318,Hippocampus,13267,,B,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,,Sus scrofa,9823.0,,,168
3319,,13047,,B,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,,Oryctolagus cuniculus,9986.0,,,168
3320,,1650,,B,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,,Rattus norvegicus,10116.0,,,10623
3321,,567,,F,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,,,,,10623
3322,,17358,,B,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,,,,,,10623
3323,,188,,B,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,,,,,,10623
3324,,670,,F,,lntrinsic activity relative to 5-HT receptor,,,,,,,10623
3325,,204,,F,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,,,,,,10623
3326,,1946,,F,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,,,,,,10623
3327,,6398,,F,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,,,,,,10623
3328,,6398,,F,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,,,,,,10623
3329,,17358,,F,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,,,,,,10623
3330,,6398,,F,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,,,,,,10623
3331,,11752,,B,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,,,,,,10623
3332,,809,,F,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,,,,,,10623
3333,,14178,,B,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,,Rattus norvegicus,10116.0,,,10623
3334,,567,,B,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,,,,,10623
3335,,1946,,B,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,,,,,,10623
3336,,1946,,B,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,,,,,,10623
3337,,13961,,B,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,,Rattus norvegicus,10116.0,,,10623
3338,Striatum,6238,,B,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,,,,,,10623
3339,,14290,,B,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,,,,,,10623
3340,,14290,,B,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,,,,,,10623
3341,Striatum,809,,B,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,,Rattus norvegicus,10116.0,,,10623
3342,Striatum,1578,,B,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,,,,,,10623
3343,Striatum,16709,,B,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,,,,,,10623
3344,Striatum,1946,,B,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,,,,,,10623
3345,Striatum,15253,,B,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,,,,,,10623
3346,Striatum,4535,,B,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,,,,,10623
3347,,13961,,B,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,,,,,,10623
3348,Brain,17358,,F,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,,,,,,10623
3349,,15847,,F,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,,,,,,10623
3350,,15847,,F,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,,,,,,10623
3351,,670,,F,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,,,,,,10623
3352,,670,,F,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,,,,,,10623
3353,,1317,,F,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,,,,,10623
3354,,12936,,B,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,,Rattus norvegicus,10116.0,,,10623
3355,Striatum,4535,,B,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,,,,,10623
3356,,14424,,F,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,,Rattus norvegicus,10116.0,,,10623
3357,,14424,,F,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,,,,,,10623
3358,,14424,,F,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,,,,,10623
3359,,14424,,F,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,,Rattus norvegicus,10116.0,,,10623
3360,,14424,,F,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,,,,,,10623
3361,,14424,,F,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,,,,,,10623
3362,,14424,,F,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,,,,,,10623
3363,,14424,,F,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,,,,,10623
3364,,1980,,F,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,,Rattus norvegicus,10116.0,,,168
3365,,4639,,F,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,,,,,,168
3366,,17358,,B,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,,,,,,168
3367,,17358,,B,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,,,,,,168
3368,,17358,,B,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,,,,,,168
3369,,1558,,B,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,,,,,,168
3370,,17358,,F,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,,,,,168
3371,,16117,,B,,In vitro binding affinity towards 5-HT4 receptor was determined,,,,,,,168
3372,,17358,,F,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,,,,,168
3373,,17358,,F,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,,,,,,168
3374,,17358,,B,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,,,,,,168
3375,,17358,,B,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,,,,,,168
3376,,17358,,B,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,,,,,,168
3377,,17358,,B,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,,,,,,168
3378,,1274,,B,,Binding affinity against 5-Hydroxytryptamine 4 receptor,,,,,,,168
3379,,10728,,B,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,,,,,Brain membranes,104698
3380,,11695,,B,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,,,,,Brain membranes,104698
3381,,11695,,B,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,,,,,Brain membranes,104698
3382,,12490,,B,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,,,,,,104698
3383,,11828,,B,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,10116.0,,,104698
3384,Hippocampus,12253,,B,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,,,,,,104698
3385,,10561,,B,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,,,,,104698
3386,,10561,,B,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,,,,,,104698
3387,,14432,,F,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,,,,,,104698
3388,,12936,,B,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,10116.0,,,104698
3389,,1274,,B,,Binding affinity against 5-Hydroxytryptamine 3 receptor,,,Rattus norvegicus,10116.0,,,104698
3390,,1980,,B,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,,,,,,104698
3391,,670,,B,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,,,,,,104698
3392,,968,,B,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,,Rattus norvegicus,10116.0,,,104698
3393,,14287,,B,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,,,,,,104698
3394,,567,,B,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,,,,,,104698
3395,,13267,,B,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,,,,,,104698
3396,,14826,,B,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,,,,,,104698
3397,,15194,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,,,,,,104698
3398,,15194,,B,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,,,,,,104698
3399,,10394,,B,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,10116.0,,,104698
3400,,13657,,B,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,,,,,,10576
3401,Brain,1879,,F,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,,,,,,12020
3402,,1879,,F,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,,,,,,12020
3403,,1879,,F,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,,,,,,12020
3404,,204,,F,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,In vivo,,,,,,12020
3405,,1879,,B,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,,,,,12020
3406,,1879,,B,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,12020
3407,,1879,,B,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,,,,,12020
3408,,1879,,B,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,,,,,,12020
3409,,10641,,B,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,,,,,,104698
3410,,773,,B,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,,,,,12020
3411,,11952,,B,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,,,,,,104698
3412,,14145,,F,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,,Rattus norvegicus,10116.0,,,12020
3413,,17066,,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,144
3414,,6398,,B,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,,,,,,104714
3415,,10321,,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,,,,,22226
3416,,511,,F,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,,,,,,104714
3417,,4639,,B,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,104714
3418,,4639,,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,104714
3419,,4639,,F,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,,Cavia porcellus,10141.0,,,104714
3420,,4639,,F,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,,Cavia porcellus,10141.0,,,104714
3421,,4639,,F,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,,Cavia porcellus,10141.0,,,104714
3422,,1558,,B,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,104714
3423,,268,,F,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,,,,,,104714
3424,,2474,,B,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,,,,,,104714
3425,,5067,,F,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,,,,,,104714
3426,,5067,,F,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,,,,,,104714
3427,,5067,,F,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,,,,,,104714
3428,,5067,,B,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,,,,,,104714
3429,,5067,,F,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,,,,,,104714
3430,,5067,,F,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,,,,,,104714
3431,,5067,,F,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,,,,,,104714
3432,,5067,,B,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,,,,,,104714
3433,,5067,,B,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,,,,,,104714
3434,,5067,,F,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,,,,,,104714
3435,,5067,,B,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,,,,,,104714
3436,,5067,,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,104714
3437,,14331,,B,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,,,,,,104714
3438,,5067,,B,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,,,,,,104714
3439,,6179,433.0,B,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,,,,NG108-15,,104714
3440,,4265,,B,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,,,,,,104714
3441,,4265,433.0,B,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,,,,NG108-15,,104714
3442,,17358,,B,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,,,,,104714
3443,,17358,,B,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,,,,,,104714
3444,,13628,,B,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,In vitro,,,,,,104714
3445,,4612,,B,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,,,,,104714
3446,,17358,,F,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,,,,,,104714
3447,,4639,,F,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,,Cavia porcellus,10141.0,,,104714
3448,,4639,,F,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,,Cavia porcellus,10141.0,,,104714
3449,,4639,,F,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,,Cavia porcellus,10141.0,,,104714
3450,,4639,,F,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,,Cavia porcellus,10141.0,,,104714
3451,,511,,B,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,,,,,,104714
3452,,1479,,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,104714
3453,,1317,,B,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,,,,,,104714
3454,,12146,,B,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,,,,,,104714
3455,,12146,,B,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,,,,,,104714
3456,,13969,,B,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,,,,,,104714
3457,,13392,,B,,Binding affinity for 5-hydroxytryptamine 2C receptor,,,,,,,108
3458,,13392,,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,104698
3459,,14159,,B,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,,,,,,144
3460,,1558,,B,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,144
3461,,16655,,B,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,,,,,144
3462,,13020,,B,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,,,,,104714
3463,,13021,,B,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,,,,,,104714
3464,,13020,,B,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,,,,,104714
3465,,10321,,B,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,,,,,144
3466,,15818,,B,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,144
3467,,15818,,B,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,144
3468,,17358,,B,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,,,,,144
3469,,2222,,B,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,,,,,144
3470,,10322,,B,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,,,,,144
3471,,16117,,B,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,,,,,144
3472,,17200,,B,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,,,,,,144
3473,,17358,,F,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,,,,,,144
3474,,16700,,B,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,,,,,,144
3475,,1980,,B,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,,,,,,144
3476,,1980,,B,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,,,,,,144
3477,,12409,,B,,Binding affinity against the 5-hydroxytryptamine 3 receptor,,,,,,,104714
3478,,4365,,B,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,,,,,144
3479,,4365,,F,,Percent efficacy against 5-hydroxytryptamine 3A receptor,,,,,,,144
3480,,4365,,B,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,,,,,144
3481,,6769,,F,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,,Rattus norvegicus,10116.0,Oocytes,,12020
3482,,6769,,F,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,,Rattus norvegicus,10116.0,Oocytes,,12020
3483,,6769,,F,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,,Rattus norvegicus,10116.0,Oocytes,,12020
3484,Ileum,809,,F,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,,Cavia porcellus,10141.0,,,20033
3485,Ileum,809,,F,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,,Cavia porcellus,10141.0,,,20033
3486,,14290,,F,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,,Cavia porcellus,10141.0,,,20033
3487,Ileum,17358,,B,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,,Cavia porcellus,10141.0,,,20033
3488,,17358,,B,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,,Cavia porcellus,10141.0,,,20033
3489,Ileum,17358,,B,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,,Cavia porcellus,10141.0,,,20033
3490,Ileum,17386,,B,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,,,,,10209
3491,,3269,,B,,Affinity against 5-hydroxytryptamine 7 receptor,,,,,,,10209
3492,,7721,,B,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,,Cavia porcellus,10141.0,,,104841
3493,,7721,,B,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,,Cavia porcellus,10141.0,,,104841
3494,Ileum,9117,,B,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,,Cavia porcellus,10141.0,,,104841
3495,,7721,,B,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,,Cavia porcellus,10141.0,,,104841
3496,,7721,,B,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,,Cavia porcellus,10141.0,,,104841
3497,,15796,,F,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,,Cavia porcellus,10141.0,,,104841
3498,,15796,,F,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,,Cavia porcellus,10141.0,,,104841
3499,Cardiac atrium,15650,,B,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,,Homo sapiens,9606.0,,,168
3500,Cardiac atrium,15650,,B,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,,Homo sapiens,9606.0,,,168
3501,,6866,,F,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,,Homo sapiens,9606.0,,,104841
3502,Cardiac atrium,15650,,F,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,,Homo sapiens,9606.0,,,168
3503,,10063,,B,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,,Mus musculus,10090.0,,,22226
3504,,12665,,B,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,,Mus musculus,10090.0,,,22226
3505,,7504,,B,,5-hydroxytryptamine receptor binding affinity was determined in rats,,,,,,,104705
3506,,7504,,B,,Binding affinity at rat 5-hydroxytryptamine receptor.,,,,,,,104705
3507,,7038,,B,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,,,,,,104705
3508,,7626,,B,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,,,,,,104705
3509,,7626,,B,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,,,,,,104705
3510,Stomach,7185,,F,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,,,,,,104705
3511,Stomach,7185,,F,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,,,,,,104705
3512,,7185,,F,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,,,,,104705
3513,,6960,,B,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,,,,,,104705
3514,,6960,,B,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,,,,,,104705
3515,Hippocampus,12416,,B,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,,,,,10576
3516,,15753,,B,,Binding affinity for rat 5-hydroxytryptamine transporter.,,,,,,,12198
3517,,8062,,B,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,,,,,,104705
3518,,9036,,B,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,,Rattus norvegicus,10116.0,,,104705
3519,,15067,,B,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,,Rattus norvegicus,10116.0,,,104705
3520,Brain,15753,,F,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,,Rattus norvegicus,10116.0,,,12198
3521,Cerebellum,15753,,F,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,,Rattus norvegicus,10116.0,,,12198
3522,,15295,,B,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,,Rattus norvegicus,10116.0,,,104705
3523,,6347,,B,,Percent binding affinity against 5-hydroxytryptamine receptor,,,Rattus norvegicus,10116.0,,,104705
3524,,6763,,B,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,,,,,,22226
3525,,12092,,B,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,,Rattus norvegicus,10116.0,,,104705
3526,,1579,,B,,Affinity against 5-hydroxytryptamine receptor was determined,,,Rattus norvegicus,10116.0,,,104705
3527,Stomach,1579,,B,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,,Rattus norvegicus,10116.0,,,104705
3528,,5963,,B,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,In vitro,,Homo sapiens,9606.0,,,121
3529,,5963,,B,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,In vitro,,Homo sapiens,9606.0,,,121
3530,,5030,,B,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,,,,,,18065
3531,,15796,,B,,Inhibition of 5-hydroxytryptamine reuptake,,,,,,,121
3532,,15413,,F,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,,,,,,18065
3533,,15413,,F,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,,,,,,18065
3534,,15413,,F,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,,,,,,18065
3535,,12409,,F,,Tested for 5-hydroxytryptamine receptor uptake,,,,,,,18065
3536,,16909,449.0,B,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,,Homo sapiens,9606.0,CHO,,51
3537,,16909,,F,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,,Homo sapiens,9606.0,,,51
3538,,15629,,B,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,,Homo sapiens,9606.0,,,10576
3539,,15629,,B,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,,,,,,10576
3540,,15629,,B,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,,,,,,10576
3541,Striatum,10034,,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,,,,,,10825
3542,Striatum,10034,,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,,,,,,10825
3543,Striatum,10034,,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,,,,,,10825
3544,Striatum,10034,,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,,,,,,10825
3545,Striatum,10034,,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,,,,,,10825
3546,Striatum,10034,,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,,,,,,10825
3547,Striatum,10034,,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,,,,,,10825
3548,Striatum,10034,,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,,,,,,10825
3549,Striatum,10034,,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,,,,,,10825
3550,Striatum,10034,,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,,,,,,10825
3551,Striatum,10034,,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,,,,,,10825
3552,Limbic system,10034,,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,,,,,,10825
3553,Limbic system,10034,,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,,,,,10825
3554,Limbic system,10034,,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,,,,,,10825
3555,Limbic system,10034,,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,,,,,,10825
3556,Limbic system,10034,,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,,,,,,10825
3557,Limbic system,10034,,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,,,,,,10825
3558,Limbic system,10034,,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,,,,,,10825
3559,,1274,,B,,Binding affinity against 5-hydroxytryptamine 4 receptor,,,,,,,168
3560,,17358,,F,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,,,,,168
3561,,14532,,B,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,,,,,,168
3562,,16989,,B,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,,,,,,168
3563,,17200,,B,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,,,,,,168
3564,,15779,,B,,Binding affinity towards 5-hydroxytryptamine 4 receptor,,,,,,,168
3565,,15779,,B,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,,,,,168
3566,,15779,,B,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,,,,,168
3567,,15650,643.0,B,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,,,,COS-7,,168
3568,,15650,643.0,B,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,,,,COS-7,,168
3569,,15650,643.0,B,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,,,,COS-7,,168
3570,,15650,643.0,B,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,,,,COS-7,,168
3571,,17046,673.0,B,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,,,,C6,,168
3572,,17046,673.0,B,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,,,,C6,,168
3573,,15650,673.0,B,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,,,,C6,,168
3574,,17046,673.0,B,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,,,,C6,,168
3575,,17066,,B,,Binding affinity towards 5-hydroxytryptamine 5 receptor,,,,,,,10624
3576,,17200,,B,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,,,,,,105
3577,,16146,,B,,Binding affinity against 5-hydroxytryptamine 5A receptor,,,Homo sapiens,9606.0,,,10624
3578,,15250,449.0,B,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,,,,CHO,,10624
3579,,6491,,B,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,,Homo sapiens,9606.0,,,10624
3580,,17066,,B,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,,Homo sapiens,9606.0,,,10624
3581,,17066,,B,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,,Homo sapiens,9606.0,,,10624
3582,,4234,,B,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,,Homo sapiens,9606.0,,,10624
3583,,6013,,B,,Binding affinity towards 5-HT5A receptor,,,,,,,10624
3584,,17175,,B,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,,,,,10624
3585,,15818,,B,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,,,,,,10624
3586,,6166,,B,,Binding affinity towards cloned human 5-HT5A receptor was determined,,,,,,,10624
3587,,15779,722.0,B,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,,HEK293,,10624
3588,,15779,722.0,B,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,,,,HEK293,,10624
3589,,5213,722.0,B,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,,,,HEK293,,10624
3590,,17066,,B,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,,Mus musculus,10090.0,,,10625
3591,,17066,,B,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,,Mus musculus,10090.0,,,10625
3592,,17066,,B,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,,Mus musculus,10090.0,,,10625
3593,,17066,,B,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,,Mus musculus,10090.0,,,10625
3594,,17066,,B,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,,Mus musculus,10090.0,,,10625
3595,,17175,,B,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,,,,,10625
3596,,16190,722.0,B,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,,,,HEK293,,10576
3597,,16190,722.0,B,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,,,,HEK293,,10626
3598,,4820,,B,,Binding affinity towards 5-HT5a receptor,,,,,,,10624
3599,,17066,,B,,Binding affinity towards 5-hydroxytryptamine 5A receptor,,,Homo sapiens,9606.0,,,10624
3600,,17066,,B,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,,,,,,10624
3601,,17175,,B,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,,,,,,10624
3602,,16633,,B,,Binding affinities against 5-hydroxytryptamine 5A receptor,,,,,,,10624
3603,,16633,,B,,Binding affinities towards 5-hydroxytryptamine 5A receptor,,,,,,,10624
3604,,16700,,B,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,,,,,,10624
3605,,4639,,F,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,,Cavia porcellus,10141.0,,,104714
3606,,5486,,B,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,,,,,,104714
3607,,16146,,B,,Inhibition of human 5-hydroxytryptamine 6 receptor,,,Homo sapiens,9606.0,,,10627
3608,,17273,,B,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,,Homo sapiens,9606.0,,,10627
3609,,17687,,B,,Inhibition against human 5-hydroxytryptamine 6 receptor,,,,,,,10627
3610,,6491,,B,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,,Homo sapiens,9606.0,,,10627
3611,,16190,308.0,B,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,,,,HeLa,,10627
3612,,17066,,B,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,,Homo sapiens,9606.0,,,10627
3613,,17066,,B,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,Homo sapiens,9606.0,,,10627
3614,,17066,,B,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,,Homo sapiens,9606.0,,,10627
3615,,17066,,B,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,,Homo sapiens,9606.0,,,10627
3616,,3555,,B,,Binding affinity against 5-hydroxytryptamine 6 receptor,,,Homo sapiens,9606.0,,,10627
3617,,5808,,B,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,10627
3618,,6013,,B,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,10627
3619,,15818,722.0,B,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,,,,HEK293,,10627
3620,,16209,,B,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,,,,,,10627
3621,,3935,722.0,B,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,,,,HEK293,,10627
3622,,15818,,B,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,10627
3623,,3805,722.0,B,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,,Homo sapiens,9606.0,HEK293,,10627
3624,,16441,,B,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,,,,,,10627
3625,,16441,,B,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,,,,,10627
3626,,6786,643.0,B,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,,,,COS-7,,10627
3627,,4234,,B,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,,Homo sapiens,9606.0,,,10627
3628,,17085,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,,,,,,10627
3629,,17200,,B,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,,,,,,10627
3630,,17451,722.0,B,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,,,,HEK293,,10627
3631,,3935,,F,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,,,,,,10627
3632,,5033,,B,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,,,,,,10627
3633,,4540,,B,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,,,,,10627
3634,,4540,308.0,B,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,,Homo sapiens,9606.0,HeLa,,10627
3635,,4540,308.0,B,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,,Homo sapiens,9606.0,HeLa,,10627
3636,,17296,308.0,B,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,,,,HeLa,,10627
3637,,17296,308.0,B,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,,,,HeLa,,10627
3638,,17296,308.0,B,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,,,,HeLa,,10627
3639,,15779,449.0,B,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,,,CHO,,10627
3640,,15779,722.0,B,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,,HEK293,,10627
3641,,15779,722.0,B,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,,,,HEK293,,10627
3642,,15779,722.0,B,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,,,,HEK293,,10627
3643,,15779,308.0,B,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,,,,HeLa,,10627
3644,,6166,,B,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,10627
3645,,17451,308.0,B,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,,,,HeLa,,10627
3646,,15316,,B,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,,,,,,10627
3647,,4199,,B,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,,,,,10627
3648,,15146,308.0,B,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,,,,HeLa,,10627
3649,,5213,,B,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,,,,,,10627
3650,,16429,,B,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,,,,,,10627
3651,,14818,308.0,B,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,,,,HeLa,,10627
3652,,4829,308.0,B,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,,,,HeLa,,10627
3653,,4829,308.0,B,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,,,,HeLa,,10627
3654,,4829,308.0,B,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,,,,HeLa,,10627
3655,,15250,449.0,B,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,,,,CHO,,10628
3656,,14423,,B,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,,,,,,10628
3657,,15086,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,,,,,,10628
3658,,4342,,B,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,,,,,,10628
3659,,16190,308.0,B,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,,Homo sapiens,9606.0,HeLa,,10627
3660,,4820,,B,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,10627
3661,,4639,,B,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,,,,,,10627
3662,,17066,,F,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,Homo sapiens,9606.0,,,10627
3663,,6011,,B,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,,,,,,10627
3664,,17066,,B,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,10627
3665,,17515,,B,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,,,,,,10627
3666,,5014,,B,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,,,,,,10627
3667,,4373,,B,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,,,,,,10627
3668,,17066,,F,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,,,,,,10627
3669,,17066,,F,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,,,,,10627
3670,,4373,,B,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,,,,,,10627
3671,,4687,,B,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,,,,,,10627
3672,,16946,,B,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,,,,,,10627
3673,,16946,,B,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,,,,,,10627
3674,,16633,,B,,Binding affinities against 5-hydroxytryptamine 6 receptor,,,,,,,10627
3675,,16633,,B,,Binding affinities towards 5-hydroxytryptamine 6 receptor,,,,,,,10627
3676,,17066,,B,,Binding affinity towards 5-hydroxytryptamine 6 receptor,,,Homo sapiens,9606.0,,,10627
3677,,16700,,B,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,,,,,,10627
3678,,3269,,B,,Affinity against 5-hydroxytryptamine 6 receptor,,,,,,,10627
3679,,5486,,B,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,,,,,,10627
3680,,16146,,B,,Inhibition of human 5-hydroxytryptamine 7 receptor,,,Homo sapiens,9606.0,,,10209
3681,,5014,722.0,B,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,,,,HEK293,,10209
3682,,15463,,B,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,,,,,,10209
3683,,3805,,B,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,,,,,,10209
3684,,5014,722.0,B,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,,,,HEK293,,10209
3685,,6491,,B,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,,Homo sapiens,9606.0,,,10209
3686,,16190,449.0,B,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,,,,CHO,,10209
3687,,17066,,B,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,,Homo sapiens,9606.0,,,10209
3688,,17066,,B,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,,Homo sapiens,9606.0,,,10209
3689,,3555,,B,,Binding affinity against 5-hydroxytryptamine 7 receptor,,,Homo sapiens,9606.0,,,10209
3690,,6588,449.0,B,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,,,,CHO,,10209
3691,,15463,,B,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,,,,,,10209
3692,,6013,,B,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,,,,,10209
3693,,16209,,B,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,,,,,10209
3694,,3935,,B,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,,,,,,10209
3695,,15818,,B,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,,,,,,10209
3696,,5014,722.0,B,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,,,,HEK293,,10209
3697,,16441,,B,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,,,,,,10209
3698,,16441,,B,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,,,,,10209
3699,,4234,,B,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,,Homo sapiens,9606.0,,,10209
3700,,17085,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,,,,,,10209
3701,,17200,,B,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,,,,,,10209
3702,,17451,449.0,B,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,,,,CHO,,10209
3703,,17085,,B,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,,,,,,10209
3704,,5104,,B,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,,,,,,10209
3705,,5104,,B,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,,,,,,10209
3706,,5033,643.0,B,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,,Homo sapiens,9606.0,COS-7,,10209
3707,,5486,643.0,B,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,,,,COS-7,,10209
3708,,4540,722.0,B,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,,Homo sapiens,9606.0,HEK293,,10209
3709,,6166,,B,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,,,,,,10209
3710,,17342,722.0,B,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,,,,HEK293,,10209
3711,,17342,,B,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,,,,,,10209
3712,,17296,,B,,Binding affinity against 5-hydroxytryptamine 7 human receptors,,,,,,,10209
3713,,16429,,B,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,,,,,,10209
3714,,15779,722.0,B,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,,,,HEK293,,10209
3715,,15779,722.0,B,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,,,HEK293,,10209
3716,,15779,722.0,B,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,,,HEK293,,10209
3717,,15779,722.0,B,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,,,HEK293,,10209
3718,,15779,722.0,B,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,,,,HEK293,,10209
3719,,17451,449.0,B,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,,,,CHO,,10209
3720,,4199,722.0,B,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,,,,HEK293,,10209
3721,,4199,722.0,B,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,,,,HEK293,,10209
3722,,4199,722.0,B,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,,,,HEK293,,10209
3723,,3680,722.0,B,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,,,,HEK293,,10209
3724,,3680,,B,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,,,,,,10209
3725,,15316,643.0,B,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,,,,COS-7,,10209
3726,,15146,722.0,B,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,,,,HEK293,,10209
3727,,5213,722.0,B,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,,,,HEK293,,10209
3728,,5213,722.0,B,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,,,,HEK293,,10209
3729,,14818,722.0,B,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,,Homo sapiens,9606.0,HEK293,,10209
3730,,14818,722.0,B,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,,,,HEK293,,10209
3731,,14818,722.0,B,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,,,,HEK293,,10209
3732,,4829,722.0,B,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,,,,HEK293,,10209
3733,,17200,,B,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,,Homo sapiens,9606.0,,,10209
3734,,17066,,B,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,,Mus musculus,10090.0,,,10022
3735,,14025,,B,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,,Oryctolagus cuniculus,9986.0,,,10209
3736,,15250,449.0,B,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,,,,CHO,,11923
3737,,16372,449.0,B,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,,,,CHO,,11923
3738,,16372,449.0,B,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,,,,CHO,,11923
3739,,16372,449.0,B,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,,,,CHO,,11923
3740,,16372,449.0,B,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,,,,CHO,,11923
3741,,16372,449.0,B,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,,,,CHO,,11923
3742,,16372,449.0,B,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,,,,CHO,,11923
3743,,16372,449.0,B,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,,,,CHO,,11923
3744,,16372,449.0,B,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,,,,CHO,,11923
3745,,16372,449.0,B,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,,,,CHO,,11923
3746,,16372,449.0,B,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,,,,CHO,,11923
3747,,16372,449.0,B,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,,,,CHO,,11923
3748,,16372,449.0,B,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,,,,CHO,,11923
3749,,17066,,B,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,,,,,,11923
3750,,17066,,B,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,,Rattus norvegicus,10116.0,,,11923
3751,,17386,,B,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,,,,,,11923
3752,,14423,,B,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,,,,,,11923
3753,,15874,,B,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,,Rattus norvegicus,10116.0,,,11923
3754,,15874,,B,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,,Rattus norvegicus,10116.0,,,11923
3755,,16372,449.0,B,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,,Rattus norvegicus,10116.0,CHO,,11923
3756,,4622,,B,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,,,,,11923
3757,,15086,,B,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,,,,,,11923
3758,,16372,449.0,B,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,,,,CHO,,11923
3759,,16372,449.0,B,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,,,,CHO,,11923
3760,,16372,449.0,B,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,,,,CHO,,11923
3761,,16372,449.0,B,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,,,,CHO,,11923
3762,Ileum,17386,,F,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,,,,,,11923
3763,Ileum,17386,,F,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,,,,,11923
3764,Ileum,17386,,F,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,,,,,,11923
3765,,5831,,B,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,,Rattus norvegicus,10116.0,,Membranes,11923
3766,,4342,,B,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,,,,,,11923
3767,,17319,,B,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,,,,,,11923
3768,Hypothalamus,17342,,B,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,,,,,,11923
3769,,17342,,B,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,,,,,,11923
3770,Hypothalamus,3680,,B,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,,,,,,11923
3771,,3680,,B,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,,,,,11923
3772,,17319,722.0,F,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,,Rattus norvegicus,10116.0,HEK293,,11923
3773,,17319,722.0,F,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,,Rattus norvegicus,10116.0,HEK293,,11923
3774,,17319,722.0,F,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,,Rattus norvegicus,10116.0,HEK293,,11923
3775,,4820,,B,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,,,,,10209
3776,,4639,,B,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,,,,,,10209
3777,,6011,,B,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,,,,,,10209
3778,,17066,,B,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,,Homo sapiens,9606.0,,,10209
3779,,17066,,B,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,,,,,,10209
3780,,17515,,B,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,,,,,,10209
3781,,4373,,B,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,,,,,10209
3782,,17066,,F,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,,,,,,10209
3783,,4373,,B,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,,,,,,10209
3784,,4373,,B,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,,,,,10209
3785,,4687,,B,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,,,,,,10209
3786,,17342,,B,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,,,,,,10209
3787,,16946,,B,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,,,,,,10209
3788,,16946,,B,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,,,,,,10209
3789,,16633,,B,,Binding affinities against 5-hydroxytryptamine 7 receptor,,,,,,,10209
3790,,16633,,B,,Binding affinities towards 5-hydroxytryptamine 7 receptor,,,,,,,10209
3791,,17066,,B,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,,,,,,10209
3792,,16700,,B,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,,,,,,10209
3793,Ileum,17386,,B,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,,,,,,10209
3794,,14080,,F,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,,,,,,55
3795,,14080,,F,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,,Homo sapiens,9606.0,,,55
3796,,409,,B,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,,,,,,55
3797,,409,,B,,In vitro inhibition of human recombinant lipoxygenase enzyme,,,,,,,55
3798,,409,,B,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,,,,,,55
3799,Blood,11090,,B,,Inhibition of 5-lipoxygenase in human whole blood.,,,,,,,55
3800,Blood,11090,,B,,Inhibition of 5-lipoxygenase in human whole blood.,,,,,,,55
3801,,948,,B,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,,,,,,55
3802,,948,,B,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,,,,,,55
3803,,13622,,F,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,,,,,,55
3804,Blood,13622,,F,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,,,,,,55
3805,,9637,,B,,In vitro inhibition of 5-lipoxygenase from human polymorphs,,,,,,,55
3806,,11320,,B,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,,,,,,55
3807,,11320,,B,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,,,,,,55
3808,,6838,,B,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,,,,,,55
3809,Blood,17667,,B,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,,Homo sapiens,9606.0,,,55
3810,,12703,,B,,In vitro potency against human 5-Lipoxygenase,,,,,,,55
3811,,14312,,F,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,,Homo sapiens,9606.0,,,55
3812,Blood,14312,,F,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,,,,,,55
3813,,5364,,F,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,,,,,55
3814,,951,,B,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,,,,,,55
3815,,951,,B,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,,,,,,55
3816,,951,,B,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,,,,,,55
3817,,951,,B,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,,,,,,55
3818,,12365,,B,,Inhibition of human 5-lipoxygenase in human cells,,,,,,,55
3819,,10603,,B,,Inhibition of human neutrophil 5-lipoxygenase,,,,,,,55
3820,,10501,,B,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,,,,,,55
3821,Blood,12281,,B,,Inhibition of 5-lipoxygenase from human whole blood,,,,,,,55
3822,,2567,,B,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,,,,,55
3823,,2567,,B,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,,,,,,55
3824,,10193,,B,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,,,,,,55
3825,,10193,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,,,,,55
3826,,13623,,B,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,,,,,,55
3827,,12780,,B,,Tested against 5-lipoxygenase,,,,,,,55
3828,,12780,,B,,Tested for activity against 5-Lipoxygenase (5-LO),,,,,,,55
3829,,12780,,B,,Tested for activity against 5-lipoxygenase,,,,,,,55
3830,,11966,,B,,Tested for inhibition of 5-HPETE production by human 5-LO,,,,,,,55
3831,,5364,,F,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,,,,,55
3832,,13165,,B,,Inhibition of Human 5-lipoxygenase,,,,,,,55
3833,,5364,,B,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,,,,,,55
3834,,11311,,B,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,,,,,55
3835,,11311,,B,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,,,,,,55
3836,,14863,,B,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,,,,,,55
3837,,14863,,B,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,,,,,,55
3838,Blood,11087,,B,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,,,,,,55
3839,,455,,B,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,,,,,,55
3840,,13183,,B,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,,,,,55
3841,,10319,,B,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,,,,,,55
3842,,10193,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,,,,,55
3843,,951,,B,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,,,,,,55
3844,,951,,B,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,,,,,,55
3845,,951,,B,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,,,,,,55
3846,,951,,B,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,,,,,,55
3847,,9859,,B,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,,,,,,55
3848,,9859,,B,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,,,,,,55
3849,,9859,,B,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,,,,,,55
3850,,2567,,B,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,,,,,55
3851,,10193,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,,,,,,55
3852,,10193,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,,,,,55
3853,,949,,B,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,,,,,,55
3854,,949,,B,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,,,,,,55
3855,,10603,,B,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,,,,,,55
3856,,10603,,B,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,,,,,55
3857,,10603,,F,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,,,,,55
3858,,10603,,B,,Inhibition of lipoxygenase at the concentration of 0.1 uM,,,,,,,55
3859,,10603,,B,,Inhibition of lipoxygenase at the concentration of 1 uM,,,,,,,55
3860,,10193,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,,,,,,55
3861,,14580,,B,,Inhibition of 5-Lipoxygenase (5-LOX),,,Homo sapiens,9606.0,,,55
3862,,11090,,B,,Inhibition of 5-lipoxygenase in mouse macrophages.,,,,,,,17087
3863,,11090,,B,,Inhibition of 5-lipoxygenase in mouse macrophages.,,,,,,,17087
3864,,6339,,B,,Inhibitory activity against lipoxygenase-2 in mice,,,,,,,17087
3865,,6339,,B,,Inhibitory activity against murine lipoxygenase-2.,,,,,,,17087
3866,,12281,,B,,Inhibition of 5-lipoxygenase from mouse macrophage,,,Mus musculus,10090.0,,,17087
3867,,11311,,B,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,,,,,,17087
3868,,11089,,B,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,,Sus scrofa,9823.0,,,55
3869,,10091,,B,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,,Sus scrofa,9823.0,,,55
3870,,14352,,B,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,,Oryctolagus cuniculus,9986.0,,,55
3871,,13329,,B,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,,Rattus norvegicus,10116.0,,,12166
3872,,13329,,B,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,,,,,,12166
3873,,13329,,B,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,,,,,12166
3874,,13329,,B,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,,,,,,12166
3875,,13329,,B,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,,,,,,12166
3876,,13329,,B,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,,,,,,12166
3877,,13329,,B,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,,,,,,12166
3878,,11311,,B,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,,,,,,12166
3879,,11311,,B,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,,,,,,12166
3880,,105,702.0,B,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,,,,RBL-1,,12166
3881,,105,702.0,B,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,,,,RBL-1,,12166
3882,,9138,,B,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,,,,,,12166
3883,,9138,,B,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,,,,,,12166
3884,,9138,,B,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,,,,,,12166
3885,,14427,,B,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,,,,,12166
3886,,13329,,B,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,,,,,12166
3887,,13329,,B,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,,,,,,12166
3888,,14427,663.0,B,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,,Rattus norvegicus,10116.0,RBL-2H3,,12166
3889,,14427,,B,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,,,,,12166
3890,,14427,,B,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,,,,,,12166
3891,,10293,702.0,B,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,,,,RBL-1,,12166
3892,,338,702.0,B,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,,Rattus norvegicus,10116.0,RBL-1,,12166
3893,,303,,B,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,,,,,,12166
3894,,303,702.0,B,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,,,,RBL-1,,12166
3895,,9247,702.0,B,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,,,,RBL-1,,12166
3896,,9247,702.0,B,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,,,,RBL-1,,12166
3897,,137,702.0,B,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,,,,RBL-1,,12166
3898,,11481,,B,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,,,,,,12166
3899,,11481,,B,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,,,,,,12166
3900,,9029,,B,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,,,,,,12166
3901,,1701,,B,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,,,,,,12166
3902,,1701,,B,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,,,,,,12166
3903,,1701,,B,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,,,,,,12166
3904,,1701,,B,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,,,,,,12166
3905,,13358,702.0,F,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,,,,RBL-1,,12166
3906,,1175,702.0,B,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,,,,RBL-1,,12166
3907,,8797,702.0,B,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,,,,RBL-1,,12166
3908,,8797,,B,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,,,,,,12166
3909,,577,,B,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,,Rattus norvegicus,10116.0,,,12166
3910,,9295,702.0,B,,In vitro inhibitory activity against RBL-1 5-LO,,,,,RBL-1,,12166
3911,,9295,702.0,B,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,,,,RBL-1,,12166
3912,,9295,702.0,B,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,,,,RBL-1,,12166
3913,,9295,,B,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,,,,,,12166
3914,,9295,,B,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,,,,,,12166
3915,,216,,B,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,,,,,,12166
3916,,11090,702.0,B,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,,,,RBL-1,,12166
3917,Blood,11090,,B,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,,,,,,12166
3918,,10091,,B,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,,,,,,12166
3919,,10274,,F,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,,,,,,12166
3920,,13622,,F,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,,,,,,12166
3921,,12118,702.0,B,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,,,,RBL-1,,12166
3922,,12576,,B,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,,,,,,12166
3923,,9546,702.0,B,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,,,,RBL-1,,12166
3924,,9521,702.0,B,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,,,,RBL-1,,12166
3925,,10626,702.0,B,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,,,,RBL-1,,12166
3926,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase,,,,,RBL-1,,12166
3927,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,,,,RBL-1,,12166
3928,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,,,,RBL-1,,12166
3929,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,,,,RBL-1,,12166
3930,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,,,,RBL-1,,12166
3931,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,,,,RBL-1,,12166
3932,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,,,,RBL-1,,12166
3933,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,,,,RBL-1,,12166
3934,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,,,,RBL-1,,12166
3935,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,,,,RBL-1,,12166
3936,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,,,,RBL-1,,12166
3937,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,,,,RBL-1,,12166
3938,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,,,,RBL-1,,12166
3939,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,,,,RBL-1,,12166
3940,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,,,,RBL-1,,12166
3941,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,,,,RBL-1,,12166
3942,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,,,,RBL-1,,12166
3943,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,,,,RBL-1,,12166
3944,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,,,,RBL-1,,12166
3945,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,,,,RBL-1,,12166
3946,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,,,,RBL-1,,12166
3947,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,,,,RBL-1,,12166
3948,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,,,,RBL-1,,12166
3949,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,,,,RBL-1,,12166
3950,,9401,,B,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,,,,,,12166
3951,,10325,,B,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,,,,,,12166
3952,,1556,663.0,F,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,,,,RBL-2H3,,12166
3953,,1556,663.0,F,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,,,,RBL-2H3,,12166
3954,,961,702.0,B,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,,Rattus norvegicus,10116.0,RBL-1,,12166
3955,,6838,,B,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,,,,,,12166
3956,,10325,,B,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,,,,,,12166
3957,,9209,702.0,B,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,,Rattus norvegicus,10116.0,RBL-1,,12166
3958,,11520,702.0,B,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,,,,RBL-1,,12166
3959,,137,,B,,In vitro inhibitory activity against 5-lipoxygenase was determined,,,,,,,12166
3960,,4717,702.0,B,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,,,,RBL-1,,12166
3961,,10636,702.0,B,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,,,,RBL-1,,12166
3962,,14312,,F,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,,Rattus norvegicus,10116.0,,,12166
3963,,1203,702.0,B,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,,,,RBL-1,,12166
3964,,1203,,B,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,,,,,,12166
3965,,13622,702.0,B,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,,,,RBL-1,,12166
3966,,9793,,B,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,,,,,,12166
3967,,1143,702.0,B,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,,Rattus norvegicus,10116.0,RBL-1,,12166
3968,,11854,702.0,B,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,,Rattus norvegicus,10116.0,RBL-1,,12166
3969,,3595,702.0,B,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,,,RBL-1,,12166
3970,,3595,702.0,B,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,,,,RBL-1,,12166
3971,,10501,702.0,B,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,,Rattus norvegicus,10116.0,RBL-1,,12166
3972,,12526,702.0,B,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,,,RBL-1,,12166
3973,Limbic system,10034,,F,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,,,,,,10825
3974,Limbic system,10034,,F,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,,,,,10825
3975,,10034,,F,,Approximate dose levels for a half maximal reduction of 5-HTP levels,,,,,,,10825
3976,Hippocampus,10046,,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,,,,,10576
3977,Hippocampus,10046,,B,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,,,,,10576
3978,,10046,,B,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,,,,,10577
3979,Blood,12079,,F,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,,Canis lupus familiaris,9615.0,,,55
3980,Blood,12079,,F,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,,,,,,55
3981,,11311,,B,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,,,,,12166
3982,,12338,,B,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,,,,,,17140
3983,,12143,,B,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,,,,,,17140
3984,,12143,,B,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,,,,,,17140
3985,,12143,,B,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,,,,,17140
3986,,12143,,B,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,,,,,17140
3987,,12365,,B,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,,,,,,17140
3988,,13500,,B,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,,,,,,17140
3989,Blood,12832,,F,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
3990,Blood,12832,,F,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
3991,Blood,12832,,F,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
3992,Blood,12832,,F,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
3993,Blood,12832,,F,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
3994,Blood,12832,,F,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
3995,Blood,12832,,F,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
3996,Blood,12832,,F,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
3997,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
3998,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
3999,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4000,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4001,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4002,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4003,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4004,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4005,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4006,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4007,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4008,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4009,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4010,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4011,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4012,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4013,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4014,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4015,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4016,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4017,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4018,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4019,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4020,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4021,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4022,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4023,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4024,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4025,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4026,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4027,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4028,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4029,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4030,Blood,12832,,F,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4031,Blood,12832,,F,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4032,Blood,12832,,F,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4033,Blood,12832,,F,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4034,Blood,12832,,F,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,9615.0,,,55
4035,,3595,,B,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,,Canis lupus familiaris,9615.0,,,55
4036,,3595,,B,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,,Canis lupus familiaris,9615.0,,,55
4037,,3595,,B,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,,Canis lupus familiaris,9615.0,,,55
4038,,3595,,B,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,,Canis lupus familiaris,9615.0,,,55
4039,,3595,,B,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,,Canis lupus familiaris,9615.0,,,55
4040,,3595,,B,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,,Canis lupus familiaris,9615.0,,,55
4041,,3595,,B,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,,Canis lupus familiaris,9615.0,,,55
4042,,3595,,B,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,,Canis lupus familiaris,9615.0,,,55
4043,,9203,,B,,Ability to inhibit 5-lipoxygenase in guinea pig,,,Cavia porcellus,10141.0,,,55
4044,,82,,B,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,,Cavia porcellus,10141.0,,,55
4045,,11090,,B,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,,Cavia porcellus,10141.0,,,55
4046,Blood,12832,,B,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,,Cavia porcellus,10141.0,,,55
4047,,1065,,B,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,,Cavia porcellus,10141.0,,,55
4048,,1065,,B,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,,Cavia porcellus,10141.0,,,55
4049,,12832,,B,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,,Cavia porcellus,10141.0,,,55
4050,,12832,,B,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,,Cavia porcellus,10141.0,,,55
4051,,12832,,B,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,,Cavia porcellus,10141.0,,,55
4052,,10504,,B,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,,Cavia porcellus,10141.0,,,55
4053,,7788,,B,,Inhibitory activity against 5-lipoxygenase,,,Cavia porcellus,10141.0,,,55
4054,,10001,,B,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,,Cavia porcellus,10141.0,,,55
4055,,10193,,B,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,,Cavia porcellus,10141.0,,,55
4056,,13243,,B,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,,Cavia porcellus,10141.0,,,55
4057,,13243,,B,,Inhibitory activity uM,,,Cavia porcellus,10141.0,,,55
4058,,969,,B,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,,Cavia porcellus,10141.0,,,55
4059,,10001,,B,,Inhibitory activity against 5-lipoxygenase at 10 uM,,,Cavia porcellus,10141.0,,,55
4060,,7788,,B,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,,Cavia porcellus,10141.0,,,55
4061,,10001,,B,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,,Cavia porcellus,10141.0,,,55
4062,,10193,,B,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,,Cavia porcellus,10141.0,,,55
4063,,13243,,B,,Inhibitory activity uM,,,Cavia porcellus,10141.0,,,55
4064,,13243,,B,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,,Cavia porcellus,10141.0,,,55
4065,,13243,,B,,Inhibitory activity uM,,,Cavia porcellus,10141.0,,,55
4066,,13243,,F,,Inhibitory activity uM,,,Cavia porcellus,10141.0,,,55
4067,,10504,,B,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,,Cavia porcellus,10141.0,,,55
4068,,7788,,B,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,,Cavia porcellus,10141.0,,,55
4069,Ileum,10546,,F,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,,Cavia porcellus,10141.0,,,55
4070,,13183,,B,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,,,,,55
4071,,13183,,B,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,,,,,55
4072,,2578,,B,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,,,,,,55
4073,,12780,,B,,In vitro inhibition of human 5-Lipoxygenase.,,,,,,,55
4074,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4075,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4076,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4077,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4078,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4079,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4080,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4081,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4082,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4083,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4084,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4085,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4086,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4087,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4088,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4089,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4090,Liver,7411,,B,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,Rattus norvegicus,10116.0,,Microsomes,22226
4091,Liver,7411,,B,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,Rattus norvegicus,10116.0,,Microsomes,22226
4092,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4093,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4094,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4095,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4096,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4097,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4098,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4099,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4100,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4101,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4102,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4103,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4104,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4105,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4106,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4107,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4108,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4109,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4110,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4111,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4112,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4113,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4114,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4115,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4116,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4117,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4118,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4119,Liver,7411,,B,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4120,Liver,7411,,B,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4121,,7411,,B,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4122,Liver,7411,,B,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,Rattus norvegicus,10116.0,,Microsomes,22226
4123,Liver,7411,,B,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,Rattus norvegicus,10116.0,,Microsomes,22226
4124,Liver,7411,,B,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",,,Rattus norvegicus,10116.0,,Microsomes,22226
4125,Liver,7411,,B,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,Rattus norvegicus,10116.0,,Microsomes,22226
4126,Liver,7411,,B,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,Rattus norvegicus,10116.0,,Microsomes,22226
4127,,10797,741.0,F,,In vitro inhibition of 7226/S myeloma cancer cell line,,,Homo sapiens,9606.0,RPMI-8226,,80433
4128,,6881,993.0,F,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,,Homo sapiens,9606.0,BEL-7404 tumor cell line,,80698
4129,,3838,391.0,F,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,,Homo sapiens,9606.0,786-0,,80640
4130,,3838,391.0,F,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,,Homo sapiens,9606.0,786-0,,80640
4131,,12981,505.0,F,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,,Cricetulus griseus,10029.0,V79,,81264
4132,,12981,505.0,F,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,,Cricetulus griseus,10029.0,V79,,81264
4133,,7653,1119.0,F,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,,Rattus norvegicus,10116.0,7800C1 cell line,,80635
4134,,7653,1119.0,F,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,,Rattus norvegicus,10116.0,7800C1 cell line,,80635
4135,,7653,1119.0,F,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,,Rattus norvegicus,10116.0,7800C1 cell line,,80635
4136,,7653,1119.0,F,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,,Rattus norvegicus,10116.0,7800C1 cell line,,80635
4137,,7653,1119.0,F,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,,Rattus norvegicus,10116.0,7800C1 cell line,,80635
4138,,7653,1119.0,F,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,,Rattus norvegicus,10116.0,7800C1 cell line,,80635
4139,,17229,391.0,F,,In vitro antitumor activity against renal 786-0 tumor cell lines,,,Homo sapiens,9606.0,786-0,,80640
4140,,12858,391.0,F,,Cytotoxic activity against 786-0 Renal cancer cell line,,,Homo sapiens,9606.0,786-0,,80640
4141,,16325,391.0,F,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,,Homo sapiens,9606.0,786-0,,80640
4142,,16325,391.0,F,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,,Homo sapiens,9606.0,786-0,,80640
4143,,5858,391.0,F,,In vitro antitumor activity against human renal 786-0 cell line,,,Homo sapiens,9606.0,786-0,,80640
4144,,16325,391.0,F,,Inhibition of Renal cancer in 786-0 cancer cell lines,,,Homo sapiens,9606.0,786-0,,80640
4145,,14696,391.0,F,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,,Homo sapiens,9606.0,786-0,,80640
4146,,3786,391.0,F,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,,Homo sapiens,9606.0,786-0,,80640
4147,,14696,391.0,F,,inhibition of the growth of renal cancer(786-0) cell line,,,Homo sapiens,9606.0,786-0,,80640
4148,,14769,391.0,F,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,,Homo sapiens,9606.0,786-0,,80640
4149,,15354,391.0,F,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,,Homo sapiens,9606.0,786-0,,80640
4150,,14255,391.0,F,,The IC50 value was measured on 786-0 cell line in ovarian tumor,,,Homo sapiens,9606.0,786-0,,80640
4151,,14255,391.0,F,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,,Homo sapiens,9606.0,786-0,,80640
4152,,14255,391.0,F,,The IC50 value was measured on 786-0 cell line in renal tumor type.,,,Homo sapiens,9606.0,786-0,,80640
4153,,14696,391.0,F,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,,Homo sapiens,9606.0,786-0,,80640
4154,,12016,391.0,F,,Tested for cytotoxic activity against renal cancer 786-0 cell line,,,Homo sapiens,9606.0,786-0,,80640
4155,,2597,391.0,F,,Compound was tested for growth inhibitory activity against 786-0 cell line,,,Homo sapiens,9606.0,786-0,,80640
4156,,12526,702.0,B,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,,,,RBL-1,,12166
4157,,12526,702.0,B,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,,,,RBL-1,,12166
4158,,14799,,B,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,,,,,,12166
4159,,3595,702.0,B,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,,,RBL-1,,12166
4160,,3595,702.0,B,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,,,,RBL-1,,12166
4161,,12767,,B,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,,,,,,12166
4162,,10997,,B,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,,,,,,12166
4163,,11388,702.0,B,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,,,,RBL-1,,12166
4164,,167,,B,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,,,,,,12166
4165,,167,,B,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,,,,,,12166
4166,,13744,,B,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,,,,,,12166
4167,,1630,,B,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,,,,,,12166
4168,,1630,,B,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,,,,,,12166
4169,,969,,B,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,,Rattus norvegicus,10116.0,,,12166
4170,,13621,702.0,B,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,,,,RBL-1,,12166
4171,,10089,,B,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,,,,,,12166
4172,,10193,,B,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,,,,,,12166
4173,,11966,,B,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,,,,,,12166
4174,,12251,,B,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,,,,,12166
4175,,211,702.0,B,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,,,,RBL-1,,12166
4176,,12251,,F,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,,,,,12166
4177,,12495,702.0,B,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,,,,RBL-1,,12166
4178,,414,,B,,Tested for its inhibitory activity against 5-lipoxygenase,,,,,,,12166
4179,,414,,B,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,,,,,,12166
4180,,10325,,B,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,,,,,,12166
4181,,11966,,B,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,,,,,12166
4182,,165,702.0,B,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,,,,RBL-1,,12166
4183,,165,702.0,B,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,,,,RBL-1,,12166
4184,,165,702.0,B,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,,,,RBL-1,,12166
4185,,165,702.0,B,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,,,,RBL-1,,12166
4186,,11311,,B,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,,,,,,12166
4187,,11311,702.0,B,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,,,,RBL-1,,12166
4188,,11311,702.0,B,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,,,,RBL-1,,12166
4189,,11311,,B,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,,,,,12166
4190,,11311,,B,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,,,,,,12166
4191,,11311,,B,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),In vivo,,,,,,12166
4192,,11311,663.0,F,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,,,,RBL-2H3,,12166
4193,,11311,663.0,F,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,,,,RBL-2H3,,12166
4194,,11311,,B,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,,,,,,12166
4195,,11732,,B,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,,,,,,12166
4196,,11732,,B,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,,,,,,12166
4197,,11087,,B,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,,,,,,12166
4198,,11087,,B,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,,,,,,12166
4199,,11087,702.0,B,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,,,,RBL-1,,12166
4200,,11087,,B,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,,Rattus norvegicus,10116.0,,,12166
4201,,496,702.0,B,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,,,,RBL-1,,12166
4202,,13986,702.0,F,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,,,,RBL-1,,12166
4203,,11520,,B,,Compound was evaluated for the inhibition of 5-lipoxygenase,,,,,,,12166
4204,,10293,702.0,B,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,,,,RBL-1,,12166
4205,,303,702.0,B,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,,,,RBL-1,,12166
4206,,303,702.0,B,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,,,,RBL-1,,12166
4207,,9247,702.0,B,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,,,,RBL-1,,12166
4208,,9247,702.0,B,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,,Rattus norvegicus,10116.0,RBL-1,,12166
4209,,9247,702.0,B,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,,,,RBL-1,,12166
4210,,9247,702.0,B,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,,,,RBL-1,,12166
4211,,9247,702.0,B,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,,,,RBL-1,,12166
4212,,9247,702.0,B,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,,,,RBL-1,,12166
4213,,9247,702.0,B,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,,,,RBL-1,,12166
4214,,9247,702.0,B,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,,,,RBL-1,,12166
4215,,11481,,B,,Inhibitory activity against 5-lipoxygenase at 10 uM,,,Rattus norvegicus,10116.0,,,12166
4216,,105,,B,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,,,,,,12166
4217,,9029,,B,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,,,,,,12166
4218,,1175,702.0,B,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,,,,RBL-1,,12166
4219,,12118,702.0,B,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,,,,RBL-1,,12166
4220,,12118,702.0,B,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,,,,RBL-1,,12166
4221,,12118,702.0,B,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,,,,RBL-1,,12166
4222,,9225,702.0,B,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,,,,RBL-1,,12166
4223,,9401,,B,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,,,,,,12166
4224,,137,,B,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,,,,,12166
4225,,137,,B,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,,,,,12166
4226,,4717,702.0,B,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,,,,RBL-1,,12166
4227,,3595,702.0,B,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,,,,RBL-1,,12166
4228,,10501,702.0,B,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,,,,RBL-1,,12166
4229,,10501,702.0,B,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,,,,RBL-1,,12166
4230,,10501,702.0,B,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,,,,RBL-1,,12166
4231,,12526,702.0,B,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,,,RBL-1,,12166
4232,,14799,702.0,B,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,,Rattus norvegicus,10116.0,RBL-1,,12166
4233,,14799,,B,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,,,,,,12166
4234,,3595,702.0,B,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,,,,RBL-1,,12166
4235,,3595,702.0,B,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,,,,RBL-1,,12166
4236,,12526,702.0,B,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,,,RBL-1,,12166
4237,,12526,702.0,B,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,,,RBL-1,,12166
4238,,10193,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,,,,,12166
4239,,10193,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,,,,,12166
4240,,10193,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,,,,,12166
4241,,10193,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,,,,,,12166
4242,,9138,,B,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,,,,,,12166
4243,,9138,,B,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,,,,,,12166
4244,,11966,,B,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,,,,,12166
4245,,165,702.0,B,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,,,,RBL-1,,12166
4246,,165,702.0,B,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,,,,RBL-1,,12166
4247,,11311,663.0,B,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,,,,RBL-2H3,,12166
4248,,11311,663.0,B,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,,,,RBL-2H3,,12166
4249,,11311,663.0,F,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,,,,RBL-2H3,,12166
4250,,11311,,F,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,,,,,,12166
4251,,11311,,B,,The compound was tested for inhibition of isolated 5-lipoxygenase,,,,,,,12166
4252,,11311,663.0,F,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,,,,RBL-2H3,,12166
4253,,11087,,B,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,,,,,,12166
4254,,11087,,B,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,,,,,,12166
4255,,11087,,B,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,,,,,,12166
4256,,11087,,B,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,,,,,12166
4257,,11087,,B,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,,,,,12166
4258,,496,702.0,B,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,,,,RBL-1,,12166
4259,,496,702.0,B,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,,,,RBL-1,,12166
4260,,13986,702.0,F,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,,,,RBL-1,,12166
4261,,13986,702.0,F,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,,,,RBL-1,,12166
4262,,13986,702.0,F,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,,,,RBL-1,,12166
4263,,13986,702.0,F,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,,,,RBL-1,,12166
4264,,13986,702.0,F,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,,,,RBL-1,,12166
4265,,13986,702.0,F,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,,,,RBL-1,,12166
4266,,13986,702.0,F,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,,,,RBL-1,,12166
4267,,13986,702.0,F,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,,,,RBL-1,,12166
4268,,13986,702.0,F,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,,,,RBL-1,,12166
4269,,13986,,F,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,,Rattus norvegicus,10116.0,,,12166
4270,,10193,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,,,,,,12166
4271,,9295,,B,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,,,,,,12166
4272,,4717,702.0,B,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,,,,RBL-1,,12166
4273,,4717,702.0,B,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,,,,RBL-1,,12166
4274,,11854,702.0,B,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,,,,RBL-1,,12166
4275,,11854,702.0,B,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,,,,RBL-1,,12166
4276,,11854,702.0,B,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,,,,RBL-1,,12166
4277,,10193,,B,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,,,,,12166
4278,,9295,702.0,B,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,,,,RBL-1,,12166
4279,,9295,702.0,B,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,,,,RBL-1,,12166
4280,,9295,702.0,B,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,,,,RBL-1,,12166
4281,,9295,702.0,B,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,,,,RBL-1,,12166
4282,,165,702.0,B,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,,,,RBL-1,,12166
4283,,11311,,B,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,,,,,,12166
4284,,10489,702.0,B,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,,Homo sapiens,9606.0,RBL-1,,12166
4285,,10489,702.0,B,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,,Rattus norvegicus,10116.0,RBL-1,,12166
4286,,10489,702.0,B,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,,Rattus norvegicus,10116.0,RBL-1,,12166
4287,,14799,,B,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,,Rattus norvegicus,10116.0,,,12166
4288,,9295,,B,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,,Glycine max,3847.0,,,12054
4289,,16811,,B,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,,,,,,22226
4290,,168,,B,,In vitro inhibition of 5-Lipoxygenase; Inactive.,,,,,,,55
4291,,6309,,B,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,,,,,,55
4292,,6309,,B,,Inhibitory concentration against 5-lipoxygenase; No inhibition,,,,,,,55
4293,,3092,702.0,B,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,,,,RBL-1,,55
4294,,168,,B,,Inhibitory activity against 5-lipoxygenase.,,,,,,,55
4295,,168,,B,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,,,,,,55
4296,,168,,B,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,,,,,,55
4297,,168,,B,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,,,,,,55
4298,,12338,,F,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,,,,,,55
4299,,4501,,B,,Tested for the inhibitory activity against 5-lipoxygenase,,,,,,,55
4300,,1132,,B,,Compound was tested for its inhibitory activity against 5-lipoxygenase,,,,,,,55
4301,,2117,,B,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,,,,,,55
4302,,168,,B,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,,,,,,55
4303,,168,,B,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,,,,,,55
4304,,13575,702.0,B,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,,,,RBL-1,,12166
4305,,11089,,B,,,,,,,,,12166
4306,,216,,B,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,,,,,,10102
4307,,13165,,B,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,,,,,,10102
4308,,3278,,B,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,,,,,,10102
4309,,3278,,B,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,,,,,,10102
4310,,11966,,B,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,,,,,,10102
4311,,175,,B,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,,,,,,10102
4312,,175,,B,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,,,,,,10102
4313,,13449,,B,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,,,,,,10102
4314,,12014,,B,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,,,,,,11238
4315,,12014,,B,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,,,,,,11238
4316,,12014,,B,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,,,,,,11238
4317,,99,,B,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,,,,,,100284
4318,,4349,,F,,The dark toxicity against 543 human galactophore carcinoma cells,,,Homo sapiens,9606.0,,,22226
4319,,4071,390.0,F,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,,Homo sapiens,9606.0,Panel (56 tumour cell lines),,80623
4320,,17589,345.0,F,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,,Homo sapiens,9606.0,5637,,80008
4321,,15002,345.0,F,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,,Homo sapiens,9606.0,5637,,80008
4322,,13958,345.0,F,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,,Homo sapiens,9606.0,5637,,80008
4323,,17589,345.0,F,,Growth inhibition against human 5637 cell lines,,,Homo sapiens,9606.0,5637,,80008
4324,,16748,345.0,F,,Antitumor activity against human bladder carcinoma 5637 cells.,,,Homo sapiens,9606.0,5637,,80008
4325,,16747,345.0,F,,Antitumor activity against human bladder carcinoma 5637 cells,,,Homo sapiens,9606.0,5637,,80008
4326,,16747,345.0,F,,Antitumor activity against human bladder carcinoma 5637 cells,,,Homo sapiens,9606.0,5637,,80008
4327,,15285,,B,,In vitro inhibition of bovine trypsin(Trp).,,,Bos taurus,9913.0,,,10443
4328,,3726,407.0,B,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,,Cercopithecidae,9527.0,CV-1,,240
4329,,5033,,B,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,,,,,,10577
4330,,11756,,F,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,,,,,,104698
4331,,11953,,F,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,In vivo,,,,,,22226
4332,,5033,,B,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,,Cavia porcellus,10141.0,,,20033
4333,,11347,,A,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,,Rattus norvegicus,10116.0,,Microsomes,17045
4334,,11347,,A,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,,Rattus norvegicus,10116.0,,Microsomes,17045
4335,,1229,,F,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,,,,,22226
4336,,1229,,F,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,,,,,22226
4337,,17588,,B,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,,Trypanosoma brucei,5691.0,,,11938
4338,,17588,,B,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,,Trypanosoma brucei,5691.0,,,11938
4339,,17588,,B,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,,Ovis aries,9940.0,,,11938
4340,,17588,,B,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,,Ovis aries,9940.0,,,11938
4341,,16485,,B,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,,,,,,11938
4342,,4337,,F,,Average inhibitory concentration against 60 human cell lines was reported,,,Homo sapiens,9606.0,,,22226
4343,,4112,,F,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,,Homo sapiens,9606.0,,,22226
4344,,16160,542.0,F,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,,Homo sapiens,9606.0,Panel NCI-60 (60 carcinoma cell lines),,80315
4345,,16160,542.0,F,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,,Homo sapiens,9606.0,Panel NCI-60 (60 carcinoma cell lines),,80315
4346,,17376,542.0,F,,In vitro mean growth inhibitory activity against 60-cell panel,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315
4347,,17376,542.0,F,,In vitro mean growth lethal concentration against 60-cell panel,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315
4348,,17376,542.0,F,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315
4349,,17376,542.0,F,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315
4350,,3241,,F,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,,,,,104775
4351,,3241,,F,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,,,,,104775
4352,,3725,,B,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,,,,,,275
4353,,10805,,F,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,,Plasmodium falciparum,5833.0,,,50425
4354,,10805,,F,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,,Plasmodium falciparum,5833.0,,,50425
4355,,10805,,F,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,,Plasmodium falciparum,5833.0,,,50425
4356,,10805,,F,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,,Plasmodium falciparum,5833.0,,,50425
4357,,10805,,F,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,,Plasmodium falciparum,5833.0,,,50425
4358,,10144,850.0,F,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,,Mus musculus,10090.0,6C3HED,,80628
4359,,10144,850.0,F,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,,Mus musculus,10090.0,6C3HED,,80628
4360,,10144,850.0,F,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,,Mus musculus,10090.0,6C3HED,,80628
4361,,10144,850.0,F,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,,Mus musculus,10090.0,6C3HED,,80628
4362,,10144,850.0,F,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,,Mus musculus,10090.0,6C3HED,,80628
4363,,10144,850.0,F,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,,Mus musculus,10090.0,6C3HED,,80628
4364,,10685,,F,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,In vivo,,Mus musculus,10090.0,,,22224
4365,,10685,,F,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,In vivo,,Mus musculus,10090.0,,,22224
4366,,10685,,F,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),In vivo,,Mus musculus,10090.0,,,22224
4367,,10685,,F,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,In vivo,,Mus musculus,10090.0,,,22224
4368,,10685,,F,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,In vivo,,Mus musculus,10090.0,,,22224
4369,,10685,,F,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,In vivo,,Mus musculus,10090.0,,,22224
4370,,10685,,F,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,In vivo,,Mus musculus,10090.0,,,22224
4371,,10685,,F,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",In vivo,,Mus musculus,10090.0,,,22224
4372,,10685,,F,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),In vivo,,Mus musculus,10090.0,,,22224
4373,,10685,,F,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),In vivo,,Mus musculus,10090.0,,,22224
4374,,10685,,F,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,In vivo,,Mus musculus,10090.0,,,22224
4375,,10144,,F,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,,Mus musculus,10090.0,,,22224
4376,,10144,,F,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,,Mus musculus,10090.0,,,22224
4377,,10144,,F,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,,Mus musculus,10090.0,,,22224
4378,,10144,,F,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,,Mus musculus,10090.0,,,22224
4379,,10685,,F,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,,Mus musculus,10090.0,,,22224
4380,,10685,,F,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,,Mus musculus,10090.0,,,22224
4381,,10685,,F,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,,Mus musculus,10090.0,,,22224
4382,,10685,,F,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,,Mus musculus,10090.0,,,22224
4383,,10685,,A,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,,Mus musculus,10090.0,,,22224
4384,,10685,,A,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,,Mus musculus,10090.0,,,22224
4385,,10685,,A,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,,Mus musculus,10090.0,,,22224
4386,,10685,,A,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,,Mus musculus,10090.0,,,22224
4387,,8831,850.0,F,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,,Mus musculus,10090.0,6C3HED,,80628
4388,,11704,,F,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,In vivo,,,,,,22224
4389,,11704,,A,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,,Mus musculus,10090.0,,,50594
4390,,10685,850.0,F,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,In vivo,,Mus musculus,10090.0,6C3HED,,80628
4391,,10685,850.0,F,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,In vivo,,Mus musculus,10090.0,6C3HED,,80628
4392,,11368,850.0,F,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,,Mus musculus,10090.0,6C3HED,,80628
4393,,11368,850.0,F,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,,Mus musculus,10090.0,6C3HED,,80628
4394,,11368,850.0,F,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,,Mus musculus,10090.0,6C3HED,,80628
4395,,17763,,B,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,,Staphylococcus aureus,1280.0,,,22226
4396,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4397,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4398,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4399,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4400,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4401,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4402,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4403,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4404,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4405,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4406,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4407,Liver,7411,,B,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,,Rattus norvegicus,10116.0,,Microsomes,22226
4408,Plasma,347,,A,,The apparent total plasma clearance in monkey,In vivo,,Cercopithecidae,9527.0,,,22224
4409,,3341,,A,,Compound was evaluated for Hepatic clearance in monkey,In vivo,,Cercopithecidae,9527.0,,,22224
4410,,17853,,A,,Lower clearance in monkey (i.v.) at 0.5 mpk,In vivo,,Cercopithecidae,9527.0,,,22224
4411,,4514,,A,,Plasma clearance in rhesus monkey,In vivo,,Cercopithecidae,9527.0,,,22224
4412,,6062,,A,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,In vivo,,Cercopithecidae,9527.0,,,22224
4413,,6821,,A,,Plasma clearance of compound was determined in monkey,In vivo,,Cercopithecidae,9527.0,,,22224
4414,,6057,,A,,Plasma clearance was calculated in rhesus monkey,In vivo,,Cercopithecidae,9527.0,,,22224
4415,,5145,,A,,Plasma clearance in rhesus monkey,In vivo,,Cercopithecidae,9527.0,,,22224
4416,,6641,,A,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,Cercopithecidae,9527.0,,,22224
4417,,5472,,A,,Plasma clearance was evaluated in rhesus,In vivo,,Cercopithecidae,9527.0,,,22224
4418,,4257,,A,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,In vivo,,Cercopithecidae,9527.0,,,22224
4419,,5546,,A,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,In vivo,,Cercopithecidae,9527.0,,,22224
4420,,5334,,A,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,,Cercopithecidae,9527.0,,,22224
4421,,5334,,A,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,,Cercopithecidae,9527.0,,,22224
4422,,17509,,A,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,In vivo,,Cercopithecidae,9527.0,,,22224
4423,,6535,,A,,Cmax in monkey after administration of 1 mg/kg iv,In vivo,,Cercopithecidae,9527.0,,,22224
4424,,5668,,A,,Cmax was determine after peroral administration at 10 mpk in Rhesus,In vivo,,Cercopithecidae,9527.0,,,22224
4425,,5922,,A,,Cmax in cynomolgus monkey by iv administration,In vivo,,Cercopithecidae,9527.0,,,22224
4426,,5922,,A,,Cmax in cynomolgus monkey by po administration,In vivo,,Cercopithecidae,9527.0,,,22224
4427,,6078,,A,,Cmax value evaluated in monkey,In vivo,,Cercopithecidae,9527.0,,,22224
4428,,2661,,A,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,In vivo,,Cercopithecidae,9527.0,,,22224
4429,Plasma,3249,,A,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,In vivo,,Cercopithecidae,9527.0,,,22224
4430,Plasma,3249,,A,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,In vivo,,Cercopithecidae,9527.0,,,22224
4431,Plasma,5553,,A,,Maximal plasma concentration in squirrel monkeys,In vivo,,Cercopithecidae,9527.0,,,22224
4432,,1916,,A,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,,Cercopithecidae,9527.0,,,22224
4433,Plasma,6227,,A,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,In vivo,,Cercopithecidae,9527.0,,,22224
4434,,4809,,A,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,,Cercopithecidae,9527.0,,,22224
4435,,5355,,A,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,In vivo,,Cercopithecidae,9527.0,,,22224
4436,,5355,,A,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,In vivo,,Cercopithecidae,9527.0,,,22224
4437,,5355,,A,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,In vivo,,Cercopithecidae,9527.0,,,22224
4438,,5355,,A,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,In vivo,,Cercopithecidae,9527.0,,,22224
4439,Plasma,6221,,A,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,In vivo,,Cercopithecidae,9527.0,,,22224
4440,,167,,A,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,,Cercopithecidae,9527.0,,,22224
4441,,167,,A,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,,Cercopithecidae,9527.0,,,22224
4442,,4257,,A,,Absolute bioavailability was evaluated in monkey,In vivo,,monkey,9443.0,,,22224
4443,,6221,,A,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,In vivo,,monkey,9443.0,,,22224
4444,,17667,,A,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,In vivo,,monkey,9443.0,,,22224
4445,,17267,,A,,Bioavailability of compound was determined in rhesus monkey,In vivo,,Macaca mulatta,9544.0,,,22224
4446,,4256,,A,,Bioavailability determined after oral administration in marmoset,In vivo,,marmosets,38020.0,,,22224
4447,,4256,,A,,Oral bioavailability in cynomolgus monkey,In vivo,,Macaca fascicularis,9541.0,,,22224
4448,,17853,,A,,Bioavailability in monkey (p.o.) at 2.0 mpk,In vivo,,monkey,9443.0,,,22224
4449,,16365,,A,,Bioavailability was evaluated after oral administration in monkey,In vivo,,monkey,9443.0,,,22224
4450,,1916,,A,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,,Macaca fascicularis,9541.0,,,22224
4451,,5334,,A,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,,Macaca mulatta,9544.0,,,22224
4452,,5334,,A,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,,Macaca mulatta,9544.0,,,22224
4453,,17592,,A,,Bioavailability of the compound was determined in monkey,In vivo,,monkey,9443.0,,,22224
4454,,1399,,A,,Bioavailability in squirrel monkey (dose 5 mg/kg),In vivo,,Saimiri sciureus,9521.0,,,22224
4455,,4809,,A,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,,monkey,9443.0,,,22224
4456,,3341,,A,,Oral bioavailability in monkey,In vivo,,monkey,9443.0,,,22224
4457,,64,,A,,Compound was tested for bioavailability in squirrel monkey,In vivo,,Saimiri sciureus,9521.0,,,22224
4458,,5005,,A,,Oral bioavailability in Rhesus monkey,In vivo,,Macaca mulatta,9544.0,,,22224
4459,,5005,,A,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),In vivo,,Macaca mulatta,9544.0,,,22224
4460,,5237,,A,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,In vivo,,Macaca fascicularis,9541.0,,,22224
4461,,5237,,A,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,In vivo,,Macaca fascicularis,9541.0,,,22224
4462,,5302,,A,,Oral bioavailability in monkey (dose 5 mg/kg),In vivo,,monkey,9443.0,,,22224
4463,,17667,,A,,Oral bioavailability of compound at 5 mg/kg in monkey,In vivo,,monkey,9443.0,,,22224
4464,,6161,,A,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
4465,,6161,,A,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
4466,Plasma,3854,,A,,Plasma half life determined,,,Canis lupus familiaris,9615.0,,,50588
4467,Plasma,993,,A,,Plasma half life in dog,,,Canis lupus familiaris,9615.0,,,50588
4468,Plasma,4514,,A,,Plasma half-life in Beagle dogs,,,Canis lupus familiaris,9615.0,,,50588
4469,Plasma,5334,,A,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),In vivo,,Canis lupus familiaris,9615.0,,,50588
4470,Plasma,5334,,A,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),In vivo,,Canis lupus familiaris,9615.0,,,50588
4471,,1466,,A,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
4472,,1466,,A,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
4473,,5313,,A,,Tested for the half life period in dog,,,Canis lupus familiaris,9615.0,,,50588
4474,,5313,,A,,Tested for the half life period in dog at dosage of 10 mpk,In vivo,,Canis lupus familiaris,9615.0,,,50588
4475,,3880,,A,,The compound was tested for half life in dog,,,Canis lupus familiaris,9615.0,,,50588
4476,Plasma,3639,,A,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,,Canis lupus familiaris,9615.0,,,50588
4477,,3880,,A,,The half life was determined,,,Canis lupus familiaris,9615.0,,,50588
4478,Plasma,3918,,A,,The plasma half-life in dogs,,,Canis lupus familiaris,9615.0,,,50588
4479,Plasma,16452,,A,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,,Canis lupus familiaris,9615.0,,,50588
4480,,17796,,A,,Half life in dog,,,Canis lupus familiaris,9615.0,,,50588
4481,,5983,,A,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,In vivo,,Canis lupus familiaris,9615.0,,,50588
4482,,1466,,A,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
4483,,16456,,A,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
4484,,6113,,A,,Cmax in ferrets after 30 mg/kg oral dose,In vivo,,Mustela putorius furo,9669.0,,,50506
4485,,6113,,F,,Emesis in ferrets at 30 mg/kg oral dose,In vivo,,Mustela putorius furo,9669.0,,,50506
4486,,17796,,A,,Bioavailability in cynomolgus monkey,In vivo,,Macaca fascicularis,9541.0,,,22224
4487,,17796,,A,,Volume of distribution in cynomolgus,In vivo,,Macaca fascicularis,9541.0,,,100710
4488,Plasma,5308,,A,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,,Cavia porcellus,10141.0,,,22224
4489,,4877,,A,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,,Cavia porcellus,10141.0,,,22224
4490,,4876,,A,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,,Cavia porcellus,10141.0,,,22224
4491,Plasma,4878,,A,,AUC in guinea pig after 3mg/kg oral dose,In vivo,,Cavia porcellus,10141.0,,,22224
4492,,5308,,A,,Bioavailability in guinea pig was tested,In vivo,,Cavia porcellus,10141.0,,,22224
4493,,4877,,A,,Tested for oral bioavailability in guinea pig at 5 mg/kg,In vivo,,Cavia porcellus,10141.0,,,22224
4494,,4876,,A,,Tested for the oral bioavailability of the compound,In vivo,,Cavia porcellus,10141.0,,,22224
4495,,4876,,A,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,In vivo,,Cavia porcellus,10141.0,,,22224
4496,,5308,,A,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,In vivo,,Cavia porcellus,10141.0,,,22224
4497,Lung,4877,,A,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,In vivo,,Cavia porcellus,10141.0,,,22224
4498,,4878,,A,,Cmax in guinea pig after 3mg/kg oral dose,In vivo,,Cavia porcellus,10141.0,,,22224
4499,Blood,5689,,A,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,,Cavia porcellus,10141.0,,,22224
4500,Brain,5689,,A,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,,Cavia porcellus,10141.0,,,22224
4501,,5689,,A,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,,Cavia porcellus,10141.0,,,22224
4502,Intestine,5689,,A,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,,Cavia porcellus,10141.0,,,22224
4503,Kidney,5689,,A,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,,Cavia porcellus,10141.0,,,22224
4504,Liver,5689,,A,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,,Cavia porcellus,10141.0,,,22224
4505,,5689,,A,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,,Cavia porcellus,10141.0,,,22224
4506,Spleen,5689,,A,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,,Cavia porcellus,10141.0,,,22224
4507,,14465,,A,,Elimination T1/2 in Guinea pig (PO dose),In vivo,,Cavia porcellus,10141.0,,,22224
4508,,5689,,A,,Partition coefficient was measured as -log (counts per min ),,,Cavia porcellus,10141.0,,,22224
4509,,611,,A,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,In vivo,,Cavia porcellus,10141.0,,,22224
4510,,611,,A,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,In vivo,,Cavia porcellus,10141.0,,,22224
4511,,14465,,A,,Elimination T1/2 in Guinea pig (PO dose),In vivo,,Cavia porcellus,10141.0,,,22224
4512,,4876,,A,,"Tested for the half life period of the compound, intravenously",In vivo,,Cavia porcellus,10141.0,,,22224
4513,,5689,,A,,Half-life was measured,,,Cavia porcellus,10141.0,,,22224
4514,,7515,,A,,The time required for onset of inotropy after addition of a single dose of delta F75,,,Cavia porcellus,10141.0,,,22224
4515,,17667,,A,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,In vivo,,Cavia porcellus,10141.0,,,22224
4516,,17667,,A,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,In vivo,,Cavia porcellus,10141.0,,,22224
4517,,4727,,A,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,In vivo,,Cricetulus griseus,10029.0,,,22224
4518,,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,10090.0,,,50594
4519,,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,Mus musculus,10090.0,,,50594
4520,,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,10090.0,,,50594
4521,,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,10090.0,,,50594
4522,,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,In vivo,,Mus musculus,10090.0,,,50594
4523,,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,10090.0,,,50594
4524,,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,10090.0,,,50594
4525,Blood,3655,,A,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4526,Blood,3655,,A,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4527,Blood,3655,,A,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,In vivo,,Mus musculus,10090.0,,,50594
4528,Bone,3655,,A,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4529,Bone,3655,,A,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4530,Bone,3655,,A,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,In vivo,,Mus musculus,10090.0,,,50594
4531,Brain,3655,,A,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4532,Brain,3655,,A,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4533,Brain,3655,,A,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,In vivo,,Mus musculus,10090.0,,,50594
4534,Heart,3655,,A,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4535,Heart,3655,,A,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4536,Heart,3655,,A,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,In vivo,,Mus musculus,10090.0,,,50594
4537,Intestine,3655,,A,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4538,Intestine,3655,,A,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4539,Intestine,3655,,A,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,In vivo,,Mus musculus,10090.0,,,50594
4540,Kidney,3655,,A,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4541,Kidney,3655,,A,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4542,Kidney,3655,,A,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,In vivo,,Mus musculus,10090.0,,,50594
4543,Liver,3655,,A,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4544,Liver,3655,,A,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4545,Liver,3655,,A,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,In vivo,,Mus musculus,10090.0,,,50594
4546,Lung,3655,,A,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4547,Lung,3655,,A,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4548,Lung,3655,,A,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,In vivo,,Mus musculus,10090.0,,,50594
4549,Muscle tissue,3655,,A,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4550,Muscle tissue,3655,,A,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4551,Muscle tissue,3655,,A,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,In vivo,,Mus musculus,10090.0,,,50594
4552,Spleen,3655,,A,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4553,Spleen,3655,,A,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4554,Spleen,3655,,A,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,In vivo,,Mus musculus,10090.0,,,50594
4555,Stomach,3655,,A,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4556,Stomach,3655,,A,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,10090.0,,,50594
4557,Stomach,3655,,A,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,In vivo,,Mus musculus,10090.0,,,50594
4558,,16597,,A,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,In vivo,,Mus musculus,10090.0,,,50594
4559,,16597,,F,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,In vivo,,Mus musculus,10090.0,,,50594
4560,,16597,,A,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,,Mus musculus,10090.0,,,50594
4561,,16597,,A,,MRT value at a dose of 10 mg/kg peroral administration in mice.,In vivo,,Mus musculus,10090.0,,,50594
4562,,17764,,A,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,In vivo,,Mus musculus,10090.0,,,50594
4563,,17764,,F,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,In vivo,,Mus musculus,10090.0,,,50594
4564,,3830,478.0,F,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,,Homo sapiens,9606.0,A2780,,81034
4565,,3829,478.0,F,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,,Homo sapiens,9606.0,A2780,,81034
4566,,2040,478.0,F,,Compound was evaluated for cytotoxicity against A2780 cell lines.,,,Homo sapiens,9606.0,A2780,,81034
4567,,15684,478.0,F,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,,Homo sapiens,9606.0,A2780,,81034
4568,,15684,478.0,F,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,,Homo sapiens,9606.0,A2780,,81034
4569,,15684,478.0,F,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,,Homo sapiens,9606.0,A2780,,81034
4570,,15684,478.0,F,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,,Homo sapiens,9606.0,A2780,,81034
4571,,15684,478.0,F,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,,Homo sapiens,9606.0,A2780,,81034
4572,,15684,478.0,F,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,,Homo sapiens,9606.0,A2780,,81034
4573,,2859,478.0,F,,Compound was evaluated for cytotoxicity against A2780 cell line,,,Homo sapiens,9606.0,A2780,,81034
4574,,5618,478.0,F,,In vitro inhibitory activity against human tumor cell line A2780,,,Homo sapiens,9606.0,A2780,,81034
4575,,15684,478.0,F,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,,Homo sapiens,9606.0,A2780,,81034
4576,,15684,478.0,F,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,,Homo sapiens,9606.0,A2780,,81034
4577,,15684,478.0,F,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,,Homo sapiens,9606.0,A2780,,81034
4578,,15684,478.0,F,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,,Homo sapiens,9606.0,A2780,,81034
4579,,2113,478.0,F,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,,Homo sapiens,9606.0,A2780,,81034
4580,,2113,478.0,F,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,,Homo sapiens,9606.0,A2780,,81034
4581,,16745,478.0,F,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,,Homo sapiens,9606.0,A2780,,81034
4582,,16597,478.0,F,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,,Homo sapiens,9606.0,A2780,,81034
4583,,15684,478.0,F,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,,Homo sapiens,9606.0,A2780,,81034
4584,,15684,478.0,F,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,,Homo sapiens,9606.0,A2780,,81034
4585,,2040,478.0,F,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,,Homo sapiens,9606.0,A2780,,81034
4586,,2040,478.0,F,,Relative resistance factor in A2780 cisplatin-resistant line,,,Homo sapiens,9606.0,A2780,,81034
4587,,16165,478.0,F,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,,Homo sapiens,9606.0,A2780,,81034
4588,,16165,478.0,F,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,,Homo sapiens,9606.0,A2780,,81034
4589,,16597,478.0,F,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,,Homo sapiens,9606.0,A2780,,81034
4590,,16597,478.0,F,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,,Homo sapiens,9606.0,A2780,,81034
4591,,3992,478.0,F,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,,Homo sapiens,9606.0,A2780,,81034
4592,,10553,478.0,F,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,,Homo sapiens,9606.0,A2780,,81034
4593,,15608,478.0,F,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,,Homo sapiens,9606.0,A2780,,81034
4594,,15608,478.0,F,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,,Homo sapiens,9606.0,A2780,,81034
4595,,15608,478.0,F,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,,Homo sapiens,9606.0,A2780,,81034
4596,,15608,478.0,F,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,,Homo sapiens,9606.0,A2780,,81034
4597,,15608,478.0,F,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,,Homo sapiens,9606.0,A2780,,81034
4598,,15608,478.0,F,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,,Homo sapiens,9606.0,A2780,,81034
4599,,15569,478.0,F,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,,Homo sapiens,9606.0,A2780,,81034
4600,,17420,478.0,F,,Antiproliferative effect of compound on A2780/DX cell line,,,Homo sapiens,9606.0,A2780,,81034
4601,,17420,478.0,F,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,,Homo sapiens,9606.0,A2780,,81034
4602,,15099,478.0,F,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,,Homo sapiens,9606.0,A2780,,81034
4603,,15099,478.0,F,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,,Homo sapiens,9606.0,A2780,,81034
4604,,17672,478.0,F,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,,Homo sapiens,9606.0,A2780,,81034
4605,,17672,478.0,F,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,,Homo sapiens,9606.0,A2780,,81034
4606,,17270,478.0,F,,In vitro cytotoxicity against A2780ADR cell line,,,Homo sapiens,9606.0,A2780,,81034
4607,,17270,478.0,F,,In vitro cytotoxicity against A2780CIS cell line,,,Homo sapiens,9606.0,A2780,,81034
4608,,5574,478.0,F,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,,Homo sapiens,9606.0,A2780,,81034
4609,,2113,478.0,F,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,,Homo sapiens,9606.0,A2780,,81034
4610,,16913,478.0,F,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,,Homo sapiens,9606.0,A2780,,81034
4611,,16913,478.0,F,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,,Homo sapiens,9606.0,A2780,,81034
4612,,17839,,A,,Oral bioavailability of compound in rhesus macaques,In vivo,,Macaca mulatta,9544.0,,,22224
4613,,6821,,A,,Oral bioavailability in monkey,In vivo,,monkey,9443.0,,,22224
4614,,6078,,A,,Oral bioavailability evaluated in monkey,In vivo,,monkey,9443.0,,,22224
4615,,6535,,A,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),In vivo,,monkey,9443.0,,,22224
4616,,4449,,A,,Oral bioavailability in Rhesus monkey,In vivo,,Macaca mulatta,9544.0,,,22224
4617,,6057,,A,,Oral bioavailability was calculated in rhesus monkey,In vivo,,Macaca mulatta,9544.0,,,22224
4618,,5922,,A,,Oral bioavailability in cynomolgus monkey,In vivo,,Macaca fascicularis,9541.0,,,22224
4619,,5940,,A,,Oral bioavailability in monkey,In vivo,,monkey,9443.0,,,22224
4620,,6265,,A,,Oral bioavailability in monkey,In vivo,,monkey,9443.0,,,22224
4621,,6265,,A,,Oral bioavailability in monkey (dose 1 mg/kg),In vivo,,monkey,9443.0,,,22224
4622,,6265,,A,,Oral bioavailability in monkey (dose 5 mg/kg),In vivo,,monkey,9443.0,,,22224
4623,,5940,,A,,Oral bioavailability in monkey,In vivo,,monkey,9443.0,,,22224
4624,,5940,,A,,Oral bioavailability in monkey,In vivo,,monkey,9443.0,,,22224
4625,,4514,,A,,Oral bioavailability in rhesus monkey,In vivo,,Macaca mulatta,9544.0,,,22224
4626,,5546,,A,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,In vivo,,Macaca mulatta,9544.0,,,22224
4627,,5553,,A,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,In vivo,,Saimiri sciureus,9521.0,,,22224
4628,,6641,,A,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,monkey,9443.0,,,22224
4629,,5472,,A,,Oral bioavailability in Rhesus monkey,In vivo,,Macaca mulatta,9544.0,,,22224
4630,,5668,,A,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),In vivo,,Macaca mulatta,9544.0,,,22224
4631,,5711,,A,,Oral bioavailability in monkey at 10 mg/kg of the compound,In vivo,,monkey,9443.0,,,22224
4632,,5145,,A,,Bioavailability in Rhesus monkey,In vivo,,Macaca mulatta,9544.0,,,22224
4633,,3443,,A,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Cercopithecidae,9527.0,,,22224
4634,,3443,,A,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Cercopithecidae,9527.0,,,22224
4635,,3249,,A,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,In vivo,,Cercopithecidae,9527.0,,,22224
4636,,3249,,A,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,In vivo,,Cercopithecidae,9527.0,,,22224
4637,,5355,,A,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,In vivo,,Cercopithecidae,9527.0,,,22224
4638,,5355,,A,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,In vivo,,Cercopithecidae,9527.0,,,22224
4639,,5355,,A,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,In vivo,,Cercopithecidae,9527.0,,,22224
4640,,4809,,A,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,,Cercopithecidae,9527.0,,,22224
4641,,4809,,A,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,,Cercopithecidae,9527.0,,,22224
4642,,14294,,A,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,,Cercopithecidae,9527.0,,Microsomes,22224
4643,,14294,,A,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,,Cercopithecidae,9527.0,,Microsomes,22224
4644,,14294,,A,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,,Cercopithecidae,9527.0,,Microsomes,22224
4645,,14294,,A,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,,Cercopithecidae,9527.0,,Microsomes,22224
4646,,3443,,A,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,,Cercopithecidae,9527.0,,,22224
4647,,3443,,A,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,,Cercopithecidae,9527.0,,,22224
4648,,11271,,A,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,,Cercopithecidae,9527.0,,,22224
4649,,3443,,A,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Cercopithecidae,9527.0,,,22224
4650,,3443,,A,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Cercopithecidae,9527.0,,,22224
4651,,6821,,A,,Elimination Half-life of compound was determined in monkey,,,Cercopithecidae,9527.0,,,22224
4652,,17267,,A,,Half life of compound was determined in rhesus monkey,,,Cercopithecidae,9527.0,,,22224
4653,Plasma,5819,,A,,Half life in monkey plasma,,,Cercopithecidae,9527.0,,,22224
4654,Plasma,5819,,A,,Half life in monkey plasma; Not detected,,,Cercopithecidae,9527.0,,,22224
4655,,1916,,A,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,,Cercopithecidae,9527.0,,,22224
4656,,17509,,A,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,In vivo,,Cercopithecidae,9527.0,,,22224
4657,,1399,,A,,Terminal half life of the compound.,,,Cercopithecidae,9527.0,,,22224
4658,,1916,,A,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,,Cercopithecidae,9527.0,,,22224
4659,,4809,,A,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,,Cercopithecidae,9527.0,,,22224
4660,,5546,,A,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,,Cercopithecidae,9527.0,,,22224
4661,Urine,3443,,A,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Cercopithecidae,9527.0,,,22224
4662,Urine,3443,,A,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Cercopithecidae,9527.0,,,22224
4663,,4257,,A,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,In vivo,,Cercopithecidae,9527.0,,,22224
4664,,6221,,A,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,In vivo,,Cercopithecidae,9527.0,,,22224
4665,,5472,,A,,Volume of distribution was evaluated in rhesus,In vivo,,Cercopithecidae,9527.0,,,22224
4666,,4727,,A,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,In vivo,,Cricetulus griseus,10029.0,,,22224
4667,,4727,,A,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,In vivo,,Cricetulus griseus,10029.0,,,22224
4668,,4727,,A,,Bioavailability in hamster was determined,In vivo,,Cricetulus griseus,10029.0,,,22224
4669,,4727,,A,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,In vivo,,Cricetulus griseus,10029.0,,,22224
4670,,4727,,A,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,In vivo,,Cricetulus griseus,10029.0,,,22224
4671,Blood,4727,,A,,Half life of compound was determined in hamster blood,,,Cricetulus griseus,10029.0,,,22224
4672,,1452,,A,,Michaelis-Menten constant of the compound.,,,Sus scrofa,9823.0,,,22224
4673,,1452,,A,,Vmax value was measured at 0 uM concentration of silyl ether.,,,Sus scrofa,9823.0,,,22224
4674,,1452,,A,,Vmax value was measured at 10 uM concentration of silyl ether.,,,Sus scrofa,9823.0,,,22224
4675,,1452,,A,,Vmax value was measured at 5 uM concentration of silyl ether.,,,Sus scrofa,9823.0,,,22224
4676,,11706,,B,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,,Homo sapiens,9606.0,,,235
4677,,1916,,A,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,,Homo sapiens,9606.0,,,22224
4678,,17791,,A,,Compound was evaluated for area under the curve expressed as (h*ug/ml),,,Homo sapiens,9606.0,,,22224
4679,,7766,,A,,Active metabolite of ifosfamide determined in humans; A-Active,,,Homo sapiens,9606.0,,,22224
4680,,6567,,A,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,,Homo sapiens,9606.0,,,22224
4681,,6567,,A,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,,Homo sapiens,9606.0,,,22224
4682,,6567,,A,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,,Homo sapiens,9606.0,,,22224
4683,,6567,,A,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,,Homo sapiens,9606.0,,,22224
4684,,17791,,A,,Compound was evaluated for oral bioavailability in human,,,Homo sapiens,9606.0,,,22224
4685,Urine,7766,,A,,Metabolite of ifosfamide determined in urine; NF-Not found,,,Homo sapiens,9606.0,,,22224
4686,,6852,,A,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,,Homo sapiens,9606.0,,,22224
4687,,6852,,A,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,,Homo sapiens,9606.0,,,22224
4688,,6852,,A,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,,Homo sapiens,9606.0,,,22224
4689,,6852,,A,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,,Homo sapiens,9606.0,,,22224
4690,,6852,,A,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,,Homo sapiens,9606.0,,,22224
4691,,6852,,A,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,,Homo sapiens,9606.0,,,22224
4692,,6852,,A,,Percent of compound in healthy individuals (Group D),,,Homo sapiens,9606.0,,,22224
4693,Liver,4397,,A,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,,Homo sapiens,9606.0,,Microsomes,22224
4694,,17409,,A,,Binding towards human plasma protein at 10 uM,,,Homo sapiens,9606.0,,,22224
4695,,17409,,A,,Binding towards human plasma protein at 100 uM,,,Homo sapiens,9606.0,,,22224
4696,,17176,,A,,Human plasma protein binding activity was determined,,,Homo sapiens,9606.0,,,22224
4697,,15444,,A,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,,Homo sapiens,9606.0,,,22224
4698,,17267,,A,,Percent binding of compound towards human plasma protein was determined,,,Homo sapiens,9606.0,,,22224
4699,Liver,5944,,A,,Plasma clearance in human liver microsomes,In vitro,,Homo sapiens,9606.0,,Microsomes,22224
4700,Liver,5668,,A,,In vitro intrinsic clearance in human liver microsome,In vitro,,Homo sapiens,9606.0,,Microsomes,22224
4701,Liver,5669,,A,,In vitro intrinsic clearance in human liver microsome,In vitro,,Homo sapiens,9606.0,,Microsomes,22224
4702,,5041,,A,,In vitro microsome metabolism clearance in human was determined,In vitro,,Homo sapiens,9606.0,,Microsomes,22224
4703,,5041,,A,,In vitro microsome metabolism clearance in human was determined; High,In vitro,,Homo sapiens,9606.0,,Microsomes,22224
4704,,5041,,A,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,In vitro,,Homo sapiens,9606.0,,Microsomes,22224
4705,Liver,5676,,A,,Pharmacokinetic property (clearance) in human liver microsome,In vitro,,Homo sapiens,9606.0,,Microsomes,22224
4706,Liver,5944,,A,,Plasma clearance in human liver microsomes,In vitro,,Homo sapiens,9606.0,,Microsomes,22224
4707,Liver,17538,,A,,In vitro clearance in human liver microsomes,In vitro,,Homo sapiens,9606.0,,Microsomes,22224
4708,Liver,6331,,A,,Intrinsic clearance in human liver microsomes was determined,In vitro,,Homo sapiens,9606.0,,Microsomes,22224
4709,Liver,5948,,A,,Intrinsic clearance in human liver microsomes was determined,In vitro,,Homo sapiens,9606.0,,Microsomes,22224
4710,,5965,,A,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,In vivo,,Homo sapiens,9606.0,,,22224
4711,,1916,,A,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,In vivo,,Homo sapiens,9606.0,,,22224
4712,,5965,,A,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,,Homo sapiens,9606.0,,,22224
4713,,1299,,A,,Stability in human plasma 2 hr after incubation expressed as percent concentration,,,Homo sapiens,9606.0,,,22224
4714,,1299,,A,,Stability in human plasma 4 hr after incubation expressed as percent concentration,,,Homo sapiens,9606.0,,,22224
4715,Urine,7766,,A,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Homo sapiens,9606.0,,,22224
4716,Urine,7766,,A,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Homo sapiens,9606.0,,,22224
4717,Urine,7766,,A,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Homo sapiens,9606.0,,,22224
4718,Urine,7766,,A,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Homo sapiens,9606.0,,,22224
4719,,17764,,F,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,In vivo,,Mus musculus,10090.0,,,50594
4720,,17764,,F,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,In vivo,,Mus musculus,10090.0,,,50594
4721,,17764,,F,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,In vivo,,Mus musculus,10090.0,,,50594
4722,,17764,,F,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,In vivo,,Mus musculus,10090.0,,,50594
4723,,14294,,A,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,,Mus musculus,10090.0,,,50594
4724,,14294,,A,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,,Mus musculus,10090.0,,,50594
4725,,14294,,A,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,,Mus musculus,10090.0,,,50594
4726,Liver,6251,,A,,In vitro metabolic potential in mouse liver microsomes,,,Mus musculus,10090.0,,,50594
4727,,17582,,A,,Ability of compound to bind to plasma protein was evaluated in HSA cells,,,Mus musculus,10090.0,,,50594
4728,Adrenal gland,17811,,A,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,,Mus musculus,10090.0,,,50594
4729,Brain,17811,,A,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,,Mus musculus,10090.0,,,50594
4730,Brain,17811,,A,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,,Mus musculus,10090.0,,,50594
4731,,17811,,A,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,,Mus musculus,10090.0,,,50594
4732,Kidney,17811,,A,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,,Mus musculus,10090.0,,,50594
4733,,17811,,A,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,,Mus musculus,10090.0,,,50594
4734,,5288,,A,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,,Mus musculus,10090.0,,,50594
4735,Serum,2717,,A,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,,Mus musculus,10090.0,,,50594
4736,Serum,2717,,A,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,,Mus musculus,10090.0,,,50594
4737,Serum,2717,,A,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,,Mus musculus,10090.0,,,50594
4738,Plasma,17753,,A,,Half life of compound was determined in plasma of mice at 24 mg/Kg,In vivo,,Mus musculus,10090.0,,,50594
4739,Plasma,17753,,A,,Half life of compound was determined in plasma of mice at 40 mg/Kg,In vivo,,Mus musculus,10090.0,,,50594
4740,Plasma,17753,,A,,Half life of compound was determined in plasma of mice at 5 mg/Kg,In vivo,,Mus musculus,10090.0,,,50594
4741,,17764,,F,,Half life after intraperitoneal administration in mice at 18 uM/kg,In vivo,,Mus musculus,10090.0,,,50594
4742,,17764,,F,,Half life after intraperitoneal administration in mice at 23 uM/kg,In vivo,,Mus musculus,10090.0,,,50594
4743,,17764,,F,,Half life after intraperitoneal administration in mice at 25 uM/kg,In vivo,,Mus musculus,10090.0,,,50594
4744,,17764,,F,,Half life after intraperitoneal administration in mice at 26 uM/kg,In vivo,,Mus musculus,10090.0,,,50594
4745,,17764,,F,,Half life after intravenous administration in mice at 23 uM/kg,In vivo,,Mus musculus,10090.0,,,50594
4746,,17764,,A,,Half life after intravenous administration in mice at 24 uM/kg,In vivo,,Mus musculus,10090.0,,,50594
4747,,16597,,A,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,In vivo,,Mus musculus,10090.0,,,50594
4748,,2675,,A,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,In vivo,,Mus musculus,10090.0,,,50594
4749,,2675,,A,,Maximum time required to reach Cp max was evaluated in mice after oral administration,In vivo,,Mus musculus,10090.0,,,50594
4750,,16597,,A,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),In vivo,,Mus musculus,10090.0,,,50594
4751,,4890,,A,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",In vivo,,Mus musculus,10090.0,,,50594
4752,,429,,A,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
4753,Blood,17837,,A,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
4754,,16597,,A,,Half life at a dose of 10 mg/kg intravenous administration in mice.,In vivo,,Mus musculus,10090.0,,,50594
4755,,16597,,A,,Half life at a dose of 10 mg/kg peroral administration in mice.,In vivo,,Mus musculus,10090.0,,,50594
4756,,6619,,A,,Half life in ob/ob mice,,,Mus musculus,10090.0,,,50594
4757,,4066,,A,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,In vivo,,Mus musculus,10090.0,,,50594
4758,,4239,,A,,Half-life was measured in mouse,,,Mus musculus,10090.0,,,50594
4759,,5969,,A,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
4760,,8999,,A,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,,Mus musculus,10090.0,,,50594
4761,,8999,,A,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,,Mus musculus,10090.0,,,50594
4762,Brain,17641,,A,,T2 in brain of mice at the oral dose of 50 mg/kg,,,Mus musculus,10090.0,,,50594
4763,Kidney,17641,,A,,T2 in kidney of mice at the oral dose of 50 mg/kg,,,Mus musculus,10090.0,,,50594
4764,Liver,17641,,A,,T2 in liver of mice at the oral dose of 50 mg/kg,,,Mus musculus,10090.0,,,50594
4765,Lung,17641,,A,,T2 in lungs of mice at the oral dose of 50 mg/kg,,,Mus musculus,10090.0,,,50594
4766,Spleen,17641,,A,,T2 in spleen of mice at the oral dose of 50 mg/kg,,,Mus musculus,10090.0,,,50594
4767,,16597,,A,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,In vivo,,Mus musculus,10090.0,,,50594
4768,,4890,,A,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",In vivo,,Mus musculus,10090.0,,,50594
4769,,429,,A,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
4770,,429,,A,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,In vivo,,Mus musculus,10090.0,,,50594
4771,,5969,,A,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
4772,,16913,478.0,F,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,,Homo sapiens,9606.0,A2780,,81034
4773,,16913,478.0,F,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,,Homo sapiens,9606.0,A2780,,81034
4774,,16913,478.0,F,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,,Homo sapiens,9606.0,A2780,,81034
4775,,16913,478.0,F,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,,Homo sapiens,9606.0,A2780,,81034
4776,,16913,478.0,F,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,,Homo sapiens,9606.0,A2780,,81034
4777,,16913,478.0,F,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,,Homo sapiens,9606.0,A2780,,81034
4778,,17270,478.0,F,,In vitro cytotoxicity against A2780TAX cell line,,,Homo sapiens,9606.0,A2780,,81034
4779,,5618,481.0,F,,In vitro inhibitory activity against human tumor cell line A2780cis,,,Homo sapiens,9606.0,A2780cisR,,80017
4780,,17777,478.0,F,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,,Homo sapiens,9606.0,A2780,,81034
4781,,16112,481.0,F,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,,Homo sapiens,9606.0,A2780cisR,,80017
4782,,15748,481.0,F,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,,Homo sapiens,9606.0,A2780cisR,,80017
4783,,6633,478.0,F,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,,Homo sapiens,9606.0,A2780,,81034
4784,,16930,478.0,F,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,,Homo sapiens,9606.0,A2780,,81034
4785,,17496,478.0,F,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,,Homo sapiens,9606.0,A2780,,81034
4786,,12989,478.0,F,,In vitro antitumor activity against A2780cisR cell line.,,,Homo sapiens,9606.0,A2780,,81034
4787,,4840,478.0,F,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,,Homo sapiens,9606.0,A2780,,81034
4788,,12989,478.0,F,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,,Homo sapiens,9606.0,A2780,,81034
4789,,16745,481.0,F,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,,Homo sapiens,9606.0,A2780cisR,,80017
4790,,16597,478.0,F,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,,Homo sapiens,9606.0,A2780,,81034
4791,,16547,,B,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,,Rattus norvegicus,10116.0,,,11736
4792,,16547,,F,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,,,,,,11736
4793,,16547,,F,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,,Rattus norvegicus,10116.0,,,11736
4794,,15856,722.0,F,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,,Homo sapiens,9606.0,HEK293,,278
4795,,15856,722.0,F,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,,Homo sapiens,9606.0,HEK293,,278
4796,,16547,,B,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,,Mus musculus,10090.0,,,11831
4797,,16547,,F,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,,,,,,11831
4798,,16547,,F,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,,Mus musculus,10090.0,,,11831
4799,,17402,,B,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,,,,,,280
4800,,11746,574.0,F,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,,Homo sapiens,9606.0,T-cells,,22226
4801,,11746,574.0,F,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,,Homo sapiens,9606.0,T-cells,,22226
4802,,5455,455.0,F,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,,Homo sapiens,9606.0,A-375,,80018
4803,,2068,455.0,F,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,,Homo sapiens,9606.0,A-375,,80018
4804,,2683,455.0,F,,In vitro antitumor activity against A375cell line extracted form melanoma,,,Homo sapiens,9606.0,A-375,,80018
4805,,15313,455.0,F,,Inhibition of cell growth in (A375) melan cell line,,,Homo sapiens,9606.0,A-375,,80018
4806,,13739,455.0,F,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,,Homo sapiens,9606.0,A-375,,80018
4807,,13739,455.0,F,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,,Homo sapiens,9606.0,A-375,,80018
4808,,14750,455.0,F,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,,Homo sapiens,9606.0,A-375,,80018
4809,,14777,797.0,F,,Antiproliferative activity measured against A427 human lung carcinoma,,,Homo sapiens,9606.0,A-427,,80019
4810,,14777,797.0,F,,Antiproliferative activity measured against A427 human lung carcinoma,,,Homo sapiens,9606.0,A-427,,80019
4811,,17672,797.0,F,,Cytotoxicity against lung carcinoma A427 tumor cell lines,,,Homo sapiens,9606.0,A-427,,80019
4812,,14368,797.0,F,,Inhibition of large cell lung carcinoma (A427),,,Homo sapiens,9606.0,A-427,,80019
4813,,14368,797.0,F,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,,Homo sapiens,9606.0,A-427,,80019
4814,,13866,797.0,F,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,,Homo sapiens,9606.0,A-427,,80019
4815,,2545,797.0,F,,Inhibitory concentration in human lung carcinoma A427 cell line,,,Homo sapiens,9606.0,A-427,,80019
4816,,2545,797.0,F,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,,Homo sapiens,9606.0,A-427,,80019
4817,,6062,,A,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,In vivo,,Cercopithecidae,9527.0,,,22224
4818,,4578,,A,,Tested for volume of distribution upon iv administration to african green monkey,In vivo,,Cercopithecidae,9527.0,,,22224
4819,,17592,,A,,Volume of distribution in monkey,In vivo,,Cercopithecidae,9527.0,,,22224
4820,,5005,,A,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,,Macaca mulatta,9544.0,,,22224
4821,,5005,,A,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,In vivo,,Macaca mulatta,9544.0,,,22224
4822,,5922,,A,,Pharmacokinetic property(Vdss) in cynomolgus monkey,In vivo,,Cercopithecidae,9527.0,,,22224
4823,,5355,,A,,The distribution volume after intravenous administration in cynomolgus monkeys,In vivo,,Cercopithecidae,9527.0,,,22224
4824,,5355,,A,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,In vivo,,Cercopithecidae,9527.0,,,22224
4825,,5355,,A,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,In vivo,,Cercopithecidae,9527.0,,,22224
4826,,6057,,A,,Volume displacement was calculated in rhesus monkey,In vivo,,Cercopithecidae,9527.0,,,22224
4827,,5145,,A,,Volume of distribution in steady state was determined in rhesus monkey,In vivo,,Cercopithecidae,9527.0,,,22224
4828,,6821,,A,,Volume of distribution of compound was determined in monkey,In vivo,,Cercopithecidae,9527.0,,,22224
4829,,5334,,A,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,,Cercopithecidae,9527.0,,,22224
4830,,5334,,A,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,,Cercopithecidae,9527.0,,,22224
4831,,6641,,A,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,Cercopithecidae,9527.0,,,22224
4832,,2661,,A,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,In vivo,,Cercopithecidae,9527.0,,,22224
4833,,6535,,A,,Volume distribution in monkey after administration of 1 mg/kg iv,In vivo,,Cercopithecidae,9527.0,,,22224
4834,,4809,,A,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,,Cercopithecidae,9527.0,,,22224
4835,,6062,,A,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,In vivo,,Cercopithecidae,9527.0,,,22224
4836,,3443,,A,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,,Cercopithecidae,9527.0,,,22224
4837,,4578,,A,,Oral systemic bioavailability upon iv administration to african green monkey,In vivo,,Cercopithecidae,9527.0,,,22224
4838,,4809,,A,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,,Cercopithecidae,9527.0,,,22224
4839,,11271,,A,,Baboon plasma free fraction. ,,,Cercopithecidae,9527.0,,,22224
4840,,6057,,A,,Area under the curve was calculated in rhesus monkey after iv administration,,,Cercopithecidae,9527.0,,,22224
4841,,6057,,A,,Area under the curve was calculated in rhesus monkey after peroral administration,,,Cercopithecidae,9527.0,,,22224
4842,,17853,,A,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,,Cercopithecidae,9527.0,,,22224
4843,,5302,,A,,Half life period in monkey after 5 mg/kg dose,In vivo,,Cercopithecidae,9527.0,,,22224
4844,,4257,,A,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,In vivo,,Cercopithecidae,9527.0,,,22224
4845,,4257,,A,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,In vivo,,Cercopithecidae,9527.0,,,22224
4846,Plasma,13501,,A,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,In vivo,,Cercopithecidae,9527.0,,,22224
4847,,5394,,A,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,In vivo,,Cercopithecidae,9527.0,,,22224
4848,,2661,,A,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,In vivo,,Cercopithecidae,9527.0,,,22224
4849,,3341,,A,,Compound was evaluated for terminal half life in monkey,,,Cercopithecidae,9527.0,,,22224
4850,,3045,,A,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,In vivo,,Cercopithecidae,9527.0,,,22224
4851,Plasma,5005,,A,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,,Macaca mulatta,9544.0,,,22224
4852,,4847,,A,,Half life of compound was determined in squirrel monkey,,,Cercopithecidae,9527.0,,,22224
4853,,4256,,A,,Half life after iv administration in cynomolgus monkey,In vivo,,Macaca fascicularis,9541.0,,,22224
4854,Plasma,6535,,A,,Half life in monkey plasma after administration of 1 mg/kg iv,In vivo,,Cercopithecidae,9527.0,,,22224
4855,,6057,,A,,Half life was calculated in rhesus monkey,,,Cercopithecidae,9527.0,,,22224
4856,,17592,,A,,Half life in monkey,,,Cercopithecidae,9527.0,,,22224
4857,,6641,,A,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,Cercopithecidae,9527.0,,,22224
4858,,5472,,A,,Half life was evaluated in rhesus,,,Cercopithecidae,9527.0,,,22224
4859,,6221,,A,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,In vivo,,Cercopithecidae,9527.0,,,22224
4860,,5668,,A,,Half life period was determine after peroral administration at 10 mpk in Rhesus,In vivo,,Cercopithecidae,9527.0,,,22224
4861,,4809,,A,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,,Cercopithecidae,9527.0,,,22224
4862,,5546,,A,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,In vivo,,Cercopithecidae,9527.0,,,22224
4863,,5553,,A,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,In vivo,,Cercopithecidae,9527.0,,,22224
4864,,6078,,A,,Half-life was calculated in monkey,,,Cercopithecidae,9527.0,,,22224
4865,,5147,,A,,Half-life in Squirrel monkey,,,Cercopithecidae,9527.0,,,22224
4866,,5145,,A,,Half-life in rhesus monkey,,,Cercopithecidae,9527.0,,,22224
4867,,6062,,A,,Half-life was measured in monkey after an iv dose of 1 mg/kg,In vivo,,Cercopithecidae,9527.0,,,22224
4868,,5355,,A,,Half-life period after intravenous administration in cynomolgus monkeys,In vivo,,Cercopithecidae,9527.0,,,22224
4869,,5355,,A,,Half-life period after oral administration in cynomolgus monkeys,In vivo,,Cercopithecidae,9527.0,,,22224
4870,,5355,,A,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,In vivo,,Cercopithecidae,9527.0,,,22224
4871,Urine,7766,,A,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Homo sapiens,9606.0,,,22224
4872,Urine,7766,,A,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Homo sapiens,9606.0,,,22224
4873,Urine,7766,,A,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Homo sapiens,9606.0,,,22224
4874,Urine,7766,,A,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Homo sapiens,9606.0,,,22224
4875,Urine,7766,,A,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,,Homo sapiens,9606.0,,,22224
4876,Urine,7766,,A,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,,Homo sapiens,9606.0,,,22224
4877,Urine,7766,,A,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,,Homo sapiens,9606.0,,,22224
4878,Urine,7766,,A,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,,Homo sapiens,9606.0,,,22224
4879,,1916,,A,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,In vivo,,Homo sapiens,9606.0,,,22224
4880,,16643,,A,,Oral bioavailability in human,In vivo,,Homo sapiens,9606.0,,,22224
4881,,17248,,A,,Compound was tested for human plasma protein binding,,,Homo sapiens,9606.0,,,22224
4882,,17248,,A,,Compound was tested for human plasma protein binding; Not determined,,,Homo sapiens,9606.0,,,22224
4883,,6241,,A,,Protein binding activity of compound in human plasma; % Free,,,Homo sapiens,9606.0,,,22224
4884,,17716,,A,,Unbound fraction (plasma),,,Homo sapiens,9606.0,,,22224
4885,Plasma,17605,,A,,Half life for the hydrolysis of compound in human blood serum,,,Homo sapiens,9606.0,,,22224
4886,Plasma,17625,,A,,Half life period in human plasma using phosphate buffer (0.08 M),,,Homo sapiens,9606.0,,,22224
4887,Plasma,17625,,A,,Half life period in human plasma using phosphate buffer (0.1 M),,,Homo sapiens,9606.0,,,22224
4888,Plasma,17747,,A,,Half-life in human plasma was determined,,,Homo sapiens,9606.0,,,22224
4889,,15613,,A,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,,Homo sapiens,9606.0,,,22224
4890,,354,,A,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,,Homo sapiens,9606.0,,,22224
4891,,3741,,A,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,,Homo sapiens,9606.0,,,22224
4892,,3741,,A,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,,Homo sapiens,9606.0,,,22224
4893,,3741,,A,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,,Homo sapiens,9606.0,,,22224
4894,,17599,,A,,Partition coefficient (logP),,,Homo sapiens,9606.0,,,22224
4895,,5486,,A,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,,Homo sapiens,9606.0,,,22224
4896,,5600,,A,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,,Homo sapiens,9606.0,,Microsomes,22224
4897,,14294,,A,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,,Homo sapiens,9606.0,,,22224
4898,,14294,,A,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,,Homo sapiens,9606.0,,,22224
4899,,14294,,A,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,,Homo sapiens,9606.0,,,22224
4900,,14294,,A,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,,Homo sapiens,9606.0,,Microsomes,22224
4901,,14294,,A,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,,Homo sapiens,9606.0,,Microsomes,22224
4902,,14294,,A,,Metabolism of compound in human microsomes; Trace,,,Homo sapiens,9606.0,,Microsomes,22224
4903,Liver,6260,,A,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,,,Homo sapiens,9606.0,,Microsomes,22224
4904,,6187,,A,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,,Homo sapiens,9606.0,,Microsomes,22224
4905,Liver,6251,,A,,In vitro metabolic potential in human liver microsomes,,,Homo sapiens,9606.0,,Microsomes,22224
4906,,3246,,A,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,,Homo sapiens,9606.0,,,22224
4907,,17313,,A,,Tested for human plasma protein binding of the compound; Not tested,,,Homo sapiens,9606.0,,,22224
4908,,6227,,A,,Compound was tested for percent protein binding (PB) in human,,,Homo sapiens,9606.0,,,22224
4909,Plasma,5530,,A,,Protein binding in human plasma,,,Homo sapiens,9606.0,,,22224
4910,,6108,,A,,Permeability coefficient (B to A) in Caco-2 cell,,,Homo sapiens,9606.0,,,22224
4911,,6108,,A,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,,Homo sapiens,9606.0,,,22224
4912,,2774,,A,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,,Homo sapiens,9606.0,,,22224
4913,,16643,,A,,In vitro rate of absorption observed as Caco-2 permeability in humans,,,Homo sapiens,9606.0,,,22224
4914,,17582,495.0,A,,Cellular permeability of compound was determined in Caco-2 cells; High,,,Homo sapiens,9606.0,Caco-2,,22224
4915,,6838,495.0,A,,Permeability in Caco-2 cells of compound,,,Homo sapiens,9606.0,Caco-2,,22224
4916,,6108,,A,,Permeability coefficient (A to B) in Caco-2 cell,,,Homo sapiens,9606.0,,,22224
4917,,6108,,A,,Permeability coefficient (B to A) in Caco-2 cell,,,Homo sapiens,9606.0,,,22224
4918,,6108,,A,,Permeability coefficient (Papp) (Caco-2 cell monolayer),,,Homo sapiens,9606.0,,,22224
4919,,2146,,A,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,,Homo sapiens,9606.0,,,22224
4920,,4514,,A,,Compound was tested for protein binding in human plasma,,,Homo sapiens,9606.0,,,22224
4921,,6108,,A,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,,Homo sapiens,9606.0,,,22224
4922,Urine,7766,,A,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,,Homo sapiens,9606.0,,,22224
4923,,5969,,A,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
4924,,3277,,A,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),In vivo,,Mus musculus,10090.0,,,50594
4925,,3802,,A,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,In vivo,,Mus musculus,10090.0,,,50594
4926,Plasma,2862,,A,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,In vivo,,Mus musculus,10090.0,,,50594
4927,Plasma,6348,,A,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,,Mus musculus,10090.0,,,50594
4928,,17764,,F,,Tmax after intraperitoneal administration in mice at 23 uM/kg,In vivo,,Mus musculus,10090.0,,,50594
4929,,5781,,A,,Tmax after oral administration at 30 mg/kg in ICR mouse,In vivo,,Mus musculus,10090.0,,,50594
4930,,17764,,A,,Tmax after peroral administration in mice at 2.4 uM/kg,In vivo,,Mus musculus,10090.0,,,50594
4931,,4066,,A,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,In vivo,,Mus musculus,10090.0,,,50594
4932,Brain,17641,,A,,Tmax in brain of mice at the oral dose of 50 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
4933,Kidney,17641,,A,,Tmax in kidney of mice at the oral dose of 50 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
4934,Liver,17641,,A,,Tmax in liver of mice at the oral dose of 50 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
4935,Lung,17641,,A,,Tmax in lungs of mice at the oral dose of 50 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
4936,,17764,,F,,Tmax in mice at 18 uM/kg i.p. administration,In vivo,,Mus musculus,10090.0,,,50594
4937,,17764,,F,,Tmax in mice at 23 uM/kg i.v. administration,In vivo,,Mus musculus,10090.0,,,50594
4938,,17764,,F,,Tmax in mice at 25 uM/kg i.p. administration,In vivo,,Mus musculus,10090.0,,,50594
4939,,17764,,F,,Tmax in mice at 26 uM/kg i.p. administration,In vivo,,Mus musculus,10090.0,,,50594
4940,Spleen,17641,,A,,Tmax in spleen of mice at the oral dose of 50 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
4941,,16597,,A,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,,Mus musculus,10090.0,,,50594
4942,,16597,,A,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,In vivo,,Mus musculus,10090.0,,,50594
4943,,5951,,A,,Tmax value in IRC mice,,,Mus musculus,10090.0,,,50594
4944,,5506,,A,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,In vivo,,Mus musculus,10090.0,,,50594
4945,,5506,,A,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,In vivo,,Mus musculus,10090.0,,,50594
4946,Urine,429,,A,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,,Mus musculus,10090.0,,,50594
4947,Urine,429,,A,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,,Mus musculus,10090.0,,,50594
4948,Urine,4066,,A,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,,Mus musculus,10090.0,,,50594
4949,,17734,,A,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,Mus musculus,10090.0,,,50594
4950,,17734,,A,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,Mus musculus,10090.0,,,50594
4951,,6062,,A,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
4952,,5969,,A,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
4953,,5969,,A,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
4954,,5969,,A,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,In vivo,,Mus musculus,10090.0,,,50594
4955,,5980,,A,,Vd in mice,In vivo,,Mus musculus,10090.0,,,50594
4956,,17592,,A,,Volume of distribution in mouse,In vivo,,Mus musculus,10090.0,,,50594
4957,,6348,,A,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,,Mus musculus,10090.0,,,50594
4958,,17753,,A,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,In vivo,,Mus musculus,10090.0,,,50594
4959,,17753,,A,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,In vivo,,Mus musculus,10090.0,,,50594
4960,,17753,,A,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,In vivo,,Mus musculus,10090.0,,,50594
4961,,4239,,A,,Pharmacokinetic property (vdss) was measured in mouse,In vivo,,Mus musculus,10090.0,,,50594
4962,,2862,,A,,Value distribution upon iv administration in mouse,In vivo,,Mus musculus,10090.0,,,50594
4963,,17734,,A,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,In vivo,,Mus musculus,10090.0,,,50594
4964,,2675,,A,,Volume of distribution was evaluated in mice after intravenous administration,In vivo,,Mus musculus,10090.0,,,50594
4965,,2675,,A,,Volume of distribution was evaluated in mice after oral administration,In vivo,,Mus musculus,10090.0,,,50594
4966,,17837,,A,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
4967,,5727,,A,,Steady state volume of distribution was determined in mice,In vivo,,Mus musculus,10090.0,,,50594
4968,,17852,,A,,Volume distribution (steady state) of compound was determined in mouse,In vivo,,Mus musculus,10090.0,,,50594
4969,,17764,,A,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,In vivo,,Mus musculus,10090.0,,,50594
4970,,16597,,A,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,,Mus musculus,10090.0,,,50594
4971,,6062,,A,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
4972,Kidney,16438,,A,,Biodistribution of compound (oxidized form) in in kidney tissue,In vivo,,Mus musculus,10090.0,,,50594
4973,Blood,16438,,A,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,In vivo,,Mus musculus,10090.0,,,50594
4974,Blood,16438,,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",In vivo,,Mus musculus,10090.0,,,50594
4975,Blood,16438,,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
4976,,10708,797.0,F,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,,Homo sapiens,9606.0,A-427,,80019
4977,,16597,500.0,F,,Inhibition of A431 human squamous cell carcinoma cell proliferation,,,Homo sapiens,9606.0,A-431,,80852
4978,,16062,500.0,F,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,,Homo sapiens,9606.0,A-431,,80852
4979,,16062,500.0,F,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,,Homo sapiens,9606.0,A-431,,80852
4980,,16958,500.0,F,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,,Homo sapiens,9606.0,A-431,,80852
4981,,6700,500.0,F,,Inhibition of A431 human carcinoma cell proliferation,,,Homo sapiens,9606.0,A-431,,80852
4982,,17226,500.0,F,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,,Homo sapiens,9606.0,A-431,,80852
4983,,6828,500.0,F,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,,Homo sapiens,9606.0,A-431,,80852
4984,,12314,500.0,F,,In vitro cytotoxicity against epidermoid carcinoma cell line,,,Homo sapiens,9606.0,A-431,,80852
4985,,13412,500.0,F,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,,Homo sapiens,9606.0,A-431,,9
4986,,13299,500.0,F,,Antiproliferative activity of compound was measured on human tumor cell line A431.,,,Homo sapiens,9606.0,A-431,,80852
4987,,17420,500.0,F,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,,Homo sapiens,9606.0,A-431,,80852
4988,,13678,500.0,F,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,,Homo sapiens,9606.0,A-431,,80852
4989,,14171,500.0,F,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,,,,A-431,,9
4990,,6333,500.0,F,,Tested for antiproliferative activity against human A431 cells,,,Homo sapiens,9606.0,A-431,,80852
4991,,2356,500.0,F,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,,Homo sapiens,9606.0,A-431,,9
4992,,15578,500.0,F,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,,Homo sapiens,9606.0,A-431,,80852
4993,,5126,500.0,F,,Inhibition of A431 cell proliferation,,,Homo sapiens,9606.0,A-431,,80852
4994,,6844,500.0,F,,Cytotoxic effect on A431 human epidermoid carcinoma cells,,,Homo sapiens,9606.0,A-431,,80852
4995,,6844,500.0,F,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,,Homo sapiens,9606.0,A-431,,80852
4996,,4925,500.0,F,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,,Homo sapiens,9606.0,A-431,,80852
4997,,4925,500.0,F,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,,Homo sapiens,9606.0,A-431,,80852
4998,,13978,500.0,F,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,,Homo sapiens,9606.0,A-431,,80852
4999,,16786,500.0,F,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,,Homo sapiens,9606.0,A-431,,80852
5000,,13412,500.0,F,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,,,,A-431,,9
5001,,17824,500.0,F,,In vivo antiproliferative activity against A431 cell line,,,Homo sapiens,9606.0,A-431,,80852
5002,,12751,500.0,F,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,,Homo sapiens,9606.0,A-431,,9
5003,,12380,500.0,F,,Inhibition of A431 human epidermoid carcinoma cell proliferation,,,Homo sapiens,9606.0,A-431,,80852
5004,,4959,500.0,F,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,,Homo sapiens,9606.0,A-431,,9
5005,,6333,500.0,F,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,,Homo sapiens,9606.0,A-431,,80852
5006,,6333,500.0,F,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,,Homo sapiens,9606.0,A-431,,80852
5007,,6333,500.0,F,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,,Homo sapiens,9606.0,A-431,,80852
5008,,5296,,F,,Inhibition of EGFR overexpressing A431 cell proliferation,,,Homo sapiens,9606.0,,,9
5009,,12624,500.0,F,,Inhibition of A431 cell proliferation,,,Homo sapiens,9606.0,A-431,,80852
5010,,14926,500.0,F,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,,Homo sapiens,9606.0,A-431,,9
5011,,14926,500.0,F,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,,Homo sapiens,9606.0,A-431,,9
5012,,14926,500.0,F,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,,,,A-431,,9
5013,,15144,500.0,F,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,,Homo sapiens,9606.0,A-431,,80852
5014,,15144,500.0,F,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,,Homo sapiens,9606.0,A-431,,80852
5015,,5245,500.0,F,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,,Homo sapiens,9606.0,A-431,,80852
5016,,5245,500.0,F,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,,Homo sapiens,9606.0,A-431,,80852
5017,,5245,500.0,F,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,,Homo sapiens,9606.0,A-431,,80852
5018,,5245,500.0,F,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,,Homo sapiens,9606.0,A-431,,80852
5019,,5245,500.0,F,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,,Homo sapiens,9606.0,A-431,,80852
5020,,5922,,A,,Half-life period in cynomolgus monkey,,,Cercopithecidae,9527.0,,,22224
5021,Plasma,1116,,A,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",In vitro,,Cercopithecidae,9527.0,,,22224
5022,,17853,,A,,Longer half-life in monkey (i.v.) at 0.5 mpk,In vivo,,Cercopithecidae,9527.0,,,22224
5023,Plasma,993,,A,,Plasma half life in monkey,,,Cercopithecidae,9527.0,,,22224
5024,Plasma,4514,,A,,Plasma half-life in rhesus monkey,,,Cercopithecidae,9527.0,,,22224
5025,Plasma,5334,,A,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,,Cercopithecidae,9527.0,,,22224
5026,Plasma,5334,,A,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,,Cercopithecidae,9527.0,,,22224
5027,,4578,,A,,Tested for half life upon iv administration to african green monkey,In vivo,,Cercopithecidae,9527.0,,,22224
5028,,2661,,A,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,In vivo,,Cercopithecidae,9527.0,,,22224
5029,,5355,,A,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,In vivo,,Cercopithecidae,9527.0,,,22224
5030,,5355,,A,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,In vivo,,Cercopithecidae,9527.0,,,22224
5031,,5355,,A,,The time for peak concentration value after oral administration in cynomolgus monkeys,In vivo,,Cercopithecidae,9527.0,,,22224
5032,,11271,,A,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,,Cercopithecidae,9527.0,,,22224
5033,,11271,,A,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,,Cercopithecidae,9527.0,,,22224
5034,,11271,,A,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,,Cercopithecidae,9527.0,,,22224
5035,,11271,,A,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,,Cercopithecidae,9527.0,,,22224
5036,,11271,,A,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,,Cercopithecidae,9527.0,,,22224
5037,,11271,,A,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,,Cercopithecidae,9527.0,,,22224
5038,,11271,,A,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,,Cercopithecidae,9527.0,,,22224
5039,,11271,,A,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,,Cercopithecidae,9527.0,,,22224
5040,,11271,,A,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,,Cercopithecidae,9527.0,,,22224
5041,,11271,,A,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,,Cercopithecidae,9527.0,,,22224
5042,,11271,,A,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,,Cercopithecidae,9527.0,,,22224
5043,,11271,,A,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,,Cercopithecidae,9527.0,,,22224
5044,,11271,,A,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,,Cercopithecidae,9527.0,,,22224
5045,,11271,,A,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,,Cercopithecidae,9527.0,,,22224
5046,,11271,,A,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,,Cercopithecidae,9527.0,,,22224
5047,,11271,,A,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,,Cercopithecidae,9527.0,,,22224
5048,,5809,,A,,Bioavailability in rat (cannulated) (dose 2 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
5049,Plasma,17720,,A,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
5050,Plasma,3546,,A,,AUC value in rat after IV administration at a dose of 10 mg/kg,,,Rattus norvegicus,10116.0,,,50597
5051,Plasma,3546,,A,,AUC value in rat after oral administration at a dose of 10 mg/kg,,,Rattus norvegicus,10116.0,,,50597
5052,,3546,,A,,Cmax value in rat after oral administration at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
5053,,3546,,A,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
5054,,3546,,A,,Tmax value in rat after oral administration at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
5055,,3546,,A,,Vc value in rat after IV administration at a dose of 10 mg/kg,,,Rattus norvegicus,10116.0,,,50597
5056,,3546,,A,,Half life period in rat after IV administration at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
5057,,10625,,A,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,,Papio hamadryas,9557.0,,,22224
5058,,10625,,A,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,,Papio hamadryas,9557.0,,,22224
5059,,10625,,A,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,,Papio hamadryas,9557.0,,,22224
5060,,10625,,A,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,,Papio hamadryas,9557.0,,,22224
5061,,10625,,A,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,,Papio hamadryas,9557.0,,,22224
5062,,10625,,A,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,,Papio hamadryas,9557.0,,,22224
5063,,10625,,A,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,,Papio hamadryas,9557.0,,,22224
5064,,10625,,A,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,,Papio hamadryas,9557.0,,,22224
5065,,3510,,A,,Area under curve after 1 mpk peroral administration to beagles,,,beagle,9615.0,,,22224
5066,,3510,,A,,Area under curve after 2 mpk peroral administration to beagles,,,beagle,9615.0,,,22224
5067,,3510,,A,,Cmax value after 1 mpk peroral administration to beagles,In vivo,,beagle,9615.0,,,22224
5068,Urine,7766,,A,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,,Homo sapiens,9606.0,,,22224
5069,Urine,7766,,A,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,,Homo sapiens,9606.0,,,22224
5070,Urine,7766,,A,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,,Homo sapiens,9606.0,,,22224
5071,Urine,7766,,A,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,,Homo sapiens,9606.0,,,22224
5072,Urine,7766,,A,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,,Homo sapiens,9606.0,,,22224
5073,Urine,7766,,A,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,,Homo sapiens,9606.0,,,22224
5074,Urine,7766,,A,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,,Homo sapiens,9606.0,,,22224
5075,Liver,16643,,A,,Metabolic stability observed at 30 min after administration in human liver microsomes,,,Homo sapiens,9606.0,,Microsomes,22224
5076,,6852,,A,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,,Homo sapiens,9606.0,,,22224
5077,,6852,,A,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,,Homo sapiens,9606.0,,,22224
5078,,6852,,A,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,,Homo sapiens,9606.0,,,22224
5079,Liver,6567,,A,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",,,Homo sapiens,9606.0,,Microsomes,22224
5080,,6570,,A,,Metabolic stability (% remaining at 30 mins) in human S9.,,,Homo sapiens,9606.0,,,22224
5081,,6570,,A,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,,Homo sapiens,9606.0,,,22224
5082,Liver,5237,,A,,Percent parent compound remaining after 20 min incubation with human liver microsomes,,,Homo sapiens,9606.0,,Microsomes,22224
5083,Liver,5237,,A,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,,,Homo sapiens,9606.0,,Microsomes,22224
5084,Liver,5237,,A,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,,,Homo sapiens,9606.0,,Microsomes,22224
5085,,5202,,A,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,,Homo sapiens,9606.0,,,22224
5086,,5481,,A,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,,Homo sapiens,9606.0,,,22224
5087,,5481,,A,,Percent remaining in human plasma after incubation for 60 min at 37 C.,,,Homo sapiens,9606.0,,,22224
5088,,3956,,A,,The percent remaining in human plasma after 30 min was determined,,,Homo sapiens,9606.0,,,22224
5089,Plasma,5074,,A,,Conversion rate of the prodrug in human plasma,,,Homo sapiens,9606.0,,,22224
5090,Plasma,5074,,A,,Conversion rate of the prodrug in human plasma; ND means no data,,,Homo sapiens,9606.0,,,22224
5091,Blood,4727,,A,,Half life of compound was determined in human blood,,,Homo sapiens,9606.0,,,22224
5092,,5965,,A,,Half life of compound was determined in man with once daily dosing,,,Homo sapiens,9606.0,,,22224
5093,,5732,,A,,Half life in human microsomes,In vitro,,Homo sapiens,9606.0,,Microsomes,22224
5094,Plasma,5819,,A,,Half life in human plasma,,,Homo sapiens,9606.0,,,22224
5095,Plasma,5819,,A,,Half life in human plasma; Not detected,,,Homo sapiens,9606.0,,,22224
5096,,1916,,A,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,In vivo,,Homo sapiens,9606.0,,,22224
5097,Liver,6597,,A,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,In vitro,,Homo sapiens,9606.0,,Microsomes,22224
5098,Plasma,5229,,A,,Half-life in human plasma,,,Homo sapiens,9606.0,,,22224
5099,Plasma,5229,,A,,Half-life of the parent prodrug in plasma,,,Homo sapiens,9606.0,,,22224
5100,Plasma,2192,,A,,In vitro half life in human plasma was determined,In vitro,,Homo sapiens,9606.0,,,22224
5101,Liver,3032,,A,,The compound was tested In Vitro for half life in human liver microsomes.,In vitro,,Homo sapiens,9606.0,,Microsomes,22224
5102,,1916,,A,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,In vivo,,Homo sapiens,9606.0,,,22224
5103,,17716,,A,,Observed volume of distribution,In vivo,,Homo sapiens,9606.0,,,22224
5104,,15778,,A,,Oral bioavailability in human,In vivo,,Homo sapiens,9606.0,,,22224
5105,,17313,,A,,Tested for human plasma protein binding of the compound,,,Homo sapiens,9606.0,,,22224
5106,,4231,,A,,"First order rate constant, k was determined in human plasma",,,Homo sapiens,9606.0,,,22224
5107,,4755,,A,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,,Homo sapiens,9606.0,,,22224
5108,,4755,,A,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,,Homo sapiens,9606.0,,,22224
5109,Liver,16907,,A,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,,Homo sapiens,9606.0,,Microsomes,22224
5110,,10839,,A,,The compound was tested for the plasma binding in human,,,Homo sapiens,9606.0,,,22224
5111,,10839,,A,,Plasma protein binding (human),,,Homo sapiens,9606.0,,,22224
5112,Liver,3199,,A,,Compound was evaluated for half-life in human liver microsomes,In vitro,,Homo sapiens,9606.0,,Microsomes,22224
5113,Blood,1345,,A,,Half life measured in vitro for its stability in human blood,In vitro,,Homo sapiens,9606.0,,,22224
5114,Serum,4297,,A,,Half life in human serum,,,Homo sapiens,9606.0,,,22224
5115,Serum,4297,,A,,Half life in human serum; ND=not determined,,,Homo sapiens,9606.0,,,22224
5116,,4297,,A,,Half life were determined in CEM-SS cell extract in decomposition step 1,,,Homo sapiens,9606.0,,,22224
5117,,4297,,A,,Half life were determined in CEM-SS cell extract in decomposition step 2,,,Homo sapiens,9606.0,,,22224
5118,Plasma,4231,,A,,Half life of the in human plasma,,,Homo sapiens,9606.0,,,22224
5119,,5633,,A,,Half life period in human hepatic S9 fraction was determined,In vitro,,Homo sapiens,9606.0,,S9,22224
5120,Liver,5633,,A,,Half life period in human liver microsome was determined,In vitro,,Homo sapiens,9606.0,,Microsomes,22224
5121,,17791,,A,,Half life period was determined; 6-7,,,Homo sapiens,9606.0,,,22224
5122,,17791,,A,,Half life period was evaluated in human,,,Homo sapiens,9606.0,,,22224
5123,Plasma,3160,,A,,Half life time in human plasma,,,Homo sapiens,9606.0,,,22224
5124,Brain,16438,,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
5125,Heart,16438,,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
5126,Heart,16438,,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
5127,Kidney,16438,,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
5128,Kidney,16438,,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",In vivo,,Mus musculus,10090.0,,,50594
5129,Kidney,16438,,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
5130,Liver,16438,,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
5131,Liver,16438,,A,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,In vivo,,Mus musculus,10090.0,,,50594
5132,Liver,16438,,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
5133,Spleen,16438,,A,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,In vivo,,Mus musculus,10090.0,,,50594
5134,Spleen,16438,,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",In vivo,,Mus musculus,10090.0,,,50594
5135,Spleen,16438,,A,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
5136,Brain,16438,,A,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,Mus musculus,10090.0,,,50594
5137,Blood,16438,,A,,Biodistribution of compound (oxidized form) in blood tissue,In vivo,,Mus musculus,10090.0,,,50594
5138,Blood,16438,,A,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
5139,Blood,16438,,A,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,,Mus musculus,10090.0,,,50594
5140,Blood,16438,,A,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,Mus musculus,10090.0,,,50594
5141,Blood,16438,,A,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
5142,Blood,16438,,A,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,,Mus musculus,10090.0,,,50594
5143,Brain,16438,,A,,Biodistribution of compound (oxidized form) in brain tissue of mice,In vivo,,Mus musculus,10090.0,,,50594
5144,Brain,16438,,A,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
5145,Brain,16438,,A,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,Mus musculus,10090.0,,,50594
5146,Brain,16438,,A,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
5147,Brain,16438,,A,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,,Mus musculus,10090.0,,,50594
5148,Brain,16438,,A,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,,Mus musculus,10090.0,,,50594
5149,Heart,16438,,A,,Biodistribution of compound (oxidized form) in heart tissue of mice,In vivo,,Mus musculus,10090.0,,,50594
5150,Heart,16438,,A,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
5151,Heart,16438,,A,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
5152,Heart,16438,,A,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,Mus musculus,10090.0,,,50594
5153,Heart,16438,,A,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
5154,Heart,16438,,A,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,,Mus musculus,10090.0,,,50594
5155,Kidney,16438,,A,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
5156,Kidney,16438,,A,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,,Mus musculus,10090.0,,,50594
5157,Kidney,16438,,A,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,Mus musculus,10090.0,,,50594
5158,Kidney,16438,,A,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
5159,Kidney,16438,,A,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,,Mus musculus,10090.0,,,50594
5160,Liver,16438,,A,,Biodistribution of compound (oxidized form) in liver tissue,In vivo,,Mus musculus,10090.0,,,50594
5161,Liver,16438,,A,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
5162,Liver,16438,,A,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,Mus musculus,10090.0,,,50594
5163,,5245,500.0,F,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,,Homo sapiens,9606.0,A-431,,80852
5164,,5245,500.0,F,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,,Homo sapiens,9606.0,A-431,,80852
5165,,16289,500.0,F,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,,,,A-431,,80852
5166,,16289,500.0,F,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,,,,A-431,,80852
5167,,16093,500.0,F,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,,Homo sapiens,9606.0,A-431,,9
5168,,16825,500.0,F,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,,Homo sapiens,9606.0,A-431,,80852
5169,,4848,500.0,F,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,,Homo sapiens,9606.0,A-431,,80852
5170,,14827,500.0,F,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,,Homo sapiens,9606.0,A-431,,9
5171,,14827,500.0,F,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,,Homo sapiens,9606.0,A-431,,9
5172,,16289,500.0,F,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,,,,A-431,,80852
5173,,16289,500.0,F,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,,,,A-431,,80852
5174,,16289,500.0,F,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,,,,A-431,,80852
5175,,16289,500.0,F,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,,,,A-431,,80852
5176,,16289,500.0,F,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,,,,A-431,,80852
5177,,16289,500.0,F,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,,Homo sapiens,9606.0,A-431,,9
5178,,16289,500.0,F,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,,,,A-431,,9
5179,,16289,500.0,F,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,,,,A-431,,80852
5180,,16289,500.0,F,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,,,,A-431,,80852
5181,,16289,500.0,F,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,,,,A-431,,80852
5182,,14555,500.0,F,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,,Mus musculus,10090.0,A-431,,80852
5183,,14555,500.0,F,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,,Mus musculus,10090.0,A-431,,80852
5184,,14555,500.0,F,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,,Mus musculus,10090.0,A-431,,80852
5185,,14555,500.0,F,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,,Mus musculus,10090.0,A-431,,80852
5186,,1937,500.0,F,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,,Homo sapiens,9606.0,A-431,,80852
5187,,13739,500.0,F,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,,Homo sapiens,9606.0,A-431,,80852
5188,,3558,500.0,F,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,,Homo sapiens,9606.0,A-431,,80852
5189,,3558,500.0,F,,Dose giving a 50% decrease in the living cell number (A437 cells),,,Homo sapiens,9606.0,A-431,,80852
5190,,17686,646.0,F,,In vitro inhibitory concentration against proliferation of A459 cell line.,,,Homo sapiens,9606.0,A549,,80682
5191,,5305,646.0,F,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,,Homo sapiens,9606.0,A549,,80682
5192,,3614,646.0,F,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,,Homo sapiens,9606.0,A549,,80682
5193,,17229,624.0,F,,In vitro antitumor activity against renal A498 tumor cell lines,,,Homo sapiens,9606.0,A498,,80021
5194,,15935,624.0,F,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,,Homo sapiens,9606.0,A498,,80021
5195,,15935,624.0,F,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,,Homo sapiens,9606.0,A498,,80021
5196,,15560,624.0,F,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,,Homo sapiens,9606.0,A498,,80021
5197,,13891,624.0,F,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,,Homo sapiens,9606.0,A498,,80021
5198,,13891,624.0,F,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,,Homo sapiens,9606.0,A498,,80021
5199,,13788,624.0,F,,Cytotoxicity on kidney carcinoma (A-498) cell line,,,Homo sapiens,9606.0,A498,,80021
5200,,15403,624.0,F,,Compound was evaluated against Human cell line renal A498,,,Homo sapiens,9606.0,A498,,80021
5201,,1009,624.0,F,,Compound was tested for inhibition of A498 human renal cancer cell line,,,Homo sapiens,9606.0,A498,,80021
5202,,1043,624.0,F,,Growth inhibitory activity against A498 human cancer cell line,,,Homo sapiens,9606.0,A498,,80021
5203,,5858,624.0,F,,In vitro antitumor activity against human renal A498 cell line,,,Homo sapiens,9606.0,A498,,80021
5204,,5958,624.0,F,,In vitro cytotoxic activity against renal (A498) cell line,,,Homo sapiens,9606.0,A498,,80021
5205,,5506,624.0,F,,In vitro cytotoxic activity against human renal cancer (A498) cell line,,,Homo sapiens,9606.0,A498,,80021
5206,,12781,624.0,F,,Tested for cytostatic activity against renal A498 cell line,,,Homo sapiens,9606.0,A498,,80021
5207,,14399,624.0,F,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,,Homo sapiens,9606.0,A498,,80021
5208,,5958,624.0,F,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,,Homo sapiens,9606.0,A498,,80021
5209,,3510,,A,,Cmax value after 2 mpk peroral administration to beagles,In vivo,,beagle,9615.0,,,22224
5210,,3510,,A,beagle,Bioavailability,In vivo,,Canis lupus familiaris,9615.0,,,22224
5211,,3510,,A,beagle,Bioavailability after 1 mpk peroral administration to beagles,In vivo,,Canis lupus familiaris,9615.0,,,22224
5212,,3510,,A,beagle,Bioavailability after 2 mpk peroral administration to beagles,In vivo,,Canis lupus familiaris,9615.0,,,22224
5213,,3085,,A,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,,Bos taurus,9913.0,,,22224
5214,,3085,,A,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,,Bos taurus,9913.0,,,22224
5215,,3085,,A,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,,Bos taurus,9913.0,,,22224
5216,,9372,,A,,Solubility against bovine alpha-chymotrypsin,,,Bos taurus,9913.0,,,22224
5217,,3085,,A,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,,Bos taurus,9913.0,,,22224
5218,,3085,,A,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,,Bos taurus,9913.0,,,22224
5219,Spleen,1469,,A,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,,Bos taurus,9913.0,,,22224
5220,,4297,,A,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,,Bos taurus,9913.0,,,22224
5221,,4297,,A,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,,Bos taurus,9913.0,,,22224
5222,,17585,,A,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,,Bos taurus,9913.0,,,22224
5223,Spleen,1336,,A,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,,Bos taurus,9913.0,,,22224
5224,,3085,,A,,Half life in presence of 2 mg/mL BSA at pH 8.8,,,Bos taurus,9913.0,,,22224
5225,,2857,,A,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,,Bos taurus,9913.0,,,22224
5226,,2857,,A,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,,Bos taurus,9913.0,,,22224
5227,,2857,,A,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,,Bos taurus,9913.0,,,22224
5228,,1540,,A,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,,Bos taurus,9913.0,,,22224
5229,Plasma,6316,,A,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
5230,Plasma,17594,,A,,AUC after administration at 100 mg/kg/day in dogs,,,Canis lupus familiaris,9615.0,,,50588
5231,Plasma,4953,,A,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,,Canis lupus familiaris,9615.0,,,50588
5232,Plasma,16907,,A,,AUC value after 15 mg/kg iv dose in Dogs,,,Canis lupus familiaris,9615.0,,,50588
5233,Plasma,16907,,A,,AUC value after 30 mg/kg po dose in Dogs,,,Canis lupus familiaris,9615.0,,,50588
5234,Plasma,2959,,A,,AUC value after administration of 4 mg/Kg oral dose in dog,,,Canis lupus familiaris,9615.0,,,50588
5235,Plasma,17594,,A,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,,Canis lupus familiaris,9615.0,,,50588
5236,,5356,,A,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,,Canis lupus familiaris,9615.0,,,50588
5237,,16807,,A,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,,Canis lupus familiaris,9615.0,,,50588
5238,,4527,,A,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,,Canis lupus familiaris,9615.0,,,50588
5239,,4527,,A,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,,Canis lupus familiaris,9615.0,,,50588
5240,,15660,,A,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
5241,,15660,,A,,Area under curve determined in dogs after oral administration of 10 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
5242,,5802,,A,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,Canis lupus familiaris,9615.0,,,50588
5243,,3598,,A,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
5244,,3598,,A,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
5245,,5944,,A,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,,Canis lupus familiaris,9615.0,,,50588
5246,,5944,,A,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,,Canis lupus familiaris,9615.0,,,50588
5247,,5944,,A,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,,Canis lupus familiaris,9615.0,,,50588
5248,,5944,,A,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,,Canis lupus familiaris,9615.0,,,50588
5249,,4186,,A,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,,Canis lupus familiaris,9615.0,,,50588
5250,,5007,,A,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,Canis lupus familiaris,9615.0,,,50588
5251,,5668,,A,,Area under curve was determine after peroral administration at 10 mpk in dog,,,Canis lupus familiaris,9615.0,,,50588
5252,,5668,,A,,Area under curve was determine after peroral administration at 5 mpk in dog,,,Canis lupus familiaris,9615.0,,,50588
5253,,5006,,A,,Area under curve was determined,,,Canis lupus familiaris,9615.0,,,50588
5254,,5006,,A,,Area under curve in dogs,,,Canis lupus familiaris,9615.0,,,50588
5255,,3771,,A,,Area under curve in dogs at 10 mg/kg dose fo oral administration,,,Canis lupus familiaris,9615.0,,,50588
5256,,3771,,A,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,,Canis lupus familiaris,9615.0,,,50588
5257,,3771,,A,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,,Canis lupus familiaris,9615.0,,,50588
5258,,1916,,A,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,Canis lupus familiaris,9615.0,,,50588
5259,,5302,,A,,Area under curve value in dog at a dose of 5 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
5260,,5600,,A,,Area under curve was determined after 0.1 mg/kg iv administration in dog,,,Canis lupus familiaris,9615.0,,,50588
5261,,5600,,A,,Area under curve was determined after 0.3 mg/kg po administration in dog,,,Canis lupus familiaris,9615.0,,,50588
5262,,17764,,A,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,,Canis lupus familiaris,9615.0,,,50588
5263,,4368,,A,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,,Canis lupus familiaris,9615.0,,,50588
5264,,5318,,A,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,,Homo sapiens,9606.0,,,22224
5265,,5318,,A,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,,Homo sapiens,9606.0,,,22224
5266,,5318,,A,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,,Homo sapiens,9606.0,,,22224
5267,,5318,,A,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,,Homo sapiens,9606.0,,,22224
5268,Blood,14518,,A,,Time taken to reduce 50% of the concentration of compound in blood plasma,,,Homo sapiens,9606.0,,,22224
5269,Plasma,2209,,A,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,,Homo sapiens,9606.0,,,22224
5270,Plasma,6787,,A,,Half life in human plasma,,,Homo sapiens,9606.0,,,22224
5271,Plasma,4898,,A,,Half life in human plasma was reported,,,Homo sapiens,9606.0,,,22224
5272,Serum,6072,,A,,Half life in human serum,,,Homo sapiens,9606.0,,,22224
5273,Plasma,16907,,A,,Half life upon exposure to human plasma,,,Homo sapiens,9606.0,,,22224
5274,,5656,,A,,t1/2 in human microsomes,In vitro,,Homo sapiens,9606.0,,Microsomes,22224
5275,Plasma,4755,,A,,Half life period in 80% human plasma at 37 degree Centigrade,,,Homo sapiens,9606.0,,,22224
5276,Zone of skin,17503,,A,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,,Homo sapiens,9606.0,,,22224
5277,Plasma,12357,,A,,Half-life measured in in vitro Cathepsin B assay in human plasma,In vitro,,Homo sapiens,9606.0,,,22224
5278,,3076,,A,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,,Homo sapiens,9606.0,,,22224
5279,Liver,6410,,A,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,In vitro,,Homo sapiens,9606.0,,Microsomes,22224
5280,Plasma,3741,,A,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,,Homo sapiens,9606.0,,,22224
5281,Plasma,3741,,A,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,,Homo sapiens,9606.0,,,22224
5282,Plasma,3741,,A,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,,Homo sapiens,9606.0,,,22224
5283,,1540,,A,,Half-life in the CEM cell extracts,,,Homo sapiens,9606.0,,,22224
5284,Plasma,2905,,A,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,,Homo sapiens,9606.0,,,22224
5285,Plasma,2905,,A,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,,Homo sapiens,9606.0,,,22224
5286,,5523,,A,,Half-life was determined,,,Homo sapiens,9606.0,,,22224
5287,Blood,1499,,A,,Half-life (human blood stability),,,Homo sapiens,9606.0,,,22224
5288,Blood,1499,,A,,Half-life (human blood stability); no data,,,Homo sapiens,9606.0,,,22224
5289,Plasma,17065,,A,,Half-life in human plasma,,,Homo sapiens,9606.0,,,22224
5290,,6861,,A,,CYP3A4 metabolism half-life (t1/2),,,Homo sapiens,9606.0,,,22224
5291,Blood,1499,,A,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,,Homo sapiens,9606.0,,,22224
5292,Plasma,530,,A,,In vitro half life in human plasma,In vitro,,Homo sapiens,9606.0,,,22224
5293,Plasma,1116,,A,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",In vitro,,Homo sapiens,9606.0,,,22224
5294,Plasma,6695,,A,,In vitro hydrolysis in human plasma,In vitro,,Homo sapiens,9606.0,,,22224
5295,Plasma,6695,,A,,In vitro hydrolysis in human plasma; no data,In vitro,,Homo sapiens,9606.0,,,22224
5296,Liver,10,,A,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,In vitro,,Homo sapiens,9606.0,,Microsomes,22224
5297,Plasma,993,,A,,Plasma half life in human,,,Homo sapiens,9606.0,,,22224
5298,Plasma,15429,,A,,Stability after incubation with human plasma (at 37 degree C),,,Homo sapiens,9606.0,,,22224
5299,Plasma,1675,,A,,T1/2 was evaluated in human plasma,,,Homo sapiens,9606.0,,,22224
5300,Plasma,2209,,A,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,,Homo sapiens,9606.0,,,22224
5301,Plasma,2209,,A,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,,Homo sapiens,9606.0,,,22224
5302,,5318,,A,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,,Homo sapiens,9606.0,,,22224
5303,,2412,,A,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,In vitro,,Homo sapiens,9606.0,,,22224
5304,,2412,,A,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,In vitro,,Homo sapiens,9606.0,,,22224
5305,Plasma,2906,,A,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,,Homo sapiens,9606.0,,,22224
5306,Plasma,2906,,A,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,,Homo sapiens,9606.0,,,22224
5307,,5495,,A,,Time taken for 50% to be consumed by serum PON1 was determined,,,Homo sapiens,9606.0,,,22224
5308,,5495,,A,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,,Homo sapiens,9606.0,,,22224
5309,Liver,4397,,A,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,,Homo sapiens,9606.0,,Microsomes,22224
5310,,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Mus sp.,10095.0,,,22224
5311,,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Mus sp.,10095.0,,,22224
5312,,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Mus sp.,10095.0,,,22224
5313,,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Mus sp.,10095.0,,,22224
5314,,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Mus sp.,10095.0,,,22224
5315,,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,Mus sp.,10095.0,,,22224
5316,,6058,391.0,F,,Compound tested for growth inhibition of renal cancer cell line 786-0,,,Homo sapiens,9606.0,786-0,,80640
5317,,17708,391.0,F,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,,Homo sapiens,9606.0,786-0,,80640
5318,,14017,391.0,F,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,,Homo sapiens,9606.0,786-0,,80640
5319,,16818,391.0,F,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,,Homo sapiens,9606.0,786-0,,80640
5320,,16818,391.0,F,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,,Homo sapiens,9606.0,786-0,,80640
5321,,16818,391.0,F,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,,Homo sapiens,9606.0,786-0,,80640
5322,,11970,391.0,F,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,,Homo sapiens,9606.0,786-0,,80640
5323,,12400,391.0,F,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,,Homo sapiens,9606.0,786-0,,80640
5324,,12888,391.0,F,,Cytotoxic effect on renal cancer line 786-0,,,Homo sapiens,9606.0,786-0,,80640
5325,,15300,391.0,F,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,,Homo sapiens,9606.0,786-0,,80640
5326,,14769,391.0,F,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,,Homo sapiens,9606.0,786-0,,80640
5327,,15895,391.0,F,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,,Homo sapiens,9606.0,786-0,,80640
5328,,17376,391.0,F,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,,Homo sapiens,9606.0,786-0,,80640
5329,,14882,391.0,F,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,,Homo sapiens,9606.0,786-0,,80640
5330,,14882,391.0,F,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,,Homo sapiens,9606.0,786-0,,80640
5331,,15176,391.0,F,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,,Homo sapiens,9606.0,786-0,,80640
5332,,12696,391.0,F,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,,Homo sapiens,9606.0,786-0,,80640
5333,,2496,391.0,F,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,,Homo sapiens,9606.0,786-0,,80640
5334,,11831,972.0,F,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,,Homo sapiens,9606.0,791T cell line,,80641
5335,,11831,972.0,F,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,,Homo sapiens,9606.0,791T cell line,,80641
5336,,11831,972.0,F,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,,Homo sapiens,9606.0,791T cell line,,80641
5337,,11831,972.0,F,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,,Homo sapiens,9606.0,791T cell line,,80641
5338,,11831,972.0,F,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,,Homo sapiens,9606.0,791T cell line,,80641
5339,,11831,972.0,F,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,,Homo sapiens,9606.0,791T cell line,,80641
5340,,11831,972.0,F,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,,Homo sapiens,9606.0,791T cell line,,80641
5341,,11831,972.0,F,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,,Homo sapiens,9606.0,791T cell line,,80641
5342,,11831,972.0,F,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,,Homo sapiens,9606.0,791T cell line,,80641
5343,,11831,972.0,F,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,,Homo sapiens,9606.0,791T cell line,,80641
5344,,12782,391.0,F,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,,Homo sapiens,9606.0,786-0,,80640
5345,,1229,,F,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,,,,,,22226
5346,,15313,741.0,F,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,,Homo sapiens,9606.0,RPMI-8226,,80433
5347,,15313,741.0,F,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,,Homo sapiens,9606.0,RPMI-8226,,80433
5348,,11544,741.0,F,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,,Homo sapiens,9606.0,RPMI-8226,,80433
5349,,9424,741.0,F,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,,Homo sapiens,9606.0,RPMI-8226,,80433
5350,,9424,741.0,F,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,,Homo sapiens,9606.0,RPMI-8226,,80433
5351,,9424,741.0,F,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,,Homo sapiens,9606.0,RPMI-8226,,80433
5352,,9424,741.0,F,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,,Homo sapiens,9606.0,RPMI-8226,,80433
5353,,9424,741.0,F,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,,Homo sapiens,9606.0,RPMI-8226,,80433
5354,,9424,741.0,F,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,,Homo sapiens,9606.0,RPMI-8226,,80433
5355,,9424,741.0,F,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,,Homo sapiens,9606.0,RPMI-8226,,80433
5356,,9424,741.0,F,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,,Homo sapiens,9606.0,RPMI-8226,,80433
5357,,9424,741.0,F,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,,Homo sapiens,9606.0,RPMI-8226,,80433
5358,,14769,624.0,F,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,,Homo sapiens,9606.0,A498,,80021
5359,,15354,624.0,F,,Compound was tested for the growth inhibition of A498 renal tumor cell line,,,Homo sapiens,9606.0,A498,,80021
5360,,17445,624.0,F,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,,Homo sapiens,9606.0,A498,,80021
5361,,4337,624.0,F,,In vitro inhibitory concentration against renal cancer cell line A498,,,Homo sapiens,9606.0,A498,,80021
5362,,15277,624.0,F,,Cytotoxicity against A 498 tumor cell line,,,Homo sapiens,9606.0,A498,,80021
5363,,4812,624.0,F,,In vitro antitumor activity against A498 human cancer cell line,,,Homo sapiens,9606.0,A498,,80021
5364,,4812,624.0,F,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,,Homo sapiens,9606.0,A498,,80021
5365,,4995,624.0,F,,Inhibitory dose required against A498 human tumor cell lines,,,Homo sapiens,9606.0,A498,,80021
5366,,5847,624.0,F,,Anticancer activity against one renal cancer (A498 cell line),,,Homo sapiens,9606.0,A498,,80021
5367,,6557,624.0,F,,In vitro cytotoxicity against melanoma A498 cell line,,,Homo sapiens,9606.0,A498,,80021
5368,,2597,624.0,F,,Compound was tested for growth inhibitory activity against A498 cell line,,,Homo sapiens,9606.0,A498,,80021
5369,,6058,624.0,F,,Compound tested for growth inhibition of renal cancer cell line A498,,,Homo sapiens,9606.0,A498,,80021
5370,,17708,624.0,F,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,,Homo sapiens,9606.0,A498,,80021
5371,,15176,624.0,F,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,,Homo sapiens,9606.0,A498,,80021
5372,,15300,624.0,F,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,,Homo sapiens,9606.0,A498,,80021
5373,,11970,624.0,F,,Tested for cytotoxicity against A498 cell lines in renal cancer,,,Homo sapiens,9606.0,A498,,80021
5374,,12400,624.0,F,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,,Homo sapiens,9606.0,A498,,80021
5375,,12888,624.0,F,,Cytotoxic effect on renal cancer lines A498,,,Homo sapiens,9606.0,A498,,80021
5376,,3030,624.0,F,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,,Homo sapiens,9606.0,A498,,80021
5377,,14769,624.0,F,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,,Homo sapiens,9606.0,A498,,80021
5378,,17376,624.0,F,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,,Homo sapiens,9606.0,A498,,80021
5379,,16558,624.0,F,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,,Homo sapiens,9606.0,A498,,80021
5380,,5194,624.0,F,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,,Homo sapiens,9606.0,A498,,80021
5381,,10708,624.0,F,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,,Homo sapiens,9606.0,A498,,80021
5382,,16880,646.0,F,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,,Homo sapiens,9606.0,A549,,80682
5383,,10196,646.0,F,,Antitumor activity against A549 human lung carcinoma cell line,,,Homo sapiens,9606.0,A549,,80682
5384,,10196,646.0,F,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,,Homo sapiens,9606.0,A549,,80682
5385,,10196,646.0,F,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,,Homo sapiens,9606.0,A549,,80682
5386,,12083,646.0,F,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,,Homo sapiens,9606.0,A549,,80682
5387,,16464,646.0,F,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,,Homo sapiens,9606.0,A549,,80682
5388,,16464,646.0,F,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,Homo sapiens,9606.0,A549,,80682
5389,,16470,646.0,F,,In vitro cytotoxic activity against human lung A549 cell line,,,Homo sapiens,9606.0,A549,,80682
5390,,16470,646.0,F,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,,Homo sapiens,9606.0,A549,,80682
5391,,16470,646.0,F,,In vitro cytotoxic activity against human lung A549 cell line),,,Homo sapiens,9606.0,A549,,80682
5392,,16470,646.0,F,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,,Homo sapiens,9606.0,A549,,80682
5393,,16582,646.0,F,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,,Homo sapiens,9606.0,A549,,80682
5394,,15935,646.0,F,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,,Homo sapiens,9606.0,A549,,80682
5395,,15935,646.0,F,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,,Homo sapiens,9606.0,A549,,80682
5396,,16597,646.0,F,,Inhibition of A549 human lung carcinoma cell proliferation,,,Homo sapiens,9606.0,A549,,80682
5397,,17376,646.0,F,,Inhibitory activity against A549 lung adenocarcinoma cell line,,,Homo sapiens,9606.0,A549,,80682
5398,,16496,646.0,F,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,,Homo sapiens,9606.0,A549,,80682
5399,,16152,646.0,F,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,,Homo sapiens,9606.0,A549,,80682
5400,,16152,646.0,F,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,,Homo sapiens,9606.0,A549,,80682
5401,,16464,646.0,F,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,Homo sapiens,9606.0,A549,,80682
5402,,2288,646.0,F,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,,Homo sapiens,9606.0,A549,,80682
5403,,17350,646.0,F,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,,Homo sapiens,9606.0,A549,,80682
5404,,4090,646.0,F,,Inhibition of A549 cancer cell proliferation,,,Homo sapiens,9606.0,A549,,80682
5405,,4090,646.0,F,,Inhibition of A549 cancer cell proliferation (Not tested),,,Homo sapiens,9606.0,A549,,80682
5406,,17350,646.0,F,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,,Homo sapiens,9606.0,A549,,80682
5407,,4197,646.0,F,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,,Homo sapiens,9606.0,A549,,80682
5408,,17072,646.0,F,,Antiproliferative potency determined as inhibitory concentration against A549 cells,,,Homo sapiens,9606.0,A549,,80682
5409,,17072,646.0,F,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,,Homo sapiens,9606.0,A549,,80682
5410,,5194,646.0,F,,Cytotoxicity against Renal cell lines A549 was determined,,,Homo sapiens,9606.0,A549,,80682
5411,,4257,,A,,Area under curve was determined in dog after a 3 mg/kg of oral dose,,,Canis lupus familiaris,9615.0,,,50588
5412,,6123,,A,,Area under curve was determined in dog after oral administration at 1 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
5413,,1337,,A,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,Canis lupus familiaris,9615.0,,,50588
5414,,1337,,A,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,Canis lupus familiaris,9615.0,,,50588
5415,,8833,,A,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,,Canis lupus familiaris,9615.0,,,50588
5416,,8833,,A,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,,Canis lupus familiaris,9615.0,,,50588
5417,,8833,,A,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,,Canis lupus familiaris,9615.0,,,50588
5418,,8833,,A,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,,Canis lupus familiaris,9615.0,,,50588
5419,Plasma,17657,,A,,Area under plasma concentration time curve in dog upon oral administration,,,Canis lupus familiaris,9615.0,,,50588
5420,Plasma,17650,,A,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,,Canis lupus familiaris,9615.0,,,50588
5421,,1977,,A,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,,Canis lupus familiaris,9615.0,,,50588
5422,,1977,,A,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,,Canis lupus familiaris,9615.0,,,50588
5423,,3132,,A,,Area under the curve for the compound was obtained when tested in dog,,,Canis lupus familiaris,9615.0,,,50588
5424,,5473,,A,,Area under the curve at a dose of 1 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
5425,,5474,,A,,Area under the curve at a dose of 1 mg/kg (oral),,,Canis lupus familiaris,9615.0,,,50588
5426,,5474,,A,,Area under the curve at i.v. dose of 0.2 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
5427,,6062,,A,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
5428,,4709,,A,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,,Canis lupus familiaris,9615.0,,,50588
5429,,2652,,A,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,,Canis lupus familiaris,9615.0,,,50588
5430,,2652,,A,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,,Canis lupus familiaris,9615.0,,,50588
5431,,2877,,A,,Compound was evaluated for area under the curve in dog blood.,,,Canis lupus familiaris,9615.0,,,50588
5432,,5444,,A,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,,Canis lupus familiaris,9615.0,,,50588
5433,Plasma,5130,,A,,AUC in dog after oral dose (1 mg/kg),,,Canis lupus familiaris,9615.0,,,50588
5434,,6265,,A,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
5435,,4657,,A,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,,Canis lupus familiaris,9615.0,,,50588
5436,,16367,,A,,Pharmacokinetic parameter AUC after intravenous administration to dogs,,,Canis lupus familiaris,9615.0,,,50588
5437,,16367,,A,,Pharmacokinetic parameter AUC after oral administration to dogs,,,Canis lupus familiaris,9615.0,,,50588
5438,,9579,,A,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,,Canis lupus familiaris,9615.0,,,50588
5439,,9579,,A,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,,Canis lupus familiaris,9615.0,,,50588
5440,,5983,,A,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,,Canis lupus familiaris,9615.0,,,50588
5441,,6241,,A,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
5442,,5313,,A,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,,Canis lupus familiaris,9615.0,,,50588
5443,,5313,,A,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,,Canis lupus familiaris,9615.0,,,50588
5444,,6642,,A,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,Canis lupus familiaris,9615.0,,,50588
5445,,6642,,A,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,Canis lupus familiaris,9615.0,,,50588
5446,,6641,,A,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,,Canis lupus familiaris,9615.0,,,50588
5447,,6642,,A,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,,Canis lupus familiaris,9615.0,,,50588
5448,,17791,,A,,Compound was evaluated for oral bioavailability in dog; 90-100,,,Canis lupus familiaris,9615.0,,,50588
5449,,17655,,A,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,,Canis lupus familiaris,9615.0,,,50588
5450,,17655,,A,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,,Canis lupus familiaris,9615.0,,,50588
5451,,6596,,A,,PAPP (membrane permeability) in dog kidney cell monolayer assay,,,Canis lupus familiaris,9615.0,,,50588
5452,,3880,,A,,Oral bioavailability in dog,,,Canis lupus familiaris,9615.0,,,50588
5453,,16367,,A,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,,Canis lupus familiaris,9615.0,,,50588
5454,Plasma,17409,,A,,Plasma protein binding towards dog plasma at 10 uM,,,Canis lupus familiaris,9615.0,,,50588
5455,Plasma,17409,,A,,Plasma protein binding towards dog plasma at 100 uM,,,Canis lupus familiaris,9615.0,,,50588
5456,,2959,,A,,Bioavailability in dog (dose 4 mg/kg p.o.),In vivo,,Canis lupus familiaris,9615.0,,,50588
5457,,13501,,A,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5458,,4527,,A,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
5459,,15145,,A,,Bioavailability in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
5460,,4219,,A,,Bioavailability,In vivo,,Canis lupus familiaris,9615.0,,,50588
5461,,17538,,A,,Oral bioavailability in dog (dose 10 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
5462,,17538,,A,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
5463,,1466,,A,,Bioavailability in dog (dose 10.0 mg/kg p.o.),In vivo,,Canis lupus familiaris,9615.0,,,50588
5464,,17650,,A,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
5465,,3132,,A,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5466,,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Mus sp.,10095.0,,,22224
5467,Liver,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Mus sp.,10095.0,,,22224
5468,Liver,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,Mus sp.,10095.0,,,22224
5469,Liver,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Mus sp.,10095.0,,,22224
5470,,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Mus sp.,10095.0,,,22224
5471,,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Mus sp.,10095.0,,,22224
5472,Muscle tissue,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Mus sp.,10095.0,,,22224
5473,Muscle tissue,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,Mus sp.,10095.0,,,22224
5474,Muscle tissue,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Mus sp.,10095.0,,,22224
5475,Spleen,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Mus sp.,10095.0,,,22224
5476,Spleen,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Mus sp.,10095.0,,,22224
5477,,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Mus sp.,10095.0,,,22224
5478,,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,Mus sp.,10095.0,,,22224
5479,,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Mus sp.,10095.0,,,22224
5480,,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,Mus sp.,10095.0,,,22224
5481,,2413,,A,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Mus sp.,10095.0,,,22224
5482,,17827,,A,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,,Cercopithecidae,9527.0,,,22224
5483,Cerebellum,17827,,A,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,,Cercopithecidae,9527.0,,,22224
5484,Frontal cortex,17827,,A,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,,Cercopithecidae,9527.0,,,22224
5485,,17827,,A,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,,Cercopithecidae,9527.0,,,22224
5486,Striatum,17827,,A,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,,Cercopithecidae,9527.0,,,22224
5487,,17827,,A,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,,Cercopithecidae,9527.0,,,22224
5488,Cerebellum,17827,,A,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,,Cercopithecidae,9527.0,,,22224
5489,Frontal cortex,17827,,A,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,,Cercopithecidae,9527.0,,,22224
5490,,17827,,A,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,,Cercopithecidae,9527.0,,,22224
5491,Striatum,17827,,A,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,,Cercopithecidae,9527.0,,,22224
5492,,17791,,A,,Compound was evaluated for oral bioavailability in rats,,,Cercopithecidae,9527.0,,,22224
5493,Plasma,17667,,A,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,In vivo,,Cercopithecidae,9527.0,,,22224
5494,,17791,,A,,Half life period was evaluated in monkey,,,Cercopithecidae,9527.0,,,22224
5495,,110,,A,,Half-life in rhesus monkeys by intravenous administration of dose,In vivo,,Cercopithecidae,9527.0,,,22224
5496,Plasma,5781,,A,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,,Mus musculus,10090.0,,,50594
5497,Plasma,17734,,A,,AUC after intraperitoneal administration of 100 mg/kg in mice,,,Mus musculus,10090.0,,,50594
5498,Plasma,17718,,A,,AUC value was determined after oral administration,,,Mus musculus,10090.0,,,50594
5499,,4573,,A,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,,Mus musculus,10090.0,,,50594
5500,,3277,,A,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,Mus musculus,10090.0,,,50594
5501,,2862,,A,,Area under curve by ioral administration in mouse,,,Mus musculus,10090.0,,,50594
5502,,2862,,A,,Area under curve by iv administration in mouse,,,Mus musculus,10090.0,,,50594
5503,,5951,,A,,Area under curve at 0-8 hr in IRC mice after peroral administration,,,Mus musculus,10090.0,,,50594
5504,,17729,,A,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,,Mus musculus,10090.0,,,50594
5505,,17728,,A,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,,Mus musculus,10090.0,,,50594
5506,,17728,,A,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,,Mus musculus,10090.0,,,50594
5507,,17729,,A,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,,Mus musculus,10090.0,,,50594
5508,,9424,741.0,F,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,,Homo sapiens,9606.0,RPMI-8226,,80433
5509,,9424,741.0,F,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,,Homo sapiens,9606.0,RPMI-8226,,80433
5510,,9424,741.0,F,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,,Homo sapiens,9606.0,RPMI-8226,,80433
5511,,9424,741.0,F,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,,Homo sapiens,9606.0,RPMI-8226,,80433
5512,,9424,741.0,F,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,,Homo sapiens,9606.0,RPMI-8226,,80433
5513,,9424,741.0,F,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,,Homo sapiens,9606.0,RPMI-8226,,80433
5514,,9424,741.0,F,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,,Homo sapiens,9606.0,RPMI-8226,,80433
5515,,9424,741.0,F,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,,Homo sapiens,9606.0,RPMI-8226,,80433
5516,,9424,741.0,F,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,,Homo sapiens,9606.0,RPMI-8226,,80433
5517,,9424,741.0,F,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,,Homo sapiens,9606.0,RPMI-8226,,80433
5518,,9424,741.0,F,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,,Homo sapiens,9606.0,RPMI-8226,,80433
5519,,9424,741.0,F,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,,Homo sapiens,9606.0,RPMI-8226,,80433
5520,,9424,741.0,F,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,,Homo sapiens,9606.0,RPMI-8226,,80433
5521,,9424,741.0,F,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,,Homo sapiens,9606.0,RPMI-8226,,80433
5522,,9424,741.0,F,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,,Homo sapiens,9606.0,RPMI-8226,,80433
5523,,9424,741.0,F,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,,Homo sapiens,9606.0,RPMI-8226,,80433
5524,,9424,741.0,F,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,,Homo sapiens,9606.0,RPMI-8226,,80433
5525,,11544,741.0,F,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,,Homo sapiens,9606.0,RPMI-8226,,80433
5526,,17378,741.0,F,,Cytotoxicity of compound against 8226/DOX1V cells,,,Homo sapiens,9606.0,RPMI-8226,,80433
5527,,17378,741.0,F,,Cytotoxicity of compound against 8226/S cells,,,Homo sapiens,9606.0,RPMI-8226,,80433
5528,,17079,741.0,F,,Inhibitory concentration against 8226 myeloma cancer cell line,,,Homo sapiens,9606.0,RPMI-8226,,80433
5529,,17079,741.0,F,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,,Homo sapiens,9606.0,RPMI-8226,,80433
5530,,13466,854.0,F,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,,Homo sapiens,9606.0,833K,,80647
5531,,13466,854.0,F,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,,Homo sapiens,9606.0,833K,,80647
5532,,2392,854.0,F,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,,Homo sapiens,9606.0,833K,,80647
5533,,2392,854.0,F,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,,Homo sapiens,9606.0,833K,,80647
5534,,6608,,B,,Inhibitory activity against caspase-1,,,,,,,22226
5535,,10199,,B,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,,Enterococcus faecalis,1351.0,,,45
5536,,17749,705.0,F,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,,Homo sapiens,9606.0,8701-BC,,80648
5537,,17749,705.0,F,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,,Homo sapiens,9606.0,8701-BC,,80648
5538,,1229,,F,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,,,,,,22226
5539,,1229,,F,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,,,,,,22226
5540,,1229,,F,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,,,,,,22226
5541,,6390,,B,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,,,,,,22226
5542,,16219,,F,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,,Streptococcus pyogenes,1314.0,,,22226
5543,,16219,,F,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,,Streptococcus pyogenes,1314.0,,,22226
5544,,17043,,B,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,,,,,,11922
5545,,6929,324.0,F,,Tested for in vitro cytotoxic potency of compound in 9KB assay,,,Homo sapiens,9606.0,KB ,,81115
5546,,6929,324.0,A,,Tested for in vitro cytotoxic potency of compound in 9KB assay,,,Homo sapiens,9606.0,KB ,,81115
5547,,7083,,F,,In vitro cytotoxicity of compound was tested against 9KB cells.,,,Homo sapiens,9606.0,,,22226
5548,,12446,392.0,F,,Cytotoxic concentration against 9L cells was determined on day 3,,,Rattus norvegicus,10116.0,9L,,80653
5549,,15345,392.0,F,,Tested in vitro for anticancer activity against 9L cells,,,Rattus norvegicus,10116.0,9L,,80653
5550,,15345,392.0,F,,Tested in vitro for anticancer activity against 9L cells; Not determined,,,Rattus norvegicus,10116.0,9L,,80653
5551,,6301,646.0,F,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,,Homo sapiens,9606.0,A549,,80682
5552,,4833,646.0,F,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,,Homo sapiens,9606.0,A549,,80682
5553,,4833,646.0,F,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,,Homo sapiens,9606.0,A549,,80682
5554,,4833,646.0,F,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,,Homo sapiens,9606.0,A549,,80682
5555,,13330,646.0,F,,Cytotoxicity against human lung carcinoma A549 cell line,,,Homo sapiens,9606.0,A549,,80682
5556,,17517,646.0,F,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,,Homo sapiens,9606.0,A549,,25
5557,,17517,646.0,F,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,,Homo sapiens,9606.0,A549,,25
5558,,14425,646.0,F,,"In vitro growth inhibition of A549, lung carcinoma",,,Homo sapiens,9606.0,A549,,80682
5559,,14425,646.0,F,,"In vitro growth inhibition of A549, lung carcinoma.",,,Homo sapiens,9606.0,A549,,80682
5560,,5228,646.0,F,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,,Homo sapiens,9606.0,A549,,80682
5561,,5351,646.0,F,,Cytotoxic activity against human lung cancer A549 cell line was determined,,,Homo sapiens,9606.0,A549,,80682
5562,,12198,646.0,F,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,,Homo sapiens,9606.0,A549,,80682
5563,,13891,646.0,F,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,,Homo sapiens,9606.0,A549,,80682
5564,,5677,646.0,F,,Cytotoxicity in A549 (human carcinoma) cell line.,,,Homo sapiens,9606.0,A549,,80682
5565,,13788,646.0,F,,Cytotoxicity on lung carcinoma (A-549) cell line,,,Homo sapiens,9606.0,A549,,80682
5566,,13384,646.0,F,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,,Homo sapiens,9606.0,A549,,80682
5567,,6726,646.0,F,,Effective dose of compound against replication of A549 cell line was evaluated,,,Homo sapiens,9606.0,A549,,80682
5568,,3455,646.0,F,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,,Homo sapiens,9606.0,A549,,80682
5569,,5726,646.0,F,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,,Homo sapiens,9606.0,A549,,80682
5570,,5726,646.0,F,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,,Homo sapiens,9606.0,A549,,80682
5571,,3936,646.0,F,,The compound was evaluated for antiproliferative activity against A549 cell line,,,Homo sapiens,9606.0,A549,,80682
5572,,14991,646.0,F,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,,Homo sapiens,9606.0,A549,,80682
5573,,5243,646.0,F,,Concentration required for growth inhibition of human lung carcinoma cell line A549,,,Homo sapiens,9606.0,A549,,80682
5574,,12858,646.0,F,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,,Homo sapiens,9606.0,A549,,80682
5575,,6776,646.0,F,,Growth inhibition against A549 cell line was evaluated,,,Homo sapiens,9606.0,A549,,80682
5576,,16558,646.0,F,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,,Homo sapiens,9606.0,A549,,80682
5577,,4583,646.0,F,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,,Homo sapiens,9606.0,A549,,80682
5578,,13514,646.0,F,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,,Homo sapiens,9606.0,A549,,80682
5579,,15166,646.0,F,,Chemosensitivity against DT-diaphorase rich A549 cell lines,,,Homo sapiens,9606.0,A549,,80682
5580,,13873,646.0,F,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,,Homo sapiens,9606.0,A549,,80682
5581,,6447,646.0,F,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,,Homo sapiens,9606.0,A549,,80682
5582,,2068,646.0,F,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,,Homo sapiens,9606.0,A549,,80682
5583,,1863,646.0,F,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,,Homo sapiens,9606.0,A549,,80682
5584,,13873,646.0,F,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,,Homo sapiens,9606.0,A549,,80682
5585,,13873,646.0,F,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,,Homo sapiens,9606.0,A549,,80682
5586,,13873,646.0,F,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,,Homo sapiens,9606.0,A549,,80682
5587,,579,646.0,F,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,,Homo sapiens,9606.0,A549,,80682
5588,,579,646.0,F,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,,Homo sapiens,9606.0,A549,,80682
5589,,4584,646.0,F,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,,Homo sapiens,9606.0,A549,,80682
5590,,5421,646.0,F,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,,Homo sapiens,9606.0,A549,,80682
5591,,5421,646.0,F,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,,Homo sapiens,9606.0,A549,,80682
5592,,5421,646.0,F,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,,Homo sapiens,9606.0,A549,,80682
5593,,5421,646.0,F,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,,Homo sapiens,9606.0,A549,,80682
5594,,14188,646.0,F,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,,Homo sapiens,9606.0,A549,,80682
5595,,14188,646.0,F,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,,Homo sapiens,9606.0,A549,,80682
5596,,15354,646.0,F,,Compound was tested for the growth inhibition of A549 lung tumor cell line,,,Homo sapiens,9606.0,A549,,80682
5597,,14253,646.0,F,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,,Homo sapiens,9606.0,A549,,80682
5598,,13873,646.0,F,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,,Homo sapiens,9606.0,A549,,80682
5599,,3043,,A,,Oral bioavailability in dog (conscious),In vivo,,Canis lupus familiaris,9615.0,,,50588
5600,,3045,,A,,Compound was evaluated for the oral bioavailability after oral administration in dog.,In vivo,,Canis lupus familiaris,9615.0,,,50588
5601,,3022,,A,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
5602,,4453,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5603,,1696,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5604,,5045,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5605,,5356,,A,,Oral bioavailability in dog (fasted),In vivo,,Canis lupus familiaris,9615.0,,,50588
5606,,17764,,A,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
5607,,6448,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5608,,1475,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5609,,3788,,A,,Percent bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5610,,3639,,A,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5611,,13397,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5612,,2137,,A,,The compound was evaluated for bioavailability in dogs; 34-44,In vivo,,Canis lupus familiaris,9615.0,,,50588
5613,,2959,,A,,Bioavailability in dog (dose 4 mg/kg p.o.),In vivo,,Canis lupus familiaris,9615.0,,,50588
5614,,6448,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5615,,6084,,A,,8 hour trough Blood level in dog was measured after administration of compound,,,Canis lupus familiaris,9615.0,,,50588
5616,Plasma,3639,,A,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,In vivo,,Canis lupus familiaris,9615.0,,,50588
5617,,6316,,A,,C24 after oral administration at 5 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
5618,,5238,,A,,Clearance after oral and iv dosing in dogs,,,Canis lupus familiaris,9615.0,,,50588
5619,Plasma,17796,,A,,Clearance of the drug was measured in the plasma of dog,,,Canis lupus familiaris,9615.0,,,50588
5620,,2652,,A,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,,Canis lupus familiaris,9615.0,,,50588
5621,,5654,,A,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
5622,,6621,,A,,Clearance of compound was determined in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
5623,,6505,,A,,Clearance on i.v. administration of 2 mg/kg was measured in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5624,,5802,,A,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5625,,17267,,A,,Plasma clearance in dog was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
5626,,4521,,A,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
5627,,6535,,A,,Plasma clearance in dog after administration of 0.25 mg/kg iv,In vivo,,Canis lupus familiaris,9615.0,,,50588
5628,,6535,,A,,Plasma clearance in dog after administration of 1 mg/kg iv,In vivo,,Canis lupus familiaris,9615.0,,,50588
5629,,6535,,A,,Plasma clearance in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
5630,,5542,,A,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
5631,,5199,,A,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,In vivo,,Canis lupus familiaris,9615.0,,,50588
5632,,16907,,A,,Plasma clearance after 15 mg/kg iv dose in Dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
5633,,16907,,A,,Plasma clearance after 30 mg/kg po dose in Dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
5634,,16367,,A,,Plasma administration to dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
5635,,5505,,A,,Plasma clearance was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
5636,,6215,,A,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5637,,1466,,A,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5638,Liver,5007,,A,,Intrinsic clearance in human liver microsomes,In vitro,,Homo sapiens,9606.0,,Microsomes,102164
5639,Liver,5007,,A,,Intrinsic clearance in human liver microsomes,In vitro,,Homo sapiens,9606.0,,Microsomes,102164
5640,,16452,,A,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,,Canis lupus familiaris,9615.0,,,50588
5641,,16452,,A,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,In vivo,,Canis lupus familiaris,9615.0,,,50588
5642,,16452,,A,,Clearance in dog (dose 1 mg/kg i.v.),In vivo,,Canis lupus familiaris,9615.0,,,50588
5643,,6221,,A,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
5644,,5007,,A,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
5645,,5668,,A,,Plasma clearance after peroral administration at 10 mpk in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5646,,5668,,A,,Plasma clearance after peroral administration at 5 mpk in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5647,,5668,,A,,Plasma clearance after peroral administration at 5 mg/kg in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5648,,15660,,A,,Plasma clearance was measured in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5649,,15660,,A,,Plasma clearance was measured in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5650,,5983,,A,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,In vivo,,Canis lupus familiaris,9615.0,,,50588
5651,,5600,,A,,Total clearance was determined after 0.1 mg/kg iv administration in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5652,,17764,,A,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
5653,,6039,,A,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
5654,,6039,,A,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
5655,,6039,,A,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
5656,,4368,,A,,Clearance by intravenous administration of 1.2 mg/kg in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5657,,4305,,A,,Clearance by iv administration in dogs at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
5658,Plasma,1918,,A,,Clearance value was evaluated in dog plasma,In vivo,,Canis lupus familiaris,9615.0,,,50588
5659,,6005,,A,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
5660,Plasma,4839,,A,,Compound was tested for plasma clearance in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5661,,4239,,A,,Pharmacokinetic property (Plasma clearance) was measured in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5662,,17729,,A,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,,Mus musculus,10090.0,,,50594
5663,,17728,,A,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,,Mus musculus,10090.0,,,50594
5664,,5302,,A,,Area under curve value in mouse at a dose of 10 mg/kg,,,Mus musculus,10090.0,,,50594
5665,,5506,,A,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,,Mus musculus,10090.0,,,50594
5666,,5506,,A,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,,Mus musculus,10090.0,,,50594
5667,,17764,,F,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,,Mus musculus,10090.0,,,50594
5668,,17764,,F,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,,Mus musculus,10090.0,,,50594
5669,,17764,,F,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,,Mus musculus,10090.0,,,50594
5670,,17764,,F,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,,Mus musculus,10090.0,,,50594
5671,,17764,,A,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,,Mus musculus,10090.0,,,50594
5672,,17753,,A,,Area under curve was determined for the compound at 24 mg/Kg,,,Mus musculus,10090.0,,,50594
5673,,17753,,A,,Area under curve was determined for the compound at 40 mg/Kg,,,Mus musculus,10090.0,,,50594
5674,,17753,,A,,Area under curve was determined for the compound at 5 mg/Kg,,,Mus musculus,10090.0,,,50594
5675,,3132,,A,,Area under the curve for the compound is obtained at dose 25 mg/kg,,,Mus musculus,10090.0,,,50594
5676,,3132,,A,,Area under the curve for the compound was obtained when tested in mouse,,,Mus musculus,10090.0,,,50594
5677,,17837,,A,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,,Mus musculus,10090.0,,,50594
5678,,17837,,A,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,,Mus musculus,10090.0,,,50594
5679,,6062,,A,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,,Mus musculus,10090.0,,,50594
5680,,4066,,A,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,,Mus musculus,10090.0,,,50594
5681,,16597,,A,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,,Mus musculus,10090.0,,,50594
5682,,14239,,A,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,,Mus musculus,10090.0,,,50594
5683,,14239,,A,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,,Mus musculus,10090.0,,,50594
5684,,4890,,A,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,,Mus musculus,10090.0,,,50594
5685,,429,,A,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,,Mus musculus,10090.0,,,50594
5686,,429,,A,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,,Mus musculus,10090.0,,,50594
5687,,5969,,A,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,,Mus musculus,10090.0,,,50594
5688,,5969,,A,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,,Mus musculus,10090.0,,,50594
5689,,5969,,A,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,,Mus musculus,10090.0,,,50594
5690,,6091,,A,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,,Mus musculus,10090.0,,,50594
5691,,6091,,A,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,,Mus musculus,10090.0,,,50594
5692,,6091,,A,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,,Mus musculus,10090.0,,,50594
5693,,6091,,A,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,,Mus musculus,10090.0,,,50594
5694,,6178,,A,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,,Mus musculus,10090.0,,,50594
5695,,6178,,A,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,,Mus musculus,10090.0,,,50594
5696,,6619,,A,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,,Mus musculus,10090.0,,,50594
5697,,6619,,A,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,,Mus musculus,10090.0,,,50594
5698,,3760,,A,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,,Mus musculus,10090.0,,,50594
5699,,3760,,A,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,,Mus musculus,10090.0,,,50594
5700,,3760,,A,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,,Mus musculus,10090.0,,,50594
5701,,3760,,A,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,,Mus musculus,10090.0,,,50594
5702,,3192,,A,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,,Mus musculus,10090.0,,,50594
5703,,3192,,A,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,,Mus musculus,10090.0,,,50594
5704,,2675,,A,,Area under the curve was evaluated in mice after intravenous administration,,,Mus musculus,10090.0,,,50594
5705,,2675,,A,,Area under the curve was evaluated in mice after oral administration,,,Mus musculus,10090.0,,,50594
5706,Plasma,16597,,A,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,,Mus musculus,10090.0,,,50594
5707,Plasma,16597,,A,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,,Mus musculus,10090.0,,,50594
5708,,16597,,A,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,,Mus musculus,10090.0,,,50594
5709,,17734,,A,,AUMC after intraperitoneal administration of 100 mg/kg in mice,,,Mus musculus,10090.0,,,50594
5710,Blood,7767,,A,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5711,,15345,392.0,F,,The compound was tested in vitro for anticancer activity against 9L cells,,,,,9L,,80653
5712,,2181,,F,,Anti proliferation activity determined; Weak effect,,,Rattus norvegicus,10116.0,,,22226
5713,,2181,,F,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,,Rattus norvegicus,10116.0,,,22226
5714,,2181,,F,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,,Rattus norvegicus,10116.0,,,22226
5715,,2181,,F,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,,Rattus norvegicus,10116.0,,,22226
5716,,10486,,F,,The cytotoxic activity was in vitro tested by 9PS assay method,,,Mus musculus,10090.0,,,22226
5717,,10486,,F,,The cytotoxic activity was in vitro tested by 9PS assay method.,,,Mus musculus,10090.0,,,22226
5718,,15508,,A,,Partition coefficient (logD6.5),,,,,,,22224
5719,,5242,478.0,F,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,,Homo sapiens,9606.0,A2780,,81034
5720,,16167,455.0,F,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,,Homo sapiens,9606.0,A-375,,80018
5721,,4782,500.0,F,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,,Homo sapiens,9606.0,A-431,,80852
5722,,16093,500.0,F,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,,Homo sapiens,9606.0,A-431,,9
5723,,2596,624.0,F,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,,Homo sapiens,9606.0,A498,,80021
5724,,2596,624.0,F,,in vitro cytotoxicity against A 498 cancer cell line,,,Homo sapiens,9606.0,A498,,80021
5725,,3239,624.0,F,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,,Homo sapiens,9606.0,A498,,80021
5726,,1847,624.0,F,,Cytotoxic activity against A 498 renal cancer cell lines.,,,Homo sapiens,9606.0,A498,,80021
5727,,10553,624.0,F,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,,Homo sapiens,9606.0,A498,,80021
5728,,16219,,F,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,,Staphylococcus aureus,1280.0,,,22226
5729,,16219,,F,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,,Staphylococcus aureus,1280.0,,,22226
5730,,16219,,F,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,,Staphylococcus aureus,1280.0,,,22226
5731,,16219,,F,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,,Staphylococcus aureus,1280.0,,,22226
5732,,4782,646.0,F,,Inhibitory concentration required against A 549 lung cancer cell line,,,Homo sapiens,9606.0,A549,,80682
5733,,11805,646.0,F,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,,Homo sapiens,9606.0,A549,,80682
5734,,11805,646.0,F,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,,Homo sapiens,9606.0,A549,,80682
5735,,2007,646.0,F,,In vitro cytotoxicity against lung cancer A 549 cell lines,,,Homo sapiens,9606.0,A549,,80682
5736,,4594,646.0,F,,Compound was tested for its cytotoxicity against A 549 cell line,,,Homo sapiens,9606.0,A549,,80682
5737,,6018,646.0,F,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,,Homo sapiens,9606.0,A549,,80682
5738,,6018,646.0,F,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,,Homo sapiens,9606.0,A549,,80682
5739,,3599,646.0,F,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,,Homo sapiens,9606.0,A549,,80682
5740,,2551,646.0,F,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,,Homo sapiens,9606.0,A549,,80682
5741,,16132,646.0,F,,In vitro inhibition of A549 (human lung cancer) cell growth.,,,Homo sapiens,9606.0,A549,,80682
5742,,16132,646.0,F,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,,Homo sapiens,9606.0,A549,,80682
5743,,2551,646.0,F,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,,Homo sapiens,9606.0,A549,,80682
5744,,2551,646.0,F,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,,Homo sapiens,9606.0,A549,,80682
5745,,11913,,F,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,,,,,,22226
5746,,12621,,F,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,In vivo,,,,,,104694
5747,,12621,,F,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,In vivo,,,,,,104694
5748,,12621,,F,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,In vivo,,,,,,104694
5749,,12621,,F,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,In vivo,,,,,,104694
5750,,12621,,F,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,In vivo,,,,,,104694
5751,,3600,624.0,F,,Inhibition of A-498 human Renal cell proliferation,,,Homo sapiens,9606.0,A498,,80021
5752,,1796,,F,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,,Rattus norvegicus,10116.0,,,22226
5753,,1796,,F,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,,Rattus norvegicus,10116.0,,,22226
5754,,1796,,F,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,,Rattus norvegicus,10116.0,,,22226
5755,,16464,622.0,F,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,,Homo sapiens,9606.0,A 172,,80012
5756,,16464,622.0,F,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,Homo sapiens,9606.0,A 172,,80012
5757,,16464,622.0,F,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,Homo sapiens,9606.0,A 172,,80012
5758,,13617,646.0,F,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,,Homo sapiens,9606.0,A549,,80682
5759,,4584,646.0,F,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,,Homo sapiens,9606.0,A549,,80682
5760,,13799,646.0,F,,Cytotoxic activity evaluated against A549 tumor cells,,,Homo sapiens,9606.0,A549,,80682
5761,,16726,646.0,F,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,,Homo sapiens,9606.0,A549,,80682
5762,,16109,646.0,F,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,,Homo sapiens,9606.0,A549,,80682
5763,,16109,646.0,F,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,,Homo sapiens,9606.0,A549,,80682
5764,,15474,646.0,F,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,,Homo sapiens,9606.0,A549,,80682
5765,,6851,646.0,F,,Cytotoxicity of compound against A549 cell line,,,Homo sapiens,9606.0,A549,,80682
5766,,17534,646.0,F,,Cytotoxicity against human lung cell carcinoma A549 cell line,,,Homo sapiens,9606.0,A549,,80682
5767,,2621,646.0,F,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,,Homo sapiens,9606.0,A549,,80682
5768,,830,646.0,F,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,,Homo sapiens,9606.0,A549,,80682
5769,,14255,646.0,F,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,,Homo sapiens,9606.0,A549,,80682
5770,,14255,646.0,F,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,,Homo sapiens,9606.0,A549,,80682
5771,,1590,646.0,F,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,,Homo sapiens,9606.0,A549,,80682
5772,,6146,646.0,F,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,,Homo sapiens,9606.0,A549,,80682
5773,,17427,646.0,F,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,,Homo sapiens,9606.0,A549,,80682
5774,,5280,646.0,F,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,,Homo sapiens,9606.0,A549,,80682
5775,,16786,646.0,F,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,,Homo sapiens,9606.0,A549,,80682
5776,,5895,646.0,F,,In vitro cytotoxicity against A549 (human lung cancer),,,Homo sapiens,9606.0,A549,,80682
5777,,14297,646.0,F,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,,Homo sapiens,9606.0,A549,,80682
5778,,17824,646.0,F,,In vivo antiproliferative activity against A549 cell line,,,Homo sapiens,9606.0,A549,,80682
5779,,14368,646.0,F,,Inhibition of non-small-cell lung adenocarcinoma (A549),,,Homo sapiens,9606.0,A549,,80682
5780,,14368,646.0,F,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,,Homo sapiens,9606.0,A549,,80682
5781,,14254,646.0,F,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,,Homo sapiens,9606.0,A549,,80682
5782,,15897,646.0,F,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,,Homo sapiens,9606.0,A549,,80682
5783,,13866,646.0,F,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,,Homo sapiens,9606.0,A549,,80682
5784,,13370,646.0,F,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,,Homo sapiens,9606.0,A549,,80682
5785,,4862,646.0,F,,Inhibitory activity against A549 lung cancer cell line,,,Homo sapiens,9606.0,A549,,80682
5786,,4862,646.0,F,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,,Homo sapiens,9606.0,A549,,80682
5787,,4862,646.0,F,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,,Homo sapiens,9606.0,A549,,80682
5788,,15970,646.0,F,,Inhibitory concentration against A549 (lung cancer) cell line,,,Homo sapiens,9606.0,A549,,80682
5789,,17713,646.0,F,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,,Homo sapiens,9606.0,A549,,80682
5790,,4833,646.0,F,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,,Homo sapiens,9606.0,A549,,80682
5791,,13736,646.0,F,,Activity against A549 cancer cell line.,,,Homo sapiens,9606.0,A549,,80682
5792,,4312,646.0,F,,The compound was evaluated for cytotoxicity against A549 cell line,,,Homo sapiens,9606.0,A549,,80682
5793,,5421,646.0,F,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,,Homo sapiens,9606.0,A549,,80682
5794,,5421,646.0,F,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,,Homo sapiens,9606.0,A549,,80682
5795,,14717,646.0,F,,Growth inhibitory activity was measured for human A549 tumor cell line.,,,Homo sapiens,9606.0,A549,,80682
5796,,4634,646.0,F,,Inhibitory activity against A549 lung cancer cell line,,,Homo sapiens,9606.0,A549,,80682
5797,,1149,646.0,F,,Inhibitory activity against A549 cell line; inactive,,,Homo sapiens,9606.0,A549,,80682
5798,,5421,646.0,F,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,,Homo sapiens,9606.0,A549,,80682
5799,,5421,646.0,F,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,,Homo sapiens,9606.0,A549,,80682
5800,,5421,646.0,F,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,,Homo sapiens,9606.0,A549,,80682
5801,,3320,646.0,F,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,,Homo sapiens,9606.0,A549,,80682
5802,,3320,646.0,F,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,,Homo sapiens,9606.0,A549,,80682
5803,,3320,646.0,F,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,,Homo sapiens,9606.0,A549,,80682
5804,,3320,646.0,F,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,,Homo sapiens,9606.0,A549,,80682
5805,,3320,646.0,F,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,,Homo sapiens,9606.0,A549,,80682
5806,,5726,646.0,F,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,,Homo sapiens,9606.0,A549,,80682
5807,,17800,,A,,Plasma clearance (in vivo) in mongrel dogs was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
5808,,5985,,A,,Plasma clearance was measured in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5809,,5530,,A,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
5810,,5530,,A,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
5811,Plasma,4839,,A,,Tested for plasma clearance in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5812,,3639,,A,,The compound was tested for clearance in dog plasma.,In vivo,,Canis lupus familiaris,9615.0,,,50588
5813,,4838,,A,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",In vivo,,Canis lupus familiaris,9615.0,,,50588
5814,,4137,,A,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5815,Plasma,5017,,A,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
5816,Liver,17538,,A,,In vitro clearance in dog liver microsomes,In vitro,,Canis lupus familiaris,9615.0,,Microsomes,50588
5817,,6161,,A,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5818,,6161,,A,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5819,,1696,,A,,Plasma clearance in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5820,,6762,,A,,Clearance rate in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5821,Plasma,5932,,A,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,In vivo,,Canis lupus familiaris,9615.0,,,50588
5822,,6305,,A,,Clearance in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
5823,,4942,,A,,Plasma clearance in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
5824,,4219,,A,,Plasma clearance was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
5825,,17853,,A,,Lower clearance in dog (i.v.) at 0.5 mpk,In vivo,,Canis lupus familiaris,9615.0,,,50588
5826,,4514,,A,,Plasma clearance in Beagle dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
5827,,6448,,A,,Plasma clearance (Clp) in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5828,,6227,,A,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
5829,,6227,,A,,Plasma clearance (pharmacokinetic parameter) in dog was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
5830,,6062,,A,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
5831,,6821,,A,,Plasma clearance of compound was determined in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5832,,4709,,A,,Plasma clearance after intravenous administration of 1 mg/kg in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5833,,4521,,A,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
5834,,5374,,A,,Plasma clearance in dog was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
5835,,6057,,A,,Plasma clearance was calculated in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5836,,4727,,A,,Plasma clearance at the dose of 2 mg/kg in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5837,,5145,,A,,Plasma clearance in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5838,,17657,,A,,Plasma clearance in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5839,,17657,,A,,Plasma clearance in dog; Unable to calculate,In vivo,,Canis lupus familiaris,9615.0,,,50588
5840,,5145,,A,,Plasma clearance in rhesus monkey,In vivo,,Canis lupus familiaris,9615.0,,,50588
5841,,6642,,A,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),In vivo,,Canis lupus familiaris,9615.0,,,50588
5842,,6641,,A,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,Canis lupus familiaris,9615.0,,,50588
5843,,6642,,A,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,Canis lupus familiaris,9615.0,,,50588
5844,,5472,,A,,Plasma clearance was evaluated in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5845,,5472,,A,,Plasma clearance was evaluated in dog; Not tested,In vivo,,Canis lupus familiaris,9615.0,,,50588
5846,,5472,,A,,Plasma clearance was evaluated in rhesus,In vivo,,Canis lupus familiaris,9615.0,,,50588
5847,,5472,,A,,Plasma clearance was evaluated in rhesus; Not tested,In vivo,,Canis lupus familiaris,9615.0,,,50588
5848,,4257,,A,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,In vivo,,Canis lupus familiaris,9615.0,,,50588
5849,,6679,,A,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
5850,,5546,,A,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
5851,,6348,,A,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
5852,,5474,,A,,Clearance value at a dose of 0.2 mg/kg i.v.,In vivo,,Canis lupus familiaris,9615.0,,,50588
5853,Plasma,6316,,A,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
5854,,17594,,A,,Cmax after oral dose of compound at 3 mg/kg in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
5855,,17594,,A,,Cmax after single intravenous bolus of 1 mg/kg in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
5856,,5802,,A,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5857,,6535,,A,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
5858,,6535,,A,,Cmax in dog after administration of 1 mg/kg iv,In vivo,,Canis lupus familiaris,9615.0,,,50588
5859,Plasma,1466,,A,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5860,,6505,,A,,Cmax on p.o. administration of 10 mg/kg was measured in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5861,,5668,,A,,Cmax was determine after peroral administration at 10 mpk in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5862,,5668,,A,,Cmax was determine after peroral administration at 5 mpk in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5863,,5668,,A,,Cmax was determine after peroral administration at 5 mg/kg in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5864,,5600,,A,,Cmax after 0.3 mg/kg po administration in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
5865,,17764,,A,,Cmax after peroral administration in dogs at 2.4 uM/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
5866,,6123,,A,,Cmax in dog after oral administration at 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
5867,,6123,,A,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,In vivo,,Canis lupus familiaris,9615.0,,,50588
5868,,6757,,A,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
5869,,16907,,A,,Cmax value after 15 mg/kg iv dose in Dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
5870,Blood,7767,,A,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5871,Blood,7767,,A,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5872,Bone,7767,,A,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5873,Bone,7767,,A,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5874,Bone,7767,,A,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5875,,7767,,A,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5876,,7767,,A,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5877,,7767,,A,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5878,Heart,7767,,A,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5879,Heart,7767,,A,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5880,Heart,7767,,A,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5881,Kidney,7767,,A,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5882,Kidney,7767,,A,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5883,Kidney,7767,,A,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5884,Intestine,7767,,A,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5885,Intestine,7767,,A,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5886,Intestine,7767,,A,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5887,Liver,7767,,A,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5888,Liver,7767,,A,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5889,Liver,7767,,A,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5890,Lung,7767,,A,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5891,Lung,7767,,A,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5892,Lung,7767,,A,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5893,Muscle tissue,7767,,A,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5894,Muscle tissue,7767,,A,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5895,Muscle tissue,7767,,A,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5896,,7767,,A,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5897,,7767,,A,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5898,,7767,,A,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5899,Intestine,7767,,A,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5900,Intestine,7767,,A,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5901,Intestine,7767,,A,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5902,Spleen,7767,,A,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5903,Spleen,7767,,A,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5904,Spleen,7767,,A,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5905,Stomach,7767,,A,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5906,Stomach,7767,,A,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
5907,,2036,622.0,F,,Cytotoxicity against A-172 human tumor cell lines,,,Homo sapiens,9606.0,A 172,,80012
5908,,2357,622.0,F,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,,Homo sapiens,9606.0,A 172,,80012
5909,,1457,623.0,F,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,,Homo sapiens,9606.0,A204,,80014
5910,,4379,478.0,F,,Tested for antiproliferative activity against A-2780 tumoral cell line,,,Homo sapiens,9606.0,A2780,,81034
5911,,1093,455.0,F,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,,Homo sapiens,9606.0,A-375,,80018
5912,,12152,455.0,F,,Tested in vitro against A-375 cell line human melanoma,,,Homo sapiens,9606.0,A-375,,80018
5913,,16464,797.0,F,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,,Homo sapiens,9606.0,A-427,,80019
5914,,16464,797.0,F,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,Homo sapiens,9606.0,A-427,,80019
5915,,16582,797.0,F,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,,Homo sapiens,9606.0,A-427,,80019
5916,,16464,797.0,F,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,Homo sapiens,9606.0,A-427,,80019
5917,,10413,797.0,F,,Antitumor activity on A-427 lung carcinoma cell lines,,,Homo sapiens,9606.0,A-427,,80019
5918,,6418,797.0,F,,Cytotoxic activity against human A-427 lung tumor cell line,,,Homo sapiens,9606.0,A-427,,80019
5919,,17134,797.0,F,,In vitro antitumor effects against human A-427 cell lines.,,,Homo sapiens,9606.0,A-427,,80019
5920,,16132,797.0,F,,In vitro inhibition of A-427 (human lung cancer) cell growth.,,,Homo sapiens,9606.0,A-427,,80019
5921,,16132,797.0,F,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,,Homo sapiens,9606.0,A-427,,80019
5922,,16780,797.0,F,,Cytotoxic activity of compound against A-427 lung human tumor cell line,,,Homo sapiens,9606.0,A-427,,80019
5923,,4085,500.0,F,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,,Homo sapiens,9606.0,A-431,,80852
5924,,1276,624.0,F,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,,Homo sapiens,9606.0,A498,,80021
5925,,3498,624.0,F,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,,Homo sapiens,9606.0,A498,,80021
5926,,1169,624.0,F,,Cytotoxicity against human kidney carcinoma A-498cell lines,,,Homo sapiens,9606.0,A498,,80021
5927,,4450,624.0,F,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,,Homo sapiens,9606.0,A498,,80021
5928,,3311,624.0,F,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,,Homo sapiens,9606.0,A498,,80021
5929,,4461,624.0,F,,Antitumor cytotoxic activity against A-498 cell line was determined,,,Homo sapiens,9606.0,A498,,80021
5930,,3311,624.0,F,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,,Homo sapiens,9606.0,A498,,80021
5931,,3311,624.0,F,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,,Homo sapiens,9606.0,A498,,80021
5932,,1457,624.0,F,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,,Homo sapiens,9606.0,A498,,80021
5933,,3664,624.0,F,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,,Homo sapiens,9606.0,A498,,80021
5934,,15895,624.0,F,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,,Homo sapiens,9606.0,A498,,80021
5935,,11843,646.0,F,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,,Homo sapiens,9606.0,A549,,80682
5936,,11843,646.0,F,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,,Homo sapiens,9606.0,A549,,80682
5937,,17705,646.0,F,,In vitro antiproliferative activity against human A-549 NSCL cell line,,,Homo sapiens,9606.0,A549,,80682
5938,,17705,646.0,F,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,,Homo sapiens,9606.0,A549,,80682
5939,,4369,646.0,F,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,,Homo sapiens,9606.0,A549,,80682
5940,,4369,646.0,F,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,,Homo sapiens,9606.0,A549,,80682
5941,,4369,646.0,F,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,,Homo sapiens,9606.0,A549,,80682
5942,,4369,646.0,F,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,,Homo sapiens,9606.0,A549,,80682
5943,,4369,646.0,F,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,,Homo sapiens,9606.0,A549,,80682
5944,,4369,646.0,F,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,,Homo sapiens,9606.0,A549,,80682
5945,,4369,646.0,F,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,,Homo sapiens,9606.0,A549,,80682
5946,,4787,646.0,F,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,,Homo sapiens,9606.0,A549,,80682
5947,,4787,646.0,F,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,,Homo sapiens,9606.0,A549,,80682
5948,,6513,646.0,F,,Cytotoxic activity against A-549 cell line,,,Homo sapiens,9606.0,A549,,80682
5949,,6690,646.0,F,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,,Homo sapiens,9606.0,A549,,80682
5950,,6690,646.0,F,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,,Homo sapiens,9606.0,A549,,80682
5951,,12263,646.0,F,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,,Homo sapiens,9606.0,A549,,80682
5952,,1054,646.0,F,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,,Homo sapiens,9606.0,A549,,80682
5953,,1359,646.0,F,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,,Homo sapiens,9606.0,A549,,80682
5954,,3547,646.0,F,,Cytotoxic activity against human lung carcinoma (A-549) cell line,,,Homo sapiens,9606.0,A549,,80682
5955,,5771,646.0,F,,Cytotoxic activity towards A-549 cells,,,Homo sapiens,9606.0,A549,,80682
5956,,14425,646.0,F,,"In vitro percent inhibition of A549, lung carcinoma.",,,Homo sapiens,9606.0,A549,,80682
5957,,14425,646.0,F,,"In vitro percent inhibition of A549, lung carcinoma",,,Homo sapiens,9606.0,A549,,80682
5958,,14425,646.0,F,,"In vitro percent inhibition of A549, lung carcinoma.",,,Homo sapiens,9606.0,A549,,80682
5959,,14425,646.0,F,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,,Homo sapiens,9606.0,A549,,80682
5960,,5280,646.0,F,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,,Homo sapiens,9606.0,A549,,80682
5961,,15176,646.0,F,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,,Homo sapiens,9606.0,A549,,80682
5962,,15300,646.0,F,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,,Homo sapiens,9606.0,A549,,80682
5963,,17824,646.0,F,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,Homo sapiens,9606.0,A549,,80682
5964,,17824,646.0,F,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,Homo sapiens,9606.0,A549,,80682
5965,,17824,646.0,F,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,Homo sapiens,9606.0,A549,,80682
5966,,17824,646.0,F,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,Homo sapiens,9606.0,A549,,80682
5967,,17824,646.0,F,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,Homo sapiens,9606.0,A549,,80682
5968,,17824,646.0,F,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,,Homo sapiens,9606.0,A549,,80682
5969,,17528,646.0,F,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,,Homo sapiens,9606.0,A549,,80682
5970,,6870,646.0,F,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,,Homo sapiens,9606.0,A549,,80682
5971,,6870,646.0,F,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,,Homo sapiens,9606.0,A549,,80682
5972,,6870,646.0,F,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,,Homo sapiens,9606.0,A549,,80682
5973,,6870,646.0,F,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,,Homo sapiens,9606.0,A549,,80682
5974,,16726,646.0,F,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,,Homo sapiens,9606.0,A549,,80682
5975,,6170,646.0,F,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,,Homo sapiens,9606.0,A549,,80682
5976,,6583,646.0,F,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,,Homo sapiens,9606.0,A549,,80682
5977,,6583,646.0,F,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,,Homo sapiens,9606.0,A549,,80682
5978,,6583,646.0,F,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,,Homo sapiens,9606.0,A549,,80682
5979,,6583,646.0,F,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,,Homo sapiens,9606.0,A549,,80682
5980,,6583,646.0,F,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,,Homo sapiens,9606.0,A549,,80682
5981,,17321,646.0,F,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,,Homo sapiens,9606.0,A549,,80682
5982,,17528,646.0,F,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,,Homo sapiens,9606.0,A549,,80682
5983,,12888,646.0,F,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,,Homo sapiens,9606.0,A549,,80682
5984,,4312,646.0,F,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,,Homo sapiens,9606.0,A549,,80682
5985,,4312,646.0,F,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,,Homo sapiens,9606.0,A549,,80682
5986,,4312,646.0,F,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,,Homo sapiens,9606.0,A549,,80682
5987,,17737,646.0,F,,In vitro antiproliferative activity against A549 cell line,,,Mus musculus,10090.0,A549,,80682
5988,,6630,646.0,F,,Synergism with indomethacin in A549 cells,,,,,A549,,80682
5989,,6630,646.0,F,,Synergism with tolmetin in A549 cells,,,,,A549,,80682
5990,,6630,646.0,F,,Synergism with sulindac in A549 cells,,,,,A549,,80682
5991,,6630,646.0,F,,Antagonism of indomethacin in A549 cells,,,,,A549,,80682
5992,,6630,646.0,F,,Antagonism of sulindac in A549 cells,,,,,A549,,80682
5993,,6630,646.0,F,,Antagonism of tolmetin in A549 cells,,,,,A549,,80682
5994,,6630,646.0,F,,Synergism with indomethacin in A549 cells,,,,,A549,,80682
5995,,6630,646.0,F,,Synergism with sulindac in A549 cells,,,,,A549,,80682
5996,,6630,646.0,F,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,,,,A549,,80682
5997,,16907,,A,,Cmax value after 30 mg/kg po dose in Dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
5998,,5944,,A,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
5999,,5944,,A,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
6000,,5944,,A,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
6001,,5944,,A,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
6002,,2959,,A,,Cmax value after administration of 4 mg/Kg oral dose in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6003,,6241,,A,,Cmax value in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6004,,6241,,A,,Cmax value in dogs after oral administration at 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6005,,2652,,A,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,In vivo,,Canis lupus familiaris,9615.0,,,50588
6006,Plasma,1806,,A,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6007,Plasma,1806,,A,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6008,,1021,,A,,Concentration maxima after oral dosing in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6009,,1021,,A,,Concentration maxima after oral dosing in dogs; not available,In vivo,,Canis lupus familiaris,9615.0,,,50588
6010,,1021,,A,,Concentration maxima after oral dosing in dogs; not available,In vivo,,Canis lupus familiaris,9615.0,,,50588
6011,,5444,,A,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,In vivo,,Canis lupus familiaris,9615.0,,,50588
6012,,5444,,A,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,In vivo,,Canis lupus familiaris,9615.0,,,50588
6013,,5444,,A,,In vivo maximal concentration was calculated at 1 mg/kg in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6014,,5444,,A,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,In vivo,,Canis lupus familiaris,9615.0,,,50588
6015,,5444,,A,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,In vivo,,Canis lupus familiaris,9615.0,,,50588
6016,Plasma,5130,,A,,Cmax in dog plasma after oral dose (1 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
6017,Plasma,3249,,A,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6018,Plasma,5473,,A,,Maximal plasma concentration at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6019,Plasma,5474,,A,,Maximal plasma concentration at a dose of 1 mg/kg (oral),In vivo,,Canis lupus familiaris,9615.0,,,50588
6020,Plasma,4657,,A,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,In vivo,,Canis lupus familiaris,9615.0,,,50588
6021,,3031,,A,,Maximum concentration of compound in dog was evaluated.,In vivo,,Canis lupus familiaris,9615.0,,,50588
6022,,4527,,A,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
6023,,4186,,A,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,In vivo,,Canis lupus familiaris,9615.0,,,50588
6024,,5007,,A,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
6025,Plasma,3132,,A,,Maximum concentration obtained in dog plasma was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
6026,,5006,,A,,Maximum concentration was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
6027,,4727,,A,,Maximum concentration at the dose of 2 mg/kg in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6028,,1916,,A,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
6029,Plasma,1918,,A,,Maximum concentration was evaluated in dog plasma,In vivo,,Canis lupus familiaris,9615.0,,,50588
6030,,3045,,A,,Maximum concentration was evaluated after 75 min after administration in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6031,Plasma,9579,,A,,Maximum plasma concentration determined in dog after oral administration of 17b,In vivo,,Canis lupus familiaris,9615.0,,,50588
6032,Plasma,9579,,A,,Maximum plasma concentration determined in dog after oral administration of 2b,In vivo,,Canis lupus familiaris,9615.0,,,50588
6033,Plasma,933,,A,,Maximum plasma concentration in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6034,Plasma,17839,,A,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6035,Plasma,17839,,A,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6036,Plasma,17839,,A,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6037,Plasma,17839,,A,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6038,Plasma,6348,,A,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
6039,Plasma,16367,,A,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6040,Plasma,1337,,A,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,In vivo,,Canis lupus familiaris,9615.0,,,50588
6041,Plasma,1337,,A,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,In vivo,,Canis lupus familiaris,9615.0,,,50588
6042,Plasma,5199,,A,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,In vivo,,Canis lupus familiaris,9615.0,,,50588
6043,Plasma,17650,,A,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6044,Plasma,6679,,A,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
6045,Plasma,5356,,A,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,In vivo,,Canis lupus familiaris,9615.0,,,50588
6046,Plasma,5356,,A,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,In vivo,,Canis lupus familiaris,9615.0,,,50588
6047,Plasma,6227,,A,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6048,Plasma,6227,,A,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6049,Plasma,6227,,A,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6050,Plasma,6227,,A,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6051,Plasma,3598,,A,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6052,,4368,,A,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6053,,6265,,A,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6054,Stomach,7767,,A,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
6055,Urine,7767,,A,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,10090.0,,,50594
6056,Urine,7767,,A,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,In vivo,,Mus musculus,10090.0,,,50594
6057,Urine,7767,,A,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,In vivo,,Mus musculus,10090.0,,,50594
6058,,17811,,A,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,,Mus musculus,10090.0,,,50594
6059,,17811,,A,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,,Mus musculus,10090.0,,,50594
6060,,17827,,A,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,,Mus musculus,10090.0,,,50594
6061,Blood,17827,,A,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,,Mus musculus,10090.0,,,50594
6062,,17827,,A,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,,Mus musculus,10090.0,,,50594
6063,,17827,,A,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,,Mus musculus,10090.0,,,50594
6064,,17827,,A,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,,Mus musculus,10090.0,,,50594
6065,Blood,17827,,A,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,,Mus musculus,10090.0,,,50594
6066,Blood,17827,,A,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,,Mus musculus,10090.0,,,50594
6067,,17827,,A,,Compound was evaluated for washout rate in mice (Radiolabeled compound),,,Mus musculus,10090.0,,,50594
6068,,17827,,A,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,,Mus musculus,10090.0,,,50594
6069,,17827,,A,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,Mus musculus,10090.0,,,50594
6070,,17827,,A,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,Mus musculus,10090.0,,,50594
6071,,17827,,A,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,Mus musculus,10090.0,,,50594
6072,,17257,,A,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,,Mus musculus,10090.0,,,50594
6073,,17257,,A,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,,Mus musculus,10090.0,,,50594
6074,,17257,,A,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,,Mus musculus,10090.0,,,50594
6075,,17257,,A,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,,Mus musculus,10090.0,,,50594
6076,,17827,,A,,Time at maximum activity in mice (Radiolabeled compound),,,Mus musculus,10090.0,,,50594
6077,,3760,,A,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,,Mus musculus,10090.0,,,50594
6078,,3760,,A,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,,Mus musculus,10090.0,,,50594
6079,,17409,,A,,Binding towards mouse plasma protein at 10 uM,,,Mus musculus,10090.0,,,50594
6080,,17409,,A,,Binding towards mouse plasma protein at 100 uM,,,Mus musculus,10090.0,,,50594
6081,,2675,,A,,Bioavailability was evaluated in mice after intravenous administration,In vivo,,Mus musculus,10090.0,,,50594
6082,,2675,,A,,Bioavailability was evaluated in mice after oral administration,In vivo,,Mus musculus,10090.0,,,50594
6083,,3132,,A,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,In vivo,,Mus musculus,10090.0,,,50594
6084,,3132,,A,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
6085,,16597,,A,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,In vivo,,Mus musculus,10090.0,,,50594
6086,,2862,,A,,Oral bioavailability in mouse,In vivo,,Mus musculus,10090.0,,,50594
6087,,17764,,A,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,In vivo,,Mus musculus,10090.0,,,50594
6088,Brain,846,,A,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6089,Brain,846,,A,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6090,Brain,846,,A,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6091,Brain,846,,A,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6092,Brain,846,,A,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6093,Brain,846,,A,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6094,Heart,846,,A,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6095,Heart,846,,A,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6096,Heart,846,,A,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6097,Heart,846,,A,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6098,,1276,646.0,F,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,,Homo sapiens,9606.0,A549,,80682
6099,,3498,646.0,F,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,,Homo sapiens,9606.0,A549,,80682
6100,,1169,646.0,F,,Cytotoxicity against human lung carcinoma A-549 cell lines,,,Homo sapiens,9606.0,A549,,80682
6101,,4450,646.0,F,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,,Homo sapiens,9606.0,A549,,80682
6102,,358,646.0,F,,In vitro cytotoxicity against human lung carcinoma cell line A-549,,,Homo sapiens,9606.0,A549,,80682
6103,,358,646.0,F,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,,Homo sapiens,9606.0,A549,,80682
6104,,358,646.0,F,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,,Homo sapiens,9606.0,A549,,80682
6105,,358,646.0,F,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,,Homo sapiens,9606.0,A549,,80682
6106,,358,646.0,F,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,,Homo sapiens,9606.0,A549,,80682
6107,,358,646.0,F,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,,Homo sapiens,9606.0,A549,,80682
6108,,358,646.0,F,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,,Homo sapiens,9606.0,A549,,80682
6109,,15167,646.0,F,,In vitro cytotoxicity against A-549 human lung cancer cells,,,Homo sapiens,9606.0,A549,,80682
6110,,4139,646.0,F,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,,Homo sapiens,9606.0,A549,,80682
6111,,833,646.0,F,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,,Homo sapiens,9606.0,A549,,80682
6112,,15718,646.0,F,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,,Homo sapiens,9606.0,A549,,80682
6113,,12373,646.0,F,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,,Homo sapiens,9606.0,A549,,80682
6114,,637,646.0,F,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,,Homo sapiens,9606.0,A549,,80682
6115,,14867,646.0,F,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,,Homo sapiens,9606.0,A549,,80682
6116,,4461,646.0,F,,Antitumor cytotoxic activity against A-549 cell line was determined,,,Homo sapiens,9606.0,A549,,80682
6117,,5406,646.0,F,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,,Homo sapiens,9606.0,A549,,80682
6118,,4457,646.0,F,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,,Homo sapiens,9606.0,A549,,80682
6119,,1386,646.0,F,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,,Homo sapiens,9606.0,A549,,80682
6120,,3265,646.0,F,,Antitumoral activity was assayed against A-549 cell line,,,Homo sapiens,9606.0,A549,,80682
6121,,2359,646.0,F,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,,Homo sapiens,9606.0,A549,,80682
6122,,4457,646.0,F,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,,Homo sapiens,9606.0,A549,,80682
6123,,12454,646.0,F,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,,Homo sapiens,9606.0,A549,,80682
6124,,1481,646.0,F,,Compound was tested for inhibition of cell growth of A-549 cells,,,Homo sapiens,9606.0,A549,,80682
6125,,1750,646.0,F,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,,Homo sapiens,9606.0,A549,,80682
6126,,5065,646.0,F,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,,Homo sapiens,9606.0,A549,,80682
6127,,808,646.0,F,,In vitro cytotoxicity against A549-human lung carcinoma cells.,,,Homo sapiens,9606.0,A549,,80682
6128,,16364,646.0,F,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,,Homo sapiens,9606.0,A549,,80682
6129,,1847,646.0,F,,Cytotoxic activity against A-549 cell lines.,,,Homo sapiens,9606.0,A549,,80682
6130,,1747,646.0,F,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,,Homo sapiens,9606.0,A549,,80682
6131,,1003,646.0,F,,Cytotoxicity against human A549 non small cell lung cell lines,,,Homo sapiens,9606.0,A549,,80682
6132,,15313,646.0,F,,Inhibition of cell growth in (A-549) lung cell line,,,Homo sapiens,9606.0,A549,,80682
6133,,3122,646.0,F,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,,Homo sapiens,9606.0,A549,,80682
6134,,16049,646.0,F,,In vitro antitumor activity against A-549 tumor cells.,,,Homo sapiens,9606.0,A549,,80682
6135,,17134,646.0,F,,In vitro antitumor effects against human A-549 cell lines.,,,Homo sapiens,9606.0,A549,,80682
6136,,6406,646.0,F,,In vitro cytotoxic activity of compound against A-549 cell line,,,Homo sapiens,9606.0,A549,,80682
6137,,627,646.0,F,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,,Homo sapiens,9606.0,A549,,80682
6138,,12307,646.0,F,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,,Homo sapiens,9606.0,A549,,80682
6139,,17861,646.0,F,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,,Homo sapiens,9606.0,A549,,80682
6140,,6682,646.0,F,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,,Homo sapiens,9606.0,A549,,80682
6141,,6663,646.0,F,,Inhibitory concentration of compound against A-549 cell line,,,Homo sapiens,9606.0,A549,,80682
6142,,2454,646.0,F,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,,Homo sapiens,9606.0,A549,,80682
6143,,14709,646.0,F,,cytotoxic activity against leukemia (A-549) cancer cell line,,,Homo sapiens,9606.0,A549,,80682
6144,,15718,646.0,F,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,,Homo sapiens,9606.0,A549,,80682
6145,,15718,646.0,F,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,,Homo sapiens,9606.0,A549,,80682
6146,,17130,646.0,F,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,,Homo sapiens,9606.0,A549,,80682
6147,,17130,646.0,F,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,,Homo sapiens,9606.0,A549,,80682
6148,,17130,646.0,F,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,,Homo sapiens,9606.0,A549,,80682
6149,,17130,646.0,F,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,,Homo sapiens,9606.0,A549,,80682
6150,,6630,646.0,F,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,,,,A549,,80682
6151,,16726,646.0,F,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,,Homo sapiens,9606.0,A549,,80682
6152,,17846,646.0,F,,Cytotoxicity against A549 cells; No cytotoxicity,,,Homo sapiens,9606.0,A549,,80682
6153,,3415,646.0,F,,Cytotoxicity against human lung carcinoma (A549) cell lines,,,Homo sapiens,9606.0,A549,,80682
6154,,3415,646.0,F,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,,Homo sapiens,9606.0,A549,,80682
6155,,5609,646.0,F,,In vitro anticancer activity against human lung (A549) cell line,,,Homo sapiens,9606.0,A549,,80682
6156,,17206,646.0,F,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,,Homo sapiens,9606.0,A549,,80682
6157,,17206,646.0,F,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,,Homo sapiens,9606.0,A549,,80682
6158,,17206,646.0,F,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,,Homo sapiens,9606.0,A549,,80682
6159,,17206,646.0,F,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,,Homo sapiens,9606.0,A549,,80682
6160,,17206,646.0,F,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,,Homo sapiens,9606.0,A549,,80682
6161,,17206,646.0,F,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,,Homo sapiens,9606.0,A549,,80682
6162,,16295,646.0,F,,Inhibition of A549 human lung tumor cell proliferation,,,Homo sapiens,9606.0,A549,,80682
6163,,16825,646.0,F,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,,Homo sapiens,9606.0,A549,,80682
6164,,3439,646.0,F,,In vitro cytotoxicity against human tumor cell line A549,,,Homo sapiens,9606.0,A549,,80682
6165,,10870,646.0,F,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,,Homo sapiens,9606.0,A549,,80682
6166,,4845,646.0,F,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,,Homo sapiens,9606.0,A549,,80682
6167,,5822,646.0,F,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,,Homo sapiens,9606.0,A549,,80682
6168,,5822,646.0,F,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,,Homo sapiens,9606.0,A549,,80682
6169,,5822,646.0,F,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,,Homo sapiens,9606.0,A549,,80682
6170,,16381,646.0,F,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,,Homo sapiens,9606.0,A549,,80682
6171,,16381,646.0,F,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,,Homo sapiens,9606.0,A549,,80682
6172,,16381,646.0,F,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,,Homo sapiens,9606.0,A549,,80682
6173,,5609,646.0,F,,In vitro anticancer activity against human lung (A549) cell line,,,Homo sapiens,9606.0,A549,,80682
6174,,4644,646.0,F,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,,Homo sapiens,9606.0,A549,,80682
6175,,4644,646.0,F,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,,Homo sapiens,9606.0,A549,,80682
6176,,4644,646.0,F,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,,Homo sapiens,9606.0,A549,,80682
6177,,4644,646.0,F,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,,Homo sapiens,9606.0,A549,,80682
6178,,5822,646.0,F,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,,Homo sapiens,9606.0,A549,,80682
6179,,3415,646.0,F,,Percentage inhibition of human lung carcinoma (A549) cell lines,,,Homo sapiens,9606.0,A549,,80682
6180,,16726,646.0,F,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,,Homo sapiens,9606.0,A549,,80682
6181,,17206,646.0,F,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,,Homo sapiens,9606.0,A549,,80682
6182,,17206,646.0,F,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,,Homo sapiens,9606.0,A549,,80682
6183,,17206,646.0,F,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,,Homo sapiens,9606.0,A549,,80682
6184,,17206,646.0,F,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,,Homo sapiens,9606.0,A549,,80682
6185,,17206,646.0,F,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,,Homo sapiens,9606.0,A549,,80682
6186,,17206,646.0,F,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,,Homo sapiens,9606.0,A549,,80682
6187,,17206,646.0,F,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,,Homo sapiens,9606.0,A549,,80682
6188,,17206,646.0,F,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,,Homo sapiens,9606.0,A549,,80682
6189,,17206,646.0,F,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,,Homo sapiens,9606.0,A549,,80682
6190,,17206,646.0,F,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,,Homo sapiens,9606.0,A549,,80682
6191,,16726,646.0,F,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,,Homo sapiens,9606.0,A549,,80682
6192,,17206,646.0,F,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,,Homo sapiens,9606.0,A549,,80682
6193,,17206,646.0,F,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,,Homo sapiens,9606.0,A549,,80682
6194,,17206,646.0,F,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,,Homo sapiens,9606.0,A549,,80682
6195,,17206,646.0,F,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,,Homo sapiens,9606.0,A549,,80682
6196,,6084,,A,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6197,,6084,,A,,Pharmacokinetic activity (Cmax) in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6198,,4809,,A,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
6199,,5983,,A,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6200,,6251,,A,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6201,Plasma,5932,,A,,Cmax in dog plasma after 30mg/kg oral dose,In vivo,,Canis lupus familiaris,9615.0,,,50588
6202,Blood,4273,,A,,Tested for the peak blood level in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6203,,5313,,A,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",In vivo,,Canis lupus familiaris,9615.0,,,50588
6204,,5313,,A,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",In vivo,,Canis lupus familiaris,9615.0,,,50588
6205,Blood,6221,,A,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
6206,,4709,,A,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,,Canis lupus familiaris,9615.0,,,50588
6207,,167,,A,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,,Canis lupus familiaris,9615.0,,,50588
6208,Plasma,6241,,A,,Final plasma concentration in dogs after oral administration at 1 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
6209,,344,,A,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,,Canis lupus familiaris,9615.0,,,50588
6210,,344,,A,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,,Canis lupus familiaris,9615.0,,,50588
6211,,344,,A,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,,Canis lupus familiaris,9615.0,,,50588
6212,,2189,,A,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,,Canis lupus familiaris,9615.0,,,50588
6213,Urine,2189,,A,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,,Canis lupus familiaris,9615.0,,,50588
6214,Urine,2189,,A,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,,Canis lupus familiaris,9615.0,,,50588
6215,Urine,2189,,A,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,,Canis lupus familiaris,9615.0,,,50588
6216,,4257,,A,,Absolute bioavailability was evaluated in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6217,,6221,,A,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
6218,,6215,,A,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6219,,17267,,A,,Bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6220,,6621,,A,,Bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6221,,3854,,A,,Bioavailability after intravenous administration in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6222,,3854,,A,,Bioavailability after peroral administration in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6223,,5007,,A,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),In vivo,,Canis lupus familiaris,9615.0,,,50588
6224,,4333,,A,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,In vivo,,Canis lupus familiaris,9615.0,,,50588
6225,Plasma,4333,,A,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
6226,,5006,,A,,Bioavailability,In vivo,,Canis lupus familiaris,9615.0,,,50588
6227,,5199,,A,,Bioavailability,In vivo,,Canis lupus familiaris,9615.0,,,50588
6228,,4368,,A,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6229,,3771,,A,,Bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6230,,4953,,A,,Bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6231,,5064,,A,,Bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6232,,17657,,A,,Bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6233,,17796,,A,,Bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6234,,17853,,A,,Bioavailability in dog (p.o.) at 2.0 mpk,In vivo,,Canis lupus familiaris,9615.0,,,50588
6235,,4521,,A,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),In vivo,,Canis lupus familiaris,9615.0,,,50588
6236,,4521,,A,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
6237,,5006,,A,,Bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6238,,16365,,A,,Bioavailability was evaluated after oral administration in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6239,,1916,,A,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
6240,,1918,,A,,Bioavailability was evaluated in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6241,,4239,,A,,Bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6242,,6505,,A,,Bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6243,,5334,,A,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),In vivo,,Canis lupus familiaris,9615.0,,,50588
6244,,5334,,A,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),In vivo,,Canis lupus familiaris,9615.0,,,50588
6245,,4809,,A,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
6246,,6348,,A,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
6247,,6005,,A,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6248,,17804,,A,,Bioavailability of compound in dog was determined after peroral administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
6249,,3184,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6250,,1806,,A,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6251,,1806,,A,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6252,,1806,,A,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,In vivo,,Canis lupus familiaris,9615.0,,,50588
6253,,4839,,A,,Bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6254,,5017,,A,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),In vivo,,Canis lupus familiaris,9615.0,,,50588
6255,Heart,846,,A,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6256,Heart,846,,A,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6257,Kidney,846,,A,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6258,Kidney,846,,A,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6259,Kidney,846,,A,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6260,Kidney,846,,A,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6261,Kidney,846,,A,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6262,Kidney,846,,A,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6263,Liver,846,,A,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6264,Liver,846,,A,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6265,Liver,846,,A,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6266,Liver,846,,A,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6267,Liver,846,,A,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6268,Liver,846,,A,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6269,Lung,846,,A,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6270,Lung,846,,A,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6271,Lung,846,,A,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6272,Lung,846,,A,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6273,Lung,846,,A,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6274,Lung,846,,A,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,10090.0,,,50594
6275,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,,Mus musculus,10090.0,CCRF S-180,,50594
6276,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6277,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,,Mus musculus,10090.0,CCRF S-180,,50594
6278,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6279,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6280,Brain,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,,,Mus musculus,10090.0,CCRF S-180,,50594
6281,Brain,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6282,Brain,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,,,Mus musculus,10090.0,CCRF S-180,,50594
6283,Brain,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6284,Brain,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6285,Heart,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,,,Mus musculus,10090.0,CCRF S-180,,50594
6286,Heart,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6287,Heart,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,,,Mus musculus,10090.0,CCRF S-180,,50594
6288,Heart,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6289,Heart,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6290,Kidney,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,,,Mus musculus,10090.0,CCRF S-180,,50594
6291,Kidney,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6292,Kidney,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,,,Mus musculus,10090.0,CCRF S-180,,50594
6293,,17130,646.0,F,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,,Homo sapiens,9606.0,A549,,80682
6294,,17130,646.0,F,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,,Homo sapiens,9606.0,A549,,80682
6295,,17130,646.0,F,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,,Homo sapiens,9606.0,A549,,80682
6296,,17130,646.0,F,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,,Homo sapiens,9606.0,A549,,80682
6297,,3263,646.0,F,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,,Homo sapiens,9606.0,A549,,80682
6298,,6663,646.0,F,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,,Homo sapiens,9606.0,A549,,80682
6299,,6663,646.0,F,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,,Homo sapiens,9606.0,A549,,80682
6300,,6663,646.0,F,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,,Homo sapiens,9606.0,A549,,80682
6301,,6663,646.0,F,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,,Homo sapiens,9606.0,A549,,80682
6302,,6663,646.0,F,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,,Homo sapiens,9606.0,A549,,80682
6303,,6663,646.0,F,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,,Homo sapiens,9606.0,A549,,80682
6304,,6663,646.0,F,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,,Homo sapiens,9606.0,A549,,80682
6305,,6663,646.0,F,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,,Homo sapiens,9606.0,A549,,80682
6306,,6663,646.0,F,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,,Homo sapiens,9606.0,A549,,80682
6307,,6663,646.0,F,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,,Homo sapiens,9606.0,A549,,80682
6308,,3983,646.0,F,,The compound was evaluated for its cytotoxic potency against A-549 cell line,,,Homo sapiens,9606.0,A549,,80682
6309,,11141,646.0,F,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,,Homo sapiens,9606.0,A549,,80682
6310,,5076,646.0,F,,Cytotoxic activity of compound against A-549 tumor cell line.,,,Homo sapiens,9606.0,A549,,80682
6311,,3311,646.0,F,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,,Homo sapiens,9606.0,A549,,80682
6312,,3311,646.0,F,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,,Homo sapiens,9606.0,A549,,80682
6313,,3311,646.0,F,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,,Homo sapiens,9606.0,A549,,80682
6314,,5076,646.0,F,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,,Homo sapiens,9606.0,A549,,80682
6315,,4150,646.0,F,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,,Homo sapiens,9606.0,A549,,80682
6316,,2150,646.0,F,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,,Homo sapiens,9606.0,A549,,80682
6317,,4644,646.0,F,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,,Homo sapiens,9606.0,A549,,80682
6318,,263,646.0,F,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,,Homo sapiens,9606.0,A549,,80682
6319,,11333,646.0,F,,Cytotoxic concentration against A-549 tumor cells.,,,Homo sapiens,9606.0,A549,,80682
6320,,11333,646.0,F,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,,Homo sapiens,9606.0,A549,,80682
6321,,15895,646.0,F,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,,Homo sapiens,9606.0,A549,,80682
6322,,16677,,F,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,,Acinetobacter baumannii,470.0,,,50191
6323,,10624,,F,,Activity against Acinetobacter calcoaceticus (AC54),,,Acinetobacter calcoaceticus,471.0,,,50192
6324,,16717,,F,,In vitro antifungal activity against Aspergillus flavus CM74,,,Aspergillus flavus,5059.0,,,50274
6325,,16717,,F,,In vitro antifungal activity against Aspergillus flavus CM74,,,Aspergillus flavus,5059.0,,,50274
6326,,5513,,F,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,,Aspergillus fumigatus,746128.0,,,50416
6327,,15962,,F,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,,Aspergillus fumigatus,746128.0,,,50416
6328,,15962,,F,,Antimicrobial activity against Aspergillus fumigatus (MIC),,,Aspergillus fumigatus,746128.0,,,50416
6329,,15962,,F,,Antimicrobial activity against Aspergillus fumigatus (MIC),,,Aspergillus fumigatus,746128.0,,,50416
6330,,15962,,F,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,,Aspergillus fumigatus,746128.0,,,50416
6331,,16717,,F,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,,Aspergillus fumigatus,746128.0,,,50416
6332,,16717,,F,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,,Aspergillus fumigatus,746128.0,,,50416
6333,,8117,,F,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,,Actinomyces naeslundii,1655.0,,,50296
6334,,8117,,F,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,,Actinomyces viscosus,1656.0,,,50366
6335,,15472,,F,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,,Acanthocheilonema viteae,6277.0,,,50535
6336,,15472,,F,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,,Acanthocheilonema viteae,6277.0,,,50535
6337,,16443,,F,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,,Aggregatibacter actinomycetemcomitans,714.0,,,50169
6338,,16443,,F,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,,Aggregatibacter actinomycetemcomitans,714.0,,,50169
6339,,16443,,F,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,,Aggregatibacter actinomycetemcomitans,714.0,,,50169
6340,,17206,646.0,F,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,,Homo sapiens,9606.0,A549,,80682
6341,,17206,646.0,F,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,,Homo sapiens,9606.0,A549,,80682
6342,,16381,646.0,F,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,,Homo sapiens,9606.0,A549,,80682
6343,,16381,646.0,F,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,,Homo sapiens,9606.0,A549,,80682
6344,,16381,646.0,F,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,,Homo sapiens,9606.0,A549,,80682
6345,,16381,646.0,F,,GI values against A549 cells (lung cancer),,,Homo sapiens,9606.0,A549,,80682
6346,,17206,646.0,F,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,,Homo sapiens,9606.0,A549,,80682
6347,,16325,646.0,F,,Inhibitory activity against A549 human adenocarcinoma,,,Homo sapiens,9606.0,A549,,80682
6348,,10708,646.0,F,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,,Homo sapiens,9606.0,A549,,80682
6349,,10708,646.0,F,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,,Homo sapiens,9606.0,A549,,80682
6350,,17376,646.0,F,,Inhibitory activity against A549 lung adenocarcinoma cell line,,,Homo sapiens,9606.0,A549,,80682
6351,,17376,646.0,F,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,,Homo sapiens,9606.0,A549,,80682
6352,,17488,646.0,F,,Cytotoxicity against human A549 lung cells,,,Homo sapiens,9606.0,A549,,80682
6353,,17404,646.0,F,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,,Homo sapiens,9606.0,A549,,80682
6354,,10958,646.0,F,,Growth inhibition of A549 (human lung carcinoma) cell line.,,,Homo sapiens,9606.0,A549,,80682
6355,,17099,646.0,F,,Effective dose required for inhibitory activity against A549 human tumor cell line.,,,Homo sapiens,9606.0,A549,,80682
6356,,17099,646.0,F,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,,Homo sapiens,9606.0,A549,,80682
6357,,4096,646.0,F,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,,Homo sapiens,9606.0,A549,,80682
6358,,4096,646.0,F,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,,Homo sapiens,9606.0,A549,,80682
6359,,4096,646.0,F,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,,Homo sapiens,9606.0,A549,,80682
6360,,2525,646.0,F,,In vitro inhibitory activity against A549 tumor cell culture,,,Homo sapiens,9606.0,A549,,80682
6361,,2525,646.0,F,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,,Homo sapiens,9606.0,A549,,80682
6362,,5302,646.0,F,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,,Homo sapiens,9606.0,A549,,80682
6363,,16325,646.0,F,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,,Homo sapiens,9606.0,A549,,80682
6364,,16939,646.0,F,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,,Homo sapiens,9606.0,A549,,80682
6365,,17229,646.0,F,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,,Homo sapiens,9606.0,A549,,80682
6366,,17380,646.0,F,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,,Homo sapiens,9606.0,A549,,80682
6367,,17380,646.0,F,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,,Homo sapiens,9606.0,A549,,80682
6368,,1903,646.0,F,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,,Homo sapiens,9606.0,A549,,80682
6369,,3838,646.0,F,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,,Homo sapiens,9606.0,A549,,80682
6370,,14696,646.0,F,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,,Homo sapiens,9606.0,A549,,80682
6371,,3838,646.0,F,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,,Homo sapiens,9606.0,A549,,80682
6372,,1522,646.0,F,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,,Homo sapiens,9606.0,A549,,80682
6373,,12400,646.0,F,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,,Homo sapiens,9606.0,A549,,80682
6374,,14696,646.0,F,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,,Homo sapiens,9606.0,A549,,80682
6375,,14769,646.0,F,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,,Homo sapiens,9606.0,A549,,80682
6376,,14696,646.0,F,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,,Homo sapiens,9606.0,A549,,80682
6377,,1888,646.0,F,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,,Homo sapiens,9606.0,A549,,80682
6378,,12016,646.0,F,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,,Homo sapiens,9606.0,A549,,80682
6379,,6058,646.0,F,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,,Homo sapiens,9606.0,A549,,80682
6380,,17708,646.0,F,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,,Homo sapiens,9606.0,A549,,80682
6381,,12301,646.0,F,,Antitumor activity against A549/ATCC cell line,,,Homo sapiens,9606.0,A549,,80682
6382,,11970,646.0,F,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,,Homo sapiens,9606.0,A549,,80682
6383,,11818,646.0,F,,In vitro cytotoxicity against A549/ATCC cell line.,,,Homo sapiens,9606.0,A549,,80682
6384,,12400,646.0,F,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,,Homo sapiens,9606.0,A549,,80682
6385,,3381,646.0,F,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,,Homo sapiens,9606.0,A549,,80682
6386,,17376,646.0,F,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,,Homo sapiens,9606.0,A549,,80682
6387,,10708,646.0,F,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,,Homo sapiens,9606.0,A549,,80682
6388,,2964,,F,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,,Homo sapiens,9606.0,,,22226
6389,,5005,,A,,Compound was tested for oral bioavailability in dogs,In vivo,,Canis lupus familiaris,9615.0,,,22224
6390,,6229,,A,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,In vivo,,Canis lupus familiaris,9615.0,,,50588
6391,,6229,,A,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,In vivo,,Canis lupus familiaris,9615.0,,,50588
6392,,5374,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6393,,5374,,A,,Compound was tested for the oral bioavailability in dog; No availability,In vivo,,Canis lupus familiaris,9615.0,,,50588
6394,,6265,,A,,Oral bioavailability in dog (dose 5 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
6395,,5654,,A,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
6396,,5654,,A,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
6397,,16456,,A,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
6398,,5302,,A,,Oral bioavailability in dog (dose 5 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
6399,,3624,,A,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),In vivo,,Canis lupus familiaris,9615.0,,,50588
6400,,16452,,A,,Oral bioavailability of active FTIs in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6401,,5802,,A,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),In vivo,,Canis lupus familiaris,9615.0,,,50588
6402,,3598,,A,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6403,,17839,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6404,,6762,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6405,,6821,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6406,,6821,,A,,Oral bioavailability of compound was determined in dog; Not tested,In vivo,,Canis lupus familiaris,9615.0,,,50588
6407,,5210,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6408,,6227,,A,,Oral bioavailability (10 mg/kg) was determined in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6409,,761,,A,,Oral bioavailability,In vivo,,Canis lupus familiaris,9615.0,,,50588
6410,,761,,A,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),In vivo,,Canis lupus familiaris,9615.0,,,50588
6411,,761,,A,,Oral bioavailability administered in solution in rats,In vivo,,Canis lupus familiaris,9615.0,,,50588
6412,,16907,,A,,Oral bioavailability after 30 mg/kg po dose in Dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6413,,5474,,A,,Oral bioavailability at a dose of 1 mg/kg in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6414,,6535,,A,,Oral bioavailability in dog (dose 1 mg/kg p.o.),In vivo,,Canis lupus familiaris,9615.0,,,50588
6415,,6535,,A,,Oral bioavailability in Dog; ND = not determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
6416,,3352,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6417,,6168,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6418,,5988,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6419,,4942,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6420,,4942,,A,,Oral bioavailability in dogs; No data,In vivo,,Canis lupus familiaris,9615.0,,,50588
6421,,14541,,A,,Oral bioavailability measured in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6422,,4449,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6423,,6057,,A,,Oral bioavailability was calculated in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6424,,5600,,A,,Oral bioavailability after 0.3 mg/kg po administration in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6425,,5542,,A,,Oral bioavailability in dog (i.v. dosing),In vivo,,Canis lupus familiaris,9615.0,,,50588
6426,,5542,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6427,,5546,,A,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
6428,,4514,,A,,Oral bioavailability in Beagle dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6429,,3624,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6430,,3854,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6431,,5836,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6432,,5940,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6433,,6168,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6434,,6227,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6435,,6251,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6436,,6448,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6437,,6647,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6438,,5940,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6439,,933,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6440,,5210,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6441,,6642,,A,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),In vivo,,Canis lupus familiaris,9615.0,,,50588
6442,,6641,,A,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),In vivo,,Canis lupus familiaris,9615.0,,,50588
6443,,6642,,A,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),In vivo,,Canis lupus familiaris,9615.0,,,50588
6444,,5472,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6445,,5985,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6446,,15660,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6447,,5530,,A,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),In vivo,,Canis lupus familiaris,9615.0,,,50588
6448,,5530,,A,,Oral bioavailability in dog (dose 1 mg/kg i.v.),In vivo,,Canis lupus familiaris,9615.0,,,50588
6449,,6305,,A,,Oral bioavailability (F) in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6450,,5210,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6451,,5238,,A,,Bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6452,,5668,,A,,Oral bioavailability in dog (dose 10 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
6453,,5668,,A,,Oral bioavailability after peroral administration at 5 mpk in Dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6454,,5668,,A,,Oral bioavailability in dog (dose 5 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
6455,,6084,,A,,Oral bioavailability in dog (dose 10 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
6456,Kidney,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6457,Kidney,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6458,Liver,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,,,Mus musculus,10090.0,CCRF S-180,,50594
6459,Liver,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6460,Liver,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,,,Mus musculus,10090.0,CCRF S-180,,50594
6461,Liver,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6462,Liver,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6463,Lung,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,,,Mus musculus,10090.0,CCRF S-180,,50594
6464,Lung,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6465,Lung,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,,,Mus musculus,10090.0,CCRF S-180,,50594
6466,Lung,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6467,Lung,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6468,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,,Mus musculus,10090.0,CCRF S-180,,50594
6469,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6470,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,,Mus musculus,10090.0,CCRF S-180,,50594
6471,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6472,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6473,Spleen,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,,,Mus musculus,10090.0,CCRF S-180,,50594
6474,Spleen,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6475,Spleen,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,,,Mus musculus,10090.0,CCRF S-180,,50594
6476,Spleen,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6477,Spleen,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6478,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,,Mus musculus,10090.0,CCRF S-180,,50594
6479,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6480,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,,Mus musculus,10090.0,CCRF S-180,,50594
6481,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6482,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6483,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,,Mus musculus,10090.0,CCRF S-180,,50594
6484,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6485,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,,Mus musculus,10090.0,CCRF S-180,,50594
6486,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6487,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6488,Heart,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,,,Mus musculus,10090.0,CCRF S-180,,50594
6489,Heart,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6490,Heart,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,,,Mus musculus,10090.0,CCRF S-180,,50594
6491,Heart,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6492,Heart,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6493,Liver,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,,,Mus musculus,10090.0,CCRF S-180,,50594
6494,Liver,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6495,Liver,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,,,Mus musculus,10090.0,CCRF S-180,,50594
6496,Liver,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6497,Liver,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6498,Lung,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,,,Mus musculus,10090.0,CCRF S-180,,50594
6499,Lung,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6500,,12269,,F,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,aeinetobacter anitrotap,107673.0,,,50067
6501,,12269,,F,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,,50067
6502,,12269,,F,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,,50067
6503,,12269,,F,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,aeinetobacter anitrotap,107673.0,,,50067
6504,,10624,,F,,Activity against Acinetobacter calcoaceticus (AC54),,,Acinetobacter calcoaceticus,471.0,,,50192
6505,,17216,,F,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,,Anolis carolinensis,28377.0,,,50714
6506,,17216,,F,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,,Anolis carolinensis,28377.0,,,50714
6507,,9560,,F,,Chlorohexidine coefficient for Actinomyces naeslundii 631,,,Actinomyces naeslundii,1655.0,,,50296
6508,,9560,,F,,Chlorohexidine coefficient for Actinomyces naeslundii B74,,,Actinomyces naeslundii,1655.0,,,50296
6509,,9560,,F,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,,Actinomyces naeslundii,1655.0,,,50296
6510,,9560,,F,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,,Actinomyces naeslundii,1655.0,,,50296
6511,,9560,,F,,Plaque bactericidal index against Actinomyces naeslundii 631,,,Actinomyces naeslundii,1655.0,,,50296
6512,,9560,,F,,Plaque bactericidal index against Actinomyces naeslundii N/9,,,Actinomyces naeslundii,1655.0,,,50296
6513,,9560,,F,,Plaque bactericidal index against Actinomyces naeslundii B74,,,Actinomyces naeslundii,1655.0,,,50296
6514,,9560,,F,,Plaque bactericidal index against Actinomyces naeslundii N/3,,,Actinomyces naeslundii,1655.0,,,50296
6515,,114,,F,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,,Artemia salina,85549.0,,,50056
6516,,114,,F,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,,Artemia salina,85549.0,,,50056
6517,,10841,,F,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,,Ascaris suum,6253.0,,,50532
6518,,10841,,F,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,,Ascaris suum,6253.0,,,50532
6519,,10841,,F,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,,Ascaris suum,6253.0,,,50532
6520,,10841,,F,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,,Ascaris suum,6253.0,,,50532
6521,,10841,,F,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,,Ascaris suum,6253.0,,,50532
6522,,10841,,F,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,,Ascaris suum,6253.0,,,50532
6523,,10841,,F,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,,Ascaris suum,6253.0,,,50532
6524,,10841,,F,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,,Ascaris suum,6253.0,,,50532
6525,,10841,,F,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,,Ascaris suum,6253.0,,,50532
6526,,10841,,F,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,,Ascaris suum,6253.0,,,50532
6527,,10841,,F,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,,Ascaris suum,6253.0,,,50532
6528,,10841,,F,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,,Ascaris suum,6253.0,,,50532
6529,,8117,,F,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,,Actinomyces viscosus,1656.0,,,50366
6530,,8117,,F,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,,Actinomyces viscosus,1656.0,,,50366
6531,,9560,,F,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,,Actinomyces viscosus,1656.0,,,50366
6532,,9560,,F,,Chlorohexidine coefficient for Actinomyces viscosus M-100,,,Actinomyces viscosus,1656.0,,,50366
6533,,9560,,F,,Chlorohexidine coefficient for Actinomyces viscosus M-626,,,Actinomyces viscosus,1656.0,,,50366
6534,,9560,,F,,Chlorohexidine coefficient for Actinomyces viscosus T14V,,,Actinomyces viscosus,1656.0,,,50366
6535,,9560,,F,,Plaque bactericidal index against Actinomyces viscosus 8A06,,,Actinomyces viscosus,1656.0,,,50366
6536,,9560,,F,,Plaque bactericidal index against Actinomyces viscosus M-100,,,Actinomyces viscosus,1656.0,,,50366
6537,,9560,,F,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,,Actinomyces viscosus,1656.0,,,50366
6538,,9560,,F,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,,Actinomyces viscosus,1656.0,,,50366
6539,,9560,,F,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,,Actinomyces viscosus,1656.0,,,50366
6540,,9560,,F,,Plaque bactericidal index against Actinomyces viscosus 626,,,Actinomyces viscosus,1656.0,,,50366
6541,,9560,,F,,Plaque bactericidal index against Actinomyces viscosus T14V,,,Actinomyces viscosus,1656.0,,,50366
6542,,10986,,F,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,,Acanthocheilonema viteae,6277.0,,,50535
6543,,10986,,F,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,,Acanthocheilonema viteae,6277.0,,,50535
6544,,10986,,F,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,,Acanthocheilonema viteae,6277.0,,,50535
6545,,10986,,F,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,,Acanthocheilonema viteae,6277.0,,,50535
6546,,10986,,F,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,,Acanthocheilonema viteae,6277.0,,,50535
6547,,10708,165.0,F,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,,Homo sapiens,9606.0,A673,,80023
6548,,10708,645.0,F,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,,Homo sapiens,9606.0,A704,,80661
6549,,416,,F,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,,Rattus norvegicus,10116.0,,,22226
6550,,14354,625.0,F,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,,Mus musculus,10090.0,A9,,80024
6551,,14354,625.0,F,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,,Mus musculus,10090.0,A9,,80024
6552,,5116,625.0,F,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,,Homo sapiens,9606.0,A9,,80024
6553,,5116,625.0,F,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,,Homo sapiens,9606.0,A9,,80024
6554,,15694,874.0,F,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,,Homo sapiens,9606.0,Human ovarian carcinoma cell line,,81037
6555,,13038,625.0,F,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,,Mus musculus,10090.0,A9,,80024
6556,,13038,625.0,F,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,,Mus musculus,10090.0,A9,,80024
6557,,10923,625.0,F,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,,Mus musculus,10090.0,A9,,80024
6558,,10923,625.0,F,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,,Mus musculus,10090.0,A9,,80024
6559,,10923,625.0,F,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,,Mus musculus,10090.0,A9,,80024
6560,,10923,,F,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,,,,,,10649
6561,,10923,625.0,F,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,,Mus musculus,10090.0,A9,,80024
6562,,10923,625.0,F,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,,Mus musculus,10090.0,A9,,80024
6563,,8158,975.0,F,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,,Cricetulus griseus,10029.0,AA6,,80663
6564,,15494,,F,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,,Homo sapiens,9606.0,,,22226
6565,,15494,,F,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,,Homo sapiens,9606.0,,,22226
6566,,12348,974.0,F,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,,Homo sapiens,9606.0,AA5,,80662
6567,,12348,974.0,F,,Cytotoxicity was measured against AA5/HIV-1(IIIB),,,Homo sapiens,9606.0,AA5,,80662
6568,,2726,974.0,F,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,,Homo sapiens,9606.0,AA5,,80662
6569,,2726,379.0,F,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,,Homo sapiens,9606.0,U-937,,80566
6570,,10747,274.0,F,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,,Cricetulus griseus,10029.0,UV4,,80578
6571,,11005,185.0,F,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6572,,12687,185.0,F,,Average intracellular compound concentration when the hypoxic SER=1.6,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6573,,12687,185.0,F,,Average intracellular compound concentration when the hypoxic SER=1.6.,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6574,,12687,185.0,F,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6575,,12687,185.0,F,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6576,,12687,185.0,F,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6577,,13436,185.0,F,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6578,,13435,185.0,F,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6579,,13302,185.0,F,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6580,,12687,185.0,F,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6581,,12687,185.0,A,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6582,,12687,185.0,A,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6583,,12878,185.0,A,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6584,,12878,185.0,A,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6585,,14367,185.0,F,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6586,,14367,185.0,F,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6587,,12398,185.0,F,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,,hampster,36483.0,CHO-AA8,,80089
6588,,12878,185.0,F,,Aerobic growth inhibition in Chinese hamster cell line AA8,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6589,,13820,185.0,F,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6590,,13436,185.0,F,,Inhibition of growth under aerobic conditions in AA8 cells,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6591,,6084,,A,,Oral bioavailability in dog (dose 10 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
6592,,5711,,A,,Oral bioavailability in dog at 10 mg/kg of the compound,In vivo,,Canis lupus familiaris,9615.0,,,50588
6593,,4353,,A,,Oral bioavailability in dog (dose 5 uM/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
6594,,4353,,A,,Oral bioavailability in dog (dose 5 uM/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
6595,,17800,,A,,Oral bioavailability in dog (mongrel),In vivo,,Canis lupus familiaris,9615.0,,,50588
6596,,3994,,A,,Oral bioavailability in dog (dose 10 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
6597,,3994,,F,,Oral bioavailability in dog (dose 10 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
6598,,5145,,A,,Bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6599,,16452,,A,,Bioavailability in dog (dose 1 mg/kg i.v.),In vivo,,Canis lupus familiaris,9615.0,,,50588
6600,,16452,,A,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),In vivo,,Canis lupus familiaris,9615.0,,,50588
6601,,5983,,A,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6602,,4273,,A,,Bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6603,,12500,,A,,Bioavailability in dog (dose 3-10 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
6604,Plasma,12500,,A,,The compound was tested for bioavailability of compound in plasma of dog; Complete,In vivo,,Canis lupus familiaris,9615.0,,,50588
6605,,3639,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6606,,3880,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6607,,4838,,A,,Bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6608,,15600,,A,,oral bioavailability was measured in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6609,,17248,,A,,Compound was tested for plasma protein binding in dog; Not determined,,,Canis lupus familiaris,9615.0,,,50588
6610,,17248,,A,,Compound was tested for plasma protein binding of dog,,,Canis lupus familiaris,9615.0,,,50588
6611,,17248,,A,,Compound was tested for plasma protein binding of dog; Not determined,,,Canis lupus familiaris,9615.0,,,50588
6612,,17443,,A,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,,Canis lupus familiaris,9615.0,,,50588
6613,,4186,,A,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,In vivo,,Canis lupus familiaris,9615.0,,,50588
6614,,3749,,A,,Half life was determined,,,Canis lupus familiaris,9615.0,,,50588
6615,,3249,,A,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6616,,3022,,A,,Half life was evaluated in dog,,,Canis lupus familiaris,9615.0,,,50588
6617,,3749,,A,,Half life was determined,,,Canis lupus familiaris,9615.0,,,50588
6618,,2517,,A,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,,Canis lupus familiaris,9615.0,,,50588
6619,Heart,2517,,A,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,,Canis lupus familiaris,9615.0,,,50588
6620,Kidney,2517,,A,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,,Canis lupus familiaris,9615.0,,,50588
6621,Liver,2517,,A,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,,Canis lupus familiaris,9615.0,,,50588
6622,Lung,2517,,A,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,,Canis lupus familiaris,9615.0,,,50588
6623,Spleen,2517,,A,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,,Canis lupus familiaris,9615.0,,,50588
6624,,3639,,A,,LogP in dog,,,Canis lupus familiaris,9615.0,,,50588
6625,,6227,,A,,Partition coefficient (logP),,,Canis lupus familiaris,9615.0,,,50588
6626,,6227,,A,,Partition coefficient in dog,,,Canis lupus familiaris,9615.0,,,50588
6627,,17764,,A,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6628,,4809,,A,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
6629,,5600,,A,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,,Canis lupus familiaris,9615.0,,,50588
6630,,14294,,A,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,,Canis lupus familiaris,9615.0,,,50588
6631,,14294,,A,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,,Canis lupus familiaris,9615.0,,,50588
6632,,14294,,A,,Metabolism of compound in dog S9 microsomes; Trace,,,Canis lupus familiaris,9615.0,,,50588
6633,Liver,6251,,A,,In vitro metabolic potential in dog liver microsomes,,,Canis lupus familiaris,9615.0,,,50588
6634,,3748,,A,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6635,,2713,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6636,,6512,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6637,,6679,,A,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
6638,,3749,,A,,The compound was tested for bioavailability in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6639,,3749,,A,,The compound was tested for oral bioavailability in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6640,,6742,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6641,,6227,,A,,Compound was tested for percent protein binding (PB) in dog,,,Canis lupus familiaris,9615.0,,,50588
6642,,6874,,A,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,,Canis lupus familiaris,9615.0,,,50588
6643,Plasma,2877,,A,,Compound was evaluated for plasma clearance.,In vivo,,Canis lupus familiaris,9615.0,,,50588
6644,Plasma,12500,,A,,The compound was tested for plasma clearance in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6645,Plasma,12500,,A,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6646,,4709,,A,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,,Canis lupus familiaris,9615.0,,,50588
6647,Liver,5542,,A,,In vitro relative rate of metabolism was determined in dog liver microsomes,,,Canis lupus familiaris,9615.0,,,50588
6648,,17594,,A,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6649,,2652,,A,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,In vivo,,Canis lupus familiaris,9615.0,,,50588
6650,,17764,,A,,Half life after intravenous administration in dogs at 1.2 uM/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6651,Lung,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,,,Mus musculus,10090.0,CCRF S-180,,50594
6652,Lung,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6653,Lung,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6654,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,,Mus musculus,10090.0,CCRF S-180,,50594
6655,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6656,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,,Mus musculus,10090.0,CCRF S-180,,50594
6657,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6658,,6599,42.0,A,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,,Mus musculus,10090.0,CCRF S-180,,50594
6659,Brain,17641,,A,,C2 in brain of mice at the oral dose of 50 mg/kg,,,Mus musculus,10090.0,,,50594
6660,Kidney,17641,,A,,C2 in kidney of mice at the oral dose of 50 mg/kg,,,Mus musculus,10090.0,,,50594
6661,Liver,17641,,A,,C2 in liver of mice at the oral dose of 50 mg/kg,,,Mus musculus,10090.0,,,50594
6662,Lung,17641,,A,,C2 in lungs of mice at the oral dose of 50 mg/kg,,,Mus musculus,10090.0,,,50594
6663,Spleen,17641,,A,,C2 in spleen of mice at the oral dose of 50 mg/kg,,,Mus musculus,10090.0,,,50594
6664,,17852,,A,,Plasma clearance in mouse,In vivo,,Mus musculus,10090.0,,,50594
6665,,17764,,A,,Clearance of compound after intravenous administration in mice at 24 uM/kg,In vivo,,Mus musculus,10090.0,,,50594
6666,,17837,,A,,Clearance from mouse blood following i.v. administration of 10 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
6667,,2675,,A,,Clearance was evaluated in mice after intravenous administration,In vivo,,Mus musculus,10090.0,,,50594
6668,,2675,,A,,Clearance was evaluated in mice after oral administration,In vivo,,Mus musculus,10090.0,,,50594
6669,,4239,,A,,Pharmacokinetic property (Plasma clearance) was measured in mouse,In vivo,,Mus musculus,10090.0,,,50594
6670,,17753,,A,,Plasma clearance of compound was determined at 40 mg/Kg,In vivo,,Mus musculus,10090.0,,,50594
6671,,17753,,A,,Plasma clearance of at 24 mg/Kg,In vivo,,Mus musculus,10090.0,,,50594
6672,,17753,,A,,Plasma clearance at 24 mg/Kg,In vivo,,Mus musculus,10090.0,,,50594
6673,,17753,,A,,Plasma clearance at 5 mg/Kg,In vivo,,Mus musculus,10090.0,,,50594
6674,,5727,,A,,Plasma clearance in mice,In vivo,,Mus musculus,10090.0,,,50594
6675,,2862,,A,,Plasma clearance value upon iv administration in mouse,In vivo,,Mus musculus,10090.0,,,50594
6676,Plasma,5980,,A,,Total plasma clearance in mice,In vivo,,Mus musculus,10090.0,,,50594
6677,,17592,,A,,Clearance in mouse,In vivo,,Mus musculus,10090.0,,,50594
6678,,17718,,A,,Clearance value was determined,In vivo,,Mus musculus,10090.0,,,50594
6679,,16597,,A,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,In vivo,,Mus musculus,10090.0,,,50594
6680,,17384,,P,,Calculated partition coefficient (clogP),,,,,,,22229
6681,,6062,,A,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
6682,,17734,,A,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,In vivo,,Mus musculus,10090.0,,,50594
6683,,6348,,A,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,,Mus musculus,10090.0,,,50594
6684,,5969,,A,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
6685,,5969,,A,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
6686,,5969,,A,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,In vivo,,Mus musculus,10090.0,,,50594
6687,,16597,,A,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,In vivo,,Mus musculus,10090.0,,,50594
6688,,5781,,A,,Cmax after oral administration at 30 mg/kg in ICR mouse,In vivo,,Mus musculus,10090.0,,,50594
6689,,17764,,A,,Cmax after peroral administration in mice at 2.4 uM/kg,In vivo,,Mus musculus,10090.0,,,50594
6690,Brain,17641,,A,,Cmax in brain of mice at the oral dose of 50 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
6691,Kidney,17641,,A,,Cmax in kidney of mice at the oral dose of 50 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
6692,Liver,17641,,A,,Cmax in liver of mice at the oral dose of 50 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
6693,Lung,17641,,A,,Cmax in lungs of mice at the oral dose of 50 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
6694,,17764,,F,,Cmax in mice at 18 uM/kg i.p. administration,In vivo,,Mus musculus,10090.0,,,50594
6695,,17764,,F,,Cmax in mice at 23 uM/kg i.v. administration,In vivo,,Mus musculus,10090.0,,,50594
6696,,17764,,F,,Cmax in mice at 24 uM/kg i.p. administration,In vivo,,Mus musculus,10090.0,,,50594
6697,,17764,,F,,Cmax in mice at 25 uM/kg i.p. administration,In vivo,,Mus musculus,10090.0,,,50594
6698,,17764,,F,,Cmax in mice at 26 uM/kg i.p. administration,In vivo,,Mus musculus,10090.0,,,50594
6699,Spleen,17641,,A,,Cmax in spleen of mice at the oral dose of 50 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
6700,,16597,,A,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,,Mus musculus,10090.0,,,50594
6701,,16597,,A,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,In vivo,,Mus musculus,10090.0,,,50594
6702,,5727,,A,,Cmax value was determined,In vivo,,Mus musculus,10090.0,,,50594
6703,,5951,,A,,Cmax value in IRC mice,In vivo,,Mus musculus,10090.0,,,50594
6704,,5506,,A,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,In vivo,,Mus musculus,10090.0,,,50594
6705,,5506,,A,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,In vivo,,Mus musculus,10090.0,,,50594
6706,Plasma,14239,,A,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,In vivo,,Mus musculus,10090.0,,,50594
6707,Plasma,4890,,A,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",In vivo,,Mus musculus,10090.0,,,50594
6708,,429,,A,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
6709,,10986,,F,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,,Acanthocheilonema viteae,6277.0,,,50535
6710,,10986,,F,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,,Acanthocheilonema viteae,6277.0,,,50535
6711,,10986,,F,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,,Acanthocheilonema viteae,6277.0,,,50535
6712,,13227,455.0,F,,Inhibitory activity against human tumor cell line A0375 melanoma.,,,Homo sapiens,9606.0,A-375,,80018
6713,,4481,,B,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,,Rattus norvegicus,10116.0,,Brain membranes,12512
6714,,16931,,F,,Forskolin-induced cAMP production at human A1 adenosine receptor,,,Homo sapiens,9606.0,,,114
6715,,3850,449.0,F,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,,,,CHO,,114
6716,,3850,449.0,F,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,,,,CHO,,114
6717,,3850,449.0,F,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,,,,CHO,,114
6718,,3850,449.0,F,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,,,,CHO,,114
6719,,3850,449.0,F,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,,,,CHO,,114
6720,,3850,449.0,F,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,,,,CHO,,114
6721,,3850,449.0,F,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,,,,CHO,,114
6722,,3850,449.0,F,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,,Homo sapiens,9606.0,CHO,,114
6723,,3850,449.0,F,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,,,,CHO,,114
6724,,3850,449.0,F,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,,,,CHO,,114
6725,,3850,449.0,F,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,,,,CHO,,114
6726,,3850,449.0,F,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,,,,CHO,,114
6727,,3850,449.0,F,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,,,,CHO,,114
6728,,3850,449.0,F,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,,,,CHO,,114
6729,,3850,449.0,F,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,,,,CHO,,114
6730,,3850,449.0,F,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,,,,CHO,,114
6731,,3850,449.0,F,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,,,,CHO,,114
6732,,3850,449.0,F,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,,,,CHO,,114
6733,,3850,449.0,F,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,,,,CHO,,114
6734,,3850,449.0,F,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,,,,CHO,,114
6735,,12680,164.0,F,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,,Oryctolagus cuniculus,9986.0,A10,,80013
6736,,1313,164.0,F,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,,Rattus norvegicus,10116.0,A10,,22226
6737,,1313,164.0,F,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,,Rattus norvegicus,10116.0,A10,,22226
6738,,17567,164.0,F,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,,Rattus norvegicus,10116.0,A10,,80013
6739,,17567,164.0,F,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,,Rattus norvegicus,10116.0,A10,,80013
6740,,11819,164.0,F,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,,Rattus norvegicus,10116.0,A10,,80013
6741,,13436,185.0,F,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6742,,12687,185.0,F,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6743,,12651,185.0,F,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6744,,13300,185.0,F,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6745,,15296,185.0,F,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6746,,15328,185.0,F,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6747,,13302,185.0,F,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6748,,14367,185.0,F,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6749,,17002,185.0,F,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6750,,13436,185.0,F,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6751,,13435,185.0,F,,Inhibitory activity against aerobic growth of AA8 cells.,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6752,,10503,185.0,A,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6753,,10503,185.0,F,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6754,,10503,185.0,F,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6755,,15090,185.0,F,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6756,,10368,185.0,F,,Cytotoxicity against AA8 cell line,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6757,,12651,185.0,F,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6758,,12687,185.0,A,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6759,,12687,185.0,F,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6760,,12687,185.0,A,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6761,,1890,185.0,F,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6762,,10747,185.0,F,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6763,,10747,185.0,F,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6764,,11616,,F,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,,Cricetulus griseus,10029.0,,,22224
6765,,11616,185.0,F,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6766,,3471,185.0,F,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6767,,3471,185.0,F,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6768,,3471,185.0,F,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6769,,3471,185.0,F,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6770,,3471,185.0,F,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6771,,3471,185.0,F,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6772,,3471,185.0,F,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6773,,11616,185.0,F,,Concentration required to reduce AA8 cell survival by 10%,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6774,,2656,185.0,F,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6775,,10518,185.0,F,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6776,,10518,185.0,F,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6777,,10518,185.0,F,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6778,,10518,185.0,F,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6779,,16156,185.0,F,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6780,,2656,185.0,F,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6781,,11005,,F,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,,Cricetulus griseus,10029.0,,,22224
6782,,11942,185.0,F,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6783,,2128,185.0,F,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6784,,16907,,A,,Half life period after 15 mg/kg iv dose in Dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6785,,16907,,A,,Half life period after 30 mg/kg po dose in Dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6786,,9579,,A,,Half life was measured after oral 2b administration (tested in 6 dogs),In vivo,,Canis lupus familiaris,9615.0,,,50588
6787,,9579,,A,,Half life was measured in dog after oral 17b administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
6788,,9579,,A,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,In vivo,,Canis lupus familiaris,9615.0,,,50588
6789,,9579,,A,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,In vivo,,Canis lupus familiaris,9615.0,,,50588
6790,,16907,,A,,Tmax value after 15 mg/kg iv dose in Dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6791,,16907,,A,,Tmax value after 30 mg/kg po dose in Dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6792,,3184,,A,,Compound was evaluated for its half life when administered intravenously in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6793,Plasma,5017,,A,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
6794,,6821,,A,,Elimination Half-life of compound was determined in dog,,,Canis lupus familiaris,9615.0,,,50588
6795,,17839,,A,,Half life of compound in dog following oral administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
6796,,17267,,A,,Half life of compound was determined in dog,,,Canis lupus familiaris,9615.0,,,50588
6797,Blood,4727,,A,,Half life of compound was determined in dog blood,,,Canis lupus familiaris,9615.0,,,50588
6798,,5238,,A,,Half life after oral and iv dosing in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6799,,4942,,A,,Half life in dogs in hours,,,Canis lupus familiaris,9615.0,,,50588
6800,,6505,,A,,Half life on i.v. administration of 2 mg/kg was measured in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6801,,5130,,A,,t1/2 in dog after oral dose (1 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
6802,,1475,,A,,Half life was evaluated in dog,,,Canis lupus familiaris,9615.0,,,50588
6803,,17804,,A,,Half life period of compound was determined after intravenous administration at 2 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6804,,17804,,A,,Half life period of compound was determined after peroral administration at 2 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6805,,6084,,A,,Half life period (10 mg/kg) was determined in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6806,,6084,,A,,Half life period (10 mg/kg) was determined in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6807,,5542,,A,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6808,,5542,,A,,Half life period by po administration in dog at a dose of 0.3 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6809,,6084,,A,,Half life period in dog,,,Canis lupus familiaris,9615.0,,,50588
6810,,6241,,A,,Half life period in dogs after oral administration at 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6811,,1916,,A,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
6812,,6621,,A,,Half-life of compound was determined in dogs,,,Canis lupus familiaris,9615.0,,,50588
6813,Plasma,1696,,A,,Half-life in dog plasma,,,Canis lupus familiaris,9615.0,,,50588
6814,,17800,,A,,Half-life in mongrel dogs was determined,,,Canis lupus familiaris,9615.0,,,50588
6815,,17657,,A,,Half-life in dog upon oral administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
6816,,17657,,A,,Half-life in dog upon oral administration; Unable to calculate,In vivo,,Canis lupus familiaris,9615.0,,,50588
6817,,4239,,A,,Half-life was measured in dog,,,Canis lupus familiaris,9615.0,,,50588
6818,,5985,,A,,Half-life was measured in dog,,,Canis lupus familiaris,9615.0,,,50588
6819,,9932,,A,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,,Canis lupus familiaris,9615.0,,,50588
6820,,5199,,A,,Oral half life was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
6821,Plasma,5199,,A,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,In vivo,,Canis lupus familiaris,9615.0,,,50588
6822,Plasma,1475,,A,,Plasma half life was evaluated,,,Canis lupus familiaris,9615.0,,,50588
6823,Plasma,1475,,A,,Plasma half life was evaluated in Dog,,,Canis lupus familiaris,9615.0,,,50588
6824,Plasma,1475,,A,,Plasma half life was evaluated in dog,,,Canis lupus familiaris,9615.0,,,50588
6825,,6316,,A,,T1/2 (Half-life) was after oral administration at 5 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6826,,4883,,A,,Tested for the half life value in dog,,,Canis lupus familiaris,9615.0,,,50588
6827,,4727,,A,,Maximum time at the dose of 2 mg/kg in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6828,,1916,,A,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
6829,Blood,1337,,A,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,In vivo,,Canis lupus familiaris,9615.0,,,50588
6830,Blood,1337,,A,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,In vivo,,Canis lupus familiaris,9615.0,,,50588
6831,,6265,,A,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6832,,4809,,A,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
6833,,5983,,A,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,In vivo,,Canis lupus familiaris,9615.0,,,50588
6834,,5313,,A,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,,Canis lupus familiaris,9615.0,,,50588
6835,,5313,,A,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",In vivo,,Canis lupus familiaris,9615.0,,,50588
6836,Plasma,17650,,A,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6837,Plasma,5199,,A,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,In vivo,,Canis lupus familiaris,9615.0,,,50588
6838,Plasma,933,,A,,Time taken for maximum plasma concentration in dog,,,Canis lupus familiaris,9615.0,,,50588
6839,,16367,,A,,Time to reach Cmax after oral administration to dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6840,Plasma,6348,,A,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
6841,,6316,,A,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6842,,6215,,A,,Tmax after peroral administration (1 mg/kg) was determined in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6843,,3598,,A,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6844,,4527,,A,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
6845,,17764,,A,,Tmax after peroral administration in dogs at 2.4 uM/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6846,,5969,,A,,In vivo Cmax in mice at dose of 100 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
6847,,5969,,A,,In vivo Cmax in mice at dose of 50 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
6848,,4573,,A,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,In vivo,,Mus musculus,10090.0,,,50594
6849,Plasma,3277,,A,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),In vivo,,Mus musculus,10090.0,,,50594
6850,Plasma,17734,,A,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,In vivo,,Mus musculus,10090.0,,,50594
6851,Plasma,3132,,A,,Maximum concentration obtained in mouse plasma was determined,In vivo,,Mus musculus,10090.0,,,50594
6852,Plasma,3132,,A,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
6853,Plasma,6348,,A,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,,Mus musculus,10090.0,,,50594
6854,Plasma,17729,,A,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
6855,Plasma,17729,,A,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
6856,Plasma,17729,,A,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
6857,Plasma,17728,,A,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,In vivo,,Mus musculus,10090.0,,,50594
6858,Plasma,17728,,A,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,In vivo,,Mus musculus,10090.0,,,50594
6859,Plasma,17728,,A,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,In vivo,,Mus musculus,10090.0,,,50594
6860,,4066,,A,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,In vivo,,Mus musculus,10090.0,,,50594
6861,,6178,,A,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,In vivo,,Mus musculus,10090.0,,,50594
6862,,6178,,A,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,In vivo,,Mus musculus,10090.0,,,50594
6863,,3760,,A,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,In vivo,,Mus musculus,10090.0,,,50594
6864,,3760,,A,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,In vivo,,Mus musculus,10090.0,,,50594
6865,,3760,,A,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,In vivo,,Mus musculus,10090.0,,,50594
6866,,3760,,A,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,In vivo,,Mus musculus,10090.0,,,50594
6868,,5961,,A,,Cmax in male mice after 2 mg/kg oral dose,In vivo,,Mus musculus,10090.0,,,50594
6869,,6137,,A,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,In vivo,,Mus musculus,10090.0,,,50594
6870,,3802,,A,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,In vivo,,Mus musculus,10090.0,,,50594
6871,,3535,,A,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,,Mus musculus,10090.0,,,50594
6872,,3535,,A,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,,Mus musculus,10090.0,,,50594
6873,,3535,,A,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,,Mus musculus,10090.0,,,50594
6874,,3535,,A,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,,Mus musculus,10090.0,,,50594
6875,,3535,,A,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,,Mus musculus,10090.0,,,50594
6876,,3535,,A,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,,Mus musculus,10090.0,,,50594
6877,Plasma,2862,,A,,Maximum concentration in plasma upon oral administration in mouse,,,Mus musculus,10090.0,,,50594
6878,Plasma,2675,,A,,Maximum plasma concentration was evaluated in mice after oral administration,,,Mus musculus,10090.0,,,50594
6879,Plasma,2675,,A,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,In vivo,,Mus musculus,10090.0,,,50594
6880,,5399,,A,,Dose at which the compound induced fecal excretion in mice,,,Mus musculus,10090.0,,,50594
6893,,11819,164.0,F,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,,Rattus norvegicus,10116.0,A10,,80013
6894,,11819,164.0,F,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,,Rattus norvegicus,10116.0,A10,,80013
6895,,11819,164.0,F,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,,Rattus norvegicus,10116.0,A10,,80013
6896,,11819,164.0,F,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,,Rattus norvegicus,10116.0,A10,,80013
6897,,16361,164.0,F,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,,Rattus norvegicus,10116.0,A10,,80013
6898,,2288,393.0,F,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,,Homo sapiens,9606.0,A121,,80655
6899,,10404,393.0,F,,Anticancer activity against human ovarian carcinoma A121 cells,,,Homo sapiens,9606.0,A121,,80655
6900,,14790,393.0,F,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,,Homo sapiens,9606.0,A121,,80655
6901,,14790,393.0,F,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,,Homo sapiens,9606.0,A121,,80655
6902,,14253,393.0,F,,Growth inhibition of human ovarian carcinoma (A121) cell line,,,Homo sapiens,9606.0,A121,,80655
6903,,13617,393.0,F,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,,Homo sapiens,9606.0,A121,,80655
6904,,1003,393.0,F,,Cytotoxicity against human A121 ovarian cells,,,Homo sapiens,9606.0,A121,,80655
6905,,830,393.0,F,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,,Homo sapiens,9606.0,A121,,80655
6906,,12307,393.0,F,,In vitro cytotoxicity against human ovarian carcinoma A21,,,Homo sapiens,9606.0,A121,,80655
6907,,14254,393.0,F,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,,Homo sapiens,9606.0,A121,,80655
6908,,13370,393.0,F,,Inhibitory activity of compound against human A121 ovarian cell line.,,,Homo sapiens,9606.0,A121,,80655
6909,,14790,393.0,F,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,,Homo sapiens,9606.0,A121,,80655
6910,,3614,393.0,F,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,,Homo sapiens,9606.0,A121,,80655
6911,,2664,622.0,F,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,,Homo sapiens,9606.0,A 172,,80012
6912,,2037,622.0,F,,In vitro cytotoxicity against A172 human tumor cell lines.,,,Homo sapiens,9606.0,A 172,,80012
6913,,14539,622.0,F,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,,Homo sapiens,9606.0,A 172,,80012
6914,,2836,622.0,F,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,,Homo sapiens,9606.0,A 172,,80012
6915,,10708,622.0,F,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,,Homo sapiens,9606.0,A 172,,80012
6916,,8975,,B,,Association constant against A2 adenosine receptor,,,Canis lupus familiaris,9615.0,,,104729
6917,,7645,1085.0,F,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,,fish,,A2,,80656
6918,,11377,,B,,Ratio of Ki for adenosine A2 and A1 receptor binding,,,Rattus norvegicus,10116.0,,,104713
6919,,13528,623.0,F,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,,Homo sapiens,9606.0,A204,,80014
6920,,10160,623.0,F,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,,Homo sapiens,9606.0,A204,,80014
6921,,15144,404.0,F,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,,Homo sapiens,9606.0,A2058,,80015
6922,,13160,973.0,F,,Growth inhibition against Human squamous cell line(A 253),,,Homo sapiens,9606.0,A253 cell line,,80657
6923,,12898,973.0,F,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,,Homo sapiens,9606.0,A253 cell line,,80657
6924,,13069,973.0,F,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,,Homo sapiens,9606.0,A253 cell line,,80657
6925,,15984,973.0,F,,Growth inhibition of A253 cell lines.,,,Homo sapiens,9606.0,A253 cell line,,80657
6926,,15564,973.0,F,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,,Homo sapiens,9606.0,A253 cell line,,80657
6927,,15564,973.0,F,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,,Homo sapiens,9606.0,A253 cell line,,80657
6928,,15564,973.0,F,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,,Homo sapiens,9606.0,A253 cell line,,80657
6929,,4720,478.0,F,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,,Homo sapiens,9606.0,A2780,,81034
6930,,16112,478.0,F,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,,Homo sapiens,9606.0,A2780,,81034
6931,,16597,478.0,F,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,,Homo sapiens,9606.0,A2780,,81034
6932,,16378,478.0,F,,Cytotoxicity against human cancer cell lines A2780 (ovarian),,,Homo sapiens,9606.0,A2780,,81034
6933,,16085,478.0,F,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,,Homo sapiens,9606.0,A2780,,81034
6934,,16317,478.0,F,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,,Homo sapiens,9606.0,A2780,,81034
6935,,15748,478.0,F,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,,Homo sapiens,9606.0,A2780,,81034
6936,,16597,478.0,F,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,,Homo sapiens,9606.0,A2780,,81034
6937,,16597,478.0,F,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,,Homo sapiens,9606.0,A2780,,81034
6938,,16597,478.0,F,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,,Homo sapiens,9606.0,A2780,,81034
6939,,15608,478.0,F,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,,Homo sapiens,9606.0,A2780,,81034
6940,,15608,478.0,F,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,,Homo sapiens,9606.0,A2780,,81034
6941,,15608,478.0,F,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,,Homo sapiens,9606.0,A2780,,81034
6942,,15296,,F,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,,Cricetulus griseus,10029.0,,,22224
6943,,10251,185.0,A,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6944,,10251,185.0,F,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6945,,10251,185.0,F,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6946,,10251,185.0,F,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6947,,11858,,F,,Growth inhibition against CHO-derived cell line AA8,,,Cricetulus griseus,10029.0,,,22224
6948,,11858,185.0,F,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6949,,11616,185.0,F,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,,hampster,36483.0,CHO-AA8,,80089
6950,,11616,185.0,F,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6951,,10518,185.0,F,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6952,,11396,185.0,F,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6953,,10518,185.0,F,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,,Cricetulus griseus,10029.0,CHO-AA8,,22224
6954,,11616,185.0,F,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,,Cricetulus griseus,10029.0,CHO-AA8,,80089
6955,,14837,,F,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,,,,,,12675
6956,,14837,,F,,Number of binding sites (n) of isolated serum protein AAG,,,,,,,12675
6957,,16037,,B,,Association constant for binding to AATT duplex,,,,,,,22222
6958,,16597,416.0,F,,Inhibition of ABAE human fibroblast cell proliferation,,,Homo sapiens,9606.0,ABAE,,100090
6959,,8831,1064.0,F,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,,Mus musculus,10090.0,AC755,,80668
6960,,13419,,F,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,,Oryctolagus cuniculus,9986.0,,,102444
6961,,13419,,F,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,In vivo,,Oryctolagus cuniculus,9986.0,,,102444
6962,,15778,,B,,Inhibitory activity against angiotensin-converting enzyme (ACE).,,,,,,,69
6963,,15778,,B,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,,,,,,69
6964,,12988,978.0,F,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,,Homo sapiens,9606.0,ACH-2 cell line,,80669
6965,,12988,978.0,F,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,,Homo sapiens,9606.0,ACH-2 cell line,,80669
6966,,12988,998.0,F,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,,Human immunodeficiency virus 1,11676.0,T cell line,,22224
6967,,12988,998.0,F,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,,Human immunodeficiency virus 1,11676.0,T cell line,,22224
6968,,12988,998.0,F,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,,Human immunodeficiency virus 1,11676.0,T cell line,,22224
6969,,11843,626.0,F,,Inhibition of growth of renal cancer ACHN cell line,,,Homo sapiens,9606.0,ACHN,,80025
6970,,16939,626.0,F,,Inhibition of growth of ACHN renal cancer cell line,,,Homo sapiens,9606.0,ACHN,,80025
6971,,4782,626.0,F,,Inhibitory concentration required against ACHN renal cancer cell line,,,Homo sapiens,9606.0,ACHN,,80025
6972,,6310,626.0,F,,Concentration required to inhibit growth of human renal (ACHN) cell line,,,Homo sapiens,9606.0,ACHN,,80025
6973,,6310,626.0,F,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,,Homo sapiens,9606.0,ACHN,,80025
6974,,12858,626.0,F,,Cytotoxic activity against ACHN Renal cancer cell line,,,Homo sapiens,9606.0,ACHN,,80025
6975,,17380,626.0,F,,Cytotoxicity evaluation against ACHN renal cancer cells,,,Homo sapiens,9606.0,ACHN,,80025
6976,,5858,626.0,F,,In vitro antitumor activity against human renal ACHN cell line,,,Homo sapiens,9606.0,ACHN,,80025
6977,,3838,626.0,F,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,,Homo sapiens,9606.0,ACHN,,80025
6978,,3838,626.0,F,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,,Homo sapiens,9606.0,ACHN,,80025
6979,,5406,626.0,F,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,,Homo sapiens,9606.0,ACHN,,80025
6980,,4071,626.0,F,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,,Homo sapiens,9606.0,ACHN,,80025
6981,,4071,626.0,F,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,,Homo sapiens,9606.0,ACHN,,80025
6982,,4071,626.0,F,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,,Homo sapiens,9606.0,ACHN,,80025
6983,,15002,626.0,F,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,,Homo sapiens,9606.0,ACHN,,80025
6984,,14769,626.0,F,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,,Homo sapiens,9606.0,ACHN,,80025
6985,,13958,626.0,F,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,,Homo sapiens,9606.0,ACHN,,80025
6986,,1665,626.0,F,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,,Homo sapiens,9606.0,ACHN,,80025
6987,,15354,626.0,F,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,,Homo sapiens,9606.0,ACHN,,80025
6988,,15354,626.0,F,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,,Homo sapiens,9606.0,ACHN,,80025
6989,,13978,626.0,F,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,,Homo sapiens,9606.0,ACHN,,80025
6990,,6798,626.0,F,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,,Homo sapiens,9606.0,ACHN,,80025
6991,,2959,,A,,Tmax value after administration of 4 mg/Kg oral dose in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6992,,9932,,A,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,,Canis lupus familiaris,9615.0,,,50588
6993,,5546,,A,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,,Canis lupus familiaris,9615.0,,,50588
6994,,16907,,A,,Volume distribution after 15 mg/kg iv dose in Dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6995,,16907,,A,,Volume distribution after 30 mg/kg po dose in Dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
6996,,4257,,A,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,In vivo,,Canis lupus familiaris,9615.0,,,50588
6997,,4305,,A,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
6998,,5472,,A,,Volume of distribution was evaluated in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
6999,,6062,,A,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7000,,3598,,A,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
7001,,12500,,A,,The compound was tested for volume of distribution in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7002,,12500,,A,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7003,,6227,,A,,Vd (1 mg/kg) was determined in dog (in vivo),In vivo,,Canis lupus familiaris,9615.0,,,50588
7004,,6227,,A,,Vd in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7005,,4219,,A,,Volume distribution was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
7006,,1696,,A,,Volume of distribution in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7007,,5542,,A,,Volume of distribution by as 4 fold increase by iv administration in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
7008,,5199,,A,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,In vivo,,Canis lupus familiaris,9615.0,,,50588
7009,,6348,,A,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
7010,,4727,,A,,Volume distribution at the dose of 2 mg/kg in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7011,,16367,,A,,Steady state volume of distribution was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
7012,,2652,,A,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,In vivo,,Canis lupus familiaris,9615.0,,,50588
7013,,16452,,A,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,,Canis lupus familiaris,9615.0,,,50588
7014,,16452,,A,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,In vivo,,Canis lupus familiaris,9615.0,,,50588
7015,,16452,,A,,Bioavailability in dog (dose 1 mg/kg i.v.),In vivo,,Canis lupus familiaris,9615.0,,,50588
7016,,5334,,A,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),In vivo,,Canis lupus familiaris,9615.0,,,50588
7017,,4239,,A,,Pharmacokinetic property (vdss) was measured in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7018,,4709,,A,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7019,,5600,,A,,Vdss was determined after iv 0.1 mg/kg administration in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7020,,6057,,A,,Volume displacement was calculated in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7021,,5654,,A,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7022,,5505,,A,,Volume distribution constant was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
7023,,4527,,A,,Volume distribution at a dose of 1 uM/kg in dog was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
7024,,4521,,A,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
7025,,4521,,A,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
7026,,15660,,A,,Volume distribution (Vdss) was measured in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7027,,15660,,A,,Volume distribution (Vdss) was measured in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7028,,6679,,A,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
7029,,5145,,A,,Volume of distribution in steady state was determined in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7030,,6821,,A,,Volume of distribution of compound was determined in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7031,,4137,,A,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7032,,5334,,A,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),In vivo,,Canis lupus familiaris,9615.0,,,50588
7033,,15660,,A,,Volume of distribution (Vdss) was measured in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7034,,6642,,A,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),In vivo,,Canis lupus familiaris,9615.0,,,50588
7035,,6641,,A,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,Canis lupus familiaris,9615.0,,,50588
7036,,6642,,A,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,Canis lupus familiaris,9615.0,,,50588
7037,,11659,,A,,Maximum rate of depolarization of the upstroke of the action potential,,,Canis lupus familiaris,9615.0,,,50588
7038,,6448,,A,,Steady state volume distribution in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7039,,5474,,A,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,In vivo,,Canis lupus familiaris,9615.0,,,50588
7040,,1466,,A,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7041,,6535,,A,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
7042,,6535,,A,,Volume distribution in dog after administration of 1 mg/kg iv,In vivo,,Canis lupus familiaris,9615.0,,,50588
7043,,17764,,A,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7044,,6215,,A,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7045,,6505,,A,,Vss on i.v. administration of 2 mg/kg was measured in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7046,,3639,,A,,Vss was determined,,,Canis lupus familiaris,9615.0,,,50588
7047,,3639,,A,,Vss in dog,,,Canis lupus familiaris,9615.0,,,50588
7048,,6062,,A,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7049,,4942,,A,,Volume distribution in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
7050,,17796,,A,,Volume of distribution in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7051,,4883,,A,,Tested for the oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7060,,17837,,A,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
7061,,17729,,A,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,In vivo,,Mus musculus,10090.0,,,50594
7062,,17729,,A,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,In vivo,,Mus musculus,10090.0,,,50594
7063,,4239,,A,,Bioavailability was measured in mouse,In vivo,,Mus musculus,10090.0,,,50594
7064,,17592,,A,,Bioavailability in mouse,In vivo,,Mus musculus,10090.0,,,50594
7065,,6348,,A,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,,Mus musculus,10090.0,,,50594
7066,,2801,,A,,Bioavailability in mouse,In vivo,,Mus musculus,10090.0,,,50594
7067,,2801,,A,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
7068,,17718,,A,,Oral bioavailability in mouse,In vivo,,Mus musculus,10090.0,,,50594
7069,,5727,,A,,Oral availability at 50 mg/kg po in male mice,In vivo,,Mus musculus,10090.0,,,50594
7070,,5302,,A,,Oral bioavailability in mouse (dose 10 mg/kg),In vivo,,Mus musculus,10090.0,,,50594
7071,,3598,,A,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
7072,,5961,,A,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",In vivo,,Mus musculus,10090.0,,,50594
7074,,6091,,A,,Oral bioavailability in mouse,In vivo,,Mus musculus,10090.0,,,50594
7075,,6091,,A,,Oral bioavailability in vivo in mice;ND=Not determined,In vivo,,Mus musculus,10090.0,,,50594
7076,,5711,,A,,Oral bioavailability in mouse at 10 mg/kg of the compound,In vivo,,Mus musculus,10090.0,,,50594
7077,,17728,,A,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),In vivo,,Mus musculus,10090.0,,,50594
7078,,17728,,A,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),In vivo,,Mus musculus,10090.0,,,50594
7079,,3802,,A,,Tested for bioavailability of the compound,In vivo,,Mus musculus,10090.0,,,50594
7080,,3802,,A,,Tested for half life at the dose of 10 mg/kg when administered intravenously,In vivo,,Mus musculus,10090.0,,,50594
7081,Plasma,14029,,A,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,,Mus musculus,10090.0,,,50594
7082,Plasma,14029,,A,,The plasma half life of compound was determined on heparin prepared by human plasma. ,,,Mus musculus,10090.0,,,50594
7083,Plasma,14029,,A,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,,Mus musculus,10090.0,,,50594
7084,Plasma,14029,,A,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,,Mus musculus,10090.0,,,50594
7085,Plasma,14029,,A,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,,Mus musculus,10090.0,,,50594
7086,,17753,,F,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,,Mus musculus,10090.0,,,50594
7087,,17753,,A,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,,Mus musculus,10090.0,,,50594
7088,,17753,,A,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,,Mus musculus,10090.0,,,50594
7089,Blood,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,10090.0,,,50594
7090,Blood,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,Mus musculus,10090.0,,,50594
7091,Blood,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,10090.0,,,50594
7092,Blood,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,10090.0,,,50594
7093,Blood,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,10090.0,,,50594
7094,Blood,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,10090.0,,,50594
7095,Blood,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,10090.0,,,50594
7096,Bone,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,10090.0,,,50594
7097,Bone,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,,Mus musculus,10090.0,,,50594
7098,,15608,478.0,F,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,,Homo sapiens,9606.0,A2780,,81034
7099,,3290,478.0,F,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,,Homo sapiens,9606.0,A2780,,81034
7100,,2859,478.0,F,,Compound was evaluated for cytotoxicity against A2780 cell line,,,Homo sapiens,9606.0,A2780,,81034
7101,,15688,478.0,F,,Inhibition of A2780 cell clonogenic assay,,,Homo sapiens,9606.0,A2780,,81034
7102,,5642,478.0,F,,Cytotoxic effect on ovarian cancer cell line (A2780),,,Homo sapiens,9606.0,A2780,,81034
7103,,6633,478.0,F,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,,Homo sapiens,9606.0,A2780,,81034
7104,,3906,478.0,F,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,,Homo sapiens,9606.0,A2780,,81034
7105,,6788,478.0,F,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,,Homo sapiens,9606.0,A2780,,81034
7106,,17582,478.0,F,,Antiproliferative activity against human A2780 cells,,,Homo sapiens,9606.0,A2780,,81034
7107,,17764,478.0,F,,Inhibition of human A2780 cell proliferation,,,Homo sapiens,9606.0,A2780,,81034
7108,,17764,478.0,F,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,,Homo sapiens,9606.0,A2780,,81034
7109,,17764,478.0,F,,Inhibition of human A2780 cell proliferation (No data),,,Homo sapiens,9606.0,A2780,,81034
7110,,2815,478.0,F,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,,Homo sapiens,9606.0,A2780,,81034
7111,,16930,478.0,F,,Compound was evaluated against human Ovarian carcinoma cell line A2780,,,Homo sapiens,9606.0,A2780,,81034
7112,,17777,478.0,F,,Growth inhibition against A2780 wild-type ovarian cell lines,,,Homo sapiens,9606.0,A2780,,81034
7113,,17777,478.0,F,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,,Homo sapiens,9606.0,A2780,,81034
7114,,16936,,F,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,,Homo sapiens,9606.0,,,104766
7115,,13759,478.0,F,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,,Homo sapiens,9606.0,A2780,,81034
7116,,13759,478.0,F,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,,Homo sapiens,9606.0,A2780,,81034
7117,,13759,478.0,F,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,,Homo sapiens,9606.0,A2780,,81034
7118,,13759,478.0,F,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,,Homo sapiens,9606.0,A2780,,81034
7119,,15292,478.0,F,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,,Homo sapiens,9606.0,A2780,,81034
7120,,15292,478.0,F,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,,Homo sapiens,9606.0,A2780,,81034
7121,,15069,478.0,F,,In vitro inhibition of human ovarian cell line A2780,,,Homo sapiens,9606.0,A2780,,81034
7122,,15069,478.0,F,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,,Homo sapiens,9606.0,A2780,,81034
7123,,14073,478.0,F,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,,Homo sapiens,9606.0,A2780,,81034
7124,,14553,478.0,F,,Concentration required to inhibit A2780-cell growth by 50%,,,Homo sapiens,9606.0,A2780,,81034
7125,,13040,478.0,F,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,,Homo sapiens,9606.0,A2780,,81034
7126,,6891,478.0,F,,Cytotoxic effect on human ovarian (A2780) cancer cell line,,,Homo sapiens,9606.0,A2780,,81034
7127,,15569,478.0,F,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,,Homo sapiens,9606.0,A2780,,81034
7128,,14190,478.0,F,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,,Homo sapiens,9606.0,A2780,,81034
7129,,15014,478.0,F,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,,Homo sapiens,9606.0,A2780,,81034
7130,,15014,478.0,F,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,,Homo sapiens,9606.0,A2780,,81034
7131,,17496,478.0,F,,Cytotoxicity against human ovarian carcinoma A2780 cell line,,,Homo sapiens,9606.0,A2780,,81034
7132,,13617,478.0,F,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,,Homo sapiens,9606.0,A2780,,81034
7133,,13617,478.0,F,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,,Homo sapiens,9606.0,A2780,,81034
7134,,13617,478.0,F,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,,Homo sapiens,9606.0,A2780,,81034
7135,,13617,478.0,F,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,,Homo sapiens,9606.0,A2780,,81034
7136,,17672,478.0,F,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,,Homo sapiens,9606.0,A2780,,81034
7137,,4544,478.0,F,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,,Homo sapiens,9606.0,A2780,,81034
7138,,4544,478.0,F,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,,Homo sapiens,9606.0,A2780,,81034
7139,,16317,478.0,F,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,,Homo sapiens,9606.0,A2780,,81034
7140,,15099,478.0,F,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,,Homo sapiens,9606.0,A2780,,81034
7141,,13978,478.0,F,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,,Homo sapiens,9606.0,A2780,,81034
7142,,12989,478.0,F,,In vitro antitumor activity against A2780 cell line.,,,Homo sapiens,9606.0,A2780,,81034
7143,,5574,478.0,F,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,,Homo sapiens,9606.0,A2780,,81034
7144,,13528,478.0,F,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,,Homo sapiens,9606.0,A2780,,81034
7145,,12782,626.0,F,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,,Homo sapiens,9606.0,ACHN,,80025
7146,,14255,626.0,F,,The IC50 value was measured on ACHN cell line in renal tumor type.,,,Homo sapiens,9606.0,ACHN,,80025
7147,,16364,626.0,F,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,,Homo sapiens,9606.0,ACHN,,80025
7148,,17376,626.0,F,,In vitro lethal concentration against most sensitive ACHN cell line,,,Homo sapiens,9606.0,ACHN,,80025
7149,,12016,626.0,F,,Tested for cytotoxic activity against renal cancer ACHN cell line,,,Homo sapiens,9606.0,ACHN,,80025
7150,,6058,626.0,F,,Compound tested for growth inhibition of renal cancer cell line ACHN,,,Homo sapiens,9606.0,ACHN,,80025
7151,,17708,626.0,F,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,,Homo sapiens,9606.0,ACHN,,80025
7152,,15176,626.0,F,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,,Homo sapiens,9606.0,ACHN,,80025
7153,,2806,626.0,F,,In vitro anticancer activity against ACHN renal cancer cell line,,,Homo sapiens,9606.0,ACHN,,80025
7154,,15300,626.0,F,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,,Homo sapiens,9606.0,ACHN,,80025
7155,,16364,626.0,F,,Percent selectivity was evaluated in renal ACHN cell lines,,,Homo sapiens,9606.0,ACHN,,80025
7156,,13859,626.0,F,,In vitro inhibitory activity against renal ACHN cancer cell line,,,Homo sapiens,9606.0,ACHN,,80025
7157,,11970,626.0,F,,Tested for cytotoxicity against ACHN cell lines in renal cancer,,,Homo sapiens,9606.0,ACHN,,80025
7158,,2450,626.0,F,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,,Homo sapiens,9606.0,ACHN,,80025
7159,,12696,626.0,F,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,,Homo sapiens,9606.0,ACHN,,80025
7160,,12400,626.0,F,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,,Homo sapiens,9606.0,ACHN,,80025
7161,,12888,626.0,F,,Cytotoxic effect on renal cancer line ACHN,,,Homo sapiens,9606.0,ACHN,,80025
7162,,3156,626.0,F,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,,Homo sapiens,9606.0,ACHN,,80025
7163,,3381,626.0,F,,In vitro inhibition of Renal Cancer ACHN cell lines,,,Homo sapiens,9606.0,ACHN,,80025
7164,,16747,626.0,F,,Antitumor activity against human renal adenocarcinoma ACHN cells,,,Homo sapiens,9606.0,ACHN,,80025
7165,,16748,626.0,F,,Antitumor activity against human renal adenocarcinoma ACHN cells.,,,Homo sapiens,9606.0,ACHN,,80025
7166,,12062,626.0,F,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,,Homo sapiens,9606.0,ACHN,,80025
7167,,14769,626.0,F,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,,Homo sapiens,9606.0,ACHN,,80025
7168,,15895,626.0,F,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,,Homo sapiens,9606.0,ACHN,,80025
7169,,17376,626.0,F,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,,Homo sapiens,9606.0,ACHN,,80025
7170,,14882,626.0,F,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,,Homo sapiens,9606.0,ACHN,,80025
7171,,14882,626.0,F,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,,Homo sapiens,9606.0,ACHN,,80025
7172,,15661,626.0,F,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,,Homo sapiens,9606.0,ACHN,,80025
7173,,9680,,A,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,,,,,,22224
7174,,14579,,F,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,,,,,,10647
7175,,17290,468.0,F,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,,Cytomegalovirus,10358.0,HEL,,50529
7176,,17290,,F,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,,Cytomegalovirus,10358.0,,,50529
7177,,15891,,B,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,,,,,,12159
7178,,15890,,B,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,,,,,,12159
7179,,3801,979.0,F,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,,Bos taurus,9913.0,ADDP cell line,,80670
7180,,9222,980.0,F,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,,Mus musculus,10090.0,ADJ/PC6,,80671
7181,,9222,980.0,F,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,,Mus musculus,10090.0,ADJ/PC6,,80671
7182,,7257,980.0,F,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,,Mus musculus,10090.0,ADJ/PC6,,80671
7183,,7257,980.0,F,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,,Mus musculus,10090.0,ADJ/PC6,,80671
7184,,7257,980.0,A,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,,Mus musculus,10090.0,ADJ/PC6,,80671
7185,,8084,980.0,F,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,,Mus musculus,10090.0,ADJ/PC6,,80671
7186,,14943,,F,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,,Mus musculus,10090.0,,,22224
7187,,14943,,F,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,,Mus musculus,10090.0,,,22224
7188,,14943,,F,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,,Mus musculus,10090.0,,,22224
7189,,10524,,A,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),In vivo,,Bacillus subtilis,1423.0,,,22224
7190,Plasma,3546,,A,,AUC value in dog after IV administration at a dose of 5 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
7191,Plasma,3546,,A,,AUC value in dog after oral administration at a dose of 5 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
7192,,3546,,A,,Cmax value in dog after oral administration at a dose of 5 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7193,,3546,,A,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7194,,3546,,A,,Tmax value in dog after oral administration at a dose of 5 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7195,,3184,,A,,Compound was evaluated for its clearance when administered intravenously in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7196,,16456,,A,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7197,,4809,,A,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
7198,,4219,,P,,Calculated partition coefficient (clogP),,,,,,,22229
7199,,3748,,A,,Half life in dog,,,Canis lupus familiaris,9615.0,,,50588
7200,,3132,,A,,Time taken for EC90 was determined when tested in dog,,,Canis lupus familiaris,9615.0,,,50588
7201,,4219,,A,,Half life (iv) was determined,,,Canis lupus familiaris,9615.0,,,50588
7202,Liver,16907,,A,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,,Canis lupus familiaris,9615.0,,,50588
7203,,6057,,A,,Area under the curve was calculated in dog after iv administration,,,Canis lupus familiaris,9615.0,,,50588
7204,,6057,,A,,Area under the curve was calculated in dog after peroral administration,,,Canis lupus familiaris,9615.0,,,50588
7205,,17853,,A,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,,Canis lupus familiaris,9615.0,,,50588
7206,,3639,,A,,pKa was evaluated in dog,,,Canis lupus familiaris,9615.0,,,50588
7207,,14541,,A,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,,Canis lupus familiaris,9615.0,,,50588
7208,,16456,,A,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7209,,16456,,A,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7210,,2652,,A,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,In vivo,,Canis lupus familiaris,9615.0,,,50588
7211,,3624,,A,,Compound was evaluated for the half-life (t 1/2) in hours,,,Canis lupus familiaris,9615.0,,,50588
7212,Blood,1337,,A,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,In vivo,,Canis lupus familiaris,9615.0,,,50588
7213,Blood,1337,,A,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,In vivo,,Canis lupus familiaris,9615.0,,,50588
7214,,4709,,A,,Half life after intravenous administration of 1 mg/kg in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7215,,15660,,A,,Half life was measured in dog,,,Canis lupus familiaris,9615.0,,,50588
7216,,5302,,A,,Half life period in dog after 5 mg/kg dose,In vivo,,Canis lupus familiaris,9615.0,,,50588
7217,,17791,,A,,Half life period was evaluated in dog; 4-4.8,,,Canis lupus familiaris,9615.0,,,50588
7218,,6348,,A,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
7219,,4257,,A,,Half-life was determined in dog after a3 mg/kg of iv dose,In vivo,,Canis lupus familiaris,9615.0,,,50588
7220,,3771,,A,,Half-life was determined,,,Canis lupus familiaris,9615.0,,,50588
7221,,6305,,A,,Half life in dogs,,,Canis lupus familiaris,9615.0,,,50588
7222,Plasma,13501,,A,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7223,,17594,,A,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
7224,,3045,,A,,Compound was evaluated for the half life period after iv administration in Beagle dog.,In vivo,,Canis lupus familiaris,9615.0,,,50588
7225,,3043,,A,,Compound was evaluated for the half life period after oral administration in conscious dog.,In vivo,,Canis lupus familiaris,9615.0,,,50588
7226,,4839,,A,,Compound was tested for half life in dog,,,Canis lupus familiaris,9615.0,,,50588
7227,,4839,,A,,Compound was tested for its half life in dog,,,Canis lupus familiaris,9615.0,,,50588
7228,,5802,,A,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7229,,17839,,A,,Half life of compound in dog was determined,,,Canis lupus familiaris,9615.0,,,50588
7230,,4219,,A,,Half life (iv) was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
7231,Blood,13966,,A,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,,Canis lupus familiaris,9615.0,,,50588
7232,Plasma,3994,,A,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
7233,Plasma,3994,,F,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
7234,,4453,,A,,Half life in dog,,,Canis lupus familiaris,9615.0,,,50588
7235,Plasma,6535,,A,,Half life in dog plasma,,,Canis lupus familiaris,9615.0,,,50588
7236,Plasma,6535,,A,,Half life in dog plasma after administration of 0.25 mg/kg iv,In vivo,,Canis lupus familiaris,9615.0,,,50588
7237,Plasma,6535,,A,,Half life in dog plasma after administration of 1 mg/kg iv,In vivo,,Canis lupus familiaris,9615.0,,,50588
7238,Plasma,3132,,A,,Half life in dog plasma was determined at dose 10 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7239,,5374,,A,,Half life in dog was determined,,,Canis lupus familiaris,9615.0,,,50588
7240,,5007,,A,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
7241,Plasma,16907,,A,,Half life upon exposure to human plasma,,,Canis lupus familiaris,9615.0,,,50588
7242,,6057,,A,,Half life was calculated in dog,,,Canis lupus familiaris,9615.0,,,50588
7243,,5006,,A,,Half life was determined,,,Canis lupus familiaris,9615.0,,,50588
7244,,5473,,A,,Half life was determined,,,Canis lupus familiaris,9615.0,,,50588
7245,,4368,,A,,Half life by intravenous administration of 1.2 mg/kg in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7246,,6448,,A,,Half life in dog,,,Canis lupus familiaris,9615.0,,,50588
7247,,4353,,A,,Half life in dog after intra venous administration of the compound,,,Canis lupus familiaris,9615.0,,,50588
7248,,4353,,A,,Half life in dog after intra venous administration of the compound; ND means Not determined,,,Canis lupus familiaris,9615.0,,,50588
7249,,4353,,A,,Half life in dog after po administration of the compound,In vivo,,Canis lupus familiaris,9615.0,,,50588
7250,,4353,,A,,Half life in dog after po administration of the compound; ND means Not determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
7251,,6265,,A,,Half life in dog at the single oral dose of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7252,,5006,,A,,Half life in dogs,,,Canis lupus familiaris,9615.0,,,50588
7253,,5356,,A,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,In vivo,,Canis lupus familiaris,9615.0,,,50588
7254,,405,,A,,Half life in rat,,,Canis lupus familiaris,9615.0,,,50588
7255,,6642,,A,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),In vivo,,Canis lupus familiaris,9615.0,,,50588
7256,Bone,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,10090.0,,,50594
7257,Bone,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,10090.0,,,50594
7258,Bone,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,10090.0,,,50594
7259,Bone,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,10090.0,,,50594
7260,Bone,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,10090.0,,,50594
7261,Gut,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,10090.0,,,50594
7262,Gut,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,Mus musculus,10090.0,,,50594
7263,Gut,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,10090.0,,,50594
7264,Gut,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,10090.0,,,50594
7265,Gut,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,10090.0,,,50594
7266,Gut,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,10090.0,,,50594
7267,Gut,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,10090.0,,,50594
7268,Heart,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,10090.0,,,50594
7269,Heart,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,Mus musculus,10090.0,,,50594
7270,Heart,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,10090.0,,,50594
7271,Heart,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,10090.0,,,50594
7272,Heart,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,10090.0,,,50594
7273,Heart,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,10090.0,,,50594
7274,Heart,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,10090.0,,,50594
7275,Kidney,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,10090.0,,,50594
7276,Kidney,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,,Mus musculus,10090.0,,,50594
7277,Kidney,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,10090.0,,,50594
7278,Kidney,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,10090.0,,,50594
7279,Kidney,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,10090.0,,,50594
7280,Kidney,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,10090.0,,,50594
7281,Kidney,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,10090.0,,,50594
7282,Liver,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,10090.0,,,50594
7283,Liver,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,Mus musculus,10090.0,,,50594
7284,Liver,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,10090.0,,,50594
7285,Liver,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,10090.0,,,50594
7286,Liver,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,10090.0,,,50594
7287,Liver,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,10090.0,,,50594
7288,Liver,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,10090.0,,,50594
7289,Lung,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,10090.0,,,50594
7290,,5895,478.0,F,,In vitro cytotoxicity against A2780 (human ovarian cancer),,,Homo sapiens,9606.0,A2780,,81034
7291,,6338,478.0,F,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,,Homo sapiens,9606.0,A2780,,81034
7292,,15163,478.0,F,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,,Homo sapiens,9606.0,A2780,,81034
7293,,15163,478.0,F,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,,Homo sapiens,9606.0,A2780,,81034
7294,,15000,478.0,F,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,,Homo sapiens,9606.0,A2780,,81034
7295,,15000,478.0,F,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,,Homo sapiens,9606.0,A2780,,81034
7296,,14729,478.0,F,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,,Homo sapiens,9606.0,A2780,,81034
7297,,17270,478.0,F,,In vitro cytotoxicity against A2780 cell line,,,Homo sapiens,9606.0,A2780,,81034
7298,,5685,478.0,F,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,,Homo sapiens,9606.0,A2780,,81034
7299,,3563,478.0,F,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,,Homo sapiens,9606.0,A2780,,81034
7300,,17753,478.0,F,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,,Homo sapiens,9606.0,A2780,,81034
7301,,16317,478.0,F,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,,Homo sapiens,9606.0,A2780,,81034
7302,,16936,478.0,F,,Inhibition of tubulin polymerization in analogy of ca.,,,Homo sapiens,9606.0,A2780,,81034
7303,,3801,478.0,F,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,,Homo sapiens,9606.0,A2780,,81034
7304,,6181,478.0,F,,Cytotoxic effect in ovarian cancer cell line (A2780),,,Homo sapiens,9606.0,A2780,,81034
7305,,5318,478.0,F,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,,Homo sapiens,9606.0,A2780,,81034
7306,,4840,478.0,F,,Tested for the cytotoxicity in A2780 ovarian cell line,,,Homo sapiens,9606.0,A2780,,81034
7307,,15748,478.0,F,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,,Homo sapiens,9606.0,A2780,,81034
7308,,15748,478.0,F,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,,Homo sapiens,9606.0,A2780,,81034
7309,,15748,481.0,F,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,,,,A2780cisR,,80017
7310,,15748,481.0,F,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,,,,A2780cisR,,80017
7311,,15748,481.0,F,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,,,,A2780cisR,,80017
7312,,15748,481.0,F,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,,,,A2780cisR,,80017
7313,,17753,478.0,F,,In vivo log of cells killed after administration of compound in A2780 cell line,,,Homo sapiens,9606.0,A2780,,81034
7314,,17753,478.0,F,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,In vivo,,Homo sapiens,9606.0,A2780,,81034
7315,,16936,478.0,F,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,,Homo sapiens,9606.0,A2780,,81034
7316,,16936,478.0,F,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,,Homo sapiens,9606.0,A2780,,81034
7317,,16936,478.0,F,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,,Homo sapiens,9606.0,A2780,,81034
7318,,16936,478.0,F,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,,Homo sapiens,9606.0,A2780,,81034
7319,,17528,478.0,F,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,,Homo sapiens,9606.0,A2780,,81034
7320,,6633,478.0,F,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,,Homo sapiens,9606.0,A2780,,81034
7321,,15000,478.0,F,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,,Homo sapiens,9606.0,A2780,,81034
7322,,17528,478.0,F,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,,Homo sapiens,9606.0,A2780,,81034
7323,,16936,478.0,F,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,,Homo sapiens,9606.0,A2780,,81034
7324,,16936,478.0,F,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,,Homo sapiens,9606.0,A2780,,81034
7325,,16936,478.0,F,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,,Homo sapiens,9606.0,A2780,,81034
7326,,16936,478.0,F,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,,Homo sapiens,9606.0,A2780,,81034
7327,,16936,478.0,F,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,,Homo sapiens,9606.0,A2780,,81034
7328,,16936,478.0,F,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,,Homo sapiens,9606.0,A2780,,81034
7329,,16936,478.0,F,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,,Homo sapiens,9606.0,A2780,,81034
7330,,16936,478.0,F,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,,Homo sapiens,9606.0,A2780,,81034
7331,,16936,478.0,F,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,,Homo sapiens,9606.0,A2780,,81034
7332,,17737,478.0,F,,In vitro antiproliferative activity against A2780 cell line,,,Mus musculus,10090.0,A2780,,81034
7333,,17764,478.0,F,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,,Mus musculus,10090.0,A2780,,81034
7334,,3830,478.0,F,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,,Homo sapiens,9606.0,A2780,,81034
7335,,3829,478.0,F,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,,Homo sapiens,9606.0,A2780,,81034
7336,,3546,,A,,Vc value in dog after IV administration at a dose of 5 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
7337,,3546,,A,,Half life period in dog after IV administration at a dose of 5 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7338,,5668,,A,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,,Cercopithecidae,9527.0,,,22224
7339,Plasma,3443,,A,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Cercopithecidae,9527.0,,,22224
7340,Plasma,3443,,A,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Cercopithecidae,9527.0,,,22224
7341,,4256,,A,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,In vivo,,Macaca fascicularis,9541.0,,,22224
7342,,4256,,A,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,In vivo,,Macaca fascicularis,9541.0,,,22224
7343,,4256,,A,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,In vivo,,Macaca fascicularis,9541.0,,,22224
7344,,4256,,A,,Oral Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,22224
7345,,1916,,A,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,Cercopithecidae,9527.0,,,22224
7346,,5302,,A,,Area under curve value in monkey at a dose of 5 mg/kg,,,Cercopithecidae,9527.0,,,22224
7347,,4257,,A,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,,Cercopithecidae,9527.0,,,22224
7348,,5355,,A,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,,Cercopithecidae,9527.0,,,22224
7349,,5355,,A,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,,Cercopithecidae,9527.0,,,22224
7350,,5355,,A,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,,Cercopithecidae,9527.0,,,22224
7351,,6078,,A,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,,Cercopithecidae,9527.0,,,22224
7352,,6078,,A,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,,Cercopithecidae,9527.0,,,22224
7353,,6062,,A,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,,Cercopithecidae,9527.0,,,22224
7354,,2661,,A,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,Cercopithecidae,9527.0,,,22224
7355,,2661,,A,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,Cercopithecidae,9527.0,,,22224
7356,,5394,,A,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,,Cercopithecidae,9527.0,,,22224
7357,,4397,,A,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,,Cercopithecidae,9527.0,,,22224
7358,,17509,,A,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,,Cercopithecidae,9527.0,,,22224
7359,,17509,,A,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,,Cercopithecidae,9527.0,,,22224
7360,,6641,,A,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),In vivo,,Cercopithecidae,9527.0,,,22224
7361,,5355,,A,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,,Cercopithecidae,9527.0,,,22224
7362,,3443,,A,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,,Cercopithecidae,9527.0,,,22224
7363,,3443,,A,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,,Cercopithecidae,9527.0,,,22224
7364,,17409,,A,,Binding towards monkey plasma protein at 10 uM,,,Cercopithecidae,9527.0,,,22224
7365,,17409,,A,,Binding towards monkey plasma protein at 100 uM,,,Cercopithecidae,9527.0,,,22224
7366,,1052,,A,,Apparent bioavailability in squirrel monkey was determined,In vivo,,Cercopithecidae,9527.0,,,22224
7367,,13501,,A,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,In vivo,,Cercopithecidae,9527.0,,,22224
7368,,17509,,A,,Bioavailability in monkey (dose 2 mg/kg),In vivo,,monkey,9443.0,,,22224
7369,,5394,,A,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,In vivo,,Cercopithecidae,9527.0,,,22224
7370,,2661,,A,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,In vivo,,Cercopithecidae,9527.0,,,22224
7371,,11219,,A,,Bioavailability in monkey (i.d. dosing),In vivo,,monkey,9443.0,,,22224
7372,,3045,,A,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,In vivo,,Cercopithecidae,9527.0,,,22224
7373,,17796,,A,,Clearance of the drug was measured in cynomolgus,,,Cercopithecidae,9527.0,,,22224
7374,,1399,,A,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,In vivo,,Cercopithecidae,9527.0,,,22224
7375,,2661,,A,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,In vivo,,Cercopithecidae,9527.0,,,22224
7376,Plasma,5005,,A,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,,Macaca mulatta,9544.0,,,22224
7377,,17267,,A,,Plasma clearance in rhesus monkey was determined,In vivo,,Cercopithecidae,9527.0,,,22224
7378,,6535,,A,,Plasma clearance in monkey after administration of 1 mg/kg iv,In vivo,,Cercopithecidae,9527.0,,,22224
7379,,5922,,A,,Plasma clearance in cynomolgus monkey,In vivo,,Cercopithecidae,9527.0,,,22224
7380,,6221,,A,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,In vivo,,Cercopithecidae,9527.0,,,22224
7381,,5668,,A,,Plasma clearance after peroral administration at 10 mpk in Rhesus,In vivo,,Cercopithecidae,9527.0,,,22224
7382,,5355,,A,,The total clearance was determined after intravenous administration in cynomolgus monkeys,In vivo,,Cercopithecidae,9527.0,,,22224
7383,,5355,,A,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,In vivo,,Cercopithecidae,9527.0,,,22224
7384,,5355,,A,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,In vivo,,Cercopithecidae,9527.0,,,22224
7385,,4578,,A,,Tested for Clearance upon iv administration to african green monkey,In vivo,,Cercopithecidae,9527.0,,,22224
7386,,17592,,A,,Clearance in monkey,In vivo,,Cercopithecidae,9527.0,,,22224
7387,,6641,,A,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,Canis lupus familiaris,9615.0,,,50588
7388,,6642,,A,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,Canis lupus familiaris,9615.0,,,50588
7389,,16367,,A,,Half life was evaluated after intravenous administration to dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
7390,,5472,,A,,Half life was evaluated in dog,,,Canis lupus familiaris,9615.0,,,50588
7391,,5474,,A,,Half life was evaluated in dog,,,Canis lupus familiaris,9615.0,,,50588
7392,,5654,,A,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7393,,6227,,A,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),In vivo,,Canis lupus familiaris,9615.0,,,50588
7394,,6227,,A,,Half life period after intravenous administration in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7395,,6221,,A,,Half life period after oral administration (2.5 mg/kg) in dog was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
7396,,4527,,A,,Half life period at a dose of 1 uM/kg in dog was determined,,,Canis lupus familiaris,9615.0,,,50588
7397,,5668,,A,,Half life period was determine after peroral administration at 10 mpk in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7398,,5668,,A,,Half life period was determine after peroral administration at 5 mpk in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7399,,3854,,A,,Half life period was determined,,,Canis lupus familiaris,9615.0,,,50588
7400,,5505,,A,,Half life period was determined,,,Canis lupus familiaris,9615.0,,,50588
7401,,6251,,A,,Half life period by iv administration in dog at a dose of 6 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7402,,1918,,A,,Half life period was evaluated in dog,,,Canis lupus familiaris,9615.0,,,50588
7403,,5546,,A,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
7404,,4809,,A,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
7405,,6215,,A,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7406,,4527,,A,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
7407,,17594,,A,,Half-life after oral dose of compound at 3 mg/kg in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
7408,,17839,,A,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7409,,17839,,A,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7410,,17839,,A,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7411,,17839,,A,,Half-life of compound in dog following p.o. administration of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7412,Plasma,5210,,A,,Half-life of compound in plasma of dog was determined,,,Canis lupus familiaris,9615.0,,,50588
7413,,5210,,A,,Half-life of compound was determined in dogs,,,Canis lupus familiaris,9615.0,,,50588
7414,,2959,,A,,Half-life after administration of 4 mg/Kg oral dose in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7415,,4137,,A,,Half-life after intravenous administration of 1 mg/kg/h in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7416,,5064,,A,,Half-life in Dog,,,Canis lupus familiaris,9615.0,,,50588
7417,,5147,,A,,Half-life in Dog,,,Canis lupus familiaris,9615.0,,,50588
7418,,5145,,A,,Half-life in dog,,,Canis lupus familiaris,9615.0,,,50588
7419,,6123,,A,,Half-life in dog after oral administration at 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7420,,6123,,A,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
7421,,4333,,A,,Half-life in dogs,,,Canis lupus familiaris,9615.0,,,50588
7422,,4333,,A,,Half-life in dogs; ND indicates not determined,,,Canis lupus familiaris,9615.0,,,50588
7423,Plasma,12500,,A,,Half-life in plasma of dog,,,Canis lupus familiaris,9615.0,,,50588
7424,Plasma,12500,,A,,Half-life in plasma of dog at dose of 3-10 mgkg,,,Canis lupus familiaris,9615.0,,,50588
7425,,6005,,A,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7426,,6062,,A,,Half-life was measured in dog after an iv dose of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7427,,17650,,A,,Half-life was measured in dogs after an oral dose of 10 uM/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7428,,5530,,A,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7429,,5530,,A,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
7430,,5600,,A,,Half-life of the compound after 0.3 mg/kg po administration in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7431,,6039,,A,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
7432,,6039,,A,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
7433,,6039,,A,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
7434,,6227,,A,,t1/2 in dog,,,Canis lupus familiaris,9615.0,,,50588
7435,,14541,,A,,Half-life period measured in dogs,,,Canis lupus familiaris,9615.0,,,50588
7436,,4521,,A,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
7437,,4521,,A,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
7438,,6679,,A,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
7439,Plasma,1116,,A,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",In vitro,,Canis lupus familiaris,9615.0,,,50588
7440,,5444,,A,,In vivo half life period was calculated at 1 mg/kg in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
7441,,5444,,A,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,In vivo,,Canis lupus familiaris,9615.0,,,50588
7442,,17853,,A,,Longer half-life in dog (i.v.) at 0.5 mpk,In vivo,,Canis lupus familiaris,9615.0,,,50588
7443,,4353,,A,,Oral bioavailability in dog (dose 5 uM/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
7444,,16452,,A,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,,Canis lupus familiaris,9615.0,,,50588
7445,,16452,,A,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,In vivo,,Canis lupus familiaris,9615.0,,,50588
7446,,16452,,A,,Bioavailability in dog (dose 1 mg/kg i.v.),In vivo,,Canis lupus familiaris,9615.0,,,50588
7447,Lung,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,,Mus musculus,10090.0,,,50594
7448,Lung,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,10090.0,,,50594
7449,Lung,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,10090.0,,,50594
7450,Lung,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,10090.0,,,50594
7451,Lung,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,10090.0,,,50594
7452,Lung,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,10090.0,,,50594
7453,Muscle tissue,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,10090.0,,,50594
7454,Muscle tissue,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,,Mus musculus,10090.0,,,50594
7455,Muscle tissue,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,10090.0,,,50594
7456,Muscle tissue,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,10090.0,,,50594
7457,Muscle tissue,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,10090.0,,,50594
7458,Muscle tissue,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,10090.0,,,50594
7459,Muscle tissue,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,10090.0,,,50594
7460,Zone of skin,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,10090.0,,,50594
7461,Zone of skin,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,Mus musculus,10090.0,,,50594
7462,Zone of skin,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,10090.0,,,50594
7463,Zone of skin,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,10090.0,,,50594
7464,Zone of skin,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,10090.0,,,50594
7465,Zone of skin,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,10090.0,,,50594
7466,Zone of skin,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,10090.0,,,50594
7467,Spleen,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,10090.0,,,50594
7468,Spleen,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,Mus musculus,10090.0,,,50594
7469,Spleen,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,10090.0,,,50594
7470,Spleen,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,10090.0,,,50594
7471,Spleen,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,10090.0,,,50594
7472,Spleen,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,10090.0,,,50594
7473,Spleen,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,10090.0,,,50594
7474,Stomach,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,10090.0,,,50594
7475,Stomach,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,Mus musculus,10090.0,,,50594
7476,Stomach,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,10090.0,,,50594
7477,Stomach,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,10090.0,,,50594
7478,Stomach,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,10090.0,,,50594
7479,Stomach,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,10090.0,,,50594
7480,Stomach,10107,,A,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,10090.0,,,50594
7481,,4689,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7482,,4950,,A,,Tested for the bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7483,,5328,,A,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
7484,,406,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7485,,12500,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7486,,12500,,A,,Bioavailability in rat (dose 3-10 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
7487,,5247,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7488,Plasma,4186,,A,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,In vivo,,Rattus norvegicus,10116.0,,,50597
7489,Plasma,4186,,A,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,In vivo,,Rattus norvegicus,10116.0,,,50597
7490,,6647,,A,,Half life after oral administration was determined in rats at 6 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7491,,6484,,A,,Half life was determined,,,Rattus norvegicus,10116.0,,,50597
7492,,3249,,A,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7493,Plasma,6281,,A,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,In vivo,,Rattus norvegicus,10116.0,,,50597
7494,,3307,,A,,Half life in rats,,,Rattus norvegicus,10116.0,,,50597
7495,Blood,12058,,A,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
7496,,8833,,A,,Hill coefficient of the compound,,,Rattus norvegicus,10116.0,,,50597
7497,Blood,3193,,A,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,,Rattus norvegicus,10116.0,,,50597
7498,Blood,3193,,A,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,,Rattus norvegicus,10116.0,,,50597
7499,Blood,3193,,A,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,,Rattus norvegicus,10116.0,,,50597
7500,Blood,3193,,A,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,,Rattus norvegicus,10116.0,,,50597
7501,Blood,3193,,A,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,,Rattus norvegicus,10116.0,,,50597
7502,Blood,3193,,A,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,,Rattus norvegicus,10116.0,,,50597
7503,Blood,3193,,A,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,,Rattus norvegicus,10116.0,,,50597
7504,,5960,,A,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,,Rattus norvegicus,10116.0,,,50597
7505,Brain,13950,,A,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,In vivo,,Rattus norvegicus,10116.0,,,50597
7506,Brain,13950,,A,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,In vivo,,Rattus norvegicus,10116.0,,,50597
7507,Brain,13950,,A,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,In vivo,,Rattus norvegicus,10116.0,,,50597
7508,Brain,13950,,A,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,In vivo,,Rattus norvegicus,10116.0,,,50597
7509,Brain,13950,,A,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,In vivo,,Rattus norvegicus,10116.0,,,50597
7510,Thyroid gland,13950,,A,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,In vivo,,Rattus norvegicus,10116.0,,,50597
7511,Thyroid gland,13950,,A,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,In vivo,,Rattus norvegicus,10116.0,,,50597
7512,Thyroid gland,13950,,A,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,In vivo,,Rattus norvegicus,10116.0,,,50597
7513,Thyroid gland,13950,,A,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,In vivo,,Rattus norvegicus,10116.0,,,50597
7514,Thyroid gland,13950,,A,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,In vivo,,Rattus norvegicus,10116.0,,,50597
7515,Blood,9866,,A,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7516,Blood,9866,,A,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,In vivo,,Rattus norvegicus,10116.0,,,50597
7517,Blood,9866,,A,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7518,Bone,9866,,A,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7519,Bone,9866,,A,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,In vivo,,Rattus norvegicus,10116.0,,,50597
7520,Bone,9866,,A,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7521,Heart,9866,,A,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7522,Heart,9866,,A,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,In vivo,,Rattus norvegicus,10116.0,,,50597
7523,Heart,9866,,A,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7524,Kidney,9866,,A,,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7525,Kidney,9866,,A,,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,In vivo,,Rattus norvegicus,10116.0,,,50597
7526,Kidney,9866,,A,,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7527,Liver,9866,,A,,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7528,Liver,9866,,A,,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,In vivo,,Rattus norvegicus,10116.0,,,50597
7529,Liver,9866,,A,,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7530,Lung,9866,,A,,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7531,Lung,9866,,A,,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,In vivo,,Rattus norvegicus,10116.0,,,50597
7532,Lung,9866,,A,,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7533,,6351,,A,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,,,Rattus norvegicus,10116.0,,,50597
7534,,1465,,A,,Compound was tested for solubility in water,,,Rattus norvegicus,10116.0,,,50597
7535,,5182,,P,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),,,,,,,22229
7536,,17847,,A,,Solubility was determined,,,Rattus norvegicus,10116.0,,,50597
7537,,15339,,A,,solubility in water (ug/mL) at 37 degree C.,,,Rattus norvegicus,10116.0,,,50597
7538,,5202,,A,,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,,,Rattus norvegicus,10116.0,,,50597
7539,,1088,,A,,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,,,Rattus norvegicus,10116.0,,,50597
7540,,3169,,A,,Half life in rats,,,Rattus norvegicus,10116.0,,,50597
7541,,5353,,A,,Half life in Dawley rat,,,Rattus norvegicus,10116.0,,,50597
7542,,2864,,A,,Half life period after 3 mg/kg iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
7543,,2864,,A,,Half life period after 3 mg/kg iv administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7544,,2864,,A,,Half life period after 3 mg/kg iv administration in the rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7545,,6362,,A,,Half life period in female Sprague-Dawley rats,,,Rattus norvegicus,10116.0,,,50597
7546,,6249,,A,,Half life period in rat,,,Rattus norvegicus,10116.0,,,50597
7547,,3169,,A,,Half-life in rats was determined,,,Rattus norvegicus,10116.0,,,50597
7548,,3169,,A,,Half-life in rats with metabolic oxidation,,,Rattus norvegicus,10116.0,,,50597
7549,,3169,,A,,Half-life in rats,,,Rattus norvegicus,10116.0,,,50597
7550,,17260,,A,,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7551,,17260,,A,,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7552,,17260,,A,,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7553,,17260,,A,,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7554,Plasma,2879,,A,,Biological half-life measured in plasma of rat,,,Rattus norvegicus,10116.0,,,50597
7555,Plasma,2879,,A,,Biological half-life measured in plasma of rat; 22-25,,,Rattus norvegicus,10116.0,,,50597
7556,Plasma,2879,,A,,Biological half-life measured in plasma of rat; 9-16,,,Rattus norvegicus,10116.0,,,50597
7557,,3184,,A,,Compound was evaluated for its half life when administered intravenously in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7558,,4891,,A,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,In vivo,,Rattus norvegicus,10116.0,,,50597
7559,,429,,A,,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7560,,5656,,A,,Half life (T1/2) after oral administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7561,,4413,,A,,Half life of compound after iv administration of 20 mg/kg dose in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7562,,3598,,A,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7563,,17267,,A,,Half life of compound was determined in rat,,,Rattus norvegicus,10116.0,,,50597
7564,Blood,4727,,A,,Half life of compound was determined in rat blood,,,Rattus norvegicus,10116.0,,,50597
7565,,17651,,A,,Half life at 1 mg/kg was determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7566,,17651,,A,,Half life at 10 mg/kg was determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7567,,401,,A,,Half life in rats,,,Rattus norvegicus,10116.0,,,50597
7568,,4942,,A,,Half life in rats in hours,,,Rattus norvegicus,10116.0,,,50597
7569,,17735,,A,,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
7570,,6056,,A,,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7571,,5213,,A,,Half life was determined,,,Rattus norvegicus,10116.0,,,50597
7572,,6616,,A,,Half life after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
7573,,5937,,A,,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7574,Plasma,5819,,A,,Half life in rat plasma,,,Rattus norvegicus,10116.0,,,50597
7575,Plasma,5819,,A,,Half life in rat plasma; Not detected,,,Rattus norvegicus,10116.0,,,50597
7576,,6803,,A,,Half life in rats,,,Rattus norvegicus,10116.0,,,50597
7577,,17804,,A,,Half life period of compound was determined after peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
7578,,17804,,A,,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,In vivo,,Rattus norvegicus,10116.0,,,50597
7579,,5948,,A,,Half life period in rat,,,Rattus norvegicus,10116.0,,,50597
7580,,1916,,A,,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
7581,,1916,,A,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,In vivo,,Rattus norvegicus,10116.0,,,50597
7582,,1916,,A,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,In vivo,,Rattus norvegicus,10116.0,,,50597
7583,,4890,,A,,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
7584,,17764,,A,,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7585,,4727,,A,,Half life time in rat the dose of 2 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7586,,17509,,A,,Half-life 24 hr after 10 mg/kg iv administration in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
7587,,17509,,A,,Half-life 24 hr after 2 mg/kg iv administration in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
7588,,6597,,A,,Half-life consistent with the observed metabolic steady state in rats,,,Rattus norvegicus,10116.0,,,50597
7589,,17735,,A,,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
7590,,6597,,A,,Half-life for oxidative metabolic stability was determined using male human,,,Rattus norvegicus,10116.0,,,50597
7591,,17670,,A,,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",In vivo,,Rattus norvegicus,10116.0,,,50597
7592,Plasma,1696,,A,,Half-life in rat plasma,,,Rattus norvegicus,10116.0,,,50597
7593,Plasma,1742,,A,,Half-life in rat plasma was determined,,,Rattus norvegicus,10116.0,,,50597
7594,,17800,,A,,Half-life in rats was determined,,,Rattus norvegicus,10116.0,,,50597
7595,,12923,,A,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,,,,,,,22224
7596,,11954,,A,,Area under curve after oral dose of 0.1 mg//kg,,,,,,,22224
7597,,11954,,A,,Area under curve after oral dose of 0.3 mg/kg,,,,,,,22224
7598,,11954,,A,,Area under curve after oral dose of 1 mg/kg,,,,,,,22224
7599,,11954,,A,,Area under curve after oral dose of 10 mg/kg,,,,,,,22224
7600,,11954,,A,,Area under curve after oral dose of 23.4 mg/kg,,,,,,,22224
7601,,11954,,A,,Area under curve after oral dose of 3 mg/kg,,,,,,,22224
7602,,11954,,A,,Area under curve after oral dose of 3.87 mg/kg,,,,,,,22224
7603,,5237,,A,,Area under curve was determined,,,,,,,22224
7604,,4026,,A,,Area under curve at a dose of 10 mg/kg,,,,,,,22224
7605,,5237,,A,,Area under curve was determined; ND=No data,,,Rattus norvegicus,10116.0,,,50597
7606,,14793,,A,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,,Rattus norvegicus,10116.0,,,50597
7607,,14793,,A,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,,Rattus norvegicus,10116.0,,,50597
7608,,14793,,A,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,,Rattus norvegicus,10116.0,,,50597
7609,,14793,,A,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,,,Rattus norvegicus,10116.0,,,50597
7610,,14793,,A,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,,Rattus norvegicus,10116.0,,,50597
7611,,14793,,A,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,,,Rattus norvegicus,10116.0,,,50597
7612,,14793,,A,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,,Rattus norvegicus,10116.0,,,50597
7613,,14793,,A,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,,,Rattus norvegicus,10116.0,,,50597
7614,Plasma,14793,,A,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,,Rattus norvegicus,10116.0,,,50597
7615,Plasma,14793,,A,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,,Rattus norvegicus,10116.0,,,50597
7616,Plasma,14793,,A,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,,Rattus norvegicus,10116.0,,,50597
7617,Plasma,14793,,A,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,,,Rattus norvegicus,10116.0,,,50597
7618,Plasma,14793,,A,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,,Rattus norvegicus,10116.0,,,50597
7619,Plasma,14793,,A,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,,,Rattus norvegicus,10116.0,,,50597
7620,Plasma,14793,,A,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,,Rattus norvegicus,10116.0,,,50597
7621,Plasma,14793,,A,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,,,Rattus norvegicus,10116.0,,,50597
7622,Plasma,11637,,A,,AUC in mice,,,Mus musculus,10090.0,,,50594
7623,,11149,,A,,Area under curve was measured from the graph obtained from concentration Vs time,,,,,,,22224
7624,,10016,,A,,Area under curve value of compound per hour after oral administration,,,,,,,22224
7625,,17796,,A,,Area under curve was determined after oral administration in rats,,,Rattus norvegicus,10116.0,,,50597
7626,,17796,,A,,Area under curve was determined after oral administration in rats; No data,,,Rattus norvegicus,10116.0,,,50597
7627,,17796,,A,,Area under curve was determined after oral administration in rats;No data,,,Rattus norvegicus,10116.0,,,50597
7628,,12923,,A,,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,,Canis lupus familiaris,9615.0,,,50588
7629,,15372,,A,,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,,,Rattus norvegicus,10116.0,,,50597
7630,,15372,,A,,Area under curve was determined for the compound after iv dose of 5.06 in rats,,,Rattus norvegicus,10116.0,,,50597
7631,,15372,,A,,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,,,Rattus norvegicus,10116.0,,,50597
7632,,15372,,A,,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,,,Rattus norvegicus,10116.0,,,50597
7633,,15372,,A,,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,,,Rattus norvegicus,10116.0,,,50597
7634,,15372,,A,,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,,,Rattus norvegicus,10116.0,,,50597
7635,,15372,,A,,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,,,Rattus norvegicus,10116.0,,,50597
7636,,14169,,A,,Area under curve was determined in Dogs after peroral administration,,,Canis lupus familiaris,9615.0,,,50588
7637,,14169,,A,,Area under curve was determined in Rats after peroral administration,,,Rattus norvegicus,10116.0,,,50597
7638,,14258,,A,,Area under curve was determined in carotid blood of rat when administered intradermally,,,Rattus norvegicus,10116.0,,,50597
7639,,14258,,A,,Area under curve was determined in portal blood of rat when administered intradermally,,,Rattus norvegicus,10116.0,,,50597
7640,,15011,,A,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,,Mus musculus,10090.0,,,50594
7641,,15011,,A,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,,Mus musculus,10090.0,,,50594
7642,,15011,,A,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,,Mus musculus,10090.0,,,50594
7643,,15011,,A,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,,Mus musculus,10090.0,,,50594
7644,,15011,,A,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),,,Mus musculus,10090.0,,,50594
7645,,15011,,A,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,,Mus musculus,10090.0,,,50594
7646,,15011,,A,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),,,Mus musculus,10090.0,,,50594
7647,Spleen,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
7648,Blood,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7649,Brain,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7650,Heart,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7651,Liver,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7652,Lung,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7653,Muscle tissue,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7654,,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7655,Spleen,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7656,Thyroid gland,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7657,Kidney,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7658,Blood,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7659,Brain,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7660,Heart,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7661,Kidney,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7662,Liver,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7663,Lung,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7664,Muscle tissue,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7665,,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7666,Spleen,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7667,Thyroid gland,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7668,Blood,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7669,Heart,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7670,Kidney,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7671,Liver,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7672,Muscle tissue,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7673,Spleen,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7674,Thyroid gland,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7675,Brain,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7676,Lung,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7677,,10130,,A,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,,,Rattus norvegicus,10116.0,,,50597
7678,,6295,,A,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,,Rattus norvegicus,10116.0,,,50597
7679,,6296,,A,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,,Rattus norvegicus,10116.0,,,50597
7680,,6296,,A,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,,,Rattus norvegicus,10116.0,,,50597
7681,,6295,,A,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,,Rattus norvegicus,10116.0,,,50597
7682,,6296,,A,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,,Rattus norvegicus,10116.0,,,50597
7683,,17260,,A,,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7684,,17260,,A,,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7685,,17686,,A,,C24h in rat p.o. at 20 mg/kg concentration,,,Rattus norvegicus,10116.0,,,50597
7686,Muscle tissue,9866,,A,,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7687,Muscle tissue,9866,,A,,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,In vivo,,Rattus norvegicus,10116.0,,,50597
7688,Muscle tissue,9866,,A,,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7689,Spleen,9866,,A,,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7690,Spleen,9866,,A,,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,In vivo,,Rattus norvegicus,10116.0,,,50597
7691,Spleen,9866,,A,,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7692,Blood,9866,,A,,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,In vivo,,Rattus norvegicus,10116.0,,,50597
7693,Blood,9866,,A,,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7694,Blood,9866,,A,,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,In vivo,,Rattus norvegicus,10116.0,,,50597
7695,Blood,9866,,A,,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,In vivo,,Rattus norvegicus,10116.0,,,50597
7696,Blood,9866,,A,,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7697,Blood,9866,,A,,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,In vivo,,Rattus norvegicus,10116.0,,,50597
7698,Blood,9866,,A,,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7699,Blood,9866,,A,,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7700,Blood,9866,,A,,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,In vivo,,Rattus norvegicus,10116.0,,,50597
7701,Blood,9866,,A,,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7702,Blood,9866,,A,,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7703,Blood,9866,,A,,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7704,Blood,9866,,A,,Biodistribution in rat blood in the presence of GdDTPA at 15 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7705,Blood,9866,,A,,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7706,Blood,9866,,A,,Biodistribution in rat blood in the presence of GdDTPA at 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7707,Blood,9866,,A,,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7708,Blood,9866,,A,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7709,Blood,9866,,A,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7710,Blood,9866,,A,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7711,Blood,9866,,A,,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7712,Blood,9866,,A,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7713,Blood,9866,,A,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7714,Blood,9866,,A,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7715,Blood,9866,,A,,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7716,Blood,9866,,A,,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7717,Blood,9866,,A,,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,In vivo,,Rattus norvegicus,10116.0,,,50597
7718,Blood,9866,,A,,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,In vivo,,Rattus norvegicus,10116.0,,,50597
7719,Bone,9866,,A,,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7720,Bone,9866,,A,,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,In vivo,,Rattus norvegicus,10116.0,,,50597
7721,Bone,9866,,A,,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,In vivo,,Rattus norvegicus,10116.0,,,50597
7722,Bone,9866,,A,,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,In vivo,,Rattus norvegicus,10116.0,,,50597
7723,Bone,9866,,A,,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7724,Bone,9866,,A,,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,In vivo,,Rattus norvegicus,10116.0,,,50597
7725,Bone,9866,,A,,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7726,Bone,9866,,A,,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7727,Bone,9866,,A,,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,In vivo,,Rattus norvegicus,10116.0,,,50597
7728,Bone,9866,,A,,Biodistribution in rat bone in the presence of GdDTPA at 15 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7729,Bone,9866,,A,,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7730,Bone,9866,,A,,Biodistribution in rat bone in the presence of GdDTPA at 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7731,Bone,9866,,A,,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7732,Bone,9866,,A,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7733,Bone,9866,,A,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7734,Bone,9866,,A,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7735,Bone,9866,,A,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7736,Bone,9866,,A,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7737,Bone,9866,,A,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7738,Bone,9866,,A,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7739,Bone,9866,,A,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7740,Bone,9866,,A,,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7741,Bone,9866,,A,,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,In vivo,,Rattus norvegicus,10116.0,,,50597
7742,Bone,9866,,A,,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,In vivo,,Rattus norvegicus,10116.0,,,50597
7743,Plasma,17752,,A,,Half-life from rat plasma at a single oral dose of 25 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7744,,5610,,A,,Half-life in male rat,,,Rattus norvegicus,10116.0,,,50597
7745,,5939,,A,,Half-life in rat after peroral administration at 10 mg/kg concentration,In vivo,,Rattus norvegicus,10116.0,,,50597
7746,,5939,,A,,Half-life in rat after peroral administration at 5 mg/kg concentration,In vivo,,Rattus norvegicus,10116.0,,,50597
7747,,17771,,A,,Half-life in rat at a dose of 3 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7748,,1974,,A,,Half-life was evaluated in rats,,,Rattus norvegicus,10116.0,,,50597
7749,,4239,,A,,Half-life was measured in rat,,,Rattus norvegicus,10116.0,,,50597
7750,,6681,,A,,Half-life period for the compound was determined in rats at 50 mg/kg dose,In vivo,,Rattus norvegicus,10116.0,,,50597
7751,,17752,,A,,Half-life period in rats after intravenous administration at 5 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7752,,6046,,A,,Half-life period in rat at 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7753,,6685,,A,,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",In vivo,,Rattus norvegicus,10116.0,,,50597
7754,,6685,,A,,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",In vivo,,Rattus norvegicus,10116.0,,,50597
7755,,6685,,A,,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",In vivo,,Rattus norvegicus,10116.0,,,50597
7756,,4727,,A,,Half-life time in rat the dose of 2 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7757,,1088,,A,,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,In vivo,,Rattus norvegicus,10116.0,,,50597
7758,,5610,,A,,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7759,Plasma,3032,,A,,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",In vivo,,Rattus norvegicus,10116.0,,,50597
7760,,5199,,A,,Oral half life was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
7761,,14941,,A,,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",In vivo,,Rattus norvegicus,10116.0,,,50597
7762,,4408,,A,,Pharmacokinetic property (t1/2) in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7763,Plasma,2552,,A,,Plasma elimination half-life was determined,,,Rattus norvegicus,10116.0,,,50597
7764,Plasma,5199,,A,,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,In vivo,,Rattus norvegicus,10116.0,,,50597
7765,Plasma,15662,,A,,Plasma half life was observed after intravenous administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7766,Plasma,1465,,A,,Plasma half-life was determined,,,Rattus norvegicus,10116.0,,,50597
7767,Plasma,1446,,A,,Plasma half-life following oral administration in Fisher rats,In vivo,,Rattus norvegicus,10116.0,,,50597
7768,Plasma,6824,,A,,Plasma half-life in rat,,,Rattus norvegicus,10116.0,,,50597
7769,Plasma,17533,,A,,Plasmatic Half-life after intravenous administration to rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7770,,5979,,A,,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7771,,4689,,A,,Terminal half life after intravenous administration (1 mg/kg) in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7772,,4689,,A,,Terminal half life in Rat at a oral dose of 5 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7773,,2463,,A,,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,In vivo,,Rattus norvegicus,10116.0,,,50597
7774,,4883,,A,,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7775,,4883,,A,,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7776,Plasma,15662,,A,,plasma half life was observed after intravenous administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7777,,3598,,A,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7778,,4576,,A,,Half life of compound determined in rat,,,Rattus norvegicus,10116.0,,,50597
7779,,4576,,A,,Mean residence time determined in rat,,,Rattus norvegicus,10116.0,,,50597
7780,,4576,,A,,Plasma half life determined in rat,,,Rattus norvegicus,10116.0,,,50597
7781,Brain,4910,,A,,Compound was evaluated for Tmax in brain after intravenous administration in male rats,In vivo,,Rattus norvegicus,10116.0,,,50597
7782,,4891,,A,,Compound was evaluated for pharmacokinetic parameter maximum time period,In vivo,,Rattus norvegicus,10116.0,,,50597
7783,,429,,A,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7784,,5974,,A,,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7785,,5974,,A,,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7786,,5974,,A,,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7787,,5974,,A,,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7788,,17582,,A,,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
7789,,4026,,A,,Maximum time (Tmax) required to reach Cmax in rats,,,Rattus norvegicus,10116.0,,,50597
7790,,4890,,A,,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
7791,,6571,,A,,Maximum time of clearance of compound in rats after peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
7792,,4727,,A,,Maximum time at the dose of 2 mg/kg in rat,,,Rattus norvegicus,10116.0,,,50597
7793,Plasma,17651,,A,,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7794,Plasma,17651,,A,,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7795,,14465,,A,,Tmax in Guinea pig (PO dose),In vivo,,Rattus norvegicus,10116.0,,,50597
7796,,14941,,A,,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",In vivo,,Rattus norvegicus,10116.0,,,50597
7797,,5960,,A,,Pharmacokinetic parameter (Tmax) in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7798,,5022,,A,,Pharmacokinetic parameter (Tmax) was estimated,In vivo,,Rattus norvegicus,10116.0,,,50597
7799,,4408,,A,,Pharmacokinetic property (Tmax) in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7800,,5983,,A,,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,In vivo,,Rattus norvegicus,10116.0,,,50597
7801,,4689,,A,,T max in Rat at a oral dose of 5 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7802,,2792,,A,,T max was determined at 10 mg/kg po dose in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
7803,,15011,,A,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),,,Mus musculus,10090.0,,,50594
7804,,14180,,A,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,,,Canis lupus familiaris,9615.0,,,50588
7805,,14180,,A,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,,,Rattus norvegicus,10116.0,,,50597
7806,,14599,,A,,Area under curve was measured after i.v. administration into Beagle dog.,,,Canis lupus familiaris,9615.0,,,50588
7807,,14599,,A,,Area under curve was measured after iv administration into Beagle dog,,,Canis lupus familiaris,9615.0,,,50588
7808,,14599,,A,,Area under curve was measured after po administration into Beagle dog,,,Canis lupus familiaris,9615.0,,,50588
7809,,14599,,A,,Area under curve was measured after po administration into Beagle dog.,,,Canis lupus familiaris,9615.0,,,50588
7810,,15675,,A,,Area under curve was measured at peroral dose of 3 mg/kg,,,,,,,22224
7811,,12706,,A,,Area under curve was measured by using concentration Vs time,,,,,,,22224
7812,,12706,,A,,Area under curve was measured by using concentration Vs time; not tested,,,,,,,22224
7813,,9750,,A,,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),,,Mus musculus,10090.0,,,50594
7814,,9750,,A,,Area under curve(AUC) was measured in mice after oral administration.,,,Mus musculus,10090.0,,,50594
7815,,14691,,A,,Area under curve(AUC) value of the compound,,,,,,,22224
7816,,14691,,A,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,,,,,,,22224
7817,,14691,,A,,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,,,Canis lupus familiaris,9615.0,,,50588
7818,Blood,2939,,A,,Area under curve(carotid artery) was determined by the availability in blood,,,,,,,22224
7819,Blood,2939,,A,,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,,,,,,,22224
7820,Blood,2939,,A,,Area under curve(carotid artery) was determined by the availability in blood; No data,,,,,,,22224
7821,Blood,2939,,A,,Area under curve(portal vein) was determined by the availability in blood,,,,,,,22224
7822,Blood,2939,,A,,Area under curve(portal vein) was determined by the availability in blood; ND means no data,,,,,,,22224
7823,Blood,2939,,A,,Area under curve(portal vein) was determined by the availability in blood; No data,,,,,,,22224
7824,Plasma,9552,,A,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,,Macaca mulatta,9544.0,,,50797
7825,Plasma,9552,,A,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,,Macaca mulatta,9544.0,,,50797
7826,Plasma,9552,,A,,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,,,Macaca mulatta,9544.0,,,50797
7827,Plasma,9552,,A,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",,,Canis lupus familiaris,9615.0,,,50588
7828,Plasma,9552,,A,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",,,Canis lupus familiaris,9615.0,,,50588
7829,Plasma,9552,,A,,Area under plasma concentration vs time curve observed in rats for 0-3 h,,,,,,,22224
7830,Plasma,11911,,A,,Area under plasma time curve determined in male rat,,,Rattus norvegicus,10116.0,,,50597
7831,,16618,,A,,Area under the MAP curve measured over 5 min.,,,,,,,22224
7832,,14387,,A,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,,,Mus musculus,10090.0,,,50594
7833,,14387,,A,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,,,Mus musculus,10090.0,,,50594
7834,,12836,,A,,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,,,Canis lupus familiaris,9615.0,,,50588
7835,,12836,,A,,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,,,Cricetinae,10026.0,,,100712
7836,,12836,,A,,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,,,Rattus norvegicus,10116.0,,,50597
7837,,14339,,A,,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,,,Canis lupus familiaris,9615.0,,,50588
7838,,14339,,A,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,,,Canis lupus familiaris,9615.0,,,50588
7839,,14339,,A,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,,,Canis lupus familiaris,9615.0,,,50588
7840,,10524,,A,,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,,Canis lupus familiaris,9615.0,,,50588
7841,,9994,,A,,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),,,Canis lupus familiaris,9615.0,,,50588
7842,,11325,,A,,Serum AUC in marmosets (IV dose),,,Canis lupus familiaris,9615.0,,,50588
7843,,12536,,A,,Area under the curve after intravenous administration at a dose of 10 umol/kg,,,,,,,22224
7844,,12536,,A,,Area under the curve after intravenous administration at a dose of 2 umol/kg,,,,,,,22224
7845,,12536,,A,,Area under the curve after intravenous administration at a dose of 4 umol/kg,,,,,,,22224
7846,,12536,,A,,Area under the curve after intravenous administration at a dose of 40 umol/kg,,,,,,,22224
7847,,12536,,A,,Area under the curve after intravenous administration at a dose of 5 umol/kg,,,,,,,22224
7848,,15556,,A,,Area under the curve for fumarate salt was evaluated in F344 Rats.,,,Rattus norvegicus,10116.0,,,50597
7849,,2809,,A,,Area under the curve for the compound was calculated.,,,,,,,22224
7850,,9511,,A,,Area under the curve in concentration/ time,,,,,,,22224
7851,,12818,,A,,Area under the curve administered intraintestinal in rats.,,,Rattus norvegicus,10116.0,,,50597
7852,,12818,,A,,Area under the curve administered intravenously in rats.,,,Rattus norvegicus,10116.0,,,50597
7853,,15118,,A,,Area under the curve during intravenous administration,,,,,,,22224
7854,,15118,,A,,Area under the curve during intravenous administration; Not determined,,,,,,,22224
7855,,15118,,A,,Area under the curve during systemic administration,,,,,,,22224
7856,,15118,,A,,Area under the curve during systemic administration; Not determined,,,,,,,22224
7857,,2632,,A,,Area under the curve was calculated for the compound.,,,,,,,22224
7858,,14346,,A,,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,,,Canis lupus familiaris,9615.0,,,50588
7859,,14346,,A,,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,,,Canis lupus familiaris,9615.0,,,50588
7860,,14346,,A,,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,,,Rattus norvegicus,10116.0,,,50597
7861,,14346,,A,,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,,,Rattus norvegicus,10116.0,,,50597
7862,,11149,,A,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,,,Rattus norvegicus,10116.0,,,50597
7863,Plasma,17796,,A,,Clearance of the drug was measured in the plasma of rat; No data,,,Rattus norvegicus,10116.0,,,50597
7864,Plasma,5247,,A,,The pharmacokinetic parameter plasma clearance in vivo in rats,,,Rattus norvegicus,10116.0,,,50597
7865,,4727,,A,,Plasma clearance at the dose of 2 mg/kg in rat,,,Rattus norvegicus,10116.0,,,50597
7866,,5654,,A,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
7867,,5654,,A,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
7868,,17260,,A,,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7869,,17065,,A,,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,In vivo,,Rattus norvegicus,10116.0,,,50597
7870,,17671,,A,,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7871,,6672,,A,,Clearance rate in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7872,,6673,,A,,Clearance rate in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7873,,5978,,A,,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7874,,5978,,A,,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7875,,5978,,A,,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7876,,5978,,A,,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7877,,4413,,A,,Clearance of compound after iv administration of 20 mg/kg dose in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7878,,2661,,A,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
7879,,2661,,A,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
7880,Plasma,5005,,A,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,,Macaca mulatta,9544.0,,,22224
7881,Plasma,5005,,A,,Compound was tested for its plasma clearance rate in Sprague Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,22224
7882,,15765,,A,,Mean (%CV) PK parameters for CL(mL/min/kg).,In vivo,,Rattus norvegicus,10116.0,,,50597
7883,,3747,,A,,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7884,Plasma,16366,,A,,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,In vivo,,Rattus norvegicus,10116.0,,,50597
7885,,4199,,A,,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
7886,,17267,,A,,Plasma clearance in rat was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
7887,,6535,,A,,Plasma clearance in rat after administration of 2 mg/kg iv,In vivo,,Rattus norvegicus,10116.0,,,50597
7888,,6535,,A,,Plasma clearance in rat after administration of 2 mg/kg iv,In vivo,,Rattus norvegicus,10116.0,,,50597
7889,,5041,,A,,Plasma clearance was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
7890,,5960,,A,,Plasma clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7891,,5937,,A,,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7892,,5871,,A,,Plasma clearance in rat by iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
7893,,5874,,A,,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7894,,6504,,A,,Plasma clearance in rat p.o.,In vivo,,Rattus norvegicus,10116.0,,,50597
7895,,6803,,A,,Plasma clearance in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
7896,,5041,,A,,Plasma clearance was determined; ND denotes no data,In vivo,,Rattus norvegicus,10116.0,,,50597
7897,,5041,,A,,Plasma clearance was determined; ND denotes not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
7898,,1916,,A,,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
7899,,5199,,A,,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,In vivo,,Rattus norvegicus,10116.0,,,50597
7900,,16367,,A,,Plasma administration to rats,In vivo,,Rattus norvegicus,10116.0,,,50597
7901,,6362,,A,,Plasma clearance of the compound in female Sprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
7902,,15662,,A,,Plasma clearance was observed after intravenous administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7903,,6215,,A,,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7904,,1466,,A,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7905,Plasma,15662,,A,,plasma clearance was observed after intravenous administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7906,,4723,,A,,In vivo CL/F determined,In vivo,,Rattus norvegicus,10116.0,,,50597
7907,Plasma,2792,,A,,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
7908,Plasma,2792,,A,,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
7909,,5213,,A,,Compound was tested for the lower blood clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7910,,4687,,A,,Evaluated for the low clearance in rat (in vivo),In vivo,,Rattus norvegicus,10116.0,,,50597
7911,,3371,,A,,Pharmacokinetic property (CLb)of the compound was determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7912,,4690,,A,,Rapid clearance after intravenous administration in rat was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
7913,,5702,,A,,Clearance measured in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7914,Plasma,740,,A,,Compound was evaluated for plasma clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7915,Plasma,4853,,A,,Low plasma clearance was calculated in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7916,,5789,,A,,Pharmacokinetic property (Clp) in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7917,,4527,,A,,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
7918,,4527,,A,,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
7919,,6518,,A,,Plasma clearance after IV dosing at 0.5 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7920,,6518,,A,,Plasma clearance after IV dosing at 1 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7921,Heart,9866,,A,,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,In vivo,,Rattus norvegicus,10116.0,,,50597
7922,Heart,9866,,A,,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7923,Heart,9866,,A,,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,In vivo,,Rattus norvegicus,10116.0,,,50597
7924,Heart,9866,,A,,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,In vivo,,Rattus norvegicus,10116.0,,,50597
7925,Heart,9866,,A,,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,In vivo,,Rattus norvegicus,10116.0,,,50597
7926,Heart,9866,,A,,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7927,Heart,9866,,A,,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7928,Heart,9866,,A,,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7929,Heart,9866,,A,,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,In vivo,,Rattus norvegicus,10116.0,,,50597
7930,Heart,9866,,A,,Biodistribution in rat heart in the presence of GdDTPA at 15 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7931,Heart,9866,,A,,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7932,Heart,9866,,A,,Biodistribution in rat heart in the presence of GdDTPA at 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7933,Heart,9866,,A,,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7934,Heart,9866,,A,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7935,Heart,9866,,A,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7936,Heart,9866,,A,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7937,Heart,9866,,A,,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7938,Heart,9866,,A,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7939,Heart,9866,,A,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7940,Heart,9866,,A,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7941,Heart,9866,,A,,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7942,Heart,9866,,A,,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7943,Heart,9866,,A,,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,In vivo,,Rattus norvegicus,10116.0,,,50597
7944,Heart,9866,,A,,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,In vivo,,Rattus norvegicus,10116.0,,,50597
7945,Kidney,9866,,A,,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7946,Kidney,9866,,A,,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,In vivo,,Rattus norvegicus,10116.0,,,50597
7947,Kidney,9866,,A,,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,In vivo,,Rattus norvegicus,10116.0,,,50597
7948,Kidney,9866,,A,,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,In vivo,,Rattus norvegicus,10116.0,,,50597
7949,Kidney,9866,,A,,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,In vivo,,Rattus norvegicus,10116.0,,,50597
7950,Kidney,9866,,A,,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,In vivo,,Rattus norvegicus,10116.0,,,50597
7951,Kidney,9866,,A,,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7952,Kidney,9866,,A,,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7953,Kidney,9866,,A,,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,In vivo,,Rattus norvegicus,10116.0,,,50597
7954,Kidney,9866,,A,,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7955,Kidney,9866,,A,,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,In vivo,,Rattus norvegicus,10116.0,,,50597
7956,Kidney,9866,,A,,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,In vivo,,Rattus norvegicus,10116.0,,,50597
7957,Intestine,9866,,A,,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7958,Intestine,9866,,A,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7959,Intestine,9866,,A,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7960,Liver,9866,,A,,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7961,Liver,9866,,A,,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,In vivo,,Rattus norvegicus,10116.0,,,50597
7962,Liver,9866,,A,,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,In vivo,,Rattus norvegicus,10116.0,,,50597
7963,Liver,9866,,A,,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,In vivo,,Rattus norvegicus,10116.0,,,50597
7964,Liver,9866,,A,,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7965,Liver,9866,,A,,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,In vivo,,Rattus norvegicus,10116.0,,,50597
7966,Liver,9866,,A,,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7967,Liver,9866,,A,,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,In vivo,,Rattus norvegicus,10116.0,,,50597
7968,Liver,9866,,A,,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7969,Liver,9866,,A,,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,In vivo,,Rattus norvegicus,10116.0,,,50597
7970,Liver,9866,,A,,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,In vivo,,Rattus norvegicus,10116.0,,,50597
7971,Liver,9866,,A,,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7972,Liver,9866,,A,,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7973,Liver,9866,,A,,Biodistribution in rat liver in the presence of GdDTPA at 15 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7974,Liver,9866,,A,,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7975,Liver,9866,,A,,Biodistribution in rat liver in the presence of GdDTPA at 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7976,Liver,9866,,A,,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
7977,Liver,9866,,A,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,In vivo,,Rattus norvegicus,10116.0,,,50597
7978,,2792,,A,,T max was determined at 3 mg/kg po dose in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
7979,,15078,,A,,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",In vivo,,Rattus norvegicus,10116.0,,,50597
7980,,15078,,A,,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",In vivo,,Rattus norvegicus,10116.0,,,50597
7981,,15022,,A,,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,,,Rattus norvegicus,10116.0,,,50597
7982,,15022,,A,,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,,,Rattus norvegicus,10116.0,,,50597
7983,,15022,,A,,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,,,Rattus norvegicus,10116.0,,,50597
7984,Plasma,4576,,A,,Time for maximum plasma concentration determined in rat,,,Rattus norvegicus,10116.0,,,50597
7985,Plasma,6681,,A,,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,In vivo,,Rattus norvegicus,10116.0,,,50597
7986,,16365,,A,,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7987,,16365,,A,,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7988,,16365,,A,,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7989,,16365,,A,,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7990,,16365,,A,,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
7991,Plasma,6824,,A,,Time of maximum plasma concentration in rat,,,Rattus norvegicus,10116.0,,,50597
7992,Plasma,6685,,A,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,,Rattus norvegicus,10116.0,,,50597
7993,Plasma,6685,,A,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,,Rattus norvegicus,10116.0,,,50597
7994,Plasma,6685,,A,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,,Rattus norvegicus,10116.0,,,50597
7995,,15662,,A,,Time required to reach maximum concentration (Cmax) after oral administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
7996,Plasma,1742,,A,,Time required to reach maximum concentration in rat plasma,,,Rattus norvegicus,10116.0,,,50597
7997,Plasma,2774,,A,,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
7998,Plasma,5199,,A,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
7999,Plasma,12873,,A,,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8000,Plasma,12873,,A,,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8001,Plasma,1916,,A,,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8002,,16367,,A,,Time to reach Cmax after oral administration to rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8003,,16366,,A,,Time to reach Cmax when a dose of 1 mg/kg is administered orally,In vivo,,Rattus norvegicus,10116.0,,,50597
8004,,216,,A,,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,,,Rattus norvegicus,10116.0,,,50597
8005,Plasma,6410,,A,,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,In vivo,,Rattus norvegicus,10116.0,,,50597
8006,Plasma,6410,,A,,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8007,,6215,,A,,Tmax after peroral administration (10 mg/kg) was determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8008,,3598,,A,,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8009,,4527,,A,,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8010,,17670,,A,,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",In vivo,,Rattus norvegicus,10116.0,,,50597
8011,,1465,,A,,Tmax was determined,,,Rattus norvegicus,10116.0,,,50597
8012,,2552,,A,,Tmax was determined,,,Rattus norvegicus,10116.0,,,50597
8013,,5656,,A,,Tmax after oral administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8014,,17764,,A,,Tmax after peroral administration in rats at 2.4 uM/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8015,,5610,,A,,Tmax in male rat,,,Rattus norvegicus,10116.0,,,50597
8016,,6046,,A,,Tmax in rat at 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8017,,5874,,A,,Tmax in rat by po administration at a dose of 40 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8018,,17596,,A,,Tmax in rats,,,Rattus norvegicus,10116.0,,,50597
8019,,17804,,A,,Tmax was measured in rats after peroral administration at 5 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8020,,1908,,A,,Tmax value after oral dose at a dose of 10 mg/kg in rats.,In vivo,,Rattus norvegicus,10116.0,,,50597
8021,,2959,,A,,Tmax value after administration of 20 mg/Kg oral dose in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8022,,6757,,A,,Tmax value at a dose of 10 mg/kg in male SD rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8023,,6757,,A,,Tmax value at a dose of 100 mg/kg in male SD rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8024,,6757,,A,,Tmax value at a dose of 50 mg/kg in male SD rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8025,Plasma,4186,,A,,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,In vivo,,Rattus norvegicus,10116.0,,,50597
8026,,15662,,A,,time required to reach maximum concentration (Cmax) after oral administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8027,Urine,429,,A,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),,,Rattus norvegicus,10116.0,,,50597
8028,Urine,429,,A,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),,,Rattus norvegicus,10116.0,,,50597
8029,,5546,,A,,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,,Rattus norvegicus,10116.0,,,50597
8030,Urine,3173,,A,,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,,,Rattus norvegicus,10116.0,,,50597
8031,Urine,3173,,A,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,,,Rattus norvegicus,10116.0,,,50597
8032,Urine,3173,,A,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,,,Rattus norvegicus,10116.0,,,50597
8033,,4257,,A,,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,In vivo,,Rattus norvegicus,10116.0,,,50597
8034,,6011,,A,,Compound distribution in rat tissues was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8035,,5472,,A,,Volume of distribution was evaluated in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8036,,14346,,A,,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,,,Rattus norvegicus,10116.0,,,50597
8037,,14346,,A,,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,,,Rattus norvegicus,10116.0,,,50597
8038,,14346,,A,,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,,,Canis lupus familiaris,9615.0,,,50588
8039,,14346,,A,,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,,,Rattus norvegicus,10116.0,,,50597
8040,,15469,,A,,Area under the curve was determined after oral administration (300 uM/Kg),,,,,,,22224
8041,,14346,,A,,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,,,Rattus norvegicus,10116.0,,,50597
8042,,14346,,A,,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,,,Rattus norvegicus,10116.0,,,50597
8043,,14346,,A,,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,,,Rattus norvegicus,10116.0,,,50597
8044,,14346,,A,,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,,,Rattus norvegicus,10116.0,,,50597
8045,,14346,,A,,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,,,Rattus norvegicus,10116.0,,,50597
8046,,15372,,A,,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,,,Rattus norvegicus,10116.0,,,50597
8047,Plasma,12935,,A,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
8048,Plasma,12935,,A,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
8049,,14813,,A,,Plasma drug AUC in rat (PO dose),,,,,,,22224
8050,,15792,,A,,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,,,Mus musculus,10090.0,,,50594
8051,,3579,,A,,Area under was determined at a dose of 30 mg/kg,,,,,,,22224
8052,,12487,,A,,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,,,Mustela putorius furo,9669.0,,,50506
8053,,12487,,A,,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,,,Rattus norvegicus,10116.0,,,50597
8054,,12487,,A,,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,,,Rattus norvegicus,10116.0,,,50597
8055,,12487,,A,,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,,,Mustela putorius furo,9669.0,,,50506
8056,,12487,,A,,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,,,Canis lupus familiaris,9615.0,,,50588
8057,,12487,,A,,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,,,Canis lupus familiaris,9615.0,,,50588
8058,,12902,,A,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",,,Rattus norvegicus,10116.0,,,50597
8059,,12902,,A,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",,,Rattus norvegicus,10116.0,,,50597
8060,,12902,,A,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",,,Rattus norvegicus,10116.0,,,50597
8061,,12902,,A,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",,,Rattus norvegicus,10116.0,,,50597
8062,,12902,,A,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",,,Rattus norvegicus,10116.0,,,50597
8063,,12902,,A,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",,,Rattus norvegicus,10116.0,,,50597
8064,,12902,,A,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",,,Rattus norvegicus,10116.0,,,50597
8065,,12902,,A,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",,,Rattus norvegicus,10116.0,,,50597
8066,,12745,,A,,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,,,Mus musculus,10090.0,,,50594
8067,,12745,,A,,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,,Mus musculus,10090.0,,,50594
8068,,12745,,A,,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,,,Mus musculus,10090.0,,,50594
8069,,12745,,A,,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,,Mus musculus,10090.0,,,50594
8070,,12745,,A,,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,,,Mus musculus,10090.0,,,50594
8071,,12745,,A,,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,,Mus musculus,10090.0,,,50594
8072,,12745,,A,,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,,,Mus musculus,10090.0,,,50594
8073,,12745,,A,,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,,Mus musculus,10090.0,,,50594
8074,Plasma,13298,,A,,AUC in mice after oral dose (50 mg/kg),,,,,,,22224
8075,Serum,12226,,A,,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,,,Mus musculus,10090.0,,,50594
8076,Plasma,12634,,A,,AUC (0-4 hr) ug/ml/h,,,,,,,22224
8077,,14810,,A,,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,,,Rattus norvegicus,10116.0,,,50597
8078,,13889,,A,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,,,,,,,22224
8079,,10018,,A,,Compound was evaluated for Area under curve in mice,,,Mus musculus,10090.0,,,50594
8080,,8758,,A,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,,Rattus norvegicus,10116.0,,,50597
8081,,8758,,F,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,,,,,,22224
8082,,8758,,A,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,,Rattus norvegicus,10116.0,,,50597
8083,,2249,,A,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,,,,,,,22224
8084,,2249,,A,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,,,,,,,22224
8085,,2249,,A,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,,,,,,,22224
8086,,2249,,A,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,,,,,,,22224
8087,,15115,,A,,Compound was evaluated for area under curve when administered through oral route in mouse,,,Mus musculus,10090.0,,,50594
8088,,6518,,A,,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,In vivo,,Rattus norvegicus,10116.0,,,50597
8089,,6518,,A,,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,In vivo,,Rattus norvegicus,10116.0,,,50597
8090,,6249,,A,,Plasma clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8091,,2463,,A,,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8092,,4969,,A,,Plasma clearance rate in Sprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8093,,17720,,F,,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8094,,3457,,A,,Pharmacokinetic property (total body clearance) in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8095,,5983,,A,,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,In vivo,,Rattus norvegicus,10116.0,,,50597
8096,,6295,,A,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,,Rattus norvegicus,10116.0,,,50597
8097,,6296,,A,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,,Rattus norvegicus,10116.0,,,50597
8098,,17686,,A,,Cl in rat i.v. at 2 mg/kg concentration,In vivo,,Rattus norvegicus,10116.0,,,50597
8099,,17764,,A,,Clearance of compound after intravenous administration in rats at 24 uM/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8100,,5503,,A,,Clearance was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8101,,4368,,A,,Clearance by intravenous administration of 3.4 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8102,,6005,,A,,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8103,,5031,,A,,Clearance rate after i.v. administration in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8104,,4890,,A,,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8105,,5182,,A,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8106,,5979,,A,,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8107,,5656,,A,,Clearance (Cl) after oral administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8108,,17804,,A,,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8109,Plasma,4839,,A,,Compound was tested for plasma clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8110,,5041,,A,,In vitro microsome metabolism clearance in rat was determined,In vitro,,Rattus norvegicus,10116.0,,Microsomes,50597
8111,,5041,,A,,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,In vitro,,Rattus norvegicus,10116.0,,Microsomes,50597
8112,,5974,,A,,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8113,Plasma,5496,,A,,In vivo plasma clearance was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8114,,5739,,A,,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8115,Liver,5676,401.0,A,,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,In vivo,,Rattus norvegicus,10116.0,Hepatocyte,,50597
8116,,4239,,A,,Pharmacokinetic property (Plasma clearance) was measured in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8117,,5676,,A,,Pharmacokinetic property (clearance) in rat i.v.,In vivo,,Rattus norvegicus,10116.0,,,50597
8118,,1918,,A,,"Plasma Clearance was evaluated in rats, iv",In vivo,,Rattus norvegicus,10116.0,,,50597
8119,,17800,,A,,Plasma clearance (in vivo) in rats was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8120,,6056,,A,,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8121,,5496,,A,,Plasma clearance was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8122,,5939,,A,,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,In vivo,,Rattus norvegicus,10116.0,,,50597
8123,,5939,,A,,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,In vivo,,Rattus norvegicus,10116.0,,,50597
8124,,17752,,A,,Plasma clearance in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8125,,4576,,A,,Plasma clearance rate determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8126,,6011,,A,,Plasma clearance was determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8127,,5510,,A,,Plasma clearance was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8128,,5948,,A,,Plasma clearance value in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8129,Liver,6125,,A,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,Ex vivo,,Rattus norvegicus,10116.0,,,50597
8130,,4839,,A,,Clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8131,,17686,,A,,Total body clearance in rat i.v. at 2 mg/kg concentration,In vivo,,Rattus norvegicus,10116.0,,,50597
8132,,6571,,A,,Clearance of compound in rats after intravenous administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8133,,3364,,A,,Clearance after iv administration to rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8134,,13569,,A,,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8135,,13569,,A,,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8136,,13569,,A,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8137,,13569,,A,,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8138,,13569,,A,,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8139,,13569,,A,,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8140,,13569,,A,,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8141,,17670,,A,,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",In vivo,,Rattus norvegicus,10116.0,,,50597
8142,,5970,,A,,Clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8143,,6495,,A,,Clearance in rat after oral administration at 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8144,,4590,,A,,Clearance in rat.,In vivo,,Rattus norvegicus,10116.0,,,50597
8145,,6193,,A,,Clearance rate following an oral dose of 20 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8146,,2832,,A,,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
8147,Plasma,1052,,A,,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,In vivo,,Rattus norvegicus,10116.0,,,50597
8148,Liver,9866,,A,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
8149,Liver,9866,,A,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
8150,Liver,9866,,A,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
8151,Liver,9866,,A,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,In vivo,,Rattus norvegicus,10116.0,,,50597
8152,Liver,9866,,A,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
8153,Liver,9866,,A,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
8154,Liver,9866,,A,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
8155,Liver,9866,,A,,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,In vivo,,Rattus norvegicus,10116.0,,,50597
8156,Liver,9866,,A,,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,In vivo,,Rattus norvegicus,10116.0,,,50597
8157,Muscle tissue,9866,,A,,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,In vivo,,Rattus norvegicus,10116.0,,,50597
8158,Muscle tissue,9866,,A,,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,In vivo,,Rattus norvegicus,10116.0,,,50597
8159,Muscle tissue,9866,,A,,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,In vivo,,Rattus norvegicus,10116.0,,,50597
8160,Muscle tissue,9866,,A,,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,In vivo,,Rattus norvegicus,10116.0,,,50597
8161,Muscle tissue,9866,,A,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
8162,Muscle tissue,9866,,A,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
8163,Muscle tissue,9866,,A,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,In vivo,,Rattus norvegicus,10116.0,,,50597
8164,Muscle tissue,9866,,A,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
8165,Muscle tissue,9866,,A,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
8166,Muscle tissue,9866,,A,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
8167,Muscle tissue,9866,,A,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,In vivo,,Rattus norvegicus,10116.0,,,50597
8168,Muscle tissue,9866,,A,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
8169,Muscle tissue,9866,,A,,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,In vivo,,Rattus norvegicus,10116.0,,,50597
8170,Muscle tissue,9866,,A,,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,In vivo,,Rattus norvegicus,10116.0,,,50597
8171,Intestine,9866,,A,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
8172,Intestine,9866,,A,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
8173,Intestine,9866,,A,,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),In vivo,,Rattus norvegicus,10116.0,,,50597
8174,Spleen,9866,,A,,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,In vivo,,Rattus norvegicus,10116.0,,,50597
8175,Spleen,9866,,A,,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,In vivo,,Rattus norvegicus,10116.0,,,50597
8176,Spleen,9866,,A,,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,In vivo,,Rattus norvegicus,10116.0,,,50597
8177,Spleen,9866,,A,,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,In vivo,,Rattus norvegicus,10116.0,,,50597
8178,Spleen,9866,,A,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,In vivo,,Rattus norvegicus,10116.0,,,50597
8179,Spleen,9866,,A,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
8180,Spleen,9866,,A,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
8181,Spleen,9866,,A,,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,In vivo,,Rattus norvegicus,10116.0,,,50597
8182,Spleen,9866,,A,,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,In vivo,,Rattus norvegicus,10116.0,,,50597
8183,Stomach,9866,,A,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,In vivo,,Rattus norvegicus,10116.0,,,50597
8184,Stomach,9866,,A,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
8185,Stomach,9866,,A,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,In vivo,,Rattus norvegicus,10116.0,,,50597
8186,Blood,13950,,A,,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8187,Blood,13950,,A,,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8188,Blood,13950,,A,,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8189,Blood,13950,,A,,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8190,Blood,13950,,A,,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8191,Brain,13950,,A,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8192,Brain,13950,,A,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8193,Brain,13950,,A,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8194,Brain,13950,,A,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8195,Brain,13950,,A,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8196,Heart,13950,,A,,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8197,Heart,13950,,A,,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8198,Heart,13950,,A,,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8199,,6062,,A,,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8200,,3598,,A,,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,,,Rattus norvegicus,10116.0,,,50597
8201,,1908,,A,,Vc value after IV dose at a dose of 5 mg/kg in rats.,In vivo,,Rattus norvegicus,10116.0,,,50597
8202,,17596,,A,,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8203,,4891,,A,,Compound was evaluated for pharmacokinetic parameter volume of distribution,In vivo,,Rattus norvegicus,10116.0,,,50597
8204,,740,,A,,Compound was evaluated for volume of distribution in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8205,,16366,,A,,Steady state volume distribution was determined; steady state(ss),In vivo,,Rattus norvegicus,10116.0,,,50597
8206,,3364,,A,,Steady state volume of distribution after iv administration to rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8207,,2552,,A,,Steady state volume of distribution dosing at 3 mg/kg iv,In vivo,,Rattus norvegicus,10116.0,,,50597
8208,,406,,A,,The compound was evaluated for volume of distribution in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8209,,12500,,A,,The compound was tested for volume of distribution in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8210,,12500,,A,,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,In vivo,,Rattus norvegicus,10116.0,,,50597
8211,,5656,,A,,Volume distribution (VD) after oral administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8212,,17671,,A,,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8213,,1094,,A,,Volume distribution in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8214,,5833,,A,,Volume distribution in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8215,,5939,,A,,Volume distribution in rat after peroral administration at 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8216,,5939,,A,,Volume distribution in rat after peroral administration at 5 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8217,,6005,,A,,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8218,,1696,,A,,Volume of distribution in rat.,In vivo,,Rattus norvegicus,10116.0,,,50597
8219,,6672,,A,,Volume of distribution in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8220,,6673,,A,,Volume of distribution in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8221,,5871,,A,,Volume of distribution in rat by iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8222,,6803,,A,,Volume of distribution in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8223,,5199,,A,,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,In vivo,,Rattus norvegicus,10116.0,,,50597
8224,,4727,,A,,Volume distribution at the dose of 2 mg/kg in rat,,,Rattus norvegicus,10116.0,,,50597
8225,,16367,,A,,Steady state volume of distribution was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8226,,5005,,A,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,,Macaca mulatta,9544.0,,,22224
8227,,5005,,A,,Compound was tested for its plasma volume distribution in Sprague Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,22224
8228,,5005,,A,,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,In vivo,,Rattus norvegicus,10116.0,,,22224
8229,,15765,,A,,Mean (%CV) PK parameters for Vdss(mL/kg).,In vivo,,Rattus norvegicus,10116.0,,,50597
8230,,2792,,A,,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8231,,2792,,A,,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8232,,5334,,A,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8233,,5334,,A,,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8234,,5739,,A,,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8235,,5789,,A,,Pharmacokinetic property (Vdss) in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8236,,4239,,A,,Pharmacokinetic property (vdss) was measured in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8237,,4709,,A,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8238,,6642,,A,,Volume of distribution in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8239,,5247,,A,,The pharmacokinetic parameter volume of distribution in vivo in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8240,,17720,,F,,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8241,,17686,,A,,Vdss in rat i.v. at 2 mg/kg concentration,In vivo,,Rattus norvegicus,10116.0,,,50597
8242,,4689,,A,,Volume distribution after intravenous administration (1 mg/kg) in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8243,,5654,,A,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8244,,5654,,A,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8245,,4527,,A,,Volume distribution at a dose of 10 uM/kg in rat was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8246,,4521,,A,,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8247,,6057,,A,,Volume distribution was calculated in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8248,,5510,,A,,Volume distribution was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8249,,2938,,A,,Volume of distribution after intravenous administration was evaluated in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8250,,6679,,A,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8251,,6685,,A,,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",In vivo,,Rattus norvegicus,10116.0,,,50597
8252,,6685,,A,,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",In vivo,,Rattus norvegicus,10116.0,,,50597
8253,,6685,,A,,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",In vivo,,Rattus norvegicus,10116.0,,,50597
8254,,5145,,A,,Volume of distribution in steady state was determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8255,,6467,,A,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8256,,6467,,A,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8257,,15115,,A,,Compound was evaluated for area under curve when administered through oral route to mouse,,,Mus musculus,10090.0,,,50594
8258,,8758,,A,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,,Rattus norvegicus,10116.0,,,50597
8259,,8758,,A,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,,Rattus norvegicus,10116.0,,,50597
8260,,8267,,F,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,In vivo,,,,,,22224
8261,,8267,,A,,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,,,Canis lupus familiaris,9615.0,,,50588
8262,,14239,,A,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,,Mus musculus,10090.0,,,50594
8263,,14239,,A,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,,Mus musculus,10090.0,,,50594
8264,Blood,10754,,A,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,,,Mus musculus,10090.0,,,50594
8265,Blood,10754,,A,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,,,Mus musculus,10090.0,,,50594
8266,,10754,,A,,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,,,Canis lupus familiaris,9615.0,,,50588
8267,,14681,,A,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,,,Rattus norvegicus,10116.0,,,50597
8268,,14681,,A,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,,,Rattus norvegicus,10116.0,,,50597
8269,,14681,,A,,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,,Rattus norvegicus,10116.0,,,50597
8270,,13118,,A,,Concentration of compound in Central nervous system,,,,,,,22224
8271,,13118,,A,,Concentration of compound in Central nervous system; Not detectable,,,,,,,22224
8272,,13318,,A,,"Concentration of diester in the blood, following oral administration in mice",,,Mus musculus,10090.0,,,50594
8273,,13318,,A,,"Concentration of monoester in the blood, following oral administration in mice",,,Mus musculus,10090.0,,,50594
8274,,13318,,A,,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,,,Mus musculus,10090.0,,,50594
8275,,15692,,A,,Evaluated for Pharmacokinetic property: Area under the curve,,,,,,,22224
8276,,14839,,A,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,,,Mus musculus,10090.0,,,50594
8277,,14839,,A,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,,,Macaca fascicularis,9541.0,,,100710
8278,,14839,,A,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,,,Macaca fascicularis,9541.0,,,100710
8279,,14839,,A,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,,,Macaca fascicularis,9541.0,,,100710
8280,,14839,,A,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,,,Macaca fascicularis,9541.0,,,100710
8281,,14839,,A,,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,,,Macaca fascicularis,9541.0,,,100710
8282,,14839,,A,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,,Macaca fascicularis,9541.0,,,100710
8283,,14839,,A,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",,,Macaca fascicularis,9541.0,,,100710
8284,,14839,,A,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,,Macaca fascicularis,9541.0,,,100710
8285,,14839,,A,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",,,Macaca fascicularis,9541.0,,,100710
8286,,14839,,A,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",,,Macaca fascicularis,9541.0,,,100710
8287,,14839,,A,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",,,Macaca fascicularis,9541.0,,,100710
8288,,14839,,A,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,,Macaca fascicularis,9541.0,,,100710
8289,,14839,,A,,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,,,Mus musculus,10090.0,,,50594
8290,,14839,,A,,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,,,Mus musculus,10090.0,,,50594
8291,,14839,,A,,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,,,Mus musculus,10090.0,,,50594
8292,,14839,,A,,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,,,Mus musculus,10090.0,,,50594
8293,,14839,,A,,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,,,Mus musculus,10090.0,,,50594
8294,,14839,,A,,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,,,Mus musculus,10090.0,,,50594
8295,,14839,,A,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",,,Mus musculus,10090.0,,,50594
8296,,14839,,A,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",,,Mus musculus,10090.0,,,50594
8297,,14839,,A,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",,,Mus musculus,10090.0,,,50594
8298,,14839,,A,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",,,Mus musculus,10090.0,,,50594
8299,,14839,,A,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",,,Mus musculus,10090.0,,,50594
8300,,14839,,A,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",,,Mus musculus,10090.0,,,50594
8301,Plasma,5408,,A,,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8302,,6827,,A,,High i.v. clearance in Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8303,Liver,17538,,A,,In vitro clearance in rat liver microsomes,In vitro,,Rattus norvegicus,10116.0,,Microsomes,50597
8304,Liver,6331,,A,,Intrinsic clearance in rat liver microsomes was determined,In vitro,,Rattus norvegicus,10116.0,,Microsomes,50597
8305,Liver,5948,401.0,A,,Intrinsic clearance in rat hepatocytes was determined,In vitro,,Rattus norvegicus,10116.0,Hepatocyte,,50597
8306,,4026,,A,,Plasma Clearance was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8307,,6647,,A,,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8308,,1696,,A,,Plasma clearance in rat.,In vivo,,Rattus norvegicus,10116.0,,,50597
8309,,6597,,A,,Plasma clearance in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8310,,347,,A,,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8311,,16423,,A,,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8312,,2879,,A,,Plasma clearance was measured in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8313,,4883,,A,,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8314,Plasma,5328,,A,,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",In vivo,,Rattus norvegicus,10116.0,,,50597
8315,,5160,,A,,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8316,,17582,,A,,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8317,,17651,,A,,Total clearance at 1 mg/kg was determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8318,,17651,,A,,Total clearance at 10 mg/kg was determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8319,,6596,,A,,Clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8320,,4796,,A,,Plasma clearance rate determined in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8321,,6850,,A,,Clearance of compound in rat was evaluated,In vivo,,Rattus norvegicus,10116.0,,,50597
8322,Plasma,5932,,A,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,In vivo,,Rattus norvegicus,10116.0,,,50597
8323,,3371,,A,,Pharmacokinetic property (blood clearance) in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8324,,2083,,A,,Plasma clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8325,,4942,,A,,Plasma clearance in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8326,Liver,6838,,A,,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,In vitro,,Rattus norvegicus,10116.0,,Microsomes,50597
8327,,5353,,A,,Clearance in Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8328,,6641,,A,,Clearance rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8329,,6641,,A,,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),In vivo,,Rattus norvegicus,10116.0,,,50597
8330,,6641,,A,,Clearance rat; Not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8331,,6444,,A,,Clearance rate was determined in rat at a dose of 1 mpk i.v.,In vivo,,Rattus norvegicus,10116.0,,,50597
8332,,6444,,A,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8333,,6444,,A,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8334,,6211,,A,,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8335,Plasma,12873,,A,,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",In vivo,,Rattus norvegicus,10116.0,,,50597
8336,,6570,,A,,Clearance of compound in rat after 1 mg/kg i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8337,,3341,,A,,Compound was evaluated for Hepatic clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8338,,4891,,A,,In vivo clearance after 5 mg/kg dose,In vivo,,Rattus norvegicus,10116.0,,,50597
8339,Plasma,1094,,A,,Compound was tested for plasma clearance in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8340,,2938,,A,,Hepatic clearance after intravenous administration was evaluated in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8341,,17853,,A,,Lower clearance in rat (i.v.) at 0.5 mpk,In vivo,,Rattus norvegicus,10116.0,,,50597
8342,Plasma,6049,,A,,Pharmacokinetic parameter expressed as plasma clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8343,,5789,,A,,Pharmacokinetic property (Clp) in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8344,,4514,,A,,Plasma clearance in Sprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8345,,6448,,A,,Plasma clearance (Clp) in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8346,,6062,,A,,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8347,,5710,,A,,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,In vivo,,Rattus norvegicus,10116.0,,,50597
8348,,4709,,A,,Plasma clearance after intravenous administration of 1 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8349,,4521,,A,,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8350,,1742,,A,,Plasma clearance in rat was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8351,,6057,,A,,Plasma clearance measured in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8352,,6057,,A,,Plasma clearance was calculated in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8353,,5145,,A,,Plasma clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8354,,5833,,A,,Plasma clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8355,,6453,,A,,Plasma clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8356,,6640,,A,,Plasma clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8357,,6305,,A,,Plasma clearance in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8358,,6642,,A,,Plasma clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8359,,5472,,A,,Plasma clearance was evaluated in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8360,,5472,,A,,Plasma clearance was evaluated in rat; Not tested,In vivo,,Rattus norvegicus,10116.0,,,50597
8361,,5144,,A,,Plasma clearance rate was determined for the compound in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8362,,6685,,A,,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",In vivo,,Rattus norvegicus,10116.0,,,50597
8363,,6685,,A,,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",In vivo,,Rattus norvegicus,10116.0,,,50597
8364,,6685,,A,,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",In vivo,,Rattus norvegicus,10116.0,,,50597
8365,Heart,13950,,A,,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8366,Heart,13950,,A,,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8367,Intestine,13950,,A,,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8368,Intestine,13950,,A,,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8369,Intestine,13950,,A,,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8370,Intestine,13950,,A,,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8371,Intestine,13950,,A,,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8372,Kidney,13950,,A,,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8373,Kidney,13950,,A,,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8374,Kidney,13950,,A,,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8375,Kidney,13950,,A,,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8376,Kidney,13950,,A,,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8377,Liver,13950,,A,,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8378,Liver,13950,,A,,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8379,Liver,13950,,A,,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8380,Liver,13950,,A,,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8381,Liver,13950,,A,,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8382,Lung,13950,,A,,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8383,Lung,13950,,A,,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8384,Lung,13950,,A,,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8385,Lung,13950,,A,,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8386,Lung,13950,,A,,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8387,Muscle tissue,13950,,A,,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8388,Muscle tissue,13950,,A,,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8389,Muscle tissue,13950,,A,,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8390,Muscle tissue,13950,,A,,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8391,Muscle tissue,13950,,A,,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8392,Spleen,13950,,A,,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8393,Spleen,13950,,A,,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8394,Spleen,13950,,A,,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8395,Spleen,13950,,A,,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8396,Spleen,13950,,A,,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8397,Stomach,13950,,A,,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8398,Stomach,13950,,A,,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8399,Stomach,13950,,A,,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8400,Stomach,13950,,A,,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8401,Stomach,13950,,A,,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
8402,Cerebellum,13950,,A,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,Rattus norvegicus,10116.0,,,50597
8403,Cerebellum,13950,,A,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,Rattus norvegicus,10116.0,,,50597
8404,,13950,,A,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,Rattus norvegicus,10116.0,,,50597
8405,,6570,,A,,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8406,,6571,,A,,Volume of distribution of compound in rats after intravenous administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8407,,6453,,A,,Volume of distribution in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8408,,6444,,A,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,In vivo,,Rattus norvegicus,10116.0,,,50597
8409,,6444,,A,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8410,,6444,,A,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8411,,5353,,A,,Volume of distribution was determined in Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8412,,5334,,A,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8413,,5334,,A,,Volume of distribution was reported in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8414,,6641,,A,,Volumes of distribution in rat after peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8415,,6641,,A,,Volumes of distribution in rat after po administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8416,,6641,,A,,Volumes of distribution in rat after po administration; Not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8417,,5676,,A,,Pharmacokinetic property (Volume) in rat i.v.,In vivo,,Rattus norvegicus,10116.0,,,50597
8418,,6410,,A,,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,In vivo,,Rattus norvegicus,10116.0,,,50597
8419,,17670,,A,,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",In vivo,,Rattus norvegicus,10116.0,,,50597
8420,,6495,,A,,Volume distribution in rat after oral administration at 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8421,,5408,,A,,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8422,,4883,,A,,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8423,,6647,,A,,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8424,,6495,,A,,Volume of distribution in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8425,,2661,,A,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8426,,2661,,A,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8427,,5974,,A,,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8428,,5974,,A,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8429,,5974,,A,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,In vivo,,Rattus norvegicus,10116.0,,,50597
8430,,5974,,A,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8431,,5960,,A,,Pharmacokinetic parameter (Vss) in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8432,,5676,,A,,Pharmacokinetic property (Volume) in rat i.v.,In vivo,,Rattus norvegicus,10116.0,,,50597
8433,,5948,,A,,Pharmacokinetic property (Vss) in rat,,,Rattus norvegicus,10116.0,,,50597
8434,,5979,,A,,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8435,,5978,,A,,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8436,,5978,,A,,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8437,,5978,,A,,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8438,,5978,,A,,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8439,,6448,,A,,Steady state volume distribution in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8440,Plasma,12873,,A,,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",In vivo,,Rattus norvegicus,10116.0,,,50597
8441,,4576,,A,,Steady state volume of distribution determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8442,,17582,,A,,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8443,,1466,,A,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8444,,5182,,A,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,,,Rattus norvegicus,10116.0,,,50597
8445,,5182,,A,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,,,Rattus norvegicus,10116.0,,,50597
8446,,6535,,A,,Volume distribution in rat after administration of 2 mg/kg iv,In vivo,,Rattus norvegicus,10116.0,,,50597
8447,,6535,,A,,Volume distribution in rat after administration of 2 mg/kg iv,In vivo,,Rattus norvegicus,10116.0,,,50597
8448,,5041,,A,,Volume in steady state distribution value was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8449,,5041,,A,,Volume in steady state distribution value was determined; ND denotes no data,In vivo,,Rattus norvegicus,10116.0,,,50597
8450,,5041,,A,,Volume in steady state distribution value was determined; ND denotes not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8451,,17065,,A,,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8452,,6597,,A,,Volume of distribution at steady state was evaluated in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8453,,15662,,A,,Volume of distribution at steady state was observed after intravenous administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8454,,6485,,A,,Volume of distribution in steady state was determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8455,,17655,,A,,Volume of distribution in steady state was determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8456,,6616,,A,,Volume of distribution after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8457,,1916,,A,,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8458,Liver,16438,,A,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,,Mus musculus,10090.0,,,50594
8459,Liver,16438,,A,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
8460,Spleen,16438,,A,,Biodistribution of compound (oxidized form) in spleen tissue,In vivo,,Mus musculus,10090.0,,,50594
8461,Spleen,16438,,A,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
8462,Spleen,16438,,A,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,,Mus musculus,10090.0,,,50594
8463,Spleen,16438,,A,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,Mus musculus,10090.0,,,50594
8464,Spleen,16438,,A,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,10090.0,,,50594
8465,Spleen,16438,,A,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,,Mus musculus,10090.0,,,50594
8466,Blood,16438,,A,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,In vivo,,Mus musculus,10090.0,,,50594
8467,Blood,16438,,A,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,Mus musculus,10090.0,,,50594
8468,Brain,16438,,A,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,In vivo,,Mus musculus,10090.0,,,50594
8469,Brain,16438,,A,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",In vivo,,Mus musculus,10090.0,,,50594
8470,Brain,16438,,A,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,Mus musculus,10090.0,,,50594
8471,Heart,16438,,A,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,In vivo,,Mus musculus,10090.0,,,50594
8472,Heart,16438,,A,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",In vivo,,Mus musculus,10090.0,,,50594
8473,Heart,16438,,A,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,Mus musculus,10090.0,,,50594
8474,Kidney,16438,,A,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,In vivo,,Mus musculus,10090.0,,,50594
8475,Kidney,16438,,A,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",In vivo,,Mus musculus,10090.0,,,50594
8476,Kidney,16438,,A,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,Mus musculus,10090.0,,,50594
8477,Liver,16438,,A,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,In vivo,,Mus musculus,10090.0,,,50594
8478,Liver,16438,,A,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,Mus musculus,10090.0,,,50594
8479,Spleen,16438,,A,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,In vivo,,Mus musculus,10090.0,,,50594
8480,Spleen,16438,,A,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",In vivo,,Mus musculus,10090.0,,,50594
8481,Spleen,16438,,A,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,Mus musculus,10090.0,,,50594
8482,,12467,,A,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,,,Mus musculus,10090.0,,,50594
8483,Brain,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8484,Brain,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8485,Brain,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8486,Brain,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8487,Brain,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8488,Brain,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8489,Heart,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8490,Heart,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8491,Heart,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8492,Heart,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8493,Heart,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8494,Heart,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8495,Kidney,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8496,Kidney,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8497,Kidney,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8498,Kidney,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8499,,5089,,A,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8500,,5089,,A,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8501,,4257,,A,,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,In vivo,,Rattus norvegicus,10116.0,,,50597
8502,,6679,,A,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8503,,5546,,A,,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8504,,6141,,A,,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8505,,5334,,A,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8506,,5334,,A,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8507,,5334,,A,,Plasma clearance was reported in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8508,,4689,,A,,Plasma clearance after intravenous administration (1 mg/kg) in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8509,,6848,,A,,Plasma clearance of compound in rats was evaluated,In vivo,,Rattus norvegicus,10116.0,,,50597
8510,,6848,,A,,Plasma clearance of compound in rats was evaluated; ND indicates not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8511,,6467,,A,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8512,,6467,,A,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8513,,4956,,A,,Plasma clearance rate in Sprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8514,,5529,,A,,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
8515,Plasma,406,,A,,The compound was evaluated for plasma clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8516,Plasma,17655,,A,,Total plasma clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8517,Blood,3293,,A,,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,In vivo,,Rattus norvegicus,10116.0,,,50597
8518,Blood,4075,,A,,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8519,,2792,,A,,C max was determined at 10 mg/kg po dose in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8520,,2792,,A,,C max was determined at 3 mg/kg po dose in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8521,,17594,,A,,Cmax after repeated oral dose of compound at 1 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8522,,17594,,A,,Cmax after single intravenous bolus of 1 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8523,,4762,,A,,Cmax of compound at 5 mg/kg after po administration was determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8524,,17509,,A,,Cmax 24 hr after 10 mg/kg oral administration in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8525,,17509,,A,,Cmax 24 hr after 2 mg/kg oral administration in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8526,Plasma,1466,,A,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8527,,6535,,A,,Cmax in rat after administration of 2 mg/kg iv,In vivo,,Rattus norvegicus,10116.0,,,50597
8528,,6535,,A,,Cmax in rat after administration of 2 mg/kg iv,In vivo,,Rattus norvegicus,10116.0,,,50597
8529,,3169,,A,,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8530,Plasma,6515,,A,,Cmax wa determined in rat plasma at 30 mg/kg after po administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8531,Blood,11149,,A,,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8532,Blood,11149,,A,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8533,,17858,,A,,Cmax after 10 mg/kg oral administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8534,,6518,,A,,Cmax after IV dosing at 0.5 mg/kg in rat; no data,In vivo,,Rattus norvegicus,10116.0,,,50597
8535,,6518,,A,,Cmax after IV dosing at 1 mg/kg in rat; no data,In vivo,,Rattus norvegicus,10116.0,,,50597
8536,,4426,,A,,Cmax after oral administration at 20 mpk in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8537,,4426,,A,,Cmax after oral administration at 20 mpk in rats; Not performed.,In vivo,,Rattus norvegicus,10116.0,,,50597
8538,,4426,,A,,Cmax after oral administration at 20 mpk in rats d; Not performed.,In vivo,,Rattus norvegicus,10116.0,,,50597
8539,,5656,,A,,Cmax after oral administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8540,,6518,,A,,Cmax after oral administration at a dose of 2 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8541,,6518,,A,,Cmax after oral administration at a dose of 4 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8542,,6113,,A,,Cmax in rats after 20 mg/kg oral dose,In vivo,,Rattus norvegicus,10116.0,,,50597
8543,,17764,,A,,Cmax after peroral administration in rats at 2.4 uM/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8544,,4756,,A,,Cmax at the dose of 2 mg/Kg administered perorally in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8545,,4756,,A,,Cmax at the dose of 5 mg/Kg administered perorally in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8546,,6402,,A,,Cmax by administering at 20 mg/kg p.o. in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8547,,5610,,A,,Cmax in male rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8548,,5207,,A,,Cmax in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8549,,6011,,A,,Cmax in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8550,,6504,,A,,Cmax in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8551,,6046,,A,,Cmax in rat at 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8552,,6504,,A,,Cmax in rat at the dose of 1 mg/kg i.v.,In vivo,,Rattus norvegicus,10116.0,,,50597
8553,,5874,,A,,Cmax in rat by po administration at a dose of 40 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8554,,17686,,A,,Cmax in rat p.o. at 20 mg/kg concentration,In vivo,,Rattus norvegicus,10116.0,,,50597
8555,,5836,,A,,Cmax in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8556,,17596,,A,,Cmax in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8557,,16423,,A,,Cmax was evaluated after 20 uM/kg of peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8558,,17804,,A,,Cmax was measured in rats after peroral administration at 3 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8559,,1908,,A,,Cmax value after oral dose at a dose of 10 mg/kg in rats.,In vivo,,Rattus norvegicus,10116.0,,,50597
8560,,13950,,A,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,Rattus norvegicus,10116.0,,,50597
8561,Frontal cortex,13950,,A,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,Rattus norvegicus,10116.0,,,50597
8562,Frontal cortex,13950,,A,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,Rattus norvegicus,10116.0,,,50597
8563,Hippocampus,13950,,A,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,Rattus norvegicus,10116.0,,,50597
8564,Hippocampus,13950,,A,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,Rattus norvegicus,10116.0,,,50597
8565,,13950,,A,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,Rattus norvegicus,10116.0,,,50597
8566,,13950,,A,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,Rattus norvegicus,10116.0,,,50597
8567,Midbrain,13950,,A,,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,Rattus norvegicus,10116.0,,,50597
8568,Midbrain,13950,,A,,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,Rattus norvegicus,10116.0,,,50597
8569,,13950,,A,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,Rattus norvegicus,10116.0,,,50597
8570,,13950,,A,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,Rattus norvegicus,10116.0,,,50597
8571,Striatum,13950,,A,,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,Rattus norvegicus,10116.0,,,50597
8572,Striatum,13950,,A,,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,Rattus norvegicus,10116.0,,,50597
8573,Blood,16434,,A,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
8574,Blood,16434,,A,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
8575,Blood,16434,,A,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
8576,Blood,16434,,A,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
8577,Blood,16434,,A,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
8578,Blood,16434,,A,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
8579,Blood,16434,,A,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
8580,Blood,16434,,A,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
8581,Blood,16435,,A,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
8582,Blood,16435,,A,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
8583,Blood,16435,,A,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
8584,Blood,16435,,A,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
8585,Blood,16435,,A,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
8586,Blood,16435,,A,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
8587,Blood,16435,,A,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
8588,Blood,16435,,A,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
8589,Blood,16434,,A,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,Rattus norvegicus,10116.0,,,50597
8590,Blood,16434,,A,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,Rattus norvegicus,10116.0,,,50597
8591,Blood,16434,,A,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,Rattus norvegicus,10116.0,,,50597
8592,Blood,16435,,A,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
8593,Blood,16435,,A,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
8594,Blood,16435,,A,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
8595,Blood,16435,,A,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
8596,Blood,16435,,A,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
8597,Blood,16435,,A,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
8598,,16434,,A,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
8599,,16434,,A,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
8600,,16434,,A,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
8601,,16434,,A,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
8602,,17764,,A,,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8603,,5031,,A,,Volume of steady state distribution after i.v. administration in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8604,,6215,,A,,Vss after intravenous administration (5.0 mg/kg) was determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8605,,17671,,A,,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8606,,17752,,A,,Vss was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8607,,6596,,A,,Vss in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8608,,16423,,A,,Vss was evaluated after 10 uM/kg of intra arterial administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8609,,15662,,A,,volume of distribution at steady state was observed after intravenous administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8610,,6062,,A,,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8611,,5874,,A,,Pharmacokinetic (PK) parameter Vz in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8612,,4942,,A,,Volume distribution in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8613,,17796,,A,,Volume of distribution in rat; No data,In vivo,,Rattus norvegicus,10116.0,,,50597
8614,,4890,,A,,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8615,Ileum,15765,,A,,% absorption predicted from in vitro rat ileum transport studies,,,Rattus norvegicus,10116.0,,,50597
8616,,13569,,A,,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8617,,13569,,A,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8618,,13569,,A,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8619,,13569,,A,,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
8620,,13569,,A,,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8621,,13569,,A,,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8622,,13569,,A,,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8623,,13569,,A,,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8624,,4576,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8625,Plasma,750,,A,,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,In vivo,,Rattus norvegicus,10116.0,,,50597
8626,,750,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8627,,4590,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8628,,1716,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8629,,1974,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8630,,4502,,A,,Oral bioavailability in rat (dose 30 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
8631,,3371,,A,,Pharmacokinetic property (cLogP) in rat,,,Rattus norvegicus,10116.0,,,50597
8632,Blood,9099,,F,,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,,,Rattus norvegicus,10116.0,,,50597
8633,Blood,9099,,F,,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,,,Rattus norvegicus,10116.0,,,50597
8634,,4590,,A,,Clearance in rat.,In vivo,,Rattus norvegicus,10116.0,,,50597
8635,,3184,,A,,Compound was evaluated for its clearance when administered intravenously in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8636,,16456,,A,,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8637,,4199,,A,,Blood: Brain distribution ratio is determined in rat,,,Rattus norvegicus,10116.0,,,50597
8638,,4199,,A,,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,,,Rattus norvegicus,10116.0,,,50597
8639,,4199,,A,,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,,,Rattus norvegicus,10116.0,,,50597
8640,Kidney,8677,,A,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
8641,,7449,,F,,Percent dose excreted in 0-48 hours administered ip to male rat,,,Rattus norvegicus,10116.0,,,50597
8642,Cerebellum,11977,,A,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,Rattus norvegicus,10116.0,,,50597
8643,Cerebellum,11977,,A,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,Rattus norvegicus,10116.0,,,50597
8644,Cerebellum,11977,,A,,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,Rattus norvegicus,10116.0,,,50597
8645,Cerebellum,11977,,A,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,Rattus norvegicus,10116.0,,,50597
8646,Cerebellum,11977,,A,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,Rattus norvegicus,10116.0,,,50597
8647,,11977,,A,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,Rattus norvegicus,10116.0,,,50597
8648,,11977,,A,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,Rattus norvegicus,10116.0,,,50597
8649,,11977,,A,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,Rattus norvegicus,10116.0,,,50597
8650,,11977,,A,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,Rattus norvegicus,10116.0,,,50597
8651,,11977,,A,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,Rattus norvegicus,10116.0,,,50597
8652,,11977,,A,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,Rattus norvegicus,10116.0,,,50597
8653,,11977,,A,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,Rattus norvegicus,10116.0,,,50597
8654,Kidney,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8655,Kidney,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8656,Liver,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8657,Liver,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8658,Liver,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8659,Liver,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8660,Liver,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8661,Liver,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8662,Lung,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8663,Lung,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8664,Lung,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8665,Lung,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8666,Lung,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8667,Lung,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8668,Muscle tissue,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8669,Muscle tissue,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8670,Muscle tissue,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8671,Muscle tissue,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8672,Muscle tissue,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8673,Muscle tissue,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8674,Zone of skin,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8675,Zone of skin,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8676,Zone of skin,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8677,Zone of skin,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8678,Zone of skin,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8679,Zone of skin,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8680,Spleen,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8681,Spleen,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8682,Spleen,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8683,Spleen,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8684,Spleen,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8685,Spleen,17208,,A,,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8686,Blood,17208,,A,,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8687,Blood,17208,,A,,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8688,Blood,17208,,A,,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8689,Blood,17208,,A,,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8690,Blood,17208,,A,,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8691,Blood,17208,,A,,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),In vivo,,Mus musculus,10090.0,,,50594
8692,,3132,,A,,Time taken for EC90 was determined when tested in mouse,,,Mus musculus,10090.0,,,50594
8693,,3132,,A,,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,,,Mus musculus,10090.0,,,50594
8694,,16597,,A,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),In vivo,,Mus musculus,10090.0,,,50594
8695,,5727,,A,,Half life in mice,,,Mus musculus,10090.0,,,50594
8696,,5302,,A,,Half life period in mouse after 10 mg/Kg dose,In vivo,,Mus musculus,10090.0,,,50594
8697,,5302,,A,,Half life period in mouse after 10 mg/kg dose,In vivo,,Mus musculus,10090.0,,,50594
8698,,6348,,A,,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,,Mus musculus,10090.0,,,50594
8699,,5964,,A,,Cmax value at 5 mg/kg po was determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8700,,6078,,A,,Cmax value evaluated in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8701,Brain,5206,,A,,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,In vivo,,Rattus norvegicus,10116.0,,,50597
8702,,2959,,A,,Cmax value after administration of 20 mg/Kg oral dose in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8703,,5964,,A,,Cmax value at 1 mg/kg po in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8704,,5964,,A,,Cmax value at 5 mg/kg po in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8705,,6757,,A,,Cmax value at a dose of 10 mg/kg in male SD rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8706,,6757,,A,,Cmax value at a dose of 100 mg/kg in male SD rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8707,,6757,,A,,Cmax value at a dose of 50 mg/kg in male SD rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8708,,17617,,A,,Cmax value in rats at 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8709,,1445,,A,,Cmax value was evaluated in rats at a dose of 20 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8710,,6082,,A,,Cmax value was determined after peroral administration of 20 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8711,,1446,,A,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,In vivo,,Rattus norvegicus,10116.0,,,50597
8712,Plasma,5407,,A,,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8713,Plasma,2690,,A,,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8714,,2661,,A,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8715,,2661,,A,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8716,Plasma,4891,,A,,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,In vivo,,Rattus norvegicus,10116.0,,,50597
8717,Plasma,2807,,A,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
8718,Plasma,2807,,A,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
8719,Plasma,2807,,A,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
8720,,3634,,A,,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8721,Plasma,1881,,A,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
8722,Plasma,1881,,A,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
8723,,429,,A,,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8724,,5974,,A,,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8725,,5974,,A,,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8726,,5974,,A,,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8727,,5974,,A,,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8728,,17582,,A,,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,In vivo,,Rattus norvegicus,10116.0,,,50597
8729,,17582,,A,,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,In vivo,,Rattus norvegicus,10116.0,,,50597
8730,Plasma,3032,,A,,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",In vivo,,Rattus norvegicus,10116.0,,,50597
8731,Plasma,6295,,A,,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8732,,6619,,A,,Maximal concentration in rat was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8733,,6616,,A,,Maximal concentration after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8734,Plasma,3249,,A,,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8735,Plasma,17791,,A,,Maximal plasma concentration in rat after oral administration at 50 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8736,Plasma,17791,,A,,Cmax in rat plasma after oral dose (50 mg/Kg),In vivo,,Rattus norvegicus,10116.0,,,50597
8737,Plasma,1360,,A,,Maximal plasma concentration was determined.,In vivo,,Rattus norvegicus,10116.0,,,50597
8738,Plasma,2552,,A,,Maximal plasma drug concentration was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8739,,6571,,A,,Maximal concentration in rats after peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8740,,6570,,A,,Maximum concentration in rat after 2 mg/kg peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8741,Plasma,6567,,A,,Maximum concentration in rat plasma after 5 mg/kg oral gavage,In vivo,,Rattus norvegicus,10116.0,,,50597
8742,,3031,,A,,Maximum concentration of compound in rat was evaluated.,In vivo,,Rattus norvegicus,10116.0,,,50597
8743,,3436,,A,,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8744,,3436,,A,,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8745,,2083,,A,,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8746,,3436,,A,,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8747,,4527,,A,,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8748,,1974,,A,,Maximum concentration was evaluated in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8749,Cerebrospinal fluid,3307,,A,,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8750,Plasma,3307,,A,,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8751,Plasma,1916,,A,,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8752,,1500,,A,,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8753,,1500,,A,,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8754,Plasma,4186,,A,,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,In vivo,,Rattus norvegicus,10116.0,,,50597
8755,,16434,,A,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
8756,,16434,,A,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
8757,,16434,,A,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
8758,,16434,,A,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
8759,,16435,,A,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
8760,,16435,,A,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
8761,,16435,,A,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
8762,,16435,,A,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
8763,,16435,,A,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
8764,,16435,,A,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
8765,,16435,,A,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
8766,,16435,,A,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
8767,,16434,,A,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,Rattus norvegicus,10116.0,,,50597
8768,,16434,,A,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,Rattus norvegicus,10116.0,,,50597
8769,,16434,,A,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,Rattus norvegicus,10116.0,,,50597
8770,,16435,,A,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
8771,,16435,,A,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
8772,,16435,,A,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
8773,,16435,,A,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
8774,,16435,,A,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
8775,,16435,,A,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
8776,Brain,16434,,A,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
8777,Brain,16434,,A,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
8778,Brain,16434,,A,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
8779,Brain,16434,,A,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
8780,Brain,16434,,A,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
8781,Brain,16434,,A,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
8782,Brain,16434,,A,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
8783,Brain,16434,,A,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
8784,Brain,16435,,A,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
8785,Brain,16435,,A,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
8786,Brain,16435,,A,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
8787,Brain,16435,,A,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
8788,Brain,16435,,A,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
8789,Brain,16435,,A,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
8790,Brain,16435,,A,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
8791,Brain,16435,,A,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
8792,Brain,16434,,A,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,Rattus norvegicus,10116.0,,,50597
8793,Brain,16434,,A,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,Rattus norvegicus,10116.0,,,50597
8794,Brain,16434,,A,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,Rattus norvegicus,10116.0,,,50597
8795,Brain,16435,,A,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
8796,Brain,16435,,A,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
8797,Brain,16435,,A,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
8798,Brain,16435,,A,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
8799,Brain,16435,,A,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
8800,Brain,16435,,A,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
8801,,11977,,A,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,Rattus norvegicus,10116.0,,,50597
8802,,11977,,A,,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,Rattus norvegicus,10116.0,,,50597
8803,Hippocampus,11977,,A,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,Rattus norvegicus,10116.0,,,50597
8804,Hippocampus,11977,,A,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,Rattus norvegicus,10116.0,,,50597
8805,Hippocampus,11977,,A,,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,Rattus norvegicus,10116.0,,,50597
8806,Hippocampus,11977,,A,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,Rattus norvegicus,10116.0,,,50597
8807,Striatum,11977,,A,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,Rattus norvegicus,10116.0,,,50597
8808,Striatum,11977,,A,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,Rattus norvegicus,10116.0,,,50597
8809,Striatum,11977,,A,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,Rattus norvegicus,10116.0,,,50597
8810,Striatum,11977,,A,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,Rattus norvegicus,10116.0,,,50597
8811,Striatum,11977,,A,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,Rattus norvegicus,10116.0,,,50597
8812,Blood,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8813,Blood,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8814,Blood,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8815,Blood,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8816,Brain,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8817,Brain,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8818,Brain,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8819,Brain,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8820,Brain,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8821,Heart,11977,,A,,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8822,Heart,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8823,Heart,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8824,Heart,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8825,Heart,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8826,Kidney,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8827,Kidney,11977,,A,,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8828,Kidney,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8829,Kidney,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8830,Liver,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8831,Liver,11977,,A,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8832,Liver,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8833,Liver,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8834,Liver,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8835,Lung,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8836,Lung,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8837,Lung,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8838,Lung,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8839,Lung,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8840,Muscle tissue,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8841,,4573,,A,,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,In vivo,,Mus musculus,10090.0,,,50594
8842,Plasma,3132,,A,,Half life in mouse plasma was determined at dose 25 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
8843,,17718,,A,,Half life was determined,,,Mus musculus,10090.0,,,50594
8844,,17728,,A,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,In vivo,,Mus musculus,10090.0,,,50594
8845,,5961,,A,,Half-life in male mice after 1 mg/kg intravenous dose,In vivo,,Mus musculus,10090.0,,,50594
8847,Plasma,17731,,A,,Half life in mice plasma,,,Mus musculus,10090.0,,,50594
8848,,17592,,A,,Half life in mouse,,,Mus musculus,10090.0,,,50594
8849,Plasma,3132,,A,,Half life in mouse plasma at dose 25 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
8850,,17729,,A,,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,In vivo,,Mus musculus,10090.0,,,50594
8851,,17729,,A,,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,In vivo,,Mus musculus,10090.0,,,50594
8852,,17729,,A,,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,In vivo,,Mus musculus,10090.0,,,50594
8853,,3277,,A,,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),In vivo,,Mus musculus,10090.0,,,50594
8854,,3760,,A,,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",In vivo,,Mus musculus,10090.0,,,50594
8855,,3760,,A,,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",In vivo,,Mus musculus,10090.0,,,50594
8856,,2862,,A,,Half-life by iv administration in mouse,In vivo,,Mus musculus,10090.0,,,50594
8857,,2862,,A,,Half-life by oral administration in mouse,In vivo,,Mus musculus,10090.0,,,50594
8858,,5980,,A,,Half-life in mice,,,Mus musculus,10090.0,,,50594
8859,Brain,6159,,A,,Half-life using mouse brain homogenate,,,Mus musculus,10090.0,,,50594
8860,,6254,,A,,Half-life was measured in mice,,,Mus musculus,10090.0,,,50594
8861,,6062,,A,,Half-life was measured in mouse after an iv dose of 1 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
8862,Blood,1574,,A,,Half-life period was determined in mouse blood,,,Mus musculus,10090.0,,,50594
8863,Brain,56,,A,,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",,,Mus musculus,10090.0,,,50594
8864,Plasma,993,,A,,Plasma half life in mouse,,,Mus musculus,10090.0,,,50594
8865,,6652,,A,,Stability of the peptide in the presence of mouse serum,,,Mus musculus,10090.0,,,50594
8866,,17852,,A,,Terminal half life of compound was determined in mouse,,,Mus musculus,10090.0,,,50594
8867,,2675,,A,,Terminal half life was evaluated in mice after intravenous administration,In vivo,,Mus musculus,10090.0,,,50594
8868,,2675,,A,,Terminal half life was evaluated in mice after oral administration,In vivo,,Mus musculus,10090.0,,,50594
8869,,499,,A,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,,,Mus musculus,10090.0,,,50594
8870,,499,,A,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,,,Mus musculus,10090.0,,,50594
8871,,499,,A,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,,,Mus musculus,10090.0,,,50594
8872,,14239,,A,,half life period is evaluated by administering intravenously at 25 mg/kg in mice,In vivo,,Mus musculus,10090.0,,,50594
8873,,5506,,A,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",In vivo,,Mus musculus,10090.0,,,50594
8874,,5506,,A,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",In vivo,,Mus musculus,10090.0,,,50594
8875,,17734,,A,,Half life after intraperitoneal administration of 100 mg/kg in mice,,,Mus musculus,10090.0,,,50594
8876,,17728,,A,,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,In vivo,,Mus musculus,10090.0,,,50594
8877,,17728,,A,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,In vivo,,Mus musculus,10090.0,,,50594
8878,,17728,,A,,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,In vivo,,Mus musculus,10090.0,,,50594
8879,,17728,,A,,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,In vivo,,Mus musculus,10090.0,,,50594
8880,,17728,,A,,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,In vivo,,Mus musculus,10090.0,,,50594
8881,,14294,,A,,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),,,Sus scrofa,9823.0,,Microsomes,22224
8882,,14294,,A,,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),,,Sus scrofa,9823.0,,Microsomes,22224
8883,,6056,,A,,Stability to porcine renal DHP-I,,,Sus scrofa,9823.0,,,22224
8884,,1317,,A,,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,In vivo,,Sus scrofa,9823.0,,,22224
8885,,1317,,A,,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,In vivo,,Sus scrofa,9823.0,,,22224
8886,,5229,,A,,Half-life of the parent prodrug in porcine esterase solution,,,Sus scrofa,9823.0,,,22224
8887,,4231,,A,,"First order rate constant, k was determined in in pig liver Esterase",,,Sus scrofa,9823.0,,,22224
8888,Liver,4231,,A,,Half life of the in pig liver Esterase,,,Sus scrofa,9823.0,,,22224
8889,Liver,5318,,A,,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,,,Sus scrofa,9823.0,,,22224
8890,Liver,5318,,A,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,,,Sus scrofa,9823.0,,,22224
8891,Liver,5318,,A,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,,,Sus scrofa,9823.0,,,22224
8892,Liver,3305,,A,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,,,Sus scrofa,9823.0,,,22224
8893,Liver,3305,,A,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,,,Sus scrofa,9823.0,,,22224
8894,Liver,2842,,A,,Half-life in the presence of pig liver esterase(PLE) was evaluated.,,,Sus scrofa,9823.0,,,22224
8895,Liver,2842,,A,,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,,,Sus scrofa,9823.0,,,22224
8896,Liver,889,,A,,Half-life in vitro in pig liver,In vitro,,Sus scrofa,9823.0,,,22224
8897,Liver,1904,,A,,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,,,Sus scrofa,9823.0,,,22224
8898,Plasma,4186,,A,,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,In vivo,,Rattus norvegicus,10116.0,,,50597
8899,Plasma,2774,,A,,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
8900,Plasma,1742,,A,,Maximum concentration in rat plasma was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
8901,,3169,,A,,Maximum concentration in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8902,,3169,,A,,Maximum concentration in rats at 1-2 hours,In vivo,,Rattus norvegicus,10116.0,,,50597
8903,,2081,,A,,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,In vivo,,Rattus norvegicus,10116.0,,,50597
8904,Brain,3307,,A,,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8905,,4727,,A,,Maximum concentration at the dose of 2 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8906,,6597,,A,,Maximum concentration was evaluated in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8907,Plasma,16365,,A,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8908,Plasma,16365,,A,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8909,Plasma,16365,,A,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8910,Plasma,16365,,A,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8911,Plasma,16365,,A,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8912,Blood,2591,,A,,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8913,Blood,2591,,A,,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8914,Blood,2591,,A,,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8915,Plasma,5978,,A,,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8916,Plasma,5978,,A,,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8917,Plasma,5978,,A,,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8918,Plasma,5978,,A,,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8919,Plasma,5978,,A,,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8920,Plasma,5978,,A,,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8921,Plasma,5978,,A,,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8922,,14465,,A,,Cmax in rat (PO dose),In vivo,,Rattus norvegicus,10116.0,,,50597
8923,Plasma,4723,,A,,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8924,Plasma,4723,,A,,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8925,Plasma,4576,,A,,Maximum plasma concentration determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8926,Plasma,12873,,A,,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8927,Plasma,12873,,A,,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
8928,Plasma,6824,,A,,Maximum plasma concentration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8929,Plasma,17065,,A,,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8930,Plasma,2932,,A,,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,In vivo,,Rattus norvegicus,10116.0,,,50597
8931,Plasma,2932,,A,,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,In vivo,,Rattus norvegicus,10116.0,,,50597
8932,Plasma,2879,,A,,Maximum plasma concentration of compound was measured in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8933,Plasma,2864,,A,,Maximum plasma concentration after 20 mg/kg oral administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
8934,Plasma,16367,,A,,Maximum plasma concentration after oral administration to rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8935,Plasma,17717,,A,,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,In vivo,,Rattus norvegicus,10116.0,,,50597
8936,Plasma,17717,,A,,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",In vivo,,Rattus norvegicus,10116.0,,,50597
8937,Plasma,17717,,A,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,In vivo,,Rattus norvegicus,10116.0,,,50597
8938,Plasma,17717,,A,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,In vivo,,Rattus norvegicus,10116.0,,,50597
8939,Plasma,17720,,F,,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8940,Plasma,17720,,F,,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8941,Plasma,17720,,F,,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8942,Plasma,4516,,A,,Maximum plasma concentration dosed orally in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8943,Plasma,4516,,A,,Maximum plasma concentration dosed orally in rats after 6 hours,In vivo,,Rattus norvegicus,10116.0,,,50597
8944,Plasma,4516,,A,,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,In vivo,,Rattus norvegicus,10116.0,,,50597
8945,Plasma,5199,,A,,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
8946,Plasma,17538,,A,,Maximum plasma concentration in rat after po administration,In vivo,,Rattus norvegicus,10116.0,,,50597
8947,Plasma,6685,,A,,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",In vivo,,Rattus norvegicus,10116.0,,,50597
8948,Plasma,6685,,A,,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",In vivo,,Rattus norvegicus,10116.0,,,50597
8949,Heart,16434,,A,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
8950,Heart,16434,,A,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
8951,Heart,16434,,A,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
8952,Heart,16434,,A,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
8953,Heart,16434,,A,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
8954,Heart,16434,,A,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
8955,Heart,16434,,A,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
8956,Heart,16434,,A,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
8957,Heart,16435,,A,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
8958,Heart,16435,,A,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
8959,Heart,16435,,A,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
8960,Heart,16435,,A,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
8961,Heart,16434,,A,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,Rattus norvegicus,10116.0,,,50597
8962,Heart,16434,,A,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,Rattus norvegicus,10116.0,,,50597
8963,Heart,16434,,A,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,Rattus norvegicus,10116.0,,,50597
8964,Heart,16435,,A,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
8965,Heart,16435,,A,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
8966,Heart,16435,,A,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
8967,Heart,16435,,A,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
8968,Heart,16435,,A,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
8969,Heart,16435,,A,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
8970,Heart,16435,,A,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
8971,Heart,16435,,A,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
8972,Heart,16435,,A,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
8973,Heart,16435,,A,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
8974,Kidney,16434,,A,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
8975,Kidney,16434,,A,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
8976,Kidney,16434,,A,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
8977,Kidney,16434,,A,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
8978,Kidney,16434,,A,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
8979,Kidney,16434,,A,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
8980,Kidney,16434,,A,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
8981,Kidney,16434,,A,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
8982,Kidney,16435,,A,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
8983,Kidney,16435,,A,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
8984,Kidney,16435,,A,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
8985,Kidney,16435,,A,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
8986,Kidney,16435,,A,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
8987,Kidney,16435,,A,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
8988,Kidney,16435,,A,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
8989,Kidney,16435,,A,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
8990,Kidney,16434,,A,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,Rattus norvegicus,10116.0,,,50597
8991,Kidney,16434,,A,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,Rattus norvegicus,10116.0,,,50597
8992,Kidney,16434,,A,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,Rattus norvegicus,10116.0,,,50597
8993,Kidney,16435,,A,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
8994,Muscle tissue,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8995,Muscle tissue,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8996,Muscle tissue,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8997,Muscle tissue,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8998,Muscle tissue,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
8999,Zone of skin,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
9000,Zone of skin,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
9001,Zone of skin,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
9002,Zone of skin,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
9003,Zone of skin,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
9004,Spleen,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
9005,Spleen,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
9006,Spleen,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
9007,Spleen,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
9008,Spleen,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
9009,Thyroid gland,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
9010,Thyroid gland,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
9011,Thyroid gland,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
9012,Thyroid gland,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
9013,Thyroid gland,11977,,A,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
9014,Liver,11977,,A,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),In vivo,,Rattus norvegicus,10116.0,,,50597
9015,,3748,,A,,Half life in rats,,,Rattus norvegicus,10116.0,,,50597
9016,,15765,,A,,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,,,Rattus norvegicus,10116.0,,,50597
9017,,4871,,A,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),,,Rattus norvegicus,10116.0,,,50597
9018,,4871,,A,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,,,Rattus norvegicus,10116.0,,,50597
9019,,4872,,A,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),,,Rattus norvegicus,10116.0,,,50597
9020,,4872,,A,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,,,Rattus norvegicus,10116.0,,,50597
9021,,5413,,A,,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),,,Rattus norvegicus,10116.0,,,50597
9022,,5413,,A,,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,,,Rattus norvegicus,10116.0,,,50597
9023,Blood,15272,,A,,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,In vivo,,Rattus norvegicus,10116.0,,,50597
9024,Liver,4689,,A,,Stability (%) in rat liver microsomes,,,Rattus norvegicus,10116.0,,,50597
9025,,6057,,A,,Area under curve was calculated after intravenous administration,,,Rattus norvegicus,10116.0,,,50597
9026,,6057,,A,,Area under the curve was calculated after iv administration in rat,,,Rattus norvegicus,10116.0,,,50597
9027,,6057,,A,,Area under the curve was calculated in rat after peroral administration,,,Rattus norvegicus,10116.0,,,50597
9028,,6211,,A,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,,Rattus norvegicus,10116.0,,,50597
9029,,5710,,A,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,,,Rattus norvegicus,10116.0,,,50597
9030,,5710,,A,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,,,Rattus norvegicus,10116.0,,,50597
9031,,17853,,A,,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,,,Rattus norvegicus,10116.0,,,50597
9032,,17853,,A,,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,,,Rattus norvegicus,10116.0,,,50597
9033,,15765,,A,,p value of the compound,,,Rattus norvegicus,10116.0,,,50597
9034,,15765,,F,,p value of the compound,,,Rattus norvegicus,10116.0,,,50597
9035,,15765,,A,,p value of the compound,,,Rattus norvegicus,10116.0,,,50597
9036,Stomach,6175,,A,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,,Rattus norvegicus,10116.0,,,50597
9037,Stomach,6175,,A,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,,Rattus norvegicus,10116.0,,,50597
9038,Stomach,6175,,A,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,,Rattus norvegicus,10116.0,,,50597
9039,,7991,,F,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),,,Oryctolagus cuniculus,9986.0,,,22224
9040,,429,,A,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),,,Oryctolagus cuniculus,9986.0,,,22224
9041,,429,,A,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),,,Oryctolagus cuniculus,9986.0,,,22224
9042,,6253,,A,,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9043,,6253,,A,,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9044,,3615,,A,,Clearance rate in rabbits,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9045,,4059,,A,,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9046,,5124,,A,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9047,,5124,,A,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9048,,5124,,A,,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9049,,429,,A,,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9050,Plasma,4059,,A,,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9051,Liver,9659,,A,,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,,,Oryctolagus cuniculus,9986.0,,Microsomes,22224
9052,Liver,9659,,A,,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,,,Oryctolagus cuniculus,9986.0,,Microsomes,22224
9053,,3639,,A,,Dose at which bioavailability of intravenously administered compound was tested in rabbit,,,Oryctolagus cuniculus,9986.0,,,22224
9054,,3639,,A,,Dose at which bioavailability of perorally administered compound was tested in rabbit,,,Oryctolagus cuniculus,9986.0,,,22224
9055,,3639,,A,,The compound was tested for its bioavailability in rabbit (by oral dosage).,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9056,,5124,,A,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9057,,5124,,A,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9058,,5124,,A,,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9059,,14294,,A,,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),,,Oryctolagus cuniculus,9986.0,,Microsomes,22224
9060,,14294,,A,,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),,,Oryctolagus cuniculus,9986.0,,Microsomes,22224
9061,,429,,A,,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9062,Plasma,5124,,A,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9063,Plasma,5124,,A,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9064,Plasma,5124,,A,,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9065,,429,,A,,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9066,Urine,429,,A,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),,,Oryctolagus cuniculus,9986.0,,,22224
9067,Urine,429,,A,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),,,Oryctolagus cuniculus,9986.0,,,22224
9068,,4059,,A,,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9069,,4137,,A,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9070,,11672,,A,,In vitro Biological half-life in crude homogenate of rabbit renal cortex,In vitro,,Oryctolagus cuniculus,9986.0,,,22224
9071,,12886,,A,,Time within which only 10% of the drug was degraded,,,Oryctolagus cuniculus,9986.0,,,22224
9072,Liver,3853,,A,,Half life period in rabbit liver homogenate,,,Oryctolagus cuniculus,9986.0,,,22224
9073,,3615,,A,,Half life value in rabbits,,,Oryctolagus cuniculus,9986.0,,,22224
9074,Blood,6253,,A,,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9075,Blood,6253,,A,,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9076,,6077,,A,,Half-life period in rabbits following intravenous administration at 2 mg/kg,In vivo,,Oryctolagus cuniculus,9986.0,,,22224
9077,Plasma,17617,,A,,AUC 0-8 hr value in rats at 10 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9078,Plasma,17594,,A,,AUC after administration at 2000 mg/kg/day in rats,,,Rattus norvegicus,10116.0,,,50597
9079,Plasma,6149,,A,,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,,,Rattus norvegicus,10116.0,,,50597
9080,Plasma,17260,,A,,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,,Rattus norvegicus,10116.0,,,50597
9081,Plasma,17260,,A,,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,,Rattus norvegicus,10116.0,,,50597
9082,Plasma,6644,,A,,AUC in rat after oral administration at 10.5 mg/kg dose,,,Rattus norvegicus,10116.0,,,50597
9083,Plasma,6644,,A,,AUC in rat after oral administration at 11.2 mg/kg dose,,,Rattus norvegicus,10116.0,,,50597
9084,Plasma,6644,,A,,AUC in rat after oral administration at 9.7 mg/kg dose,,,Rattus norvegicus,10116.0,,,50597
9085,Brain,6495,,A,,AUC in rat brain after oral administration at 10 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9086,Plasma,6504,,A,,AUC in rat p.o.,,,Rattus norvegicus,10116.0,,,50597
9087,Plasma,17686,,A,,AUC in rat p.o. at 20 mg/kg concentration,,,Rattus norvegicus,10116.0,,,50597
9088,Plasma,6495,,A,,AUC in rat plasma after oral administration at 10 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9089,Plasma,216,,A,,AUC in rats,,,Rattus norvegicus,10116.0,,,50597
9090,Plasma,1908,,A,,AUC value after IV dose at a dose of 5 mg/kg in rats.,,,Rattus norvegicus,10116.0,,,50597
9091,Plasma,1908,,A,,AUC value after oral dose at a dose of 10 mg/kg in rats.,,,Rattus norvegicus,10116.0,,,50597
9092,Plasma,6685,,A,,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",In vivo,,Rattus norvegicus,10116.0,,,50597
9093,Plasma,216,,A,,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,In vivo,,Rattus norvegicus,10116.0,,,50597
9094,Plasma,6049,,A,,Maximum plasma concentration was evaluated in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9095,Plasma,2463,,A,,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9096,Plasma,6679,,A,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9097,Plasma,6681,,A,,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,In vivo,,Rattus norvegicus,10116.0,,,50597
9098,Plasma,4890,,A,,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9099,Plasma,6410,,A,,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9100,Plasma,6410,,A,,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9101,Plasma,16366,,A,,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,In vivo,,Rattus norvegicus,10116.0,,,50597
9102,Plasma,6227,,A,,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9103,Plasma,3598,,A,,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9104,Plasma,1465,,A,,Maximum plasma drug concentration was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
9105,,4368,,A,,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9106,Plasma,15662,,A,,Mean peak plasma concentration was observed after intravenous administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9107,Plasma,15662,,A,,Mean peak plasma concentration was observed after oral administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9108,,5355,,A,,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9109,,5355,,A,,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9110,Plasma,1567,,A,,Peak oral plasma concentration was determined in rats by oral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9111,Plasma,4026,,A,,Peak plasma concentration (Cmax) was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
9112,Plasma,6193,,A,,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9113,Plasma,4026,,A,,Peak plasma concentration (Cmax) in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9114,Plasma,6485,,A,,Peak plasma concentration at 1 mg/kg peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9115,Plasma,17655,,A,,Peak plasma concentration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9116,Plasma,14941,,A,,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",In vivo,,Rattus norvegicus,10116.0,,,50597
9117,,5394,,A,,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9118,,4408,,A,,Pharmacokinetic property (Cmax) in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9119,,5983,,A,,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,In vivo,,Rattus norvegicus,10116.0,,,50597
9120,,4878,,A,,Cmax in rat after 3mg/kg oral dose,In vivo,,Rattus norvegicus,10116.0,,,50597
9121,,5862,,A,Sprague-Dawley,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,In vivo,,Rattus norvegicus,10116.0,,,50597
9122,,4517,,A,,Cmax in rats after 20 mg/kg oral dose,In vivo,,Rattus norvegicus,10116.0,,,50597
9123,Plasma,5932,,A,,Cmax in rat plasma after 30mg/kg oral dose,In vivo,,Rattus norvegicus,10116.0,,,50597
9124,Plasma,5436,,A,,Plasma concentration after oral administration of 100 mg/kg to rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9125,Brain,4910,,A,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9126,,4950,,A,,Tested for the Cmax in rat at 10 mg/kg per orally,In vivo,,Rattus norvegicus,10116.0,,,50597
9127,,15078,,A,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",In vivo,,Rattus norvegicus,10116.0,,,50597
9128,,15078,,A,,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",In vivo,,Rattus norvegicus,10116.0,,,50597
9129,,3360,,A,,Bioavailability as oral Cmax in rats at 30 mins,In vivo,,Rattus norvegicus,10116.0,,,50597
9130,,3360,,A,,Bioavailability as oral Cmax in rats at 6hr,In vivo,,Rattus norvegicus,10116.0,,,50597
9131,,15022,,A,,The maximum concentration of compound was measured at the dose of 100 umol/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9132,,15022,,A,,The maximum concentration of compound was measured at the dose of 300 umol/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9133,,15022,,A,,The maximum concentration of compound was measured at the dose of 30 umol/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9134,Plasma,5160,,A,,The maximum plasma levels for the compounds were determined by LC-MS.,In vivo,,Rattus norvegicus,10116.0,,,50597
9135,Plasma,15662,,A,,mean peak plasma concentration was observed after intravenous administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9136,Plasma,15662,,A,,mean peak plasma concentration was observed after oral administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9137,,4709,,A,,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,,,Rattus norvegicus,10116.0,,,50597
9138,,3535,,A,,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,,,Rattus norvegicus,10116.0,,,50597
9139,,3535,,A,,Concentration in plasma (portal) following oral dose in rats at 1 hr,,,Rattus norvegicus,10116.0,,,50597
9140,,3535,,A,,Concentration in plasma (portal) following oral dose in rats at 2 hr,,,Rattus norvegicus,10116.0,,,50597
9141,,3535,,A,,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,,,Rattus norvegicus,10116.0,,,50597
9142,,3535,,A,,Concentration in plasma (systemic) following oral dose in rats at 1 hr,,,Rattus norvegicus,10116.0,,,50597
9143,,3535,,A,,Concentration in plasma (systemic) following oral dose in rats at 2 hr,,,Rattus norvegicus,10116.0,,,50597
9144,Plasma,5005,,A,,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,In vivo,,Rattus norvegicus,10116.0,,,22224
9145,Hypothalamus,6326,,A,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",,,Rattus norvegicus,10116.0,,,50597
9146,Hypothalamus,6326,,A,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",,,Rattus norvegicus,10116.0,,,50597
9147,,6326,,A,,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",,,Rattus norvegicus,10116.0,,,50597
9148,,6326,,A,,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",,,Rattus norvegicus,10116.0,,,50597
9149,,17411,,A,,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9150,Kidney,16435,,A,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
9151,Kidney,16435,,A,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
9152,Kidney,16435,,A,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
9153,Kidney,16435,,A,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
9154,Kidney,16435,,A,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
9155,Liver,16434,,A,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9156,Liver,16434,,A,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9157,Liver,16434,,A,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9158,Liver,16434,,A,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9159,Liver,16434,,A,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9160,Liver,16434,,A,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9161,Liver,16434,,A,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9162,Liver,16434,,A,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9163,Liver,16435,,A,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9164,Liver,16435,,A,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9165,Liver,16435,,A,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9166,Liver,16435,,A,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9167,Liver,16435,,A,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9168,Liver,16435,,A,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9169,Liver,16435,,A,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9170,Liver,16435,,A,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9171,Liver,16434,,A,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,Rattus norvegicus,10116.0,,,50597
9172,Liver,16434,,A,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,Rattus norvegicus,10116.0,,,50597
9173,Liver,16434,,A,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,Rattus norvegicus,10116.0,,,50597
9174,Liver,16435,,A,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
9175,Liver,16435,,A,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
9176,Liver,16435,,A,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
9177,Liver,16435,,A,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
9178,Liver,16435,,A,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
9179,Liver,16435,,A,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
9180,Lung,16434,,A,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9181,Lung,16434,,A,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9182,Lung,16434,,A,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9183,Lung,16434,,A,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9184,Lung,16434,,A,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9185,Lung,16434,,A,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9186,Lung,16434,,A,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9187,Lung,16434,,A,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9188,Lung,16435,,A,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9189,Lung,16435,,A,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9190,Lung,16435,,A,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9191,Lung,16435,,A,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9192,Lung,16435,,A,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9193,Lung,16435,,A,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9194,Lung,16434,,A,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,,,Rattus norvegicus,10116.0,,,50597
9195,Stomach,6175,,A,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,,Rattus norvegicus,10116.0,,,50597
9196,Stomach,6175,,A,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,,Rattus norvegicus,10116.0,,,50597
9197,Stomach,6175,,A,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,,Rattus norvegicus,10116.0,,,50597
9198,Stomach,6175,,A,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,,Rattus norvegicus,10116.0,,,50597
9199,,10839,,A,,The compound was tested for the plasma binding in rat,,,Rattus norvegicus,10116.0,,,50597
9200,,16459,,A,,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",,,Rattus norvegicus,10116.0,,,50597
9201,,16459,,A,,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",,,Rattus norvegicus,10116.0,,,50597
9202,,16459,,A,,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",,,Rattus norvegicus,10116.0,,,50597
9203,,16459,,A,,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),,,Rattus norvegicus,10116.0,,,50597
9204,,16459,,A,,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),,,Rattus norvegicus,10116.0,,,50597
9205,,16459,,A,,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),,,Rattus norvegicus,10116.0,,,50597
9206,,3278,,A,,Plasma level at 2 hr after administration of the compound,,,Rattus norvegicus,10116.0,,,50597
9207,,3278,,A,,plasma level at 2 hr after administration of the compound,,,Rattus norvegicus,10116.0,,,50597
9208,Serum,4684,,A,,Stability in rat serum measured as % recovery at 1 min,,,Rattus norvegicus,10116.0,,,50597
9209,Serum,4684,,A,,Stability in rat serum measured as % recovery at 10 min,,,Rattus norvegicus,10116.0,,,50597
9210,Serum,4684,,A,,Stability in rat serum measured as % recovery at 10 mins,,,Rattus norvegicus,10116.0,,,50597
9211,Serum,4684,,A,,Stability in rat serum measured as % recovery at 2 hr,,,Rattus norvegicus,10116.0,,,50597
9212,Serum,4684,,A,,Stability in rat serum measured as % recovery at 3 min,,,Rattus norvegicus,10116.0,,,50597
9213,Serum,4684,,A,,Stability in rat serum measured as % recovery at 3 mins,,,Rattus norvegicus,10116.0,,,50597
9214,Serum,4684,,A,,Stability in rat serum measured as % recovery at 5 min,,,Rattus norvegicus,10116.0,,,50597
9215,Serum,4684,,A,,Stability in rat serum measured as % recovery at 5 mins,,,Rattus norvegicus,10116.0,,,50597
9216,,16456,,A,,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9217,,16456,,A,,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9218,Plasma,723,,A,,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,,,Rattus norvegicus,10116.0,,,50597
9219,Plasma,723,,A,,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,,,Rattus norvegicus,10116.0,,,50597
9220,,5160,,A,,Half life tested in mature male rat at a dose of 30 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9221,,4709,,A,,Half life after intravenous administration of 1 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9222,,5633,,A,,Half life period after administration (30 mg/kg) in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9223,,5302,,A,,Half life period in rat after 5 mg/Kg dose,In vivo,,Rattus norvegicus,10116.0,,,50597
9224,,5302,,A,,Half life period in rat after 5 mg/kg dose,In vivo,,Rattus norvegicus,10116.0,,,50597
9225,,17791,,A,,Half life period was determined,,,Rattus norvegicus,10116.0,,,50597
9226,,17791,,A,,Half life period was evaluated in rat,,,Rattus norvegicus,10116.0,,,50597
9227,,17791,,A,,Half life period was evaluated in rat; 0.5-1.0,,,Rattus norvegicus,10116.0,,,50597
9228,,17791,,A,,Half life period was evaluated in rat; 5.9-7.5,,,Rattus norvegicus,10116.0,,,50597
9229,Plasma,14512,,A,,Half-life in rat plasma,,,Rattus norvegicus,10116.0,,,50597
9230,,6230,,A,,Half-life time in rat was determined,,,Rattus norvegicus,10116.0,,,50597
9231,,3364,,A,,Terminal half-life after iv administration to rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9232,,6874,,A,,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9233,,857,,A,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,,,Rattus norvegicus,10116.0,,,50597
9234,,858,,A,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),In vivo,,Rattus norvegicus,10116.0,,,50597
9235,,858,,A,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),In vivo,,Rattus norvegicus,10116.0,,,50597
9236,,5355,,A,,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9237,,5355,,A,,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9238,,6305,,A,,Half life in rats,,,Rattus norvegicus,10116.0,,,50597
9239,Plasma,13501,,A,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9240,,17594,,A,,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9241,Plasma,4186,,A,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,In vivo,,Rattus norvegicus,10116.0,,,50597
9242,Plasma,2932,,A,,Biological half-life was measured in plasma of rats,,,Rattus norvegicus,10116.0,,,50597
9243,,17065,,A,,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9244,,15765,,A,,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,In vivo,,Rattus norvegicus,10116.0,,,50597
9245,,2713,,A,,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9246,,2661,,A,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9247,,2661,,A,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9248,Plasma,740,,A,,Compound was evaluated for plasma half life in rat,,,Rattus norvegicus,10116.0,,,50597
9249,Plasma,6597,,A,,AUC value at a dose of 5 mg/kg (p.o.) in rats,,,Rattus norvegicus,10116.0,,,50597
9250,Plasma,2959,,A,,AUC value after administration of 20 mg/Kg oral dose in rat,,,Rattus norvegicus,10116.0,,,50597
9251,Plasma,17594,,A,,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,,,Rattus norvegicus,10116.0,,,50597
9252,Plasma,17596,,A,,AUC0-96 after administration at 50 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9253,Plasma,17594,,A,,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,,,Rattus norvegicus,10116.0,,,50597
9254,,3293,,A,,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",,,Rattus norvegicus,10116.0,,,50597
9255,,6757,,A,,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,,,Rattus norvegicus,10116.0,,,50597
9256,,6757,,A,,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,,,Rattus norvegicus,10116.0,,,50597
9257,,6757,,A,,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,,,Rattus norvegicus,10116.0,,,50597
9258,Kidney,5979,,A,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,,,Rattus norvegicus,10116.0,,,50597
9259,,5979,,A,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,,,Rattus norvegicus,10116.0,,,50597
9260,,5979,,A,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,,,Rattus norvegicus,10116.0,,,50597
9261,,4026,,A,,Area under curve (AUC) at a dose of 30 mg/kg in rats,,,Rattus norvegicus,10116.0,,,50597
9262,,5355,,A,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,,Rattus norvegicus,10116.0,,,50597
9263,,5355,,A,,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,,,Rattus norvegicus,10116.0,,,50597
9264,,5355,,A,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,,Rattus norvegicus,10116.0,,,50597
9265,,5633,,A,,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,,,Rattus norvegicus,10116.0,,,50597
9266,,1716,,A,,Area under curve (Pharmacokinetic property) was determined,,,Rattus norvegicus,10116.0,,,50597
9267,,1716,,A,,Area under curve (Pharmacokinetic property) of the compound; Not determined,,,Rattus norvegicus,10116.0,,,50597
9268,,4689,,A,,Area under curve after intravenous administration (1 mg/kg) in rat,,,Rattus norvegicus,10116.0,,,50597
9269,,4527,,A,,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,,,Rattus norvegicus,10116.0,,,50597
9270,,4527,,A,,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,,,Rattus norvegicus,10116.0,,,50597
9271,,15662,,A,,Area under curve in male SD rats was observed after oral administration in rat,,,Rattus norvegicus,10116.0,,,50597
9272,,4413,,A,,Area under curve of compound after iv administration of 20 mg/kg dose in rat,,,Rattus norvegicus,10116.0,,,50597
9273,,3598,,A,,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9274,,3598,,A,,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9275,,5964,,A,,Area under curve at 5 mg/kg po was determined in rat,,,Rattus norvegicus,10116.0,,,50597
9276,,4689,,A,,Area under curve in Rat at a oral dose of 5 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9277,,4186,,A,,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,,Rattus norvegicus,10116.0,,,50597
9278,,5510,,A,,Area under curve was determined,,,Rattus norvegicus,10116.0,,,50597
9279,,17858,,A,,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,,,Rattus norvegicus,10116.0,,,50597
9280,,17804,,A,,Area under curve after intravenous administration at 3 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9281,,6106,,A,,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,,,Rattus norvegicus,10116.0,,,50597
9282,,5964,,A,,Area under curve at 4 hr in rat,,,Rattus norvegicus,10116.0,,,50597
9283,,4026,,A,,Area under curve at a dose of 30 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9284,,4756,,A,,Area under curve at the dose of 2 mg/Kg administered perorally in rats,,,Rattus norvegicus,10116.0,,,50597
9285,,4756,,A,,Area under curve at the dose of 5 mg/Kg administered perorally in rats,,,Rattus norvegicus,10116.0,,,50597
9286,,5862,,A,,Area under curve for a 2-mpk po dose in SD rats,,,Rattus norvegicus,10116.0,,,50597
9287,,5862,,A,,Area under curve in SD rats,,,Rattus norvegicus,10116.0,,,50597
9288,,6644,,A,,Area under curve in rat after oral administration at 13 mg/kg dose,,,Rattus norvegicus,10116.0,,,50597
9289,,5871,,A,,Area under curve in rat by po administration at 0-24 hr,,,Rattus norvegicus,10116.0,,,50597
9290,Plasma,5919,,A,,Area under curve in rat plasma,,,Rattus norvegicus,10116.0,,,50597
9291,,5939,,A,,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9292,,5939,,A,,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9293,,10,,A,,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,,,Rattus norvegicus,10116.0,,,50597
9294,,11149,,A,,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,,,Rattus norvegicus,10116.0,,,50597
9295,,5302,,A,,Area under curve value in rat at a dose of 5 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9296,,17796,,A,,Area under curve was determined after oral administration in rats,,,Rattus norvegicus,10116.0,,,50597
9297,,4890,,A,,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,,Rattus norvegicus,10116.0,,,50597
9298,,6011,,A,,Area under curve was determined after peroral administration in rat,,,Rattus norvegicus,10116.0,,,50597
9299,,5375,,A,,Area under curve was determined at a dose 30 mpk administered orally.,,,Rattus norvegicus,10116.0,,,50597
9300,,17764,,A,,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,,,Rattus norvegicus,10116.0,,,50597
9301,,4368,,A,,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,,,Rattus norvegicus,10116.0,,,50597
9302,,5610,,A,,Area under curve was determined in male rat,,,Rattus norvegicus,10116.0,,,50597
9303,,5833,,A,,Area under curve was determined in rat after PO administration,,,Rattus norvegicus,10116.0,,,50597
9304,,4257,,A,,Area under curve was determined in rat after a 3 mg/kg of oral dose,,,Rattus norvegicus,10116.0,,,50597
9305,,5937,,A,,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9306,,5932,,A,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9307,,5932,,A,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,,,Rattus norvegicus,10116.0,,,50597
9308,,17411,,A,,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9309,,17411,,A,,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9310,Plasma,17771,,A,,Peak plasma concentration in rat at a dose of 3 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9311,,1628,,A,,Plasma concentration at 2 hr in rats was evaluated.,,,Rattus norvegicus,10116.0,,,50597
9312,,1628,,A,,Plasma concentration at 2 hr in rats was evaluated; Not available,,,Rattus norvegicus,10116.0,,,50597
9313,,17411,,A,,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9314,,4910,,A,,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,,Rattus norvegicus,10116.0,,,50597
9315,,4910,,A,,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,,,Rattus norvegicus,10116.0,,,50597
9316,Plasma,4910,,A,,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,,Rattus norvegicus,10116.0,,,50597
9317,Plasma,4910,,A,,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,,,Rattus norvegicus,10116.0,,,50597
9318,Plasma,4910,,A,,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,,Rattus norvegicus,10116.0,,,50597
9319,Plasma,4910,,A,,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,,,Rattus norvegicus,10116.0,,,50597
9320,,5510,,A,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,,,Rattus norvegicus,10116.0,,,50597
9321,,5510,,A,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,,,Rattus norvegicus,10116.0,,,50597
9322,,5510,,A,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,,,Rattus norvegicus,10116.0,,,50597
9323,,5510,,A,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,,,Rattus norvegicus,10116.0,,,50597
9324,,16427,,A,,PK study was carried to determine the relative absorption ranking in rat.,,,Rattus norvegicus,10116.0,,,50597
9325,Plasma,4689,,A,,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9326,Blood,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9327,Blood,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9328,Blood,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9329,Blood,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",,,Rattus norvegicus,10116.0,,,50597
9330,Blood,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9331,Blood,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",,,Rattus norvegicus,10116.0,,,50597
9332,Brain,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9333,Brain,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9334,Brain,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9335,Brain,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9336,Brain,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9337,Brain,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9338,Heart,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9339,Heart,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9340,Heart,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9341,Heart,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9342,Heart,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9343,Heart,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9344,Lung,16434,,A,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,,Rattus norvegicus,10116.0,,,50597
9345,Lung,16434,,A,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,Rattus norvegicus,10116.0,,,50597
9346,Lung,16435,,A,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
9347,Lung,16435,,A,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
9348,Lung,16435,,A,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
9349,Lung,16435,,A,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
9350,Lung,16435,,A,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
9351,Lung,16435,,A,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
9352,Lung,16435,,A,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9353,Lung,16435,,A,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9354,Muscle tissue,16434,,A,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9355,Muscle tissue,16434,,A,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9356,Muscle tissue,16434,,A,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9357,Muscle tissue,16434,,A,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9358,Muscle tissue,16434,,A,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9359,Muscle tissue,16434,,A,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9360,Muscle tissue,16434,,A,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9361,Muscle tissue,16434,,A,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9362,Muscle tissue,16435,,A,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9363,Muscle tissue,16435,,A,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9364,Muscle tissue,16435,,A,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9365,Muscle tissue,16435,,A,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9366,Muscle tissue,16435,,A,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9367,Muscle tissue,16435,,A,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9368,Muscle tissue,16435,,A,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9369,Muscle tissue,16435,,A,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9370,Muscle tissue,16434,,A,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,Rattus norvegicus,10116.0,,,50597
9371,Muscle tissue,16434,,A,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,,Rattus norvegicus,10116.0,,,50597
9372,Muscle tissue,16434,,A,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,Rattus norvegicus,10116.0,,,50597
9373,Muscle tissue,16435,,A,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
9374,Muscle tissue,16435,,A,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
9375,Muscle tissue,16435,,A,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
9376,Muscle tissue,16435,,A,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
9377,Muscle tissue,16435,,A,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
9378,Muscle tissue,16435,,A,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
9379,,16434,,A,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9380,,16434,,A,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9381,,16434,,A,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9382,,16434,,A,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9383,,16434,,A,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9384,,16434,,A,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9385,,16434,,A,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9386,,16434,,A,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9387,,16435,,A,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9388,,16435,,A,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9389,,3341,,A,,Compound was evaluated for terminal half life in rat,,,Rattus norvegicus,10116.0,,,50597
9390,Plasma,3634,,A,,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,In vivo,,Rattus norvegicus,10116.0,,,50597
9391,Plasma,3634,,A,,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,In vivo,,Rattus norvegicus,10116.0,,,50597
9392,,4839,,A,,Compound was tested for its half life in rat,,,Rattus norvegicus,10116.0,,,50597
9393,Plasma,5005,,A,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,In vivo,,Macaca mulatta,9544.0,,,22224
9394,Plasma,5005,,A,,Compound was tested for its plasma half life in Sprague Dawley rats,,,Rattus norvegicus,10116.0,,,22224
9395,Plasma,5005,,A,,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,,,Rattus norvegicus,10116.0,,,22224
9396,Plasma,1094,,A,,Compound was tested for plasma half-life period in rat,,,Rattus norvegicus,10116.0,,,50597
9397,,5031,,A,,Elimination half life after i.v. administration of compound in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9398,,6518,,A,,Elimination half-life after IV dosing at 0.5 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9399,,6518,,A,,Elimination half-life after IV dosing at 1 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9400,,6518,,A,,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9401,,6518,,A,,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9402,Brain,5408,,A,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
9403,Plasma,5408,,A,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,In vivo,,Rattus norvegicus,10116.0,,,50597
9404,Brain,5408,,A,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,In vivo,,Rattus norvegicus,10116.0,,,50597
9405,Plasma,5408,,A,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,In vivo,,Rattus norvegicus,10116.0,,,50597
9406,,4687,,A,,Evaluated for the half life in rat (in vivo),In vivo,,Rattus norvegicus,10116.0,,,50597
9407,,6640,,A,,Hafl life in rat,,,Rattus norvegicus,10116.0,,,50597
9408,,6640,,A,,Hafl life rat,,,Rattus norvegicus,10116.0,,,50597
9409,,6641,,A,,Hafl life rat,,,Rattus norvegicus,10116.0,,,50597
9410,,6640,,A,,Hafl life rat; Not determined,,,Rattus norvegicus,10116.0,,,50597
9411,,6641,,A,,Hafl life rat; Not determined,,,Rattus norvegicus,10116.0,,,50597
9412,Kidney,17411,,A,,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9413,Liver,17411,,A,,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9414,Lung,17411,,A,,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9415,,6570,,A,,Half life in rat after 1 mg/kg i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9416,,6570,,A,,Half life in rat after 2 mg/kg peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9417,,17411,,A,,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9418,,4722,,A,,Half life of 10 mg/kg oral dose determined in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9419,,5978,,A,,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9420,,5978,,A,,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9421,,5978,,A,,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9422,,5978,,A,,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9423,,5978,,A,,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9424,,5978,,A,,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9425,,5978,,A,,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9426,,5978,,A,,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9427,,4762,,A,,Half life of compound at 5 mg/kg after po administration was determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9428,,5327,,A,,Half life of compound determined after intravenous administration to rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9429,,4847,,A,,Half life of compound was determined in rat,,,Rattus norvegicus,10116.0,,,50597
9430,Plasma,17720,,A,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9431,,4723,,A,,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9432,,4723,,A,,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9433,,4256,,A,,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,In vivo,,Macaca fascicularis,9541.0,,,22224
9434,,4256,,A,,Half life determined in rat by intravenous administration,In vivo,,Rattus norvegicus,10116.0,,,22224
9435,,4722,,A,,Half life determined in rats after iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9436,Plasma,6535,,A,,Half life in rat plasma after administration of 2 mg/kg iv,In vivo,,Rattus norvegicus,10116.0,,,50597
9437,Plasma,6535,,A,,Half life in rat plasma after administration of 2 mg/kg iv,In vivo,,Rattus norvegicus,10116.0,,,50597
9438,Plasma,1435,,A,,Half life in rat plasma was determined,,,Rattus norvegicus,10116.0,,,50597
9439,Plasma,1435,,A,,Half life in rat plasma was determined; NA means not applicable,,,Rattus norvegicus,10116.0,,,50597
9440,,5206,,A,,Half life in rat was tested,,,Rattus norvegicus,10116.0,,,50597
9441,Plasma,6080,,A,,Half life measured in rat plasma,,,Rattus norvegicus,10116.0,,,50597
9442,,4449,,A,,Half life recorded in rats,,,Rattus norvegicus,10116.0,,,50597
9443,,6057,,A,,Half life was calculated,,,Rattus norvegicus,10116.0,,,50597
9444,,6057,,A,,Half life was calculated in rat,,,Rattus norvegicus,10116.0,,,50597
9445,,3747,,A,,Half life was determined,,,Rattus norvegicus,10116.0,,,50597
9446,,17858,,A,,Half life after 10 mg/kg oral administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9447,,16365,,A,,Half life after administering orally a dose of 10 mg/kg to a fasting rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9448,,16365,,A,,Half life after administering orally a dose of 30 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9449,,5031,,A,,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,,,Rattus norvegicus,10116.0,,,50597
9450,,4722,,A,,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,,,Rattus norvegicus,10116.0,,,50597
9451,,6078,,A,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,,,Rattus norvegicus,10116.0,,,50597
9452,,6078,,A,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,,,Rattus norvegicus,10116.0,,,50597
9453,,6078,,A,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9454,,6078,,A,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,,,Rattus norvegicus,10116.0,,,50597
9455,,17065,,A,,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,,,Rattus norvegicus,10116.0,,,50597
9456,,1353,,A,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,,,Rattus norvegicus,10116.0,,,50597
9457,,1353,,A,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),,,Rattus norvegicus,10116.0,,,50597
9458,,1353,,A,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),,,Rattus norvegicus,10116.0,,,50597
9459,,1353,,A,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),,,Rattus norvegicus,10116.0,,,50597
9460,,1353,,A,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),,,Rattus norvegicus,10116.0,,,50597
9461,,16423,,A,,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,,,Rattus norvegicus,10116.0,,,50597
9462,,16423,,A,,Area under the curve was evaluated after 20 uM/kg of peroral administration,,,Rattus norvegicus,10116.0,,,50597
9463,,6062,,A,,Area under the curve was measured in rat after an iv dose of 1 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9464,,6056,,A,,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,,,Rattus norvegicus,10116.0,,,50597
9465,,5182,,A,,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,,,Rattus norvegicus,10116.0,,,50597
9466,,6410,,A,,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9467,,6410,,A,,Area under the curve was evaluated at an oral dose of 30 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9468,,4723,,A,,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,,Rattus norvegicus,10116.0,,,50597
9469,,4723,,A,,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,,Rattus norvegicus,10116.0,,,50597
9470,,4723,,A,,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,,Rattus norvegicus,10116.0,,,50597
9471,,4723,,A,,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,,Rattus norvegicus,10116.0,,,50597
9472,,4723,,A,,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,,Rattus norvegicus,10116.0,,,50597
9473,,4723,,A,,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,,Rattus norvegicus,10116.0,,,50597
9474,Plasma,2463,,A,,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,,,Rattus norvegicus,10116.0,,,50597
9475,,4709,,A,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,,,Rattus norvegicus,10116.0,,,50597
9476,,4075,,A,,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,,,Rattus norvegicus,10116.0,,,50597
9477,,5394,,A,,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,,,Rattus norvegicus,10116.0,,,50597
9478,,2661,,A,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,,,Rattus norvegicus,10116.0,,,50597
9479,,2661,,A,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,,,Rattus norvegicus,10116.0,,,50597
9480,,2661,,A,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,,,Rattus norvegicus,10116.0,,,50597
9481,,2661,,A,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,,,Rattus norvegicus,10116.0,,,50597
9482,,17791,,A,,Compound was evaluated for area under the curve expressed as (h*ug/ml),,,Rattus norvegicus,10116.0,,,50597
9483,,2591,,A,,Compound was tested for area under curve in rat,,,Rattus norvegicus,10116.0,,,50597
9484,,6567,,A,,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,,,Rattus norvegicus,10116.0,,,50597
9485,,6211,,A,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,,Rattus norvegicus,10116.0,,,50597
9486,,5529,,A,,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),,,Rattus norvegicus,10116.0,,,50597
9487,,5408,,A,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,,Rattus norvegicus,10116.0,,,50597
9488,,5408,,A,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,,Rattus norvegicus,10116.0,,,50597
9489,,5408,,A,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,,Rattus norvegicus,10116.0,,,50597
9490,,5408,,A,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,,Rattus norvegicus,10116.0,,,50597
9491,,429,,A,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),,,Rattus norvegicus,10116.0,,,50597
9492,,429,,A,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),,,Rattus norvegicus,10116.0,,,50597
9493,,429,,A,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),,,Rattus norvegicus,10116.0,,,50597
9494,,4796,,A,,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,,Rattus norvegicus,10116.0,,,50597
9495,,5974,,A,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,,Rattus norvegicus,10116.0,,,50597
9496,,5974,,A,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,Rattus norvegicus,10116.0,,,50597
9497,,5974,,A,,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,,Rattus norvegicus,10116.0,,,50597
9498,Kidney,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9499,Kidney,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9500,Kidney,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9501,Kidney,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9502,Kidney,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9503,Kidney,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9504,Liver,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9505,Liver,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9506,Liver,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9507,Liver,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9508,Liver,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9509,Liver,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9510,Lung,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9511,Lung,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9512,Lung,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9513,Lung,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",,,Rattus norvegicus,10116.0,,,50597
9514,Lung,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9515,Lung,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9516,Thyroid gland,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9517,Thyroid gland,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9518,Thyroid gland,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9519,Thyroid gland,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9520,Thyroid gland,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9521,Thyroid gland,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9522,Thyroid gland,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9523,Thyroid gland,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9524,Thyroid gland,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9525,Thyroid gland,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9526,,16435,,A,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9527,,16435,,A,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9528,,16435,,A,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9529,,16435,,A,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9530,,16435,,A,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9531,,16435,,A,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9532,,16434,,A,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,Rattus norvegicus,10116.0,,,50597
9533,,16434,,A,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,,Rattus norvegicus,10116.0,,,50597
9534,,16434,,A,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,,,Rattus norvegicus,10116.0,,,50597
9535,,16435,,A,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
9536,,16435,,A,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
9537,,16435,,A,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
9538,,16435,,A,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
9539,,16435,,A,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
9540,,16435,,A,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
9541,Spleen,16434,,A,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9542,Spleen,16434,,A,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9543,Spleen,16434,,A,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9544,Spleen,16434,,A,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9545,Spleen,16434,,A,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9546,Spleen,16434,,A,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9547,Spleen,16434,,A,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9548,Spleen,16434,,A,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9549,Spleen,16435,,A,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9550,Spleen,16435,,A,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9551,Spleen,16435,,A,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9552,Spleen,16435,,A,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9553,Spleen,16435,,A,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9554,Spleen,16435,,A,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9555,Spleen,16435,,A,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9556,Spleen,16435,,A,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9557,Spleen,16434,,A,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,Rattus norvegicus,10116.0,,,50597
9558,Spleen,16434,,A,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,Rattus norvegicus,10116.0,,,50597
9559,Spleen,16434,,A,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,Rattus norvegicus,10116.0,,,50597
9560,Spleen,16435,,A,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
9561,Spleen,16435,,A,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
9562,Spleen,16435,,A,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
9563,Spleen,16435,,A,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
9564,Spleen,16435,,A,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
9565,Spleen,16435,,A,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
9566,,16434,,A,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9567,,16434,,A,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9568,,16434,,A,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9569,,16434,,A,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9570,,16434,,A,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9571,,16365,,A,,Half life after administering orally a dose of 3 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9572,,16365,,A,,Half life after administering orally a dose of 3 mg/kg to a fasting rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9573,,16365,,A,,Half life after administering intravenously a dose of 1 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9574,,526,,A,,Half life after oral dosing in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9575,,16365,,A,,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9576,,4368,,A,,Half life by intravenous administration of 3.4 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9577,,3371,,A,,Half life in rat,,,Rattus norvegicus,10116.0,,,50597
9578,,6448,,A,,Half life in rat,,,Rattus norvegicus,10116.0,,,50597
9579,,6453,,A,,Half life in rat,,,Rattus norvegicus,10116.0,,,50597
9580,,4353,,A,,Half life in rat after intravenous administration of the compound,In vivo,,Rattus norvegicus,10116.0,,,50597
9581,Plasma,4353,,A,,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,In vivo,,Rattus norvegicus,10116.0,,,50597
9582,,4353,,A,,Half life in rat after po administration of the compound,In vivo,,Rattus norvegicus,10116.0,,,50597
9583,,4353,,A,,Half life in rat after po administration of the compound; ND means Not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
9584,Plasma,4353,,A,,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,In vivo,,Rattus norvegicus,10116.0,,,50597
9585,Plasma,4353,,A,,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,In vivo,,Rattus norvegicus,10116.0,,,50597
9586,,5789,,A,,Half life in rat i.v.,In vivo,,Rattus norvegicus,10116.0,,,50597
9587,,17686,,A,,Half life in rat i.v. at 2 mg/kg concentration,In vivo,,Rattus norvegicus,10116.0,,,50597
9588,,6495,,A,,Half life in rats,,,Rattus norvegicus,10116.0,,,50597
9589,,484,,A,,Half life in rats after intravenous administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9590,,6467,,A,,Half life in rats at the dose of 1.0 mpk by i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9591,,6642,,A,,Half life in rat,,,Rattus norvegicus,10116.0,,,50597
9592,,16367,,A,,Half life was evaluated after intravenous administration to rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9593,,1369,,A,,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),,,Rattus norvegicus,10116.0,,,50597
9594,,5472,,A,,Half life was evaluated in rat,,,Rattus norvegicus,10116.0,,,50597
9595,,6049,,A,,Half life was evaluated in rat,,,Rattus norvegicus,10116.0,,,50597
9596,,5472,,A,,Half life was evaluated in rat; Not tested,,,Rattus norvegicus,10116.0,,,50597
9597,,16366,,A,,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9598,,11149,,A,,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9599,Blood,11149,,A,,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9600,,2891,,A,,Half life was measured in monkey at dose of 10 mg/kg by po administration,In vivo,,Primates,9443.0,,,22224
9601,,2891,,A,,Half life was measured in monkey at dose of 10 mg/kg by po administration,In vivo,,Primates,9443.0,,,22224
9602,,2891,,A,,Half life was measured in rat at dose of 30 mg/kg by iv administration,In vivo,,Rattus norvegicus,10116.0,,,22224
9603,,2891,,A,,Half life was measured in rat at dose of 30 mg/kg by po administration,In vivo,,Rattus norvegicus,10116.0,,,22224
9604,,4026,,A,,Half life (t1/2) was determined,,,Rattus norvegicus,10116.0,,,50597
9605,,4527,,A,,Half life period at a dose of 10 uM/kg in rat was determined,,,Rattus norvegicus,10116.0,,,50597
9606,,4527,,A,,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
9607,,5503,,A,,Half life period was determined,,,Rattus norvegicus,10116.0,,,50597
9608,,4426,,A,,Half life period after intravenous administration at 20 mpk in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9609,,4426,,A,,Half life period after intravenous administration at 20 mpk in rats; Not performed.,In vivo,,Rattus norvegicus,10116.0,,,50597
9610,,6109,,A,,Half life period after intravenous administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9611,,5654,,A,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9612,,5654,,A,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9613,Plasma,4755,,A,,Half life period in 80% rat plasma at 37 degree Centigrade,,,Rattus norvegicus,10116.0,,,50597
9614,,5862,,A,,Half life period in SD rats,,,Rattus norvegicus,10116.0,,,50597
9615,Plasma,1515,,A,,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),,,Rattus norvegicus,10116.0,,,50597
9616,Plasma,1515,,A,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),,,Rattus norvegicus,10116.0,,,50597
9617,Plasma,1515,,A,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,,Rattus norvegicus,10116.0,,,50597
9618,Plasma,1515,,A,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,,Rattus norvegicus,10116.0,,,50597
9619,,5960,,A,,Half life period in rat,,,Rattus norvegicus,10116.0,,,50597
9620,,6103,,A,,Half life period in rat,,,Rattus norvegicus,10116.0,,,50597
9621,,6317,,A,,Half life period in rat,,,Rattus norvegicus,10116.0,,,50597
9622,,6644,,A,,Half life period in rat after oral administration at 10.5 mg/kg dose,In vivo,,Rattus norvegicus,10116.0,,,50597
9623,,6644,,A,,Half life period in rat after oral administration at 11.2 mg/kg dose,In vivo,,Rattus norvegicus,10116.0,,,50597
9624,,6644,,A,,Half life period in rat after oral administration at 13 mg/kg dose,In vivo,,Rattus norvegicus,10116.0,,,50597
9625,,6644,,A,,Half life period in rat after oral administration at 9.7 mg/kg dose,In vivo,,Rattus norvegicus,10116.0,,,50597
9626,,5974,,A,,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,,Rattus norvegicus,10116.0,,,50597
9627,,6295,,A,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9628,,6296,,A,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9629,,16427,,A,,PK study was carried to determine AUC (area under curve) value in rat,,,Rattus norvegicus,10116.0,,,50597
9630,,16367,,A,,Pharmacokinetic parameter AUC after intravenous administration to rats,,,Rattus norvegicus,10116.0,,,50597
9631,,16367,,A,,Pharmacokinetic parameter AUC after oral administration to rats,,,Rattus norvegicus,10116.0,,,50597
9632,,16365,,A,,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9633,,16365,,A,,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,,,Rattus norvegicus,10116.0,,,50597
9634,,16365,,A,,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,,,Rattus norvegicus,10116.0,,,50597
9635,,16365,,A,,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,,,Rattus norvegicus,10116.0,,,50597
9636,,16365,,A,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,,,Rattus norvegicus,10116.0,,,50597
9637,,16365,,A,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,,,Rattus norvegicus,10116.0,,,50597
9638,,5394,,A,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9639,,5394,,A,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9640,,2792,,A,,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,,,Rattus norvegicus,10116.0,,,50597
9641,,2792,,A,,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,,,Rattus norvegicus,10116.0,,,50597
9642,,2792,,A,,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,,,Rattus norvegicus,10116.0,,,50597
9643,,2792,,A,,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,,,Rattus norvegicus,10116.0,,,50597
9644,,5334,,A,,Pharmacokinetic parameter area under curve was reported,,,Rattus norvegicus,10116.0,,,50597
9645,,4408,,A,,Pharmacokinetic property (AUC) in rat,,,Rattus norvegicus,10116.0,,,50597
9646,,5983,,A,,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,,,Rattus norvegicus,10116.0,,,50597
9647,,4397,,A,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,,,Rattus norvegicus,10116.0,,,50597
9648,,4397,,A,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,,,Rattus norvegicus,10116.0,,,50597
9649,,5491,,A,,Pharmacokinetic property was determined,,,Rattus norvegicus,10116.0,,,50597
9650,,5491,,A,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9651,,5491,,A,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,,,Rattus norvegicus,10116.0,,,50597
9652,Plasma,4199,,A,,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,,Rattus norvegicus,10116.0,,,50597
9653,Plasma,4199,,A,,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,,,Rattus norvegicus,10116.0,,,50597
9654,Plasma,4199,,A,,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,,,Rattus norvegicus,10116.0,,,50597
9655,,5173,,A,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",,,Rattus norvegicus,10116.0,,,50597
9656,,5173,,A,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",,,Rattus norvegicus,10116.0,,,50597
9657,,5173,,A,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",,,Rattus norvegicus,10116.0,,,50597
9658,,5173,,A,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",,,Rattus norvegicus,10116.0,,,50597
9659,,16366,,A,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,,,Rattus norvegicus,10116.0,,,50597
9660,,16366,,A,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,,,Rattus norvegicus,10116.0,,,50597
9661,,5327,,A,,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,,,Rattus norvegicus,10116.0,,,50597
9662,,6681,,A,,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,,,Rattus norvegicus,10116.0,,,50597
9663,,12873,,A,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),,,Rattus norvegicus,10116.0,,,50597
9664,,12873,,A,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),,,Rattus norvegicus,10116.0,,,50597
9665,,6685,,A,,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,,Rattus norvegicus,10116.0,,,50597
9666,,6685,,A,,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,,Rattus norvegicus,10116.0,,,50597
9667,,6685,,A,,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",,,Rattus norvegicus,10116.0,,,50597
9668,,6619,,A,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",,,Rattus norvegicus,10116.0,,,50597
9669,,6619,,A,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",,,Rattus norvegicus,10116.0,,,50597
9670,,10363,,A,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,,Rattus norvegicus,10116.0,,,50597
9671,,4796,,A,,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,,Rattus norvegicus,10116.0,,,50597
9672,,4910,,A,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,,Rattus norvegicus,10116.0,,,50597
9673,Plasma,4910,,A,,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,,,Rattus norvegicus,10116.0,,,50597
9674,,4839,,A,,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,,,Rattus norvegicus,10116.0,,,50597
9675,,15078,,A,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,,Rattus norvegicus,10116.0,,,50597
9676,,15078,,A,,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",,,Rattus norvegicus,10116.0,,,50597
9677,,15078,,A,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,,Rattus norvegicus,10116.0,,,50597
9678,,15078,,A,,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",,,Rattus norvegicus,10116.0,,,50597
9679,Thyroid gland,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",,,Rattus norvegicus,10116.0,,,50597
9680,Thyroid gland,11450,,A,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",,,Rattus norvegicus,10116.0,,,50597
9681,,8151,,A,,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,,Rattus norvegicus,10116.0,,,50597
9682,,8151,,A,,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,Rattus norvegicus,10116.0,,,50597
9683,Urine,8151,,A,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,,Rattus norvegicus,10116.0,,,50597
9684,Blood,8677,,A,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9685,Blood,8677,,A,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9686,Blood,8677,,A,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9687,Blood,8677,,A,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9688,Brain,8677,,A,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9689,Brain,8677,,A,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9690,Brain,8677,,A,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9691,Brain,8677,,A,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9692,Brain,8677,,A,,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
9693,Heart,8677,,A,,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9694,Heart,8677,,A,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9695,Heart,8677,,A,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9696,Kidney,8677,,A,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9697,Kidney,8677,,A,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9698,Kidney,8677,,A,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9699,Kidney,8677,,A,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9700,Liver,8677,,A,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9701,Liver,8677,,A,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9702,Liver,8677,,A,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9703,Liver,8677,,A,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9704,Lung,8677,,A,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9705,Lung,8677,,A,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9706,Lung,8677,,A,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9707,Lung,8677,,A,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9708,Muscle tissue,8677,,A,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9709,Muscle tissue,8677,,A,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9710,Muscle tissue,8677,,A,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9711,Muscle tissue,8677,,A,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9712,Zone of skin,8677,,A,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9713,Zone of skin,8677,,A,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9714,Zone of skin,8677,,A,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9715,Zone of skin,8677,,A,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9716,Intestine,8677,,A,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9717,Intestine,8677,,A,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9718,Intestine,8677,,A,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9719,Intestine,8677,,A,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9720,Spleen,8677,,A,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9721,Spleen,8677,,A,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9722,Spleen,8677,,A,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9723,Spleen,8677,,A,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9724,,16434,,A,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9725,,16434,,A,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9726,,16434,,A,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9727,,16435,,A,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9728,,16435,,A,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9729,,16435,,A,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9730,,16435,,A,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9731,,16435,,A,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9732,,16435,,A,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,Rattus norvegicus,10116.0,,,50597
9733,,16435,,A,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9734,,16435,,A,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9735,,16434,,A,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,Rattus norvegicus,10116.0,,,50597
9736,,16434,,A,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,Rattus norvegicus,10116.0,,,50597
9737,,16434,,A,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,Rattus norvegicus,10116.0,,,50597
9738,,16435,,A,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
9739,,16435,,A,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
9740,,16435,,A,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
9741,,16435,,A,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
9742,,16435,,A,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
9743,,16435,,A,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
9744,,16434,,A,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,Rattus norvegicus,10116.0,,,50597
9745,,16434,,A,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,Rattus norvegicus,10116.0,,,50597
9746,,16434,,A,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,Rattus norvegicus,10116.0,,,50597
9747,,16434,,A,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,Rattus norvegicus,10116.0,,,50597
9748,,16434,,A,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,Rattus norvegicus,10116.0,,,50597
9749,,16434,,A,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,Rattus norvegicus,10116.0,,,50597
9750,,16435,,F,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
9751,,16435,,A,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
9752,,16435,,A,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
9753,,16435,,F,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,Rattus norvegicus,10116.0,,,50597
9754,,16435,,A,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,Rattus norvegicus,10116.0,,,50597
9755,,16435,,A,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,Rattus norvegicus,10116.0,,,50597
9756,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,,,Rattus norvegicus,10116.0,,,50597
9757,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,,,Rattus norvegicus,10116.0,,,50597
9758,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9759,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9760,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,,,Rattus norvegicus,10116.0,,,50597
9761,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,,,Rattus norvegicus,10116.0,,,50597
9762,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9763,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9764,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,,,Rattus norvegicus,10116.0,,,50597
9765,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,,,Rattus norvegicus,10116.0,,,50597
9766,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9767,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9768,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,,,Rattus norvegicus,10116.0,,,50597
9769,,5874,,A,,Half life period in rat by iv administration at a dose of 3 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9770,Plasma,1515,,A,,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),,,Rattus norvegicus,10116.0,,,50597
9771,Plasma,1515,,A,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),,,Rattus norvegicus,10116.0,,,50597
9772,Plasma,1515,,A,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,,Rattus norvegicus,10116.0,,,50597
9773,Plasma,1515,,A,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,,Rattus norvegicus,10116.0,,,50597
9774,Plasma,5491,,A,,Half life period was evaluated in rat plasma,,,Rattus norvegicus,10116.0,,,50597
9775,Plasma,5491,,A,,Half life period was evaluated in rat plasma; Not tested,,,Rattus norvegicus,10116.0,,,50597
9776,,1918,,A,,Half life period was evaluated in rats,,,Rattus norvegicus,10116.0,,,50597
9777,,1918,,A,,"Half life period was evaluated in rats, iv",In vivo,,Rattus norvegicus,10116.0,,,50597
9778,,6113,,A,,Half life period after intravenous administration at 5 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9779,,5546,,A,,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9780,,5553,,A,,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9781,Plasma,4188,,A,,Half life stability of compound was evaluated in rat plasma,,,Rattus norvegicus,10116.0,,,50597
9782,,6215,,A,,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9783,,6141,,A,,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9784,,5182,,A,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9785,,5182,,A,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,In vivo,,Rattus norvegicus,10116.0,,,50597
9786,,5710,,A,,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,In vivo,,Rattus norvegicus,10116.0,,,50597
9787,,5789,,A,,Half in rat i.v.,In vivo,,Rattus norvegicus,10116.0,,,50597
9788,,6011,,A,,Half period in rat after intravenous administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9789,,17594,,A,,Half-life after repeated oral dose of compound at 1 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9790,Liver,12357,,A,,Half-life measured in in vitro Cathepsin B assay in rat liver,In vitro,,Rattus norvegicus,10116.0,,,50597
9791,,5210,,A,,Half-life of compound was determined in rats,,,Rattus norvegicus,10116.0,,,50597
9792,,17596,,A,,Half-life at 10 mg/kg in rat upon intravenous administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9793,,6672,,A,,Half-life determined in rat,,,Rattus norvegicus,10116.0,,,50597
9794,,6673,,A,,Half-life determined in rat,,,Rattus norvegicus,10116.0,,,50597
9795,Brain,4910,,A,,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9796,Plasma,3741,,A,,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",,,Rattus norvegicus,10116.0,,,50597
9797,,17671,,A,,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9798,Plasma,4910,,A,,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9799,Plasma,17537,,A,,Half-life in rat plasma,,,Rattus norvegicus,10116.0,,,50597
9800,Plasma,4965,,A,,Half-life in rat plasma was determined,,,Rattus norvegicus,10116.0,,,50597
9801,Plasma,17537,,A,,Half-life in rat plasma; Not tested,,,Rattus norvegicus,10116.0,,,50597
9802,Serum,6124,,A,,Half-life in rat serum,,,Rattus norvegicus,10116.0,,,50597
9803,Serum,6124,,A,,Half-life in rat serum; na is not available,,,Rattus norvegicus,10116.0,,,50597
9804,,6078,,A,,Half-life was calculated in rat,,,Rattus norvegicus,10116.0,,,50597
9805,Plasma,17668,,A,,Half-life was calculated in rat plasma,,,Rattus norvegicus,10116.0,,,50597
9806,,3185,,A,,Half-life was determined,,,Rattus norvegicus,10116.0,,,50597
9807,,4883,,A,,Half-life was determined,,,Rattus norvegicus,10116.0,,,50597
9808,,2959,,A,,Half-life after administration of 20 mg/Kg oral dose in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9809,,4029,,A,,Half-life after administration of 3.2 mg/kg intravenously in male rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9810,,4029,,A,,Half-life after intravenous administration in female rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9811,,4029,,A,,Half-life after intravenous administration in male rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9812,,6180,,A,,Half-life after intravenous dose in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9813,Liver,1557,,A,,Half-life in a rat liver homogenate preparation,,,Rattus norvegicus,10116.0,,,50597
9814,Plasma,12500,,A,,Half-life in plasma of rat,,,Rattus norvegicus,10116.0,,,50597
9815,Plasma,12500,,A,,Half-life in plasma of rat at dose of 3-10 mgkg,,,Rattus norvegicus,10116.0,,,50597
9816,,5064,,A,,Half-life in rat,,,Rattus norvegicus,10116.0,,,50597
9817,,5145,,A,,Half-life in rat,,,Rattus norvegicus,10116.0,,,50597
9818,,5147,,A,,Half-life in rat,,,Rattus norvegicus,10116.0,,,50597
9819,,5833,,A,,Half-life in rat,,,Rattus norvegicus,10116.0,,,50597
9820,,6596,,A,,Half-life in rat,,,Rattus norvegicus,10116.0,,,50597
9821,,17655,,A,,Half-life in rat,,,Rattus norvegicus,10116.0,,,50597
9822,,6495,,A,,Half-life in rat after oral administration at 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9823,,17538,,A,,Half-life in rat after po administration at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9824,,17538,,A,,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
9825,,10,,A,,Half-life in rat at 3 mg/kg dose administered intravenously,In vivo,,Rattus norvegicus,10116.0,,,50597
9826,Brain,17669,,A,,Half-life in rat brain homogenate,,,Rattus norvegicus,10116.0,,,50597
9827,Plasma,17065,,A,,Half-life in rat plasma,,,Rattus norvegicus,10116.0,,,50597
9828,,4333,,A,,Half-life in rats,,,Rattus norvegicus,10116.0,,,50597
9829,,6827,,A,,Half-life in Dawley rats,,,Rattus norvegicus,10116.0,,,50597
9830,Plasma,889,,A,,Half-life in vitro in rat plasma,In vitro,,Rattus norvegicus,10116.0,,,50597
9831,Plasma,889,,A,,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,In vitro,,Rattus norvegicus,10116.0,,,50597
9832,,3747,,A,,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",,,Rattus norvegicus,10116.0,,,50597
9833,,15022,,A,,The area under the curve of compound was measured at the dose of 100 umol/kg,,,Rattus norvegicus,10116.0,,,50597
9834,,15022,,A,,The area under the curve of compound was measured at the dose of 300 umol/kg,,,Rattus norvegicus,10116.0,,,50597
9835,,15022,,A,,The area under the curve of compound was measured at the dose of 30 umol/kg,,,Rattus norvegicus,10116.0,,,50597
9836,,3360,,A,,Bioavailability as oral AUC in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9837,Plasma,5334,,A,,The plasma concentration versus time curve (AUC) was determined,,,Rattus norvegicus,10116.0,,,50597
9838,,17411,,A,,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9839,,17411,,A,,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9840,,17411,,A,,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9841,,6570,,A,,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,,,Rattus norvegicus,10116.0,,,50597
9842,,6570,,A,,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,,,Rattus norvegicus,10116.0,,,50597
9843,,17411,,A,,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9844,Plasma,14941,,A,,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",,,Rattus norvegicus,10116.0,,,50597
9845,Plasma,14941,,A,,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",,,Rattus norvegicus,10116.0,,,50597
9846,Plasma,17538,,A,,AUC in rat after po administration at a dose of 10 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9847,Plasma,17752,,A,,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9848,,17509,,A,,Area under curve value 24 hr after 10 mg/kg iv administration in rats,,,Rattus norvegicus,10116.0,,,50597
9849,,17509,,A,,Area under curve value 24 hr after 10 mg/kg oral administration in rats,,,Rattus norvegicus,10116.0,,,50597
9850,,17509,,A,,Area under curve value 24 hr after 2 mg/kg iv administration in rats,,,Rattus norvegicus,10116.0,,,50597
9851,,17509,,A,,Area under curve value 24 hr after 2 mg/kg oral administration in rats,,,Rattus norvegicus,10116.0,,,50597
9852,,17509,,A,,Area under curve value 6 hr after po administration in rat,,,Rattus norvegicus,10116.0,,,50597
9853,,17717,,A,,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,,Rattus norvegicus,10116.0,,,50597
9854,,17717,,A,,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",,,Rattus norvegicus,10116.0,,,50597
9855,,17717,,A,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,,Rattus norvegicus,10116.0,,,50597
9856,,17717,,A,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,,,Rattus norvegicus,10116.0,,,50597
9857,Plasma,6642,,A,,AUC normalized for dose (AUCN) in rat,,,Rattus norvegicus,10116.0,,,50597
9858,,6640,,A,,Area under curve in rat after p.o. administration,,,Rattus norvegicus,10116.0,,,50597
9859,,6641,,A,,Area under curve in rat after p.o. administration,,,Rattus norvegicus,10116.0,,,50597
9860,,6641,,A,,Area under curve in rat after p.o. administration; Not determined,,,Rattus norvegicus,10116.0,,,50597
9861,,6641,,A,,Area under curve in rat after peroral administration,,,Rattus norvegicus,10116.0,,,50597
9862,,3603,,A,,Area under curve (carotid artery) value of the compound,,,Rattus norvegicus,10116.0,,,50597
9863,,3550,,A,,Bioavailability expressed as the area under curve of rat carotid artery,,,Rattus norvegicus,10116.0,,,50597
9864,,15662,,A,,Area under curve in male SD rats was observed after intravenous administration in rat,,,Rattus norvegicus,10116.0,,,50597
9865,,17720,,A,,Area under curve of the compound was determined,,,Rattus norvegicus,10116.0,,,50597
9866,,5407,,A,,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,,,Rattus norvegicus,10116.0,,,50597
9867,Plasma,17752,,A,,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9868,Plasma,17752,,A,,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,,,Rattus norvegicus,10116.0,,,50597
9869,,3603,,A,,Area under curve (portal vein) value of the compound,,,Rattus norvegicus,10116.0,,,50597
9870,,3550,,A,,Bioavailability expressed as the area under curve of rat portal vein,,,Rattus norvegicus,10116.0,,,50597
9871,Plasma,17655,,A,,Area Under plasma concentration time curve in rat upon peroral administration,,,Rattus norvegicus,10116.0,,,50597
9872,,17582,,A,,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,,,Rattus norvegicus,10116.0,,,50597
9873,,17582,,A,,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,,,Rattus norvegicus,10116.0,,,50597
9874,,17791,,A,,Compound was evaluated for oral bioavailability in rats,,,Rattus norvegicus,10116.0,,,50597
9875,,17791,,A,,Compound was evaluated for oral bioavailability in rats after iv administration,,,Rattus norvegicus,10116.0,,,50597
9876,,17791,,A,,Compound was evaluated for oral bioavailability in rats; 30-80,,,Rattus norvegicus,10116.0,,,50597
9877,,17791,,A,,Compound was evaluated for oral bioavailability in rats; 50-60,,,Rattus norvegicus,10116.0,,,50597
9878,,17791,,A,,Compound was evaluated for oral bioavailability in rats; no data,,,Rattus norvegicus,10116.0,,,50597
9879,,17791,,A,,Compound was evaluated for oral bioavailability in rats; peptide,,,Rattus norvegicus,10116.0,,,50597
9880,Blood,7768,,A,,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",,,Rattus norvegicus,10116.0,,,50597
9881,Blood,7768,,A,,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",,,Rattus norvegicus,10116.0,,,50597
9882,Blood,7768,,A,,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",,,Rattus norvegicus,10116.0,,,50597
9883,Blood,7768,,A,,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",,,Rattus norvegicus,10116.0,,,50597
9884,Stomach,8677,,A,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9885,Stomach,8677,,A,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9886,Stomach,8677,,A,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9887,Stomach,8677,,A,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9888,Thyroid gland,8677,,A,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9889,Thyroid gland,8677,,A,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9890,Thyroid gland,8677,,A,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9891,Thyroid gland,8677,,A,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9892,Heart,8677,,A,,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",In vivo,,Rattus norvegicus,10116.0,,,50597
9893,Urine,6899,,A,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,,Rattus norvegicus,10116.0,,,50597
9894,Urine,6899,,A,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,,Rattus norvegicus,10116.0,,,50597
9895,Liver,6899,,A,,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,,,Rattus norvegicus,10116.0,,,50597
9896,Urine,6899,,A,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,,Rattus norvegicus,10116.0,,,50597
9897,Urine,6899,,A,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,,Rattus norvegicus,10116.0,,,50597
9898,Muscle tissue,8677,,A,,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,Rattus norvegicus,10116.0,,,50597
9899,,6899,,A,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,,,Rattus norvegicus,10116.0,,,50597
9900,Urine,6899,,A,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,,Rattus norvegicus,10116.0,,,50597
9901,,2189,,A,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,,,Rattus norvegicus,10116.0,,,50597
9902,Urine,2189,,A,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,,,Rattus norvegicus,10116.0,,,50597
9903,Urine,2189,,A,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,,,Rattus norvegicus,10116.0,,,50597
9904,Blood,10839,,A,,Biodistribution of compound in rat blood after 5 min of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9905,Blood,10839,,A,,Biodistribution of compound in rat blood after 5 min of administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
9906,Brain,10839,,A,,Biodistribution of compound in rat brain after 5 min of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9907,Heart,10839,,A,,Biodistribution of compound in rat heart after 5 min of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9908,Heart,10839,,A,,Biodistribution of compound in rat heart after 5 min of administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
9909,Kidney,10839,,A,,Biodistribution of compound in rat kidney after 5 min of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9910,Kidney,10839,,A,,Biodistribution of compound in rat kidney after 5 min of administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
9911,Liver,10839,,A,,Biodistribution of compound in rat liver after 5 min of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9912,Liver,10839,,A,,Biodistribution of compound in rat liver after 5 min of administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
9913,Lung,10839,,A,,Biodistribution of compound in rat lung after 5 min of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9914,Lung,10839,,A,,Biodistribution of compound in rat lung after 5 min of administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
9915,Muscle tissue,10839,,A,,Biodistribution of compound in rat muscle after 5 min of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9916,Muscle tissue,10839,,A,,Biodistribution of compound in rat muscle after 5 min of administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
9917,Heart,4043,,A,,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,Rattus norvegicus,10116.0,,,50597
9918,Heart,4043,,A,,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,Rattus norvegicus,10116.0,,,50597
9919,Liver,4043,,A,,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,Rattus norvegicus,10116.0,,,50597
9920,Liver,4043,,A,,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,Rattus norvegicus,10116.0,,,50597
9921,,4043,,A,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,Rattus norvegicus,10116.0,,,50597
9922,,4043,,A,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,Rattus norvegicus,10116.0,,,50597
9923,Spleen,4043,,A,,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,Rattus norvegicus,10116.0,,,50597
9924,Spleen,4043,,A,,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,Rattus norvegicus,10116.0,,,50597
9925,,4043,,A,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,Rattus norvegicus,10116.0,,,50597
9926,,4043,,A,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,Rattus norvegicus,10116.0,,,50597
9927,,1446,,A,,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,,,Rattus norvegicus,10116.0,,,50597
9928,Urine,9971,,A,,Dose required to lower urine osmolality to 300 mOsm/kg in rat,,,Rattus norvegicus,10116.0,,,50597
9929,Urine,9971,,A,,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,,,Rattus norvegicus,10116.0,,,50597
9930,,5765,,A,,% Bioavailability after 1 day of the drug administration in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9931,,5765,,A,,% Bioavailability after 4 day of the drug administration in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9932,,4257,,A,,Absolute bioavailability was evaluated in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
9933,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,,,Rattus norvegicus,10116.0,,,50597
9934,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9935,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9936,Kidney,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,,,Rattus norvegicus,10116.0,,,50597
9937,Kidney,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,,,Rattus norvegicus,10116.0,,,50597
9938,Kidney,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9939,Kidney,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9940,Liver,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,,,Rattus norvegicus,10116.0,,,50597
9941,Liver,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,,,Rattus norvegicus,10116.0,,,50597
9942,Liver,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9943,Liver,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9944,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,,,Rattus norvegicus,10116.0,,,50597
9945,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,,,Rattus norvegicus,10116.0,,,50597
9946,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9947,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9948,Muscle tissue,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,,,Rattus norvegicus,10116.0,,,50597
9949,Muscle tissue,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,,,Rattus norvegicus,10116.0,,,50597
9950,Muscle tissue,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9951,Muscle tissue,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9952,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,,,Rattus norvegicus,10116.0,,,50597
9953,Female gonad,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,,,Rattus norvegicus,10116.0,,,50597
9954,Female gonad,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9955,Female gonad,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9956,Uterus,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,,,Rattus norvegicus,10116.0,,,50597
9957,Uterus,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,,,Rattus norvegicus,10116.0,,,50597
9958,Uterus,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9959,Uterus,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9960,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,,,Rattus norvegicus,10116.0,,,50597
9961,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,,,Rattus norvegicus,10116.0,,,50597
9962,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9963,,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9964,Muscle tissue,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,,,Rattus norvegicus,10116.0,,,50597
9965,Muscle tissue,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,,,Rattus norvegicus,10116.0,,,50597
9966,Muscle tissue,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9967,Muscle tissue,13091,,A,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,,,Rattus norvegicus,10116.0,,,50597
9968,,11977,,A,,Dissociation constant was determined,,,Rattus norvegicus,10116.0,,,50597
9969,,14941,,A,,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",,,Rattus norvegicus,10116.0,,,50597
9970,,15078,,A,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,,Rattus norvegicus,10116.0,,,50597
9971,,15078,,A,,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",,,Rattus norvegicus,10116.0,,,50597
9972,,4755,,A,,Observed rate constant in 80% rat plasma at 37 degree Centigrade,,,Rattus norvegicus,10116.0,,,50597
9973,,589,,A,,LogP value was evaluated in the in situ rat gut perfusion assay,,,Rattus norvegicus,10116.0,,,50597
9974,,17582,,A,,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9975,,5031,,A,,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9976,,17764,,A,,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9977,,17720,,A,,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,,,Rattus norvegicus,10116.0,,,50597
9978,,2862,,F,,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,,,Rattus norvegicus,10116.0,,,50597
9979,,16423,,A,,Half-life was evaluated after 10 uM/kg of intra arterial administration,,,Rattus norvegicus,10116.0,,,50597
9980,,16423,,A,,Half-life was evaluated after 20 uM/kg of peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9981,,6005,,A,,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9982,Plasma,2938,,A,,Half-life was evaluated in plasma of rat,,,Rattus norvegicus,10116.0,,,50597
9983,,6410,,A,,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9984,,6410,,A,,Half-life was evaluated in rats at an oral dose of 30 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9985,,6062,,A,,Half-life was measured in rat after an iv dose of 1 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9986,,6571,,A,,Half-life period of compound in rats after peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9987,Plasma,3136,,A,,Half-life period of compound was measured in rat plasma.,,,Rattus norvegicus,10116.0,,,50597
9988,Plasma,3136,,A,,Half-life period of compound was measured in rat plasma; ND is not determined,,,Rattus norvegicus,10116.0,,,50597
9989,Plasma,3136,,A,,Half-life period of compound was measured in rat plasma; not determined,,,Rattus norvegicus,10116.0,,,50597
9990,,4521,,A,,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9991,,5871,,A,,Half-life period in rat by iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9992,,6077,,A,,Half-life period in rats following intravenous administration at 2 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
9993,,6679,,A,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,,Rattus norvegicus,10116.0,,,50597
9994,,5144,,A,,Half-life period was determined for the compound in rat,,,Rattus norvegicus,10116.0,,,50597
9995,,4498,,A,,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",In vivo,,Rattus norvegicus,10116.0,,,50597
9996,,4498,,A,,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",In vivo,,Rattus norvegicus,10116.0,,,50597
9997,,1908,,A,,Half-life value after IV dose at a dose of 5 mg/kg in rats.,In vivo,,Rattus norvegicus,10116.0,,,50597
9998,,6211,,A,,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
9999,,5529,,A,,Half-life was determined in rat after intravenous administration (0.5 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10000,,6444,,A,,Half-life was determined in rat at a dose of 1 mpk i.v.,In vivo,,Rattus norvegicus,10116.0,,,50597
10001,,6444,,A,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
10002,,6444,,A,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
10003,,5207,,A,,Half-life in rat,,,Rattus norvegicus,10116.0,,,50597
10004,Plasma,530,,A,,In vitro half life in rat plasma,In vitro,,Rattus norvegicus,10116.0,,,50597
10005,Plasma,1116,,A,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",In vitro,,Rattus norvegicus,10116.0,,,50597
10006,,3219,,A,,In vitro half life in rat,In vitro,,Rattus norvegicus,10116.0,,,50597
10007,,6109,,A,,In vivo half life period after intravenous administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10008,,17582,,A,,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10009,,17582,,A,,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10010,,5974,,A,,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10011,,5974,,A,,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10012,,5974,,A,,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10013,,5974,,A,,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10014,,17853,,A,,Longer half-life in rat (i.v.) at 0.5 mpk,In vivo,,Rattus norvegicus,10116.0,,,50597
10015,,17853,,A,,Longer half-life in rat (p.o.) at 2.0 mpk,In vivo,,Rattus norvegicus,10116.0,,,50597
10016,,3457,,A,,Pharmacokinetic property (half life) in rat,,,Rattus norvegicus,10116.0,,,50597
10017,,2792,,A,,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10018,,2792,,A,,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10019,,2792,,A,,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10020,,2792,,A,,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10021,,5739,,A,,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10022,,15765,,A,,Pharmacokinetic half time was determined intravenously in rats.,In vivo,,Rattus norvegicus,10116.0,,,50597
10023,Plasma,6567,,A,,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,In vivo,,Rattus norvegicus,10116.0,,,50597
10024,Plasma,2448,,A,,Plasma half life of hydrolysis of the compound,,,Rattus norvegicus,10116.0,,,50597
10025,Plasma,5423,,A,,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10026,Plasma,4853,,A,,Plasma half life period was calculated in rat,,,Rattus norvegicus,10116.0,,,50597
10027,Plasma,4514,,A,,Plasma half-life in Sprague-Dawley rats,,,Rattus norvegicus,10116.0,,,50597
10028,Plasma,4514,,A,,Plasma half-life in Sprague-Dawley rats; Not determined,,,Rattus norvegicus,10116.0,,,50597
10029,Plasma,1500,,A,,Plasma half-life in rats,,,Rattus norvegicus,10116.0,,,50597
10030,Plasma,1500,,A,,Plasma half-life in rats; <MQL,,,Rattus norvegicus,10116.0,,,50597
10031,Plasma,5334,,A,,Plasma half-life period (0-8 h) was determined,,,Rattus norvegicus,10116.0,,,50597
10032,Plasma,5334,,A,,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,,,Rattus norvegicus,10116.0,,,50597
10033,Plasma,5334,,A,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10034,Plasma,5334,,A,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10035,Plasma,4956,,A,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,,,Rattus norvegicus,10116.0,,,50597
10036,Plasma,4956,,A,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,,,Rattus norvegicus,10116.0,,,50597
10037,Blood,7768,,A,,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",,,Rattus norvegicus,10116.0,,,50597
10038,Blood,7768,,A,,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",,,Rattus norvegicus,10116.0,,,50597
10039,Blood,7768,,A,,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",,,Rattus norvegicus,10116.0,,,50597
10040,,7768,,A,,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",,,Rattus norvegicus,10116.0,,,50597
10041,,7768,,A,,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",,,Rattus norvegicus,10116.0,,,50597
10042,,7768,,A,,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",,,Rattus norvegicus,10116.0,,,50597
10043,,7768,,A,,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",,,Rattus norvegicus,10116.0,,,50597
10044,,7768,,A,,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",,,Rattus norvegicus,10116.0,,,50597
10045,,7768,,A,,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",,,Rattus norvegicus,10116.0,,,50597
10046,,7768,,A,,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",,,Rattus norvegicus,10116.0,,,50597
10047,Heart,7768,,A,,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,,Rattus norvegicus,10116.0,,,50597
10048,Heart,7768,,A,,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",,,Rattus norvegicus,10116.0,,,50597
10049,Heart,7768,,A,,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",,,Rattus norvegicus,10116.0,,,50597
10050,Heart,7768,,A,,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",,,Rattus norvegicus,10116.0,,,50597
10051,Heart,7768,,A,,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",,,Rattus norvegicus,10116.0,,,50597
10052,Heart,7768,,A,,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",,,Rattus norvegicus,10116.0,,,50597
10053,Heart,7768,,A,,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",,,Rattus norvegicus,10116.0,,,50597
10054,Liver,7768,,A,,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,,Rattus norvegicus,10116.0,,,50597
10055,Liver,7768,,A,,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",,,Rattus norvegicus,10116.0,,,50597
10056,Liver,7768,,A,,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",,,Rattus norvegicus,10116.0,,,50597
10057,Liver,7768,,A,,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",,,Rattus norvegicus,10116.0,,,50597
10058,Liver,7768,,A,,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",,,Rattus norvegicus,10116.0,,,50597
10059,Liver,7768,,A,,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",,,Rattus norvegicus,10116.0,,,50597
10060,Liver,7768,,A,,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",,,Rattus norvegicus,10116.0,,,50597
10061,Lung,7768,,A,,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",,,Rattus norvegicus,10116.0,,,50597
10062,Lung,7768,,A,,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",,,Rattus norvegicus,10116.0,,,50597
10063,Lung,7768,,A,,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",,,Rattus norvegicus,10116.0,,,50597
10064,Lung,7768,,A,,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",,,Rattus norvegicus,10116.0,,,50597
10065,Lung,7768,,A,,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",,,Rattus norvegicus,10116.0,,,50597
10066,Lung,7768,,A,,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",,,Rattus norvegicus,10116.0,,,50597
10067,Lung,7768,,A,,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",,,Rattus norvegicus,10116.0,,,50597
10068,Thyroid gland,7768,,A,,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",,,Rattus norvegicus,10116.0,,,50597
10069,Thyroid gland,7768,,A,,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",,,Rattus norvegicus,10116.0,,,50597
10070,Thyroid gland,7768,,A,,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",,,Rattus norvegicus,10116.0,,,50597
10071,Thyroid gland,7768,,A,,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",,,Rattus norvegicus,10116.0,,,50597
10072,Thyroid gland,7768,,A,,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",,,Rattus norvegicus,10116.0,,,50597
10073,Thyroid gland,7768,,A,,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",,,Rattus norvegicus,10116.0,,,50597
10074,,4498,,A,,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",In vivo,,Rattus norvegicus,10116.0,,,50597
10075,,4498,,A,,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",In vivo,,Rattus norvegicus,10116.0,,,50597
10076,,3603,,A,,Bioavailability after a dose of 10 mg/kg p.o.,In vivo,,Rattus norvegicus,10116.0,,,50597
10077,,6215,,A,,Bioavailability after peroral administration (10 mg/kg) was determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10078,,5710,,A,,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,In vivo,,Rattus norvegicus,10116.0,,,50597
10079,,5710,,A,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10080,,5676,,A,,Bioavailability in rat po was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
10081,,17667,,A,,Bioavailability of compound at 10 mg/kg in rat after oral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10082,,17667,,A,,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10083,,6848,,A,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10084,,6848,,A,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10085,,17267,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10086,,6362,,A,,Bioavailability in rat (Sprague-Dawley) (female),In vivo,,Rattus norvegicus,10116.0,,,50597
10087,,17671,,A,,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10088,,17671,,A,,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10089,,4333,,A,,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
10090,,6077,,A,,Bioavailability in rat at an oral dose of 2 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10091,,3278,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10092,,5964,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10093,,4884,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10094,,4905,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10095,,4884,,A,,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,In vivo,,Rattus norvegicus,10116.0,,,50597
10096,,6850,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10097,,2864,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10098,,5780,,A,,Bioavailability was determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10099,,1465,,A,,Bioavailability,In vivo,,Rattus norvegicus,10116.0,,,50597
10100,,5199,,A,,Bioavailability,In vivo,,Rattus norvegicus,10116.0,,,50597
10101,,5765,,A,,Bioavailability in rat after 1 day dosing,In vivo,,Rattus norvegicus,10116.0,,,50597
10102,,5765,,A,,Bioavailability in rat after 4 day dosing,In vivo,,Rattus norvegicus,10116.0,,,50597
10103,,6518,,A,,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,In vivo,,Rattus norvegicus,10116.0,,,50597
10104,,6518,,A,,Bioavailability after IV dosing at 1 mg/kg in rat; no data,In vivo,,Rattus norvegicus,10116.0,,,50597
10105,,6518,,A,,Bioavailability after oral administration at a dose of 2 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10106,,6518,,A,,Bioavailability after oral administration at a dose of 4 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10107,,2083,,A,,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10108,,17260,,A,,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10109,,4956,,A,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10110,,4368,,A,,Bioavailability by intravenous administration of 3.4 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10111,Plasma,17752,,A,,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10112,,1446,,A,,Bioavailability in rat (Fisher) (fasted),In vivo,,Rattus norvegicus,10116.0,,,50597
10113,,2891,,A,,Bioavailability in monkey after po administration of 10 mg/kg dose,In vivo,,Primates,9443.0,,,22224
10114,,2891,,A,,Oral bioavailability in monkey (dose 10 mg/kg),In vivo,,Primates,9443.0,,,22224
10115,,6672,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10116,,6673,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10117,,17655,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10118,,17796,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10119,,17853,,A,,Bioavailability in rat (dose 2.0 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10120,,4521,,A,,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),In vivo,,Rattus norvegicus,10116.0,,,50597
10121,,4940,,A,,Oral bioavailability in rat (dose 5 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10122,,2891,,A,,Bioavailability in rat after po administration of 30 mg/kg dose,In vivo,,Rattus norvegicus,10116.0,,,22224
10123,,2891,,A,,Bioavailability in rat after po administration of 30 mg/kg dose,In vivo,,Rattus norvegicus,10116.0,,,22224
10124,,4521,,A,,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10125,,17686,,A,,Bioavailability in rat (dose 2 mg/kg i.v.),In vivo,,Rattus norvegicus,10116.0,,,50597
10126,,17796,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10127,Plasma,17796,,A,,Bioavailability in rat; Only traces detected in rat plasma,In vivo,,Rattus norvegicus,10116.0,,,50597
10128,,5064,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10129,,5147,,A,,Bioavailability upon oral administration of compound,In vivo,,Rattus norvegicus,10116.0,,,50597
10130,,1916,,A,,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10131,,6049,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10132,,1445,,A,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",In vivo,,Rattus norvegicus,10116.0,,,50597
10133,,1445,,A,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",In vivo,,Rattus norvegicus,10116.0,,,50597
10134,,2862,,F,,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,,,Rattus norvegicus,10116.0,,,50597
10135,,2862,,F,,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,,,Rattus norvegicus,10116.0,,,50597
10136,,4194,,A,,In vitro and metabolic stability was determined,,,Rattus norvegicus,10116.0,,,50597
10137,,4194,,A,,In vitro metabolic stability in rat hepatocytes,,,Rattus norvegicus,10116.0,,,50597
10138,,5486,,A,,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,,,Rattus norvegicus,10116.0,,,50597
10139,Liver,17582,401.0,A,,Metabolic rate for compound was observed in rat hepatocytes,In vitro,,Rattus norvegicus,10116.0,Hepatocyte,,50597
10140,,5600,,A,,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,,,Rattus norvegicus,10116.0,,,50597
10141,,14294,,A,,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),,,Rattus norvegicus,10116.0,,,50597
10142,,14294,,A,,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),,,Rattus norvegicus,10116.0,,,50597
10143,,14294,,A,,Metabolism of compound in rat S9 microsomes; Trace,,,Rattus norvegicus,10116.0,,,50597
10144,,17847,,A,,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,,,Rattus norvegicus,10116.0,,,50597
10145,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,,,Rattus norvegicus,10116.0,,,50597
10146,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,,,Rattus norvegicus,10116.0,,,50597
10147,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,,,Rattus norvegicus,10116.0,,,50597
10148,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,,,Rattus norvegicus,10116.0,,,50597
10149,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,,,Rattus norvegicus,10116.0,,,50597
10150,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,,,Rattus norvegicus,10116.0,,,50597
10151,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,,,Rattus norvegicus,10116.0,,,50597
10152,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,,,Rattus norvegicus,10116.0,,,50597
10153,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,,,Rattus norvegicus,10116.0,,,50597
10154,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,,,Rattus norvegicus,10116.0,,,50597
10155,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,,,Rattus norvegicus,10116.0,,,50597
10156,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,,,Rattus norvegicus,10116.0,,,50597
10157,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,,,Rattus norvegicus,10116.0,,,50597
10158,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,,,Rattus norvegicus,10116.0,,,50597
10159,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,,,Rattus norvegicus,10116.0,,,50597
10160,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,,Rattus norvegicus,10116.0,,,50597
10161,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,,,Rattus norvegicus,10116.0,,,50597
10162,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,,Rattus norvegicus,10116.0,,,50597
10163,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,,,Rattus norvegicus,10116.0,,,50597
10164,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,,,Rattus norvegicus,10116.0,,,50597
10165,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,,,Rattus norvegicus,10116.0,,,50597
10166,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,,Rattus norvegicus,10116.0,,,50597
10167,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,,,Rattus norvegicus,10116.0,,,50597
10168,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,,,Rattus norvegicus,10116.0,,,50597
10169,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,,Rattus norvegicus,10116.0,,,50597
10170,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,,,Rattus norvegicus,10116.0,,,50597
10171,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,,Rattus norvegicus,10116.0,,,50597
10172,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,,,Rattus norvegicus,10116.0,,,50597
10173,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,,Rattus norvegicus,10116.0,,,50597
10174,Plasma,4969,,A,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,,,Rattus norvegicus,10116.0,,,50597
10175,Plasma,6737,,A,,Stability in rat plasma was determined,,,Rattus norvegicus,10116.0,,,50597
10176,Plasma,6737,,A,,Stability in rat plasma was determined; ND= no data,,,Rattus norvegicus,10116.0,,,50597
10177,Plasma,5089,,A,,Tested for plasma half life period in rat (0-8 hr),,,Rattus norvegicus,10116.0,,,50597
10178,Plasma,5089,,A,,Tested for plasma half life period in rat (0-8 hr); Not determined,,,Rattus norvegicus,10116.0,,,50597
10179,,1466,,A,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10180,,1466,,A,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10181,,4950,,A,,Tested for the half life in rat,,,Rattus norvegicus,10116.0,,,50597
10182,,2412,,A,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,In vitro,,Rattus norvegicus,10116.0,,,50597
10183,,2412,,A,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,In vitro,,Rattus norvegicus,10116.0,,,50597
10184,,2412,,A,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,In vitro,,Rattus norvegicus,10116.0,,,50597
10185,,2412,,A,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,In vitro,,Rattus norvegicus,10116.0,,,50597
10186,,2412,,A,,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,In vitro,,Rattus norvegicus,10116.0,,,50597
10187,,15022,,A,,The biological half life the compound was measured at the dose of 100 umol/kg,,,Rattus norvegicus,10116.0,,,50597
10188,,15022,,A,,The biological half life the compound was measured at the dose of 30 umol/kg,,,Rattus norvegicus,10116.0,,,50597
10189,Plasma,406,,A,,The compound was evaluated for plasma half life period in rat,,,Rattus norvegicus,10116.0,,,50597
10190,,15078,,A,,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",In vivo,,Rattus norvegicus,10116.0,,,50597
10191,,15078,,A,,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",In vivo,,Rattus norvegicus,10116.0,,,50597
10192,,5247,,A,,The pharmacokinetic parameter half-life period in vivo in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10193,,5041,,A,,"The pharmacokinetic property, Half-life was determined",In vivo,,Rattus norvegicus,10116.0,,,50597
10194,,5041,,A,,"The pharmacokinetic property, Half-life in rat in vivo",In vivo,,Rattus norvegicus,10116.0,,,50597
10195,,5041,,A,,"The pharmacokinetic property, Half-life was determined; ND denotes no data",In vivo,,Rattus norvegicus,10116.0,,,50597
10196,,5041,,A,,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",In vivo,,Rattus norvegicus,10116.0,,,50597
10197,Plasma,3918,,A,,The plasma half life period in rats,,,Rattus norvegicus,10116.0,,,50597
10198,Liver,2906,,A,,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,,,Rattus norvegicus,10116.0,,,50597
10199,,6467,,A,,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
10200,,5510,,A,,t1/2 (apparent elimination)of the compound was determined,,,Rattus norvegicus,10116.0,,,50597
10201,,3788,,A,,t1/2 value in rat,,,Rattus norvegicus,10116.0,,,50597
10202,,17796,,A,,Half life in rat,,,Rattus norvegicus,10116.0,,,50597
10203,Plasma,12873,,A,,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",In vivo,,Rattus norvegicus,10116.0,,,50597
10204,,5983,,A,,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,In vivo,,Rattus norvegicus,10116.0,,,50597
10205,,15765,,A,,Half-life period in fasted rats,,,Rattus norvegicus,10116.0,,,50597
10206,,2661,,A,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10207,,2661,,A,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10208,,429,,A,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10209,,17655,,A,,Maximum time required to achieve Cmax was determined in rat,,,Rattus norvegicus,10116.0,,,50597
10210,,17717,,A,,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,In vivo,,Rattus norvegicus,10116.0,,,50597
10211,,17717,,A,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,In vivo,,Rattus norvegicus,10116.0,,,50597
10212,,17717,,A,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,In vivo,,Rattus norvegicus,10116.0,,,50597
10213,,6570,,A,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10214,,6570,,A,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,In vivo,,Rattus norvegicus,10116.0,,,50597
10215,,5978,,A,,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10216,,5978,,A,,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10217,,5978,,A,,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10218,,5978,,A,,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10219,Plasma,17720,,A,,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10220,,4723,,A,,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10221,,4723,,A,,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10222,,4756,,A,,Tmax at the dose of 2 mg/Kg administered perorally in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10223,,4756,,A,,Tmax at the dose of 5 mg/Kg administered perorally in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10224,Plasma,17720,,A,,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10225,Plasma,17720,,A,,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10226,,1466,,A,,tmax upon peroral administration of 10.0 mg/Kg dose in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10227,,7449,,F,,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,,,Rattus norvegicus,10116.0,,,50597
10228,,7449,,F,,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,,,Rattus norvegicus,10116.0,,,50597
10229,,7449,,F,,Percent total excretion of 3-methoxyacetaminophen glucuronide,,,Rattus norvegicus,10116.0,,,50597
10230,,7449,,F,,Percent total excretion of N-methoxyacetaminophen glucuronide,,,Rattus norvegicus,10116.0,,,50597
10231,,7449,,F,,Percent total excretion of N-methoxyacetaminophen sulfate,,,Rattus norvegicus,10116.0,,,50597
10232,,7449,,F,,Percent total excretion of acetaminophen,,,Rattus norvegicus,10116.0,,,50597
10233,Thyroid gland,7768,,A,,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",,,Rattus norvegicus,10116.0,,,50597
10234,,17655,,A,,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",,,Rattus norvegicus,10116.0,,,50597
10235,,17735,,A,,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,,,Rattus norvegicus,10116.0,,,50597
10236,,5960,,A,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,,Rattus norvegicus,10116.0,,,50597
10237,,17735,,A,,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,,Rattus norvegicus,10116.0,,,50597
10238,,7116,,A,,Compound was tested for antidiuretic activity in rats,,,Rattus norvegicus,10116.0,,,50597
10239,Plasma,4878,,A,,AUC in rat after 3mg/kg oral dose,In vivo,,Rattus norvegicus,10116.0,,,50597
10240,,5939,,A,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,,,Rattus norvegicus,10116.0,,,50597
10241,,5939,,A,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,,,Rattus norvegicus,10116.0,,,50597
10242,,16367,,A,,Bioavailability administered orally at a dose of 10 mg/kg to rats,,,Rattus norvegicus,10116.0,,,50597
10243,,16366,,A,,Oral Bioavailability was determined,,,Rattus norvegicus,10116.0,,,50597
10244,,4426,,A,,Oral bioavailability in rat,,,Rattus norvegicus,10116.0,,,50597
10245,,4426,,A,,Oral bioavailability in rat; Not performed.,,,Rattus norvegicus,10116.0,,,50597
10246,,5041,,A,,Bioavailability,,,Rattus norvegicus,10116.0,,,50597
10247,,5041,,A,,Bioavailability was determined; ND denotes no data,,,Rattus norvegicus,10116.0,,,50597
10248,,1500,,A,,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,,,Rattus norvegicus,10116.0,,,50597
10249,,1500,,A,,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,,,Rattus norvegicus,10116.0,,,50597
10250,,17409,,A,,Binding towards rat plasma protein at 10 uM,,,Rattus norvegicus,10116.0,,,50597
10251,,17409,,A,,Binding towards rat plasma protein at 100 uM,,,Rattus norvegicus,10116.0,,,50597
10252,,2959,,A,,Bioavailability in rat (dose 20 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10253,,13501,,A,,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10254,,6567,,A,,Bioavailability in rat after 5 mg/kg oral gavage,In vivo,,Rattus norvegicus,10116.0,,,50597
10255,,6571,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10256,,6715,,A,,Bioavailability in rat (dose 1 mg/kg i.v.),In vivo,,Rattus norvegicus,10116.0,,,50597
10257,,6715,,A,,Bioavailability in rat (dose 3 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10258,,2932,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10259,,4171,,A,,Bioavailability of the compound in rats after administration of 30 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10260,,17509,,A,,Bioavailability after administration of 10 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10261,,17509,,A,,Bioavailability after administration of 2 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10262,,4527,,A,,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
10263,,4026,,A,,Bioavailability in dogs was determined; high,In vivo,,Rattus norvegicus,10116.0,,,50597
10264,,6659,,A,,Bioavailability in monkey after intravenous administration at 1 mpk,In vivo,,Rattus norvegicus,10116.0,,,50597
10265,,6659,,A,,Bioavailability in monkey after peroral administration at 10 mpk,In vivo,,Rattus norvegicus,10116.0,,,50597
10266,,6659,,A,,Bioavailability in rat after intravenous administration at 1 mpk,In vivo,,Rattus norvegicus,10116.0,,,50597
10267,,6659,,F,,Bioavailability in rat after intravenous administration at 2 mpk,In vivo,,Rattus norvegicus,10116.0,,,50597
10268,,6659,,A,,Bioavailability in rat after peroral administration at 30 mpk,In vivo,,Rattus norvegicus,10116.0,,,50597
10269,,6659,,F,,Bioavailability in rat after peroral administration at at 100 mpk,In vivo,,Rattus norvegicus,10116.0,,,50597
10270,,6597,,A,,Bioavailability in rats was evaluated,In vivo,,Rattus norvegicus,10116.0,,,50597
10271,,1202,,A,,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
10272,,1202,,A,,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
10273,,1202,,A,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
10274,,1202,,A,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,In vivo,,Rattus norvegicus,10116.0,,,50597
10275,,5207,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10276,,5970,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10277,,17538,,A,,Oral bioavailability in rat (dose 10 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10278,,17538,,A,,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
10279,,1466,,A,,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10280,,2879,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10281,,2879,,A,,Bioavailability was measured in rat after oral administration; 2-4,In vivo,,Rattus norvegicus,10116.0,,,50597
10282,,2879,,A,,Bioavailability was measured in rat after oral administration; 3-7,In vivo,,Rattus norvegicus,10116.0,,,50597
10283,,3777,,A,,Bioavailability in rat (intraduodenal administration),In vivo,,Rattus norvegicus,10116.0,,,50597
10284,,3777,,A,,Bioavailability in rat (intraduodenal administration),In vivo,,Rattus norvegicus,10116.0,,,50597
10285,,3777,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10286,,3777,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10287,,5423,,A,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10288,,16365,,A,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,In vivo,,Rattus norvegicus,10116.0,,,50597
10289,,16365,,A,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10290,,4239,,A,,Bioavailability was measured in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10291,,5438,,A,,Bioavailability was reported,In vivo,,Rattus norvegicus,10116.0,,,50597
10292,,5334,,A,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),In vivo,,Rattus norvegicus,10116.0,,,50597
10293,,5334,,A,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10294,,4199,,A,,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10295,,4199,,A,,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10296,,4199,,A,,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),In vivo,,Rattus norvegicus,10116.0,,,50597
10297,,4890,,A,,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10298,,2792,,A,,Bioavailability was determined at 3 mg/kg po dose in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10299,,5529,,A,,Oral bioavailability in rat (dose 2 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10300,,6685,,A,,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",In vivo,,Rattus norvegicus,10116.0,,,50597
10301,,6685,,A,,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",In vivo,,Rattus norvegicus,10116.0,,,50597
10302,,6685,,A,,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",In vivo,,Rattus norvegicus,10116.0,,,50597
10303,,6005,,A,,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10304,,6410,,A,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,In vivo,,Rattus norvegicus,10116.0,,,50597
10305,,6410,,A,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10306,,6103,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10307,,6410,,A,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,In vivo,,Rattus norvegicus,10116.0,,,50597
10308,,6410,,A,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10309,,5353,,A,,Bioavailability in rat (Sprague-Dawley),In vivo,,Rattus norvegicus,10116.0,,,50597
10310,,4727,,A,,Bioavailability in rat at the dose of 2 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10311,,17804,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10312,,5809,,A,,Bioavailability in rat (cannulated) (dose 2 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10313,,17804,,A,,Bioavailability value of compound in rats was determined after peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10314,,3634,,A,,Oral bioavailability in rat (dose 20 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10315,,3341,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10316,,2690,,A,,Oral bioavailability in rat (dose 5 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10317,,3184,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10318,,740,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10319,,1806,,A,,Compound was evaluated for oral bioavailability in rats; 15-27 %,In vivo,,Rattus norvegicus,10116.0,,,50597
10320,,4891,,A,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,In vivo,,Rattus norvegicus,10116.0,,,50597
10321,,3634,,A,,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),In vivo,,Rattus norvegicus,10116.0,,,50597
10322,,64,,A,,Compound was tested for bioavailability in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10323,,4839,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10324,,1094,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10325,,5005,,A,,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,In vivo,,Macaca mulatta,9544.0,,,22224
10326,,5005,,A,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,22224
10327,,4687,,A,,Evaluated for the bioavailability in rat (in vivo),In vivo,,Rattus norvegicus,10116.0,,,50597
10328,,17804,,A,,F value of compound in rats was determined after peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10329,,5974,,A,,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10330,,5974,,A,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10331,,5974,,A,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10332,,5974,,A,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10333,,1088,,A,,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",In vivo,,Rattus norvegicus,10116.0,,,50597
10334,,1742,,A,,Maximum fall in carotid flow in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10335,,4689,,A,,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10336,,2463,,A,,Oral bioavailability in rat (dose 5 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10337,,5654,,A,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10338,,5654,,A,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10339,,6874,,A,,Oral bioavailability in rat (male Wistar),In vivo,,Rattus norvegicus,10116.0,,,50597
10340,,5633,,A,,Oral bioavailability after administration (30 mg/kg) in rat; good,In vivo,,Rattus norvegicus,10116.0,,,50597
10341,,5496,,A,,Oral bioavailability at the dose of 2 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10342,,2358,,A,,Oral bioavailability determined in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10343,,16456,,A,,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10344,,5302,,A,,Oral bioavailability in rat (dose single 10 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10345,,5302,,A,,Oral bioavailability in rat (dose single 10 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10346,,5302,,A,,Oral bioavailability in rat (dose 5 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10347,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,,,Rattus norvegicus,10116.0,,,50597
10348,,11020,,A,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,,,Rattus norvegicus,10116.0,,,50597
10349,,11020,,A,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,,,Rattus norvegicus,10116.0,,,50597
10350,,11020,,A,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,,,Rattus norvegicus,10116.0,,,50597
10351,,11020,,A,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,,,Rattus norvegicus,10116.0,,,50597
10352,,11020,,A,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,,,Rattus norvegicus,10116.0,,,50597
10353,,11020,,A,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,,,Rattus norvegicus,10116.0,,,50597
10354,,11020,,A,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,,,Rattus norvegicus,10116.0,,,50597
10355,,11020,,A,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,,,Rattus norvegicus,10116.0,,,50597
10356,,11020,,A,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,,,Rattus norvegicus,10116.0,,,50597
10357,,11020,,A,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,,,Rattus norvegicus,10116.0,,,50597
10358,,11020,,A,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,,,Rattus norvegicus,10116.0,,,50597
10359,,11020,,A,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,,,Rattus norvegicus,10116.0,,,50597
10360,,11020,,A,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,,,Rattus norvegicus,10116.0,,,50597
10361,,11020,,A,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,,,Rattus norvegicus,10116.0,,,50597
10362,,11020,,A,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,,,Rattus norvegicus,10116.0,,,50597
10363,,11020,,A,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,,,Rattus norvegicus,10116.0,,,50597
10364,,11020,,A,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",,,Rattus norvegicus,10116.0,,,50597
10365,,11020,,A,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",,,Rattus norvegicus,10116.0,,,50597
10366,,11020,,A,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",,,Rattus norvegicus,10116.0,,,50597
10367,,11020,,A,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",,,Rattus norvegicus,10116.0,,,50597
10368,,11020,,A,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",,,Rattus norvegicus,10116.0,,,50597
10369,,11020,,A,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",,,Rattus norvegicus,10116.0,,,50597
10370,,11020,,A,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",,,Rattus norvegicus,10116.0,,,50597
10371,,11020,,A,,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",,,Rattus norvegicus,10116.0,,,50597
10372,,11020,,A,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",,,Rattus norvegicus,10116.0,,,50597
10373,,11020,,A,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",,,Rattus norvegicus,10116.0,,,50597
10374,,11020,,A,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",,,Rattus norvegicus,10116.0,,,50597
10375,,11020,,A,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",,,Rattus norvegicus,10116.0,,,50597
10376,,11020,,A,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,,Rattus norvegicus,10116.0,,,50597
10377,,11020,,A,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,,,Rattus norvegicus,10116.0,,,50597
10378,,11020,,A,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,,,Rattus norvegicus,10116.0,,,50597
10379,,11020,,A,,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,,,Rattus norvegicus,10116.0,,,50597
10380,,11020,,A,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,,,Rattus norvegicus,10116.0,,,50597
10381,,11020,,A,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,,,Rattus norvegicus,10116.0,,,50597
10382,,11020,,A,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,,,Rattus norvegicus,10116.0,,,50597
10383,,11020,,A,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,,,Rattus norvegicus,10116.0,,,50597
10384,,11020,,A,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,,Rattus norvegicus,10116.0,,,50597
10385,,11020,,A,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,,Rattus norvegicus,10116.0,,,50597
10386,,11020,,A,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,,Rattus norvegicus,10116.0,,,50597
10387,,7449,,F,,Percent total excretion of acetaminophen cysteine conjugate,,,Rattus norvegicus,10116.0,,,50597
10388,,7449,,F,,Percent total excretion of acetaminophen glucuronide,,,Rattus norvegicus,10116.0,,,50597
10389,,7449,,F,,Percent total excretion of acetaminophen sulfate,,,Rattus norvegicus,10116.0,,,50597
10390,,7449,,F,,Percent total excretion of acetaminophen-mercapturic acid,,,Rattus norvegicus,10116.0,,,50597
10391,Urine,3172,,A,,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,,,Rattus norvegicus,10116.0,,,50597
10392,,16456,,A,,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10393,Muscle tissue,10839,,A,,Biodistribution of compound in rat muscle after 5 min of administration,In vivo,,ratrat,8656.0,,,22224
10394,Muscle tissue,10839,,A,,Biodistribution of compound in rat muscle after 5 min of administration.,In vivo,,ratrat,8656.0,,,22224
10395,,5334,,A,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),In vivo,,Ovis aries,9940.0,,,22224
10396,,5334,,A,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),In vivo,,Ovis aries,9940.0,,,22224
10397,,5334,,A,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),In vivo,,Ovis aries,9940.0,,,22224
10398,,5334,,A,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),In vivo,,Ovis aries,9940.0,,,22224
10399,,5334,,A,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),In vivo,,Ovis aries,9940.0,,,22224
10400,,5334,,A,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),In vivo,,Ovis aries,9940.0,,,22224
10401,Plasma,5334,,A,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),In vivo,,Ovis aries,9940.0,,,22224
10402,Plasma,5334,,A,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),In vivo,,Ovis aries,9940.0,,,22224
10403,,1735,,A,,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),,,Serpentes,8570.0,,,50497
10404,,1469,,A,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,,,Serpentes,8570.0,,,50497
10405,,1336,,A,,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,,,Serpentes,8570.0,,,50497
10406,Plasma,12403,,A,,The human biological plasma half life of the compound,,,Homo sapiens,9606.0,,,22224
10407,Urine,8151,,A,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,,Rattus norvegicus,10116.0,,,50597
10408,,8004,,A,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,,,Rattus norvegicus,10116.0,,,50597
10409,,8004,,A,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,,,Rattus norvegicus,10116.0,,,50597
10410,,8004,,A,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,,,Rattus norvegicus,10116.0,,,50597
10411,,8004,,A,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,,,Rattus norvegicus,10116.0,,,50597
10412,,8004,,A,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,,,Rattus norvegicus,10116.0,,,50597
10413,,8004,,A,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,,,Rattus norvegicus,10116.0,,,50597
10414,,8004,,A,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,,,Rattus norvegicus,10116.0,,,50597
10415,,8004,,A,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,,,Rattus norvegicus,10116.0,,,50597
10416,,8004,,A,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,,,Rattus norvegicus,10116.0,,,50597
10417,,8004,,A,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,,,Rattus norvegicus,10116.0,,,50597
10418,,8004,,A,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,,,Rattus norvegicus,10116.0,,,50597
10419,,8004,,A,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,,,Rattus norvegicus,10116.0,,,50597
10420,,8004,,A,,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,,,Rattus norvegicus,10116.0,,,50597
10421,Blood,8004,,A,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,,,Rattus norvegicus,10116.0,,,50597
10422,Blood,8004,,A,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,,,Rattus norvegicus,10116.0,,,50597
10423,,15917,,B,,Dissociation constant against binding to human cyclophilin A,,,Homo sapiens,9606.0,,,180
10424,,12396,,B,,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,,,Bos taurus,9913.0,,,11591
10425,,7065,,A,,-Log C was determined by performing the electroshock minimum test,,,,,,,22224
10426,,7065,,A,,-Log C was determined by performing the foot shock test,,,,,,,22224
10427,,7065,,A,,-Log C was determined by performing the incl screen test,,,,,,,22224
10428,,7065,,A,,-Log C was determined by performing the maximum electroshock test,,,,,,,22224
10429,,7065,,A,,-Log C was determined by performing the pentylenetetrazole test,,,,,,,22224
10430,,12415,,A,,Tested for experimental arotinoid inhibitory dose,,,,,,,22224
10431,,10256,,A,,Negative log transformed activity,,,,,,,22224
10432,,7991,,A,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",,,,,,,22224
10433,,14342,,A,,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,,,Cavia porcellus,10141.0,,,50512
10434,,14342,,A,,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,,,Cavia porcellus,10141.0,,,50512
10435,,14342,,A,,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,,,Cavia porcellus,10141.0,,,50512
10436,Ileum,14342,,A,,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,,,Cavia porcellus,10141.0,,,50512
10437,,6047,,P,,Solubility in water was determined; values expressed as -log,,,,,,,22229
10438,,17269,,A,,Ratio of Kcat to that of Km was determined,,,,,,,22224
10439,,10026,,A,,Observed first order rate constant,,,,,,,22224
10440,,14583,,A,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,,,,,,,22224
10441,,2661,,A,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10442,,2661,,A,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10443,,4029,,A,,Oral Bioavailability after administration of 10 mg/kg in male rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10444,,17735,,A,,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10445,,4576,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10446,,17582,,A,,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10447,,17651,,A,,Oral bioavailability at 1 mg/kg was determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10448,,17651,,A,,Oral bioavailability at 10 mg/kg was determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10449,,17670,,A,,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",In vivo,,Rattus norvegicus,10116.0,,,50597
10450,,5045,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10451,,1696,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10452,,17764,,A,,Oral bioavailability after intravenous administration in rats at 24 uM/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10453,,6448,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10454,,6596,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10455,,17547,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10456,,17771,,A,,Oral bioavailability in rat at a dose of 3 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10457,,6495,,A,,Oral bioavailability in rat after oral administration at 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10458,,4558,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10459,,17596,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10460,,6827,,A,,Oral bioavailability in Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10461,,4026,,A,,Oral bioavailability,In vivo,,Rattus norvegicus,10116.0,,,50597
10462,,10,,A,,Oral bioavailability in rat (dose 30 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10463,,17717,,A,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,In vivo,,Rattus norvegicus,10116.0,,,50597
10464,,17717,,A,,Bioavailability in rat (dose 3 mg/kg i.v.),In vivo,,Rattus norvegicus,10116.0,,,50597
10465,,17717,,A,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,In vivo,,Rattus norvegicus,10116.0,,,50597
10466,,17717,,A,,Oral bioavailability in rat (dose 60 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10467,,4796,,A,,Percent oral bioavailability determined in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10468,,4883,,A,,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10469,,2137,,A,,The compound was evaluated for bioavailability in rats; 32-51,In vivo,,Rattus norvegicus,10116.0,,,50597
10470,,2959,,A,,Bioavailability in rat (dose 20 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10471,,1361,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10472,,4727,,A,,Bioavailability percent in rat at the dose of 2 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10473,,16423,,A,,Bioavailability was evaluated after 20 uM/kg of peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10474,,5206,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10475,,6448,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10476,,17723,,A,,Bioavailability in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10477,Blood,17738,,A,,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10478,Blood,17738,,A,,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10479,Blood,17738,,A,,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10480,Blood,17738,,A,,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10481,Blood,17738,,A,,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10482,Bone,17738,,A,,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10483,Bone,17738,,A,,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10484,Bone,17738,,A,,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10485,Bone,17738,,A,,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10486,Brain,17738,,A,,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10487,Brain,17738,,A,,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10488,Brain,17738,,A,,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10489,Brain,17738,,A,,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10490,,17738,,A,,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10491,,17738,,A,,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10492,,17738,,A,,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10493,,17738,,A,,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10494,,5237,,A,,Oral bioavailability in rats was determined; High,In vivo,,Rattus norvegicus,10116.0,,,50597
10495,,5503,,A,,Oral bioavailability in the rat was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
10496,,15765,,A,,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,In vivo,,Rattus norvegicus,10116.0,,,50597
10497,,15660,,A,,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),In vivo,,Rattus norvegicus,10116.0,,,50597
10498,,5978,,A,,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10499,,5978,,A,,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10500,,5978,,A,,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10501,,5978,,A,,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10502,,5656,,A,,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10503,,3598,,A,,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10504,,4216,,A,,Oral bioavailability of compound in Sprague Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10505,,17839,,A,,Oral bioavailability of compound in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10506,,6570,,A,,Oral bioavailability in rat (dose 2 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10507,,5334,,A,,Oral bioavailability of compound in rat was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
10508,,6886,,A,,Oral bioavailability of compound in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10509,,5210,,A,,Oral bioavailability of compound was determined in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10510,,4170,,A,,Oral bioavailability at a dose of 30 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10511,,6028,,A,,Oral bioavailability in rat (dose 10 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10512,,6028,,A,,Oral bioavailability in rat (dose 10 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10513,,6078,,A,,Oral bioavailability evaluated in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10514,,6168,,A,,Oral bioavailability in fasted rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10515,,6168,,A,,Oral bioavailability in fed rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10516,,5160,,A,,Oral bioavailability in rat (mature male) (dose 30 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10517,,6057,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10518,,6535,,A,,Oral bioavailability in rat (dose 10 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10519,,6535,,A,,Oral bioavailability in rat after administration of 10 mg/kg po,In vivo,,Rattus norvegicus,10116.0,,,50597
10520,,4194,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10521,,6230,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10522,,6619,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10523,,17607,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10524,,4942,,A,,Oral bioavailability in ratrs,In vivo,,Rattus norvegicus,10116.0,,,50597
10525,,4942,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10526,,6646,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10527,,5237,,A,,Oral bioavailability in rats was determined; High,In vivo,,Rattus norvegicus,10116.0,,,50597
10528,,6646,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10529,,4449,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10530,,6057,,A,,Oral bioavailability was calculated in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10531,,2552,,A,,Oral bioavailability,In vivo,,Rattus norvegicus,10116.0,,,50597
10532,,5496,,A,,Oral bioavailability,In vivo,,Rattus norvegicus,10116.0,,,50597
10533,,6484,,A,,Oral bioavailability,In vivo,,Rattus norvegicus,10116.0,,,50597
10534,,6485,,A,,Oral bioavailability,In vivo,,Rattus norvegicus,10116.0,,,50597
10535,,6616,,A,,Oral bioavailability after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10536,,4969,,A,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),In vivo,,Rattus norvegicus,10116.0,,,50597
10537,,5862,,A,,Oral bioavailability in rat (Sprague-Dawley),In vivo,,Rattus norvegicus,10116.0,,,50597
10538,,4514,,A,,Oral bioavailability in Sprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10539,,4514,,A,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),In vivo,,Rattus norvegicus,10116.0,,,50597
10540,,4514,,A,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10541,,5546,,A,,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10542,,6168,,A,,Oral bioavailability in fasted rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10543,,6168,,A,,Oral bioavailability in fed rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10544,,3624,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10545,,5213,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10546,,5496,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10547,,5553,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10548,,5833,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10549,,5836,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10550,,5865,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10551,,5960,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10552,,6249,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10553,,6448,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10554,,6453,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10555,,6640,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10556,,17607,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10557,,5939,,A,,Oral bioavailability in rat after peroral administration at 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10558,,5939,,A,,Oral bioavailability in rat after peroral administration at 5 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10559,,6281,,A,,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10560,,5874,,A,,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10561,,5213,,A,,Oral bioavailability in rat; Not measured,In vivo,,Rattus norvegicus,10116.0,,,50597
10562,,4964,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10563,,11020,,A,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,,,Rattus norvegicus,10116.0,,,50597
10564,Liver,6251,,A,,In vitro metabolic potential in rat liver microsomes,,,Rattus norvegicus,10116.0,,,50597
10565,,1568,,A,,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",In vivo,,Rattus norvegicus,10116.0,,,50597
10566,,3032,,A,,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",In vivo,,Rattus norvegicus,10116.0,,,50597
10567,,3748,,A,,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10568,,401,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10569,,6512,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10570,,17617,,A,,Oral bioavailability in rats at 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10571,,6679,,A,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10572,,6742,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10573,,589,,A,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,,,Rattus norvegicus,10116.0,,,50597
10574,,589,,A,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,,,Rattus norvegicus,10116.0,,,50597
10575,,3185,,A,,Plasma clearance of the compound,In vivo,,Rattus norvegicus,10116.0,,,50597
10576,,17596,,A,,Plasma clearance at 10 mg/kg in rat upon intravenous administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10577,,2713,,A,,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10578,Plasma,12500,,A,,The compound was tested for plasma clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10579,Plasma,12500,,A,,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,In vivo,,Rattus norvegicus,10116.0,,,50597
10580,,2713,,A,,Plasma concentration upon oral administration of 1 mg/Kg in rats,,,Rattus norvegicus,10116.0,,,50597
10581,,1446,,A,,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,,,Rattus norvegicus,10116.0,,,50597
10582,,6227,,A,,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,,,Rattus norvegicus,10116.0,,,50597
10583,,4709,,A,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,,,Rattus norvegicus,10116.0,,,50597
10584,,5510,,A,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",,,Rattus norvegicus,10116.0,,,50597
10585,,5510,,A,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,,Rattus norvegicus,10116.0,,,50597
10586,,5510,,A,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,,Rattus norvegicus,10116.0,,,50597
10587,,5510,,A,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",,,Rattus norvegicus,10116.0,,,50597
10588,,4514,,A,,Compound was tested for protein binding in rat plasma,,,Rattus norvegicus,10116.0,,,50597
10589,,2713,,A,,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,,,Rattus norvegicus,10116.0,,,50597
10590,,2713,,A,,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,,,Rattus norvegicus,10116.0,,,50597
10591,Liver,5340,,A,,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,,,Rattus norvegicus,10116.0,,,50597
10592,,12058,,A,,Area under curve ratio was determined (po/iv) in rat,,,Rattus norvegicus,10116.0,,,50597
10593,,11195,,A,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,,,Rattus norvegicus,10116.0,,,50597
10594,,11195,,A,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,,,Rattus norvegicus,10116.0,,,50597
10595,,11195,,A,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,,,Rattus norvegicus,10116.0,,,50597
10596,,6495,,A,,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,,,Rattus norvegicus,10116.0,,,50597
10597,,6078,,A,,Ratio of AUCbrain to AUCplasma,,,Rattus norvegicus,10116.0,,,50597
10598,,5656,,A,,Ratio of brain to plasma,,,Rattus norvegicus,10116.0,,,50597
10599,,4910,,A,,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,,,Rattus norvegicus,10116.0,,,50597
10600,,4910,,A,,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,,Rattus norvegicus,10116.0,,,50597
10601,,4910,,A,,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,,Rattus norvegicus,10116.0,,,50597
10602,,10130,,A,,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,,,Rattus norvegicus,10116.0,,,50597
10603,,10130,,A,,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,,,Rattus norvegicus,10116.0,,,50597
10604,,10130,,A,,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,,,Rattus norvegicus,10116.0,,,50597
10605,,5213,,A,,Steady state brain :blood ratio was determined,,,Rattus norvegicus,10116.0,,,50597
10606,,4910,,A,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,,Rattus norvegicus,10116.0,,,50597
10607,,4910,,A,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,,Rattus norvegicus,10116.0,,,50597
10608,,4910,,A,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,,,Rattus norvegicus,10116.0,,,50597
10609,,4910,,A,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,,Rattus norvegicus,10116.0,,,50597
10610,,2083,,A,,Percentage recovery after 3h incubation with rat hapatocytes was determined,,,Rattus norvegicus,10116.0,,,50597
10611,,2082,,A,,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,,,Rattus norvegicus,10116.0,,,50597
10612,,2082,,A,,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,,,Rattus norvegicus,10116.0,,,50597
10613,,6351,,A,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,,,Rattus norvegicus,10116.0,,,50597
10614,,14583,,A,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",,,,,,,22224
10615,,14583,,A,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,,,,,,,22224
10616,,4608,495.0,A,,In vivo absorption in Caco-2 cell line monolayers was determined,,,Homo sapiens,9606.0,Caco-2,,50587
10617,,13668,,P,,Calculated partition coefficient (clogP),,,,,,,22229
10618,,5669,,A,,Area under curve was determine after peroral administration at 10 mpk in Rat,,,Rattus norvegicus,10116.0,,,50597
10619,,5669,,A,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,,Macaca mulatta,9544.0,,,50797
10620,,5669,,A,,Area under curve was determine after peroral administration at 160 mpk in Rat,,,Rattus norvegicus,10116.0,,,50597
10621,,5669,,A,,Area under curve was determine after peroral administration at 20 mpk in Rat,,,Rattus norvegicus,10116.0,,,50597
10622,,5669,,A,,Area under curve was determine after peroral administration at 50 mpk in Rat,,,Rattus norvegicus,10116.0,,,50597
10623,,6472,,P,,Calculated partition coefficient (clogP) (AlogP),,,,,,,22229
10624,,15106,,A,,Activated partial thromboplastin time measured,,,,,,,22224
10625,,15207,,P,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),,,,,,,22224
10626,,15207,,P,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),,,,,,,22224
10627,Plasma,13941,,A,,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,,,Canis lupus familiaris,9615.0,,,50588
10628,Plasma,13941,,A,,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,,,Rattus norvegicus,10116.0,,,50597
10629,Plasma,13941,,A,,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,,,Rattus norvegicus,10116.0,,,50597
10630,Plasma,13941,,A,,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,,,Canis lupus familiaris,9615.0,,,50588
10631,Plasma,15240,,A,,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,,,Cavia porcellus,10141.0,,,50512
10632,Brain,10655,,A,,AUC in brain,,,,,,,22224
10633,Serum,10655,,A,,AUC in serum,,,,,,,22224
10634,Plasma,6504,,A,,AUC was determined,,,,,,,22224
10635,Plasma,10615,,A,,AUC of the compound.,,,,,,,22224
10636,Plasma,10353,,A,,AUC value (0-4 hr),,,,,,,22224
10637,Plasma,14907,,A,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",,,,,,,22224
10638,Plasma,14907,,A,,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,,,,,,,22224
10639,Plasma,14907,,A,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",,,,,,,22224
10640,Plasma,14907,,A,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",,,,,,,22224
10641,Plasma,16359,,A,,AUC(area under curve) was determined after intravenous administration in rats,,,Rattus norvegicus,10116.0,,,50597
10642,Plasma,16359,,A,,AUC(area under curve) was determined after oral administration in rats,,,Rattus norvegicus,10116.0,,,50597
10643,Plasma,15240,,A,,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,,,Cavia porcellus,10141.0,,,50512
10644,Plasma,15240,,A,,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,,,Rattus norvegicus,10116.0,,,50597
10645,,15469,,A,,Area Under Curve after oral dosing of 100 uM/Kg,,,,,,,22224
10646,,15469,,A,,Area Under Curve after oral dosing of 30 uM/Kg,,,,,,,22224
10647,,13520,,A,,Area Under Curve was measured by ploting the graph between concentration verses time,,,,,,,22224
10648,,17025,,A,,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,,,Canis lupus familiaris,9615.0,,,50588
10649,,17025,,A,,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,,,Simiiformes,314293.0,,,22224
10650,,17025,,A,,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,,,Oryctolagus cuniculus,9986.0,,,50592
10651,,17025,,A,,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,,,Rattus norvegicus,10116.0,,,50597
10652,Blood,12032,,A,,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,,,Rattus norvegicus,10116.0,,,50597
10653,,10291,,A,,Area under curve (AUC) was determined,,,,,,,22224
10654,,5767,,A,,Area under curve (AUC) following ip administration at 1 mg/kg,,,,,,,22224
10655,,1434,,A,,Area under curve (AUC) was determined; ND is Not determined,,,,,,,22224
10656,,14925,,A,,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,,,Canis lupus familiaris,9615.0,,,50588
10657,,14925,,A,,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,,,Canis lupus familiaris,9615.0,,,50588
10658,,14925,,A,,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,,,Canis lupus familiaris,9615.0,,,50588
10659,,1434,,A,,Area under curve (AUR) was determined,,,,,,,22224
10660,,11883,,A,,Area under curve at 1 uM/dg administered intravenously,,,,,,,22224
10661,,11883,,A,,Area under curve at 10 uM/dg administered perorally,,,,,,,22224
10662,,11883,,A,,Area under curve at 2 uM/dg administered intravenously,,,,,,,22224
10663,,11883,,A,,Area under curve at 20 uM/dg administered perorally,,,,,,,22224
10664,,15233,,A,,Area under curve at a peroral dose of 3 mg/kg in dog,,,Canis lupus familiaris,9615.0,,,50588
10665,,15233,,A,,Area under curve at a peroral dose of 3 mg/kg in rat,,,Rattus norvegicus,10116.0,,,50597
10666,,15233,,A,,Area under curve at an iv dose of 1 mg/kg in dog,,,Canis lupus familiaris,9615.0,,,50588
10667,,15233,,A,,Area under curve at an iv dose of 1 mg/kg in rat,,,Rattus norvegicus,10116.0,,,50597
10668,,12978,,A,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,,,,,,,22224
10669,,12978,,A,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,,,,,,,22224
10670,,11355,,A,,Area under curve measured as conc vs time after intravenous administration to mice.,,,Mus musculus,10090.0,,,50594
10671,,11355,,A,,Area under curve measured as conc vs time after peroral administration to mice.,,,Mus musculus,10090.0,,,50594
10672,,12923,,A,,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,,Canis lupus familiaris,9615.0,,,50588
10673,,12923,,A,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,,,Canis lupus familiaris,9615.0,,,50588
10674,,12923,,A,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,,,Canis lupus familiaris,9615.0,,,50588
10675,,12923,,A,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,,,Canis lupus familiaris,9615.0,,,50588
10676,Heart,17738,,A,,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10677,Heart,17738,,A,,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10678,Heart,17738,,A,,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10679,Heart,17738,,A,,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10680,Kidney,17738,,A,,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10681,Kidney,17738,,A,,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10682,Kidney,17738,,A,,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10683,Kidney,17738,,A,,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10684,Kidney,17738,,A,,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10685,Liver,17738,,A,,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10686,Liver,17738,,A,,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10687,Liver,17738,,A,,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10688,Liver,17738,,A,,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10689,Liver,17738,,A,,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10690,Lung,17738,,A,,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10691,Lung,17738,,A,,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10692,Lung,17738,,A,,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10693,Lung,17738,,A,,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10694,Muscle tissue,17738,,A,,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10695,Muscle tissue,17738,,A,,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10696,Muscle tissue,17738,,A,,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10697,Muscle tissue,17738,,A,,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,In vivo,,Rattus norvegicus,10116.0,,,50597
10698,Blood,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10699,Blood,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10700,Blood,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10701,Brain,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10702,Brain,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10703,Brain,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10704,Heart,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10705,Heart,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10706,Heart,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10707,Kidney,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10708,Kidney,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10709,Kidney,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10710,Liver,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10711,Liver,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10712,Liver,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10713,Lung,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10714,Lung,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10715,Lung,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10716,Muscle tissue,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10717,Muscle tissue,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10718,Muscle tissue,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10719,Zone of skin,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10720,Zone of skin,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10721,Zone of skin,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10722,Spleen,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10723,Spleen,11195,,A,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10724,,6193,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10725,,6803,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10726,,6647,,A,,Oral bioavailability in rats at 6 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10727,,6647,,A,,Oral bioavailability in rat (dose 6 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10728,,6647,,A,,Oral bioavailability in rats at 6 mg/kg dose; Not tested,In vivo,,Rattus norvegicus,10116.0,,,50597
10729,,6640,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10730,,6641,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10731,,6641,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10732,,6642,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10733,,5472,,A,,Oral bioavailability,In vivo,,Rattus norvegicus,10116.0,,,50597
10734,,6141,,A,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10735,,4390,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10736,,5472,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10737,,5472,,A,,Oral bioavailability was evaluated; Not tested,In vivo,,Rattus norvegicus,10116.0,,,50597
10738,,5438,,A,,Oral bioavailability,In vivo,,Rattus norvegicus,10116.0,,,50597
10739,,4883,,A,,Oral bioavailability in rat by oral dosing,In vivo,,Rattus norvegicus,10116.0,,,50597
10740,,1908,,A,,Oral bioavailability in rat (dose 10 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10741,,4853,,A,,Oral bioavailability in rat (Sprague-Dawley),In vivo,,Rattus norvegicus,10116.0,,,50597
10742,,4853,,A,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),In vivo,,Rattus norvegicus,10116.0,,,50597
10743,,4853,,A,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),In vivo,,Rattus norvegicus,10116.0,,,50597
10744,,4853,,A,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10745,,4853,,A,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10746,,4853,,A,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10747,,4853,,A,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10748,,12873,,A,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,In vivo,,Rattus norvegicus,10116.0,,,50597
10749,,12873,,A,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,In vivo,,Rattus norvegicus,10116.0,,,50597
10750,,3169,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10751,,6305,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10752,,4762,,A,,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10753,,17847,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10754,,6211,,A,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10755,,6011,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10756,,6317,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10757,,6644,,A,,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,In vivo,,Rattus norvegicus,10116.0,,,50597
10758,,6644,,A,,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,In vivo,,Rattus norvegicus,10116.0,,,50597
10759,,6644,,A,,Oral bioavailability in rat after oral administration at 13 mg/kg dose,In vivo,,Rattus norvegicus,10116.0,,,50597
10760,,6644,,A,,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,In vivo,,Rattus norvegicus,10116.0,,,50597
10761,,6113,,A,,Oral bioavailability (dose 20 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10762,,5937,,A,,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10763,,5711,,A,,Oral bioavailability in rat at 10 mg/kg of the compound,In vivo,,Rattus norvegicus,10116.0,,,50597
10764,,17717,,A,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,In vivo,,Rattus norvegicus,10116.0,,,50597
10765,,17717,,A,,Bioavailability in rat (dose 3 mg/kg i.v.),In vivo,,Rattus norvegicus,10116.0,,,50597
10766,,17717,,A,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,In vivo,,Rattus norvegicus,10116.0,,,50597
10767,,17717,,A,,Oral bioavailability in rat (dose 60 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10768,,4722,,A,,Percent bioavailability (F) in rats after iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
10769,,4722,,A,,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10770,,4353,,A,,Bioavailability in rat (dose 5 uM/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10771,,15662,,A,,Oral bioavailability,In vivo,,Rattus norvegicus,10116.0,,,50597
10772,,4756,,A,,Bioavailability in rat (dose 2 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10773,,4756,,A,,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10774,,3436,,A,,Oral bioavailability in rat (dose 20 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
10775,,17800,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10776,,15762,,A,,Percent oral bioavailability evaluated in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10777,,5089,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10778,,5089,,A,,Percent oral bioavailability in rat; Not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
10779,,3185,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10780,,5145,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10781,,3457,,A,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),In vivo,,Rattus norvegicus,10116.0,,,50597
10782,,3457,,A,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),In vivo,,Rattus norvegicus,10116.0,,,50597
10783,,5983,,A,,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10784,,5739,,A,,Oral bioavailability in rat (dose 20 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,50597
10785,,3579,,A,,Cmax at a dose of 30 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10786,,17788,,A,,Cmax in monkeys at a dose of 1 mg/kg,In vivo,,Simiiformes,314293.0,,,22224
10787,,14956,,A,,Cmax in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10788,,17788,,A,,Cmax in rats at a dose of 1 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
10789,,9750,,A,,Cmax was measured in mice after an oral dose of 50 mg/kg.,In vivo,,Mus musculus,10090.0,,,50594
10790,,12767,,A,,"Cmax value at a dose of 12.7 uM/kg, po",In vivo,,,,,,22224
10791,,12767,,A,,"Cmax value at a dose of 6.3 uM/kg, iv",In vivo,,,,,,22224
10792,,12767,,A,,"Cmax value at a dose of 7.1 uM/kg, iv",In vivo,,,,,,22224
10793,,12703,,A,,Cmax value of compound was determined after 1 hr,In vivo,,,,,,22224
10794,,15778,,A,,Cmax value of the compound,In vivo,,,,,,22224
10795,,12818,,A,,Cmax value administered intraintestinal in rats.,In vivo,,Rattus norvegicus,10116.0,,,50597
10796,,14964,,A,,Cmax value administered perorally was determined in rat; Not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
10797,,15808,,A,,Cmax value at the dose of 2.3 mg/kg,In vivo,,,,,,22224
10798,,15808,,A,,Cmax value at the dose of 5 mg/kg,In vivo,,,,,,22224
10799,,15778,,A,,Cmax value in the period of 8 hr after dosing. ,In vivo,,,,,,22224
10800,,3715,,A,,Cmax value at a oral dose of 20 mg/kg; Not tested,In vivo,,,,,,22224
10801,,3715,,A,,Cmax value at a oral dose of 20 mg/kg,In vivo,,,,,,22224
10802,,1446,,A,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,In vivo,,Rattus norvegicus,10116.0,,,50597
10803,,15240,,A,,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,In vivo,,Cavia porcellus,10141.0,,,50512
10804,,15240,,A,,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,In vivo,,Rattus norvegicus,10116.0,,,50597
10805,Plasma,14810,,A,,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,In vivo,,Rattus norvegicus,10116.0,,,50597
10806,Plasma,14239,,A,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,In vivo,,Mus musculus,10090.0,,,50594
10807,Liver,12555,,A,,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,In vivo,,Canis lupus familiaris,9615.0,,,50588
10808,,10754,,A,,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,In vivo,,Canis lupus familiaris,9615.0,,,50588
10809,Blood,10754,,A,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,In vivo,,Mus musculus,10090.0,,,50594
10810,Blood,10754,,A,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,In vivo,,Mus musculus,10090.0,,,50594
10811,Blood,10754,,A,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,In vivo,,Mus musculus,10090.0,,,50594
10812,Blood,10754,,A,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,In vivo,,Mus musculus,10090.0,,,50594
10813,Blood,10754,,A,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,In vivo,,Mus musculus,10090.0,,,50594
10814,,14600,,F,,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
10815,,14600,,F,,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
10816,,14600,,F,,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
10817,Plasma,13543,,A,,Bioavailability as maximal plasma concentration in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
10818,Plasma,13543,,A,,Bioavailability as maximal plasma concentration in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
10819,Plasma,13543,,A,,Bioavailability as maximal plasma concentration in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10820,Plasma,13543,,A,,Bioavailability as maximal plasma concentration in rats,In vivo,,Rattus norvegicus,10116.0,,,22224
10821,Blood,14600,,A,,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,In vivo,,Canis lupus familiaris,9615.0,,,50588
10822,Blood,14600,,A,,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,In vivo,,Canis lupus familiaris,9615.0,,,50588
10823,Blood,14600,,A,,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,In vivo,,Canis lupus familiaris,9615.0,,,50588
10824,Blood,14600,,A,,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,In vivo,,Canis lupus familiaris,9615.0,,,50588
10825,Blood,14600,,A,,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,In vivo,,Canis lupus familiaris,9615.0,,,50588
10826,Blood,14600,,A,,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,In vivo,,Canis lupus familiaris,9615.0,,,50588
10827,,14681,,A,,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,In vivo,,Rattus norvegicus,10116.0,,,50597
10828,,15905,,A,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,In vivo,,,,,,22224
10829,Plasma,15905,,A,,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,In vivo,,,,,,22224
10830,Plasma,13304,,A,,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",In vivo,,Rattus norvegicus,10116.0,,,50597
10831,Plasma,15137,,A,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,In vivo,,Rattus norvegicus,10116.0,,,50597
10832,Plasma,15137,,A,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,In vivo,,Rattus norvegicus,10116.0,,,50597
10833,Plasma,15137,,A,,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,In vivo,,Rattus norvegicus,10116.0,,,50597
10834,Plasma,15137,,A,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,In vivo,,Rattus norvegicus,10116.0,,,50597
10835,Plasma,15137,,A,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,In vivo,,Rattus norvegicus,10116.0,,,50597
10836,Plasma,14839,,A,,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,In vivo,,Macaca fascicularis,9541.0,,,100710
10837,Plasma,14839,,A,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,In vivo,,Mus musculus,10090.0,,,50594
10838,Plasma,14839,,A,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,In vivo,,Mus musculus,10090.0,,,50594
10839,Plasma,14839,,A,,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,In vivo,,Macaca fascicularis,9541.0,,,100710
10840,Heart,8418,,A,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,,,Rattus norvegicus,10116.0,,,50597
10841,Heart,8418,,A,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,,,Rattus norvegicus,10116.0,,,50597
10842,Heart,8418,,A,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,,,Rattus norvegicus,10116.0,,,50597
10843,Heart,8418,,A,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,,,Rattus norvegicus,10116.0,,,50597
10844,Heart,8418,,A,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,,,Rattus norvegicus,10116.0,,,50597
10845,Heart,8418,,A,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,,,Rattus norvegicus,10116.0,,,50597
10846,Heart,8418,,A,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,,,Rattus norvegicus,10116.0,,,50597
10847,Heart,8418,,A,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,,,Rattus norvegicus,10116.0,,,50597
10848,Heart,8418,,A,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,,,Rattus norvegicus,10116.0,,,50597
10849,Heart,8418,,A,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,,,Rattus norvegicus,10116.0,,,50597
10850,Heart,8418,,A,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,,,Rattus norvegicus,10116.0,,,50597
10851,Heart,8418,,A,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,,,Rattus norvegicus,10116.0,,,50597
10852,Heart,8418,,A,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,,,Rattus norvegicus,10116.0,,,50597
10853,Heart,8418,,A,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,,,Rattus norvegicus,10116.0,,,50597
10854,Heart,8418,,A,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,,,Rattus norvegicus,10116.0,,,50597
10855,Heart,8418,,A,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,,,Rattus norvegicus,10116.0,,,50597
10856,Heart,8418,,A,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,,,Rattus norvegicus,10116.0,,,50597
10857,Heart,8418,,A,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,,,Rattus norvegicus,10116.0,,,50597
10858,Heart,8418,,A,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,,,Rattus norvegicus,10116.0,,,50597
10859,Kidney,8418,,A,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,,,Rattus norvegicus,10116.0,,,50597
10860,Kidney,8418,,A,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,,,Rattus norvegicus,10116.0,,,50597
10861,Kidney,8418,,A,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,,,Rattus norvegicus,10116.0,,,50597
10862,Kidney,8418,,A,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,,,Rattus norvegicus,10116.0,,,50597
10863,Kidney,8418,,A,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,,,Rattus norvegicus,10116.0,,,50597
10864,Kidney,8418,,A,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,,,Rattus norvegicus,10116.0,,,50597
10865,Kidney,8418,,A,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,,,Rattus norvegicus,10116.0,,,50597
10866,Kidney,8418,,A,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,,,Rattus norvegicus,10116.0,,,50597
10867,Kidney,8418,,A,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,,,Rattus norvegicus,10116.0,,,50597
10868,Kidney,8418,,A,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,,,Rattus norvegicus,10116.0,,,50597
10869,Kidney,8418,,A,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,,,Rattus norvegicus,10116.0,,,50597
10870,Kidney,8418,,A,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,,,Rattus norvegicus,10116.0,,,50597
10871,Kidney,8418,,A,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,,,Rattus norvegicus,10116.0,,,50597
10872,Kidney,8418,,A,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,,,Rattus norvegicus,10116.0,,,50597
10873,Kidney,8418,,A,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,,,Rattus norvegicus,10116.0,,,50597
10874,Kidney,8418,,A,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,,,Rattus norvegicus,10116.0,,,50597
10875,Kidney,8418,,A,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,,,Rattus norvegicus,10116.0,,,50597
10876,Kidney,8418,,A,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,,,Rattus norvegicus,10116.0,,,50597
10877,Kidney,8418,,A,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,,,Rattus norvegicus,10116.0,,,50597
10878,Liver,8418,,A,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,,,Rattus norvegicus,10116.0,,,50597
10879,Liver,8418,,A,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,,,Rattus norvegicus,10116.0,,,50597
10880,Liver,8418,,A,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,,,Rattus norvegicus,10116.0,,,50597
10881,Liver,8418,,A,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,,,Rattus norvegicus,10116.0,,,50597
10882,Liver,8418,,A,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,,,Rattus norvegicus,10116.0,,,50597
10883,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
10884,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,,,Canis lupus familiaris,9615.0,,,50588
10885,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
10886,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,,Canis lupus familiaris,9615.0,,,50588
10887,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,,Canis lupus familiaris,9615.0,,,50588
10888,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
10889,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,,,Rattus norvegicus,10116.0,,,50597
10890,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
10891,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,,Rattus norvegicus,10116.0,,,50597
10892,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,,Rattus norvegicus,10116.0,,,50597
10893,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,,Rattus norvegicus,10116.0,,,50597
10894,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
10895,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,,,Rattus norvegicus,10116.0,,,50597
10896,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
10897,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,,Rattus norvegicus,10116.0,,,50597
10898,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,,Rattus norvegicus,10116.0,,,50597
10899,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,,Rattus norvegicus,10116.0,,,50597
10900,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
10901,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,,,Rattus norvegicus,10116.0,,,50597
10902,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
10903,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,,Rattus norvegicus,10116.0,,,50597
10904,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,,Rattus norvegicus,10116.0,,,50597
10905,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,,Rattus norvegicus,10116.0,,,50597
10906,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
10907,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,,,Rattus norvegicus,10116.0,,,50597
10908,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
10909,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,,Rattus norvegicus,10116.0,,,50597
10910,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,,Rattus norvegicus,10116.0,,,50597
10911,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,,Rattus norvegicus,10116.0,,,50597
10912,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
10913,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,,,Canis lupus familiaris,9615.0,,,50588
10914,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
10915,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,,,Canis lupus familiaris,9615.0,,,50588
10916,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
10917,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
10918,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
10919,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
10920,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
10921,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
10922,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
10923,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,,Canis lupus familiaris,9615.0,,,50588
10924,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,,Canis lupus familiaris,9615.0,,,50588
10925,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
10926,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,,,Canis lupus familiaris,9615.0,,,50588
10927,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
10928,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,,Canis lupus familiaris,9615.0,,,50588
10929,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,In vivo,,Canis lupus familiaris,9615.0,,,50588
10930,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,In vivo,,Canis lupus familiaris,9615.0,,,50588
10931,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,In vivo,,Canis lupus familiaris,9615.0,,,50588
10932,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,In vivo,,Canis lupus familiaris,9615.0,,,50588
10933,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,In vivo,,Canis lupus familiaris,9615.0,,,50588
10934,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,In vivo,,Canis lupus familiaris,9615.0,,,50588
10935,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,In vivo,,Canis lupus familiaris,9615.0,,,50588
10936,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,In vivo,,Canis lupus familiaris,9615.0,,,50588
10937,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,In vivo,,Canis lupus familiaris,9615.0,,,50588
10938,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,In vivo,,Canis lupus familiaris,9615.0,,,50588
10939,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,In vivo,,Canis lupus familiaris,9615.0,,,50588
10940,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,In vivo,,Canis lupus familiaris,9615.0,,,50588
10941,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,In vivo,,Canis lupus familiaris,9615.0,,,50588
10942,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,In vivo,,Canis lupus familiaris,9615.0,,,50588
10943,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,In vivo,,Canis lupus familiaris,9615.0,,,50588
10944,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,In vivo,,Canis lupus familiaris,9615.0,,,50588
10945,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,In vivo,,Canis lupus familiaris,9615.0,,,50588
10946,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,In vivo,,Canis lupus familiaris,9615.0,,,50588
10947,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,In vivo,,Canis lupus familiaris,9615.0,,,50588
10948,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,In vivo,,Canis lupus familiaris,9615.0,,,50588
10949,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,In vivo,,Canis lupus familiaris,9615.0,,,50588
10950,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,In vivo,,Canis lupus familiaris,9615.0,,,50588
10951,,2249,,A,,Compound was evaluated for its bioavailability in the dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
10952,,2249,,A,,Compound was evaluated for its bioavailability in the rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10953,,17515,,A,,Compound was evaluated for oral bioavailability,In vivo,,,,,,22224
10954,,14541,,A,,Compound was evaluated for percentage of Oral bioavailability in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
10955,,12797,,A,,Bioavailability in guinea pig,In vivo,,Cavia porcellus,10141.0,,,22224
10956,,12797,,A,,Compound was evaluated for the oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10957,,12797,,A,,Compound was evaluated for the oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
10958,,12797,,A,,Compound was evaluated for the oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10959,,11727,,F,,Bioavailability in dog (dosed i.v.),In vivo,,Canis lupus familiaris,9615.0,,,22224
10960,,13249,,A,,Compound was tested for in vivo bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
10961,,13249,,A,,Compound was tested for in vivo bioavailability in hamsters,In vivo,,Cricetinae,10026.0,,,100712
10962,,13249,,A,,Compound was tested for in vivo bioavailability in monkey,In vivo,,Simiiformes,314293.0,,,22224
10963,,13249,,A,,Compound was tested for in vivo bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10964,,9552,,A,,Oral bioavailability in mouse,In vivo,,Mus musculus,10090.0,,,22224
10965,,9552,,A,,Compound was tested for percent of oral bioavailability in mice; 56-74,In vivo,,Mus musculus,10090.0,,,50594
10966,,14839,,A,,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),In vivo,,Mus musculus,10090.0,,,22224
10967,,14839,,A,,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),In vivo,,Macaca fascicularis,9541.0,,,22224
10968,,14839,,A,,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),In vivo,,Macaca fascicularis,9541.0,,,22224
10969,,14839,,A,,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),In vivo,,Mus musculus,10090.0,,,50594
10970,,14839,,A,,Oral bioavailability in nude mice,In vivo,,Mus musculus,10090.0,,,50594
10971,,11219,,A,,Bioavailability in monkey (i.d. dosing),In vivo,,Primates,9443.0,,,22224
10972,,9552,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,22224
10973,,11732,,A,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,In vivo,,,,,,22224
10974,,11732,,A,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,In vivo,,,,,,22224
10975,,14839,,A,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",In vivo,,Macaca fascicularis,9541.0,,,100710
10976,,14839,,A,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",In vivo,,Macaca fascicularis,9541.0,,,100710
10977,,14839,,A,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",In vivo,,Macaca fascicularis,9541.0,,,100710
10978,Plasma,14839,,A,,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,In vivo,,Macaca fascicularis,9541.0,,,100710
10979,Plasma,14839,,A,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,In vivo,,Mus musculus,10090.0,,,50594
10980,Plasma,14839,,A,,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,In vivo,,Macaca fascicularis,9541.0,,,100710
10981,Plasma,14839,,A,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,In vivo,,Mus musculus,10090.0,,,50594
10982,Plasma,14839,,A,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,In vivo,,Mus musculus,10090.0,,,50594
10983,Plasma,14839,,A,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,In vivo,,Mus musculus,10090.0,,,50594
10984,Plasma,13932,,A,,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,In vivo,,,,,,22224
10985,Plasma,11637,,A,,Cmax in mouse plasma,In vivo,,Mus musculus,10090.0,,,50594
10986,Plasma,11637,,A,,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,In vivo,,,,,,22224
10987,Plasma,13960,,A,,Maximal plasma concentration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10988,Plasma,15905,,A,,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10989,,14062,,A,,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10990,,14062,,A,,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10991,,14062,,A,,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10992,,14062,,A,,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10993,,14062,,A,,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10994,,14062,,A,,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
10995,,15011,,A,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
10996,,15011,,A,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
10997,,15011,,A,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),In vivo,,Mus musculus,10090.0,,,50594
10998,,15011,,A,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
10999,,15011,,A,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
11000,,10291,,A,,Maximum Concentration of the compound.,In vivo,,,,,,22224
11001,,14599,,A,,Maximum Concentration was measured after iv administration into Beagle dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
11002,,14599,,A,,Maximum Concentration was measured after iv administration into Beagle dog.,In vivo,,Canis lupus familiaris,9615.0,,,50588
11003,,14599,,A,,Maximum Concentration was measured after po administration into Beagle dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
11004,,14599,,A,,Maximum Concentration was measured after po administration into Beagle dog.,In vivo,,Canis lupus familiaris,9615.0,,,50588
11005,Blood,12767,,A,,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,In vivo,,,,,,22224
11006,Blood,12767,,A,,Maximum blood level reached after an iv dose of 12.2 uM/kg,In vivo,,,,,,22224
11007,Blood,12767,,A,,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,In vivo,,,,,,22224
11008,Blood,12767,,A,,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,In vivo,,,,,,22224
11009,Blood,12767,,A,,Maximum blood level reached after an oral dose of 5.0 mg/kg,In vivo,,,,,,22224
11010,Blood,12767,,A,,Maximum blood level reached at dose of 10.6 uM/kg orally,In vivo,,,,,,22224
11011,,14706,,A,,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,In vivo,,Cavia porcellus,10141.0,,,50512
11012,,14706,,A,,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,In vivo,,Cavia porcellus,10141.0,,,50512
11013,Brain,14793,,A,,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11014,Brain,14793,,A,,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11015,Brain,14793,,A,,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11016,Brain,14793,,A,,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11017,,14793,,A,,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11018,,14793,,A,,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11019,,14793,,A,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11020,,14793,,A,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11021,,10524,,A,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),In vivo,,Bacillus subtilis,1423.0,,,50278
11022,,11871,,A,,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,In vivo,,Simiiformes,314293.0,,,22224
11023,,11871,,A,,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11024,,3437,,A,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,In vivo,,,,,,22224
11025,,12038,,A,,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,In vivo,,Mus musculus,10090.0,,,50594
11026,,12038,,A,,Maximum concentration in male rats after iv administration of 20 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11027,Liver,8418,,A,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,,,Rattus norvegicus,10116.0,,,50597
11028,Liver,8418,,A,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,,,Rattus norvegicus,10116.0,,,50597
11029,Liver,8418,,A,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,,,Rattus norvegicus,10116.0,,,50597
11030,Liver,8418,,A,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,,,Rattus norvegicus,10116.0,,,50597
11031,Liver,8418,,A,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,,,Rattus norvegicus,10116.0,,,50597
11032,Liver,8418,,A,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,,,Rattus norvegicus,10116.0,,,50597
11033,Liver,8418,,A,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,,,Rattus norvegicus,10116.0,,,50597
11034,Liver,8418,,A,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,,,Rattus norvegicus,10116.0,,,50597
11035,Liver,8418,,A,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,,,Rattus norvegicus,10116.0,,,50597
11036,Liver,8418,,A,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,,,Rattus norvegicus,10116.0,,,50597
11037,Liver,8418,,A,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,,,Rattus norvegicus,10116.0,,,50597
11038,Liver,8418,,A,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,,,Rattus norvegicus,10116.0,,,50597
11039,Liver,8418,,A,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,,,Rattus norvegicus,10116.0,,,50597
11040,Liver,8418,,A,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,,,Rattus norvegicus,10116.0,,,50597
11041,Lung,8418,,A,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,,,Rattus norvegicus,10116.0,,,50597
11042,Lung,8418,,A,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,,,Rattus norvegicus,10116.0,,,50597
11043,Lung,8418,,A,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,,,Rattus norvegicus,10116.0,,,50597
11044,Lung,8418,,A,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,,,Rattus norvegicus,10116.0,,,50597
11045,Lung,8418,,A,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,,,Rattus norvegicus,10116.0,,,50597
11046,Lung,8418,,A,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,,,Rattus norvegicus,10116.0,,,50597
11047,Lung,8418,,A,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,,,Rattus norvegicus,10116.0,,,50597
11048,Lung,8418,,A,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,,,Rattus norvegicus,10116.0,,,50597
11049,Lung,8418,,A,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,,,Rattus norvegicus,10116.0,,,50597
11050,Lung,8418,,A,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,,,Rattus norvegicus,10116.0,,,50597
11051,Lung,8418,,A,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,,,Rattus norvegicus,10116.0,,,50597
11052,Lung,8418,,A,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,,,Rattus norvegicus,10116.0,,,50597
11053,Lung,8418,,A,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,,,Rattus norvegicus,10116.0,,,50597
11054,Lung,8418,,A,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,,,Rattus norvegicus,10116.0,,,50597
11055,Lung,8418,,A,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,,,Rattus norvegicus,10116.0,,,50597
11056,Lung,8418,,A,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,,,Rattus norvegicus,10116.0,,,50597
11057,Lung,8418,,A,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,,,Rattus norvegicus,10116.0,,,50597
11058,Lung,8418,,A,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,,,Rattus norvegicus,10116.0,,,50597
11059,Lung,8418,,A,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,,,Rattus norvegicus,10116.0,,,50597
11060,,9796,,A,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,,Rattus norvegicus,10116.0,,,50597
11061,,9796,,A,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,,Rattus norvegicus,10116.0,,,50597
11062,,9796,,A,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,,Rattus norvegicus,10116.0,,,50597
11063,,9796,,A,,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,,Rattus norvegicus,10116.0,,,50597
11064,,9796,,A,,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,,Rattus norvegicus,10116.0,,,50597
11065,Liver,9796,,A,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,,Rattus norvegicus,10116.0,,,50597
11066,Liver,9796,,A,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,,Rattus norvegicus,10116.0,,,50597
11067,Liver,9796,,A,,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,,Rattus norvegicus,10116.0,,,50597
11068,Liver,9796,,A,,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,,Rattus norvegicus,10116.0,,,50597
11069,Liver,9796,,A,,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,,Rattus norvegicus,10116.0,,,50597
11070,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
11071,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,,,Canis lupus familiaris,9615.0,,,50588
11072,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
11073,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,,Canis lupus familiaris,9615.0,,,50588
11074,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,,Canis lupus familiaris,9615.0,,,50588
11075,,6996,,A,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
11076,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,,,Rattus norvegicus,10116.0,,,50597
11077,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
11078,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,,Rattus norvegicus,10116.0,,,50597
11079,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,,Rattus norvegicus,10116.0,,,50597
11080,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,,Rattus norvegicus,10116.0,,,50597
11081,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
11082,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,,,Rattus norvegicus,10116.0,,,50597
11083,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,,Rattus norvegicus,10116.0,,,50597
11084,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,,Rattus norvegicus,10116.0,,,50597
11085,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
11086,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,,Rattus norvegicus,10116.0,,,50597
11087,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
11088,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,,,Rattus norvegicus,10116.0,,,50597
11089,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
11090,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,,Rattus norvegicus,10116.0,,,50597
11091,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,,Rattus norvegicus,10116.0,,,50597
11092,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
11093,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,,,Rattus norvegicus,10116.0,,,50597
11094,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
11095,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,,Rattus norvegicus,10116.0,,,50597
11096,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,,Rattus norvegicus,10116.0,,,50597
11097,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,,Rattus norvegicus,10116.0,,,50597
11098,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
11099,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,,,Canis lupus familiaris,9615.0,,,50588
11100,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
11101,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,,,Canis lupus familiaris,9615.0,,,50588
11102,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
11103,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
11104,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
11105,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
11106,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
11107,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
11108,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
11109,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,,Canis lupus familiaris,9615.0,,,50588
11110,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,,Canis lupus familiaris,9615.0,,,50588
11111,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
11112,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,,,Canis lupus familiaris,9615.0,,,50588
11113,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
11114,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,,Canis lupus familiaris,9615.0,,,50588
11115,,11732,,A,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,In vivo,,,,,,22224
11116,,11732,,A,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,In vivo,,,,,,22224
11117,,11732,,A,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,In vivo,,,,,,22224
11118,,11732,,A,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,In vivo,,,,,,22224
11119,,11732,,A,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,In vivo,,,,,,22224
11120,,13359,,A,,Oral bioavailability in rat (dose 10 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,22224
11121,,16618,,A,,Oral bioavailability in rat (Sprague-Dawley),In vivo,,Rattus norvegicus,10116.0,,,22224
11122,,13960,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,22224
11123,,13917,,A,,Oral bioavailability in rats was determined in vivo,In vivo,,Rattus norvegicus,10116.0,,,22224
11124,,14266,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,22224
11125,,12359,,A,,Oral bioavailability of compound in monkey,In vivo,,Simiiformes,314293.0,,,22224
11126,,12359,,A,,Oral bioavailability of compound in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
11127,,12359,,A,,Bioavailability in rat of PMEA prodrug,In vivo,,Rattus norvegicus,10116.0,,,22224
11128,,12359,,A,,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,In vivo,,Rattus norvegicus,10116.0,,,50597
11129,,10791,,A,,Serum conc at 3 hours following 25 mg/kg dose,In vivo,,Macaca mulatta,9544.0,,,22224
11130,Urine,10791,,A,,Urine conc 0-5 hours following 25 mg/kg dose,In vivo,,Macaca mulatta,9544.0,,,22224
11131,Urine,10791,,A,,Urine conc 0-24 hours following 25 mg/kg dose,In vivo,,Macaca mulatta,9544.0,,,22224
11132,,138,,A,,Oral bioavailability in African green monkeys; 20-25,In vivo,,Chlorocebus aethiops,9534.0,,,22224
11133,,14521,,A,,Oral bioavailability in cynomolgus monkey.,In vivo,,Macaca fascicularis,9541.0,,,100710
11134,,13953,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,22224
11135,,12836,,A,,Oral bioavailability in dog at 10 mg/kg oral dose,In vivo,,Canis lupus familiaris,9615.0,,,50588
11136,,12836,,A,,Oral bioavailability in hamster at 10 mg/kg oral dose,In vivo,,Cricetinae,10026.0,,,100712
11137,,12836,,A,,Oral bioavailability in rat at 10 mg/kg oral dose,In vivo,,Rattus norvegicus,10116.0,,,50597
11138,,14521,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,22224
11139,,13953,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,22224
11140,,6799,,A,,Oral bioavailability,In vivo,,Eutheria,9347.0,,,22224
11141,,11311,,A,,Oral bioavailability was determined; range 49-102%,In vivo,,,,,,22224
11142,,4013,,A,,Oral bioavailability was determined in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
11143,,4013,,A,,Oral bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,22224
11144,,17591,,A,,Oral bioavailability,In vivo,,Eutheria,9347.0,,,22224
11145,,17591,,A,,Oral bioavailability was determined; Not orally available,In vivo,,,,,,22224
11146,,15011,,A,,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),In vivo,,Mus musculus,10090.0,,,50594
11147,,15011,,A,,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),In vivo,,Mus musculus,10090.0,,,22224
11148,,15011,,A,,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,In vivo,,Mus musculus,10090.0,,,22224
11149,,9552,,A,,Oral bioavailability in Rhesus monkey,In vivo,,Macaca mulatta,9544.0,,,22224
11150,,9552,,A,,Oral bioavailability in dog (female mongrel),In vivo,,Canis lupus familiaris,9615.0,,,22224
11151,,3639,,A,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,In vivo,,,,,,22224
11152,,13397,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,22224
11153,,3031,,A,,Percentage Bioavailability was evaluated.,In vivo,,,,,,22224
11154,,12818,,A,,Bioavailability in rat administered i.d.,In vivo,,Rattus norvegicus,10116.0,,,22224
11155,,4847,,A,,Bioavailability,In vivo,,Eutheria,9347.0,,,22224
11156,,12421,,A,,Bioavailability in dog (male Beagle) i.v. administration,In vivo,,Canis lupus familiaris,9615.0,,,22224
11157,,11966,,A,,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",In vivo,,Rattus norvegicus,10116.0,,,22224
11158,,11218,,A,,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),In vivo,,Primates,9443.0,,,22224
11159,,13129,,A,,Oral bioavailability in rat (Sprague-Dawley) (male),In vivo,,Rattus norvegicus,10116.0,,,22224
11160,,12350,,A,,The oral bioavailability was measured on rats after oral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
11161,,2231,,A,,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11162,,2231,,A,,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,In vivo,,Macaca mulatta,9544.0,,,50797
11163,,12187,,A,,Bioavailability in rat (dose 10 mg/kg i.d.),In vivo,,Rattus norvegicus,10116.0,,,22224
11164,,12421,,A,,Bioavailability in dog (male Beagle) i.v. administration,In vivo,,Canis lupus familiaris,9615.0,,,22224
11165,,13256,,A,,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11166,Blood,13256,,A,,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11167,Cerebellum,13256,,A,,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11168,,13256,,A,,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11169,Plasma,2231,,A,,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11170,Plasma,2231,,A,,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,In vivo,,Macaca mulatta,9544.0,,,50797
11171,Blood,12178,,A,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),In vivo,,Rattus norvegicus,10116.0,,,50597
11172,Blood,12178,,A,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),In vivo,,,,,,22224
11173,Blood,12178,,A,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),In vivo,,,,,,22224
11174,,15633,,A,,Maximum concentration observed in rats at an oral dose of 50 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11175,Plasma,14258,,A,,Maximum concentration of compound in plasma administered orally to rats,In vivo,,Rattus norvegicus,10116.0,,,50597
11176,Plasma,14224,,A,,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",In vivo,,Canis lupus familiaris,9615.0,,,50588
11177,Plasma,14224,,A,,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",In vivo,,Canis lupus familiaris,9615.0,,,50588
11178,Plasma,14224,,A,,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",In vivo,,Canis lupus familiaris,9615.0,,,50588
11179,,5566,,A,,Maximum concentration after 10 mg/kg by oral administration,In vivo,,,,,,22224
11180,,16935,,A,,Maximum concentration at a dose of 1.5 mg/kg,In vivo,,,,,,22224
11181,,16935,,A,,Maximum concentration at a dose of 2.0 mg/kg,In vivo,,,,,,22224
11182,Plasma,14224,,A,,Maximum concentration in dog plasma,In vivo,,Canis lupus familiaris,9615.0,,,50588
11183,Plasma,12536,,A,,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,In vivo,,,,,,22224
11184,Plasma,12536,,A,,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,In vivo,,,,,,22224
11185,Plasma,12536,,A,,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,In vivo,,,,,,22224
11186,Plasma,12536,,A,,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,In vivo,,,,,,22224
11187,Plasma,12536,,A,,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,In vivo,,,,,,22224
11188,Plasma,9994,,A,,Maximum concentration in plasma after oral administration in dog (25 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
11189,Plasma,1434,,A,,Maximum concentration in plasma at Tmax,In vivo,,,,,,22224
11190,Plasma,12836,,A,,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,In vivo,,Canis lupus familiaris,9615.0,,,50588
11191,Plasma,12836,,A,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,In vivo,,Cricetinae,10026.0,,,100712
11192,Plasma,12836,,A,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,In vivo,,Rattus norvegicus,10116.0,,,50597
11193,Plasma,12545,,A,,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11194,Plasma,13856,,A,,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,In vivo,,Oryctolagus cuniculus,9986.0,,,50592
11195,,3550,,A,,Maximum concentration was calculated,In vivo,,,,,,22224
11196,,2632,,A,,Maximum concentration was calculated.,In vivo,,,,,,22224
11197,,5566,,A,,Maximum concentration at a peroral dose of 10 mg/kg,In vivo,,,,,,22224
11198,,11883,,A,,Maximum concentration of the drug at 10 uM/dg administered perorally,In vivo,,,,,,22224
11199,,11883,,A,,Maximum concentration of the drug at 2 uM/dg administered intravenously,In vivo,,,,,,22224
11200,Plasma,14122,,A,,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",In vivo,,Canis lupus familiaris,9615.0,,,50588
11201,Plasma,14122,,A,,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",In vivo,,Cricetinae,10026.0,,,100712
11202,Plasma,14122,,A,,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",In vivo,,Rattus norvegicus,10116.0,,,50597
11203,Plasma,12542,,A,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,In vivo,,Rattus norvegicus,10116.0,,,50597
11204,Plasma,12542,,A,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,In vivo,,Canis lupus familiaris,9615.0,,,50588
11205,Plasma,12542,,A,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,In vivo,,Cricetinae,10026.0,,,100712
11206,Plasma,12542,,A,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,In vivo,,Cricetinae,10026.0,,,100712
11207,Plasma,12542,,A,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,In vivo,,Rattus norvegicus,10116.0,,,50597
11208,Plasma,14080,,A,,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,In vivo,,Rattus norvegicus,10116.0,,,50597
11209,,11911,,A,,Maximum concentration reached following intravenous administration in male rat,In vivo,,Rattus norvegicus,10116.0,,,50597
11210,,13204,,A,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
11211,,13204,,A,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
11212,,14346,,A,,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
11213,,14346,,A,,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
11214,,14346,,A,,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
11215,,14346,,A,,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
11216,,14127,,A,,Maximum drug concentration is determined after oral dosing in rats.,In vivo,,Rattus norvegicus,10116.0,,,50597
11217,,14339,,A,,Maximum observed concentration in oral (5 mg/kg) fasted dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
11218,,14339,,A,,Maximum observed concentration in oral (5 mg/kg) fed dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
11219,Plasma,13494,,A,,Maximum plasma concentration,In vivo,,,,,,22224
11220,Plasma,14925,,A,,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,In vivo,,Rattus norvegicus,10116.0,,,50597
11221,Plasma,14474,,A,,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
11222,Plasma,14474,,A,,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
11223,Plasma,13917,,A,,Maximum plasma concentration following oral administration of 30 umol/kg,In vivo,,,,,,22224
11224,Plasma,9796,,A,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,,,Rattus norvegicus,10116.0,,,50597
11225,Plasma,9796,,A,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,,Rattus norvegicus,10116.0,,,50597
11226,Plasma,9796,,A,,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,,Rattus norvegicus,10116.0,,,50597
11227,Plasma,9796,,A,,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,,Rattus norvegicus,10116.0,,,50597
11228,Plasma,9796,,A,,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,,Rattus norvegicus,10116.0,,,50597
11229,Uterus,9796,,A,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,,Rattus norvegicus,10116.0,,,50597
11230,Uterus,9796,,A,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,,Rattus norvegicus,10116.0,,,50597
11231,Uterus,9796,,A,,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,,Rattus norvegicus,10116.0,,,50597
11232,Uterus,9796,,A,,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,,Rattus norvegicus,10116.0,,,50597
11233,Uterus,9796,,A,,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,,Rattus norvegicus,10116.0,,,50597
11234,,8363,,A,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),,,Rattus norvegicus,10116.0,,,50597
11235,,8363,,A,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),,,Rattus norvegicus,10116.0,,,50597
11236,,8363,,A,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),,,Rattus norvegicus,10116.0,,,50597
11237,,8363,,A,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),,,Rattus norvegicus,10116.0,,,50597
11238,,8363,,A,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),,,Rattus norvegicus,10116.0,,,50597
11239,,8363,,A,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),,,Rattus norvegicus,10116.0,,,50597
11240,,8363,,A,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),,,Rattus norvegicus,10116.0,,,50597
11241,,8363,,A,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),,,Rattus norvegicus,10116.0,,,50597
11242,,8363,,A,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),,,Rattus norvegicus,10116.0,,,50597
11243,,8363,,A,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),,,Rattus norvegicus,10116.0,,,50597
11244,,8363,,A,,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),,,Rattus norvegicus,10116.0,,,50597
11245,,8363,,A,,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),,,Rattus norvegicus,10116.0,,,50597
11246,Blood,8684,,A,,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11247,Blood,8684,,A,,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11248,Blood,8684,,A,,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11249,Blood,8684,,A,,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11250,Blood,8684,,A,,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11251,Blood,8684,,A,,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11252,Blood,8684,,A,,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11253,Blood,8684,,A,,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11254,Brain,8684,,A,,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11255,Brain,8684,,A,,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11256,Brain,8684,,A,,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11257,Brain,8684,,A,,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11258,Brain,8684,,A,,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11259,Brain,8684,,A,,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11260,Brain,8684,,A,,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11261,Brain,8684,,A,,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11262,,8684,,A,,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11263,,8684,,A,,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11264,,8684,,A,,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11265,,8684,,A,,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11266,,8684,,A,,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11267,,8684,,A,,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11268,,8684,,A,,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11269,,8684,,A,,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11270,,8684,,A,,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11271,,8684,,A,,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11272,,8684,,A,,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11273,,8684,,A,,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11274,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
11275,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,,,Canis lupus familiaris,9615.0,,,50588
11276,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
11277,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,,Canis lupus familiaris,9615.0,,,50588
11278,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,,Canis lupus familiaris,9615.0,,,50588
11279,,6996,,A,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
11280,,15599,,A,,Observed diffusion coefficient in organic solvent for Escherichia coli,,,Escherichia coli,562.0,,,50212
11281,Blood,9614,,A,,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,Rattus norvegicus,10116.0,,,50597
11282,Blood,9614,,A,,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,Rattus norvegicus,10116.0,,,50597
11283,Cardiac atrium,9614,,A,,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,Rattus norvegicus,10116.0,,,50597
11284,Cardiac atrium,9614,,A,,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,Rattus norvegicus,10116.0,,,50597
11285,,9614,,A,,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,Rattus norvegicus,10116.0,,,50597
11286,,9614,,A,,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,Rattus norvegicus,10116.0,,,50597
11287,Liver,9614,,A,,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,Rattus norvegicus,10116.0,,,50597
11288,Liver,9614,,A,,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,Rattus norvegicus,10116.0,,,50597
11289,Cardiac atrium,9614,,A,,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,Rattus norvegicus,10116.0,,,50597
11290,Cardiac atrium,9614,,A,,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,Rattus norvegicus,10116.0,,,50597
11291,,9614,,A,,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,Rattus norvegicus,10116.0,,,50597
11292,,9614,,A,,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,Rattus norvegicus,10116.0,,,50597
11293,Spleen,9614,,A,,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,Rattus norvegicus,10116.0,,,50597
11294,Spleen,9614,,A,,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,Rattus norvegicus,10116.0,,,50597
11295,Blood,9071,,A,,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,,,Rattus norvegicus,10116.0,,,50597
11296,Blood,9071,,A,,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,,,Rattus norvegicus,10116.0,,,50597
11297,Heart,9071,,A,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,,,Rattus norvegicus,10116.0,,,50597
11298,Heart,9071,,A,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,,,Rattus norvegicus,10116.0,,,50597
11299,Heart,9071,,A,,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,,,Rattus norvegicus,10116.0,,,50597
11300,Kidney,9071,,A,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,,,Rattus norvegicus,10116.0,,,50597
11301,Kidney,9071,,A,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,,,Rattus norvegicus,10116.0,,,50597
11302,Kidney,9071,,A,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,,,Rattus norvegicus,10116.0,,,50597
11303,Liver,9071,,A,,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,,,Rattus norvegicus,10116.0,,,50597
11304,Liver,9071,,A,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,,,Rattus norvegicus,10116.0,,,50597
11305,Liver,9071,,A,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,,,Rattus norvegicus,10116.0,,,50597
11306,Lung,9071,,A,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,,,Rattus norvegicus,10116.0,,,50597
11307,Lung,9071,,A,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,,,Rattus norvegicus,10116.0,,,50597
11308,Lung,9071,,A,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,,,Rattus norvegicus,10116.0,,,50597
11309,Lung,9071,,A,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,,,Rattus norvegicus,10116.0,,,50597
11310,,10677,,A,,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",,,,,,,22224
11311,Urine,9750,,A,,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,,,Mus musculus,10090.0,,,50594
11312,,8319,,A,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11313,,8319,,A,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,,Rattus norvegicus,10116.0,,,50597
11314,,8319,,A,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11315,,8319,,A,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,,Rattus norvegicus,10116.0,,,50597
11316,,8319,,A,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11317,Kidney,8319,,A,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,,,Rattus norvegicus,10116.0,,,50597
11318,Kidney,8319,,A,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11319,Liver,8319,,A,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,,Rattus norvegicus,10116.0,,,50597
11320,,13256,,A,,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11321,Liver,13256,,A,,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11322,,13256,,A,,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11323,,13256,,A,,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11324,Blood,13256,,A,,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11325,Cerebellum,13256,,A,,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11326,,13256,,A,,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11327,,13256,,A,,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11328,Liver,13256,,A,,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11329,,13256,,A,,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11330,,13256,,A,,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11331,Blood,13256,,A,,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11332,Cerebellum,13256,,A,,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11333,,13256,,A,,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11334,,13256,,A,,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11335,Liver,13256,,A,,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11336,,13256,,A,,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11337,,13256,,A,,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11338,Blood,13256,,A,,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11339,Cerebellum,13256,,A,,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11340,,13256,,A,,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11341,,13256,,A,,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11342,Liver,13256,,A,,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11343,,13256,,A,,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),In vivo,,Mus musculus,10090.0,,,50594
11344,Blood,8829,,A,,Biodistribution in Rat blood after 24 hours of iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
11345,Blood,8829,,A,,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
11346,Blood,8829,,A,,Biodistribution in Rat blood after 30 minutes of iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
11347,Blood,8829,,A,,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
11348,Blood,8829,,A,,Biodistribution in Rat blood after 5 minutes of iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
11349,Blood,8829,,A,,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
11350,Heart,8829,,A,,Biodistribution in Rat heart after 24 hours of iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
11351,Heart,8829,,A,,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
11352,Heart,8829,,A,,Biodistribution in Rat heart after 30 minutes of iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
11353,Heart,8829,,A,,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
11354,Heart,8829,,A,,Biodistribution in Rat heart after 5 minutes of iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
11355,Heart,8829,,A,,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
11356,Liver,8829,,A,,Biodistribution in Rat liver after 24 hours of iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
11357,Liver,8829,,A,,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
11358,Liver,8829,,A,,Biodistribution in Rat liver after 30 minutes of iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
11359,Liver,8829,,A,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
11360,Liver,8829,,A,,Biodistribution in Rat liver after 30 minutes of iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
11361,Plasma,13249,,A,,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,In vivo,,Canis lupus familiaris,9615.0,,,50588
11362,,13622,,A,,Cmax in cynomolgus monkey (PO dose),In vivo,,Macaca fascicularis,9541.0,,,100710
11363,,13622,,A,,Cmax in rat (PO dose),In vivo,,Rattus norvegicus,10116.0,,,50597
11364,,13622,,A,,Cmax in rat (PO dose),In vivo,,Rattus norvegicus,10116.0,,,50597
11365,Plasma,13494,,A,,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11366,Plasma,12170,,A,,Cmax in rat plasma after oral dose (10 mg/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
11367,Plasma,12170,,A,,Cmax in plasma after oral dose (10 mg/kg),In vivo,,,,,,22224
11368,Plasma,17025,,A,,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,In vivo,,Canis lupus familiaris,9615.0,,,50588
11369,Plasma,17025,,A,,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,In vivo,,Simiiformes,314293.0,,,22224
11370,Plasma,17025,,A,,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,In vivo,,Oryctolagus cuniculus,9986.0,,,50592
11371,Plasma,17025,,A,,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,In vivo,,Rattus norvegicus,10116.0,,,50597
11372,Plasma,14187,,A,,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,In vivo,,Rattus norvegicus,10116.0,,,50597
11373,Plasma,14816,,A,,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,In vivo,,Mus musculus,10090.0,,,50594
11374,Plasma,17820,,A,,Maximum plasma concentration after oral dosing in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
11375,Plasma,14380,,A,,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,In vivo,,,,,,22224
11376,Plasma,14380,,A,,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,In vivo,,,,,,22224
11377,Plasma,14691,,A,,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
11378,Plasma,14691,,A,,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
11379,Plasma,13375,,A,,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11380,Plasma,6236,,A,,Maximum plasma concentration was determined,In vivo,,,,,,22224
11381,Plasma,14380,,A,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,In vivo,,,,,,22224
11382,Plasma,14380,,A,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,In vivo,,,,,,22224
11383,Plasma,14380,,A,,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,In vivo,,,,,,22224
11384,Plasma,14380,,A,,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,In vivo,,,,,,22224
11385,Plasma,14380,,A,,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,In vivo,,,,,,22224
11386,Plasma,14380,,A,,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,In vivo,,,,,,22224
11387,Plasma,14380,,A,,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,In vivo,,,,,,22224
11388,Plasma,14380,,A,,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,In vivo,,,,,,22224
11389,Plasma,13622,,A,,Plasma Cmax in rat (PO dose),In vivo,,Rattus norvegicus,10116.0,,,50597
11390,,15372,,A,,Maximum serum concentration after po dose of 5.22 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
11391,,15372,,A,,Maximum serum concentration after po dose of 5.46 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
11392,,15372,,A,,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
11393,,15372,,A,,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
11394,Plasma,14925,,A,,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,In vivo,,Canis lupus familiaris,9615.0,,,50588
11395,Plasma,14925,,A,,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,In vivo,,Canis lupus familiaris,9615.0,,,50588
11396,,11883,,A,,Maximum concentration of the drug at 1 uM/dg administered intravenously,In vivo,,,,,,22224
11397,,11883,,A,,Maximum concentration of the drug at 20 uM/dg administered perorally,In vivo,,,,,,22224
11398,,13391,,A,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,In vivo,,,,,,22224
11399,Blood,13391,,A,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,In vivo,,,,,,22224
11400,Blood,13391,,A,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,In vivo,,,,,,22224
11401,Blood,13391,,A,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,In vivo,,,,,,22224
11402,Plasma,16360,,A,,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
11403,Plasma,3673,,A,,Cmax in dog plasma after 1mg/kg oral dose,In vivo,,Canis lupus familiaris,9615.0,,,50588
11404,Plasma,14431,,A,,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,In vivo,,Canis lupus familiaris,9615.0,,,50588
11405,Plasma,14431,,A,,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,In vivo,,Rattus norvegicus,10116.0,,,50597
11406,,14964,,A,,Oral maximum concentration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
11407,,14964,,A,,Oral maximum concentration in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
11408,Plasma,14209,,A,,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,In vivo,,Mus musculus,10090.0,,,50594
11409,Blood,11355,,A,,Peak concentration in blood after intravenous administration to mice,In vivo,,Mus musculus,10090.0,,,50594
11410,Blood,11355,,A,,Peak concentration in blood after peroral administration to mice,In vivo,,Mus musculus,10090.0,,,50594
11411,Plasma,11966,,A,,Peak concentration in rat plasma was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
11412,Plasma,8918,,A,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,In vivo,,Simiiformes,314293.0,,,22224
11413,Plasma,8918,,A,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,In vivo,,Mus musculus,10090.0,,,50594
11414,Plasma,8918,,A,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11415,,8684,,A,,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11416,,8684,,A,,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11417,,8684,,A,,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11418,,8684,,A,,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11419,Intestine,8684,,A,,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11420,Intestine,8684,,A,,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11421,Intestine,8684,,A,,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11422,Intestine,8684,,A,,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11423,Intestine,8684,,A,,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11424,Intestine,8684,,A,,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11425,Intestine,8684,,A,,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11426,Intestine,8684,,A,,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11427,,8684,,A,,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11428,,8684,,A,,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11429,,8684,,A,,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11430,,8684,,A,,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11431,,8684,,A,,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11432,,8684,,A,,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11433,,8684,,A,,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11434,,8684,,A,,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11435,,8684,,A,,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11436,,8684,,A,,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11437,,8684,,A,,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11438,,8684,,A,,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11439,,8684,,A,,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11440,,8684,,A,,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11441,,8684,,A,,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11442,,8684,,A,,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11443,,8684,,A,,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11444,,8684,,A,,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11445,,8684,,A,,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11446,,8684,,A,,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11447,,8684,,A,,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11448,,8684,,A,,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11449,,8684,,A,,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11450,,8684,,A,,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11451,Muscle tissue,8684,,A,,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11452,Muscle tissue,8684,,A,,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11453,Muscle tissue,8684,,A,,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11454,Muscle tissue,8684,,A,,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11455,Muscle tissue,8684,,A,,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11456,Muscle tissue,8684,,A,,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11457,Muscle tissue,8684,,A,,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11458,Muscle tissue,8684,,A,,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11459,,8684,,A,,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11460,,8684,,A,,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11461,,8684,,A,,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11462,,8684,,A,,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11463,,8684,,A,,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11464,,8684,,A,,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11465,,8684,,A,,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11466,,8684,,A,,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11467,Liver,8319,,A,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11468,,8319,,A,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11469,,8319,,A,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11470,,8319,,A,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,,Rattus norvegicus,10116.0,,,50597
11471,,8319,,A,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11472,,8319,,A,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,,Rattus norvegicus,10116.0,,,50597
11473,,8319,,A,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11474,Kidney,8319,,A,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,,,Rattus norvegicus,10116.0,,,50597
11475,Kidney,8319,,A,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11476,Liver,8319,,A,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,,Rattus norvegicus,10116.0,,,50597
11477,Liver,8319,,A,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11478,,8319,,A,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11479,Urine,14571,,A,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,,,Mus musculus,10090.0,,,50594
11480,Urine,14571,,A,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,,,Rattus norvegicus,10116.0,,,50597
11481,,8319,,A,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11482,,8319,,A,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,,Rattus norvegicus,10116.0,,,50597
11483,,8319,,A,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11484,,8319,,A,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,,Rattus norvegicus,10116.0,,,50597
11485,,8319,,A,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11486,Kidney,8319,,A,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,,,Rattus norvegicus,10116.0,,,50597
11487,Kidney,8319,,A,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11488,,8319,,A,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,,Rattus norvegicus,10116.0,,,50597
11489,,8319,,A,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11490,,8319,,A,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11491,,8319,,A,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11492,,8319,,A,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,,Rattus norvegicus,10116.0,,,50597
11493,,8319,,A,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11494,,8319,,A,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,,Rattus norvegicus,10116.0,,,50597
11495,,8319,,A,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11496,Kidney,8319,,A,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,,,Rattus norvegicus,10116.0,,,50597
11497,Kidney,8319,,A,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11498,,8319,,A,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,,Rattus norvegicus,10116.0,,,50597
11499,,8319,,A,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11500,,8319,,A,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,,Rattus norvegicus,10116.0,,,50597
11501,Urine,12064,,A,,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,,,Rattus norvegicus,10116.0,,,50597
11502,Urine,12064,,A,,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,,,Rattus norvegicus,10116.0,,,50597
11503,Urine,12064,,A,,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,,,Rattus norvegicus,10116.0,,,50597
11504,Urine,12038,,A,,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,,,Rattus norvegicus,10116.0,,,50597
11505,,14314,,A,,% dose converted to 2-amino-5-chlorophenyl sulfate,,,,,,,22224
11506,,14314,,A,,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),,,,,,,22224
11507,Feces,11488,,A,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",,,Rattus norvegicus,10116.0,,,50597
11508,Feces,11488,,A,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",,,Rattus norvegicus,10116.0,,,50597
11509,Feces,11488,,A,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",,,Rattus norvegicus,10116.0,,,50597
11510,Feces,11488,,A,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",,,Rattus norvegicus,10116.0,,,50597
11511,Liver,8829,,A,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
11512,Liver,8829,,A,,Biodistribution in Rat liver after 5 minutes of iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
11513,Liver,8829,,A,,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
11514,Lung,8829,,A,,Biodistribution in Rat lung after 24 hours of iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
11515,Lung,8829,,A,,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
11516,Lung,8829,,A,,Biodistribution in Rat lung after 30 minutes of iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
11517,Lung,8829,,A,,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
11518,Lung,8829,,A,,Biodistribution in Rat lung after 5 minutes of iv administration,In vivo,,Rattus norvegicus,10116.0,,,50597
11519,Lung,8829,,A,,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,In vivo,,Rattus norvegicus,10116.0,,,50597
11520,Cerebellum,14972,,A,,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",In vivo,,Rattus norvegicus,10116.0,,,50597
11521,,14972,,A,,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",In vivo,,Rattus norvegicus,10116.0,,,50597
11522,Thalamus,14972,,A,,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",In vivo,,Rattus norvegicus,10116.0,,,50597
11523,Blood,14608,,A,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11524,Blood,14608,,A,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11525,Blood,14608,,A,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11526,Hippocampus,14608,,A,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,In vivo,,,,,,22224
11527,Hippocampus,14608,,A,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,In vivo,,,,,,22224
11528,Hippocampus,14608,,A,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,In vivo,,,,,,22224
11529,Brain,14608,,A,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11530,Brain,14608,,A,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11531,Brain,14608,,A,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11532,Cerebellum,14608,,A,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11533,Cerebellum,14608,,A,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11534,Cerebellum,14608,,A,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11535,,14608,,A,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11536,,14608,,A,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11537,,14608,,A,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11538,Heart,14608,,A,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11539,Heart,14608,,A,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11540,Heart,14608,,A,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11541,Hippocampus,14608,,A,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11542,Hippocampus,14608,,A,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11543,Hippocampus,14608,,A,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11544,Kidney,14608,,A,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11545,Kidney,14608,,A,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11546,Kidney,14608,,A,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11547,Liver,14608,,A,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11548,Liver,14608,,A,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11549,Liver,14608,,A,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11550,Lung,14608,,A,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11551,Lung,14608,,A,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11552,Lung,14608,,A,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11553,Muscle tissue,14608,,A,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11554,Plasma,8918,,A,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,In vivo,,Simiiformes,314293.0,,,22224
11555,Plasma,8918,,A,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,In vivo,,Mus musculus,10090.0,,,50594
11556,Plasma,8918,,A,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11557,Plasma,14470,,A,,Peak plasma concentration was measured in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
11558,,14393,,A,,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
11559,,14886,,A,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11560,,14886,,A,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11561,,14886,,A,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11562,,14393,,A,,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
11563,,13465,,A,,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
11564,,13465,,A,,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,In vivo,,Simiiformes,314293.0,,,22224
11565,,13465,,A,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
11566,,13465,,A,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
11567,,13465,,A,,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,In vivo,,Rattus norvegicus,10116.0,,,50597
11568,,13465,,A,,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,In vivo,,Rattus norvegicus,10116.0,,,50597
11569,,13465,,A,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
11570,,13465,,A,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,In vivo,,Rattus norvegicus,10116.0,,,50597
11571,,13465,,A,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,In vivo,,Rattus norvegicus,10116.0,,,50597
11572,,13465,,A,,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
11573,,13465,,A,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
11574,,13465,,A,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,In vivo,,Simiiformes,314293.0,,,22224
11575,,13465,,A,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,In vivo,,Simiiformes,314293.0,,,22224
11576,,13465,,A,,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,In vivo,,Rattus norvegicus,10116.0,,,50597
11577,,14731,,A,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,In vivo,,Macaca fascicularis,9541.0,,,100710
11578,,14731,,A,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,In vivo,,Mus musculus,10090.0,,,50594
11579,,13376,,A,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
11580,,13376,,A,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
11581,,14443,,A,,Maximum concentration (Cmax) in rat when administered orally,In vivo,,Rattus norvegicus,10116.0,,,50597
11582,Plasma,13465,,A,,Maximal concentration in monkey plasma after 25 mg/kg oral dose,In vivo,,Simiiformes,314293.0,,,22224
11583,,16359,,A,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",In vivo,,Rattus norvegicus,10116.0,,,22224
11584,,16359,,A,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",In vivo,,Rattus norvegicus,10116.0,,,22224
11585,Plasma,15618,,A,,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,In vivo,,,,,,22224
11586,,14554,,A,,Pharmacokinetic profile Cmax was evaluated in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
11587,,11537,,A,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
11588,,11537,,A,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),In vivo,,Mus musculus,10090.0,,,50594
11589,,11537,,A,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),In vivo,,Canis lupus familiaris,9615.0,,,50588
11590,,11537,,A,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),In vivo,,Mus musculus,10090.0,,,50594
11591,Plasma,2021,,A,,Cmax in rat plasma,In vivo,,Rattus norvegicus,10116.0,,,22224
11592,Plasma,5932,,A,,Cmax in dog plasma after 30mg/kg oral dose,In vivo,,Canis lupus familiaris,9615.0,,,50588
11593,Plasma,5932,,A,,Cmax in rat plasma after 30mg/kg oral dose,In vivo,,Rattus norvegicus,10116.0,,,50597
11594,Plasma,17320,,A,,Plasma level in rats at 30 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
11595,Plasma,15831,,A,,Tested for maximum plasma concentration in mice,In vivo,,Mus musculus,10090.0,,,50594
11596,,15078,,A,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",In vivo,,Rattus norvegicus,10116.0,,,50597
11597,,14941,,A,,The Cmax values in female wistar rats.,In vivo,,Rattus norvegicus,10116.0,,,50597
11598,Plasma,15343,,A,,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,In vivo,,Canis lupus familiaris,9615.0,,,50588
11599,Plasma,15343,,A,,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,In vivo,,Rattus norvegicus,10116.0,,,50597
11600,Plasma,14856,,A,,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,In vivo,,Rattus norvegicus,10116.0,,,50597
11601,,13129,,A,,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,In vivo,,Rattus norvegicus,10116.0,,,50597
11602,Blood,13098,,A,,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
11603,Blood,13098,,A,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
11604,Blood,13098,,A,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
11605,Blood,15478,,A,,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,In vivo,,Mus musculus,10090.0,,,22224
11606,,15341,,A,,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,In vivo,,Canis lupus familiaris,9615.0,,,50588
11607,,15341,,A,,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
11608,,8684,,A,,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11609,,8684,,A,,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11610,,8684,,A,,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11611,,8684,,A,,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11612,,8684,,A,,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11613,,8684,,A,,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11614,,8684,,A,,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11615,,8684,,A,,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11616,Spleen,8684,,A,,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11617,Spleen,8684,,A,,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11618,Spleen,8684,,A,,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11619,Spleen,8684,,A,,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11620,Spleen,8684,,A,,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11621,Spleen,8684,,A,,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11622,Spleen,8684,,A,,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11623,Spleen,8684,,A,,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11624,Uterus,8684,,A,,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11625,Uterus,8684,,A,,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11626,Uterus,8684,,A,,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11627,Uterus,8684,,A,,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11628,Uterus,8684,,A,,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11629,Uterus,8684,,A,,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11630,Uterus,8684,,A,,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11631,Uterus,8684,,A,,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",,,Rattus norvegicus,10116.0,,,50597
11632,,8926,,A,,Distribution in the blood after 120 min of intravenous administration,,,,,,,22224
11633,,8926,,A,,Distribution in the blood after 15 min of intravenous administration,,,,,,,22224
11634,,8926,,A,,Distribution in the blood after 30 min of intravenous administration,,,,,,,22224
11635,,8926,,A,,Distribution in the blood after 5 min of intravenous administration,,,,,,,22224
11636,,8926,,A,,Distribution in the blood after 60 min of intravenous administration,,,,,,,22224
11637,,8926,,A,,Distribution in the blood after 90 min of intravenous administration,,,,,,,22224
11638,,8926,,A,,Distribution in the bone after 120 min of intravenous administration,,,,,,,22224
11639,,8926,,A,,Distribution in the bone after 15 min of intravenous administration,,,,,,,22224
11640,,8926,,A,,Distribution in the bone after 30 min of intravenous administration,,,,,,,22224
11641,,8926,,A,,Distribution in the bone after 5 min of intravenous administration,,,,,,,22224
11642,,8926,,A,,Distribution in the bone after 60 min of intravenous administration,,,,,,,22224
11643,,8926,,A,,Distribution in the bone after 90 min of intravenous administration,,,,,,,22224
11644,,8926,,A,,Distribution in the heart after 120 min of intravenous administration,,,,,,,22224
11645,,8926,,A,,Distribution in the heart after 15 min of intravenous administration,,,,,,,22224
11646,,8926,,A,,Distribution in the heart after 30 min of intravenous administration,,,,,,,22224
11647,,8926,,A,,Distribution in the heart after 5 min of intravenous administration,,,,,,,22224
11648,,8926,,A,,Distribution in the heart after 60 min of intravenous administration,,,,,,,22224
11649,,8926,,A,,Distribution in the heart after 90 min of intravenous administration,,,,,,,22224
11650,,8926,,A,,Distribution in the kidneys after 120 min of intravenous administration,,,,,,,22224
11651,,8926,,A,,Distribution in the kidneys after 15 min of intravenous administration,,,,,,,22224
11652,,8926,,A,,Distribution in the kidneys after 30 min of intravenous administration,,,,,,,22224
11653,,8926,,A,,Distribution in the kidneys after 5 min of intravenous administration,,,,,,,22224
11654,,8926,,A,,Distribution in the kidneys after 60 min of intravenous administration,,,,,,,22224
11655,,8926,,A,,Distribution in the kidneys after 90 min of intravenous administration,,,,,,,22224
11656,,8926,,A,,Distribution in the liver after 120 min of intravenous administration,,,,,,,22224
11657,,8926,,A,,Distribution in the liver after 15 min of intravenous administration,,,,,,,22224
11658,,8926,,A,,Distribution in the liver after 30 min of intravenous administration,,,,,,,22224
11659,,8926,,A,,Distribution in the liver after 5 min of intravenous administration,,,,,,,22224
11660,,8926,,A,,Distribution in the liver after 60 min of intravenous administration,,,,,,,22224
11661,,8926,,A,,Distribution in the liver after 90 min of intravenous administration,,,,,,,22224
11662,,8926,,A,,Distribution in the lung after 120 min of intravenous administration,,,,,,,22224
11663,,14839,,A,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",,,Mus musculus,10090.0,,,50594
11664,,14839,,A,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",,,Mus musculus,10090.0,,,50594
11665,,14839,,A,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",,,Mus musculus,10090.0,,,50594
11666,,14839,,A,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",,,Mus musculus,10090.0,,,50594
11667,,12178,,A,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,,,Rattus norvegicus,10116.0,,,50597
11668,,12178,,A,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,,,Rattus norvegicus,10116.0,,,50597
11669,,12178,,A,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,,,,,,,22224
11670,,12186,,A,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,,Macaca fascicularis,9541.0,,,100710
11671,,12186,,A,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,,Macaca fascicularis,9541.0,,,100710
11672,,12186,,A,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,,Macaca fascicularis,9541.0,,,100710
11673,,12186,,A,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,,Macaca fascicularis,9541.0,,,100710
11674,,12187,,A,,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,,Simiiformes,314293.0,,,22224
11675,,12187,,A,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,,Mustela putorius furo,9669.0,,,50506
11676,,12187,,A,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,,Mustela putorius furo,9669.0,,,50506
11677,,12187,,A,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,,Simiiformes,314293.0,,,22224
11678,,12187,,A,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,,,Simiiformes,314293.0,,,22224
11679,,12187,,A,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,,Rattus norvegicus,10116.0,,,50597
11680,,12187,,A,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,,Rattus norvegicus,10116.0,,,50597
11681,,14122,,A,,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",,,Canis lupus familiaris,9615.0,,,50588
11682,,14122,,A,,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",,,Cricetinae,10026.0,,,100712
11683,,14122,,A,,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",,,Rattus norvegicus,10116.0,,,50597
11684,,13391,,A,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,,,,,,,22224
11685,Blood,13391,,A,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,,,,,,,22224
11686,Blood,13391,,A,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,,,,,,,22224
11687,Blood,13391,,A,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,,,,,,,22224
11688,,16360,,A,,Oral absorption expressed as Area under curve was determined,,,,,,,22224
11689,,3673,,A,,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,,,Canis lupus familiaris,9615.0,,,50588
11690,,14122,,A,,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",,,Canis lupus familiaris,9615.0,,,50588
11691,,14122,,A,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,,Cricetinae,10026.0,,,100712
11692,,14122,,A,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,,Cricetinae,10026.0,,,100712
11693,,14122,,A,,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",,,Rattus norvegicus,10116.0,,,50597
11694,,13889,,A,,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,,,,,,,22224
11695,,14393,,A,,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,Rattus norvegicus,10116.0,,,50597
11696,,17279,,A,,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),,,Rattus norvegicus,10116.0,,,50597
11697,,14548,,A,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,,Macaca fascicularis,9541.0,,,100710
11698,,14548,,A,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,,Macaca fascicularis,9541.0,,,100710
11699,,14548,,A,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,,,Macaca fascicularis,9541.0,,,100710
11700,,14548,,A,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,,Canis lupus familiaris,9615.0,,,50588
11701,,14548,,A,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,,,Canis lupus familiaris,9615.0,,,50588
11702,,14548,,A,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,,Rattus norvegicus,10116.0,,,50597
11703,,14548,,A,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,,,Rattus norvegicus,10116.0,,,50597
11704,,14548,,A,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,,,Rattus norvegicus,10116.0,,,50597
11705,Muscle tissue,14608,,A,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11706,Muscle tissue,14608,,A,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11707,Zone of skin,14608,,A,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,In vivo,,Mus musculus,10090.0,,,50594
11708,Zone of skin,14608,,A,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11709,Zone of skin,14608,,A,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11710,Spleen,14608,,A,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11711,Spleen,14608,,A,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11712,Spleen,14608,,A,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11713,Striatum,14608,,A,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11714,Striatum,14608,,A,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11715,Striatum,14608,,A,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11716,Thyroid gland,14608,,A,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11717,Thyroid gland,14608,,A,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11718,Thyroid gland,14608,,A,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,In vivo,,Rattus norvegicus,10116.0,,,50597
11719,,15383,,A,,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,Mus musculus,10090.0,,,50594
11720,,15383,,A,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,,Mus musculus,10090.0,,,50594
11721,,15383,,A,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,,Mus musculus,10090.0,,,50594
11722,,15383,,A,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,Mus musculus,10090.0,,,50594
11723,,15383,,A,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,Mus musculus,10090.0,,,50594
11724,Brain,15383,,A,,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,Mus musculus,10090.0,,,50594
11725,Brain,15383,,A,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,Mus musculus,10090.0,,,50594
11726,Brain,15383,,A,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,Mus musculus,10090.0,,,50594
11727,,15383,,A,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,Mus musculus,10090.0,,,50594
11728,,15383,,A,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,Mus musculus,10090.0,,,50594
11729,Kidney,15383,,A,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,,,Mus musculus,10090.0,,,50594
11730,Kidney,15383,,A,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,Mus musculus,10090.0,,,50594
11731,Kidney,15383,,A,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,,Mus musculus,10090.0,,,50594
11732,Kidney,15383,,A,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,,Mus musculus,10090.0,,,50594
11733,Kidney,15383,,A,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,Mus musculus,10090.0,,,50594
11734,Kidney,15383,,A,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,Mus musculus,10090.0,,,50594
11735,Liver,15383,,A,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,,,Mus musculus,10090.0,,,50594
11736,Liver,15383,,A,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,Mus musculus,10090.0,,,50594
11737,Liver,15383,,A,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,,Mus musculus,10090.0,,,50594
11738,Liver,15383,,A,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,,Mus musculus,10090.0,,,50594
11739,Liver,15383,,A,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,Mus musculus,10090.0,,,50594
11740,Liver,15383,,A,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,Mus musculus,10090.0,,,50594
11741,Muscle tissue,15383,,A,,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,Mus musculus,10090.0,,,50594
11742,Muscle tissue,15383,,A,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,,Mus musculus,10090.0,,,50594
11743,Muscle tissue,15383,,A,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,,Mus musculus,10090.0,,,50594
11744,Muscle tissue,15383,,A,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,Mus musculus,10090.0,,,50594
11745,Muscle tissue,15383,,A,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,Mus musculus,10090.0,,,50594
11746,,15383,,A,,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,Mus musculus,10090.0,,,50594
11747,,15383,,A,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,Mus musculus,10090.0,,,50594
11748,,15383,,A,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,Mus musculus,10090.0,,,50594
11749,,15383,,A,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,Mus musculus,10090.0,,,50594
11750,,15383,,A,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,Mus musculus,10090.0,,,50594
11751,,15341,,A,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
11752,,15341,,A,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
11753,,15341,,A,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
11754,Plasma,14906,,A,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,In vivo,,Canis lupus familiaris,9615.0,,,50588
11755,Plasma,14906,,A,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,In vivo,,Rattus norvegicus,10116.0,,,50597
11756,Plasma,14906,,A,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,In vivo,,Rattus norvegicus,10116.0,,,50597
11757,Plasma,14215,,A,,The maximum plasma concentration (100 mg/kg) administered orally in human,In vivo,,Homo sapiens,9606.0,,,50587
11758,Plasma,14215,,A,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,In vivo,,Callithrix,9481.0,,,22224
11759,Plasma,14215,,A,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,In vivo,,Simiiformes,314293.0,,,22224
11760,Plasma,14215,,A,,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
11761,Plasma,14215,,A,,The maximum plasma concentration (200 mg/kg) administered orally in human,In vivo,,Homo sapiens,9606.0,,,50587
11762,Plasma,14215,,A,,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
11763,Plasma,14215,,A,,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,In vivo,,Callithrix,9481.0,,,22224
11764,Plasma,14215,,A,,The maximum plasma concentration (25 mg/kg) administered orally in monkey,In vivo,,Simiiformes,314293.0,,,22224
11765,Plasma,14215,,A,,The maximum plasma concentration (30 mg/kg) administered orally in dog,In vivo,,Canis lupus familiaris,9615.0,,,22224
11766,Plasma,14215,,A,,The maximum plasma concentration (400 mg/kg) administered orally in human,In vivo,,Homo sapiens,9606.0,,,50587
11767,Plasma,14215,,A,,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,In vivo,,Rattus norvegicus,10116.0,,,50597
11768,Plasma,14215,,A,,The maximum plasma concentration (50 mg/kg) administered orally in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
11769,Plasma,14215,,A,,The maximum plasma concentration (800 mg/kg) administered orally in human,In vivo,,Homo sapiens,9606.0,,,50587
11770,Plasma,14067,,A,,The maximum plasma concentration was measured on rats,In vivo,,Rattus norvegicus,10116.0,,,50597
11771,Plasma,12350,,A,,The maximum plasma concentration was measured on rats after oral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
11772,Plasma,14813,,A,,Plasma drug Cmax in rat (PO dose),In vivo,,Rattus norvegicus,10116.0,,,50597
11773,,12536,,A,,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,In vivo,,,,,,22224
11774,Plasma,14169,,A,,maximum Plasma concentration in Dog was determined after Peroral administration,In vivo,,Canis lupus familiaris,9615.0,,,50588
11775,Plasma,14169,,A,,maximum Plasma concentration in Rats was determined after Peroral administration,In vivo,,Rattus norvegicus,10116.0,,,50597
11776,Plasma,15604,,A,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
11777,Plasma,15604,,A,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,In vivo,,Simiiformes,314293.0,,,22224
11778,Plasma,15604,,A,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
11779,,14387,,A,,maximum concentration was measured when administered through oral route in mice,In vivo,,Mus musculus,10090.0,,,50594
11780,,15115,,A,,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,,,Mus musculus,10090.0,,,50594
11781,,15115,,A,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,,,Simiiformes,314293.0,,,22224
11782,,15115,,A,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,,,Simiiformes,314293.0,,,22224
11783,,15115,,A,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,,,Simiiformes,314293.0,,,22224
11784,,16359,,A,,Pharmacokinetic parameter was evaluated in rats,,,Rattus norvegicus,10116.0,,,50597
11785,,12829,,A,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,,Mus musculus,10090.0,,,50594
11786,,12829,,A,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,,,Mus musculus,10090.0,,,50594
11787,,12829,,A,,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,,Mus musculus,10090.0,,,50594
11788,,12829,,A,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,,,Mus musculus,10090.0,,,50594
11789,,12829,,A,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,,,Mus musculus,10090.0,,,50594
11790,Plasma,15137,,A,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,,,Rattus norvegicus,10116.0,,,50597
11791,Plasma,15137,,A,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,,,Rattus norvegicus,10116.0,,,50597
11792,Plasma,15137,,A,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,,,Rattus norvegicus,10116.0,,,50597
11793,Plasma,15137,,A,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,,,Mus musculus,10090.0,,,50594
11794,,13509,,A,,Plasma Concentration after 120 min of oral administration to mice,,,Mus musculus,10090.0,,,50594
11795,,13509,,A,,Plasma Concentration after 30 min of oral administration to mice,,,Mus musculus,10090.0,,,50594
11796,,13509,,A,,Plasma Concentration after 60 min of oral administration to mice,,,Macaca fascicularis,9541.0,,,100710
11797,,13509,,A,,Plasma Concentration after 60 min of oral administration to mice; Not determined,,,Mus musculus,10090.0,,,50594
11798,,13509,,A,,Plasma Concentration after 90 min of oral administration to mice,,,Mus musculus,10090.0,,,50594
11799,,12064,,A,,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,,,Rattus norvegicus,10116.0,,,50597
11800,,12064,,A,,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,,,Rattus norvegicus,10116.0,,,50597
11801,,12064,,A,,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,,,Rattus norvegicus,10116.0,,,50597
11802,,10677,,A,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,,,Rattus norvegicus,10116.0,,,50597
11803,,10677,,A,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,,,Rattus norvegicus,10116.0,,,50597
11804,,8926,,A,,Distribution in the lung after 15 min of intravenous administration,,,,,,,22224
11805,,8926,,A,,Distribution in the lung after 30 min of intravenous administration,,,,,,,22224
11806,,8926,,A,,Distribution in the lung after 5 min of intravenous administration,,,,,,,22224
11807,,8926,,A,,Distribution in the lung after 60 min of intravenous administration,,,,,,,22224
11808,,8926,,A,,Distribution in the lung after 90 min of intravenous administration,,,,,,,22224
11809,Muscle tissue,8926,,A,,Distribution in the muscle after 120 min of intravenous administration,,,,,,,22224
11810,Muscle tissue,8926,,A,,Distribution in the muscle after 15 min of intravenous administration,,,,,,,22224
11811,Muscle tissue,8926,,A,,Distribution in the muscle after 30 min of intravenous administration,,,Mus musculus,10090.0,,,50594
11812,Muscle tissue,8926,,A,,Distribution in the muscle after 5 min of intravenous administration,,,,,,,22224
11813,Muscle tissue,8926,,A,,Distribution in the muscle after 60 min of intravenous administration,,,,,,,22224
11814,Muscle tissue,8926,,A,,Distribution in the muscle after 90 min of intravenous administration,,,,,,,22224
11815,Spleen,8926,,A,,Distribution in the spleen after 120 min of intravenous administration,,,,,,,22224
11816,Spleen,8926,,A,,Distribution in the spleen after 15 min of intravenous administration,,,,,,,22224
11817,Spleen,8926,,A,,Distribution in the spleen after 30 min of intravenous administration,,,,,,,22224
11818,Spleen,8926,,A,,Distribution in the spleen after 5 min of intravenous administration,,,,,,,22224
11819,Spleen,8926,,A,,Distribution in the spleen after 60 min of intravenous administration,,,,,,,22224
11820,Spleen,8926,,A,,Distribution in the spleen after 90 min of intravenous administration,,,,,,,22224
11821,Adrenal cortex,7570,,A,,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,,,Rattus norvegicus,10116.0,,,50597
11822,Blood,7570,,A,,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,,,Rattus norvegicus,10116.0,,,50597
11823,Liver,7570,,A,,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,,,Rattus norvegicus,10116.0,,,50597
11824,Female gonad,7570,,A,,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,,,Rattus norvegicus,10116.0,,,50597
11825,Thyroid gland,7570,,A,,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,,,Rattus norvegicus,10116.0,,,50597
11826,Adrenal cortex,7570,,A,,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,,,Rattus norvegicus,10116.0,,,50597
11827,Blood,7570,,A,,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,,,Rattus norvegicus,10116.0,,,50597
11828,Liver,7570,,A,,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,,,Rattus norvegicus,10116.0,,,50597
11829,Female gonad,7570,,A,,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,,,Rattus norvegicus,10116.0,,,50597
11830,Thyroid gland,7570,,A,,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,,,Rattus norvegicus,10116.0,,,50597
11831,Blood,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",,,Rattus norvegicus,10116.0,,,50597
11832,Blood,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",,,Rattus norvegicus,10116.0,,,50597
11833,Blood,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",,,Rattus norvegicus,10116.0,,,50597
11834,Blood,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",,,Rattus norvegicus,10116.0,,,50597
11835,Blood,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",,,Rattus norvegicus,10116.0,,,50597
11836,Blood,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",,,Rattus norvegicus,10116.0,,,50597
11837,Blood,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",,,Rattus norvegicus,10116.0,,,50597
11838,Blood,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",,,Rattus norvegicus,10116.0,,,50597
11839,Blood,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",,,Rattus norvegicus,10116.0,,,50597
11840,Blood,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",,,Rattus norvegicus,10116.0,,,50597
11841,Blood,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",,,Rattus norvegicus,10116.0,,,50597
11842,Blood,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",,,Rattus norvegicus,10116.0,,,50597
11843,Blood,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",,,Rattus norvegicus,10116.0,,,50597
11844,Blood,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",,,Rattus norvegicus,10116.0,,,50597
11845,Blood,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",,,Rattus norvegicus,10116.0,,,50597
11846,Blood,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",,,Rattus norvegicus,10116.0,,,50597
11847,Blood,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",,,Rattus norvegicus,10116.0,,,50597
11848,Blood,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",,,Rattus norvegicus,10116.0,,,50597
11849,,13792,,A,,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,,,Mus musculus,10090.0,,,50594
11850,,13376,,A,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
11851,,13376,,A,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
11852,,14380,,A,,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,,,,,22224
11853,,14380,,A,,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,,,,,22224
11854,,14380,,A,,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,,,,,,,22224
11855,,14380,,A,,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,,,,,,22224
11856,,14380,,A,,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,,,,,,22224
11857,,14380,,A,,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,,,,,,22224
11858,,14380,,A,,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,,,,,,,22224
11859,,14380,,A,,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,,,,,,,22224
11860,,13701,,A,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,,,Mus musculus,10090.0,,,50594
11861,,13701,,A,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,,Mus musculus,10090.0,,,50594
11862,,13701,,A,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,,Mus musculus,10090.0,,,50594
11863,,13701,,A,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,,Mus musculus,10090.0,,,50594
11864,,13701,,A,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,,Mus musculus,10090.0,,,50594
11865,,13701,,A,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,,,Mus musculus,10090.0,,,50594
11866,,13701,,A,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,,Mus musculus,10090.0,,,50594
11867,,13701,,A,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,,Mus musculus,10090.0,,,50594
11868,,13701,,A,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,,Mus musculus,10090.0,,,50594
11869,,13701,,A,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),,,Mus musculus,10090.0,,,50594
11870,,13701,,A,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,,Mus musculus,10090.0,,,50594
11871,,13701,,A,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,,,Mus musculus,10090.0,,,50594
11872,,13701,,A,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,,Mus musculus,10090.0,,,50594
11873,,13701,,A,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,,Mus musculus,10090.0,,,50594
11874,,13701,,A,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,,Mus musculus,10090.0,,,50594
11875,,13701,,A,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,,Mus musculus,10090.0,,,50594
11876,,13701,,A,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,,,Mus musculus,10090.0,,,50594
11877,,13701,,A,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),,,Mus musculus,10090.0,,,50594
11878,,13701,,A,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,,Mus musculus,10090.0,,,50594
11879,,13701,,A,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,,,Mus musculus,10090.0,,,50594
11880,,13701,,A,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,,Mus musculus,10090.0,,,50594
11881,,13701,,A,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),,,Mus musculus,10090.0,,,50594
11882,,13701,,A,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),,,Mus musculus,10090.0,,,50594
11883,,13701,,A,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,,,Mus musculus,10090.0,,,50594
11884,,14393,,A,,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,Rattus norvegicus,10116.0,,,50597
11885,,14731,,A,,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,,,Mus musculus,10090.0,,,50594
11886,,14731,,A,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,,,Macaca fascicularis,9541.0,,,100710
11887,,14731,,A,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,,Macaca fascicularis,9541.0,,,100710
11888,Brain,13758,,A,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,,,,,,22224
11889,Serum,13758,,A,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,,,,,,,22224
11890,Brain,13758,,A,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,,,,,,22224
11891,Serum,13758,,A,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,,,,,,,22224
11892,,16359,,A,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),,,,,,,22224
11893,,16359,,A,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),,,,,,,22224
11894,Spleen,15383,,A,,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,Mus musculus,10090.0,,,50594
11895,Spleen,15383,,A,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,Mus musculus,10090.0,,,50594
11896,Spleen,15383,,A,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,Mus musculus,10090.0,,,50594
11897,,15383,,A,,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,Mus musculus,10090.0,,,50594
11898,,15383,,A,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,,Mus musculus,10090.0,,,50594
11899,,15383,,A,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,Mus musculus,10090.0,,,50594
11900,,15383,,A,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,Mus musculus,10090.0,,,50594
11901,,14439,,A,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),,,Mus musculus,10090.0,,,50594
11902,,14439,,A,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),,,Mus musculus,10090.0,,,50594
11903,,14439,,A,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),,,Mus musculus,10090.0,,,50594
11904,,14439,,A,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),,,Mus musculus,10090.0,,,50594
11905,,14439,,A,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),,,Mus musculus,10090.0,,,50594
11906,,14439,,A,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),,,Mus musculus,10090.0,,,50594
11907,,14439,,A,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),,,Mus musculus,10090.0,,,50594
11908,,14439,,A,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),,,Mus musculus,10090.0,,,50594
11909,,14439,,A,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),,,Mus musculus,10090.0,,,50594
11910,,14439,,A,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),,,Mus musculus,10090.0,,,50594
11911,,14439,,A,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),,,Mus musculus,10090.0,,,50594
11912,,14439,,A,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),,,Mus musculus,10090.0,,,50594
11913,,13751,,A,,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11914,,13751,,A,,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11915,,13751,,A,,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11916,,13751,,A,,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11917,,13751,,A,,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11918,,13751,,A,,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11919,,13751,,A,,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11920,,13751,,A,,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11921,Blood,13751,,A,,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11922,Blood,13751,,A,,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11923,Blood,13751,,A,,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11924,Blood,13751,,A,,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11925,Blood,13751,,A,,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11926,Blood,13751,,A,,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11927,Blood,13751,,A,,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11928,Bone,13751,,A,,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11929,Bone,13751,,A,,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11930,Bone,13751,,A,,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11931,Bone,13751,,A,,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11932,Brain,13751,,A,,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11933,Brain,13751,,A,,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11934,Brain,13751,,A,,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11935,Brain,13751,,A,,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11936,Brain,13751,,A,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11937,Brain,13751,,A,,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
11938,,10677,,A,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,,,Rattus norvegicus,10116.0,,,50597
11939,,10677,,A,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,,,Rattus norvegicus,10116.0,,,50597
11940,,10677,,A,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,,,Rattus norvegicus,10116.0,,,50597
11941,,10677,,A,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,,,Rattus norvegicus,10116.0,,,50597
11942,,10677,,A,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,,,Rattus norvegicus,10116.0,,,50597
11943,Adrenal gland,10911,,A,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11944,Adrenal gland,10911,,A,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11945,Adrenal gland,10911,,A,,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11946,Adrenal gland,10911,,A,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,In vivo,,Rattus norvegicus,10116.0,,,50597
11947,Adrenal gland,10911,,A,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11948,Blood,10911,,A,,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11949,Blood,10911,,A,,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11950,Blood,10911,,A,,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11951,Blood,10911,,A,,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11952,Blood,10911,,A,,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11953,Brain,10911,,A,,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11954,Brain,10911,,A,,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11955,Brain,10911,,A,,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11956,Brain,10911,,A,,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11957,Brain,10911,,A,,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11958,Brain,10911,,A,,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11959,,10911,,A,,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11960,,10911,,A,,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11961,,10911,,A,,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11962,,10911,,A,,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11963,Kidney,10911,,A,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11964,Kidney,10911,,A,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11965,Kidney,10911,,A,,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11966,Kidney,10911,,A,,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11967,Liver,10911,,A,,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11968,Liver,10911,,A,,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11969,Liver,10911,,A,,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11970,Liver,10911,,A,,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11971,Lung,10911,,A,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11972,Lung,10911,,A,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11973,Lung,10911,,A,,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11974,Lung,10911,,A,,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11975,Muscle tissue,10911,,A,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11976,Muscle tissue,10911,,A,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
11977,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",,,Rattus norvegicus,10116.0,,,50597
11978,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",,,Rattus norvegicus,10116.0,,,50597
11979,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",,,Rattus norvegicus,10116.0,,,50597
11980,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",,,Rattus norvegicus,10116.0,,,50597
11981,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",,,Rattus norvegicus,10116.0,,,50597
11982,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",,,Rattus norvegicus,10116.0,,,50597
11983,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",,,Rattus norvegicus,10116.0,,,50597
11984,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",,,Rattus norvegicus,10116.0,,,50597
11985,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",,,Rattus norvegicus,10116.0,,,50597
11986,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",,,Rattus norvegicus,10116.0,,,50597
11987,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",,,Rattus norvegicus,10116.0,,,50597
11988,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",,,Rattus norvegicus,10116.0,,,50597
11989,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",,,Rattus norvegicus,10116.0,,,50597
11990,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",,,Rattus norvegicus,10116.0,,,50597
11991,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",,,Rattus norvegicus,10116.0,,,50597
11992,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",,,Rattus norvegicus,10116.0,,,50597
11993,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",,,Rattus norvegicus,10116.0,,,50597
11994,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",,,Rattus norvegicus,10116.0,,,50597
11995,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",,,Rattus norvegicus,10116.0,,,50597
11996,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",,,Rattus norvegicus,10116.0,,,50597
11997,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",,,Rattus norvegicus,10116.0,,,50597
11998,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",,,Rattus norvegicus,10116.0,,,50597
11999,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",,,Rattus norvegicus,10116.0,,,50597
12000,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",,,Rattus norvegicus,10116.0,,,50597
12001,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,,Rattus norvegicus,10116.0,,,50597
12002,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",,,Rattus norvegicus,10116.0,,,50597
12003,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",,,Rattus norvegicus,10116.0,,,50597
12004,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",,,Rattus norvegicus,10116.0,,,50597
12005,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",,,Rattus norvegicus,10116.0,,,50597
12006,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",,,Rattus norvegicus,10116.0,,,50597
12007,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",,,Rattus norvegicus,10116.0,,,50597
12008,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",,,Rattus norvegicus,10116.0,,,50597
12009,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",,,Rattus norvegicus,10116.0,,,50597
12010,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",,,Rattus norvegicus,10116.0,,,50597
12011,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",,,Rattus norvegicus,10116.0,,,50597
12012,,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",,,Rattus norvegicus,10116.0,,,50597
12013,,16359,,A,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),,,,,,,22224
12014,,13701,,A,,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,,Mus musculus,10090.0,,,50594
12015,,14554,,A,,Pharmacokinetic profile AUC was evaluated in rats,,,Rattus norvegicus,10116.0,,,50597
12016,,6241,,A,,Pharmacokinetic property (Area under curve),,,,,,,22224
12017,,11537,,A,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",,,Canis lupus familiaris,9615.0,,,50588
12018,,11537,,A,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",,,Mus musculus,10090.0,,,50594
12019,,11537,,A,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",,,Canis lupus familiaris,9615.0,,,50588
12020,,11537,,A,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",,,Mus musculus,10090.0,,,50594
12021,,13118,,A,,Plasma concentration (AUC) was determined,,,,,,,22224
12022,,13118,,A,,Plasma concentration (AUC) was determined; Not detectable,,,,,,,22224
12023,,9562,,A,,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),,,Cavia porcellus,10141.0,,,50512
12024,,10363,,A,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,,,Rattus norvegicus,10116.0,,,50597
12025,,10363,,A,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,,Rattus norvegicus,10116.0,,,50597
12026,,10363,,A,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,,,Rattus norvegicus,10116.0,,,50597
12027,,10363,,A,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,,,Rattus norvegicus,10116.0,,,50597
12028,,12504,,A,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,,,Rattus norvegicus,10116.0,,,50597
12029,,12504,,A,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,,,Rattus norvegicus,10116.0,,,50597
12030,,12504,,A,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,,,Rattus norvegicus,10116.0,,,50597
12031,,12504,,A,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,,,Rattus norvegicus,10116.0,,,50597
12032,,13317,,A,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,,,Canis lupus familiaris,9615.0,,,50588
12033,,15078,,A,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,,Rattus norvegicus,10116.0,,,50597
12034,,14941,,A,,The AUC(0-infinity) values in female wistar rats.,,,Rattus norvegicus,10116.0,,,50597
12035,,15078,,A,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,,Rattus norvegicus,10116.0,,,50597
12036,,15078,,A,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",,,Rattus norvegicus,10116.0,,,50597
12037,,14941,,A,,The AUC(0-t)values in female wistar rats.,,,Rattus norvegicus,10116.0,,,50597
12038,,14067,,A,,The Area under the concentration time curve of compound was measured on rats,,,Rattus norvegicus,10116.0,,,50597
12039,,14215,,A,,The area under curve (100 mg/kg) administered orally in humans,,,Homo sapiens,9606.0,,,50587
12040,,14215,,A,,The area under curve (12.5 mg/kg) administered intravenously in marmoset,,,Callithrix,9481.0,,,22224
12041,,14215,,A,,The area under curve (12.5 mg/kg) administered intravenously in monkey,,,Simiiformes,314293.0,,,22224
12042,,14215,,A,,The area under curve (15 mg/kg) administered intravenously in dog,,,Canis lupus familiaris,9615.0,,,50588
12043,,14215,,A,,The area under curve (200 mg/kg) administered orally in humans,,,Homo sapiens,9606.0,,,50587
12044,,14215,,A,,The area under curve (25 mg/kg) administered intravenously in rat,,,Rattus norvegicus,10116.0,,,50597
12045,,14215,,A,,The area under curve (25 mg/kg) administered orally in marmoset,,,Callithrix,9481.0,,,22224
12046,,14215,,A,,The area under curve (25 mg/kg) administered orally in monkey,,,Simiiformes,314293.0,,,22224
12047,,14215,,A,,The area under curve (30 mg/kg) administered orally in dog,,,Canis lupus familiaris,9615.0,,,50588
12048,,14215,,A,,The area under curve (400 mg/kg) administered orally in humans,,,Homo sapiens,9606.0,,,50587
12049,,14215,,A,,The area under curve (50 mg/kg) administered orally in fasted rat,,,Rattus norvegicus,10116.0,,,50597
12050,,14215,,A,,The area under curve (50 mg/kg) administered orally in rat,,,Rattus norvegicus,10116.0,,,50597
12051,,14215,,A,,The area under curve (800 mg/kg) administered orally in humans,,,Homo sapiens,9606.0,,,50587
12052,,11324,,A,,The compound was evaluated for area under the curve,,,,,,,22224
12053,,11324,,A,,The compound was evaluated for area under the curve in marmosets,,,Callithrix,9481.0,,,22224
12054,,11324,,A,,The compound was evaluated for area under the curve in marmosets,,,Callithrix,9481.0,,,22224
12055,,13875,,A,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,,Rattus norvegicus,10116.0,,,50597
12056,,13875,,A,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,,,Rattus norvegicus,10116.0,,,50597
12057,,13875,,A,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),,,,,,,22224
12058,,13875,,A,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,,Rattus norvegicus,10116.0,,,50597
12059,,13875,,A,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,,Rattus norvegicus,10116.0,,,50597
12060,,13875,,A,,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,,,Rattus norvegicus,10116.0,,,50597
12061,,13807,,A,,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,,,Rattus norvegicus,10116.0,,,50597
12062,,14127,,A,,Total drug exposure is determined after oral dosing in rats.,,,Rattus norvegicus,10116.0,,,50597
12063,,15116,,A,,Total drug exposure (5 mg/kg) when administered intravenously,,,,,,,22224
12064,,15116,,A,,Total drug exposure (5 mg/kg) when administered orally,,,,,,,22224
12065,,15604,,A,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,,Simiiformes,314293.0,,,22224
12066,,15604,,A,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,,Rattus norvegicus,10116.0,,,50597
12067,,15604,,A,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,,Canis lupus familiaris,9615.0,,,50588
12068,,15604,,A,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,,Canis lupus familiaris,9615.0,,,50588
12069,Brain,13751,,A,,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12070,Brain,13751,,A,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12071,,13751,,A,,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12072,,13751,,A,,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12073,,13751,,A,,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12074,,13751,,A,,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12075,,13751,,A,,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12076,,13751,,A,,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12077,,13751,,A,,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12078,Heart,13751,,A,,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12079,Heart,13751,,A,,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12080,Heart,13751,,A,,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12081,Heart,13751,,A,,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12082,Heart,13751,,A,,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12083,Heart,13751,,A,,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12084,Heart,13751,,A,,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12085,Kidney,13751,,A,,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12086,Kidney,13751,,A,,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12087,Kidney,13751,,A,,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12088,Kidney,13751,,A,,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12089,Kidney,13751,,A,,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12090,Kidney,13751,,A,,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12091,Kidney,13751,,A,,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12092,Liver,13751,,A,,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12093,Lung,13751,,A,,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12094,Lung,13751,,A,,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12095,Lung,13751,,A,,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12096,Lung,13751,,A,,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12097,Lung,13751,,A,,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12098,Lung,13751,,A,,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12099,Lung,13751,,A,,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12100,Muscle tissue,13751,,A,,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12101,Muscle tissue,13751,,A,,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12102,Muscle tissue,13751,,A,,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12103,Muscle tissue,13751,,A,,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12104,Muscle tissue,13751,,A,,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12105,Muscle tissue,13751,,A,,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12106,Muscle tissue,13751,,A,,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12107,,13751,,A,,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12108,Liver,13751,,A,,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12109,Liver,13751,,A,,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12110,Liver,13751,,A,,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12111,Muscle tissue,10911,,A,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12112,Muscle tissue,10911,,A,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12113,Muscle tissue,10911,,A,,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12114,Female gonad,10911,,A,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12115,Female gonad,10911,,A,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12116,Female gonad,10911,,A,,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12117,Female gonad,10911,,A,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,In vivo,,Rattus norvegicus,10116.0,,,50597
12118,Female gonad,10911,,A,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12119,Plasma,10911,,A,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12120,Plasma,10911,,A,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12121,Plasma,10911,,A,,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12122,Plasma,10911,,A,,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12123,Spleen,10911,,A,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12124,Spleen,10911,,A,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12125,Spleen,10911,,A,,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12126,Spleen,10911,,A,,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12127,Thyroid gland,10911,,A,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12128,Thyroid gland,10911,,A,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12129,Thyroid gland,10911,,A,,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12130,Thyroid gland,10911,,A,,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12131,Uterus,10911,,A,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12132,Uterus,10911,,A,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12133,Uterus,10911,,A,,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12134,Uterus,10911,,A,,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,In vivo,,Rattus norvegicus,10116.0,,,50597
12135,,8081,,A,,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,,,,,,,22224
12136,Plasma,17248,,A,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),,,Macaca fascicularis,9541.0,,,100710
12137,Plasma,17248,,A,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,,,Macaca fascicularis,9541.0,,,100710
12138,Plasma,17248,,A,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,,,Macaca fascicularis,9541.0,,,100710
12139,Plasma,17248,,A,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),,,Canis lupus familiaris,9615.0,,,50588
12140,Plasma,17248,,A,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,,,Canis lupus familiaris,9615.0,,,50588
12141,Plasma,17248,,A,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,,,Canis lupus familiaris,9615.0,,,50588
12142,Plasma,17248,,A,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,,,Canis lupus familiaris,9615.0,,,50588
12143,,15592,,A,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,,Canis lupus familiaris,9615.0,,,50588
12144,,7040,,A,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,,,,,,,22224
12145,,7040,,A,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,,,,,,,22224
12146,,7040,,A,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,,,,,,,22224
12147,,7040,,A,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,,,,,,,22224
12148,,7040,,A,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,,,,,,,22224
12149,,7040,,A,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,,,,,,,22224
12150,,7040,,A,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,,,,,,,22224
12151,Adrenal medulla,9614,,A,,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",,,Canis lupus familiaris,9615.0,,,50588
12152,Adrenal medulla,9614,,A,,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",,,Canis lupus familiaris,9615.0,,,50588
12153,Blood,9614,,A,,"Concentration of compound in blood of dog 1, after administering intravenously",,,Canis lupus familiaris,9615.0,,,50588
12154,Liver,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",,,Rattus norvegicus,10116.0,,,50597
12155,Liver,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",,,Rattus norvegicus,10116.0,,,50597
12156,Liver,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",,,Rattus norvegicus,10116.0,,,50597
12157,Liver,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",,,Rattus norvegicus,10116.0,,,50597
12158,Liver,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",,,Rattus norvegicus,10116.0,,,50597
12159,Liver,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",,,Rattus norvegicus,10116.0,,,50597
12160,Liver,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",,,Rattus norvegicus,10116.0,,,50597
12161,Liver,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,,Rattus norvegicus,10116.0,,,50597
12162,Liver,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",,,Rattus norvegicus,10116.0,,,50597
12163,Liver,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",,,Rattus norvegicus,10116.0,,,50597
12164,Liver,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",,,Rattus norvegicus,10116.0,,,50597
12165,Liver,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",,,Rattus norvegicus,10116.0,,,50597
12166,Liver,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",,,Rattus norvegicus,10116.0,,,50597
12167,Liver,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",,,Rattus norvegicus,10116.0,,,50597
12168,Liver,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",,,Rattus norvegicus,10116.0,,,50597
12169,Liver,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",,,Rattus norvegicus,10116.0,,,50597
12170,Liver,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",,,Rattus norvegicus,10116.0,,,50597
12171,Liver,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",,,Rattus norvegicus,10116.0,,,50597
12172,Lung,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",,,Rattus norvegicus,10116.0,,,50597
12173,Lung,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",,,Rattus norvegicus,10116.0,,,50597
12174,Lung,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",,,Rattus norvegicus,10116.0,,,50597
12175,Lung,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",,,Rattus norvegicus,10116.0,,,50597
12176,Lung,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",,,Rattus norvegicus,10116.0,,,50597
12177,Lung,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",,,Rattus norvegicus,10116.0,,,50597
12178,Lung,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",,,Rattus norvegicus,10116.0,,,50597
12179,Lung,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",,,Rattus norvegicus,10116.0,,,50597
12180,Lung,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",,,Rattus norvegicus,10116.0,,,50597
12181,Lung,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",,,Rattus norvegicus,10116.0,,,50597
12182,Lung,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",,,Rattus norvegicus,10116.0,,,50597
12183,Lung,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",,,Rattus norvegicus,10116.0,,,50597
12184,Lung,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",,,Rattus norvegicus,10116.0,,,50597
12185,Lung,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",,,Rattus norvegicus,10116.0,,,50597
12186,Lung,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",,,Rattus norvegicus,10116.0,,,50597
12187,Lung,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",,,Rattus norvegicus,10116.0,,,50597
12188,Lung,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",,,Rattus norvegicus,10116.0,,,50597
12189,Lung,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",,,Rattus norvegicus,10116.0,,,50597
12190,,15604,,A,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,,Simiiformes,314293.0,,,22224
12191,,15604,,A,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,,Rattus norvegicus,10116.0,,,50597
12192,Plasma,1806,,A,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,,,,,,,22224
12193,Plasma,1806,,A,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,,,,,,,22224
12194,Plasma,17237,,A,,AUC 0-inf in dog,,,Canis lupus familiaris,9615.0,,,50588
12195,Plasma,17237,,A,,AUC 0-inf in guinea pig,,,Cavia porcellus,10141.0,,,50512
12196,Plasma,17237,,A,,AUC 0-t in dog,,,Canis lupus familiaris,9615.0,,,50588
12197,Plasma,17237,,A,,AUC 0-t in guinea pig,,,Cavia porcellus,10141.0,,,50512
12198,,15194,,A,,The compound was tested for brain to plasma partition in rat,,,Rattus norvegicus,10116.0,,,50597
12199,,15194,,A,,The compound was tested for brain to plasma partition in rat.,,,Rattus norvegicus,10116.0,,,50597
12200,Blood,8787,,A,,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,,,,,,,22224
12201,,17025,,A,,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,,,Canis lupus familiaris,9615.0,,,50588
12202,,17025,,A,,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,,,Simiiformes,314293.0,,,22224
12203,,17025,,A,,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,,,Oryctolagus cuniculus,9986.0,,,50592
12204,,17025,,A,,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,,,Rattus norvegicus,10116.0,,,50597
12205,,4236,,A,,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,,,Macaca mulatta,9544.0,,,50797
12206,,15343,,A,,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,,,Canis lupus familiaris,9615.0,,,50588
12207,,15343,,A,,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,,,Rattus norvegicus,10116.0,,,50597
12208,,17720,,A,,Area under curve of the compound was determined,,,,,,,22224
12209,Plasma,17788,,A,,AUC in monkeys at a dose of 1 mg/kg,,,Simiiformes,314293.0,,,22224
12210,Plasma,17788,,A,,AUC in rats at a dose of 1 mg/kg,,,Rattus norvegicus,10116.0,,,50597
12211,,8778,,A,,Compound was evaluated for the overall absorbance loss at pH of 2,,,,,,,22224
12212,,8778,,A,,Compound was evaluated for the overall absorbance loss at pH of 4,,,,,,,22224
12213,,8778,,A,,Compound was evaluated for the overall absorbance loss at pH of 7,,,,,,,22224
12214,,2249,,A,,Compound was evaluated for its absorption in the rats,,,Rattus norvegicus,10116.0,,,50597
12215,Urine,8881,,A,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,,,Rattus norvegicus,10116.0,,,50597
12216,Urine,8881,,A,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,,,Rattus norvegicus,10116.0,,,50597
12217,Urine,8881,,A,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,,,Rattus norvegicus,10116.0,,,50597
12218,Urine,8881,,A,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,,,Rattus norvegicus,10116.0,,,50597
12219,,15286,,A,,In vitro percent permeability into rat ileum,,,Rattus norvegicus,10116.0,,,50597
12220,,15286,,A,,In vitro percent permeability into rat ileum; Range is 10-17,,,Rattus norvegicus,10116.0,,,50597
12221,,15286,,A,,In vitro percent permeability into rat ileum; Range is 10-18,,,Rattus norvegicus,10116.0,,,50597
12222,,15286,,A,,In vitro percent permeability into rat ileum; Range is 10-19,,,Rattus norvegicus,10116.0,,,50597
12223,,15286,,A,,In vitro percent permeability into rat ileum; Range is 12-15,,,Rattus norvegicus,10116.0,,,50597
12224,,15286,,A,,In vitro percent permeability into rat ileum; Range is 13-19,,,Rattus norvegicus,10116.0,,,50597
12225,,15286,,A,,In vitro percent permeability into rat ileum; Range is 14-17,,,Rattus norvegicus,10116.0,,,50597
12226,,15286,,A,,In vitro percent permeability into rat ileum; Range is 15-18,,,Rattus norvegicus,10116.0,,,50597
12227,,15286,,A,,In vitro percent permeability into rat ileum; Range is 2-5,,,Rattus norvegicus,10116.0,,,50597
12228,Ileum,15286,,A,,In vitro percent permeability into rat ileum; Range is 23-42,,,,,,,22224
12229,,15286,,A,,In vitro percent permeability into rat ileum; Range is 28-36,,,Rattus norvegicus,10116.0,,,50597
12230,,15286,,A,,In vitro percent permeability into rat ileum; Range is 29-35,,,Rattus norvegicus,10116.0,,,50597
12231,,15286,,A,,In vitro percent permeability into rat ileum; Range is 46-66,,,Rattus norvegicus,10116.0,,,50597
12232,,15286,,A,,In vitro percent permeability into rat ileum; Range is 50-68,,,Rattus norvegicus,10116.0,,,50597
12233,,15286,,A,,In vitro percent permeability into rat ileum; Range is 78-81,,,Rattus norvegicus,10116.0,,,50597
12234,,15286,,A,,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,,,Rattus norvegicus,10116.0,,,50597
12235,,15286,,A,,In vitro percent permeability into rat ileum; nd indicates not detected,,,Rattus norvegicus,10116.0,,,50597
12236,,15286,,A,,In vitro percent permeability into rat ileum; nt indicates not detected,,,Rattus norvegicus,10116.0,,,50597
12237,,15286,,A,,In vitro percent permeability into rat ileum; nt indicates not tested,,,Rattus norvegicus,10116.0,,,50597
12238,,13770,,A,,Compound was tested for oral absorption in bile-duct cannulated rats,,,Rattus norvegicus,10116.0,,,50597
12239,,13770,,A,,Compound was tested for oral absorption in bile-duct cannulated rats.,,,Rattus norvegicus,10116.0,,,50597
12240,,5202,,A,,Oral absorption using Caco-2 cell monolayers.,,,Homo sapiens,9606.0,,,50587
12241,,14920,,A,,Percent of the drug absorbed after administration to humans was determined,,,Homo sapiens,9606.0,,,50587
12242,Plasma,14103,,A,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,,,Rattus norvegicus,10116.0,,,50597
12243,Plasma,14103,,A,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,,,Rattus norvegicus,10116.0,,,50597
12244,Plasma,14103,,A,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,,,Rattus norvegicus,10116.0,,,50597
12245,Liver,13751,,A,,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12246,Liver,13751,,A,,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12247,Liver,13751,,A,,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",In vivo,,Rattus norvegicus,10116.0,,,50597
12248,,15807,,A,,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",,,Rattus norvegicus,10116.0,,,50597
12249,Striatum,15807,,A,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",,,Rattus norvegicus,10116.0,,,50597
12250,Striatum,15807,,A,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",,,Rattus norvegicus,10116.0,,,50597
12251,,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,,,Rattus norvegicus,10116.0,,,50597
12252,,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,,,Rattus norvegicus,10116.0,,,50597
12253,,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,,,Rattus norvegicus,10116.0,,,50597
12254,,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,,,Rattus norvegicus,10116.0,,,50597
12255,,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,,,Rattus norvegicus,10116.0,,,50597
12256,Kidney,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,,,Rattus norvegicus,10116.0,,,50597
12257,Kidney,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,,,Rattus norvegicus,10116.0,,,50597
12258,,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,,,Rattus norvegicus,10116.0,,,50597
12259,,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,,,Rattus norvegicus,10116.0,,,50597
12260,Lung,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,,,Rattus norvegicus,10116.0,,,50597
12261,Lung,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,,,Rattus norvegicus,10116.0,,,50597
12262,Muscle tissue,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,,,Rattus norvegicus,10116.0,,,50597
12263,Muscle tissue,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,,,Rattus norvegicus,10116.0,,,50597
12264,Prostate gland,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,,,Rattus norvegicus,10116.0,,,50597
12265,Prostate gland,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,,,Rattus norvegicus,10116.0,,,50597
12266,,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,,,Rattus norvegicus,10116.0,,,50597
12267,,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,,,Rattus norvegicus,10116.0,,,50597
12268,,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,,,Rattus norvegicus,10116.0,,,50597
12269,Spleen,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,,,Rattus norvegicus,10116.0,,,50597
12270,Spleen,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,,,Rattus norvegicus,10116.0,,,50597
12271,Thyroid gland,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,,,Rattus norvegicus,10116.0,,,50597
12272,Thyroid gland,14950,,A,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,,,Rattus norvegicus,10116.0,,,50597
12273,,14950,,A,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,,,Rattus norvegicus,10116.0,,,50597
12274,,14950,,A,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,,,Rattus norvegicus,10116.0,,,50597
12275,Muscle tissue,14950,,A,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,,,Rattus norvegicus,10116.0,,,50597
12276,,14950,,A,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,,,Rattus norvegicus,10116.0,,,50597
12277,Thyroid gland,14950,,A,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,,,Rattus norvegicus,10116.0,,,50597
12278,Blood,8631,,A,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,,,Rattus norvegicus,10116.0,,,50597
12279,Blood,8631,,A,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,,,Rattus norvegicus,10116.0,,,50597
12280,Blood,8631,,A,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,,,Rattus norvegicus,10116.0,,,50597
12281,Blood,8631,,A,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,,,Rattus norvegicus,10116.0,,,50597
12282,Blood,9614,,A,,"Concentration of compound in blood of dog 2, after administering intravenously",,,Canis lupus familiaris,9615.0,,,50588
12283,,9614,,A,,"Concentration of compound in left ventricle of dog 1, after administering intravenously",,,Canis lupus familiaris,9615.0,,,50588
12284,,9614,,A,,"Concentration of compound in left ventricle of dog 2, after administering intravenously",,,Canis lupus familiaris,9615.0,,,50588
12285,Liver,9614,,A,,"Concentration of compound in liver of dog 1, after administering intravenously",,,Canis lupus familiaris,9615.0,,,50588
12286,Liver,9614,,A,,"Concentration of compound in liver of dog 2, after administering intravenously",,,Canis lupus familiaris,9615.0,,,50588
12287,Lung,9614,,A,,"Concentration of compound in lung of dog 1, after administering intravenously",,,Canis lupus familiaris,9615.0,,,50588
12288,Lung,9614,,A,,"Concentration of compound in lung of dog 2, after administering intravenously",,,Canis lupus familiaris,9615.0,,,50588
12289,Muscle tissue,9614,,A,,"Concentration of compound in muscle of dog 1, after administering intravenously",,,Canis lupus familiaris,9615.0,,,50588
12290,Muscle tissue,9614,,A,,"Concentration of compound in muscle of dog 2, after administering intravenously",,,Canis lupus familiaris,9615.0,,,50588
12291,Spleen,9614,,A,,"Concentration of compound in spleen of dog 1,after administering intravenously",,,Canis lupus familiaris,9615.0,,,50588
12292,Spleen,9614,,A,,"Concentration of compound in spleen of dog 2, after administering intravenously",,,Canis lupus familiaris,9615.0,,,50588
12293,,10353,,F,,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,,,,,,,22224
12294,,10353,,F,,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,,,,,,,22224
12295,,10353,,A,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,,,,,,22224
12296,,10353,,F,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,,,,,,22224
12297,,10353,,F,,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,,,,,,,22224
12298,,9196,,A,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,,,,,,,22224
12299,,9196,,A,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,,,,,,22224
12300,,9196,,A,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,,,,,22224
12301,,9196,,A,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,,,,,22224
12302,,9196,,A,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,,,,,22224
12303,,9196,,A,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,,,,,22224
12304,,9196,,A,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,,,,,22224
12305,,9196,,A,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,,,,,,22224
12306,,9196,,A,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,,,,,,,22224
12307,,9196,,A,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,,,,,,,22224
12308,,9196,,A,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,,,,,,22224
12309,,9196,,A,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,,,,,,22224
12310,,9196,,A,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,,,,,22224
12311,,9196,,A,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,,,,,,22224
12312,,9196,,A,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,,,,,,,22224
12313,,9196,,A,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,,,,,,,22224
12314,,9196,,A,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,,,,,22224
12315,,9196,,A,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,,,,,22224
12316,,9196,,A,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,,,,,,,22224
12317,,9196,,A,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,,,,,22224
12318,,9196,,A,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,,,,,22224
12319,,9196,,A,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,,,,,,22224
12320,,9196,,A,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,,,,,22224
12321,,9196,,A,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,,,,,,22224
12322,,9196,,A,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,,,,,,22224
12323,,9196,,A,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,,,,,,,22224
12324,,9196,,A,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,,,,,,22224
12325,,9196,,A,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,,,,,,,22224
12326,Thyroid gland,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",,,Rattus norvegicus,10116.0,,,50597
12327,Thyroid gland,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",,,Rattus norvegicus,10116.0,,,50597
12328,Thyroid gland,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",,,Rattus norvegicus,10116.0,,,50597
12329,Thyroid gland,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",,,Rattus norvegicus,10116.0,,,50597
12330,Thyroid gland,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",,,Rattus norvegicus,10116.0,,,50597
12331,Thyroid gland,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",,,Rattus norvegicus,10116.0,,,50597
12332,Thyroid gland,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",,,Rattus norvegicus,10116.0,,,50597
12333,Thyroid gland,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",,,Rattus norvegicus,10116.0,,,50597
12334,Thyroid gland,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",,,Rattus norvegicus,10116.0,,,50597
12335,Thyroid gland,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",,,Rattus norvegicus,10116.0,,,50597
12336,Thyroid gland,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",,,Rattus norvegicus,10116.0,,,50597
12337,Thyroid gland,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",,,Rattus norvegicus,10116.0,,,50597
12338,Thyroid gland,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",,,Rattus norvegicus,10116.0,,,50597
12339,Thyroid gland,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",,,Rattus norvegicus,10116.0,,,50597
12340,Thyroid gland,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",,,Rattus norvegicus,10116.0,,,50597
12341,Thyroid gland,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",,,Rattus norvegicus,10116.0,,,50597
12342,Thyroid gland,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",,,Rattus norvegicus,10116.0,,,50597
12343,Thyroid gland,8608,,A,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",,,Rattus norvegicus,10116.0,,,50597
12344,,8085,,A,,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,Rattus norvegicus,10116.0,,,50597
12345,,8085,,A,,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,Rattus norvegicus,10116.0,,,50597
12346,,8085,,A,,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,Rattus norvegicus,10116.0,,,50597
12347,Uterus,8085,,A,,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,Rattus norvegicus,10116.0,,,50597
12348,Uterus,8085,,A,,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,Rattus norvegicus,10116.0,,,50597
12349,Uterus,8085,,A,,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,Rattus norvegicus,10116.0,,,50597
12350,Uterus,8085,,A,,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,Rattus norvegicus,10116.0,,,50597
12351,Uterus,8085,,A,,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,Rattus norvegicus,10116.0,,,50597
12352,Uterus,8085,,A,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,Rattus norvegicus,10116.0,,,50597
12353,Uterus,8085,,A,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,Rattus norvegicus,10116.0,,,50597
12354,,7657,,P,,Distribution coefficient (D %) between octanol and buffer of pH 7.4,,,,,,,22224
12355,,8935,,A,,Partition coefficient (logD7.4),,,Mus musculus,10090.0,,,50594
12356,,13792,,A,,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,,Mus musculus,10090.0,,,50594
12357,Brain,13792,,A,,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",,,Mus musculus,10090.0,,,50594
12358,,13792,,A,,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,,Mus musculus,10090.0,,,50594
12359,Brain,13792,,A,,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,,,Mus musculus,10090.0,,,50594
12360,,13792,,A,,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,,Mus musculus,10090.0,,,50594
12361,Brain,13792,,A,,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",,,Mus musculus,10090.0,,,50594
12362,,13792,,A,,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,,Mus musculus,10090.0,,,50594
12363,Brain,13792,,A,,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,,,Rattus norvegicus,10116.0,,,50597
12364,Plasma,14103,,A,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,,,Rattus norvegicus,10116.0,,,50597
12365,Plasma,14103,,A,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,,,Rattus norvegicus,10116.0,,,50597
12366,Plasma,14103,,A,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,,,Rattus norvegicus,10116.0,,,50597
12367,Plasma,14103,,A,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,,,Rattus norvegicus,10116.0,,,50597
12368,Plasma,14103,,A,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,,,Rattus norvegicus,10116.0,,,50597
12369,Plasma,14103,,A,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,,,Rattus norvegicus,10116.0,,,50597
12370,Plasma,14103,,A,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,,,Rattus norvegicus,10116.0,,,50597
12371,Plasma,14103,,A,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,,,Rattus norvegicus,10116.0,,,50597
12372,Plasma,14103,,A,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,,,Rattus norvegicus,10116.0,,,50597
12373,Plasma,14103,,A,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,,,Rattus norvegicus,10116.0,,,50597
12374,Plasma,14103,,A,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,,,Rattus norvegicus,10116.0,,,50597
12375,Plasma,14103,,A,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,,,Rattus norvegicus,10116.0,,,50597
12376,Plasma,14103,,A,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,,,Rattus norvegicus,10116.0,,,50597
12377,Plasma,14103,,A,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,,,Rattus norvegicus,10116.0,,,50597
12378,Plasma,14103,,A,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,,,Rattus norvegicus,10116.0,,,50597
12379,Plasma,14103,,A,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,,,Rattus norvegicus,10116.0,,,50597
12380,Plasma,14103,,A,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,,,Rattus norvegicus,10116.0,,,50597
12381,Plasma,14103,,A,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,,,Rattus norvegicus,10116.0,,,50597
12382,Plasma,14103,,A,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,,,Rattus norvegicus,10116.0,,,50597
12383,Plasma,14103,,A,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,,,Rattus norvegicus,10116.0,,,50597
12384,Plasma,14103,,A,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,,,Rattus norvegicus,10116.0,,,50597
12385,Plasma,14103,,A,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,,,Rattus norvegicus,10116.0,,,50597
12386,,12904,,A,,Amount of acetic acid produced by the compound,,,,,,,22224
12387,,12904,,A,,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,,,,,,,22224
12388,,9663,,A,,Log of (Cbrain/Cblood) in rats,,,Rattus norvegicus,10116.0,,,50597
12389,,7652,,A,,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),,,,,,,22224
12390,,7652,,A,,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,,,,,,22224
12391,,7652,,A,,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),,,,,,,22224
12392,,7652,,B,,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),,,,,,,22224
12393,,7652,,A,,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,,,,,,22224
12394,,7652,,A,,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),,,,,,,22224
12395,,7652,,A,,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),,,,,,,22224
12396,,7652,,A,,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),,,,,,,22224
12397,,7652,,A,,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,,,,,,22224
12398,,7652,,A,,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),,,,,,,22224
12399,,7652,,A,,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),,,,,,,22224
12400,,7652,,A,,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),,,,,,,22224
12401,,7652,,A,,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),,,,,,,22224
12402,,7652,,A,,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),,,,,,,22224
12403,,7652,,A,,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),,,,,,,22224
12404,,7652,,A,,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),,,,,,,22224
12405,,8267,,F,,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,In vivo,,,,,,22224
12406,,8267,,A,,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,,,Canis lupus familiaris,9615.0,,,50588
12407,,14479,,A,,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,,,,,,,22224
12408,,17515,,A,,Compound was evaluated for total body clearance,,,,,,,22224
12409,,17515,,A,,Compound was evaluated for volume of distribution at steady state,,,,,,,22224
12410,,8142,,A,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,,,,,,,22224
12411,,14849,,A,,Percentage of the diamine which is monoprotonated at pH 7.4,,,,,,,22224
12412,,7653,,A,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,,,,,,,22224
12413,Blood,8631,,A,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,,,Rattus norvegicus,10116.0,,,50597
12414,Blood,8631,,A,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,,Rattus norvegicus,10116.0,,,50597
12415,Blood,8631,,A,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,,Rattus norvegicus,10116.0,,,50597
12416,Blood,8631,,A,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,,Rattus norvegicus,10116.0,,,50597
12417,Blood,8631,,A,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,,,Rattus norvegicus,10116.0,,,50597
12418,Blood,8631,,A,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,,Rattus norvegicus,10116.0,,,50597
12419,Blood,8631,,A,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,,,Rattus norvegicus,10116.0,,,50597
12420,Blood,8631,,A,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,,,Rattus norvegicus,10116.0,,,50597
12421,Blood,8631,,A,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,,,Rattus norvegicus,10116.0,,,50597
12422,Blood,8631,,A,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,,,Rattus norvegicus,10116.0,,,50597
12423,Blood,8631,,A,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,,,Rattus norvegicus,10116.0,,,50597
12424,Blood,8631,,A,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,,,Rattus norvegicus,10116.0,,,50597
12425,Blood,8631,,A,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,,Rattus norvegicus,10116.0,,,50597
12426,Blood,8631,,A,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,,Rattus norvegicus,10116.0,,,50597
12427,Blood,8631,,A,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,,Rattus norvegicus,10116.0,,,50597
12428,Blood,8631,,A,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,,Rattus norvegicus,10116.0,,,50597
12429,Blood,8631,,A,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,,Rattus norvegicus,10116.0,,,50597
12430,Blood,8631,,A,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,,Rattus norvegicus,10116.0,,,50597
12431,Blood,8631,,A,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,,Rattus norvegicus,10116.0,,,50597
12432,Blood,8631,,A,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,,Rattus norvegicus,10116.0,,,50597
12433,Blood,8631,,A,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,,Rattus norvegicus,10116.0,,,50597
12434,Blood,8631,,A,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,,Rattus norvegicus,10116.0,,,50597
12435,Blood,8631,,A,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,,,Rattus norvegicus,10116.0,,,50597
12436,Blood,8631,,A,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,,Rattus norvegicus,10116.0,,,50597
12437,,10263,,A,,Maximum biodistribution (Bmax) was determined.,,,,,,,22224
12438,,12364,,A,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,,,Mus musculus,10090.0,,,50594
12439,,12364,,A,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,,,Mus musculus,10090.0,,,50594
12440,,12364,,A,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,,,Mus musculus,10090.0,,,50594
12441,,12364,,A,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,,,Mus musculus,10090.0,,,50594
12442,,14793,,A,,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,,,,,,,22224
12443,,14793,,A,,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,,,,,,,22224
12444,,14793,,A,,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,,,,,,,22224
12445,,14793,,A,,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,,,,,,,22224
12446,,14793,,A,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,,,,,,,22224
12447,,14793,,A,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,,,,,,,22224
12448,,14793,,A,,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,,,,,,,22224
12449,,14793,,A,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,,,,,,,22224
12450,,14793,,A,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,,,,,,,22224
12451,,14793,,A,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,,,,,,,22224
12452,,9196,,A,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,,,,,22224
12453,,9196,,A,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,,,,,,22224
12454,,9196,,A,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,,,,,,22224
12455,Blood,8374,,A,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12456,Blood,8374,,A,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,,,Rattus norvegicus,10116.0,,,50597
12457,Blood,8374,,A,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,,,Rattus norvegicus,10116.0,,,50597
12458,Blood,8374,,A,,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",,,Rattus norvegicus,10116.0,,,50597
12459,Blood,8374,,A,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,,,Rattus norvegicus,10116.0,,,50597
12460,Blood,8374,,A,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12461,Blood,8374,,A,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,,Rattus norvegicus,10116.0,,,50597
12462,Blood,8374,,A,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,,,Rattus norvegicus,10116.0,,,50597
12463,Blood,8374,,A,,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12464,Blood,8374,,A,,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12465,Blood,8374,,A,,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12466,Blood,8374,,A,,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12467,Blood,8374,,A,,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12468,Blood,8374,,A,,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12469,Blood,8374,,A,,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12470,Blood,8374,,A,,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12471,Blood,8374,,A,,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12472,Blood,8374,,A,,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12473,Blood,8374,,A,,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,,,Rattus norvegicus,10116.0,,,50597
12474,Blood,8374,,A,,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,,Rattus norvegicus,10116.0,,,50597
12475,Blood,8374,,A,,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12476,Blood,8374,,A,,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12477,Blood,8374,,A,,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12478,Blood,8374,,A,,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12479,Blood,8374,,A,,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12480,Blood,8374,,A,,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12481,Blood,8374,,A,,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12482,Blood,8374,,A,,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12483,Blood,8374,,A,,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,,,Rattus norvegicus,10116.0,,,50597
12484,Blood,8374,,A,,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,,Rattus norvegicus,10116.0,,,50597
12485,Blood,8374,,A,,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,,,Rattus norvegicus,10116.0,,,50597
12486,Blood,8374,,A,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,,Rattus norvegicus,10116.0,,,50597
12487,Blood,8374,,A,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12488,,9196,,A,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,,,,,22224
12489,,9196,,A,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,,,,,22224
12490,,9196,,A,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,,,,,,22224
12491,,9196,,A,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,,,,,22224
12492,,9196,,A,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,,,,,,22224
12493,,9196,,A,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,,,,,,22224
12494,,9196,,A,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,,,,,22224
12495,,9196,,A,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,,,,,22224
12496,,12023,,A,,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,,,Canis lupus familiaris,9615.0,,,50588
12497,,12023,,A,,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,,,Rattus norvegicus,10116.0,,,50597
12498,,12023,,A,,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,,,Macaca fascicularis,9541.0,,,100710
12499,,10580,,P,,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,,,,,,,22224
12500,,10580,,P,,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,,,,,,,22224
12501,,16032,,A,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,,,,,,,22224
12502,Urine,16032,,A,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,,,,,,,22224
12503,Blood,8594,,A,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12504,Blood,8594,,A,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12505,Blood,8594,,A,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12506,Blood,8594,,A,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12507,Blood,8594,,A,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12508,Blood,8594,,A,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12509,Blood,8594,,A,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12510,Blood,8594,,A,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12511,Blood,8594,,A,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12512,Blood,8594,,A,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12513,Heart,8594,,A,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12514,Heart,8594,,A,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12515,Heart,8594,,A,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12516,Heart,8594,,A,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12517,Heart,8594,,A,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12518,Heart,8594,,A,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12519,Heart,8594,,A,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12520,Heart,8594,,A,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12521,Heart,8594,,A,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12522,Heart,8594,,A,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12523,Heart,8594,,A,,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",,,Rattus norvegicus,10116.0,,,50597
12524,Kidney,8594,,A,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12525,Kidney,8594,,A,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12526,Kidney,8594,,A,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12527,Kidney,8594,,A,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12528,Kidney,8594,,A,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12529,Kidney,8594,,A,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12530,Kidney,8594,,A,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12531,Kidney,8594,,A,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12532,Kidney,8594,,A,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12533,Kidney,8594,,A,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12534,Liver,8594,,A,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12535,Liver,8594,,A,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12536,Liver,8594,,A,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12537,,7653,,A,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),,,,,,,22224
12538,,7653,,A,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),,,,,,,22224
12539,,7653,,A,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,,,,,,,22224
12540,,7653,,A,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,,,,,,,22224
12541,,9104,,A,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",,,Rattus norvegicus,10116.0,,,50597
12542,,9104,,A,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",,,Rattus norvegicus,10116.0,,,50597
12543,,9104,,A,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",,,Rattus norvegicus,10116.0,,,50597
12544,,9104,,A,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",,,Rattus norvegicus,10116.0,,,50597
12545,,9104,,A,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",,,Rattus norvegicus,10116.0,,,50597
12546,,9104,,A,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",,,Rattus norvegicus,10116.0,,,50597
12547,,9104,,A,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",,,Rattus norvegicus,10116.0,,,50597
12548,,9104,,A,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",,,Rattus norvegicus,10116.0,,,50597
12549,,12902,,A,,Free level in rat plasma,,,Rattus norvegicus,10116.0,,,50597
12550,,6614,,A,,Level reaching in blood plasma of rat or human was determined,,,,,,,22224
12551,,9663,,A,,Log (Cbrain/Cblood) in rats,,,Rattus norvegicus,10116.0,,,50597
12552,,17658,,A,,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,,,,,,,22224
12553,,17658,,A,,Mean percentage of compound transport through membrane; expressed as membrane transport,,,,,,,22224
12554,,14314,,A,,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,,,,,,,22224
12555,,7385,,A,,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,,,,,,,22224
12556,,7385,,A,,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",,,,,,,22224
12557,,7385,,A,,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,,,,,,,22224
12558,,1329,,A,,Net water uptake by a carrier mediated transport (%cm) mechanism,,,,,,,22224
12559,,12187,,A,,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,,Simiiformes,314293.0,,,22224
12560,,12187,,A,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,,Mustela putorius furo,9669.0,,,50506
12561,,12187,,A,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,,Mustela putorius furo,9669.0,,,50506
12562,,12187,,A,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,,Simiiformes,314293.0,,,22224
12563,,12187,,A,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",,,Simiiformes,314293.0,,,22224
12564,,12187,,A,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,,Rattus norvegicus,10116.0,,,50597
12565,,12187,,A,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,,Rattus norvegicus,10116.0,,,50597
12566,Plasma,9278,,A,,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",,,Rattus norvegicus,10116.0,,,50597
12567,Plasma,9278,,A,,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,,Rattus norvegicus,10116.0,,,50597
12568,Plasma,9278,,A,,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",,,Macaca fascicularis,9541.0,,,100710
12569,Plasma,9278,,A,,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",,,Homo sapiens,9606.0,,,50587
12570,Plasma,9278,,A,,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",,,Rattus norvegicus,10116.0,,,50597
12571,Plasma,9278,,A,,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,,Rattus norvegicus,10116.0,,,50597
12572,Plasma,9278,,A,,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,,Rattus norvegicus,10116.0,,,50597
12573,,12186,,A,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,,Macaca fascicularis,9541.0,,,100710
12574,,12186,,A,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,,Macaca fascicularis,9541.0,,,100710
12575,,12186,,A,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,,,,,,22224
12576,,12041,,A,,% metabolized in monkey S-9 after 2 hours (10 ug/mL),,,Simiiformes,314293.0,,,22224
12577,,12041,,A,,% metabolized in monkey S-9 after 2 hours (1 ug/ml),,,Simiiformes,314293.0,,,22224
12578,,12041,,A,,% metabolized in monkey S-9 after 2 hours (10 ug/ml),,,Simiiformes,314293.0,,,22224
12579,,6737,,A,,Permeability in Caco-2 assay at 10E-6,,,Homo sapiens,9606.0,,,50587
12580,Brain,13758,,A,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,,,,,,22224
12581,Brain,13758,,A,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,,,,,,22224
12582,,5676,,A,,Plasma protein binding was determined,,,,,,,22224
12583,,14793,,A,,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,,,,,,,22224
12584,,14793,,A,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,,,,,,,22224
12585,,14793,,A,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,,,,,,,22224
12586,,14793,,A,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,,,,,,,22224
12587,,14793,,A,,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,,,,,,,22224
12588,,14793,,A,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,,,,,,,22224
12589,,14793,,A,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,,,,,,,22224
12590,,14793,,A,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,,,,,,,22224
12591,,14793,,A,,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,,,,,,,22224
12592,,14793,,A,,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,,,,,,,22224
12593,,14000,,A,,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,,,,,,,22224
12594,,5948,,A,,Partition coefficient (logP),,,,,,,22224
12595,,13824,,P,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,,,,,,22229
12596,,10778,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12597,,17237,,A,,C max in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
12598,,17237,,A,,C max in guinea pig,In vivo,,Cavia porcellus,10141.0,,,50512
12599,,2809,,A,,C max value was evaluated,In vivo,,,,,,22224
12600,,11954,,A,,Cmax value after oral dose of 0.1 mg//kg,In vivo,,,,,,22224
12601,,11954,,A,,Cmax value after oral dose of 0.3 mg/kg,In vivo,,,,,,22224
12602,,11954,,A,,Cmax value after oral dose of 1 mg/kg,In vivo,,,,,,22224
12603,,11954,,A,,Cmax value after oral dose of 10 mg/kg,In vivo,,,,,,22224
12604,,11954,,A,,Cmax value after oral dose of 23.4 mg/kg,In vivo,,,,,,22224
12605,,11954,,A,,Cmax value after oral dose of 3 mg/kg,In vivo,,,,,,22224
12606,,11954,,A,,Cmax value after oral dose of 3.87 mg/kg,In vivo,,,,,,22224
12607,,12768,,A,,Cmax value in female Beagle dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
12608,,12768,,A,,Cmax value in male rats,In vivo,,Rattus norvegicus,10116.0,,,50597
12609,Plasma,12780,,A,,Cmax value in rat plasma when administered 20 mg/kg perorally,In vivo,,Rattus norvegicus,10116.0,,,50597
12610,Plasma,15592,,A,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,In vivo,,Canis lupus familiaris,9615.0,,,50588
12611,Plasma,15592,,A,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,In vivo,,Canis lupus familiaris,9615.0,,,50588
12612,,17025,,A,,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,,,Canis lupus familiaris,9615.0,,,50588
12613,,17025,,A,,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,,,Simiiformes,314293.0,,,22224
12614,,17025,,A,,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,,,Oryctolagus cuniculus,9986.0,,,50592
12615,,17025,,A,,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,,,Rattus norvegicus,10116.0,,,50597
12616,Plasma,4236,,A,,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,,,Macaca mulatta,9544.0,,,50797
12617,,15791,,A,,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,,,Rattus norvegicus,10116.0,,,50597
12618,,11149,,A,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,,,,,,,22224
12619,,15592,,A,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,,Canis lupus familiaris,9615.0,,,50588
12620,,15778,,A,,cytotoxicity against HIV protease enzyme.,,,Human immunodeficiency virus,12721.0,,,50677
12621,,12745,,A,,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,,,Mus musculus,10090.0,,,50594
12622,,12745,,A,,Apparent clearance in mice after oral administration of 100 mg/kg of dose,,,Mus musculus,10090.0,,,50594
12623,Plasma,13941,,A,,The plasma clearance in dog.,In vivo,,Canis lupus familiaris,9615.0,,,50588
12624,Plasma,13941,,A,,The plasma clearance in rat.,In vivo,,Rattus norvegicus,10116.0,,,50597
12625,Plasma,16449,,A,,Clearance from plasma in male Sprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
12626,Plasma,16449,,A,,Clearance from plasma in male cynomolgus monkeys,In vivo,,Macaca fascicularis,9541.0,,,100710
12627,Plasma,14224,,A,,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",In vivo,,Canis lupus familiaris,9615.0,,,50588
12628,Plasma,14224,,A,,Clearance of compound in dog plasma,In vivo,,Canis lupus familiaris,9615.0,,,50588
12629,Plasma,14224,,A,,Clearance of compound in human plasma,In vivo,,Homo sapiens,9606.0,,,50587
12630,,14317,,A,,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,In vivo,,Canis lupus familiaris,9615.0,,,50588
12631,,14317,,A,,Clearance of compound when administered intravenously as an individual dose to a single dog.,In vivo,,Canis lupus familiaris,9615.0,,,50588
12632,Plasma,14224,,A,,"Clearance (10 mg/kg, intravenously) in dog plasma",In vivo,,Canis lupus familiaris,9615.0,,,50588
12633,,17237,,A,,Clearance value in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
12634,,17237,,A,,Clearance value in guinea pig,In vivo,,Cavia porcellus,10141.0,,,50512
12635,,14187,,A,,Clearance values in rats after iv administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
12636,Plasma,4806,,A,,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,In vivo,,,,,,22224
12637,,15025,,A,,In vivo clearance (5 mg/kg) was determined in rabbits,In vivo,,Oryctolagus cuniculus,9986.0,,,50592
12638,,13197,,A,,Plasma Clearance rate was determined for the compound in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
12639,,13197,,A,,Plasma Clearance rate was determined for the compound in squirrel monkeys,In vivo,,Saimiri,9520.0,,,22224
12640,,13960,,A,,Plasma clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
12641,,17820,,A,,Plasma clearance of the compound,In vivo,,,,,,22224
12642,,14706,,A,,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,In vivo,,Cavia porcellus,10141.0,,,50512
12643,,14706,,A,,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,In vivo,,Cavia porcellus,10141.0,,,50512
12644,,6504,,A,,Plasma clearance was determined,In vivo,,,,,,22224
12645,,14925,,A,,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,In vivo,,Canis lupus familiaris,9615.0,,,50588
12646,,13197,,A,,Plasma clearance rate was determined for the compound in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
12647,,13197,,A,,Plasma clearance rate was determined for the compound in squirrel monkeys,In vivo,,Saimiri,9520.0,,,22224
12648,,3437,,A,,Slow clearance (CL) was determined,In vivo,,,,,,22224
12649,,9196,,A,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,,,,,,22224
12650,,9196,,A,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,,,,,,,22224
12651,,9196,,A,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,,,,,,22224
12652,,9196,,A,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,,,,,,22224
12653,,9196,,A,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,,,,,,22224
12654,,9196,,A,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,,,,,,22224
12655,,9196,,A,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,,,,,,22224
12656,,9196,,A,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,,,,,22224
12657,,9196,,A,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,,,,,22224
12658,,9196,,A,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,,,,,22224
12659,,9196,,A,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,,,,,,22224
12660,,9196,,A,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,,,,,22224
12661,,9196,,A,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,,,,,,22224
12662,,9196,,A,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,,,,,22224
12663,,9196,,A,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,,,,,,22224
12664,,9196,,A,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,,,,,22224
12665,,9196,,A,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,,,,,,22224
12666,,9196,,A,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,,,,,,22224
12667,,9196,,A,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,,,,,22224
12668,,9196,,A,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,,,,,,22224
12669,,9196,,A,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,,,,,,22224
12670,,9196,,A,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,,,,,,22224
12671,Blood,8374,,A,,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12672,Blood,8374,,A,,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,Rattus norvegicus,10116.0,,,50597
12673,,13477,,A,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,,,Rattus norvegicus,10116.0,,,50597
12674,,13477,,A,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,,,Rattus norvegicus,10116.0,,,50597
12675,,13477,,A,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,,,Rattus norvegicus,10116.0,,,50597
12676,Brain,10009,,A,,Distribution of compound in mice brain was measured after 1 hr,,,Mus musculus,10090.0,,,50594
12677,Brain,10009,,A,,Distribution of compound in mice brain was measured after 24 hr r,,,Mus musculus,10090.0,,,50594
12678,Brain,10009,,A,,Distribution of compound in mice brain was measured after 2 hr,,,Mus musculus,10090.0,,,50594
12679,Brain,10009,,A,,Distribution of compound in mice brain was measured after 3 hr,,,Mus musculus,10090.0,,,50594
12680,Brain,10009,,A,,Distribution of compound in mice brain was measured after 6 hr,,,Mus musculus,10090.0,,,50594
12681,,10009,,A,,Distribution of compound in mice liver was measured after 1 hr,,,Mus musculus,10090.0,,,50594
12682,,10009,,A,,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,,,Mus musculus,10090.0,,,50594
12683,,10009,,A,,Distribution of compound in mice liver was measured after 2 hr,,,Mus musculus,10090.0,,,50594
12684,,10009,,A,,Distribution of compound in mice liver was measured after 3 hr,,,Mus musculus,10090.0,,,50594
12685,,10009,,A,,Distribution of compound in mice liver was measured after 6 hr,,,Mus musculus,10090.0,,,50594
12686,Adrenal medulla,8170,,A,,Distribution in dog adrenal medulla 30 min after administration.,,,Canis lupus familiaris,9615.0,,,50588
12687,Adrenal medulla,8170,,A,,Distribution in dog adrenal medulla 72 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12688,,8170,,A,,Distribution in female dog Ovary 24 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12689,,8170,,A,,Distribution in female dog Ovary 72 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12690,,8170,,A,,Distribution in female dog adipose 24 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12691,,8170,,A,,Distribution in female dog adipose 72 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12692,Adrenal cortex,8170,,A,,Distribution in female dog adrenal cortex 72 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12693,Adrenal cortex,8170,,A,,Distribution in female dog adrenal cortex 72 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12694,Liver,8594,,A,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12695,Liver,8594,,A,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12696,Liver,8594,,A,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12697,Liver,8594,,A,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12698,Liver,8594,,A,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12699,Liver,8594,,A,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12700,Lung,8594,,A,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12701,Lung,8594,,A,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12702,Lung,8594,,A,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12703,Lung,8594,,A,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12704,Lung,8594,,A,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12705,Lung,8594,,A,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12706,Lung,8594,,A,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12707,Lung,8594,,A,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12708,Lung,8594,,A,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12709,Lung,8594,,A,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12710,,8594,,A,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12711,,8594,,A,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12712,,8594,,A,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12713,,8594,,A,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12714,,8594,,A,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12715,,8594,,A,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12716,,8594,,A,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12717,,8594,,A,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12718,,8594,,A,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12719,,8594,,A,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12720,Thyroid gland,8594,,A,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12721,Thyroid gland,8594,,A,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12722,Thyroid gland,8594,,A,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12723,Thyroid gland,8594,,A,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12724,Thyroid gland,8594,,A,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12725,Thyroid gland,8594,,A,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12726,Thyroid gland,8594,,A,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12727,Thyroid gland,8594,,A,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12728,Thyroid gland,8594,,A,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12729,,8594,,A,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12730,,8594,,A,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12731,,8594,,A,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,Rattus norvegicus,10116.0,,,50597
12732,,8594,,A,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12733,,12904,,A,,Rate of acetate production by the compound was determined,,,,,,,22224
12734,,12904,,A,,Rate of acetate production by the compound was determined; Not determined,,,,,,,22224
12735,,3730,,A,,Rate of hydrolysis of nitrocefin by compound was evaluated in water,,,,,,,22224
12736,,3627,,A,,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,,,,,,,22224
12737,,13799,,A,,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,,Oryctolagus cuniculus,9986.0,,,50592
12738,Plasma,13799,,A,,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,,Oryctolagus cuniculus,9986.0,,,50592
12739,,13799,,A,,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,,Mus musculus,10090.0,,,50594
12740,,13799,,A,,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,,Rattus norvegicus,10116.0,,,50597
12741,Plasma,13799,,A,,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,,Rattus norvegicus,10116.0,,,50597
12742,Plasma,13799,,A,,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,,Rattus norvegicus,10116.0,,,50597
12743,,6629,,P,,Solubility after at a pH 1.2,,,,,,,22229
12744,,6629,,P,,Solubility after at pH 1.2,,,,,,,22229
12745,,6629,,P,,Solubility after injection of water,,,,,,,22229
12746,,14000,,A,,Statistical significance of IC 50 values; Expressed as R value,,,,,,,22224
12747,,8267,,A,,Systemic availability with respect to methyldopa was determined,,,,,,,22224
12748,,13799,,A,,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,,,Rattus norvegicus,10116.0,,,50597
12749,Plasma,13799,,A,,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,,,Rattus norvegicus,10116.0,,,50597
12750,Feces,7132,,A,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",,,Oryctolagus cuniculus,9986.0,,,50592
12751,Feces,7132,,A,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",,,Oryctolagus cuniculus,9986.0,,,50592
12752,Feces,7132,,A,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",,,Oryctolagus cuniculus,9986.0,,,50592
12753,Urine,7132,,A,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",,,Oryctolagus cuniculus,9986.0,,,50592
12754,Urine,7132,,A,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",,,Oryctolagus cuniculus,9986.0,,,50592
12755,Urine,7132,,A,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",,,Oryctolagus cuniculus,9986.0,,,50592
12756,Urine,7132,,A,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",,,Oryctolagus cuniculus,9986.0,,,50592
12757,Urine,7132,,A,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",,,Oryctolagus cuniculus,9986.0,,,50592
12758,Kidney,7132,,A,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",,,Oryctolagus cuniculus,9986.0,,,50592
12759,Feces,7132,,A,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",,,Oryctolagus cuniculus,9986.0,,,50592
12760,Feces,7132,,A,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",,,Oryctolagus cuniculus,9986.0,,,50592
12761,Feces,7132,,A,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",,,Oryctolagus cuniculus,9986.0,,,50592
12762,Urine,7132,,A,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",,,Oryctolagus cuniculus,9986.0,,,50592
12763,Feces,7132,,A,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",,,Oryctolagus cuniculus,9986.0,,,50592
12764,Feces,7132,,A,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",,,Oryctolagus cuniculus,9986.0,,,50592
12765,Urine,7132,,A,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",,,Oryctolagus cuniculus,9986.0,,,50592
12766,Urine,7132,,A,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",,,Oryctolagus cuniculus,9986.0,,,50592
12767,Urine,7132,,A,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",,,Oryctolagus cuniculus,9986.0,,,50592
12768,Urine,7132,,A,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",,,Oryctolagus cuniculus,9986.0,,,50592
12769,Urine,7132,,A,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",,,Oryctolagus cuniculus,9986.0,,,50592
12770,Kidney,7132,,A,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",,,Oryctolagus cuniculus,9986.0,,,50592
12771,Feces,7132,,A,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",,,Oryctolagus cuniculus,9986.0,,,50592
12772,Feces,7132,,A,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",,,Oryctolagus cuniculus,9986.0,,,50592
12773,Feces,7132,,A,,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,,,Oryctolagus cuniculus,9986.0,,,50592
12774,,7132,,A,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,,,Oryctolagus cuniculus,9986.0,,,50592
12775,,7132,,A,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,,,Oryctolagus cuniculus,9986.0,,,50592
12776,,13317,,A,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,In vivo,,Canis lupus familiaris,9615.0,,,50588
12777,,15341,,A,,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,In vivo,,Canis lupus familiaris,9615.0,,,50588
12778,,15341,,A,,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
12779,,15341,,A,,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
12780,,15341,,A,,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
12781,esophageal tunica muscularis mucosae,12801,,A,,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,In vitro,,Rattus norvegicus,10116.0,,,50597
12782,esophageal tunica muscularis mucosae,12801,,A,,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,In vitro,,Rattus norvegicus,10116.0,,,50597
12783,Plasma,14856,,A,,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,In vivo,,Rattus norvegicus,10116.0,,,50597
12784,,14062,,A,,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
12785,,14062,,A,,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
12786,,14062,,A,,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
12787,,14062,,A,,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
12788,Plasma,14346,,A,,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
12789,Plasma,14346,,A,,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
12790,Plasma,14346,,A,,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
12791,Plasma,14346,,A,,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
12792,Plasma,14346,,A,,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
12793,Plasma,14346,,A,,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
12794,Plasma,14346,,A,,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
12795,Plasma,15711,,A,,plasma clearance in human,In vivo,,Homo sapiens,9606.0,,,50587
12796,,14886,,A,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
12797,,14886,,A,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
12798,,14886,,A,,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
12799,,4115,,P,,1-Octanol/water partition coefficient measured at 7.4,,,,,,,22229
12800,,13733,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12801,,12102,,A,,Partition coefficient (logP),,,,,,,22224
12802,,12676,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12803,,13733,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12804,,13740,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12805,,12766,,P,,Calculated partition coefficient (clogP) (relative to BAY K 8644),,,,,,,22229
12806,,2764,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12807,,12355,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12808,,11314,,P,,Calculated partition coefficient of the compound,,,,,,,22229
12809,,12706,,A,,Partition coefficient (logP),,,,,,,22224
12810,,12645,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12811,,13668,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12812,,12819,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12813,,13668,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12814,,13017,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12815,,2448,,A,,Partition coefficient of the compound,,,,,,,22224
12816,,11526,,A,,Partition coefficient of the compound,,,,,,,22224
12817,,12426,,A,,Partition coefficient of compound was determined,,,,,,,22224
12818,,2448,,A,,Partition coefficient was determined,,,,,,,22224
12819,,12001,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12820,,12426,,P,,partition coefficient of compound was determined,,,,,,,22229
12821,,13204,,A,,The total body administered intravenously in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
12822,,13204,,A,,The total body administered intravenously in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
12823,,13889,,A,,Time taken for the administration to female NIH mice weighing 25-30 g.,,,Mus musculus,10090.0,,,50594
12824,,13889,,A,,Time taken for the administration,,,,,,,22224
12825,,17025,,A,,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,In vivo,,Canis lupus familiaris,9615.0,,,50588
12826,,17025,,A,,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,In vivo,,Simiiformes,314293.0,,,22224
12827,,17025,,A,,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,In vivo,,Oryctolagus cuniculus,9986.0,,,50592
12828,,17025,,A,,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,In vivo,,Rattus norvegicus,10116.0,,,50597
12829,,15067,,A,,Plasma clearance for the compound was determined.,,,,,,,22224
12830,,3091,,P,,CLog P value of the compound,,,,,,,22224
12831,,15592,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12832,,14738,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12833,,14738,,P,,ClogP value of the compound; nd ='no data',,,,,,,22224
12834,,14738,,P,,ClogP value of the compound; nd ='not determined',,,,,,,22224
12835,,6076,,P,,CLog P was determined,,,,,,,22224
12836,,17840,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12837,,13589,,A,,CLogP was calculated,,,,,,,22224
12838,,17655,,A,,CLogP value was determined,,,,,,,22224
12839,,5867,,A,,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,,,,,,,22224
12840,,5867,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12841,,10783,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12842,,14849,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12843,Adrenal medulla,8170,,A,,Distribution in female dog adrenal medulla 24 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12844,Adrenal medulla,8170,,A,,Distribution in female dog adrenal medulla 72 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12845,,8170,,A,,Distribution in female dog bile 24 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12846,,8170,,A,,Distribution in female dog bile 72 hr after administration.,,,Canis lupus familiaris,9615.0,,,50588
12847,,8170,,A,,Distribution in female dog blood 24 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12848,,8170,,A,,Distribution in female dog blood 72 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12849,,8170,,A,,Distribution in female dog heart 24 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12850,,8170,,A,,Distribution in female dog heart 72 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12851,,8170,,A,,Distribution in female dog kidney 24 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12852,,8170,,A,,Distribution in female dog kidney 72 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12853,Intestine,8170,,A,,Distribution in female dog large intestine 24 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12854,Intestine,8170,,A,,Distribution in female dog large intestine 72 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12855,,8170,,A,,Distribution in female dog liver 24 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12856,,8170,,A,,Distribution in female dog liver 72 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12857,,8170,,A,,Distribution in female dog lung 24 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12858,,8170,,A,,Distribution in female dog lung 72 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12859,Muscle tissue,8170,,A,,Distribution in female dog muscle 24 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12860,Muscle tissue,8170,,A,,Distribution in female dog muscle 72 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12861,,8170,,A,,Distribution in female dog pancreas 24 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12862,,8170,,A,,Distribution in female dog pancreas 72 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12863,Intestine,8170,,A,,Distribution in female dog small intestine 24 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12864,Intestine,8170,,A,,Distribution in female dog small intestine 72 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12865,Spleen,8170,,A,,Distribution in female dog spleen 24 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12866,Spleen,8170,,A,,Distribution in female dog spleen 72 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12867,Stomach,8170,,A,,Distribution in female dog stomach 24 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12868,Stomach,8170,,A,,Distribution in female dog stomach 72 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12869,Thyroid gland,8170,,A,,Distribution in female dog thyroid 24 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12870,Thyroid gland,8170,,A,,Distribution in female dog thyroid 72 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12871,Urine,8170,,A,,Distribution in female dog urine 24 hours after administration.,,,Canis lupus familiaris,9615.0,,,50588
12872,Urine,8170,,A,,Distribution in female dog urine 72 hr after administration.,,,Canis lupus familiaris,9615.0,,,50588
12873,Plasma,14283,,A,,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,,,,,,,22224
12874,,5623,,A,,Plasma concentration at 7 hr after intravenous dosing,,,,,,,22224
12875,,13477,,A,,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,,,Rattus norvegicus,10116.0,,,50597
12876,,13477,,A,,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,,,Rattus norvegicus,10116.0,,,50597
12877,,13477,,A,,Plasma concentration of 3 mg/kg iv after 1 hr in rats,,,Rattus norvegicus,10116.0,,,50597
12878,,13477,,A,,Plasma concentration of 3 mg/kg iv after 2 hr in rats,,,Rattus norvegicus,10116.0,,,50597
12879,,13477,,A,,Plasma concentration of 3 mg/kg iv after 4 hr in rats,,,Rattus norvegicus,10116.0,,,50597
12880,,13477,,A,,Plasma concentration of 3 mg/kg iv after 6 hr in rats,,,Rattus norvegicus,10116.0,,,50597
12881,,13477,,A,,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,,,Rattus norvegicus,10116.0,,,50597
12882,,13477,,A,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,,,Rattus norvegicus,10116.0,,,50597
12883,,13477,,A,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,,,Rattus norvegicus,10116.0,,,50597
12884,,13477,,A,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,,,Rattus norvegicus,10116.0,,,50597
12885,,13477,,A,,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,,,Rattus norvegicus,10116.0,,,50597
12886,,13477,,A,,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,,,Rattus norvegicus,10116.0,,,50597
12887,,13477,,A,,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,,,Rattus norvegicus,10116.0,,,50597
12888,,13477,,A,,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,,,Rattus norvegicus,10116.0,,,50597
12889,,13477,,A,,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,,,Rattus norvegicus,10116.0,,,50597
12890,,12553,,A,,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,,,,,,,22224
12891,Plasma,14548,,A,,The concentration in plasmat; Not determined,,,,,,,22224
12892,,14393,,A,,Tissue level at 10 mg/kg/po in wistar rats in blood,,,Rattus norvegicus,10116.0,,,50597
12893,,14393,,A,,Tissue level at 10 mg/kg/po in wistar rats in brown fat,,,Rattus norvegicus,10116.0,,,50597
12894,,14393,,A,,Tissue level at 10 mg/kg/po in wistar rats in heart,,,Rattus norvegicus,10116.0,,,50597
12895,Liver,14393,,A,,Tissue level at 10 mg/kg/po in wistar rats in liver,,,Rattus norvegicus,10116.0,,,50597
12896,,14393,,A,,Tissue level at 10 mg/kg/po in wistar rats in plasma,,,Rattus norvegicus,10116.0,,,50597
12897,Muscle tissue,14393,,A,,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,,,Rattus norvegicus,10116.0,,,50597
12898,,14393,,A,,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,,,Rattus norvegicus,10116.0,,,50597
12899,,1629,,A,,Water solubility at 37 degree C.,,,,,,,22224
12900,,8194,,P,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,,,,,,22229
12901,,8194,,P,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,,,,,,22229
12902,Blood,8594,,A,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12903,Blood,8594,,A,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12904,Blood,8594,,A,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12905,Blood,8594,,A,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12906,Blood,8594,,A,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12907,Heart,8594,,A,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12908,Heart,8594,,A,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12909,Heart,8594,,A,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12910,Heart,8594,,A,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12911,Heart,8594,,A,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12912,Kidney,8594,,A,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12913,Kidney,8594,,A,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12914,Kidney,8594,,A,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12915,Kidney,8594,,A,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12916,Kidney,8594,,A,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12917,Liver,8594,,A,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12918,Liver,8594,,A,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12919,Liver,8594,,A,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12920,Liver,8594,,A,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12921,Liver,8594,,A,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12922,Lung,8594,,A,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12923,Lung,8594,,A,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12924,Lung,8594,,A,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12925,Lung,8594,,A,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12926,Lung,8594,,A,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12927,Thyroid gland,8594,,A,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12928,Thyroid gland,8594,,A,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12929,Thyroid gland,8594,,A,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12930,Thyroid gland,8594,,A,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12931,Thyroid gland,8594,,A,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12932,,8594,,A,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12933,,8594,,A,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12934,,8594,,A,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12935,,8594,,A,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12936,,8594,,A,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,,,Rattus norvegicus,10116.0,,,50597
12937,,8151,,A,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,,,,,,,22224
12938,,8151,,A,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,,,,,22224
12939,,7132,,A,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,,,Oryctolagus cuniculus,9986.0,,,50592
12940,,7132,,A,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,,,Oryctolagus cuniculus,9986.0,,,50592
12941,,5797,,A,,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),,,,,,,22224
12942,,7849,,A,,Alkylating activity was determined,,,,,,,22224
12943,,14220,,A,,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),,,,,,Microsomes,22224
12944,,8650,,A,,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",,,Oryctolagus cuniculus,9986.0,,,50592
12945,,8650,,A,,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",,,Oryctolagus cuniculus,9986.0,,,50592
12946,,8650,,A,,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",,,Oryctolagus cuniculus,9986.0,,,50592
12947,,8650,,A,,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",,,Oryctolagus cuniculus,9986.0,,,50592
12948,,8650,,A,,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",,,Oryctolagus cuniculus,9986.0,,,50592
12949,,7116,,A,,Compound was tested for antidiuretic activity in rats,,,Rattus norvegicus,10116.0,,,50597
12950,,14131,,A,,Compound was tested for inactivation kinetic values,,,,,,,22224
12951,,7415,,A,,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,In vivo,,,,,,22224
12952,,13178,,A,,Dissociation rate calculated from the first-order equation using the t1/2 value,,,,,,,22224
12953,,8815,,P,,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,,,,,,,22229
12954,,1450,,P,,Aqueous solubility was measured,,,,,,,22229
12955,,1450,,P,,Aqueous solubility was measured at a pH 4,,,,,,,22229
12956,,1450,,P,,Aqueous solubility (pH 7),,,,,,,22229
12957,,1450,,P,,Aqueous solubility was measured at a pH 9,,,,,,,22229
12958,,12711,,A,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",,,,,,,22224
12959,,12711,,A,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,,,,,,22224
12960,,12711,,A,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,,,,,,22224
12961,,15032,,P,,Aqueous solubility of the compound,,,,,,,22229
12962,,9964,,P,,Aqueous solubility at 37 degree Celsius at pH 7.38,,,,,,,22229
12963,,14962,,P,,Aqueous solubility in pH 7.4 phosphate buffer,,,,,,,22229
12964,,12487,,A,,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,,,Canis lupus familiaris,9615.0,,,50588
12965,,12487,,A,,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,,,Canis lupus familiaris,9615.0,,,50588
12966,,10026,,A,,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,,,Homo sapiens,9606.0,,,50587
12967,,10026,,A,,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,,,Homo sapiens,9606.0,,,50587
12968,,10026,,A,,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,,,Homo sapiens,9606.0,,,50587
12969,,10026,,A,,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,,,Homo sapiens,9606.0,,,50587
12970,,10026,,A,,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,,,Homo sapiens,9606.0,,,50587
12971,,10026,,A,,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,,,,,,,22224
12972,,7415,,A,,Compound was evaluated for the average bile flow rat in rats,,,Rattus norvegicus,10116.0,,,50597
12973,,17025,,A,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,,Oryctolagus cuniculus,9986.0,,,50592
12974,,17025,,A,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,,Oryctolagus cuniculus,9986.0,,,50592
12975,,10184,,A,,Average half life period was determined,,,,,,,22224
12976,,10184,,A,,Average half life period was determined,,,,,,,22224
12977,,8613,,A,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,,Human herpesvirus 1,10298.0,,,50602
12978,,8613,,A,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,,Human herpesvirus 1,10298.0,,,50602
12979,,8613,,A,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,,,Human herpesvirus 1,10298.0,,,50602
12980,,8613,,A,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,,,Human herpesvirus 1,10298.0,,,50602
12981,,8613,,A,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,,Human herpesvirus 1,10298.0,,,50602
12982,,8613,,A,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,,Human herpesvirus 1,10298.0,,,50602
12983,,8613,,A,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,,,Human herpesvirus 1,10298.0,,,50602
12984,,8613,,A,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,,,Human herpesvirus 1,10298.0,,,50602
12985,,8613,,A,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,,,Human herpesvirus 1,10298.0,,,50602
12986,,6030,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12987,,6147,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12988,,14556,,P,,Calculated partition coefficient (clogP) (MacLogP),,,,,,,22229
12989,,768,,A,,Hydrophilicity was determined,,,,,,,22224
12990,,14452,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12991,,5237,,A,,Increased absorption was determined,,,,,,,22224
12992,,14378,,P,,Lipophilicity value was evaluated,,,,,,,22224
12993,,14418,,P,,Log P value of the compound.,,,,,,,22224
12994,,5249,,A,,Partition coefficient of compound was determined,,,,,,,22224
12995,,14621,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12996,,12542,,P,,Calculated partition coefficient (clogP),,,,,,,22229
12997,,12542,,A,,Partition coefficient was measured by medchem software; Not calculated,,,,,,,22224
12998,,12542,,P,,Partition coefficient was measured by octanol-water using standard shake-flask method,,,,,,,22224
12999,,15462,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13000,,14884,,A,,Partition coefficient (logP),,,,,,,22224
13001,,16526,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13002,,13693,,P,,The Octanol/Water partition coefficient CLogP,,,,,,,22229
13003,,13693,,A,,The pharmacokinetic parameter C Log p was reported,,,,,,,22224
13004,,13779,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13005,,14772,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13006,,14393,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13007,Plasma,14793,,A,,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
13008,Plasma,14793,,A,,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
13009,Plasma,13744,,A,,Compound was administered intravenously in dog to evaluate plasma clearance values,In vivo,,Canis lupus familiaris,9615.0,,,50588
13010,Plasma,13744,,A,,Compound was administered intravenously in monkey to evaluate plasma clearance values,In vivo,,Simiiformes,314293.0,,,22224
13011,Plasma,13744,,A,,Compound was administered intravenously in mouse to evaluate plasma clearance values,In vivo,,Mus musculus,10090.0,,,50594
13012,Plasma,13207,,A,,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
13013,Liver,5669,,A,,Intrinsic clearance in Rhesus liver microsome,In vitro,,Macaca mulatta,9544.0,,Microsomes,50797
13014,Liver,5669,,A,,Intrinsic clearance in dog liver microsome,In vitro,,Canis lupus familiaris,9615.0,,Microsomes,50588
13015,Liver,5669,,A,,Intrinsic clearance in rat liver microsome,In vitro,,Rattus norvegicus,10116.0,,Microsomes,50597
13016,Plasma,4853,,A,,Low plasma clearance was calculated in rhesus monkey,In vivo,,Macaca mulatta,9544.0,,,50797
13017,,16452,,A,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,,Canis lupus familiaris,9615.0,,,50588
13018,,11954,,A,,Plasma clearance after intravenous dose of 0.3 mg/kg,In vivo,,,,,,22224
13019,,11954,,A,,Plasma clearance after intravenous dose of 1 mg/kg,In vivo,,,,,,22224
13020,,11954,,A,,Plasma clearance after intravenous dose of 3 mg/kg,In vivo,,,,,,22224
13021,,11954,,A,,Plasma clearance after intravenous dose of 3.87 mg/kg,In vivo,,,,,,22224
13022,,5669,,A,,Plasma clearance after peroral administration at 10 mpk in Rat,In vivo,,Rattus norvegicus,10116.0,,,50597
13023,,5669,,A,,Plasma clearance after peroral administration at 10 mpk in Rhesus,In vivo,,Macaca mulatta,9544.0,,,50797
13024,,5669,,A,,Plasma clearance after peroral administration at 10 mpk in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
13025,,13662,,A,,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
13026,,8272,,A,,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),,,,,,,22224
13027,,13410,,A,,Critical Micellar concentration was determined,,,,,,,22224
13028,,13410,,A,,Critical Micellar concentration of the compound. was determined,,,,,,,22224
13029,,12628,,A,,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,,,,,,,22224
13030,,9675,,A,,Critical micellar concentration was measured in water by the dye solubilization method,,,,,,,22224
13031,,12628,,B,,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,,,,,,,22224
13032,,12766,,A,,CMR value (relative to BAY K 8644),,,,,,,22224
13033,,7849,,A,,Carbamoylating activity was determined,,,,,,,22224
13034,,12187,,A,,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,,,Simiiformes,314293.0,,,22224
13035,,2040,,A,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,,,,,,,22224
13036,,2040,,A,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,,,,,,,22224
13037,Plasma,14180,,A,,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,In vivo,,Canis lupus familiaris,9615.0,,,50588
13038,Plasma,14180,,A,,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,In vivo,,Rattus norvegicus,10116.0,,,50597
13039,,14474,,A,,"Clearance rate at 0.46 mg/kg, iv, in dogs",In vivo,,Canis lupus familiaris,9615.0,,,50588
13040,,14474,,A,,"Clearance rate at 5.5 mg/kg, iv, in rat",In vivo,,Rattus norvegicus,10116.0,,,50597
13041,,14548,,A,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,In vivo,,Macaca fascicularis,9541.0,,,100710
13042,,14548,,A,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,In vivo,,Macaca fascicularis,9541.0,,,100710
13043,,14548,,A,,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,In vivo,,Canis lupus familiaris,9615.0,,,50588
13044,,14548,,A,,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,In vivo,,Rattus norvegicus,10116.0,,,50597
13045,Liver,6125,,A,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,Ex vivo,,Rattus norvegicus,10116.0,,,50597
13046,,6874,,A,,Tested for the total clearance of the compound,In vivo,,,,,,22224
13047,,15343,,A,,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,In vivo,,Canis lupus familiaris,9615.0,,,50588
13048,,6236,,A,,Total body clearance was determined,In vivo,,,,,,22224
13049,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13050,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13051,,8194,,P,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,,,,,,22229
13052,,8194,,P,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,,,,,,22229
13053,,8194,,P,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,,,,,,,22229
13054,,8194,,P,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,,,,,,22229
13055,,8194,,P,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,,,,,,22229
13056,,8194,,P,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,,,,,,22229
13057,,13273,,A,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),,,Pneumocystis carinii,4754.0,,,50339
13058,,13273,,A,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,,,Pneumocystis carinii,4754.0,,,50339
13059,,13273,,A,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,,,Pneumocystis carinii,4754.0,,,50339
13060,,13273,,A,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,,,Pneumocystis carinii,4754.0,,,50339
13061,,13273,,A,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,,,Pneumocystis carinii,4754.0,,,50339
13062,,13273,,A,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,,,Pneumocystis carinii,4754.0,,,50339
13063,,13273,,A,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),,,Pneumocystis carinii,4754.0,,,50339
13064,,13273,,A,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),,,Pneumocystis carinii,4754.0,,,50339
13065,,13273,,A,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),,,Pneumocystis carinii,4754.0,,,50339
13066,,13273,,A,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),,,Pneumocystis carinii,4754.0,,,50339
13067,,13273,,A,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),,,Pneumocystis carinii,4754.0,,,50339
13068,,13273,,A,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),,,Pneumocystis carinii,4754.0,,,50339
13069,,13118,,A,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,,,,,,,22224
13070,,13118,,A,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,,,,,,,22224
13071,,13118,,A,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,,,,,,,22224
13072,,13118,,A,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,,,,,,,22224
13073,,13118,,A,,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,,,,,,,22224
13074,,13118,,A,,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,,,,,,,22224
13075,,10633,,A,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",,,Rattus norvegicus,10116.0,,,50597
13076,,10633,,A,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",,,Rattus norvegicus,10116.0,,,50597
13077,,10633,,A,,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",,,Rattus norvegicus,10116.0,,,50597
13078,,10633,,A,,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",,,Rattus norvegicus,10116.0,,,50597
13079,,5767,,A,,Cp max following ip administration at 1 mg/kg,,,,,,,22224
13080,Plasma,3302,,A,,Maximum concentration in plasma was reported at 0.5 hour,In vivo,,,,,,22224
13081,Plasma,3302,,A,,Maximum concentration in plasma was reported at 2 hour,In vivo,,,,,,22224
13082,,12467,,A,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,,,Mus musculus,10090.0,,,50594
13083,,11778,,P,,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),,,,,,,22229
13084,,4321,,A,,Steady state concentration was evaluated,,,,,,,22224
13085,,14884,,A,,Partition coefficient (logP),,,,,,,22224
13086,,15234,,A,,Partition coefficient (logD7.4),,,,,,,22224
13087,Liver,14198,,A,,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13088,Bone,14198,,A,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13089,Cerebellum,14198,,A,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13090,,14198,,A,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13091,,14198,,A,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13092,Heart,14198,,A,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13093,Intestine,14198,,A,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13094,,8151,,A,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,,,,,,22224
13095,,8151,,A,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,,,,,22224
13096,Urine,8151,,A,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,,,,,,,22224
13097,Urine,8151,,A,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,,,,,,22224
13098,Urine,8151,,A,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,,,,,,,22224
13099,,8151,,A,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,,,Rattus norvegicus,10116.0,,,50597
13100,,8151,,A,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,Rattus norvegicus,10116.0,,,50597
13101,,8151,,A,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,,Rattus norvegicus,10116.0,,,50597
13102,,8151,,A,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,,Rattus norvegicus,10116.0,,,50597
13103,,8151,,A,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,,,Rattus norvegicus,10116.0,,,50597
13104,,8151,,A,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,,Rattus norvegicus,10116.0,,,50597
13105,,6996,,A,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,,Canis lupus familiaris,9615.0,,,50588
13106,,6996,,A,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,,Canis lupus familiaris,9615.0,,,50588
13107,,6996,,A,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,,Canis lupus familiaris,9615.0,,,50588
13108,,6996,,F,,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
13109,,6996,,A,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,,Canis lupus familiaris,9615.0,,,50588
13110,,6996,,A,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,,,Canis lupus familiaris,9615.0,,,50588
13111,,6996,,A,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,,Canis lupus familiaris,9615.0,,,50588
13112,,6996,,A,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,,Canis lupus familiaris,9615.0,,,50588
13113,,6996,,A,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,,Canis lupus familiaris,9615.0,,,50588
13114,,6996,,A,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,,,Canis lupus familiaris,9615.0,,,50588
13115,,6996,,A,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,,Canis lupus familiaris,9615.0,,,50588
13116,,6996,,A,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,,Canis lupus familiaris,9615.0,,,50588
13117,,6996,,A,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,,Canis lupus familiaris,9615.0,,,50588
13118,,6996,,A,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,,,Canis lupus familiaris,9615.0,,,50588
13119,,6996,,A,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,,,Canis lupus familiaris,9615.0,,,50588
13120,,6996,,A,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,,Canis lupus familiaris,9615.0,,,50588
13121,,6996,,A,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,,Canis lupus familiaris,9615.0,,,50588
13122,,6996,,A,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,,Canis lupus familiaris,9615.0,,,50588
13123,,6996,,B,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",,,,,,,22224
13124,,6996,,A,,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,,Canis lupus familiaris,9615.0,,,50588
13125,,6996,,F,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",,,Rattus norvegicus,10116.0,,,50597
13126,,6996,,B,,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,,,,,,22224
13127,,6996,,A,,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,,Rattus norvegicus,10116.0,,,50597
13128,,6996,,A,,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,,Rattus norvegicus,10116.0,,,50597
13129,,7114,,A,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,,,,,,,22224
13130,,7114,,A,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,,,Rattus norvegicus,10116.0,,,50597
13131,,8613,,A,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,,,Human herpesvirus 1,10298.0,,,50602
13132,,8613,,A,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,,,Human herpesvirus 1,10298.0,,,50602
13133,,8613,,A,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,,,Human herpesvirus 1,10298.0,,,50602
13134,,8613,,A,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,,,Human herpesvirus 1,10298.0,,,50602
13135,,8613,,A,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,,Human herpesvirus 1,10298.0,,,50602
13136,,8613,,A,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,,,Human herpesvirus 1,10298.0,,,50602
13137,,8613,,A,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,,,Human herpesvirus 1,10298.0,,,50602
13138,,8613,,A,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,,,Human herpesvirus 1,10298.0,,,50602
13139,,8613,,A,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,,,Human herpesvirus 1,10298.0,,,50602
13140,,8613,,A,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,,Human herpesvirus 1,10298.0,,,50602
13141,,8613,,A,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,,Human herpesvirus 1,10298.0,,,50602
13142,,8613,,A,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,,Mus musculus,10090.0,,,50594
13143,,11219,,A,,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",,,Mustela putorius furo,9669.0,,,50506
13144,,11219,,A,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,,Mustela putorius furo,9669.0,,,50506
13145,,11219,,A,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,,Mustela putorius furo,9669.0,,,50506
13146,,11219,,A,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,,Mustela putorius furo,9669.0,,,50506
13147,,11219,,A,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,,,Mustela putorius furo,9669.0,,,50506
13148,,11219,,A,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,,Mustela putorius furo,9669.0,,,50506
13149,,11219,,A,,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,,,Mustela putorius furo,9669.0,,,50506
13150,,14837,,A,,Pharmacokinetic parameter :drug bound to plasma was reported,,,,,,,22224
13151,,14837,,A,,compound was evaluated for drug bound in plasma,,,,,,,22224
13152,,15343,,A,,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,,,Rattus norvegicus,10116.0,,,50597
13153,,13761,,A,,Bioavailability,,,Eutheria,9347.0,,,22224
13154,,14810,,A,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,,,Rattus norvegicus,10116.0,,,50597
13155,,14810,,A,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,,,Rattus norvegicus,10116.0,,,50597
13156,,13249,,A,,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,,Canis lupus familiaris,9615.0,,,50588
13157,Bile,9267,,A,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,,,Rattus norvegicus,10116.0,,,50597
13158,Bile,9267,,A,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,,,Rattus norvegicus,10116.0,,,50597
13159,Bile,9267,,A,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,,,Rattus norvegicus,10116.0,,,50597
13160,Bile,9267,,A,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,,,Rattus norvegicus,10116.0,,,50597
13161,Bile,9267,,A,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,,,Rattus norvegicus,10116.0,,,50597
13162,Bile,9267,,A,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,,,Rattus norvegicus,10116.0,,,50597
13163,Serum,15549,,A,,In vitro protein binding in human serum at 5 ug/ml,,,Homo sapiens,9606.0,,,50587
13164,,10929,,A,,Serum protein binding ability was measured,,,,,,,22224
13165,,15444,,A,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,,,,,,22224
13166,,12860,,A,,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,22224
13167,,12170,,A,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,In vivo,,Rattus norvegicus,10116.0,,,50597
13168,,15173,,A,,Absolute oral bioavailability at an iv dose of 14 mg/kg,In vivo,,,,,,22224
13169,,15173,,A,,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,In vivo,,,,,,22224
13170,,15173,,A,,Oral bioavailability (dose 15 mg/kg i.v.),In vivo,,Eutheria,9347.0,,,22224
13171,,15173,,A,,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,In vivo,,,,,,22224
13172,,15173,,A,,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,In vivo,,,,,,22224
13173,,15173,,A,,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,In vivo,,,,,,22224
13174,,15173,,A,,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,In vivo,,,,,,22224
13175,,11767,,A,,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,In vivo,,Canis lupus familiaris,9615.0,,,50588
13176,,11219,,A,,Bioavailability in ferret,In vivo,,Mustela putorius furo,9669.0,,,22224
13177,,12186,,A,,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,In vivo,,Macaca fascicularis,9541.0,,,100710
13178,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13179,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13180,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13181,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13182,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13183,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,,Rattus norvegicus,10116.0,,,50597
13184,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13185,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13186,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13187,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13188,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13189,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13190,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13191,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13192,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13193,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13194,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13195,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13196,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13197,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13198,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13199,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13200,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13201,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13202,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13203,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13204,,11510,,A,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13205,,7199,,A,,Total body clearance was measured at given dose,,,,,,,22224
13206,,7199,,A,,Total body clearance was measured at given dose.,,,,,,,22224
13207,,7095,,A,,Metabolic clearance from the body in rat,,,Rattus norvegicus,10116.0,,,50597
13208,,7095,,A,,Renal clearance from the body,In vivo,,,,,,22224
13209,,7095,,A,,Renal clearance from the body in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
13210,,12528,,A,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
13211,,12528,,A,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
13212,,7095,,A,,Total clearance from the body in rat,,,Rattus norvegicus,10116.0,,,50597
13213,Plasma,14223,,A,,Clearance into cortex from rat plasma or PBS,In vivo,,Rattus norvegicus,10116.0,,,50597
13214,,13569,,A,,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,In vivo,,,,,,22224
13215,,13569,,A,,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,In vivo,,,,,,22224
13216,,13569,,A,,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,In vivo,,,,,,22224
13217,,13569,,A,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,In vivo,,,,,,22224
13218,,13569,,A,,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,In vivo,,,,,,22224
13219,,13979,,A,,Clearance was determined,In vivo,,,,,,22224
13220,,14315,,A,,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,In vivo,,Mus musculus,10090.0,,,50594
13221,,14315,,A,,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,In vivo,,Oryctolagus cuniculus,9986.0,,,50592
13222,,14315,,A,,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,In vivo,,Rattus norvegicus,10116.0,,,50597
13223,,12174,,A,,Clearance in rat after iv dose (100 ug/kg),In vivo,,Rattus norvegicus,10116.0,,,50597
13224,,12797,,A,,Clearance in guinea pig,In vivo,,Cavia porcellus,10141.0,,,22224
13225,,12797,,A,,Compound was evaluated for clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
13226,,12797,,A,,Compound was evaluated for the clearance in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
13227,,12797,,A,,Compound was evaluated for the clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
13228,,11500,,A,,Compound was tested in vivo for clearance after iv administration in the rat,In vivo,,Rattus norvegicus,10116.0,,,50597
13229,,15173,,A,,IV clearance determined at an iv dose of 14 mg/kg,In vivo,,,,,,22224
13230,,15173,,A,,IV clearance determined at an iv dose of 15.2 mg/kg,In vivo,,,,,,22224
13231,,15173,,A,,IV clearance determined at an iv dose of 15 mg/kg,In vivo,,,,,,22224
13232,,15173,,A,,IV clearance determined at an peroral dose of 30 mg/kg.,In vivo,,,,,,22224
13233,,15173,,A,,IV clearance determined at an peroral dose of 30.2 mg/kg.,In vivo,,,,,,22224
13234,,15173,,A,,IV clearance determined at an peroral dose of 30.3 mg/kg.,In vivo,,,,,,22224
13235,Kidney,14198,,A,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13236,Liver,14198,,A,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13237,Lung,14198,,A,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13238,Muscle tissue,14198,,A,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13239,Plasma,14198,,A,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13240,,14198,,A,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13241,Spleen,14198,,A,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13242,Trachea,14198,,A,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13243,Bone,14198,,A,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13244,Cerebellum,14198,,A,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13245,,14198,,A,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13246,,14198,,A,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13247,Heart,14198,,A,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13248,Bone,14198,,A,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13249,Kidney,14198,,A,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13250,Liver,14198,,A,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13251,Lung,14198,,A,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13252,Muscle tissue,14198,,A,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13253,Plasma,14198,,A,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13254,,14198,,A,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13255,Spleen,14198,,A,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13256,Trachea,14198,,A,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13257,Bone,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13258,Cerebellum,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13259,,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13260,,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13261,Heart,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13262,Intestine,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13263,Kidney,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13264,Liver,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13265,Lung,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13266,Muscle tissue,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13267,Plasma,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13268,,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13269,Spleen,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13270,Trachea,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13271,Bone,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13272,Cerebellum,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13273,,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13274,,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13275,Heart,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13276,Intestine,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13277,Kidney,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13278,Lung,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13279,Muscle tissue,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13280,Plasma,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13281,,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13282,Spleen,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13283,Trachea,14198,,A,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13284,,15599,,A,,Normal diffusion coefficient in water for Escherichia coli,,,Escherichia coli,562.0,,,50212
13285,,8204,,A,,Average max percent decrease in RVR (renal vascular resistance) was determined,,,,,,,22224
13286,,8204,,A,,Average max percent decrease in RVR (renal vascular resistance) was determined.,,,,,,,22224
13287,,6154,,A,,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,,,,,,,22224
13288,,6154,,A,,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,,,,,,,22224
13289,,6154,,A,,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,,,,,,,22224
13290,,6154,,A,,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,,,,,,,22224
13291,,7114,,A,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,,,,,,,22224
13292,,7114,,A,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,,,Rattus norvegicus,10116.0,,,50597
13293,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13294,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13295,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13296,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13297,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13298,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13299,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13300,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13301,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13302,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13303,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,,Simiiformes,314293.0,,,22224
13304,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",,,Simiiformes,314293.0,,,22224
13305,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,,Simiiformes,314293.0,,,22224
13306,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",,,Simiiformes,314293.0,,,22224
13307,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",,,Simiiformes,314293.0,,,22224
13308,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13309,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13310,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13311,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13312,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13313,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13314,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13315,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13316,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13317,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13318,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13319,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13320,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13321,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13322,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13323,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13324,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13325,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13326,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13327,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13328,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13329,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13330,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13331,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,,Simiiformes,314293.0,,,22224
13332,,12170,,A,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,In vivo,,Rattus norvegicus,10116.0,,,22224
13333,,12170,,A,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,In vivo,,Rattus norvegicus,10116.0,,,22224
13334,,4985,,A,,Bioavailability (dose 20 mg/kg),In vivo,,Eutheria,9347.0,,,22224
13335,,15145,,A,,Bioavailability in dog,In vivo,,Canis lupus familiaris,9615.0,,,22224
13336,,14080,,A,,Bioavailability in rat (Sprague-Dawley) (male),In vivo,,Rattus norvegicus,10116.0,,,22224
13337,,11219,,A,,Bioavailability in monkey (dose 10 mg/kg i.d.),In vivo,,Primates,9443.0,,,22224
13338,,15145,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,22224
13339,,15145,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,22224
13340,,1202,,A,,Bioavailability in dog (dose 3.0 mg/kg p.o.),In vivo,,Canis lupus familiaris,9615.0,,,22224
13341,,1202,,A,,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,In vivo,,Canis lupus familiaris,9615.0,,,22224
13342,,1202,,A,,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,In vivo,,Pan troglodytes,9598.0,,,50505
13343,,4026,,A,,Bioavailability,In vivo,,Eutheria,9347.0,,,22224
13344,,1492,,A,,Bioavailability in squirrel monkey,In vivo,,Saimiri,9520.0,,,22224
13345,,12793,,A,,Bioavailability was evaluated in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
13346,,12793,,A,,Bioavailability was evaluated in hamster,In vivo,,Cricetinae,10026.0,,,100712
13347,,12793,,A,,Bioavailability in rat,In vivo,,Rattus norvegicus,10116.0,,,22224
13348,Plasma,14793,,A,,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
13349,Plasma,14793,,A,,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,In vivo,,Rattus norvegicus,10116.0,,,50597
13350,,14793,,A,,Bioavailability in rat (dose 10 mg/kg p.o.),In vivo,,Rattus norvegicus,10116.0,,,22224
13351,,14731,,A,,Bioavailability was measured in cynomolgus monkeys.,In vivo,,Macaca fascicularis,9541.0,,,100710
13352,,14731,,A,,Bioavailability was measured in nude mice.,In vivo,,Mus musculus,10090.0,,,50594
13353,,12187,,A,,Bioavailability in ferret (dose 10 mg/kg i.d.),In vivo,,Mustela putorius furo,9669.0,,,22224
13354,,12187,,A,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),In vivo,,Simiiformes,314293.0,,,22224
13355,,12187,,A,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",In vivo,,Simiiformes,314293.0,,,22224
13356,,12187,,A,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),In vivo,,Simiiformes,314293.0,,,22224
13357,,12187,,A,,Bioavailability in rat (dose 10 mg/kg i.d.),In vivo,,Rattus norvegicus,10116.0,,,22224
13358,,12187,,A,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",In vivo,,Rattus norvegicus,10116.0,,,50597
13359,,17431,,A,,Bioavailability was determined; extremely poor,In vivo,,,,,,22224
13360,,13318,,A,,% bioavailability in mice after oral administration of prodrug,In vivo,,Mus musculus,10090.0,,,50594
13361,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,In vivo,,Canis lupus familiaris,9615.0,,,50588
13362,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,In vivo,,Canis lupus familiaris,9615.0,,,50588
13363,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,In vivo,,Canis lupus familiaris,9615.0,,,50588
13364,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,In vivo,,Canis lupus familiaris,9615.0,,,50588
13365,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,In vivo,,Canis lupus familiaris,9615.0,,,50588
13366,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),In vivo,,Canis lupus familiaris,9615.0,,,50588
13367,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,In vivo,,Canis lupus familiaris,9615.0,,,50588
13368,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,In vivo,,Canis lupus familiaris,9615.0,,,50588
13369,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,In vivo,,Canis lupus familiaris,9615.0,,,50588
13370,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,In vivo,,Canis lupus familiaris,9615.0,,,50588
13371,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,In vivo,,Canis lupus familiaris,9615.0,,,50588
13372,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,In vivo,,Canis lupus familiaris,9615.0,,,50588
13373,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,In vivo,,Canis lupus familiaris,9615.0,,,50588
13374,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,In vivo,,Canis lupus familiaris,9615.0,,,50588
13375,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,In vivo,,Canis lupus familiaris,9615.0,,,50588
13376,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,In vivo,,Canis lupus familiaris,9615.0,,,50588
13377,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,In vivo,,Canis lupus familiaris,9615.0,,,50588
13378,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,In vivo,,Canis lupus familiaris,9615.0,,,50588
13379,,15173,,A,,IV clearance determined at an peroral dose of 15 mg/kg.,In vivo,,,,,,22224
13380,,7732,,F,,Mouse oral clearance was measured against Hymenolepiasis nana.,In vivo,,Hymenolepis nana,102285.0,,,50064
13381,,7732,,F,,Mouse oral clearance was measured against Nematospiroides dubius,In vivo,,Heligmosomoides polygyrus,6339.0,,,50545
13382,,7732,,F,,Mouse oral clearance was measured against N. dubius; NT is Not Tested,In vivo,,,,,,22224
13383,,7732,,A,,Mouse oral clearance was measured against N. nana; NT is Not Tested,In vivo,,Mus musculus,10090.0,,,50594
13384,,7732,,B,,Mouse oral clearance was measured against N. nana; NT is Not Tested,In vivo,,,,,,22224
13385,,8328,,A,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,In vivo,,,,,,22224
13386,,8328,,A,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,In vivo,,,,,,22224
13387,,8328,,A,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,In vivo,,,,,,22224
13388,,8328,,A,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,In vivo,,,,,,22224
13389,,8328,,A,,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,In vivo,,,,,,22224
13390,,8328,,A,,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,In vivo,,,,,,22224
13391,,8328,,A,,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,In vivo,,,,,,22224
13392,,8328,,A,,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,In vivo,,,,,,22224
13393,,8328,,A,,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,In vivo,,,,,,22224
13394,,13376,,A,,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,In vivo,,Canis lupus familiaris,9615.0,,,50588
13395,,13477,,A,,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,In vivo,,Macaca mulatta,9544.0,,,50797
13396,,13477,,A,,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
13397,,13477,,A,,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
13398,,13313,,A,,Plasma clearance was determined for the compound in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13399,,12504,,A,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,In vivo,,Rattus norvegicus,10116.0,,,50597
13400,,12504,,A,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,In vivo,,Rattus norvegicus,10116.0,,,50597
13401,,12504,,A,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,In vivo,,Rattus norvegicus,10116.0,,,50597
13402,,12504,,A,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,In vivo,,Rattus norvegicus,10116.0,,,50597
13403,,13129,,A,,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,In vivo,,Rattus norvegicus,10116.0,,,50597
13404,,7732,,A,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,In vivo,,Heligmosomoides polygyrus,6339.0,,,50545
13405,,7732,,A,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,In vivo,,Heligmosomoides polygyrus,6339.0,,,50545
13406,,7732,,A,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,In vivo,,Heligmosomoides polygyrus,6339.0,,,50545
13407,,7732,,A,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,In vivo,,Heligmosomoides polygyrus,6339.0,,,50545
13408,,7732,,A,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,In vivo,,Heligmosomoides polygyrus,6339.0,,,50545
13409,Urine,9278,,A,,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,In vivo,,Rattus norvegicus,10116.0,,,22224
13410,,9278,,A,,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,In vivo,,Rattus norvegicus,10116.0,,,22224
13411,,9278,,A,,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,In vivo,,Rattus norvegicus,10116.0,,,22224
13412,Urine,9278,,A,,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,In vivo,,Rattus norvegicus,10116.0,,,22224
13413,Urine,9278,,A,,Urinary clearance was determined in rat at 25 mg/kg os dosage,In vivo,,Rattus norvegicus,10116.0,,,22224
13414,Urine,9278,,A,,Urinary clearance was determined at 100 mg/kg oral dosage in human,In vivo,,Homo sapiens,9606.0,,,50587
13415,Urine,9278,,A,,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,In vivo,,Canis lupus familiaris,9615.0,,,50588
13416,Plasma,5932,,A,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,In vivo,,Canis lupus familiaris,9615.0,,,50588
13417,Plasma,5932,,A,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,In vivo,,Rattus norvegicus,10116.0,,,50597
13418,,5182,,A,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,In vivo,,Rattus norvegicus,10116.0,,,50597
13419,,10499,,A,,Clearance rate in dogs,In vivo,,Canis lupus familiaris,9615.0,,,50588
13420,,6051,,A,,Compound was measured for intrinsic clearance,In vitro,,,,,,22224
13421,,17508,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13422,,6228,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13423,,6231,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13424,,17740,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13425,,6495,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13426,,2171,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13427,,3255,,A,,Partition coefficient of the compound,,,,,,,22224
13428,,6821,,A,,Permeability,,,,,,,22224
13429,,2685,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13430,,17584,,A,,Partition coefficient (logD),,,,,,,22224
13431,,13824,,P,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,,,,,,22229
13432,,13824,,P,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,,,,,,22229
13433,,16479,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13434,,11997,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13435,,2988,,P,,Calculated logarithm of partition coefficient (P) was determined,,,,,,,22229
13436,,931,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13437,,4381,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13438,,4397,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13439,,5889,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13440,,6154,,A,,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,,,,,,,22224
13441,,6154,,A,,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,,,,,,,22224
13442,,6154,,A,,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,,,,,,,22224
13443,,6154,,A,,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,,,,,,,22224
13444,,6154,,A,,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,,,,,,,22224
13445,,6154,,A,,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,,,,,,,22224
13446,,6887,,A,,Percent degradation of compound at a pH of 1 over a 18 hr period,,,,,,,22224
13447,,6887,,A,,Percent degradation of compound at pH of 1 over an 18 hr period,,,,,,,22224
13448,,14116,,A,,Delta Logarithm of Partition Coefficient value was determined.,,,,,,,22224
13449,,11137,,A,,Delta logPoct-cyc,,,,,,,22224
13450,,7230,,P,,Lipophilicity estimated on reversed phase TLC,,,,,,,22224
13451,,15741,,A,,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,,,,,,,22224
13452,,9663,,A,,Delta logPoct-cyc,,,,,,,22224
13453,,9663,,P,,Change in logarithm of partition coefficient of the compound,,,,,,,22229
13454,,13807,,A,,Delta logD (pH 6.5),,,,,,,22224
13455,,13807,,P,,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",,,,,,,22224
13456,,17425,,A,,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,,,,,,,22224
13457,,12143,,A,,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),,,,,,,22224
13458,,12608,,A,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,,,,,,,22224
13459,,12608,,A,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,,,,,,,22224
13460,,8649,,A,,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,,,Rattus norvegicus,10116.0,,,50597
13461,,8649,,A,,Amount of deuterium retained was reported after normal workup in rats,,,Rattus norvegicus,10116.0,,,50597
13462,,8649,,A,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,,,Rattus norvegicus,10116.0,,,50597
13463,,8649,,A,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,,,Rattus norvegicus,10116.0,,,50597
13464,,8649,,A,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,,Rattus norvegicus,10116.0,,,50597
13465,,8649,,A,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,,Rattus norvegicus,10116.0,,,50597
13466,,8649,,A,,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,,,Rattus norvegicus,10116.0,,,50597
13467,,9659,,A,,Compound was subjected to electrochemical oxidation,,,,,,,22224
13468,,9659,,A,,Compound was subjected to photochemical oxidation,,,,,,,22224
13469,,9659,,A,,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,,,,,,,22224
13470,,9659,,A,,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,,,,,,,22224
13471,,9659,,A,,Oxidation of compound by methemoglobin in presence of hydroperoxide,,,,,,,22224
13472,,9607,,A,,Percent diffusion through fuzzy rat skin after 48 h of incubation,,,Rattus norvegicus,10116.0,,,50597
13473,,7057,,P,,Dissociation constant (pKa),,,,,,,22229
13474,,7057,,P,,Dissociation constant value of the compound; ND means not determined.,,,,,,,22224
13475,Blood,7911,,A,,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,,,Rattus norvegicus,10116.0,,,50597
13476,Blood,7911,,A,,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,,Rattus norvegicus,10116.0,,,50597
13477,,7911,,A,,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,,,Rattus norvegicus,10116.0,,,50597
13478,,7911,,A,,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,,Rattus norvegicus,10116.0,,,50597
13479,Liver,7911,,A,,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,,,Rattus norvegicus,10116.0,,,50597
13480,Liver,7911,,A,,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,,,Rattus norvegicus,10116.0,,,50597
13481,Spleen,7911,,A,,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,,,Rattus norvegicus,10116.0,,,50597
13482,Spleen,7911,,A,,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,,Rattus norvegicus,10116.0,,,50597
13483,,7911,,A,,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,,,Rattus norvegicus,10116.0,,,50597
13484,Urine,7911,,A,,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,,,Rattus norvegicus,10116.0,,,50597
13485,Feces,7911,,A,,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,,Rattus norvegicus,10116.0,,,50597
13486,Urine,7911,,A,,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,,,Rattus norvegicus,10116.0,,,50597
13487,Cerebellum,13792,,A,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,,,Mus musculus,10090.0,,,50594
13488,Brain,13792,,A,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,,,Mus musculus,10090.0,,,50594
13489,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",,,Simiiformes,314293.0,,,22224
13490,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,,Simiiformes,314293.0,,,22224
13491,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",,,Simiiformes,314293.0,,,22224
13492,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",,,Simiiformes,314293.0,,,22224
13493,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13494,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13495,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13496,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13497,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13498,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13499,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13500,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13501,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13502,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13503,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13504,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13505,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13506,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13507,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13508,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13509,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13510,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13511,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13512,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13513,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13514,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13515,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",,,Canis lupus familiaris,9615.0,,,50588
13516,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,,Simiiformes,314293.0,,,22224
13517,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",,,Simiiformes,314293.0,,,22224
13518,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,,Simiiformes,314293.0,,,22224
13519,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",,,Simiiformes,314293.0,,,22224
13520,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",,,Simiiformes,314293.0,,,22224
13521,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13522,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13523,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13524,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13525,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13526,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13527,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13528,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13529,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13530,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,In vivo,,Canis lupus familiaris,9615.0,,,50588
13531,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,In vivo,,Canis lupus familiaris,9615.0,,,50588
13532,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,In vivo,,Canis lupus familiaris,9615.0,,,50588
13533,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,In vivo,,Canis lupus familiaris,9615.0,,,50588
13534,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,In vivo,,Canis lupus familiaris,9615.0,,,50588
13535,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),In vivo,,Canis lupus familiaris,9615.0,,,50588
13536,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,In vivo,,Canis lupus familiaris,9615.0,,,50588
13537,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,In vivo,,Canis lupus familiaris,9615.0,,,50588
13538,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,In vivo,,Canis lupus familiaris,9615.0,,,50588
13539,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,In vivo,,Canis lupus familiaris,9615.0,,,50588
13540,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,In vivo,,Canis lupus familiaris,9615.0,,,50588
13541,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,In vivo,,Canis lupus familiaris,9615.0,,,50588
13542,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,In vivo,,Canis lupus familiaris,9615.0,,,50588
13543,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,In vivo,,Canis lupus familiaris,9615.0,,,50588
13544,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,In vivo,,Canis lupus familiaris,9615.0,,,50588
13545,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,In vivo,,Canis lupus familiaris,9615.0,,,50588
13546,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,In vivo,,Canis lupus familiaris,9615.0,,,50588
13547,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,In vivo,,Canis lupus familiaris,9615.0,,,50588
13548,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,In vivo,,Canis lupus familiaris,9615.0,,,50588
13549,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,In vivo,,Canis lupus familiaris,9615.0,,,50588
13550,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,In vivo,,Canis lupus familiaris,9615.0,,,50588
13551,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,In vivo,,Canis lupus familiaris,9615.0,,,50588
13552,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,In vivo,,Canis lupus familiaris,9615.0,,,50588
13553,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,In vivo,,Canis lupus familiaris,9615.0,,,50588
13554,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,In vivo,,Canis lupus familiaris,9615.0,,,50588
13555,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,In vivo,,Canis lupus familiaris,9615.0,,,50588
13556,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,In vivo,,Canis lupus familiaris,9615.0,,,50588
13557,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,In vivo,,Canis lupus familiaris,9615.0,,,50588
13558,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,In vivo,,Canis lupus familiaris,9615.0,,,50588
13559,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),In vivo,,Canis lupus familiaris,9615.0,,,50588
13560,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,In vivo,,Canis lupus familiaris,9615.0,,,50588
13561,,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,In vivo,,Rattus norvegicus,10116.0,,,50597
13562,Artery,9025,,A,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,In vivo,,Canis lupus familiaris,9615.0,,,50588
13563,,6448,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13564,,17221,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13565,,6545,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13566,,577,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13567,,6285,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13568,,6500,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13569,,6716,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13570,,13658,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13571,,6549,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13572,,14685,,P,,Calculated partition coefficient (clogP) (MacLogP),,,,,,,22229
13573,,6893,,A,,Partition coefficient (logP),,,,,,,22224
13574,,3687,,A,,Kinetic parameter was determined,,,,,,,22224
13575,,4207,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13576,,4626,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13577,,1021,,P,,Lipophilicity was determined,,,,,,,22224
13578,,3777,,P,,Lipophilicity was determined,,,,,,,22224
13579,,17533,,P,,Lipophilicity was determined,,,,,,,22224
13580,,6524,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13581,,17533,,P,,Lipophilicity was determined,,,,,,,22224
13582,,6480,,P,,Lipophilicity in octanol-water,,,,,,,22224
13583,,17606,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13584,,6863,,P,,Octanol-water partition coefficient was determined,,,,,,,22229
13585,,1356,,A,,Partition coefficient (logP),,,,,,,22224
13586,,3326,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13587,,1356,,A,,Partition coefficient was determined; ND means not determined,,,,,,,22224
13588,,12984,,P,,Calculated partition coefficient (clogP),,,,,,,22229
13589,,17363,,A,,Partition coefficient of the compound,,,,,,,22224
13590,,6827,,A,,Permeability was determined,,,,,,,22224
13591,,261,,P,,The compound was evaluated for the partition coefficient,,,,,,,22229
13592,,2685,,A,,Partition coefficient (logP),,,,,,,22224
13593,,414,,P,,The lipophilicity was reported,,,,,,,22224
13594,,15769,,P,,logarithm of the octanol-water partition coefficient for the compound,,,,,,,22229
13595,,17248,,A,,Clogp value was determined,,,,,,,22224
13596,,16935,,A,,Clp at a dose of 1.5 mg/kg,In vivo,,,,,,22224
13597,,16935,,A,,Clp at a dose of 2.0 mg/kg,In vivo,,,,,,22224
13598,Plasma,14832,,A,,"Clp, plasma clearance at a dose of 10 mg/kg",In vivo,,,,,,22224
13599,Plasma,14832,,A,,"Clp, plasma clearance at a dose of 50 mg/kg",In vivo,,,,,,22224
13600,Plasma,2399,,A,,Compound was tested for plasma clearance in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
13601,Plasma,2399,,A,,Compound was tested for plasma clearance in rat; Not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
13602,,6227,,A,,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,10116.0,,,50597
13603,,6227,,A,,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,In vivo,,Macaca mulatta,9544.0,,,50797
13604,,5623,,A,,Plasma clearance by iv administration at a dose 0.003 ug/mL,In vivo,,,,,,22224
13605,,4854,,A,,Plasma clearance determined,In vivo,,,,,,22224
13606,,4493,,A,,Plasma clearance after iv administration at 3 mg/kg in hamster,In vivo,,Cricetinae,10026.0,,,100712
13607,,4493,,A,,Plasma clearance after iv administration at 4 mg/kg in hamster,In vivo,,Cricetinae,10026.0,,,100712
13608,,14956,,A,,Rate of clearance in rat was determined,In vivo,,Rattus norvegicus,10116.0,,,50597
13609,Plasma,15372,,A,,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13610,Plasma,15372,,A,,Total plasma clearance after iv dose of 5.10 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13611,Plasma,15372,,A,,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13612,Plasma,15372,,A,,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13613,Plasma,15604,,A,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,In vivo,,Simiiformes,314293.0,,,22224
13614,Plasma,15604,,A,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
13615,Plasma,15604,,A,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
13616,,14964,,A,,Clpl value in rat,In vivo,,Rattus norvegicus,10116.0,,,50597
13617,,15240,,A,,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,In vivo,,Cavia porcellus,10141.0,,,50512
13618,,16449,,A,,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,50597
13619,,16449,,A,,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,In vivo,,Macaca fascicularis,9541.0,,,100710
13620,,12902,,A,,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,In vivo,,,,,,22224
13621,,12902,,A,,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,In vivo,,,,,,22224
13622,,12902,,A,,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,In vivo,,,,,,22224
13623,,12902,,A,,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,In vivo,,,,,,22224
13624,,12902,,A,,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,In vivo,,,,,,22224
13625,,12902,,A,,Cmax in minutes at a po dose of 10.0(pmol/g/h).,In vivo,,,,,,22224
13626,,12902,,A,,Cmax in minutes at a po dose of 20.0(pmol/g/h).,In vivo,,,,,,22224
13627,,12902,,A,,Cmax in minutes at a po dose of 40.0(pmol/g/h).,In vivo,,,,,,22224
13628,Blood,11149,,A,,Cmax was calculated as maximum concentration reached in the blood,In vivo,,,,,,22224
13629,Blood,11149,,A,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,In vivo,,,,,,22224
13630,,5669,,A,,Cmax was determine after peroral administration at 10 mpk in Rat,In vivo,,Rattus norvegicus,10116.0,,,50597
13631,,5669,,A,,Cmax was determine after peroral administration at 10 mpk in Rhesus,In vivo,,Macaca mulatta,9544.0,,,50797
13632,,5669,,A,,Cmax was determine after peroral administration at 10 mpk in dog,In vivo,,Canis lupus familiaris,9615.0,,,50588
13633,,5669,,A,,Cmax was determine after peroral administration at 160 mpk in Rat,In vivo,,Rattus norvegicus,10116.0,,,50597
13634,,5669,,A,,Cmax was determine after peroral administration at 20 mpk in Rat,In vivo,,Rattus norvegicus,10116.0,,,50597
13635,,5669,,A,,Cmax was determine after peroral administration at 50 mpk in Rat,In vivo,,Rattus norvegicus,10116.0,,,50597
13636,,4236,,A,,Cmax was determined,In vivo,,,,,,22224
13637,Brain,13792,,A,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,,,Mus musculus,10090.0,,,50594
13638,Brain,13792,,A,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,,,Mus musculus,10090.0,,,50594
13639,Brain,13792,,A,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,,,Mus musculus,10090.0,,,50594
13640,Brain,13792,,A,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,,,Mus musculus,10090.0,,,50594
13641,Striatum,13792,,A,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,,,Mus musculus,10090.0,,,50594
13642,Blood,8418,,A,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,,,Rattus norvegicus,10116.0,,,50597
13643,Blood,8418,,A,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,,,Rattus norvegicus,10116.0,,,50597
13644,Blood,8418,,A,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,,,Rattus norvegicus,10116.0,,,50597
13645,Blood,8418,,A,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,,,Rattus norvegicus,10116.0,,,50597
13646,Blood,8418,,A,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,,,Rattus norvegicus,10116.0,,,50597
13647,Blood,8418,,A,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,,,Rattus norvegicus,10116.0,,,50597
13648,Blood,8418,,A,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,,,Rattus norvegicus,10116.0,,,50597
13649,Blood,8418,,A,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,,,Rattus norvegicus,10116.0,,,50597
13650,Blood,8418,,A,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,,,Rattus norvegicus,10116.0,,,50597
13651,Blood,8418,,A,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,,,Rattus norvegicus,10116.0,,,50597
13652,Blood,8418,,A,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,,,Rattus norvegicus,10116.0,,,50597
13653,Blood,8418,,A,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,,,Rattus norvegicus,10116.0,,,50597
13654,Blood,8418,,A,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,,,Rattus norvegicus,10116.0,,,50597
13655,Blood,8418,,A,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,,,Rattus norvegicus,10116.0,,,50597
13656,Blood,8418,,A,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,,,Rattus norvegicus,10116.0,,,50597
13657,Blood,8418,,A,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,,,Rattus norvegicus,10116.0,,,50597
13658,Blood,8418,,A,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,,,Rattus norvegicus,10116.0,,,50597
13659,Blood,8418,,A,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,,,Rattus norvegicus,10116.0,,,50597
13660,Blood,8418,,A,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,,,Rattus norvegicus,10116.0,,,50597
13661,,8418,,A,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,,,Rattus norvegicus,10116.0,,,50597
13662,,8418,,A,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,,,Rattus norvegicus,10116.0,,,50597
13663,,8418,,A,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,,,Rattus norvegicus,10116.0,,,50597
13664,,8418,,A,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,,,Rattus norvegicus,10116.0,,,50597
13665,,8418,,A,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,,,Rattus norvegicus,10116.0,,,50597
13666,,8418,,A,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,,,Rattus norvegicus,10116.0,,,50597
13667,,8418,,A,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,,,Rattus norvegicus,10116.0,,,50597
13668,,8418,,A,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,,,Rattus norvegicus,10116.0,,,50597
13669,,8418,,A,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,,,Rattus norvegicus,10116.0,,,50597
13670,,8418,,A,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,,,Rattus norvegicus,10116.0,,,50597
13671,,8418,,A,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,,,Rattus norvegicus,10116.0,,,50597
13672,,8418,,A,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,,,Rattus norvegicus,10116.0,,,50597
13673,,8418,,A,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,,,Rattus norvegicus,10116.0,,,50597
13674,,8418,,A,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,,,Rattus norvegicus,10116.0,,,50597
13675,,8418,,A,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,,,Rattus norvegicus,10116.0,,,50597
13676,,8418,,A,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,,,Rattus norvegicus,10116.0,,,50597
13677,,8418,,A,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,,,Rattus norvegicus,10116.0,,,50597
13678,,8418,,A,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,,,Rattus norvegicus,10116.0,,,50597
13679,,8418,,A,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,,,Rattus norvegicus,10116.0,,,50597
13680,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13681,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13682,Urine,8133,,A,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",,,Rattus norvegicus,10116.0,,,50597
13683,,6996,,A,,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,,Rattus norvegicus,10116.0,,,50597
13684,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,,,Rattus norvegicus,10116.0,,,50597
13685,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
13686,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,,Rattus norvegicus,10116.0,,,50597
13687,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,,Rattus norvegicus,10116.0,,,50597
13688,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,,Rattus norvegicus,10116.0,,,50597
13689,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
13690,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,,,Rattus norvegicus,10116.0,,,50597
13691,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
13692,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,,Rattus norvegicus,10116.0,,,50597
13693,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,,Rattus norvegicus,10116.0,,,50597
13694,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,,Rattus norvegicus,10116.0,,,50597
13695,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
13696,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,,,Rattus norvegicus,10116.0,,,50597
13697,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
13698,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,,Rattus norvegicus,10116.0,,,50597
13699,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,,Rattus norvegicus,10116.0,,,50597
13700,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,,Rattus norvegicus,10116.0,,,50597
13701,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
13702,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,,,Rattus norvegicus,10116.0,,,50597
13703,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
13704,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,,Rattus norvegicus,10116.0,,,50597
13705,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,,Rattus norvegicus,10116.0,,,50597
13706,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,,Rattus norvegicus,10116.0,,,50597
13707,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,Rattus norvegicus,10116.0,,,50597
13708,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,,,Canis lupus familiaris,9615.0,,,50588
13709,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
13710,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,,,Canis lupus familiaris,9615.0,,,50588
13711,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
13712,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
13713,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
13714,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
13715,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
13716,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
13717,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
13718,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,,Canis lupus familiaris,9615.0,,,50588
13719,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,,Canis lupus familiaris,9615.0,,,50588
13720,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
13721,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
13722,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,,,Canis lupus familiaris,9615.0,,,50588
13723,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),,,Canis lupus familiaris,9615.0,,,50588
13724,,6996,,A,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,,Canis lupus familiaris,9615.0,,,50588
13725,Zone of skin,9716,,A,,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",In vivo,,Mus musculus,10090.0,,,50594
13726,Zone of skin,9716,,A,,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",In vivo,,Mus musculus,10090.0,,,50594
13727,Spleen,9716,,A,,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",In vivo,,Mus musculus,10090.0,,,50594
13728,Spleen,9716,,A,,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",In vivo,,Mus musculus,10090.0,,,50594
13729,Spleen,9716,,A,,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",In vivo,,Mus musculus,10090.0,,,50594
13730,Spleen,9716,,A,,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",In vivo,,Mus musculus,10090.0,,,50594
13731,Stomach,9716,,A,,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",In vivo,,Mus musculus,10090.0,,,50594
13732,Stomach,9716,,A,,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",In vivo,,Mus musculus,10090.0,,,50594
13733,Stomach,9716,,A,,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",In vivo,,Mus musculus,10090.0,,,50594
13734,Stomach,9716,,A,,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",In vivo,,Mus musculus,10090.0,,,50594
13735,,9716,,A,,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",In vivo,,Mus musculus,10090.0,,,50594
13736,,9716,,A,,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",In vivo,,Mus musculus,10090.0,,,50594
13737,,9716,,A,,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",In vivo,,Mus musculus,10090.0,,,50594
13738,,9716,,A,,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",In vivo,,Mus musculus,10090.0,,,50594
13739,Kidney,12192,,A,,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),,,Mus musculus,10090.0,,,50594
13740,Kidney,12192,,A,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,,,Mus musculus,10090.0,,,50594
13741,Kidney,12192,,A,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),,,Mus musculus,10090.0,,,50594
13742,,12192,,A,,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,,,Mus musculus,10090.0,,,50594
13743,,12192,,A,,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),,,Mus musculus,10090.0,,,50594
13744,,12192,,A,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,,,Mus musculus,10090.0,,,50594
13745,,12192,,A,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),,,Mus musculus,10090.0,,,50594
13746,,12192,,A,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,,,Mus musculus,10090.0,,,50594
13747,,12192,,A,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),,,Mus musculus,10090.0,,,50594
13748,,12192,,A,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,,,Mus musculus,10090.0,,,50594
13749,,12192,,A,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),,,Mus musculus,10090.0,,,50594
13750,Feces,12192,,A,,Removal of 238-Plutonium(IV) in feces at 24 h,,,,,,,22224
13751,Feces,12192,,A,,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),,,,,,,22224
13752,,12192,,A,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,,,,,,,22224
13753,,12192,,A,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),,,,,,,22224
13754,Urine,12192,,A,,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),,,,,,,22224
13755,Urine,12192,,A,,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),,,,,,,22224
13756,Urine,12192,,A,,Removal of 238-Plutonium(IV) in urine after 0-24 h,,,,,,,22224
13757,Urine,12192,,A,,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),,,,,,,22224
13758,Urine,12192,,A,,Removal of 238-Plutonium(IV) in urine after 0-4 h,,,,,,,22224
13759,Urine,12192,,A,,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),,,,,,,22224
13760,Urine,12192,,A,,Removal of 238-Plutonium(IV) in urine after 4-24 h,,,,,,,22224
13761,Urine,12192,,A,,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),,,,,,,22224
13762,Urine,12192,,A,,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),,,,,,,22224
13763,Urine,12192,,A,,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),,,,,,,22224
13764,Blood,12017,,A,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13765,Blood,12017,,A,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13766,Blood,12017,,A,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
13767,Blood,12017,,A,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13768,Blood,12017,,A,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13769,,12017,,A,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13770,,12017,,A,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13771,,12017,,A,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
13772,,12017,,A,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13773,,12017,,A,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13774,,11836,,A,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,,,Rattus norvegicus,10116.0,,,50597
13775,,11836,,A,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,,Rattus norvegicus,10116.0,,,50597
13776,,11836,,A,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,,Rattus norvegicus,10116.0,,,50597
13777,Muscle tissue,11836,,A,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,,,Rattus norvegicus,10116.0,,,50597
13778,Muscle tissue,11836,,A,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,,,Rattus norvegicus,10116.0,,,50597
13779,Muscle tissue,11836,,A,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,,,Rattus norvegicus,10116.0,,,50597
13780,Muscle tissue,11836,,A,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,,,Rattus norvegicus,10116.0,,,50597
13781,Muscle tissue,11836,,A,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,,,Rattus norvegicus,10116.0,,,50597
13782,Muscle tissue,11836,,A,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,,,Rattus norvegicus,10116.0,,,50597
13783,Muscle tissue,11836,,A,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,,,Rattus norvegicus,10116.0,,,50597
13784,Muscle tissue,11836,,A,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,,,Rattus norvegicus,10116.0,,,50597
13785,Muscle tissue,11836,,A,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,,,Rattus norvegicus,10116.0,,,50597
13786,Muscle tissue,11836,,A,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,,Rattus norvegicus,10116.0,,,50597
13787,Muscle tissue,11836,,A,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,,Rattus norvegicus,10116.0,,,50597
13788,,11836,,A,,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,,Rattus norvegicus,10116.0,,,50597
13789,Uterus,11836,,A,,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,,,Rattus norvegicus,10116.0,,,50597
13790,,12640,,A,,Tested in vitro for intrinsic activity relative to quinpirole,,,,,,,22224
13791,,14218,,A,,"Relative ion enhancement, determined in pulsed ultrafiltration",,,,,,,22224
13792,,11296,,A,,% ionization at the pH 7.4 at 37 degree Centigrade,,,,,,,22224
13793,,10929,,A,,Percentage ionization was measured,,,,,,,22224
13794,,13841,,A,,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,,,Bos taurus,9913.0,,,50591
13795,,10431,,A,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,,,,,,,22224
13796,,10431,,A,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,,,,,,,22224
13797,,10431,,A,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,,,,,,,22224
13798,,8826,,P,,Compound was evaluated for the partition coefficient in octanol/water,,,,,,,22229
13799,,8826,,P,,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),,,,,,,22229
13800,,9884,,A,,Equilibrium constant measured by the pulse radiolysis at pH 7,,,,,,,22224
13801,,9827,,A,,In vitro hydrolytic rate constant determined in human blood,,,Homo sapiens,9606.0,,,50587
13802,,10009,,A,,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,,,Homo sapiens,9606.0,,,50587
13803,,10009,,A,,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,,,,,,,22224
13804,,10009,,A,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,,,Mus musculus,10090.0,,,50594
13805,,10009,,A,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,,,Mus musculus,10090.0,,,50594
13806,,10009,,A,,In vitro oxidation of compound in presence of human plasma,,,Homo sapiens,9606.0,,,50587
13807,,10009,,A,,In vitro oxidation of compound in presence of hydrogen peroxide,,,,,,,22224
13808,,10009,,A,,In vitro oxidation of compound in presence of mouse brain homogenate,,,Mus musculus,10090.0,,,50594
13809,,10009,,A,,In vitro oxidation of compound in presence of mouse liver homogenate,,,Mus musculus,10090.0,,,50594
13810,,11510,,A,,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13811,,11510,,A,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13812,,11510,,A,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13813,,11510,,A,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13814,,11510,,A,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13815,,11510,,A,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13816,,11510,,A,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13817,,11510,,A,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,,Rattus norvegicus,10116.0,,,50597
13818,,11510,,A,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13819,,11510,,A,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13820,,11510,,A,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13821,,11510,,A,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13822,,11510,,A,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13823,Blood,13100,,A,,Biodistribution in rat blood at 240 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13824,Blood,13100,,A,,Biodistribution in rat blood at 30 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13825,Blood,13100,,A,,Biodistribution in rat blood at 360 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13826,Blood,13100,,A,,Biodistribution in rat blood at 3 hr after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13827,Blood,13100,,A,,Biodistribution in rat blood at 60 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13828,Cerebellum,13100,,A,,Biodistribution in rat cerebellum at 120 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13829,Cerebellum,13100,,A,,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13830,Cerebellum,13100,,A,,Biodistribution in rat cerebellum at 15 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13831,Cerebellum,13100,,A,,Biodistribution in rat cerebellum at 240 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13832,Cerebellum,13100,,A,,Biodistribution in rat cerebellum at 30 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13833,Cerebellum,13100,,A,,Biodistribution in rat cerebellum at 360 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13834,Cerebellum,13100,,A,,Biodistribution in rat cerebellum at 3 hr after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13835,Cerebellum,13100,,A,,Biodistribution in rat cerebellum at 60 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13836,,13100,,A,,Biodistribution in rat cortex at 120 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13837,,13100,,A,,Biodistribution in rat cortex at 1440 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13838,,13100,,A,,Biodistribution in rat cortex at 15 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13839,,13100,,A,,Biodistribution in rat cortex at 240 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13840,,13100,,A,,Biodistribution in rat cortex at 30 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13841,,13100,,A,,Biodistribution in rat cortex at 360 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13842,,13100,,A,,Biodistribution in rat cortex at 3 hr after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13843,,13100,,A,,Biodistribution in rat cortex at 60 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13844,Heart,13100,,A,,Biodistribution in rat heart at 120 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13845,Heart,13100,,A,,Biodistribution in rat heart at 15 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13846,Heart,13100,,A,,Biodistribution in rat heart at 240 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13847,Heart,13100,,A,,Biodistribution in rat heart at 30 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13848,Heart,13100,,A,,Biodistribution in rat heart at 360 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13849,Heart,13100,,A,,Biodistribution in rat heart at 3 hr after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13850,Heart,13100,,A,,Biodistribution in rat heart at 60 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13851,Hippocampus,13100,,A,,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13852,Hippocampus,13100,,A,,Biodistribution in rat hippocampus at 240 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13853,Hippocampus,13100,,A,,Biodistribution in rat hippocampus at 30 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13854,Hippocampus,13100,,A,,Biodistribution in rat hippocampus at 360 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13855,Hippocampus,13100,,A,,Biodistribution in rat hippocampus at 15 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13856,Kidney,13100,,A,,Biodistribution in rat kidney at 120 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13857,Kidney,13100,,A,,Biodistribution in rat kidney at 1440 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13858,Kidney,13100,,A,,Biodistribution in rat kidney at 15 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13859,Kidney,13100,,A,,Biodistribution in rat kidney at 240 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13860,Kidney,13100,,A,,Biodistribution in rat kidney at 30 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13861,Kidney,13100,,A,,Biodistribution in rat kidney at 360 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13862,Kidney,13100,,A,,Biodistribution in rat kidney at 60 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13863,Liver,13100,,A,,Biodistribution in rat liver at 120 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13864,Liver,13100,,A,,Biodistribution in rat liver at 1440 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13865,Liver,13100,,A,,Biodistribution in rat liver at 15 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13866,Liver,13100,,A,,Biodistribution in rat liver at 240 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13867,Liver,13100,,A,,Biodistribution in rat liver at 30 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13868,Liver,13100,,A,,Biodistribution in rat liver at 360 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13869,Liver,13100,,A,,Biodistribution in rat liver at 60 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13870,Lung,13100,,A,,Biodistribution in rat lung at 120 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13871,Lung,13100,,A,,Biodistribution in rat lung at 1440 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13872,Lung,13100,,A,,Biodistribution in rat lung at 15 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13873,Lung,13100,,A,,Biodistribution in rat lung at 240 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13874,Lung,13100,,A,,Biodistribution in rat lung at 30 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13875,Lung,13100,,A,,Biodistribution in rat lung at 360 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
13876,Thoracic aorta,12361,,A,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,,,Rattus norvegicus,10116.0,,,50597
13877,Thoracic aorta,12361,,A,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,,,Rattus norvegicus,10116.0,,,50597
13878,Thoracic aorta,12361,,A,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,,,Rattus norvegicus,10116.0,,,50597
13879,Thoracic aorta,12361,,A,,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,,,Rattus norvegicus,10116.0,,,50597
13880,Thoracic aorta,12361,,A,,Percent of maximal contractile response to compound in rat thoracic aorta strips v,,,Rattus norvegicus,10116.0,,,50597
13881,Thoracic aorta,12361,,A,,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,,,Rattus norvegicus,10116.0,,,50597
13882,Thoracic aorta,12361,,A,,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,,,Rattus norvegicus,10116.0,,,50597
13883,Urine,12712,,A,,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,,,Rattus norvegicus,10116.0,,,50597
13884,Feces,7415,,A,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,,,Rattus norvegicus,10116.0,,,50597
13885,Urine,7415,,A,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,,,Rattus norvegicus,10116.0,,,50597
13886,,7415,,A,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,,,Rattus norvegicus,10116.0,,,50597
13887,,7415,,A,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,,,Rattus norvegicus,10116.0,,,50597
13888,Feces,7415,,A,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",,,Rattus norvegicus,10116.0,,,50597
13889,Urine,7415,,A,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",,,Rattus norvegicus,10116.0,,,50597
13890,,7415,,A,,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",,,Rattus norvegicus,10116.0,,,50597
13891,,8050,,A,,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,,,Mus musculus,10090.0,,,50594
13892,,8050,,A,,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,,,Mus musculus,10090.0,,,50594
13893,,8050,,A,,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,,,Mus musculus,10090.0,,,50594
13894,,8050,,A,,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,,,Mus musculus,10090.0,,,50594
13895,Urine,8050,,A,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,,,Mus musculus,10090.0,,,50594
13896,Urine,8050,,A,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,,,Mus musculus,10090.0,,,50594
13897,Urine,8050,,A,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,,,Mus musculus,10090.0,,,50594
13898,Urine,8050,,A,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,,,Mus musculus,10090.0,,,50594
13899,Urine,8050,,A,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,,,Mus musculus,10090.0,,,50594
13900,Urine,8050,,A,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,,,Mus musculus,10090.0,,,50594
13901,Urine,8050,,A,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,,,Mus musculus,10090.0,,,50594
13902,Urine,8050,,A,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,,,Mus musculus,10090.0,,,50594
13903,Urine,8050,,A,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,,,Mus musculus,10090.0,,,50594
13904,Urine,8050,,A,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,,,Mus musculus,10090.0,,,50594
13905,Urine,8050,,A,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,,,Mus musculus,10090.0,,,50594
13906,Urine,8050,,A,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,,,Mus musculus,10090.0,,,50594
13907,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
13908,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
13909,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
13910,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
13911,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
13912,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
13913,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
13914,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
13915,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
13916,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
13917,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
13918,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
13919,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
13920,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
13921,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
13922,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
13923,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
13924,Kidney,12017,,A,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13925,Kidney,12017,,A,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13926,Kidney,12017,,A,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
13927,Kidney,12017,,A,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13928,Kidney,12017,,A,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13929,Liver,12017,,A,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13930,Liver,12017,,A,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13931,Liver,12017,,A,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
13932,Liver,12017,,A,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13933,Liver,12017,,A,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13934,Lung,12017,,A,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13935,Lung,12017,,A,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13936,Lung,12017,,A,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
13937,Lung,12017,,A,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13938,Lung,12017,,A,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13939,Muscle tissue,12017,,A,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13940,Muscle tissue,12017,,A,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13941,Muscle tissue,12017,,A,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
13942,Muscle tissue,12017,,A,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13943,Muscle tissue,12017,,A,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13944,Spleen,12017,,A,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13945,Spleen,12017,,A,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13946,Spleen,12017,,A,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
13947,Spleen,12017,,A,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13948,Spleen,12017,,A,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13949,Thyroid gland,12017,,A,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13950,Thyroid gland,12017,,A,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13951,Thyroid gland,12017,,A,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
13952,Thyroid gland,12017,,A,,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13953,Thyroid gland,12017,,A,,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13954,,12017,,A,,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13955,,12017,,A,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13956,,12017,,A,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
13957,,12017,,A,,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13958,,12017,,A,,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
13959,Spleen,12017,,A,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",In vivo,,Rattus norvegicus,10116.0,,,50597
13960,Spleen,12017,,A,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",In vivo,,Rattus norvegicus,10116.0,,,50597
13961,Spleen,12017,,A,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",In vivo,,Rattus norvegicus,10116.0,,,50597
13962,Spleen,12017,,A,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",In vivo,,Rattus norvegicus,10116.0,,,50597
13963,Spleen,12017,,A,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",In vivo,,Rattus norvegicus,10116.0,,,50597
13964,Spleen,12017,,A,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",In vivo,,Rattus norvegicus,10116.0,,,50597
13965,,11510,,A,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13966,,11510,,A,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13967,,11510,,A,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13968,,11510,,A,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13969,,11510,,A,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13970,,11510,,A,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13971,,11510,,A,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13972,,11510,,A,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13973,,11510,,A,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13974,,11510,,A,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13975,,11510,,A,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13976,,11510,,A,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13977,,11510,,A,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13978,,11510,,A,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13979,,11510,,A,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13980,,11510,,A,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,,Rattus norvegicus,10116.0,,,50597
13981,,8362,,P,,Octanol:water partition coefficient is evaluated,,,,,,,22229
13982,,8257,,P,,Partition coefficient in 1-octanol/water system,,,,,,,22224
13983,,8257,,P,,Partition coefficient in 1-octanol/water system measured using radio active compounds,,,,,,,22224
13984,,9468,,P,,Partition coefficient in octanol/water system was determined,,,,,,,22224
13985,,9468,,P,,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,,,,,,,22224
13986,,10568,,A,,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,,,,,,,22224
13987,,10568,,A,,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",,,,,,,22224
13988,,15359,,A,,Pseudo-first-order rate constant of the compound,,,,,,,22224
13989,,15359,,A,,Pseudo-first-order rate constant with 1-min time point,,,,,,,22224
13990,,15359,,A,,Pseudo-first-order rate constant without 1-min time point,,,,,,,22224
13991,,10431,,A,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,,,,,,,22224
13992,,10431,,A,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,,,,,,,22224
13993,,10431,,A,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,,,,,,,22224
13994,,15704,,A,,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,,,,,,,22224
13995,,15287,,A,,The alkaline hydrolysis second order rate constant(K OH) of the compound,,,,,,,22224
13996,,7516,,A,,The efflux rate constant of the compound,,,,,,,22224
13997,,12973,,A,,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,,,,,,22224
13998,,12973,,A,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,,,,,,22224
13999,,12973,,F,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,,,,,,22224
14000,,12973,,A,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,,,,,,,22224
14001,,8696,,A,,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,,,,,,,22224
14002,,15052,,A,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,,,,,,,22224
14003,,15052,,A,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,,,,,,,22224
14004,,10503,,A,,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),,,,,,,22224
14005,,8354,,A,,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
14006,,8354,,A,,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
14007,,8354,,A,,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
14008,,8354,,A,,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
14009,,8354,,A,,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",,,,,,,22224
14010,,10503,,A,,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,,,,,,,22224
14011,,8354,,A,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
14012,,8354,,A,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
14013,,8354,,A,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
14014,,8354,,A,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
14015,Lung,13100,,A,,Biodistribution in rat lung at 60 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14016,,13100,,A,,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14017,,13100,,A,,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14018,,13100,,A,,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14019,,13100,,A,,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14020,,13100,,A,,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14021,,13100,,A,,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14022,Striatum,13100,,A,,Biodistribution in rat striatum at 120 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14023,Striatum,13100,,A,,Biodistribution in rat striatum at 1440 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14024,Striatum,13100,,A,,Biodistribution in rat striatum at 15 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14025,Striatum,13100,,A,,Biodistribution in rat striatum at 240 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14026,Striatum,13100,,A,,Biodistribution in rat striatum at 30 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14027,Striatum,13100,,A,,Biodistribution in rat striatum at 360 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14028,Striatum,13100,,A,,Biodistribution in rat striatum at 3 hr after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14029,Striatum,13100,,A,,Biodistribution in rat striatum at 60 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14030,Thyroid gland,13100,,A,,Biodistribution in rat thyroid at 120 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14031,Thyroid gland,13100,,A,,Biodistribution in rat thyroid at 1440 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14032,Thyroid gland,13100,,A,,Biodistribution in rat thyroid at 15 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14033,Thyroid gland,13100,,A,,Biodistribution in rat thyroid at 240 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14034,Thyroid gland,13100,,A,,Biodistribution in rat thyroid at 30 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14035,Thyroid gland,13100,,A,,Biodistribution in rat thyroid at 360 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14036,Thyroid gland,13100,,A,,Biodistribution in rat thyroid at 60 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14037,Brain,13100,,A,,Biodistribution in rest of brain of rat 120 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14038,Brain,13100,,A,,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14039,Brain,13100,,A,,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14040,Brain,13100,,A,,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14041,Brain,13100,,A,,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14042,Brain,13100,,A,,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14043,Brain,13100,,A,,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,In vivo,,Rattus norvegicus,10116.0,,,50597
14044,,13331,,A,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",,,,,,,22224
14045,,13331,,A,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,,,,,,22224
14046,,13331,,A,,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),,,,,,,22224
14047,,13331,,A,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",,,,,,,22224
14048,,13331,,A,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",,,,,,,22224
14049,,13331,,A,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,,,,,,22224
14050,,13331,,A,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",,,,,,,22224
14051,,13331,,A,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",,,,,,,22224
14052,Urine,10086,,A,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,,,Rattus norvegicus,10116.0,,,50597
14053,Urine,10086,,F,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,,,,,,,22224
14054,Urine,10086,,A,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,,,Rattus norvegicus,10116.0,,,50597
14055,Urine,10086,,F,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,,,,,,,22224
14056,Urine,10086,,A,,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,,,Rattus norvegicus,10116.0,,,50597
14057,Urine,10086,,A,,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,,,Rattus norvegicus,10116.0,,,50597
14058,Urine,10086,,A,,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,,,Rattus norvegicus,10116.0,,,50597
14059,Urine,10086,,A,,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,,,Rattus norvegicus,10116.0,,,50597
14060,,13248,,A,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,,,Rattus norvegicus,10116.0,,,50597
14061,,13248,,A,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,,,Rattus norvegicus,10116.0,,,50597
14062,Liver,14527,,A,,In vitro metabolism in human liver microsomes,,,Homo sapiens,9606.0,,,50587
14063,,3008,,A,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,,,Homo sapiens,9606.0,,,50587
14064,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14065,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14066,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14067,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14068,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14069,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14070,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14071,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14072,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14073,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14074,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14075,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14076,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14077,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14078,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14079,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14080,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14081,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14082,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14083,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14084,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14085,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14086,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14087,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14088,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14089,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14090,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14091,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14092,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14093,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14094,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14095,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14096,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14097,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14098,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14099,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14100,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14101,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14102,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14103,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14104,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14105,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14106,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14107,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14108,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14109,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14110,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14111,Spleen,12017,,A,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",In vivo,,Rattus norvegicus,10116.0,,,50597
14112,Uterus,12017,,A,,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14113,Uterus,12017,,A,,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14114,Uterus,12017,,A,,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14115,Blood,14045,,A,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),In vivo,,Rattus norvegicus,10116.0,,,50597
14116,Blood,14045,,A,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),In vivo,,Rattus norvegicus,10116.0,,,50597
14117,Blood,14045,,A,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),In vivo,,Rattus norvegicus,10116.0,,,50597
14118,Blood,14045,,A,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),In vivo,,Rattus norvegicus,10116.0,,,50597
14119,Brain,14045,,A,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),In vivo,,Rattus norvegicus,10116.0,,,50597
14120,Brain,14045,,A,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),In vivo,,Rattus norvegicus,10116.0,,,50597
14121,Brain,14045,,A,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),In vivo,,Rattus norvegicus,10116.0,,,50597
14122,Brain,14045,,A,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),In vivo,,Rattus norvegicus,10116.0,,,50597
14123,,14045,,A,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),In vivo,,Rattus norvegicus,10116.0,,,50597
14124,,14045,,A,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),In vivo,,Rattus norvegicus,10116.0,,,50597
14125,,14045,,A,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),In vivo,,Rattus norvegicus,10116.0,,,50597
14126,,14045,,A,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),In vivo,,Rattus norvegicus,10116.0,,,50597
14127,,14045,,A,,Biodistribution in mice bladder plus excreted urine was determined,In vivo,,Mus musculus,10090.0,,,50594
14128,,14045,,A,,"Percentage biodistribution in mouse blood, 10 minutes post injection",,,Mus musculus,10090.0,,,50594
14129,,14045,,A,,"Percentage biodistribution in mouse blood, 30 minutes post injection",,,Mus musculus,10090.0,,,50594
14130,,14045,,A,,"Percentage biodistribution in mouse blood, 5 minutes post injection",,,Mus musculus,10090.0,,,50594
14131,,14045,,A,,"Percentage biodistribution in mouse blood, 60 minutes post injection",,,Mus musculus,10090.0,,,50594
14132,Brain,14045,,A,,"Percentage biodistribution in mouse brain, 10 minutes post injection",,,Mus musculus,10090.0,,,50594
14133,Brain,14045,,A,,"Percentage biodistribution in mouse brain, 30 minutes post injection",,,Mus musculus,10090.0,,,50594
14134,Brain,14045,,A,,"Percentage biodistribution in mouse brain, 5 minutes post injection",,,Mus musculus,10090.0,,,50594
14135,Brain,14045,,A,,"Percentage biodistribution in mouse brain, 60 minutes post injection",,,Mus musculus,10090.0,,,50594
14136,,14045,,A,,"Percentage biodistribution in mouse heart, 10 minutes post injection",,,Mus musculus,10090.0,,,50594
14137,,14045,,A,,"Percentage biodistribution in mouse heart, 30 minutes post injection",,,Mus musculus,10090.0,,,50594
14138,,14045,,A,,"Percentage biodistribution in mouse heart, 5 minutes post injection",,,Mus musculus,10090.0,,,50594
14139,,14045,,A,,"Percentage biodistribution in mouse heart, 60 minutes post injection",,,Mus musculus,10090.0,,,50594
14140,Intestine,14045,,A,,"Percentage biodistribution in mouse intestine, 10 minutes post injection",,,Mus musculus,10090.0,,,50594
14141,Intestine,14045,,A,,"Percentage biodistribution in mouse intestine, 30 minutes post injection",,,Mus musculus,10090.0,,,50594
14142,Intestine,14045,,A,,"Percentage biodistribution in mouse intestine, 5 minutes post injection",,,Mus musculus,10090.0,,,50594
14143,Intestine,14045,,A,,"Percentage biodistribution in mouse intestine, 60 minutes post injection",,,Mus musculus,10090.0,,,50594
14144,Liver,14045,,A,,"Percentage biodistribution in mouse liver, 10 minutes post injection",,,Mus musculus,10090.0,,,50594
14145,Liver,14045,,A,,"Percentage biodistribution in mouse liver, 30 minutes of post injection",,,Mus musculus,10090.0,,,50594
14146,Liver,14045,,A,,"Percentage biodistribution in mouse liver, 5 minutes post injection",,,Mus musculus,10090.0,,,50594
14147,Liver,14045,,A,,Biodistribution in mice liver at 60 minutes of post injection,In vivo,,Mus musculus,10090.0,,,50594
14148,Lung,14045,,A,,Biodistribution in mice lungs at 10 min of post injection,In vivo,,Mus musculus,10090.0,,,50594
14149,,14045,,A,,"Percentage biodistribution in mouse lung, 30 minutes post injection",,,Mus musculus,10090.0,,,50594
14150,,14045,,A,,"Percentage biodistribution in mousee lung, 5 minutes post injection",,,Mus musculus,10090.0,,,50594
14151,Lung,14045,,A,,Biodistribution in mice lungs at 60 min of post injection,In vivo,,Mus musculus,10090.0,,,50594
14152,Spleen,14045,,A,,Percentage biodistribution in mouse spleen,,,Mus musculus,10090.0,,,50594
14153,Stomach,14045,,A,,Percentage biodistribution in mouse stomach,,,Mus musculus,10090.0,,,50594
14154,Urine,11745,,A,,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,,,Mus musculus,10090.0,,,50594
14155,Urinary bladder,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,In vivo,,,,,,22224
14156,Blood,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,In vivo,,,,,,22224
14157,Bone element,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,In vivo,,,,,,22224
14158,,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,In vivo,,,,,,22224
14159,Kidney,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,In vivo,,,,,,22224
14160,Liver,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,In vivo,,,,,,22224
14161,Lung,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,In vivo,,,,,,22224
14162,Muscle tissue,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,In vivo,,,,,,22224
14163,,8354,,A,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",,,,,,,22224
14164,Serum,7095,,A,,Affinity for protein binding expressed as association constant in fresh rat serum,,,Rattus norvegicus,10116.0,,,50597
14165,,12185,,A,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,,,,,,22224
14166,,12185,,A,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,,,,,,22224
14167,,12185,,A,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,,,,,,22224
14168,,12185,,A,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,,,,,,22224
14169,,12686,,A,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,,,,,,,22224
14170,,12686,,A,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,,,,,,22224
14171,,12686,,A,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,,,,,,,22224
14172,,12686,,A,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,,,,,,22224
14173,,8057,,A,,Apparent rate constant Koff for inactivation of dTMP synthase.,,,,,,,22224
14174,,15778,,A,,The irreversible inhibitor activity by second order rate equation.,,,,,,,22224
14175,,12375,,A,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,,,Rattus norvegicus,10116.0,,,50597
14176,,12375,,A,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,,,Rattus norvegicus,10116.0,,,50597
14177,,12375,,A,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,,,Rattus norvegicus,10116.0,,,50597
14178,,13588,,A,,Dissociation rate calculated from the first-order equation using t1/2 value,,,,,,,22224
14179,,15039,,A,,The compound was tested for Binding constant against DNA,,,,,,,22224
14180,,9500,,A,,First order rate constant for cyclization of the compound,,,,,,,22224
14181,,10014,,A,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,,,,,,22224
14182,,10014,,A,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,,,,,,22224
14183,,568,,A,,Hydrolysis rate constant was determined,,,,,,,22224
14184,,10026,,A,,Observed first order rate constant,,,,,,,22224
14185,,10281,,A,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,,,,,,22224
14186,,10281,,A,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,,,,,,22224
14187,,9680,,A,,Second-order rate constant for attack on PNPA at 25 degree Centigrade,,,,,,,22224
14188,,13028,,A,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14189,,13028,,A,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14190,,13028,,A,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14191,,13028,,A,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14192,,13028,,A,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14193,,13028,,A,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14194,,13028,,A,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14195,,13028,,A,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14196,,13028,,A,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14197,,13028,,A,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14198,,13028,,A,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14199,,13028,,A,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14200,,13028,,A,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14201,,13028,,A,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14202,,13028,,A,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14203,,13028,,A,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14204,,13028,,A,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14205,,13028,,A,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14206,,13028,,A,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14207,,13028,,A,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14208,,3008,,A,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,,,Homo sapiens,9606.0,,,50587
14209,,4509,,A,,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,,Homo sapiens,9606.0,,,50587
14210,,4509,,A,,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,,Homo sapiens,9606.0,,,50587
14211,,8613,,A,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,,,Human herpesvirus 1,10298.0,,,50602
14212,,8613,,A,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,,,Human herpesvirus 1,10298.0,,,50602
14213,,8613,,A,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,,,Human herpesvirus 1,10298.0,,,50602
14214,,8613,,A,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,,,Human herpesvirus 1,10298.0,,,50602
14215,,8613,,A,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,,,Human herpesvirus 1,10298.0,,,50602
14216,,8613,,A,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,,,Human herpesvirus 1,10298.0,,,50602
14217,,8613,,A,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,,,Human herpesvirus 1,10298.0,,,50602
14218,,8613,,A,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,,,Human herpesvirus 1,10298.0,,,50602
14219,,8613,,A,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,,,Human herpesvirus 1,10298.0,,,50602
14220,,8613,,A,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,,,Human herpesvirus 1,10298.0,,,50602
14221,,8613,,A,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,,,Human herpesvirus 1,10298.0,,,50602
14222,,6021,,P,,Calculated partition coefficient (clogP) (MlogP),,,,,,,22229
14223,,9348,,A,,Equipotent potent ratio relative to carbachol (nicotinic activity),,,,,,,22224
14224,,15592,,A,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",,,Canis lupus familiaris,9615.0,,,50588
14225,,15592,,A,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",,,Canis lupus familiaris,9615.0,,,50588
14226,,15592,,P,,Solubility at pH 7.4 in micro g/mL;NA denotes available,,,,,,,22229
14227,,15592,,P,,Solubility at pH 7.4 in micro g/mL;NA denotes not available,,,,,,,22229
14228,,15592,,P,,Solubility at pH 7.4 in ug/mL;NA denotes not available,,,,,,,22229
14229,Plasma,15592,,A,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,In vivo,,Canis lupus familiaris,9615.0,,,50588
14230,Serum,7095,,A,,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,,,Rattus norvegicus,10116.0,,,50597
14231,,16618,,A,,Area under the MAP curve measured over 5 min; ND means Not determined,,,,,,,22224
14232,,16835,,P,,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,,,,,,,22224
14233,,15284,,P,,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,,,,,,,22229
14234,,15750,,A,,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,,,,,,,22224
14235,,16618,,A,,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,In vivo,,Rattus norvegicus,10116.0,,,50597
14236,,16618,,A,,Half life after oral tested,In vivo,,,,,,22224
14237,Plasma,15812,,A,,Half life was determined in plasma of rat; NT indicates not tested,,,Rattus norvegicus,10116.0,,,50597
14238,,16618,,A,,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,In vivo,,Rattus norvegicus,10116.0,,,50597
14239,,16618,,A,,Oral bioavailability after oral tested,In vivo,,,,,,22224
14240,,13098,,A,,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),,,Rattus norvegicus,10116.0,,,50597
14241,,13098,,A,,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),,,Rattus norvegicus,10116.0,,,50597
14242,Plasma,15812,,A,,half life was determined in plasma of rat; NT indicates not tested,,,Rattus norvegicus,10116.0,,,50597
14243,Plasma,15812,,A,,half life was determined in plasma of rat; NT means not tested,,,Rattus norvegicus,10116.0,,,50597
14244,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,,,Rattus norvegicus,10116.0,,,50597
14245,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); inactive,,,Rattus norvegicus,10116.0,,,50597
14246,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,,,Rattus norvegicus,10116.0,,,50597
14247,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,,,Rattus norvegicus,10116.0,,,50597
14248,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,,,Rattus norvegicus,10116.0,,,50597
14249,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,,,Rattus norvegicus,10116.0,,,50597
14250,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,,,Rattus norvegicus,10116.0,,,50597
14251,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,,,Rattus norvegicus,10116.0,,,50597
14252,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,,,Rattus norvegicus,10116.0,,,50597
14253,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,,,Rattus norvegicus,10116.0,,,50597
14254,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,,,Rattus norvegicus,10116.0,,,50597
14255,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,,,Rattus norvegicus,10116.0,,,50597
14256,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,,,Rattus norvegicus,10116.0,,,50597
14257,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,,,Rattus norvegicus,10116.0,,,50597
14258,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,,,Rattus norvegicus,10116.0,,,50597
14259,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,,,Rattus norvegicus,10116.0,,,50597
14260,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,,,Rattus norvegicus,10116.0,,,50597
14261,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14262,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14263,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14264,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14265,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14266,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14267,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14268,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14269,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14270,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14271,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14272,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14273,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14274,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14275,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14276,Urine,12582,,A,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14277,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14278,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14279,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14280,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14281,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14282,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14283,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14284,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14285,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14286,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14287,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14288,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14289,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14290,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14291,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14292,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14293,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14294,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14295,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14296,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14297,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14298,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14299,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14300,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14301,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14302,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14303,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14304,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14305,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14306,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14307,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14308,Prostate gland,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),In vivo,,,,,,22224
14309,Prostate gland,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,In vivo,,,,,,22224
14310,Muscle tissue,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,In vivo,,,,,,22224
14311,Prostate gland,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),In vivo,,,,,,22224
14312,,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,In vivo,,,,,,22224
14313,Muscle tissue,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,In vivo,,,,,,22224
14314,Spleen,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,In vivo,,,,,,22224
14315,Urinary bladder,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,In vivo,,,,,,22224
14316,Blood,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,In vivo,,,,,,22224
14317,Bone element,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,In vivo,,,,,,22224
14318,,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,In vivo,,,,,,22224
14319,Kidney,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,In vivo,,,,,,22224
14320,Liver,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,In vivo,,,,,,22224
14321,Lung,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,In vivo,,,,,,22224
14322,Muscle tissue,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,In vivo,,,,,,22224
14323,Prostate gland,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),In vivo,,,,,,22224
14324,Muscle tissue,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,In vivo,,,,,,22224
14325,Prostate gland,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),In vivo,,,,,,22224
14326,,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,In vivo,,,,,,22224
14327,Muscle tissue,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,In vivo,,,,,,22224
14328,Spleen,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,In vivo,,,,,,22224
14329,Prostate gland,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,In vivo,,,,,,22224
14330,Urinary bladder,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,In vivo,,,,,,22224
14331,Blood,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,In vivo,,,,,,22224
14332,Bone element,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,In vivo,,,,,,22224
14333,,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,In vivo,,,,,,22224
14334,Kidney,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,In vivo,,,,,,22224
14335,Liver,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,In vivo,,,,,,22224
14336,Lung,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,In vivo,,,,,,22224
14337,Muscle tissue,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,In vivo,,,,,,22224
14338,Prostate gland,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),In vivo,,,,,,22224
14339,Prostate gland,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,In vivo,,,,,,22224
14340,Muscle tissue,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,In vivo,,,,,,22224
14341,Prostate gland,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),In vivo,,,,,,22224
14342,,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,In vivo,,,,,,22224
14343,Muscle tissue,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,In vivo,,,,,,22224
14344,Spleen,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,In vivo,,,,,,22224
14345,Urinary bladder,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,In vivo,,,,,,22224
14346,Blood,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,In vivo,,,,,,22224
14347,Bone element,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,In vivo,,,,,,22224
14348,,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,In vivo,,,,,,22224
14349,Liver,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,In vivo,,,,,,22224
14350,Lung,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,In vivo,,,,,,22224
14351,Muscle tissue,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,In vivo,,,,,,22224
14352,,2193,,A,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,,,,,,,22224
14353,,2193,,A,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,,,,,,,22224
14354,,2193,,A,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,,,,,,,22224
14355,,2193,,A,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,,,,,,,22224
14356,,2193,,A,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,,,,,,,22224
14357,,2193,,A,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,,,,,,,22224
14358,,568,,A,,Hydrolysis rate constant was determined,,,,,,,22224
14359,,9680,,A,,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",,,,,,,22224
14360,,9680,,A,,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,,,,,,22224
14361,,9680,,A,,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,,,,,,22224
14362,,10026,,A,,Observed second order rate constant,,,,,,,22224
14363,,10281,,A,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,,,,,,22224
14364,,10014,,A,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,,,,,,22224
14365,,10014,,A,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,,,,,,22224
14366,,9680,,A,,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,,,,,,22224
14367,,9680,,A,,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,,,,,,22224
14368,,13028,,A,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14369,,13028,,A,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14370,,13028,,A,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14371,,13028,,A,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14372,,13028,,A,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14373,,13028,,A,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14374,,13028,,A,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14375,,13028,,A,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14376,,13028,,A,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14377,,13028,,A,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,22224
14378,,10014,,A,,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,,,Rattus norvegicus,10116.0,,,50597
14379,,9962,,A,,Association constant for compound at 31 degree C was determined,,,,,,,22224
14380,,12029,,A,,Calculated antagonist equilibrium dissociation constant of the compound,,,,,,,22224
14381,,12029,,A,,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,,,,,,,22224
14382,Trachea,10583,,A,,Dissociation constants vs LTE4 on guinea pig trachea,,,Cavia porcellus,10141.0,,,50512
14383,,568,,A,,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",,,,,,,22224
14384,,568,,A,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",,,,,,,22224
14385,,568,,A,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",,,,,,,22224
14386,,568,,A,,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",,,,,,,22224
14387,,7493,,A,,Affinity constant KD value was derived from TMP,,,,,,,22224
14388,,8371,,A,,Apparent dissociation (binding) rate constant was evaluated,,,,,,,22224
14389,,13114,,P,,Dissociation constant (KD) of the compound,,,,,,,22224
14390,,15515,,P,,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,,,,,,,22224
14391,,522,,P,,Dissociation constant from ESR titration experiments,,,,,,,22224
14392,,13888,,,,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,,,,,,22224
14393,,2616,,P,,Dissociation constant was evaluated.,,,,,,,22224
14394,,3798,,P,,Dissociation constant was reported,,,,,,,22224
14395,,8731,,A,,Dissociation constant was determined in rat pituitary cells.,,,Rattus norvegicus,10116.0,,,50597
14396,,11892,,A,,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,,,,,,,22224
14397,,11892,,A,,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,,,,,,,22224
14398,,2582,,A,,Equilibrium dissociation constant of the compound,,,,,,,22224
14399,,11892,,A,,Equilibrium dissociation constant was determined,,,,,,,22224
14400,,13396,,A,,Kinetic constant KD was evaluated,,,,,,,22224
14401,,603,,A,,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,,,,,,,22224
14402,,15673,,A,,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,,,,,,,22224
14403,,10368,,A,,Rate constant for hydrolysis in aqueous acetone.,,,,,,,22224
14404,,14228,,A,,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,,,,,,,22224
14405,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,,,Rattus norvegicus,10116.0,,,50597
14406,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,,,Rattus norvegicus,10116.0,,,50597
14407,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,,,Rattus norvegicus,10116.0,,,50597
14408,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,,,Rattus norvegicus,10116.0,,,50597
14409,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,,,Rattus norvegicus,10116.0,,,50597
14410,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,,,Rattus norvegicus,10116.0,,,50597
14411,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,,,Rattus norvegicus,10116.0,,,50597
14412,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,,,Rattus norvegicus,10116.0,,,50597
14413,,11510,,A,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,,,Rattus norvegicus,10116.0,,,50597
14414,,11510,,A,,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14415,,11510,,A,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14416,,11510,,A,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14417,,11510,,A,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14418,,11510,,A,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14419,,11510,,A,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14420,,11510,,A,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14421,,11510,,A,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,,Rattus norvegicus,10116.0,,,50597
14422,,11510,,A,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14423,,11510,,A,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14424,,11510,,A,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14425,,11510,,A,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14426,,11510,,A,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14427,,11510,,A,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14428,,11510,,A,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14429,,11510,,A,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14430,,11510,,A,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14431,,11510,,A,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14432,,11510,,A,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14433,,11510,,A,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14434,,11510,,A,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14435,,11510,,A,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14436,,11510,,A,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14437,,11510,,A,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14438,,11510,,A,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14439,,11510,,A,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14440,,11510,,A,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14441,,11510,,A,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14442,,11510,,A,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,,Rattus norvegicus,10116.0,,,50597
14443,,8310,,A,,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,,,Canis lupus familiaris,9615.0,,,50588
14444,,8310,,A,,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,,,Canis lupus familiaris,9615.0,,,50588
14445,,8310,,A,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,,Mus musculus,10090.0,,,50594
14446,,8310,,A,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,,Mus musculus,10090.0,,,50594
14447,,8310,,A,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,,Mus musculus,10090.0,,,50594
14448,,8310,,A,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,,,Mus musculus,10090.0,,,50594
14449,,8310,,A,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,,Mus musculus,10090.0,,,50594
14450,,8310,,A,,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,,,Canis lupus familiaris,9615.0,,,50588
14451,,8310,,A,,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,,,Mus musculus,10090.0,,,50594
14452,,8310,,A,,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,,,Canis lupus familiaris,9615.0,,,50588
14453,,8310,,A,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,,,Canis lupus familiaris,9615.0,,,50588
14454,,8310,,A,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,,Mus musculus,10090.0,,,50594
14455,,8310,,A,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,,Mus musculus,10090.0,,,50594
14456,,8310,,A,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,,Mus musculus,10090.0,,,50594
14457,,8310,,A,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,,,Mus musculus,10090.0,,,50594
14458,,8310,,A,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,,,Mus musculus,10090.0,,,50594
14459,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14460,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14461,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14462,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14463,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14464,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14465,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14466,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14467,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14468,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14469,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14470,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14471,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14472,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14473,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14474,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14475,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14476,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14477,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14478,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14479,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14480,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14481,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14482,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14483,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14484,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14485,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14486,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14487,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14488,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14489,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14490,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14491,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14492,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14493,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14494,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14495,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14496,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14497,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14498,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14499,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14500,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14501,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14502,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14503,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14504,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14505,Urine,12582,,A,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14506,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14507,Prostate gland,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),In vivo,,,,,,22224
14508,Prostate gland,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),In vivo,,,,,,22224
14509,,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,In vivo,,,,,,22224
14510,Muscle tissue,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,In vivo,,,,,,22224
14511,Spleen,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,In vivo,,,,,,22224
14512,Kidney,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,In vivo,,,,,,22224
14513,Urinary bladder,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,In vivo,,,,,,22224
14514,Blood,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,In vivo,,,,,,22224
14515,Bone element,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,In vivo,,,,,,22224
14516,,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,In vivo,,,,,,22224
14517,Kidney,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,In vivo,,,,,,22224
14518,Liver,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,In vivo,,,,,,22224
14519,Lung,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,In vivo,,,,,,22224
14520,Muscle tissue,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,In vivo,,,,,,22224
14521,Prostate gland,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),In vivo,,,,,,22224
14522,Prostate gland,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,In vivo,,,,,,22224
14523,Muscle tissue,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,In vivo,,,,,,22224
14524,Prostate gland,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),In vivo,,,,,,22224
14525,,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,In vivo,,,,,,22224
14526,Muscle tissue,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,In vivo,,,,,,22224
14527,Spleen,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,In vivo,,,,,,22224
14528,Prostate gland,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,In vivo,,,,,,22224
14529,Muscle tissue,13257,,A,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,In vivo,,,,,,22224
14530,,15413,,A,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,In vivo,,Rattus norvegicus,10116.0,,,50597
14531,,15413,,A,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,In vivo,,Rattus norvegicus,10116.0,,,50597
14532,,15413,,A,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,In vivo,,Rattus norvegicus,10116.0,,,50597
14533,,15413,,A,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,In vivo,,Rattus norvegicus,10116.0,,,50597
14534,Hippocampus,15413,,A,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,In vivo,,Rattus norvegicus,10116.0,,,50597
14535,Hippocampus,15413,,A,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,In vivo,,Rattus norvegicus,10116.0,,,50597
14536,Hypothalamus,15413,,A,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,In vivo,,Rattus norvegicus,10116.0,,,50597
14537,Hypothalamus,15413,,A,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,In vivo,,Rattus norvegicus,10116.0,,,50597
14538,,15413,,A,,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,In vivo,,Rattus norvegicus,10116.0,,,50597
14539,,15413,,A,,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,In vivo,,Rattus norvegicus,10116.0,,,50597
14540,Hippocampus,15413,,A,,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,In vivo,,Rattus norvegicus,10116.0,,,50597
14541,Hypothalamus,15413,,A,,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,In vivo,,Rattus norvegicus,10116.0,,,50597
14542,,15413,,A,,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,In vivo,,Rattus norvegicus,10116.0,,,50597
14543,,15413,,A,,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,In vivo,,Rattus norvegicus,10116.0,,,50597
14544,Hippocampus,15413,,A,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,In vivo,,Rattus norvegicus,10116.0,,,50597
14545,Hypothalamus,15413,,A,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
14546,Cerebellum,15413,,A,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,In vivo,,Rattus norvegicus,10116.0,,,50597
14547,Cerebellum,15413,,A,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,In vivo,,Rattus norvegicus,10116.0,,,50597
14548,,15413,,A,,Biodistribution of the [11C]-radiolabeled compound in rat cortex,In vivo,,Rattus norvegicus,10116.0,,,50597
14549,,15413,,A,,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,In vivo,,Rattus norvegicus,10116.0,,,50597
14550,Hippocampus,15413,,A,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,In vivo,,Rattus norvegicus,10116.0,,,50597
14551,Hippocampus,15413,,A,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,In vivo,,Rattus norvegicus,10116.0,,,50597
14552,Hypothalamus,15413,,A,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,In vivo,,Rattus norvegicus,10116.0,,,50597
14553,Hypothalamus,15413,,A,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,In vivo,,Rattus norvegicus,10116.0,,,50597
14554,Cerebellum,15413,,A,,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,In vivo,,Rattus norvegicus,10116.0,,,50597
14555,,15413,,A,,Biodistribution of the [18F]-radiolabeled compound in rat cortex,In vivo,,Rattus norvegicus,10116.0,,,50597
14556,,12404,,A,,Reaction rate parameter value for phosphate with transfer with respect to ATP,,,,,,,22224
14557,,568,,A,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",,,,,,,22224
14558,,568,,A,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,,,,,,22224
14559,,568,,A,,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,,,,,,22224
14560,,12404,,A,,Reaction rate parameter value for phosphate with transfer with respect to ATP,,,,,,,22224
14561,,7624,,A,,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,,,Escherichia coli,562.0,,,50212
14562,,7624,,A,,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",,,Rattus norvegicus,10116.0,,,50597
14563,,7624,,A,,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",,,Rattus norvegicus,10116.0,,,50597
14564,,4643,,A,,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",,,,,,,22224
14565,,11532,,A,,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,,,,,,,22224
14566,,11018,,A,,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,,,,,,,22224
14567,,2276,,A,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,,,,,,22224
14568,,2276,,A,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",,,,,,,22224
14569,,2276,,A,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",,,,,,,22224
14570,,2276,,A,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,,,,,,22224
14571,,2276,,A,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",,,,,,,22224
14572,,8949,,A,,Michaelis constant (KM) was evaluated,,,,,,,22224
14573,,12404,,A,,Reaction rate parameter value for phosphate with transfer with respect to ATP,,,,,,,22224
14574,,7625,,B,,Substrate concentration for half maximal velocity was reported for rat hexokinase I,,,,,,,22224
14575,,7625,,B,,Substrate concentration for half maximal velocity was reported for rat hexokinase II,,,,,,,22224
14576,,7625,,B,,Substrate concentration for half maximal velocity was reported for rat hexokinase III,,,,,,,22224
14577,,7625,,B,,Substrate concentration for half maximal velocity was reported for yeast hexokinase,,,,,,,22224
14578,,12908,,A,,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,,,,,,,22224
14579,,10368,,A,,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,,,,,,,22224
14580,,13108,,A,,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,,,,,,22224
14581,,13108,,A,,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,,,,,,22224
14582,,15217,,A,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,,,,,,,22224
14583,,15217,,A,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,,,,,,,22224
14584,,10933,,A,,Binding constant was determined,,,,,,,22224
14585,,2363,,A,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,,,,,,,22224
14586,,2363,,A,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,,,,,,,22224
14587,,2276,,A,,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,,,,,,,22224
14588,,14915,,P,,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,,,,,,,22224
14589,,8847,,A,,Catalytic rate constant of the compound,,,,,,,22224
14590,,15357,,B,,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,,,,,,,22224
14591,,2869,,A,,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),,,,,,,22224
14592,,3484,,A,,Catalytic rate constant against phospholipase A2 was determined,,,,,,,22224
14593,,1373,,A,,"Compound was evaluated for catalytic constant, Kcat",,,,,,,22224
14594,,8142,,A,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,,,,,,,22224
14595,,14131,,A,,Kcat calculated from 0.693/T1/2,,,,,,,22224
14596,,17269,,A,,Kcat was determined,,,,,,,22224
14597,,3485,,A,,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,,,,,,,22224
14598,,3485,,A,,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,,,,,,,22224
14599,,3485,,A,,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,,,,,,,22224
14600,,5962,,A,,Kcat value was determined,,,,,,,22224
14601,,3133,,A,,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,,,,,,,22224
14602,,3133,,A,,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,,,,,,,22224
14603,,2276,,A,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,,,,,,22224
14604,,2276,,A,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",,,,,,,22224
14605,,2276,,A,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",,,,,,,22224
14606,,2276,,A,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,,,,,,22224
14607,,2276,,A,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",,,,,,,22224
14608,,4892,,A,,Kinetic parameter for rate of conversion to PABA was determined,,,,,,,22224
14609,,3133,,A,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,,,,,,22224
14610,Feces,11488,,A,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",,,Rattus norvegicus,10116.0,,,50597
14611,Urine,11488,,A,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",,,Rattus norvegicus,10116.0,,,50597
14612,Urine,11488,,A,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",,,Rattus norvegicus,10116.0,,,50597
14613,Urine,11488,,A,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",,,Rattus norvegicus,10116.0,,,50597
14614,Urine,11488,,A,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",,,Rattus norvegicus,10116.0,,,50597
14615,Urine,11488,,A,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",,,Rattus norvegicus,10116.0,,,50597
14616,,11488,,A,,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,,,Rattus norvegicus,10116.0,,,50597
14617,,11488,,A,,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,,,Rattus norvegicus,10116.0,,,50597
14618,,11488,,A,,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,,,Rattus norvegicus,10116.0,,,50597
14619,,11488,,A,,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,,,Rattus norvegicus,10116.0,,,50597
14620,,11488,,A,,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,,,Rattus norvegicus,10116.0,,,50597
14621,,11488,,A,,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,,,Rattus norvegicus,10116.0,,,50597
14622,,11488,,A,,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,,,Rattus norvegicus,10116.0,,,50597
14623,,11488,,A,,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,,,Rattus norvegicus,10116.0,,,50597
14624,,11488,,A,,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,,,Rattus norvegicus,10116.0,,,50597
14625,,11488,,A,,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,,,Rattus norvegicus,10116.0,,,50597
14626,,11488,,A,,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,,,Rattus norvegicus,10116.0,,,50597
14627,,11488,,A,,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,,,Rattus norvegicus,10116.0,,,50597
14628,,11488,,A,,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,,,Rattus norvegicus,10116.0,,,50597
14629,,11488,,A,,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,,,Rattus norvegicus,10116.0,,,50597
14630,,11488,,A,,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,,,Rattus norvegicus,10116.0,,,50597
14631,,11488,,A,,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,,,Rattus norvegicus,10116.0,,,50597
14632,,11488,,A,,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,,,Rattus norvegicus,10116.0,,,50597
14633,,11488,,A,,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,,,Rattus norvegicus,10116.0,,,50597
14634,Feces,7132,,A,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",,,Oryctolagus cuniculus,9986.0,,,50592
14635,Feces,7132,,A,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",,,Oryctolagus cuniculus,9986.0,,,50592
14636,Feces,7132,,A,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",,,Oryctolagus cuniculus,9986.0,,,50592
14637,Feces,7132,,A,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",,,Oryctolagus cuniculus,9986.0,,,50592
14638,Urine,7132,,A,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",,,Oryctolagus cuniculus,9986.0,,,50592
14639,Urine,7132,,A,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",,,Oryctolagus cuniculus,9986.0,,,50592
14640,Urine,7132,,A,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",,,Oryctolagus cuniculus,9986.0,,,50592
14641,Urine,7132,,A,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",,,Oryctolagus cuniculus,9986.0,,,50592
14642,Urine,7132,,A,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",,,Oryctolagus cuniculus,9986.0,,,50592
14643,Feces,7132,,A,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",,,Oryctolagus cuniculus,9986.0,,,50592
14644,Feces,7132,,A,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",,,Oryctolagus cuniculus,9986.0,,,50592
14645,Feces,7132,,A,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",,,Oryctolagus cuniculus,9986.0,,,50592
14646,Feces,7132,,A,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",,,Oryctolagus cuniculus,9986.0,,,50592
14647,Urine,7132,,A,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",,,Oryctolagus cuniculus,9986.0,,,50592
14648,Urine,7132,,A,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",,,Oryctolagus cuniculus,9986.0,,,50592
14649,Urine,7132,,A,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",,,Oryctolagus cuniculus,9986.0,,,50592
14650,Urine,7132,,A,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",,,Oryctolagus cuniculus,9986.0,,,50592
14651,Urine,7132,,A,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",,,Oryctolagus cuniculus,9986.0,,,50592
14652,Blood,13925,,A,,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,In vivo,,Rattus norvegicus,10116.0,,,50597
14653,Blood,13925,,A,,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,In vivo,,Rattus norvegicus,10116.0,,,50597
14654,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14655,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14656,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14657,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14658,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14659,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14660,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14661,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14662,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14663,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14664,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14665,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14666,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14667,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14668,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14669,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14670,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14671,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,,Canis lupus familiaris,9615.0,,,50588
14672,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14673,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14674,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14675,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14676,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14677,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14678,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14679,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14680,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14681,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14682,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14683,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14684,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14685,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14686,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14687,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14688,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14689,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14690,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14691,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14692,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14693,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14694,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14695,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14696,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14697,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14698,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14699,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14700,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14701,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14702,Hippocampus,15413,,A,,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,In vivo,,Rattus norvegicus,10116.0,,,50597
14703,Hypothalamus,15413,,A,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,In vivo,,Rattus norvegicus,10116.0,,,50597
14704,Hypothalamus,15413,,A,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,In vivo,,Rattus norvegicus,10116.0,,,50597
14705,Blood,12017,,A,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14706,Blood,12017,,A,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14707,Blood,12017,,A,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
14708,Blood,12017,,A,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14709,Blood,12017,,A,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14710,Blood,12017,,A,,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14711,Blood,12017,,A,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14712,Blood,12017,,A,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
14713,Blood,12017,,A,,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14714,Blood,12017,,A,,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14715,Blood,12017,,A,,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
14716,,12017,,A,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14717,,12017,,A,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14718,,12017,,A,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
14719,,12017,,A,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14720,,12017,,A,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14721,,12017,,A,,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14722,,12017,,A,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14723,,12017,,A,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
14724,,12017,,A,,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14725,,12017,,A,,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14726,Kidney,12017,,A,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14727,Kidney,12017,,A,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14728,Kidney,12017,,A,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
14729,Kidney,12017,,A,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14730,Kidney,12017,,A,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14731,Kidney,12017,,A,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14732,Kidney,12017,,A,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14733,Kidney,12017,,A,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
14734,Kidney,12017,,A,,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14735,Kidney,12017,,A,,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14736,Kidney,12017,,A,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14737,Liver,12017,,A,,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
14738,Liver,12017,,A,,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14739,Liver,12017,,A,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14740,Liver,12017,,A,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14741,Liver,12017,,A,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
14742,Liver,12017,,A,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14743,Liver,12017,,A,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14744,Liver,12017,,A,,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14745,Liver,12017,,A,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14746,,3133,,A,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,,,,,,22224
14747,,2742,,A,,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,,,,,,,22224
14748,,2742,,A,,Compound was tested for amidase rate in the presence of N62C screen enzyme,,,,,,,22224
14749,,2742,,A,,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,,,,,,,22224
14750,,2742,,A,,Compound was tested for amidase rate in the presence of S166C screen enzyme,,,,,,,22224
14751,,2742,,A,,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,,,,,,,22224
14752,,2742,,A,,Compound was tested for esterase rate in the presence of N62C screen enzyme,,,,,,,22224
14753,,2742,,A,,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,,,,,,,22224
14754,,2742,,A,,Compound was tested for esterase rate in the presence of S166C screen enzyme,,,,,,,22224
14755,,2276,,A,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,,,,,22224
14756,,2276,,A,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,,,,,22224
14757,,2276,,A,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",,,,,,,22224
14758,,2276,,A,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,,,,,22224
14759,,2276,,A,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,,,,,22224
14760,,2276,,A,,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",,,,,,,22224
14761,,17269,,A,,Ratio of Kcat to that of Km was determined,,,,,,,22224
14762,,2276,,A,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,,,,,,22224
14763,,2276,,A,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,,,,,,22224
14764,,15917,,A,,"Compound was evaluated for constant, Kd",,,,,,,22224
14765,,10933,,A,,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,,,,,,,22224
14766,,10933,,A,,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,,,,,,,22224
14767,,14293,,A,,Dissociation Constant of compound determined,,,,,,,22224
14768,,6698,,B,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,,,,,,,22224
14769,,6698,,B,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,,,,,,,22224
14770,,4318,,P,,Dissociation constant of compound with Fructose was determined,,,,,,,22224
14771,,4318,,P,,Dissociation constant of compound with Fructose was determined; Not determined,,,,,,,22224
14772,,4318,,P,,Dissociation constant of compound with Lactulose was determined,,,,,,,22224
14773,,4318,,P,,Dissociation constant of compound with Lactulose was determined; Not determined,,,,,,,22224
14774,,14959,,P,,Dissociation constant of the Compound,,,,,,,22224
14775,,5913,,P,,Dissociation constant by non-linear regression analysis,,,,,,,22224
14776,,14218,,P,,Dissociation constant was determined,,,,,,,22224
14777,,10689,,P,,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,,,,,,,22224
14778,,13925,,P,,Dissociation constant was determined,,,,,,,22224
14779,,16359,,P,,Dissociation constant was determined,,,,,,,22224
14780,Muscle tissue,10944,,A,,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,,,Rattus norvegicus,10116.0,,,50597
14781,,11080,,A,,The dissociation constant determined by fluorescence displacement assay,,,,,,,22224
14782,,17805,,A,,kd value surface plasmon resonance (SPR) method,,,,,,,22224
14783,Muscle tissue,10944,,A,,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,,,Rattus norvegicus,10116.0,,,50597
14784,,16645,,F,,First dissociation constant of the binding of compound to V30M TTR,,,,,,,22224
14785,,16645,,F,,Second dissociation constant of the binding of compound to V30M TTR,,,,,,,22224
14786,,7793,,A,,"Compound was evaluated for equilibrium constant, Ke",,,,,,,22224
14787,Hypothalamus,12199,,A,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,,,,,,,22224
14788,Hypothalamus,12199,,A,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,,,,,,,22224
14789,,9680,,A,,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,,,,,,,22224
14790,,9680,,A,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,,,,,,22224
14791,,9680,,A,,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,,,,,,,22224
14792,,13758,,A,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,,Mus musculus,10090.0,,,50594
14793,,13758,,A,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,,Mus musculus,10090.0,,,50594
14794,,13758,,A,,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,,Mus musculus,10090.0,,,50594
14795,,13758,,A,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,,Mus musculus,10090.0,,,50594
14796,,13758,,A,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,,,Mus musculus,10090.0,,,50594
14797,,13758,,A,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,,Mus musculus,10090.0,,,50594
14798,,13758,,A,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,,,Mus musculus,10090.0,,,50594
14799,,13758,,A,,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,,Mus musculus,10090.0,,,50594
14800,,14393,,A,,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,Rattus norvegicus,10116.0,,,50597
14801,,14393,,A,,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,Rattus norvegicus,10116.0,,,50597
14802,,15078,,A,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,,Rattus norvegicus,10116.0,,,50597
14803,Brain,13925,,A,,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,In vivo,,Rattus norvegicus,10116.0,,,50597
14804,Brain,13925,,A,,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,In vivo,,Rattus norvegicus,10116.0,,,50597
14805,Heart,13925,,A,,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,In vivo,,Rattus norvegicus,10116.0,,,50597
14806,Heart,13925,,A,,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,In vivo,,Rattus norvegicus,10116.0,,,50597
14807,Kidney,13925,,A,,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,In vivo,,Rattus norvegicus,10116.0,,,50597
14808,Kidney,13925,,A,,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,In vivo,,Rattus norvegicus,10116.0,,,50597
14809,Liver,13925,,A,,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,In vivo,,Rattus norvegicus,10116.0,,,50597
14810,Liver,13925,,A,,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,In vivo,,Rattus norvegicus,10116.0,,,50597
14811,Lung,13925,,A,,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,In vivo,,Rattus norvegicus,10116.0,,,50597
14812,Lung,13925,,A,,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,In vivo,,Rattus norvegicus,10116.0,,,50597
14813,Muscle tissue,13925,,A,,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,In vivo,,Rattus norvegicus,10116.0,,,50597
14814,Muscle tissue,13925,,A,,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,In vivo,,Rattus norvegicus,10116.0,,,50597
14815,Zone of skin,13925,,A,,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,In vivo,,Rattus norvegicus,10116.0,,,50597
14816,Zone of skin,13925,,A,,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,In vivo,,Rattus norvegicus,10116.0,,,50597
14817,Spleen,13925,,A,,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,In vivo,,Rattus norvegicus,10116.0,,,50597
14818,Spleen,13925,,A,,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,In vivo,,Rattus norvegicus,10116.0,,,50597
14819,Blood,9712,,A,,Biodistribution of Compound in rat blood after 15 minutes of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
14820,Blood,9712,,A,,Biodistribution of Compound in rat blood after 2 minutes of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
14821,Brain,9712,,A,,Biodistribution of Compound in rat brain after 15 minutes of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
14822,Brain,9712,,A,,Biodistribution of Compound in rat brain after 2 minutes of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
14823,Heart,9712,,A,,Biodistribution of Compound in rat heart after 15 minutes of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
14824,Heart,9712,,A,,Biodistribution of Compound in rat heart after 2 minutes of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
14825,Liver,9712,,A,,Biodistribution of Compound in rat liver after 15 minutes of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
14826,Liver,9712,,A,,Biodistribution of Compound in rat liver after 2 minutes of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
14827,Lung,9712,,A,,Biodistribution of Compound in rat lung after 15 minutes of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
14828,Lung,9712,,A,,Biodistribution of Compound in rat lung after 2 minutes of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
14829,Muscle tissue,9712,,A,,Biodistribution of Compound in rat muscle after 15 minutes of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
14830,Muscle tissue,9712,,A,,Biodistribution of Compound in rat muscle after 2 minutes of administration,In vivo,,Rattus norvegicus,10116.0,,,50597
14831,,13925,,A,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,,,Rattus norvegicus,10116.0,,,50597
14832,,13925,,A,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,,,Rattus norvegicus,10116.0,,,50597
14833,,13925,,A,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,,,Rattus norvegicus,10116.0,,,50597
14834,,6941,,A,,Organ distribution in rat blood 2 minutes after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14835,,6941,,A,,Organ distribution in rat blood 2 hr after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14836,,6941,,A,,Organ distribution in rat blood 30 minutes after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14837,,6941,,A,,Organ distribution in rat blood 30 min after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14838,,6941,,A,,Organ distribution in rat brain 2 minutes after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14839,,6941,,A,,Organ distribution in rat brain 2 hr after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14840,,6941,,A,,Organ distribution in rat brain 30 minutes after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14841,,6941,,A,,Organ distribution in rat heart 2 minutes after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14842,,6941,,A,,Organ distribution in rat heart 2 hr after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14843,,6941,,A,,Organ distribution in rat heart 30 minutes after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14844,,6941,,A,,Organ distribution in rat kidney 2 minutes after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14845,,6941,,A,,Organ distribution in rat kidney 2 hr after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14846,,6941,,A,,Organ distribution in rat kidney 30 minutes after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14847,Liver,6941,,A,,Organ distribution in rat liver 2 minutes after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14848,Liver,6941,,A,,Organ distribution in rat liver 2 hr after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14849,Liver,6941,,A,,Organ distribution in rat liver 30 minutes after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14850,,6941,,A,,Organ distribution in rat lung 2 minutes after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14851,,6941,,A,,Organ distribution in rat lung 2 hr after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14852,,6941,,A,,Organ distribution in rat lung 30 minutes after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14853,Muscle tissue,6941,,A,,Organ distribution in rat muscle 2 minutes after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14854,Muscle tissue,6941,,A,,Organ distribution in rat muscle 2 hr after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14855,Muscle tissue,6941,,A,,Organ distribution in rat muscle 30 minutes after intravenous injection,,,Rattus norvegicus,10116.0,,,50597
14856,,14439,,A,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),In vivo,,Mus musculus,10090.0,,,50594
14857,,14439,,A,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),In vivo,,Mus musculus,10090.0,,,50594
14858,,14439,,A,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),In vivo,,Mus musculus,10090.0,,,50594
14859,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14860,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14861,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14862,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14863,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14864,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14865,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14866,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14867,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14868,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14869,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14870,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14871,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14872,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14873,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14874,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14875,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14876,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14877,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14878,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14879,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14880,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14881,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14882,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14883,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14884,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14885,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14886,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14887,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14888,Urine,12582,,A,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,,,Rattus norvegicus,10116.0,,,50597
14889,,7415,,A,,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",,,Rattus norvegicus,10116.0,,,50597
14890,,7313,,A,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,,,,,,,22224
14891,,7313,,A,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,,,,,,,22224
14892,,7313,,A,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,,,,,,,22224
14893,Adrenal cortex,7570,,A,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,,,,,,22224
14894,Adrenal cortex,7570,,A,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,,,,,,22224
14895,,7570,,A,,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,,,,,,,22224
14896,,7570,,A,,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,,,,,,,22224
14897,Adrenal cortex,7570,,A,,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,,,,,,22224
14898,Adrenal cortex,7570,,A,,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,,,,,,,22224
14899,,7570,,A,,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,,,,,,,22224
14900,,7570,,A,,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,,,,,,,22224
14901,,7570,,A,,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,,,,,,,22224
14902,,7570,,A,,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,,,,,,,22224
14903,Adrenal cortex,7570,,A,,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,,,,,,,22224
14904,,7570,,A,,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,,,,,,,22224
14905,,7570,,A,,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,,,,,,,22224
14906,Adrenal cortex,7570,,A,,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,,,,,,22224
14907,,7570,,A,,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,,,,,,,22224
14908,,7570,,A,,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,,,,,,,22224
14909,,14122,,A,,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",In vivo,,Canis lupus familiaris,9615.0,,,22224
14910,,16449,,A,,Absolute bioavailability in male cynomolgus monkeys,In vivo,,Macaca fascicularis,9541.0,,,22224
14911,,16449,,A,,Absolute bioavailability in maleSprague-Dawley rats,In vivo,,Rattus norvegicus,10116.0,,,22224
14912,Liver,12017,,A,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
14913,Liver,12017,,A,,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14914,Liver,12017,,A,,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14915,Lung,12017,,A,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14916,Lung,12017,,A,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14917,Lung,12017,,A,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
14918,Lung,12017,,A,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14919,Lung,12017,,A,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14920,Lung,12017,,A,,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14921,Lung,12017,,A,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14922,Lung,12017,,A,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
14923,Lung,12017,,A,,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14924,Lung,12017,,A,,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14925,Muscle tissue,12017,,A,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14926,Muscle tissue,12017,,A,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14927,Muscle tissue,12017,,A,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
14928,Muscle tissue,12017,,A,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14929,Muscle tissue,12017,,A,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14930,Muscle tissue,12017,,A,,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14931,Muscle tissue,12017,,A,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14932,Muscle tissue,12017,,A,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
14933,Muscle tissue,12017,,A,,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14934,Muscle tissue,12017,,A,,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14935,Blood,15045,,A,,Biodistribution in normal mice blood after 120 hr,In vivo,,Mus musculus,10090.0,,,50594
14936,Blood,15045,,A,,Biodistribution in normal mice blood after 24 hr,In vivo,,Mus musculus,10090.0,,,50594
14937,Blood,15045,,A,,Biodistribution in normal mice blood after 4 hr,In vivo,,Mus musculus,10090.0,,,50594
14938,Bone,15045,,A,,Biodistribution in normal mice bone after 120 hr,In vivo,,Mus musculus,10090.0,,,50594
14939,Bone,15045,,A,,Biodistribution in normal mice bone after 24 hr,In vivo,,Mus musculus,10090.0,,,50594
14940,Bone,15045,,A,,Biodistribution in normal mice bone after 4 hr,In vivo,,Mus musculus,10090.0,,,50594
14941,Heart,15045,,A,,Biodistribution in normal mice heart after 120 hr,In vivo,,Mus musculus,10090.0,,,50594
14942,Heart,15045,,A,,Biodistribution in normal mice heart after 24 hr,In vivo,,Mus musculus,10090.0,,,50594
14943,Heart,15045,,A,,Biodistribution in normal mice heart after 4 hr,In vivo,,Mus musculus,10090.0,,,50594
14944,Kidney,15045,,A,,Biodistribution in normal mice kidney after 120 hr,In vivo,,Mus musculus,10090.0,,,50594
14945,Kidney,15045,,A,,Biodistribution in normal mice kidney after 24 hr,In vivo,,Mus musculus,10090.0,,,50594
14946,Kidney,15045,,A,,Biodistribution in normal mice kidney after 4 hr,In vivo,,Mus musculus,10090.0,,,50594
14947,Liver,15045,,A,,Biodistribution in normal mice liver after 120 hr,In vivo,,Mus musculus,10090.0,,,50594
14948,Liver,15045,,A,,Biodistribution in normal mice liver after 24 hr,In vivo,,Mus musculus,10090.0,,,50594
14949,Liver,15045,,A,,Biodistribution in normal mice liver after 4 hr,In vivo,,Mus musculus,10090.0,,,50594
14950,Spleen,15045,,A,,Biodistribution in normal mice spleen after 120 hr,In vivo,,Mus musculus,10090.0,,,50594
14951,Spleen,15045,,A,,Biodistribution in normal mice spleen after 24 hr,In vivo,,Mus musculus,10090.0,,,50594
14952,Spleen,15045,,A,,Biodistribution in normal mice spleen after 4 hr,In vivo,,Mus musculus,10090.0,,,50594
14953,Spleen,12017,,A,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14954,Spleen,12017,,A,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14955,Spleen,12017,,A,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
14956,Spleen,12017,,A,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14957,Spleen,12017,,A,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14958,Spleen,12017,,A,,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14959,Spleen,12017,,A,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14960,Spleen,12017,,A,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),In vivo,,Rattus norvegicus,10116.0,,,50597
14961,Spleen,12017,,A,,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14962,Spleen,12017,,A,,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14963,Thyroid gland,12017,,A,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,In vivo,,Rattus norvegicus,10116.0,,,50597
14964,,14941,,A,,The Kel values in female wistar rats.,,,Rattus norvegicus,10116.0,,,50597
14965,,4646,,A,,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,,,,,,,22224
14966,,8847,,A,,Hydrolysis rate constant of the compound,,,,,,,22224
14967,,11778,,P,,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,,,,,,,22229
14968,,2363,,A,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",,,,,,,22224
14969,,2363,,A,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",,,,,,,22224
14970,,2363,,A,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",,,,,,,22224
14971,,2363,,A,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",,,,,,,22224
14972,,8371,,A,,Apparent inactivation rate constant was evaluated,,,,,,,22224
14973,,14883,,A,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,,,,,,,22224
14974,,14883,,A,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,,,,,,,22224
14975,,4643,,A,,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,,,,,,,22224
14976,,3519,,A,,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,,,,,,,22224
14977,,10600,,A,,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,,,,,,,22224
14978,,8501,,F,,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,,,,,,,22224
14979,,8505,,P,,Dissociation constant was determined,,,,,,,22224
14980,,9778,,P,,Dissociation constant was determined,,,,,,,22224
14981,,9778,,P,,Dissociation constant at pH 7.4,,,,,,,22224
14982,,9778,,P,,Dissociation constant in presence of 1 mM dithiothreitol,,,,,,,22224
14983,,13007,,A,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,,,,,,22224
14984,,13007,,A,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,,,,,,22224
14985,,13007,,A,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,,,,,,22224
14986,,13007,,A,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,,,,,,22224
14987,,11482,,A,,Kinetic constant for aromatization of androstenedione,,,,,,,22224
14988,,11482,,A,,Kinetic constant for aromatization of testosterone,,,,,,,22224
14989,,2303,,A,,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,,,,,,,22224
14990,,11964,,A,,Local inhibition constant was determined,,,,,,,22224
14991,,3140,,A,,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,,,Saccharomyces cerevisiae,4932.0,,,50347
14992,,10650,,P,,Dissociation constant value of the compound,,,,,,,22224
14993,Cornea,4667,,A,,In vitro permeability through cornea without epithelium,,,,,,,22224
14994,Cornea,4667,,A,,In vitro permeability through intact cornea,,,,,,,22224
14995,Cornea,9199,,A,,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,,,Oryctolagus cuniculus,9986.0,,,50592
14996,,11966,,A,,Rate of enzyme inactivation for the compound was determined,,,,,,,22224
14997,Cornea,4667,,A,,In vitro permeability through cornea without epithelium,,,,,,,22224
14998,Cornea,4667,,A,,In vitro permeability through intact cornea,,,,,,,22224
14999,,8354,,A,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
15000,,8354,,A,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
15001,,8354,,A,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
15002,,8354,,A,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
15003,,8354,,A,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
15004,,8354,,A,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
15005,,8354,,A,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
15006,,8354,,A,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
15007,,8354,,A,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
15008,,8354,,A,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
15009,,8354,,A,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
15010,,8354,,A,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
15011,,8354,,A,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
15012,,8354,,A,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
15013,,8354,,A,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,22224
15014,,14439,,A,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),In vivo,,Mus musculus,10090.0,,,50594
15015,,14439,,A,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,In vivo,,Homo sapiens,9606.0,,,50587
15016,,14439,,A,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),In vivo,,Mus musculus,10090.0,,,50594
15017,,14439,,A,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),In vivo,,Mus musculus,10090.0,,,50594
15018,,14439,,A,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),In vivo,,Mus musculus,10090.0,,,50594
15019,,14439,,A,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),In vivo,,Mus musculus,10090.0,,,50594
15020,,14439,,A,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,In vivo,,Mus musculus,10090.0,,,50594
15021,,14439,,A,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),In vivo,,Mus musculus,10090.0,,,50594
15022,,14439,,A,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),In vivo,,Mus musculus,10090.0,,,50594
15023,,14439,,A,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),In vivo,,Mus musculus,10090.0,,,50594
15024,,14439,,A,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),In vivo,,Mus musculus,10090.0,,,50594
